⊕EPA

TOXICOLOGICAL REVIEW

OF

METHANOL

(CAS No. 67-56-1)

In Support of Summary Information on the Integrated Risk Information System (IRIS)

December 2009

NOTICE

This document is an **External peer review draft**. This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. It is being circulated for review of its technical accuracy and science policy implications.

U.S. Environmental Protection Agency
Washington, DC

DISCLAIMER

This document is a preliminary draft for review purposes only. This information is
distributed solely for the purpose of pre-dissemination peer review under applicable information
quality guidelines. It has not been formally disseminated by EPA. It does not represent and
should not be construed to represent any Agency determination or policy. Mention of trade
names or commercial products does not constitute endorsement or recommendation for use.

NOTE

Hyperlinks to the reference citations throughout this document will take you to the
NCEA HERO database (Health and Environmental Research Online) at http://epa.gov/hero.
HERO is a database of scientific literature used by U.S. EPA in the process of developing
science assessments such as the Integrated Science Assessments (ISAs) and the Integrated Risk
Information System (IRIS).

CONTENTS TOXICOLOGICAL REVIEW OF METHANOL
(CAS NO. 67-56-1)

LIST OF TABLES

LIST OF FIGURES

LIST OF ABBREVIATIONS AND ACRONYMS

ACGIH	American Conference of Governmental and Industrial Hygienists
ADH	alcohol dehydrogenase
ADH1	alcohol dehydrogenase-1
ADH3	formaldehyde dehydrogenase-3
AIC	Akaike Information Criterion
ALD	aldehyde dehydrogenase
ALDH2	mitochondrial aldehyde dehydrogenase-2
ALT	alanine aminotransferase
ANOVA	analysis of variance
AP	alkaline phosphatase
AST	aspartate aminotransferase
ATP	adenosine triphosphate
ATSDR	Agency for Toxic Substances and Disease Registry
AUC	area under the curve, representing the cumulative product of time and concentration for a substance in the blood
β-NAG	N-acetyl-beta-D-glucosaminidase
BMC	benchmark concentration
BMCL	benchmark concentration, 95% lower bound
BMD	benchmark dose(s)
BMD_{1SD}	BMD for response one standard deviation from control mean
BMDL	95% lower bound confidence limit on BMD (benchmark dose)
$BMDL_{1SD}$	BMDL for response one standard deviation from control mean
BMDS	benchmark dose software
BMR	benchmark response
BSO	butathione sulfoximine
BUN	blood urea nitrogen
BW, bw	body weight
C_1 pool	one carbon pool
C_{max}	peak concentration of a substance in the blood during the exposure period
C-section	Cesarean section
CA	chromosomal aberrations
CAR	conditioned avoidance response
CASRN	Chemical Abstracts Service Registry Number
CAT	catalase
CERHR	Center for the Evaluation of Risks to Human Reproduction
CH_3OH	methanol

CHL	Chinese hamster lung (cells)
CI	confidence interval
Cl_S	clearance rate
CNS	central nervous system
CO_2	carbon dioxide
con-A	concanavalin-A
CR	crown-rump length
CSF	Cancer slope factor
CT	computed tomography
CYP450	cytochrome P450
d, δ, Δ	delta, difference, change
D_2	dopamine receptor
DA	dopamine
DIPE	diisopropylether
DMDC	dimethyl dicarbonate
DNA	deoxyribonucleic acid
DNT	developmental neurotoxicity test(ing)
DOPAC	dihydroxyphenyl acetic acid
DPC	days past conception
DTH	delayed-type hypersensitivity
EFSA	European Food Safety Authority
EKG	electrocardiogram
EO	Executive Order
EPA	U.S. Environmental Protection Agency
ERF	European Ramazzini Foundation
EtOH	ethanol
F	fractional bioavailability
F_0	parental generation
F_1	first generation
F_2	second generation
F344	Fisher 344 rat strain
FAD	folic acid deficient
FAS	folic acid sufficient
FD	formate dehydrogenase
FP	folate paire
FR	folate reduced
FRACIN	fraction inhaled
FS	folate sufficient

FSH	follicular stimulating hormone
γ-GT	gamma glutamyl transferase
g	gravity
g, kg, mg, μg	gram, kilogram, milligram, microgram
G6PD	glucose-6-phosphate dehydrogenase
GAP43	growth-associated protein (neuronal growth cone)
GD	gestation day
GFR	glomerular filtration rate
GI	gastrointestinal track
GLM	generalized linear model
GLP	good laboratory practice
GSH	glutathione
HAP	hazardous air pollutant
HCHO	formaldehyde
HCOO	formate
Hct	hematocrit
HEC	human equivalent concentration
HED	human equivalent dose
HEI	Health Effects Institute
HH	hereditary hemochromatosis
5_HIAA	5-hydroxyindolacetic acid
HMGSH	S-hydroxymethylglutathione
Hp	haptoglobin
HPA	hypothalamus-pituitary-adrenal (axis)
HPLC	high-performance liquid chromatography
HSDB	Hazardous Substances Databank
HSP70	biomarker of cellular stress
5-HT	serotonin
IL	interleukins
i.p.	intraperitoneal
IPCS	International Programme on Chemical Safety
IQ	intelligence quotient
IRIS	Integrated Risk Information System
IUR	inhalation unit risk
i.v.	intravenous
K_1	first order rate loss
K1C	first order clearance of methanol from the blood to the bladder for urinary elimination

KAI	first order uptake from the intestine
KAS	first order methanol oral absorption rate from stomach
KBL	rate constant for urinary excretion from bladder
KIA	first order uptake from intestine
KLH	keyhole limpet hemocyanin
KLL	alternate first order rate constant
K_m	substrate concentration at half the enzyme maximum velocity (V_{max})
K_m2	Michaelis-Menten rate constant for low affinity metabolic clearance of methanol
KSI	first order transfer between stomach and intestine
L, dL, mL	liter, deciliter, milliliter
LD_{50}	median lethal dose
LDH	lactate dehydrogenase
LH	luteinizing hormone
LLF	(maximum) log likelihood function
LMI	leukocyte migration inhibition (assay)
LOAEL	lowest-observed-adverse-effect level
M, mM, µM	molar, millimolar, micromolar
MeOH	methanol
MLE	maximum likelihood estimate
M-M	Michaelis-Menten
MN	micronuclei
MOA	mode of action
4-MP	4-methylpyrazale messenger RNA
MRI	magnetic resonance imaging
MTBE	methyl tertiary butyl ether
MTX	methotrexate
N_2O/O_2	nitrous oxide
NAD^+	nicotinamide adenine dinucleotide
NADH	reduced form of nicotinamide adenine dinucleotide
NBT	nitroblue tetrazolium (test)
NCEA	National Center for Environmental Assessment
ND	not determined
NEDO	New Energy Development Organization (of Japan)
NIEHS	National Institute of Environmental Health Sciences
NIOSH	National Institute of Occupational Safety and Health
nmol	nanomole

NOAEL	no-observed-adverse-effect level
NOEL	no-observed-effect level
NP	nonpregnant
NR	not reported
NRC	National Research Council
NS	not specified
NTP	National Toxicology Program
OR	osmotic resistance
OSF	oral slope factor
OU	ocular uterque (each eye)
OXA	oxazolone
P, p	probability
PBPK	physiologically based pharmacokinetic
PEG	polyethylene glycol
PFC	plaque-forming cell
PK	pharmacokinetic
PMN	polymorphonuclear leucocytes
PND	postnatal day
POD	point of departure
ppb, ppm	parts per billion, parts per million
PWG	Pathology Working Group of the NTP of NIEHS
Q wave	the initial deflection of the QRS complex
QCC	cardiac output
QPC	pulmonary (alveolar) ventilation scaling coefficient
QRS	portion of electrocardiogram corresponding to the depolarization of ventricular cardiac cells.
R^2	square of the correlation coefficient, a measure of the reliability of a linear relationship.
RBC	red blood cell
RfC	reference concentration
RfD	reference dose
RNA	ribonucleic acid
ROS	reactive oxygen species
S9	microsomal fraction from liver
SAP	serum alkaline phosphatase
s.c.	subcutaneous
SCE	sister chromatid exchange
S.D.	standard deviation

S.E.	standard error
SEM	standard error of mean
SGPT	serum glutamate pyruvate transaminase
SHE	Syrian hamster embryo
SOD	superoxide dismutase
SOP	standard operating procedure(s)
t	time
$T_{1/2}$, $t_{1/2}$	half-life
T wave	the next deflection in the electrocardiogram after the QRS complex; represents ventricular repolarization
TAME	tertiary amyl methyl ether
TAS	total antioxidant status
Tau	taurine
THF	tetrahydrofolate
TLV	threshold limit value
TNFα	tumor necrosis factor-alpha
TNP-LPS	trinitrophenyl-lipopolysaccharide
TRI	Toxic Release Inventory
U83836E	vitamin E derivative
UF(s)	uncertainty factor(s)
UF_A	UF associated with interspecies (animal to human) extrapolation
UF_D	UF associated with deficiencies in the toxicity database
UF_H	UF associated with variation in sensitivity within the human population
UF_S	UF associated with subchronic to chronic exposure
V_d	volume of distribution
V_{max}	maximum enzyme velocity
$V_{max}C$	maximum velocity of the high-affinity/low-capacity pathway
v/v	volume/volume
VDR	visually directed reaching test
VitC	vitamin C
VYS	visceral yolk sac
WBC	white blood cell
WOE	weight of evidence
w/v	weight/volume
χ^2	chi square

FOREWORD

1   The purpose of this Toxicological Review is to provide scientific support and rationale
2 for the hazard and dose-response assessment in IRIS pertaining to chronic exposure to methanol.
3 It is not intended to be a comprehensive treatise on the chemical or toxicological nature of
4 methanol.

5   The intent of Section 6, *Major Conclusions in the Characterization of Hazard and Dose*
6 *Response,* is to present the major conclusions reached in the derivation of the reference dose,
7 reference concentration and cancer assessment, where applicable, and to characterize the overall
8 confidence in the quantitative and qualitative aspects of hazard and dose response by addressing
9 the quality of data and related uncertainties. The discussion is intended to convey the
10 limitations of the assessment and to aid and guide the risk assessor in the ensuing steps of the
11 risk assessment process.

12   For other general information about this assessment or other questions relating to IRIS,
13 the reader is referred to EPA's IRIS Hotline at (202) 566-1676 (phone), (202) 566-1749 (fax), or
14 hotline.iris@epa.gov.

AUTHORS, CONTRIBUTORS, AND REVIEWERS

CHEMICAL MANAGER

Jeffrey Gift, Ph.D.
National Center for Environmental Assessment
U.S Environmental Protection Agency
Research Triangle Park, NC

AUTHORS

Stanley Barone, Ph.D.
National Center for Environmental Assessment
U.S. Environmental Protection Agency
Washington, DC

Allen Davis, MSPH
National Center for Environmental Assessment
U.S. Environmental Protection Agency
Research Triangle Park, NC

Jeffrey Gift, Ph.D.
National Center for Environmental Assessment
U.S. Environmental Protection Agency
Research Triangle Park, NC

Annette Iannucci, M.S.
Sciences International (first draft)
2200 Wilson Boulevard
Arlington, VA

Paul Schlosser, Ph.D.
National Center for Environmental Assessment
U.S. Environmental Protection Agency
Washington, DC

CONTRIBUTORS

Bruce Allen, Ph.D.
Bruce Allen Consulting
101 Corbin Hill Circle
Chapel Hill, SC

Hugh Barton, Ph.D.
National Center for Computational Toxicology
U.S. Environmental Protection Agency
Research Triangle Park, NC

J. Michael Davis, Ph.D.
National Center for Environmental Assessment
U.S. Environmental Protection Agency
Research Triangle Park, NC

Robinan Gentry, M.S.
ENVIRON International
650 Poydras Street
New Orleans, LA

Susan Goldhaber, M.S.
Alpha-Gamma Technologies, Inc.
3301 Benson Drive
Raleigh, NC

Mark Greenberg, Ph.D.
Senior Environmental Employee Program
U.S. Environmental Protection Agency
Research Triangle Park, NC

George Holdsworth, Ph.D.
Oak Ridge Institute for Science and Education (second draft)
Badger Road
Oak Ridge, TN

Angela Howard, Ph.D.
National Center for Environmental Assessment
U.S. Environmental Protection Agency
Research Triangle Park, NC

Connie Meacham, M.S.
National Center for Environmental Assessment
U.S. Environmental Protection Agency
Research Triangle Park, NC

Greg Miller
Office of Policy, Economics & Innovation
U.S. Environmental Protection Agency
Washington, DC

Sharon Oxendine, Ph.D.
Office of Policy, Economics & Innovation
U.S. Environmental Protection Agency
Washington, DC

Torka Poet, Ph.D.
Battelle, Pacific Northwest National Laboratories (Appendix B)
902 Battelle Boulevard
Richland, WA

John Rogers, Ph.D.
National Health & Environmental Effects Research laboratory
U.S. Environmental Protection Agency
Research Triangle Park, NC

Reeder Sams, II, Ph.D.
National Center for Environmental Assessment
U.S. Environmental Protection Agency
Research Triangle Park, NC

Roy Smith, Ph.D.
Air Quality Planning & Standards
U.S. Environmental Protection Agency
Research Triangle Park, NC

Frank Stack
Alpha-Gamma Technologies, Inc.
3301 Benson Drive
Raleigh, NC

Justin TeeGuarden, Ph.D.
Battelle, Pacific Northwest National Laboratories
902 Battelle Boulevard
Richland, WA

Chad Thompson, Ph.D., MBA
National Center for Environmental Assessment
U.S. Environmental Protection Agency
Washington, DC

Cynthia VanLandingham, M.S.
ENVIRON International (Appendix E)
650 Poydras Street
New Orleans, LA

Deborah Wales
National Center for Environmental Assessment
U.S. Environmental Protection Agency
Research Triangle Park, NC

Lutz Weber, Ph.D., DABT
Oak Ridge Institute for Science and Education
Badger Road
Oak Ridge, TN

Errol Zeiger, Ph.D.
Alpha-Gamma Technologies, Inc.
3301 Benson Drive
Raleigh, NC

REVIEWERS

This document has been provided for review to EPA scientists and interagency reviewers from other federal agencies and White House offices.

INTERNAL EPA REVIEWERS

Jane Caldwell, Ph.D.
National Center for Environmental Assessment
U.S Environmental Protection Agency
Washington, DC

Ila Cote, Ph.D., DABT
National Center for Environmental Assessment
U.S Environmental Protection Agency
Washington, DC

Robert Dewoskin Ph.D., DABT
National Center for Environmental Assessment
U.S Environmental Protection Agency
Research Triangle Park, NC

Joyce Donahue, Ph.D.
Office of Water
U.S. Environmental Protection Agency
Washington, DC

Marina Evans, Ph.D.
National Health and Environmental Effects Research Laboratory
U.S Environmental Protection Agency
Research Triangle Park, NC

Lynn Flowers, Ph.D., DABT
National Center for Environmental Assessment
U.S Environmental Protection Agency
Research Triangle Park, NC

Brenda Foos, M.S.
Office of Children's Health Protection and Environmental Education
U.S Environmental Protection Agency
Washington, DC

Jennifer Jinot, Ph.D.
National Center for Environmental Assessment
U.S Environmental Protection Agency
Washington, DC

Eva McLanahan, Ph.D.
National Center for Environmental Assessment
U.S Environmental Protection Agency
Research Triangle Park, NC

John Vandenberg, Ph.D.
National Center for Environmental Assessment
U.S Environmental Protection Agency
Research Triangle Park, NC

Debra Walsh, M.S.
National Center for Environmental Assessment
U.S Environmental Protection Agency
Research Triangle Park, NC

1. INTRODUCTION

1   This document presents background information and justification for the Integrated Risk
2   Information System (IRIS) Summary of the hazard and dose-response assessment of methanol.
3   IRIS Summaries may include oral reference dose (RfD) and inhalation reference concentration
4   (RfC) values for chronic and other exposure durations, and a carcinogenicity assessment.

5   The RfD and RfC, if derived, provide quantitative information for use in risk assessments
6   for health effects known or assumed to be produced through a nonlinear (presumed threshold)
7   mode of action (MOA). The RfD (expressed in units of milligrams per kilogram per day
8   [mg/kg-day]) is defined as an estimate (with uncertainty spanning perhaps an order of
9   magnitude) of a daily exposure to the human population (including sensitive subgroups) that is
10   likely to be without an appreciable risk of deleterious effects during a lifetime. The inhalation
11   RfC (expressed in units of milligrams per cubic meter [mg/m^3]) is analogous to the oral RfD but
12   provides a continuous inhalation exposure estimate. The inhalation RfC considers toxic effects
13   for both the respiratory system (portal-of-entry) and for effects peripheral to the respiratory
14   system (extrarespiratory or systemic effects). Reference values are generally derived for chronic
15   exposures (up to a lifetime), but may also be derived for acute ($\leq$ 24 hours), short-term
16   (>24 hours up to 30 days), and subchronic (>30 days up to 10% of lifetime) exposure durations,
17   all of which are derived based on an assumption of continuous exposure throughout the duration
18   specified. Unless specified otherwise, the RfD and RfC are derived for chronic exposure
19   duration.

20   The carcinogenicity assessment provides information on the carcinogenic hazard
21   potential of the substance in question, and quantitative estimates of risk from oral and inhalation
22   exposure may be derived. The information includes a weight-of-evidence (WOE) judgment of
23   the likelihood that the agent is a human carcinogen and the conditions under which the
24   carcinogenic effects may be expressed. Quantitative risk estimates may be derived from the
25   application of a low-dose extrapolation procedure. If derived, the oral slope factor is a plausible
26   upper bound on the estimate of risk per mg/kg-day of oral exposure. Similarly, an inhalation unit
27   risk (IUR) is a plausible upper bound on the estimate of risk per microgram per cubic meter
28   (μg/m^3) air breathed.

29   Development of these hazard identification and dose-response assessments for methanol
30   has followed the general guidelines for risk assessment as set forth by the National Research
31   Council (NRC) (1983, 194806). EPA Guidelines and Risk Assessment Forum Technical Panel
32   Reports that may have been used in the development of this assessment include the following:
33   *Guidelines for the Health Risk Assessment of Chemical Mixtures* (U.S. EPA, 1986, 001468),

Guidelines for Mutagenicity Risk Assessment (U.S. EPA, 1986, 001466), *Recommendations for and Documentation of Biological Values for Use in Risk Assessment* (U.S. EPA, 1988, 064560), *Guidelines for Developmental Toxicity Risk Assessment* (U.S. EPA, 1991, 008567), *Interim Policy for Particle Size and Limit Concentration Issues in Inhalation Toxicity Studies* (U.S. EPA, 1994, 076133), *Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry* (U.S. EPA, 1994, 006488), *Use of the Benchmark Dose Approach in Health Risk Assessment* (U.S. EPA, 1995, 005992), *Guidelines for Reproductive Toxicity Risk Assessment* (U.S. EPA, 1996, 030019), *Guidelines for Neurotoxicity Risk Assessment* (U.S. EPA, 1998, 030021), *Science Policy Council Handbook*: *Risk Characterization* (U.S. EPA, 2000, 052149), *Benchmark Dose Technical Guidance Document (U.S. EPA, 2000, 052150)*, *Supplementary Guidance for Conducting Health Risk Assessment of Chemical Mixtures* (U.S. EPA, 2000, 004421), *A Review of the Reference Dose and Reference Concentration Processes* (U.S. EPA, 2002, 088824), *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005, 194126), *Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens* (U.S. EPA, 2005, 088823), *Science Policy Council Handbook: Peer Review* (U.S. EPA, 2006, 194566), and *A Framework for Assessing Health Risks of Environmental Exposures to Children* (U.S. EPA, 2006, 194567).

The literature search strategy employed for this compound was based on the Chemical Abstracts Service Registry Number (CASRN) and at least one common name. Any pertinent scientific information submitted by the public to the IRIS Submission Desk was also considered in the development of this document. The relevant literature was reviewed through January, 2009.

2. CHEMICAL AND PHYSICAL INFORMATION

1   Methanol is also known as methyl alcohol, wood alcohol; Carbinol; Methylol; colonial

2   spirit; columbian spirit; methyl hydroxide; monohydroxymethane; pyroxylic spirit; wood

3   naphtha; and wood spirit. Some relevant physical and chemical properties are listed in Table 2-1

4   below (HSDB, 2009, 200738; IPCS, 1997, 196253).

Table 2-1. Relevant physical and chemical properties of methanol

CASRN:	67-56-1
Empirical formula:	CH_3OH
Molecular weight:	32.04
Vapor pressure:	160 mmHg at 30 ^{o}C
Vapor Density:	1.11
Specific gravity:	0.7866 g/mL (25 ^{o}C)
Boiling point:	64.7 ^{o}C
Melting point:	-98 ^{o}C
Water solubility:	Miscible
Log octanol-water partition coefficient:	-0.82 to -0.68
Conversion factor (in air):	1 ppm = 1.31 mg/m^3; 1 mg/m^3 = 0.763 ppm

5   Methanol is a clear, colorless liquid that has an alcoholic odor (IPCS, 1997, 196253).

6   Endogenous levels of methanol are present in the human body as a result of both metabolism[1]

7   and dietary sources such as fruit, fruit juices, vegetables and alcoholic beverages,[2] and can be

8   measured in exhaled breath and body fluids (CERHR, 2004, 091201; IPCS, 1997, 196253;

9   Turner et al., 2006, 196733). Dietary exposure to methanol also occurs through the intake of

---

[1] Methanol is generated metabolically through enzymatic pathways such as the methyltransferase system (Fisher et al., 2000, 009750).

[2] Fruits and vegetables contain methanol. Further, ripe fruits and vegetables contain natural pectin, which is degraded to methanol in the body by bacteria present in the colon (Siragusa et al., 1988, 031610). Increased levels of methanol in blood and exhaled breath have also been observed after the consumption of ethanol (Fisher et al., 2000, 009750).

some food additives. The artificial sweetener aspartame and the beverage yeast inhibitor dimethyl dicarbonate (DMDC) release methanol as they are metabolized (Steginck et al., 1989, 031945). In general, aspartame exposure does not contribute significantly to the background body burden of methanol (Butchko et al., 2002, 034722). Oral, dermal, or inhalation exposure to methanol in the environment, consumer products, or workplace also occur.

Methanol is a high production volume chemical with many commercial uses and it is a basic building block for hundreds of chemical products. Many of its derivatives are used in the construction, housing or automotive industries. Consumer products that contain methanol include varnishes, shellacs, paints, windshield washer fluid, antifreeze, adhesives, de-icers, and Sterno heaters. In 2009, the Methanol Institute (2009, 200739) estimated a global production capacity for methanol of about 35 million metric tons per year (close to 12 billion gallons), a production capacity in the United States (U.S.) of nearly 3.7 million metric tons (1.3 billion gallons), and a total U.S. demand for methanol of over 8 million metric tons. Methanol is among the highest production volume chemicals reported in the U.S. EPA's Toxic Release Inventory (TRI).[3] It is among the top chemicals on the 2008 TRI lists of chemicals with the largest total on-site and off-site recycling (6th), energy recovery (2nd) and treatment (1st) (U.S. EPA, 2009, 200741). TRI also reports that approximately 135,000,000 pounds of methanol was released or disposed of in the United States in 2008, making methanol among the top five chemicals on the list entitled "TRI On-site and Off-site Reported Disposed of or Otherwise Released in pounds for facilities in All Industries for Hazardous Air Pollutant Chemicals U.S. 2008" (U.S. EPA, 2009, 200742).

While production has switched to other regions of the world, demand for methanol is growing steadily in almost all end uses. A large reason for the increase in demand is its use in the production of biodiesel, a low-sulfur, high-lubricity fuel source. Global demand for biodiesel is forecast to increase by 32% per year, rising from 30 million gallons in 2004, to 150 million gallons by 2008, and to 350 million gallons by 2013.(Methanol Institute, 2009, 200744). Power generation and fuel cells could also be large end users of methanol in the near future (Methanol Institute, 2009, 200739).

---

[3] The information in TRI does not indicate whether (or to what degree) the public has been exposed to toxic chemicals. Therefore, no conclusions on the potential risks can be made based solely on this information (including any ranking information). For more detailed information on this subject refer to The Toxics Release Inventory (TRI) and Factors to Consider When Using TRI Data (U.S. EPA, 2009, 200746).

3. TOXICOKINETICS

3.1. OVERVIEW

1   As has been noted, methanol occurs naturally in the human body as a product of
2 metabolism and through intake of fruits, vegetables, and alcoholic beverages (CERHR, 2004,
3 091201; IPCS, 1997, 196253; Turner et al., 2006, 196733). Table 3-1 summarizes background
4 blood methanol levels in healthy humans which were found to range from 0.25-4.7 mg/L. One
5 study reported a higher background blood methanol level in females versus males (Batterman
6 and Franzblau, 1997, 056331), but most studies did not evaluate gender differences. Formate, a
7 metabolite of methanol, also occurs naturally in the human body (IPCS, 1997, 196253). Table 3-
8 1 outlines background levels of formate in human blood. In most cases, methanol and formate
9 blood levels were measured in healthy adults following restriction of methanol-producing foods
10 from the diet.[4]

11   The absorption, excretion, and metabolism of methanol are well known and have been
12 consistently summarized in reviews such as CERHR (2004, 091201), IPCS (1997, 196253), U.S.
13 EPA (1996, 030019), Kavet and Nauss (1990, 032274), HEI (1987, 031207), and Tephly and
14 McMartin (1984, 031035). Therefore, the major portion of this toxicokinetics overview is based
15 upon those reviews.

16   Studies conducted in humans and animals demonstrate rapid absorption of methanol by
17 inhalation, oral, and dermal routes of exposure. Table 3-2 outlines increases in human blood
18 methanol levels following various exposure scenarios. Blood levels of methanol following
19 various exposure conditions have also been measured in monkeys, mice, and rats, and are
20 summarized in Tables 3-3, 3-4, and 3-5, respectively. Once absorbed, methanol pharmacokinetic
21 (PK) data and physiologically based pharmacokinetic (PBPK) model predictions indicate rapid
22 distribution to all organs and tissues according to water content, as an aqueous-soluble alcohol.
23 Tissue:blood concentration ratios for methanol are predicted to be similar through different
24 exposure routes, though the kinetics will vary depending on exposure route and timing (e.g.,
25 bolus oral exposure versus longer-term inhalation). Because smaller species generally have
26 faster respiration rates relative to body weight than larger species, they are predicted to have a
27 higher rate of increase of methanol concentrations in the body when exposed to the same
28 concentration in air.

---

[4] In general, background levels among people who are on normal/non-restricted diets will be higher than those
reported.

Table 3-1. Background blood methanol and formate levels in humans

Description of human subjects	Methanol (mg/L) mean ± S.D. (Range)	Formate (mg/L) mean ± S.D. (Range)	Reference
12 males on restricted diet (no methanol-containing or methanol-producing foods) for 12 hr	0.570 ± 0.305 (0.25-1.4)	3.8 ± 1.1 (2.2-6.6)	Cook et al. (1991, 032367)
22 adults on restricted diet (no methanol-containing or methanol-producing foods) for 24 hr	1.8 ± 2.6 (No range data)	11.2 ± 9.1 (No range data)	Osterloh et al. (1996, 056314); Chuwers et al. (1995, 081298)
3 males who ate a breakfast with no aspartame-containing cereals and no juice	1.82 ± 1.21 (0.57-3.57)	9.08 ± 1.26 (7.31-10.57)	Lee et al. (1992, 032629)
5 males who ate a breakfast with no aspartame-containing cereals and no juice (second experiment)	1.93 ± 0.93 (0.54-3.15)	8.78 ± 1.82 (5.36-10.83)	Lee et al. (1992, 032629)
Adults who drank no alcohol for 24 hr	1.8 ± 0.7 (No range data)	No data	Batterman et al.(1998, 086797)
12 adults who drank no alcohol for 24 hr	1.7 ± 0.9 (0.4-4.7)	No data	Batterman and Franzblau (1997, 056331)
4 adult males who fasted for 8 hr, drank no alcohol for 24 hr, and took in no fruits, vegetables, or juices for 18 hr	No mean data (1.4-2.6)	No data	Davoli et al. (1986, 056313)
30 fasted adults	<4 (No range data)	19.1 (No range data)	Stegink et al. (1981, 030982)
24 fasted infants	<3.5 (No range data)	No data	Stegink et al. (1983, 056316)

Source: CERHR (2004, 091201).

Table 3-2. Human blood methanol and formate levels following methanol exposure

Human subjects; type of sample collected [b,c]	Exposure route	Exposure duration or method	Methanol exposure concentration	Blood methanol mean or range (mg/L)	Blood formate mean or range (mg/L)	Reference
Adult males and females administered aspartame; peak methanol level and range of formate levels up to 24 hr after dosing	Oral	1 dose in juice	0 3.4 mg/kg bw[a] 10 mg/kg bw[a] 15 mg/kg bw[a] 20 mg/kg bw[a]	 <4 12.7 21.4 25.8	19.1 No data No data No data 8.4–22.8	Stegink et al. (1981, 030982)
Infants administered aspartame; peak exposure level	Oral	1 dose in beverage	0 3.4 mg/kg bw[a] 5 mg/kg bw[a] 10 mg/kg bw[a]	 <3.5 3.0 10.2	No data	Stegink et al. (1983, 056316)
Adult males administered aspartame; range of peak serum methanol levels in all subjects	Oral	1 dose in water	0 0.6 – 0.87 mg/kg bw[a]	1.4–2.6 2.4–3.6	No data	Davoli et al. (1986, 056313)
Males; post exposure samples	Inhalation	75 min	0 191 ppm	0.570 1.881	3.8 3.6	Cook et al. (1991, 032367)
Males and females; post exposure serum levels	Inhalation	4 hr	0 200 ppm	1.8 6.5	11.2 14.3	Osterloh et al. (1996, 056314)

Human subjects; type of sample collected [b,c]	Exposure route	Exposure duration or method	Methanol exposure concentration	Blood methanol mean or range (mg/L)	Blood formate mean or range (mg/L)	Reference
Males without exercise; post exposure blood methanol and plasma formate	Inhalation	6 hr	0 200 ppm	1.82 6.97	9.08 8.70	Lee et al. (1992, 032629)
Males with exercise; post exposure blood methanol and plasma formate	Inhalation	6 hr	0 200 ppm	1.93 8.13	8.78 9.52	
Females; post exposure samples	Inhalation	8 hr	0 800 ppm	1.8 30.7	No data	Batterman et al. (1998, 086797)

[a]Methanol doses resulting from intake of aspartame.
[b]Unless otherwise specified, it is assumed that whole blood was used for measurements.
[c]Information about dietary restrictions is included in Table 3-1.

Source: CERHR (2004, 091201).

Table 3-3. Monkey blood methanol and formate levels following methanol exposure

Strain-sex	Exposure route	Exposure duration	Methanol exposure concentration	Blood methanol mean in mg/L	Blood formate mean in mg/L	Reference
Monkey; Cynomolgus; female; mean blood methanol and range of plasma formate at 30 min post daily exposure during premating, mating, and pregnancy	Inhalation	2.5 hr/day, 7days/wk during premating, mating, and gestation (348 days)	0 200 ppm 600 ppm 1,800 ppm	2.4 5 11 35	8.7 8.7 8.7 10	Burbacher et al. (1999, 009752; 2004, 056018)
Monkey; Rhesus male; post exposure blood level	Inhalation	6 hr	200 ppm 1,200 ppm 2,000 ppm	3.9 37.6 64.4	5.4-13.2 at all doses	Horton et al. (1992, 196222)

Source: CERHR (2004, 091201).

Table 3-4. Mouse blood methanol and formate levels following methanol exposure

Species/strain/sex	Exposure route	Exposure duration	Methanol exposure concentration	Blood methanol mean (mg/L)	Blood formate mean (mg/L)	Reference
Mouse;CD-1;female; post exposure plasma methanol and peak formate level	Inhalation	6 hr on GD8	10,000 ppm 10,000 ppm + 4-MP 15,000 ppm	2,080 2,400 7,140	28.5 23 34.5	Dorman et al. (1995, 078081)
Mouse;CD-1;female; post exposure blood methanol level	Inhalation	8 hr	2,500 ppm 5,000 ppm 10,000 ppm 15,000 ppm	1,883 3,580 6,028 11,165	No data	Pollack and Brouwer (1996, 079812); Perkins et al. (1995, 085259)
Mouse;CD-1;female; mean post exposure plasma methanol level	Inhalation	7 hr/day on GD6–GD15	0 1,000 ppm 2,000 ppm 5,000 ppm 7,500 ppm 10,000 ppm 15,000 ppm	1.6 97 537 1,650 3,178 4,204 7,330	No data	Rogers et al. (1993, 032696)
Mouse;CD-1;female; plasma level 1 hr post dosing	Oral-Gavage	GD6–GD15	4,000 mg/kg bw	3,856	No data	
Mouse;CD-1;female; peak plasma level	Oral-Gavage	GD8	1,500 mg/kg bw 1,500 mg/kg bw + 4-MP	1,610 1,450	35 43	Dorman et al. (1995, 078081)

4-MP=4-methylpyrazole

Source: CERHR (2004, 091201).

Table 3-5. Rat blood methanol and formate levels following methanol exposure

Species;strain/sex: type of sample collected	Exposure route	Exposure duration	Methanol exposure concentration	Blood methanol level in mg/L	Blood formate level in mg/L	Reference
Rat;Sprague-Dawley; female; post exposure blood methanol level on 3 days	Inhalation	7 hr/day for 19 days	5,000 ppm 10,000 ppm 20,000 ppm	1,000–2,170 1,840–2,240 5,250–8,650	No data	Nelson et al. (1985, 064573)
Rat;Sprague-Dawley; female; post exposure blood methanol level	Inhalation	8 hr	1,000 ppm 5,000 ppm 10,000 ppm 15,000 ppm 20,000 ppm	83 1,047 1,656 2,667 3,916	No data	Pollack and Brouwer (1996, 079812); Perkins et al. (1995, 085259)
Rat;LongEvans;female; post exposure plasma level on GD7-GD12	Inhalation	7 hr/day on GD7-GD19	0 15,000 ppm	2.7–1.8 3,826–3,169	No data	Stanton et al. (1995, 085231)
Rat;LongEvans;female; 1 hr post exposure blood level	Inhalation	6 hr/day on GD6-PND21	4,500 ppm	555	No data	Weiss et al. (1996, 079211)
Rat;Long-Evans;male and female; 1 hr post exposure blood level in pups	Inhalation	6 hr/day on PND1-PND21	4,500 ppm	1,260	No data	
Rat/Fischer-344/male; post exposure blood level	Inhalation	6 hr	200 ppm 1,200 ppm 2,000 ppm	3.1 26.6 79.7	5.4–13.2 at all doses	Horton et al. (1992, 196222)
Rat;Long-Evans;male; post- exposure serum level	Inhalation	6 hr	200 ppm 5,000 ppm 10,000 ppm	7.4 680–873 1,468	No data	Cooper et al. (1992, 196348)
Rat/Fischer-344/male; 25 min post exposure blood level for 4-wk animals; ~250 min post exposure for 104-wk animals	Inhalation	19.5 hr/day for 4/104 wk	0 ppm 10 ppm 100 ppm 1,000 ppm	4.01 / 3.78 1.56 / 3.32 3.84 / 3.32 53.59 / 12.08	No data	NEDO (2008, 196316)
Rat/Fischer-344/ female; 25 min post exposure blood level for 4-wk animals; ~250 min post exposure for 104-wk animals	Inhalation	19 hr/day for 4/104 wk	0 ppm 10 ppm 100 ppm 1,000 ppm	13.39 / 3.60 6.73 / 3.70 4.34 / 4.32 88.33 / 8.50	No data	NEDO (2008, 196316)
Rat;Long-Evans;male; peak blood formate level	Inhalation	6 hr	0 FS 0 FS 1,200 ppm-FS 1,200 ppm-FR 2,000 ppm-FS 2,000 ppm-FR	No data	8.3 10.1 8.3 46 8.3 83	Lee et al. (1994, 032712)

Species;strain/sex: type of sample collected	Exposure route	Exposure duration	Methanol exposure concentration	Blood methanol level in mg/L	Blood formate level in mg/L	Reference
Rat;Long-Evans;male; peak blood methanol and formate	Oral-gavage	Single dose	3,500 mg/kg bw-FS 3,500 mg/kg bw-FP 3,500 mg/kg bw-FR 3,000 mg/kg bw/day-FS 3,000 mg/kg bw/day FR 2,000 mg/kg bw/day FS 2,000 mg/kg bw/day FR	4,800 4,800 4,800 No data	Baseline level 382 860 9.2 718 9.2 538	Lee et al. (1994, 032712)

FS = Folate sufficient; FR = Folate reduced; FP = Folate paire

Source: CERHR (2004, 091201).

1   At doses that do not saturate metabolic pathways, a small percentage of methanol is
2 excreted directly in urine. Because of the high blood:air partition coefficient for methanol and
3 rapid metabolism in all species studied, the bulk of clearance occurs by metabolism, though
4 exhalation and urinary clearance become more significant when doses or exposures are
5 sufficiently high to saturate metabolism (subsequently in this document, "clearance" refers to
6 elimination by all routes, including metabolism, as indicated by the decline in methanol blood
7 concentrations.) Metabolic saturation and the corresponding clearance shift have not been
8 observed in humans and nonhuman primates because doses used were limited to the linear range,
9 but the enzymes involved in primate metabolism are also saturable.

10   The primary route of methanol elimination in mammals is through a series of oxidation
11 reactions that form formaldehyde, formate, and carbon dioxide (Figure 3-1). As noted in
12 Figure 3-1, methanol is converted to formaldehyde by alcohol dehydrogenase-1 (ADH1) in
13 primates and by catalase (CAT) and ADH1 in rodents. Although the first step of metabolism
14 occurs through different pathways in rodents and nonhuman primates, Kavet and Nauss (1990,
15 032274) report that the reaction proceeds at similar rates (V_{max} = 30 and 48 mg/h/kg in rats and
16 nonhuman primates, respectively). In addition to enzymatic metabolism, methanol can react
17 with hydroxyl radicals to spontaneously yield formaldehyde (Harris et al., 2003, 047369).
18 Mannering et al. (1969, 031429) also reported a similar rate of methanol metabolism in rats and
19 monkeys, with 10 and 14% of a 1 g/kg dose oxidized in 4 hours, respectively; the rate of
20 oxidation by mice was about twice as fast, 25% in 4 hours. In an HEI study by Pollack and
21 Brouwer (1996, 079812), the metabolism of methanol was 2 times as fast in mice versus rats,
22 with a V_{max} for elimination of 117 and 60.7 mg/h/kg, respectively. Despite the faster elimination
23 rate of methanol in mice versus rats, mice consistently exhibited higher blood methanol levels

than rats when inhaling equivalent methanol concentrations (See Tables 3-4 and 3-5). Possible explanations for the higher methanol accumulation in mice include faster respiration (inhalation rate/body weight) and increased fraction of absorption by the mouse (Perkins et al., 1995, 085259). Because smaller species generally have faster breathing rates than larger species, humans would be expected to absorb methanol via inhalation more slowly than rats or mice inhaling equivalent concentrations. If humans eliminate methanol at a comparable rate to rats and mice, then humans would also be expected to accumulate less methanol than those smaller species. However, if humans eliminate methanol more slowly than rats and mice, such that the ratio of absorption to elimination stays the same, then humans would be expected to accumulate methanol to the same internal concentration but to take longer to reach that concentration.

In all species, formaldehyde is rapidly converted to formate, with the half-life for formaldehyde being ~1 minute. Formaldehyde is oxidized to formate by two metabolic pathways (Teng et al., 2001, 017289). The first pathway (not shown in Figure 3-1) involves conversion of free formaldehyde to formate by the so-called low-affinity pathway (affinity = $1/K_m = 0.002/\mu M$) mitochondrial aldehyde dehydrogenase-2 (ALDH2). The second pathway (Figure 3-1) involves a two-enzyme system that converts glutathione-conjugated formaldehyde (*S*-hydroxymethylglutathione [HMGSH]) to the intermediate *S*-formylglutathione, which is subsequently metabolized to formate and glutathione (GSH) by *S*-formylglutathione hydrolase.[5] The first enzyme in this pathway, formaldehyde dehydrogenase-3 (ADH3), is rate limiting, and the affinity of HMGSH for ADH3 (affinity = $1/K_m = 0.15/\mu M$) is about a 100-fold higher than that of free formaldehyde for ALDH2. In addition to the requirement of GSH for ADH3 activity, oxidation by ADH3 is nicotinamide adenine dinucleotide- (NAD^+-)dependent. Under normal physiological conditions NAD^+ levels are about two orders of magnitude higher than NADH, and intracellular GSH levels (mM range) are often high enough to rapidly scavenge formaldehyde (Meister and Anderson, 1983, 001404; Svensson et al., 1999, 196732); thus, the oxidation of HMGSH is favorable. In addition, genetic ablation of ADH3 results in increased formaldehyde toxicity (Deltour et al., 1999, 056397). These data indicate that ADH3 is likely to be the predominant enzyme responsible for formaldehyde oxidation at physiologically relevant concentrations, whereas ALDHs likely contribute to formaldehyde elimination at higher concentrations (Dicker and Cedebaum, 1986, 196741).

---

[5] Other enzymatic pathways for the oxidation of formaldehyde have been identified in other organisms, but this is the pathway that is recognized as being present in humans (Caspi et al. (2006, 196186); http://metacyc.org)

	CH₃OH (Methanol)	

Primates　　　　　CH₃OH (Methanol)　　　　　**Rodents**

Alcohol dehydrogenase
(ADH1)

↓
HCHO
(Formaldehyde)

Catalase (CAT) and ADH1

↓(+ GSH)

HMGSH
(hydroxymethyl-GSH)

Formaldehyde dehydrogenase
(ADH3)

↓
(*S*-formyl glutathione)

Formaldehyde dehydrogenase
(ADH3)

↓(- GSH)

S-formylglutathione hydrolase

Folate dependent pathway

(see Figure 3-2)

HCOO (Formate)

↓
↓

CO₂ (Carbon dioxide)

S-formylglutathione hydrolase

CAT-peroxide and

Folate-dependent pathway

(see Figure 3-2)

Figure 3-1. Methanol metabolism and key metabolic enzymes in primates and rodents.

Source: IPCS (1997, 196253).

Rodents convert formate to carbon dioxide (CO_2) through a folate-dependent enzyme system and a CAT-peroxide system (Dikalova et al., 2001, 196742). Formate can undergo adenosine triphosphate- (ATP-) dependent addition to tetrahydrofolate (THF), which can carry either one or two one-carbon groups. Formate can conjugate with THF to form N^{10}-formyl-THF and its isomer N^5-formyl-THF, both of which can be converted to N^5, N^{10}-methenyl-THF and subsequently to other derivatives that are ultimately incorporated into DNA and proteins via biosynthetic pathways (Figure 3-2). There is also evidence that formate generates CO_2^- radicals, and can be metabolized to CO_2 via CAT and via the oxidation of N^{10}-formyl-THF (Dikalova et al., 2001, 196742).

Cytoplasm

Mitochondria

10-formyl**THF**   10-formyl**THF** ⟹ **PURINES**

MTHFD1

FDH

formate ⇌ formate

CO_2 methenyl**THF**

methenyl**THF**   **THF**   **THF**

serine ⇌ serine   *cSHMT*

mSHMT

methylene**THF**   glycine ⇌ glycine   methylene**THF** ⟹ **dTMP**

MTHFR

5-methyl**THF**

MS

homocysteine   **Methionine**

AdoHyc

AdoMet

Figure 3-2. Folate-dependent formate metabolism. Tetrahydrofolate (THF)-mediated one carbon metabolism is required for the synthesis of purines, thymidylate, and methionine.

Unlike rodents, formate metabolism in primates occurs solely through a folate-dependent pathway. Black et al. (1985, 094937) reported that hepatic THF levels in monkeys are 60% of that in rats, and that primates are far less efficient in clearing formate than are rats and dogs. Studies involving [^{14}C]formate suggest that ~80% is exhaled as $^{14}CO_2$, 2-7% is excreted in the urine, and ~10% undergoes metabolic incorporation (Hanzlik et al., 2005, 030632, and references therein). Mice deficient in formyl-THF dehydrogenase exhibit no change in LD_{50} (via intraperitoneal [i.p.]) for methanol or in oxidation of high doses of formate. Thus it has been suggested that rodents efficiently clear formate via folate-dependent pathways, peroxidation by CAT, and by an unknown third pathway; conversely, primates do not appear to exhibit such capacity and are more sensitive to metabolic acidosis following methanol poisoning (Cook et al., 2001, 019564).

Blood methanol and formate levels measured in humans under various exposure scenarios are reported in Table 3-2. As noted in Table 3-2, 75-minute to 6-hour exposures of healthy humans to 200 parts per million (ppm) methanol vapors, the American Council of Governmental Industrial Hygienists (ACGIH) threshold limit value (TLV) for occupational exposure (ACGIH, 2000, 002886), results in increased levels of blood methanol but not formate.

A limited number of monitoring studies indicate that levels of methanol in outdoor air are orders of magnitude lower than the TLV (IPCS, 1997, 196253). Table 3-3 indicates that exposure of monkeys to 600 ppm methanol vapors for 2.5 hours increased blood methanol but not blood formate levels. Normal dietary exposure to aspartame, which releases 10% methanol during metabolism, is unlikely to significantly increase blood methanol or formate levels (Butchko et al., 2002, 034722). Data in Table 3-2 suggest that exposure to high concentrations of aspartame is unlikely to increase blood formate levels; no increase in blood formate levels were observed in adults ingesting "abusive doses" (100-200 mg/kg) of aspartame (Stegink et al., 1981, 030982). Kerns et al. (2002, 035438) studied the kinetics of formate in 11 methanol-poisoned patients (mean initial methanol level of 57.2 mmol/L or 1.83 g/L) and determined an elimination half-life of 3.4 hours for formate. Kavet and Nauss (1990, 032274) estimated that a methanol dose of 11 mM or 210 mg/kg is needed to saturate folate-dependent metabolic pathways in humans. There are no data on blood methanol and formate levels following methanol exposure of humans with reduced ADH activity or marginal folate tissue levels, a possible concern regarding sensitive populations. As discussed in greater detail in Section 3.2, a limited study in folate-deficient monkeys demonstrated no increase in blood formate levels following exposure to 900 ppm methanol vapors for 2 hours. In conclusion, limited available data suggest that typical occupational, environmental, and dietary exposures are likely to increase baseline blood methanol but not formate levels in most humans.

3.2. KEY STUDIES

Some recent toxicokinetic and metabolism studies (Burbacher et al., 1999, 009753; Burbacher et al., 2004, 059070; Dorman et al., 1994, 196743; Medinsky et al., 1997, 084177; Pollack and Brouwer, 1996, 079812) provide key information on interspecies differences, methanol metabolism during gestation, metabolism in the nonhuman primate, and the impact of folate deficiency on the accumulation of formate.

As part of an effort to develop a physiologically based toxicokinetic model for methanol distribution in pregnancy, Pollack and Brouwer (1996, 079812) conducted a large study that compared toxicokinetic differences in pregnant and nonpregnant (NP) rats and mice. Methanol disposition[6] was studied in Sprague-Dawley rats and CD-1 mice that were exposed to 100-2,500 mg/kg of body weight pesticide-grade methanol in saline by intravenous (i.v.) or oral routes. Exposures were conducted in NP rats and mice, pregnant rats on gestation days (GD)7, GD14, and GD20, and pregnant mice on GD9 and GD18. Disposition was also studied in

---

[6] Methanol concentrations in whole blood and urine were determined by gas chromatography with flame ionization detection (Pollack and Kawagoe, 1991, 032412)

pregnant rats and mice exposed to 1,000-20,000 ppm methanol vapors for 8 hours. Three to five animals were examined at each dose and exposure condition.

Based on the fit of various kinetic models to methanol measurements taken from all routes of exposure, the authors concluded that high exposure conditions resulted in nonlinear disposition of methanol in mice and rats.[7] Both linear and nonlinear pathways were observed with the relative contribution of each pathway dependent on concentration. At oral doses of 100-500 mg/kg of body weight, methanol was metabolized to formaldehyde and then formic acid through the saturable nonlinear pathway. A parallel, linear route characteristic of passive-diffusion accounted for an increased fraction of total elimination at higher concentrations. Nearly 90% of methanol elimination occurred through the linear route at the highest oral dose of 2,500 mg/kg of body weight.

Oral exposure resulted in rapid and essentially complete absorption of methanol. No significant change in blood area under the curve (AUC) methanol was seen between NP and GD7, GD14 and GD20 rats exposed to single oral gavage doses of 100 and 2,500 mg/kg, nor between NP and GD9 and GD18 mice at 2,500 mg/kg. The data as a whole suggested that the distribution of orally and i.v. administered methanol was similar in rats versus mice and in pregnant rodents versus NP rodents with the following exceptions:

- There was a statistically significant increase in the ratio of apparent volume of distribution (Vd) to fractional bioavailability (F) by ~20% (while F decreased but not significantly), between NP and GD20 rats exposed to 100 mg/kg orally. However, this trend was not seen in rats or mice exposed to 2,500 mg/kg, and the result in rats at 100 mg/kg could well be a statistical artifact since both Vd and F were being estimated from the same data, making the model effectively over-parameterized.
- There were statistically significant decreases in the fraction of methanol absorbed by the fast process (resulting in a slower rise to peak blood concentrations, though the peak is unchanged) and in the Vmax for metabolic elimination between NP and GD18 mice. No such differences were observed between NP and GD9 mice.
- The authors estimated a twofold higher Vmax for methanol elimination in mice versus rats following oral administration of 2,500 mg/kg methanol, suggesting that similar oral doses would result in lower methanol concentrations in the mouse versus rat.

---

[7] A model incorporating parallel linear and nonlinear routes of methanol clearance was required to fit the data from the highest exposure groups.

1   Methanol penetration from maternal blood to the fetal compartment was examined in

2   GD20 rats by microdialysis.[8] A plot of the amniotic concentration versus maternal blood

3   concentration (calculated from digitization of Figure 17 of Pollack and Brouwer (1996, 079812)

4   report) is shown in Figure 3-3. The ratio is slightly less than 1:1 (dashed line in plot) and

5   appears to be reduced with increasing methanol concentrations, possibly due to decreased blood

6   flow to the fetal compartment. Nevertheless, this is a very minor departure from linearity,

7   consistent with a substrate such as methanol that penetrates cellular membranes readily and

8   distributes throughout total body water.

The plot shows the equation $y = -4E\text{-}05x^2 + 1.0782x$ with $R^2 = 0.9919$.

Figure 3-3. Plot of fetal (amniotic) versus maternal methanol concentrations in GD20 rats. Note: Data extracted from Figure 17 by digitization, and amniotic concentration obtains as ("Fetal Amniotic Fluid/Maternal Blood Methanol")×("Maternal Methanol").

Source: Pollack and Brouwer (1996, 079812).

9   Inhalation exposure resulted in less absorption in both rats and mice as concentrations of

10   methanol vapors increased, which was hypothesized to be due to decreased breathing rate and

11   decreased absorption efficiency from the upper respiratory tract.[9] Based on blood methanol

---

[8] Microdialysis was conducted by exposing the uterus (midline incision), selecting a single fetus in the middle of the uterine horn and inserting a microdialysis probe through a small puncture in the uterine wall proximal to the head of the fetus.

[9] Exposed mice spent some exposure time in an active state, characterized by a higher ventilation rate, and the remaining time in an inactive state, with lower (~½ of active) ventilation. The inactive ventilation rate was

concentrations measured following 8-hour inhalation exposures to concentrations ranging from 1,000–20,000 ppm, the study authors (Pollack and Brouwer, 1996, 079812) concluded that methanol accumulation in the mouse occurred at a two- to threefold greater rate compared to the rat. They speculated that faster respiration rate and more complete absorption in the nasal cavity of mice may explain the higher methanol accumulation and greater sensitivity to certain developmental toxicity endpoints (see Section 4.3.2).

The Pollack and Brouwer (1996, 079812) study was useful for comparing effects in pregnant and NP rodents exposed to high doses, but the implication of these results for humans exposed to ambient levels of methanol is not clear (CERHR, 2004, 091201).

Burbacher et al. (1999, 009752; 2004, 056018) examined toxicokinetics in *Macaca fascicularis* monkeys prior to and during pregnancy. The study objectives were to assess the effects of repeated methanol exposure on disposition kinetics, determine whether repeated methanol exposures result in formate accumulation, and examine the effects of pregnancy on methanol disposition and metabolism. Reproductive, developmental and neurological toxicity associated with this study were also examined and are discussed in Sections 4.3.2 and 4.4.2. In a 2-cohort design, 48 adult females (6 animals/dose/group/cohort) were exposed to 0, 200, 600, or 1,800 ppm methanol vapors (99.9% purity) for 2.5 hours/day, 7 days/week for 4 months prior to breeding and during the entire breeding and gestation periods. Six-hour methanol clearance studies were conducted prior to and during pregnancy. Burbacher et al. (1999, 009752; 2004, 056018) reported that:

- At no point during pregnancy was there a significant change in endogenous methanol blood levels, which ranged from 2.2-2.4 mg/L throughout.
- PK studies were performed initially (Study 1), after 90 days of pre-exposure and prior to mating (Study 2), between GD66 and GD72 (Study 3), and again between GD126 and GD132 (Study 4). These studies were analyzed using classical PK (one-compartment) models.

---

unchanged by methanol exposure, but the active ventilation showed a statistically significant methanol-concentration-related decline. There was also some decline in the fraction of time spent in the active state, but this too was not statistically significant.

- Disproportionate mean, dose-normalized, and net blood methanol dose-time profiles in the 600 and 1,800 ppm groups suggested saturation of the metabolism-dependent pathway. Data from the 600 ppm group fit a linear model, while data from the 1,800 ppm group fit a Michaelis-Menten model.
- Methanol elimination rates modestly increased between Study 1 and Study 2 (90 days prior to mating). This change was attributed to enzyme induction from the subchronic exposure.
- Blood methanol levels were measured every 2 weeks throughout pregnancy, and while there was measurement-to-measurement variation, there was no significant change or trend over the course of pregnancy. There appears to be an upward trend in elimination half-life and corresponding downward trend in blood methanol clearance between Studies 2, 3, and 4. However, the changes are not statistically significant and the time-courses for blood methanol concentration (elimination phase) appear fairly similar.
- Significant differences between pre-breeding and gestational blood plasma formate levels were observed but were not dose dependent (Table 3-6).
- Significant differences in serum folate levels in periods prior to and during pregnancy were not dose dependent (Table 3-7).

Table 3-6. Plasma formate concentrations in monkeys

Exposure Group	Mean plasma formate level (mg/L) during each exposure period			
	Baseline	Pre-breeding	Breeding	Pregnancy
Control	8.3	7.8	10	8.3
200 ppm	7.4	8.3	9.7	7.8
600 ppm	6.9	7.8	9.2	8.7
1,800 ppm	6.4	8.7	11	10

Source: Burbacher et al. (1999, 009752).

Table 3-7. Serum folate concentrations in monkeys

Exposure Group	Mean serum folate level (µg/L) during each exposure period				
	Baseline	Day 70 Pre-pregnancy[a]	Day 98 Pre-pregnancy[a]	Day 55 Pregnancy[a]	Day 113 Pregnancy[a]
Control	14.4	14.0	13.4	16.0	15.6
200 ppm	11.9	13.2	12.9	15.5	13.4
600 ppm	12.5	15.4	13.4	14.8	16.4
1,800 ppm	12.6	14.8	15.3	15.9	15.7

[a]Number of days exposed to methanol

Source: Burbacher et al. (1999, 009752).

1 An HEI review committee (Burbacher et al., 1999, 009752) noted that this was a quality
2 study using a relevant species. Although the study can be used to predict effects in adequately
3 nourished individuals, the study may not be relevant to persons who are folate deficient.
4 A series of studies by Medinsky et al. (1997, 084177) and Dorman et al. (1994, 196743)
5 examined metabolism and pharmacokinetics of [14C]methanol and [14C]formate in normal and
6 folate-deficient cynomolgus, *M. fascicularis* monkeys that were exposed to environmentally
7 relevant concentrations of [14C]methanol through an endotracheal tube while anesthetized. In
8 the first stage of the study, 4 normal 12-year-old cynomolgus monkeys were each exposed to 10,
9 45, 200, and 900 ppm [14C]methanol vapors (>98% purity) for 2 hours. Each exposure was
10 separated by at least 2 months. After the first stage of the study was completed, monkeys were
11 given a folate-deficient diet supplemented with 1% succinylsulfathiozole (an antibacterial
12 sulfonamide used to inhibit folic acid biosynthesis from intestinal bacteria) for 6–8 weeks in
13 order to obtain folate concentrations of <3 ng/mL serum and <120 ng/mL erythrocytes. Folate
14 deficiency did not alter hematocrit level, red blood cell count, mean corpuscular volume, or
15 mean corpuscular hemoglobin level. The folate-deficient monkeys were exposed to 900 ppm
16 [14C]methanol for 2 hours. The results of the Medinsky et al. (1997, 084177) and Dorman et al.
17 (1994, 196743) studies showed:

18 ▪ Dose-dependent changes in toxicokinetics and metabolism did not occur as indicated by a
19   linear relationship between inhaled [14C]methanol concentration and end-of-exposure
20   blood [14C]methanol level, [14C]methanol AUC and total amounts of exhaled
21   [14C]methanol and [14C]carbon dioxide.
22 ▪ Methanol concentration had no effect on elimination half-life (<1 hour) and percent
23   urinary [14C]methanol excretion (<0.01%) at all doses.
24 ▪ Following exposure to 900 ppm methanol, urinary excretion or exhalation of
25   [14C]methanol did not differ significantly between monkeys in the folate sufficient and
26   deficient state. There was no significant [14C] formate accumulation at any dose.

- Peak blood [^{14}C]formate levels were significantly higher in folate-deficient monkeys, but did not exceed endogenous blood levels reported by the authors to be between 0.1 and 0.2 mmol/L (4.6-9.2 mg/L).

An HEI review committee (Medinsky et al., 1997, 084177) noted that absolute values in this study cannot be extrapolated to humans because the use of an endotracheal tube in anesthetized animals results in an exposure scenario that is not relevant to humans. However, the data in this study suggest that a single exposure to an environmentally relevant concentration of methanol is unlikely to result in a hazardous elevation in formate levels, even in individuals with moderate folate deficiency.

3.3. HUMAN VARIABILITY IN METHANOL METABOLISM

The ability to metabolize methanol may vary among individuals as a result of genetic, age, and environmental factors. Reviews by Agarwal (2001, 056332), Burnell et al. (1989, 088308), Bosron and Li (1986, 056330), and Pietruszko (1980, 056337), discuss genetic polymorphisms for ADH. Class I ADH, the primary ADH in human liver, is a hetero- or homodimer composed of randomly associated polypeptide units encoded by three separate gene loci (ADH1A, ADH1B, and ADH1C). Polymorphisms have been found to occur at the ADH1B (ADH1B*2, ADH1B*3) and ADH1C (ADH1C*2) gene loci; however, no human allelic polymorphism has been found in ADH1A. The ADH1B*2 phenotype is estimated to occur in ~15% of Caucasians of European descent, 85% of Asians, and <5% of African Americans. Fifteen percent of African Americans have the ADH1B*3 phenotype, while it is found in <5% of Caucasian Europeans and Asians. To date, there are two reports of polymorphisms in ADH3 (Cichoz-Lach et al., 2007, 196229; Hedberg et al., 2001, 196206), yet the functional consequence(s) for these polymorphisms remains unclear.

Although racial and ethnical differences in the frequency of the occurrence of ADH alleles in different populations have been reported, ADH enzyme kinetics (V_{max} and K_m) have not been reported for methanol. There is an abundance of information pertaining to the kinetic characteristics of the ADH dimers to metabolize ethanol in vitro; however, the functional and biological significance is not well understood due to the lack of data documenting metabolism and disposition of methanol or ethanol in individuals of known genotype. While potentially significant, the contribution of ethnic and genetic polymorphisms of ADH to the interindividual variability in methanol disposition and metabolism can not be reliably quantified at this time.

Because children generally have higher baseline breathing rates and are more active, they may receive higher methanol doses than adults exposed to equivalent concentrations of any air

pollutant (CERHR, 2004, 091201). There is evidence that children under 5 years of age have reduced ADH activity. A study by Pikkarainen and Raiha (1967, 056315) measured liver ADH activity using ethanol as a substrate and found that 2-month-old fetal livers have ~3-4% of adult ADH liver activity. ADH activity in 4-5 month old fetuses is ~10% of adult activity, and an infant's activity is ~20% of adult activity. ADH continues to increase in children with age and reaches a level that is within adult ranges at 5 years of age. Adults were found to have great variation in ADH activity (1,625-6,530/g liver wet weight or 2,030-5,430 mU/100 mg soluble protein). Smith et al. (1971, 053549) also compared liver ADH activity in 56 fetuses (9-22 weeks gestation), 37 infants (premature to <1 year old), and 129 adults (>20 years old) using ethanol as a substrate. ADH activity was 30% of adult activity in fetuses and 50% of adult activity in infants. There is evidence that some human infants are able to efficiently eliminate methanol at high exposure levels, however, possibly via CAT (Tran et al., 2007, 196724).

ADH3 exhibits little or no activity toward small alcohols, thus the previous discussion is not relevant to the ontogeny of formaldehyde elimination (clearance). While such data on ADH3 activity does not exist, ADH3 mRNA is abundantly expressed in the mouse fetus (Ang et al., 1996, 196181) and is detectible in human fetal tissues (third trimester), neonates and children (Estonius et al., 1996, 196107; Hines and McCarver, 2002, 196221).

As noted earlier in this section, folate-dependent reactions are important in the metabolism of formate. Individuals who are commonly folate deficient include those who are pregnant or lactating, have gastrointestinal (GI) disorders, have nutritionally inadequate diets, are alcoholics, smoke, have psychiatric disorders, have pernicious anemia, or are taking folic acid antagonist medications such as some antiepileptic drugs (CERHR, 2004, 091201; IPCS, 1997, 196253). Groups which are known to have increased incidence of folate deficiencies include Hispanic and African American women, low-income elderly, and mentally ill elderly (CERHR, 2004, 091201). A polymorphism in methylene tetrahydrofolate reductase reduces folate activity and is found in 21% of Hispanics in California and 12% of Caucasians in the United States. Genetic variations in folic acid metabolic enzymes and folate receptor activity are theoretical causes of folate deficiencies.

3.4. PHYSIOLOGICALLY BASED TOXICOKINETIC MODELS

In accordance with the needs of this human health risk assessment, particularly the derivation of human health effect benchmarks from studies of the developmental effects of methanol inhalation exposure in mice (Rogers et al., 1993, 032696) and rats (NEDO, 1987, 064574) and carcinogenic effects of methanol in rats exposed via drinking water (Soffritti et al., 2002, 091004) and inhalation (NEDO, 1987, 064574; 2008, 196316), mouse and rat models were

1 developed to allow for the estimation of mouse and rat internal dose metrics. A human model

2 was developed to extrapolate those internal metrics to inhalation and oral exposure

3 concentrations that would result in the same internal dose in humans (human equivalent

4 concentrations [HECs] and human equivalent doses [HEDs]). The procedures used for the

5 development, calibration and use of these models are summarized in this section, with further

6 details provided in Appendix B, "Development, Calibration and Application of a Methanol

7 PBPK Model."

3.4.1. Model Requirements for EPA Purposes

3.4.1.1. *MOA and Selection of a Dose Metric*

8   Dose metrics closely associated with one or more key events that lead to the selected

9 critical effect are preferred for dose-response analyses compared to metrics not clearly

10 correlated. For instance, internal (e.g., blood, target tissue) measures of dose are preferred over

11 external measures of dose (e.g., atmospheric or drinking water concentrations), especially when,

12 as with methanol, blood methanol concentrations increase disproportionally with dose (Rogers et

13 al., 1993, 032696). This is likely due to the saturable metabolism of methanol. In addition,

14 respiratory and GI absorption may vary between and within species. Mode of action (MOA)

15 considerations can also influence whether to model the parent compound with or without its

16 metabolites for selection of the most adequate dose metric.

17   As discussed in Section 4.3, developmental effects following methanol exposures have

18 been noted in both rats and mice (NEDO, 1987, 064574; Nelson et al., 1985, 064573; Rogers et

19 al., 1993, 032696; Rogers et al., 1993, 032697), but are not as evident or clear in primate

20 exposure studies (Andrews et al., 1987, 030946; Burbacher et al., 2004, 059070; Clary, 2003,

21 047003; Nelson et al., 1985, 064573; Rogers et al., 1993, 032696; Rogers et al., 1993, 032697),

22 and carcinogenic effects have been observed in a drinking water studies of Sprague-Dawley rats

23 (Soffritti et al., 2002, 091004) and Eppley Swiss Webster mice (Apaja, 1980, 191208) and an

24 inhalation study of F344 rats (NEDO, 2008, 196316). The report of the New Energy

25 Development Organization (NEDO, 1987, 064574) of Japan, which investigated developmental

26 effects of methanol in rats, indicated that there is a potential that developing rat brain weight is

27 reduced following maternal and neonatal exposures. These exposures included both in utero and

28 postnatal exposures. The methanol PBPK models developed for this assessment do not

29 explicitly describe these exposure routes. Mathematical modeling efforts have focused on the

30 estimation of human equivalent external exposures that would lead to an increase in internal

31 blood levels of methanol or its metabolites presumed to be associated with developmental effects

as reported in rats (NEDO, 1987, 064574) and mice (Rogers et al., 1993, 032696), and carcinogenic effects as reported in rats by Soffritti et al. (2002, 091004).

In a recent review of the reproductive and developmental toxicity of methanol, a panel of experts concluded that methanol, not formate, is likely to be the proximate teratogen and determined that blood methanol level is a useful biomarker of exposure (CERHR, 2004, 091201; Dorman et al., 1995, 078081). The CERHR Expert Panel based their assessment of potential methanol toxicity on an assessment of circulating blood levels (CERHR, 2004, 091201). While recent in vitro evidence indicates that formaldehyde is more embryotoxic than methanol and formate (2003, 047369; Harris et al., 2004, 059082), the high reactivity of formaldehyde would limit its unbound and unaltered transport as free formaldehyde from maternal to fetal blood (Thrasher and Kilburn, 2001, 196728), and the capacity for the metabolism of methanol to formaldehyde is likely lower in the fetus and neonate versus adults (see discussion in Section 3.3). Thus, even if formaldehyde is ultimately identified as the proximate teratogen, methanol would likely play a prominent role, at least in terms of transport to the target tissue.

It has been suggested that the lymphomas observed in Sprague-Dawley rats following methanol exposure are associated with formaldehyde because formaldehyde and other compounds that metabolize to formaldehyde have been reported to cause lymphomas in Sprague-Dawley rats (Soffritti et al., 2005, 087840). Given the reactivity of formaldehyde, models that predict levels of formaldehyde in the blood are difficult to validate. However, production of formaldehyde or formate following exposure to methanol can be estimated by summing the total amount of methanol cleared by metabolic processes.[10] This metric of formaldehyde or formate dose has limited value since it ignores important processes that may differ between species, such as elimination (all routes) of these two metabolites, but it can be roughly be equated to the total amount of metabolites produced and may be the more relevant dose metric if formaldehyde is found to be the proximate toxic moiety. Thus, both blood methanol and total metabolism metrics are considered to be important components of the PBPK models. Dose metric selection and MOA issues are discussed further in Sections 3.3, 4.6, 4.8 and 4.9.2.

3.4.1.2. *Criteria for the Development of Methanol PBPK Models*

The development of methanol PBPK models that would meet the needs of this assessment was organized around a set of criteria that reflect: (1) the MOA(s) being considered for methanol; (2) absorption, distribution, metabolism, and elimination characteristics; (3) dose

---

[10] This assumption is more likely to be appropriate for formaldehyde than formate as formaldehyde is a direct metabolite of methanol.

routes necessary for interpreting toxicity studies or estimating HECs; and (4) general parameters needed for the development of predictive PK models.

The criteria with a brief justification are provided below:

- Must simulate blood methanol concentrations and total methanol metabolism. Blood methanol is the recommended dose metric for developmental effects, but total metabolism may be a useful metric, particularly for cancer endpoints.

- Must be capable of simulating experimental blood methanol and total metabolism for the inhalation route of exposure in mice and rats (a) and humans (b), and the oral route in rats (c) and humans (d). These routes are important for determining dose metrics in the most sensitive test species under the conditions of the toxicity study and in the relevant exposure routes in humans.

- The model code should easily allow designation of respiration rates during inhalation exposures. A standard variable in inhalation route risk assessments is ventilation rate. Blood methanol concentrations will depend strongly on ventilation rate, which varies significantly between species.

- Must address the potential for saturable metabolism of methanol. Saturable metabolism has the potential to bring nonlinearities into the exposure: tissue dose relationship.

- Model complexity should be consistent with modeling needs and limitations of the available data. Model should adequately describe the biological mechanisms that determine the internal dose metrics (blood methanol and total metabolism) to assure that it can be reliably used to predict those metrics in exposure conditions and scenarios where data are lacking. Compartments or processes should not be added that cannot be adequately characterized by the available data.

Although the rat and mouse models are useful for the evaluation of the dose metrics associated with methanol's developmental effects and the relevant toxicity studies, including gestational exposures, no pregnancy-specific PBPK model exists for methanol, and inadequate data exists for the development and validation of a fetal/gestational/conceptus compartment. However, EPA determined that nonpregnancy models for the appropriate species and routes of exposure could prove to be valuable because levels of methanol in NP, pregnant and fetal blood are expected to be similar following the same oral or inhalation exposure. Pollack and Brouwer (1996, 079812) determined that methanol distribution in rats and mice following repeated oral and i.v. exposures up to day 20 of gestation is "virtually unaffected by pregnancy, with the possible exception of the immediate perinatal period." The critical window for methanol

induction of cervical rib malformations in CD-1 mice has been identified as occurring between GD6 and GD7 (Rogers and Mole, 1997, 009755; Rogers et al., 1993, 032697), a developmental period roughly equivalent to week 3 of human development (Chernoff and Rogers, 2004, 069993). Methanol blood kinetics measured during and after inhalation exposure in NP and pregnant mice on GD6-GD10 and GD6-GD15 (Dorman et al., 1995, 078081; Perkins et al., 1995, 085259; Perkins et al., 1996, 196147; Rogers et al., 1993, 032696) are also similar. Further, the available data indicate that the maternal blood:fetal partition coefficient is approximately 1 at dose levels most relevant to this assessment (Horton et al., 1992, 196222; Ward et al., 1997, 083652). The same has been found in rat (Guerri and Sanchis, 1985, 005706; Zorzano and Herrera, 1989, 095202) and sheep (Brien et al., 1985, 031551; Cumming et al., 1984, 031556) studies of ethanol, a structurally related chemical that also penetrates cellular membranes readily and distributes throughout total body water. Consequently, fetal methanol concentrations are expected to be roughly equivalent to that in the mother's blood. Thus, pharmacokinetics and blood dose metrics for NP mice and humans are expected to provide reasonable approximations of pregnancy levels and fetal exposure, particularly during early gestation, that improve upon default estimations from external exposure concentrations.

3.4.2. Methanol PBPK Models

As has been discussed, methanol is well absorbed by both inhalation and oral routes and is readily metabolized to formaldehyde, which is rapidly converted to formate in both rodents and humans. As was discussed in Section 3.1, the enzymes responsible for metabolizing methanol are different in rodents and humans. Several rat, mouse and human PBPK models which attempt to account for these species differences have been published (Fisher et al., 2000, 009750; Horton et al., 1992, 196222; Perkins et al., 1995, 085259; Ward et al., 1997, 083652). In addition, a gestational model for a similar water soluble compound, isopropanol, with the potential to be adapted to methanol pharmacokinetics, was of interest (Clewell et al., 2001, 030673; Gentry et al., 2002, 034904; Gentry et al., 2003, 194592). Three PK models (Bouchard et al., 2001, 030672; Gentry et al., 2003, 194592; Ward et al., 1997, 083652) were identified as potentially appropriate for use in animal-to-human extrapolation of methanol metabolic rates and blood concentrations. An additional methanol PBPK model by Fisher et al. (2000, 009750) was considered principally because it had an important feature – pulmonary compartmentalization (see below for details) – worth adopting in the final model.

3.4.2.1. *Ward et al. (1997)*

The PBPK model of Ward et al. (1997, 083652) describes inhalation, oral and i.v. routes of exposure and is parameterized for both NP and pregnant mice and rats (Table 3-8). The model has not been parameterized for humans.

Respiratory uptake of methanol is described as a constant infusion into arterial blood at a rate equal to the minute ventilation times the inhaled concentration and includes a parameter for respiratory bioavailability, which for methanol is <100%. This simple approach is nonstandard for volatile compounds but is expected to be appropriate for a compound like methanol, for which there is little clearance from the blood via exhalation. Oral absorption is described as a biphasic process, dependent on a rapid and a slow first-order rate constant. This is conceptually similar to the isopropanol model discussed below (Clewell et al., 2001, 030673; Gentry et al., 2002, 034904), which also employs slow and fast absorption processes but functionally separates them into stomach and duodenal compartments.

Methanol elimination in the Ward et al. (1997, 083652) model is primarily via saturable hepatic metabolism. The parameters describing this metabolism come from the literature, primarily previous work by Ward and Pollack (1996, 025978) and Pollack et al. (1993, 032685). A first-order elimination of methanol from the kidney compartment includes a lumped metabolic term that accounts for both renal and pulmonary excretion.

The model adequately fits the experimental blood kinetics of methanol in rat and mice and is therefore suitable for simulating blood dosimetry in the relevant test species and routes of exposure (oral and i.v.). The Ward et al. (1997, 083652) model meets criteria 1, 2a, 2c, 3, 4, and 5. The most significant limitation is the absence of parameters for the oral and inhalation routes in the human. A modified version of this model that includes human parameters and a standard PBPK lung compartment might be suitable for the purposes of this assessment.

3.4.2.2. *Bouchard et al. (2001)*

The Bouchard et al. (2001, 030672) model is not actually a PBPK model but is an elaborate classical PK model, since the transfer rates are not determined from blood flows, ventilation, partition coefficients, and the like. The Bouchard et al. (2001, 030672) model uses a single compartment for methanol: a central compartment represented by a volume of distribution where the concentration is assumed to equal that in blood. The model was developed for inhalation and i.v. kinetics only. Methanol is primarily eliminated via saturable metabolism. The model adequately simulates blood kinetics in NP rats and humans following inhalation exposure and in NP rats following i.v. exposure; there is no description for oral absorption. Because methanol distributes with total body water (Horton et al., 1992, 196222; Ward et al.,

1 1997, 083652), this simple model structure is sufficient for predicting blood concentrations of

2 methanol following inhalation and i.v. dosing.

3   The Bouchard et al. (2001, 030672) model has the advantage of simplicity, reflecting the

4 minimum number of compartments necessary for representing blood methanol pharmacokinetics.

5   Because volume of distribution can be easily and directly estimated for water-soluble

6 compounds like methanol or fit directly to experimental kinetics data, concern over the

7 scalability of this parameter is absent. The model has been parameterized for a required human

8 exposure route, inhalation (Table 3-8). The model meets criteria 1, 2b, 3, 4, and 5 described in

9 Section 3.4.1.2. However, the Bouchard model has specific and significant limitations. The

10 model has neither been parameterized for the mouse, a test species of concern (Table 3-8), nor

11 for the oral route in humans. As such, the model cannot be used to conduct the necessary

12 interspecies extrapolation.

3.4.2.3. *Ward et al. (1997)*

13   The PBPK model of Ward et al. (1997, 083652) describes inhalation, oral and i.v. routes

14 of exposure and is parameterized for both NP and pregnant mice and rats (Table 3-8). The model

15 has not been parameterized for humans.

16   Respiratory uptake of methanol is described as a constant infusion into arterial blood at a

17 rate equal to the minute ventilation times the inhaled concentration and includes a parameter for

18 respiratory bioavailability, which for methanol is <100%. This simple approach is nonstandard

19 for volatile compounds but is expected to be appropriate for a compound like methanol, for

20 which there is little clearance from the blood via exhalation. Oral absorption is described as a

21 biphasic process, dependent on a rapid and a slow first-order rate constant. This is conceptually

22 similar to the isopropanol model discussed below (Clewell et al., 2001, 030673; Gentry et al.,

23 2002, 034904), which also employs slow and fast absorption processes but functionally separates

24 them into stomach and duodenal compartments.

25   Methanol elimination in the Ward et al. (1997, 083652) model is primarily via saturable

26 hepatic metabolism. The parameters describing this metabolism come from the literature,

27 primarily previous work by Ward and Pollack (1996, 025978) and Pollack et al. (1993, 032685).

28 A first-order elimination of methanol from the kidney compartment includes a lumped metabolic

29 term that accounts for both renal and pulmonary excretion.

30   The model adequately fits the experimental blood kinetics of methanol in rat and mice

31 and is therefore suitable for simulating blood dosimetry in the relevant test species and routes of

32 exposure (oral and i.v.). The Ward et al. (1997, 083652) model meets criteria 1, 2a, 2c, 3, 4, and

33 5. The most significant limitation is the absence of parameters for the oral and inhalation routes

1 in the human. A modified version of this model that includes human parameters and a standard

2 PBPK lung compartment might be suitable for the purposes of this assessment.

Table 3-8. Routes of exposure optimized in models – optimized against blood concentration data.

Route	Ward et al.			Bouchard et al.		
	Mouse	Rat	Human	Mouse	Rat	Human
i.v.	P/NP	P/NP	--	--	NP	--
Inhalation	P/NP	--	--	--	NP	NP
Oral	P/NP	NP	--	--	--	--

P = Pregnant
NP = Nonpregnant

Source: Bouchard et al. (2001, 030672); Ward et al. (1997, 083652).

3.4.2.4. *Gentry et al. and Clewell et al.*

3 The rat and human models described in three papers by Gentry et al. (2002, 034904;

4 2003, 194592) and Clewell et al. (2001, 030673) is for isopropanol, not methanol, and therefore

5 lacks any immediately useful parameterization for the purposes of a methanol risk assessment.

6 Although the overall model structure, the description of kinetics for both parent compound and

7 primary metabolite, gestational compartments, lactational transfer, oral and i.v. routes, etc., are

8 attractive for application to methanol, this model is not ideal. In particular, the model structure is

9 more elaborate than necessary; because methanol partition coefficients are near 1 for all tissues

10 except fat, there is no need to individually represent these tissues. Similarly, a fetal compartment

11 may not be necessary because methanol kinetics in the fetus (conceptus) is expected to parallel

12 maternal blood concentrations in the rodent. However, even if a fetal model was considered

13 necessary, other than the partition coefficient, there are insufficient data to identify conceptus

14 compartment parameters for methanol. This model would require the most modification and

15 parameterization to be useful for methanol risk assessment since parameters would have to be

16 estimated for all relevant species (at least rat and humans) and for several routes of exposure.

17 Therefore the isopropanol model was not considered further.

3.4.3. Selected Modeling Approach

18 As discussed earlier regarding model criteria, fetal methanol concentrations can

19 reasonably be assumed to equal maternal blood concentration. Thus, methanol pharmacokinetics

20 and blood dose metrics for NP laboratory animals and humans are expected to improve upon

1 default extrapolations from external exposures as estimates of fetal exposure during early

2 gestation. The same level of confidence cannot be placed on the whole-body rate of metabolism,

3 in particular as a surrogate for formaldehyde dose. Because of formaldehyde's reactivity and the

4 limited fetal metabolic (ADH) activity (see Sections 3.3 and 4.10.1), fetal formaldehyde

5 concentration increases (from methanol) will probably not equal maternal increases in

6 formaldehyde concentration. But since there is no model that explicitly describes formaldehyde

7 concentration in the adult, let alone the fetus, the metabolism metric is the closest one can come

8 to predicting fetal formaldehyde dose. This metric is expected to be a better predictor of

9 formaldehyde dose than applied methanol dose or even methanol blood levels, which do not

10 account for species differences in conversion of methanol to formaldehyde.

11   Most of the published rodent kinetic models for methanol describe the metabolism of

12 methanol to formaldehyde as a saturable process but differ in the description of metabolism to

13 and excretion of formate (Bouchard et al., 2001, 030672; Fisher et al., 2000, 009750; Ward et al.,

14 1997, 083652). The model of Ward et al. (1997, 083652) used one saturable and one first-order

15 pathway to describe methanol elimination in mice. The saturable pathway described in Ward

16 et al. (1997, 083652) can specifically be ascribed to metabolic formation of formaldehyde in the

17 liver, while the renal first-order elimination described in the model represents nonspecific

18 clearance of methanol (e.g., metabolism, excretion, or exhalation). The model of Ward et al.

19 (1997, 083652) does not describe kinetics of formaldehyde subsequent to its formation and does

20 not include any description of formate.

21   Bouchard et al. (2001, 030672) employed a metabolic pathway for conversion of

22 methanol to formaldehyde and a second pathway described as urinary elimination of methanol in

23 rats and humans. They then explicitly describe two pathways of formaldehyde transformation,

24 one to formate and the other to "other, unobserved formaldehyde byproducts." Finally, formate

25 removal is described by two pathways, one to urinary elimination and one via metabolism to

26 CO_2 (which is exhaled). All of these metabolic and elimination steps are described as first-order

27 processes, but the explicit descriptions of formaldehyde and formate kinetics significantly

28 distinguish the model of Bouchard et al. (2001, 030672) from that of Ward et al. (1997, 083652),

29 which only describes methanol.

30   There are two other important distinctions between the Ward et al. (1997, 083652) and

31 Bouchard et al. (2001, 030672) models. The former is currently capable of simulating blood data

32 for all exposure routes in mice but not humans, while the latter is capable of simulating human

33 inhalation route blood pharmacokinetics but not those in mice. The Ward et al. (1997, 083652)

34 model has more compartments than is necessary to adequately represent methanol disposition

35 but has been fit to PK data in pregnant and NP mice for all routes of exposure (i.v., oral, and

inhalation). The Ward et al. (1997, 083652) model has also been fit to i.v. and oral route PK data in rats. Based primarily on the extensive amount of fitting that has already been demonstrated for this model, it was determined that a modified Ward et al. (1997, 083652) model, with the addition of a lung compartment as described by Fisher et al. (2000, 009750), should be used for the purposes of this assessment. See Appendix B for a more complete discussion of the selected modeling approach and modeling considerations.

3.4.3.1. *Available PK Data*

Although limited human data are available, several studies exist that contain PK and metabolic data in mice, rats, and nonhuman primates for model parameterization. Table 3-9 contains references that were used to verify the model fits as reported in Ward et al. (1997, 083652).

3.4.3.2. *Model Structure*

A model was developed which includes compartments for alveolar air/blood methanol exchange, liver, fat, bladder (human simulations) and the rest of the body (Figure 3-4). This model is a revision of the model reported by Ward et al. (1997, 083652), reflecting significant simplifications (removal of compartments for placenta, embryo/fetus, and extraembrionic fluid) and three elaborations (addition of an intestine lumen compartment to the existing stomach lumen compartment, use of a saturable rate of absorption from the stomach (but not intestine), and addition of a bladder compartment which impacts simulations for human urinary excretion), while maintaining the ability to describe methanol blood kinetics in mice, rats, and humans. A fat compartment was included because it is the only tissue with a tissue:blood partitioning coefficient appreciably different than 1, and the liver is included because it is the primary site of metabolism. A bladder compartment was also added for use in simulating human urinary excretion to capture the difference in kinetics between changes in blood methanol concentration and urinary methanol concentration; the difference in model fit to human urinary data with vs. without the bladder compartment is shown in Figure 3-11. The model code describes inhalation, oral, and i.v. dose routes, and data exist (Table 3-9) that were used to fit parameters and evaluate model predictions for all three of those routes in both mice and rats. In humans, inhalation exposure data were available for model calibration and validation but not oral or i.v. data. However, oral exposures were simulated in humans assuming a continuous, zero-order ingestion rate, thereby obviating the need for oral uptake parameters.

Table 3-9. Key methanol kinetic studies for model validation

Reference	i.v. dose (mg/kg)	Inhalation (ppm)	Oral/dermal/ IP	Species	Samples	Digitized figures[A]
Batterman & Franzblau (1997, 056331)			Dermal	Human Male/female	Blood	Figure 1
Batterman et al., (1998, 086797)		800 (8 hr)			Blood, urine, exhaled	
Burbacher, (2004, 059070; 2004, 056018)		0-1,800 (2.5 hr, 4 mo)		Monkeys Cynomolgus Pregnant, NP	Blood	
Osterloh et al. (1996, 056314); Chuwers et al. (1995, 081298); D'Alessandro et al. (1994, 077257)		200 (4 hr)		Human Male/female	Blood, urine	Figure 1, Osterloh et al. (1996, 056314)
Medinsky et al. (1997, 084177); Dorman et al., (1994, 196743)		10-900 (2 hr)		Monkeys Cynomolgus Folate deficient	Blood, urine, exhaled	
Gonzalez-Quevedo et al., (2002, 037282)			IP: 2 mg/kg-day, 2 wk	Rat	Blood	
Horton et al. (1992, 196222)	100 (rats only)	50-2,000 (6 hr)		Rat & Monkey Rhesus	Blood, urine, exhaled	Figure 7
Perkins et al., (1995, 085259; 1995, 078067; 1996, 196147)		1,000-20,000 (8 hr)		Mouse and Rat	Blood, urine	
Pollack and Brouwer (1996, 079812); Pollack et al., (1993, 032685)	100-2,500	1,000-20,000 (8 hr)	Oral: 100-2,500 mg/kg	Rat: Sprague-Dawley, & Mouse; CD-1 Pregnant, NP	Blood	
Rogers and Mole, (1997, 009755); Rogers et al. (1993, 032696);		1,000-15,000 (7 hr, 10 days)		Mouse Pregnant	Blood	
Sedivec et al. (1981, 031154)		78-231 (8 hr)		Human	Urine, blood	Figures 2, 3, 6, 7, 8
Ward et al., (1997, 083652); Ward and Pollack, (1996, 025978)	100, 500 (Rat), 2,500 (Mouse)		Oral: 2,500 mg/kg	GD18 Mouse, GD14 & GD20 Rats	Blood, conceptus	

[a]Data obtained from the reported figure

1   PK data from intravenous exposures were used to test or further refine the parameters for

2   methanol metabolism in mice and rats. Monkey data were evaluated for insight into primate

3   kinetics. Data from Batterman et al., (1998, 086797), Osterloh et al. (1996, 056314), and

4   Sedivec et al. (1981, 031154) were used to estimate (fit) model parameters for humans

subsequent to the addition of the bladder compartment. The fact that optimized human parameters were similar to those predicted in monkeys was important to the validation process (Bouchard et al., 2001, 030672)(see section 3.4.7 and Appendix B). Blood levels of methanol have been reported following i.v., oral, and inhalation exposure in rats and mice and inhalation exposure in nonhuman primates and humans.

The metabolism of methanol was represented in mice, rats, and humans by specifying separate rate constants for the species-specific enzymes: two saturable processes for mice and Sprague-Dawley (SD) rats[11] and one for F344 rats and humans. The requirement for two saturable processes in the mouse and SD rat models may reflect saturation of CAT and ADH1. Simulated methanol elimination by these metabolic processes is not linked in the PBPK model to production of formaldehyde or formate, although the metabolic rate is assumed to equal the rate of formaldehyde production for the cancer risk assessment. For the PBPK model, methanol metabolism is simply another route of methanol elimination. Metabolism of formaldehyde (to formate) is not explicitly simulated by the model, and this model tracks neither formate nor formaldehyde. Since the metabolic conversion of formaldehyde to formate is rapid (<1 minute) in all species (Kavet and Nauss, 1990, 032274), the rate of methanol metabolism may approximate a formate production rate, though this has not been verified.

---

[11] The need for two saturable metabolic pathways in the mouse model was confirmed through simulation and optimization. High exposure (>2,000 ppm methanol) and low exposure (1,000 ppm methanol) blood data could not be fit visually, or by more formal optimization, without the second saturable metabolic pathway.

Figure 3-4. Schematic of the PBPK model used to describe the inhalation, oral, and i.v. route pharmacokinetics of methanol. KAS, first-order oral absorption rate from stomach; VmAS and KMAS, Michaelis-Menten rate constants for saturable absorption from stomach; KAI, first-order uptake from the intestine; KSI, first-order transfer between stomach and intestine; Vmax, Km, Vmax2, and Km2, Michaelis-Menten rate constants for high affinity/low capacity and low affinity/high capacity metabolism of MeOH; KLL, alternate first-order rate constant; KBL, rate constant for urinary excretion from bladder. Both metabolic pathways were used to describe MeOH metabolism in the mouse and SD rat, while a single pathway describes metabolism in the F344 rat and human.

1 The primary purpose of this assessment is for the determination of noncancer and cancer
2 risk associated with exposures that increase the body burden of methanol or its metabolites (e.g.,
3 formate, formaldehyde) above prevailing, endogenous levels. Thus, the focus of model
4 development was on obtaining predictions of increased body burdens over background following
5 external exposures. To accomplish this, the PBPK models used in this assessment do not
6 account for background levels of methanol, formaldehyde or formate. In addition, background
7 levels were subtracted from the reported data before use in model fitting or validation (in many
8 cases the published data already have background subtracted by study authors). This approach
9 for dealing with endogenous background levels of methanol and its metabolites assumes that:

1 (1) endogenous levels do not contribute significantly to the adverse effects of methanol or its

2 metabolites; and (2) the exclusion of endogenous levels does not significantly alter PBPK model

3 predictions. There is uncertainty associated with the former assumption. Human data are not

4 available to evaluate whether there is a relationship between background levels of methanol or

5 its metabolites and adverse effects, and dose-response data from rat cancer bioassays do not

6 provide evidence to refute the possibility (see discussion in Appendix E, Section E.5). To test

7 the assumption that the exclusion of endogenous background levels does not significantly alter

8 PBPK model predictions, EPA performed the following alternative analysis using models that

9 incorporate background levels of methanol and its metabolites.

10 **3.4.3.2.1. *Alternative modeling approach – incorporation of background.*** If background

11 methanol levels are high enough compared to those which induce metabolic saturation, they may

12 have a significant impact on parameter estimation and hence internal dose predictions. To gauge

13 the impact of background levels on PBPK model predictions of exposure-induced changes in

14 internal doses, alternate (test) versions of the rat and human PBPK models were created which

15 incorporate a zero-order liver infusion term for methanol designed to approximate reported rat

16 and human background levels. Internal dose estimates for various exposure levels obtained from

17 the PBPK models that exclude background up front could then be compared with those from

18 models for which background levels were modeled, but then subtracted for benchmark dose

19 (BMD) modeling. For example, when background levels are included in the PBPK model and

20 the metric is blood AUC, BMD analysis used the PBPK-predicted difference, AUC(exposed rats)

21 – AUC(control rats), as the dose metric. After obtaining an internal dose point of departure

22 (POD) at a specific effect level for the rat with that metric, the human equivalent internal dose

23 was taken to be POD + AUC(human background). In short the level of effect (above

24 background) was correlated with the internal dose *above* background in the animal, then the

25 human background internal dose was added to the POD obtained with that metric to yield an

26 estimate of the dose when humans would have the same level of effect.

27 The two PBPK modeling approaches (i.e., including or excluding background levels in

28 the PBPK model) did not differ significantly (<1%) with respect to their internal dose point of

29 departure (POD, level above background) estimates from the principal <u>rat</u> noncancer and cancer

30 studies. Differences between the two <u>human</u> PBPK models were similarly low (<1%) for HEC

31 and HED estimates from the <u>cancer</u> studies. HEC and HED estimates from the principal

32 <u>noncancer</u> studies using the human PBPK model with background included were only about 14%

33 lower than those estimated using the human PBPK model with background excluded. Because

34 the more complex PBPK modeling required to include background levels was estimated to have

1   a minimal impact on dose extrapolations, the use of simpler methanol models that do not

2   incorporate background levels is considered adequate for the purposes of this assessment.

3.4.3.3. *Model Parameters*

3   The EPA methanol model uses a consistent set of physiological parameters obtained

4   predominantly from the open literature (Table 3-10); the Ward et al. (1997, 083652) model

5   employed a number of data-set specific parameters.[12] Parameters for blood flow, ventilation,

6   and metabolic capacity were scaled as a function of body weight raised to the 0.75 power,

7   according to the methods of Ramsey and Andersen (1984, 063020).

Table 3-10. Parameters used in the mouse, rat and human PBPK models

	Mouse	Rat SD | F344	Human		Source
Body weight (kg)	0.03[a]	0.275[b]	70		Measured/estimated
Tissue volume (% body weight)					
Liver	5.5	3.7	2.6		
Blood arterial	1.23	1.85	1.98		
venous	3.68	4.43	5.93		Brown et al. (1997, 020304)
Fat	7.0	7.0	21.4		
Lung	0.73	0.50	0.8		
Rest of body	72.9	73.9	58.3		Calculated[c]
Flows (L/hr/kg$^{0.75}$)					
Alveolar ventilation[d]	25.4	16.4	16.5		Perkins et al. (1995, 085259); Brown et al. (1997, 020304); U.S. EPA, (2004, 196369)
Cardiac output	25.4	16.4	24.0		
Percentage of cardiac output					
Liver	25.0	25.0	22.7		Brown et al. (1997, 020304)
Fat	5.0	7.0	5.2		
Rest of body	70.0	68	72.1		Calculated
Biochemical constants[e]				1st order / saturable	
$V_{max}C$ (mg/hr/kg$^{0.75}$)	19	5.0	0	NA / 33.1	Fitted
Km (mg/L)	5.2	6.3	NA	NA / 23.7	
$V_{max}2C$ (mg/hr/kg$^{0.75}$)	3.2	8.4	22.3	NA	

---

[12] Some data sets provided in the Ward et al., (1997, 083652) model code were corrected to be consistent with figures in the published literature describing the experimental data.

	Mouse	Rat SD | F344		Human		Source
Km2 (mg/L)	660	65	100	NA		
K1C (BW$^{0.25}$/hr)	NA	NA		0.0373	0.0342	
KLLC (BW$^{0.25}$/hr)[f]	NA	NA		95.7	NA	
Oral absorption						
VmASC (mg/hr/kg$^{0.75}$)	1830	5570		377		Mouse and rat fitted (mouse and human KMASC assumed = rat); other human values are those for ethanol from Sultatos et al. (2004, 090530), with VmASC set so that for a 70-kg person VmAS/KMAS = the first-order constant of Sultatos et al.
KMASC (mg/kg)	620	620		620		
KSI (hr^{-1})	2.2	7.4		3.17		
KAI (hr^{-1})	0.33	0.051		3.28		
Kfec (hr^{-1})	0	0.029		0		
Partition coefficients						
Liver:Blood	1.06	1.06		0.583[h]		Ward et al., (1997, 083652); Fiserova-Bergerova and Diaz, (1986, 064569)
Fat:Blood	0.083	0.083		0.142		
Blood:Air	1350[i]	1350		1626		Horton et al. (1992, 196222); Fiserova-Bergerova and Diaz, (1986, 064569)
Body:Blood	0.66	0.66		0.805		Rodent: estimated; human: Fiserova-Bergerova and Diaz, (1986, 064569) (human "body" assumed = muscle)
Lung:Blood	1	1		1.07		
KBL (hr^{-1}), bladder time-constant [j]	NA			0.564	0.612	Fitted (human)
FRACIN (%), nhalation fractional availability	0.665	0.20		0.866[k]		Rodent: fitted; human Ernstgard et al., (2005, 088075)

NA - Not applicable for that species

[a]Both sources of mouse data report body weights of approximately 30 g

[b]The midpoints of rat weights reported for each study was used and ranged from 0.22 to 0.33 kg

[c]The volume of the other tissues was subtracted from 91% (whole body minus a bone volume of approximately 9%) to get the volume of the remaining tissues

[d]Minute ventilation was measured and reported for much of the data from Perkins et al. (1996, 196147) and the average alveolar ventilation (estimated as 2/3 minute ventilation) for each exposure concentration was used in the model. When ventilation rates were not available, a mouse QPC (Alveolar Ventilation/BW$^{0.75}$) of 25.4 was used (average from Perkins et al., (1995, 085259)). The QPC used to fit the human data was obtained from U.S. EPA (2004, 196369). This QPC was somewhat higher than calculated from Brown et al. (1997, 020304) (~13 L/hr/kg$^{0.75}$)

[e]V_{max}, Km, and $V_{max}2$, Km2 represent the two saturable metabolic elimination processes assumed to occur solely in the liver. The V_{max} used in the model = $V_{max}C$ (mg/kg$^{0.75}$·hr)×BW$^{0.75}$. K1C is the first-order loss from the blood for human simulations that represents urinary elimination. Allometric scaling for first-order clearance processes was done as previously described (Teeguarden et al., 2005, 194624); The K1 used in the model= K1C / BW$^{0.25}$

[f]KLLC – alternate human first-order metabolism rate (used only when $V_{max}C = V_{max}2C = 0$)

[g]Human oral simulations used a zero order dose rate equal to the mg/kg-day dose

[h]Human liver:blood estimated from correlation to (measured) fat:blood, based on data from 28 other solvents

[i]Rat partition coefficient used for mice as done by Ward et al. (1997, 083652)

[j]KBL – a first-order rate constant for clearance from the bladder compartment, used to account for the difference between blood kinetics and urinary excretion data as observed in humans

[k]For human exposures, the fractional availability was from Šedivec et al. (1981, 031154), corrected for the fact that alveolar ventilation is 2/3 of total respiration rate

3.4.4. Mouse Model Calibration and Sensitivity Analysis

The process by which the mouse, rat, and human inhalation and oral models were calibrated is discussed in more detail in Appendix B, "Development, Calibration and Application of a Methanol PBPK Model." The calibrated mouse inhalation model predicted blood methanol blood concentration time-course agreed well with measured values in adult mice in the critical inhalation studies of Rogers and Mole (1997, 009755) (Figure 3-5), Perkins et al. (1995, 085259; 1995, 078067), and Rogers et al. (1993, 032696), as well as in NP and early gestation (GD8) mice of Dorman et al. (1995, 078081) (Figure 3-6). Parameter values used in the calibrated model are given in Table 3-10.

The mouse model was also calibrated for the oral route by fitting all but one of the rate constants for oral uptake of methanol to the oral-route blood methanol kinetics of Ward et al. (1995, 077617; 1997, 083652). The best model fit to the mouse oral route blood methanol PK data was obtained using a two-compartment GI tract model, as depicted in Figure 3-4. Because the oral data in rats led to the conclusion that a saturable rate of uptake from the stomach lumen was necessary (see section 3.4.5), the same equation was used for uptake in the mouse. But attempts to identify the uptake saturation constant, KMASC, from the mouse data were unsuccessful; therefore KMASC for the mouse was set equal to the value obtained for rats. Adjusting the other mouse oral uptake parameters gave an adequate fit to those data. This calibration allows inhalation to oral dose-route extrapolations in the mouse, which can then be extrapolated to identify human oral route exposures equivalent to mouse inhalation exposures (if equivalent human exposures exist).

Figure 3-5. Model fits to data sets from GD6, GD7, and GD10 mice for 6- to 7-hour inhalation exposures to 1,000–15,000 ppm methanol. Maximum concentrations are from Table 2 in Rogers et al. (1993, 032696). The dataset for GD7 mice exposed to 10,000 ppm is from Rogers and Mole (1997, 009755) and personal communication. Symbols are concentration ± SEM of a minimum of N=4 mice/concentration. Default ventilation rates (Table 3-10) were used to simulate these data.

Source: Rogers and Mole (1997, 009755); Rogers et al. (1993, 032696)

Figure 3-6. Simulation of inhalation exposures to methanol in NP mice from Perkins et al. (1995, 085259) (8-hour exposures) and GD8 mice from Dorman et al. (1995, 078081)(6-hour exposures). Data points are measured blood methanol levels and lines represent PBPK model simulations. DigitizIt (SharIt! Inc., Greensburg, PA) was used to digitize data from Figure 2 of Perkins et al. (1995, 085259) and Figure 2 from Dorman et al. (1995, 078081). Default ventilation rates (Table 3-10) were used to simulate the Dorman data. The alveolar ventilation rate for each data set from Perkins et al. (1995, 085259) was set equal to the measured value reported in that manuscript. For the 2,500, 5,000, and 10,000 ppm exposure groups, the alveolar ventilation rates were 29, 24, and 21 (L/hours/kg$^{0.75}$), respectively. The cardiac output for these simulations was set equal to the alveolar ventilation rate.

Source: Dorman et al. (1995, 078081); Perkins et al. (1995, 085259).

1   The parameterization of methanol metabolism (high-and low-affinity metabolic
2   pathways) was also verified by simulation of datasets describing the pharmacokinetics of
3   methanol following i.v. administration. The results of this calibration of the methanol PBPK
4   model are described in Appendix B and were generally consistent with both the available
5   inhalation and oral-route data. Up to 20 hours post exposure, blood methanol kinetics appears
6   similar for NP and pregnant mice. However, some data suggests that clearance in GD18 mice is
7   slower than in NP and earlier in gestation (GD10 and less), particularly beyond 20 hours post
8   exposure (see the i.v. and oral data of Ward et al. (1997, 083652) in Appendix B).

1   Intravenous-route blood methanol kinetic data in NP mice were only available for a
2 single i.v. dose of 2,500 mg/kg, but were available for GD18 mice following administration of a
3 broader range of doses: 100, 500, and 2,500 mg/kg. The i.v. maternal PK data in GD18 mice
4 appeared to show an unexpected dose-dependent nonlinearity in initial blood concentrations.
5 Before discussing the nonlinearity, it is first noted that data values used here were obtained from
6 a computational "command file" provided by Ward et al. (1997, 083652). These values appear to
7 be consistent with the plots in their publication but are *inconsistent* with some of the values in
8 their Table 6 (Ward et al., 1997, 083652). In particular, the initial maternal blood concentration
9 (i.e., the C_{max}) after the 2,500 mg/kg i.v. is listed as 4,250 mg/L in their command file but as
10 3,251 mg/L in their published table. The corresponding data point in their Figure 5A is distinctly
11 centered above 4,000 mg/L (digitizing yields 4,213 mg/L), and so must be 4,250 rather than
12 3,251 mg/L. Therefore the data values listed in the command file were used in the subsequent
13 analysis, rather than those in the published table.

14   After i.v. dosing the ratio of the administered doses to the first concentrations measured
15 by Ward et al. (1997, 083652) (5-minute time points) were 0.588 L/kg, 0.585 L/kg, and 0.397
16 L/kg at doses of 2,500, 500, and 100 mg/kg, respectively. The discrepancy between the first two
17 values and the third value suggests either a dose dependence in the V_d or some source of
18 experimental variability.[13] It may be that V_d, which is not impacted by any other PBPK
19 parameters and is only determined by the biochemical partitioning properties of methanol, is
20 1.5-fold lower at 100 mg/kg than at the higher concentrations, while the V_d at 500 and
21 2,500 mg/kg are exactly as predicted by the PBPK model without adjustment. However, it was
22 found that the PBPK model, obtained with measured partition coefficients and otherwise
23 calibrated to inhalation data, could adequately fit the data at the nominal dose of 100 mg/kg
24 without other parameter adjustment simply by simulating a dose of 200 mg/kg, as shown in
25 Appendix B, Figure B-5. The fact that the alternate dose (200 mg/kg) differs by a factor of 2
26 from the nominal dose suggests that the data could also be the result of a simple dilution error in
27 dose preparation. If the first two of the dose/concentration values were *not* virtually identical
28 (0.588 and 0.585 L/kg), but instead the 500 mg/kg value was more intermediate between those
29 for 2,500 and 100 mg/kg, then a regular dose dependence in V_d would seem more likely.
30 However, based on these values, the U.S. EPA has concluded that the apparent dose dependency
31 is probably the result of a dosing error and therefore, that dose-dependent parameter changes
32 (e.g., in the partition coefficients) should not be introduced in an attempt to otherwise better fit
33 these data.

---

[13] It is possible that Ward et al., (1997, 083652) were unaware of that discrepancy because they plotted the results
for each dose in separate figures, and it only becomes obvious when all the data and simulations are plotted together.

1   Further, the nominal "nonlinearity" between the maternal blood and conceptus shown in
2   Figure 8 of Ward et al. (1997, 083652) is the result of those data being plotted on a log-y/linear-x
3   scale. Replotting the data from Tables 5 and 6 (using the value of 4,250 mg/L from the
4   command file as the GD18 maternal C_{max} for the 2,500 mg/kg) shows the results to be linear,
5   especially in the low-dose region which is of the most concern (Figure 3-7). Therefore, the
6   current model uses a consistent set of parameters that are not varied by dose and fit the 2,500 and
7   500 mg/kg i.v. data adequately, although they do not fit the 100 mg/kg i.v. data unless, as noted
8   above, a presumed i.v. dose of 200 mg/kg is employed. With that exception, both the single set
9   of parameters used herein and the assumption that maternal blood methanol is a good metric of
10 fetal exposure are well supported by the data.

Figure 3-7. Conceptus versus maternal blood AUC values for rats and mice plotted (A) on a log-linear scale, as in Figure 8 of Ward et al. (1997, 083652), and (B) on a linear-linear scale.   In both panels the line y = x is plotted (dashed line) for comparison. Thus the apparent "nonlinear" relationship indicated by Ward et al. (1997, 083652) is seen to be primarily a simple artifact of the choice of axes. However, as evident in panel B, there appears to be some nonlinearity at the two highest doses in the mouse (results of 2,500 mg/kg i.v. in GD18 mice and 15,000 ppm exposure to GD8 mice), where distribution from the dam to the conceptus is below 1:1.

Source: Ward et al. (1997, 083652).

To summarize the mouse model calibration: using the single set of parameters listed for the mouse in Table 3-10, the PBPK model has been shown to adequately fit or reproduce methanol PK data from a variety of laboratories and publications, including both NP mice and pregnant mice up to GD10. Two saturable metabolic pathways are thus described by the model and supported by the data. Also, it is thereby demonstrated that a model based on NP mouse physiology adequately describes (predicts) dosimetry in the pregnant mouse dam through GD10. Finally, as illustrated in Figure 3-7b, methanol PK in the conceptus and dam of both mice (including lower doses at GD18) and rats (GD14 and GD20) are virtually identical, except for the very highest doses in mice. Thus the existing model appears to be adequate for predicting internal methanol doses, including fetal exposures, at bioassay conditions.

An evaluation of the importance of selected parameters on mouse model estimates of blood methanol AUC was performed by conducting a sensitivity analysis using the subroutines within acslXtreme v2.3 (Aegis Technologies, Huntsville, Alabama). The analysis was conducted by measuring the change in model output corresponding to a 1% change in a given model parameter when all other parameters were held fixed. Sensitivity analyses were conducted for the inhalation and oral routes. The inhalation route analysis was conducted under the exposure conditions of Rogers and Mole (1997, 009755) and Rogers et al. (1993, 032696): 7-hour inhalation exposures at the no-observed-effect level (NOEL) concentration of 1,000 ppm. The oral route sensitivity analysis was conducted for an oral dose of 1,000 mg/kg.

The parameters with the largest sensitivity coefficients for the inhalation route at 1,000 ppm (absolute values >1) were pulmonary ventilation scaling coefficient (QPC) and maximum velocity of the high-affinity/low-capacity pathway ($V_{max}C$). The sensitivity coefficient for QPC increases during the exposure period as metabolism begins to saturate. Following oral exposure, mouse blood methanol AUC was sensitive to the rate constants for oral uptake. Blood AUC was most sensitive to the maximum and saturation rate constants for uptake from the stomach (VmASC and KMASC).   The sensitivity coefficient for VmASC decreased during the first hours after exposure from 1 to less than 0.1 at the end of exposure.   Blood methanol AUC was also modestly sensitive to first-order uptake from the intestine (KAI), and first-order transfer between stomach and intestine (KSI), the rate constants for uptake from the intestine and transfer rates between compartments, respectively. For a more complete description of this sensitivity analysis for the mouse methanol PBPK model see Appendix B.

3.4.5. Rat Model Calibration

The rat model was calibrated to fit data from i.v., inhalation, and oral exposures in rats, using data provided in the command file of Ward et al. (1997, 083652) and obtained from figures

in Horton et al. (1992, 196222) using DigitizIt. Holding other parameters constant, the rat PBPK model was initially calibrated against the entire set of i.v.-route blood PK data (Figure 3-8) by fitting Michaelis-Menten constants for one high-affinity/low-capacity and one low-affinity/high-capacity enzyme to both the Ward et al. (1997, 083652) data for Sprague-Dawley (SD) rats and the Horton et al. (1992, 196222) data for Fischer 344 (F344) rats, assuming that any difference between the two data sets (100 mg/kg data) were from experimental variability and that a single set of parameters could be fit to data for both strains of rat. However when the resulting parameters were then used to simulate the F344 inhalation uptake data of Horton et al. (with the fractional absorption for inhalation, FRACIN, adjusted to fit those data), it was found that the clearance rate predicted (decline in blood concentrations) after the end of inhalation exposure was much more rapid than shown by the data. More careful examination of the i.v. data then revealed that there too the clearance for F344 rats was slower than for SD rats, and that the metabolic parameters obtained from fitting the combined i.v. data best represented the SD rat data. It was concluded that the combined data set indicated a true strain difference in metabolic parameters. The metabolic parameters for SD rats were then obtained by fitting only the Ward et al. (1997, 083652) i.v. data (both doses).

The 100 mg/kg i.v. data of Horton et al. (1992, 196222) were combined with their inhalation data and a simultaneous optimization of the metabolic parameters and FRACIN for F344 rats was attempted over that data set. For this data set, however, the optimization either converged with the metabolic Vmax for the high affinity (low Km) pathway at zero, or with that Km value increasing to be statistically indistinguishable from the high Km value. Therefore the Vmax for the high affinity pathway was allowed to be zero, the Km for that pathway was not estimated, and only a single Vmax and low affinity (high Km) were fit to those data, with a simultaneous identification of FRACIN. Since there are no inhalation data for SD rats, this value of FRACIN was assumed to apply for both strains. The optimized parameters for both strains of rats are given in Table 3-10.

When the model was calibrated using the available inhalation and i.v. data for F344 rats (Horton et al., 1992, 196222), a low fractional absorption of 20% was optimized to best fit the data, vs. 66.5% for the mouse. This lower fractional absorption is consistent with values presented by Perkins et al. (1995, 085259), who also found that the fractional absorption of methanol from inhalation studies was lower in rats than in mice.

Figure 3-8. NP rat i.v. route methanol blood kinetics. Methanol (MeOH) was infused into: female Sprague-Dawley rats (275 g; solid diamonds and lines) at target doses of 100 or 2,500 mg/kg (Ward et al., 1997, 083652); or male F-344 rats (220 g; open triangles and dashed line) at target doses of 100 mg/kg (Horton et al., 1992, 196222). Data points represent measured blood concentrations and lines represent PBPK model simulations.

Source: Ward et al. (1997, 083652); Horton et al. (1992, 196222).

Figure 3-9. Model fits to data sets from inhalation exposures to 200 (triangles), 1,200 (diamonds), or 2,000 (squares) ppm methanol in male F-344 rats. The model was calibrated against all three sets of concentration data, though it converged to parameter values that only fit the lower two data sets well. Symbols are concentrations obtained from Horton et al. (1992, 196222) using DigitizIt! Lines represent PBPK model fits. Since the 2000 ppm data peak occurred at 7 hour, a 7-hour simulated exposure is also shown for comparison.

Source: Horton et al. (1992, 196222).

1   Finally, oral absorption parameters were optimized to the oral absorption data reported by

2 Ward et al. (1997, 083652), also using the optimization routines in acslXtreme v2.5.0.6 (Aegis

3 Technologies, Huntsville, Alabama) (Table 3-10: Figure 3-9). While the two-compartment GI

4 model (Figure 3-4) allows for both slow and fast absorption modes, it was not possible to fit both

5 the 100 mg/kg data and the first several hours of the 2,500 mg/kg data with that model structure

6 using linear absorption and inter-compartment transfer rates. In particular the shorter-time data

7 for 2,500 mg/kg indicate a much slower rate of increase in blood levels than the linear-

8 absorption model (top, thick line in upper panel of Figure 3-10), but the 100 mg/kg data (lower

9 panel of Figure 3-10) are indeed consistent with a linear model, showing a rapid rise to a fairly

10 narrow peak, then dropping rapidly. As long as linear rate equations were used, the shape of the

11 absorption curve at 2,500 mg/kg would mirror that at 100 mg/kg, but the data show a clear

12 difference. It was concluded that the rate of absorption must at least partly saturate at the higher

13 dose, and hence that Michaelis-Menten kinetics should be used.

1   Even with the addition of saturable absorption from the stomach, it was also found that
2   the 2,500 mg/kg model simulations over-predicted all of those data (result not shown) and it was
3   hypothesized that fecal elimination might become significant at such a high exposure level, so a
4   term for fecal elimination from the intestine compartment was added. When that fecal rate
5   constant and the saturable absorption from the stomach compartment were both used, the
6   resulting fit to the data (thin, dashed line in upper panel of Figure 3-10) was considerably
7   improved with an almost identical (excellent) fit to the 100 mg/kg data (saturable curve can be
8   distinguished from the linear curve just after the peak is reached in the lower panel of
9   Figure 3-10). For the purpose of scaling across individuals, strains, and species, the Km for
10   absorption from the stomach (KMAS) was assumed to scale in proportion to the stomach
11   (lumen) volume; i.e., with BW^1. The Vmax (VmAS) was assumed to scale as $BW^{0.75}$, with the
12   result that for low doses the effective linear rate constant (VmAS/KMAS) scales as $BW^{-0.25}$,
13   which is a standard assumption for linear rates. Since the quantity on which the rate depends is
14   the total amount in the stomach (mg methanol), the resulting scaling constant for the Km,
15   KMASC, conveniently has units of mg/kg BW; i.e., the standard units for oral dosing.

Figure 3-10. Model fits to datasets from oral exposures to 100 and 2,500 mg/kg methanol in female Sprague-Dawley rats. Symbols are concentration data obtained from the command file. Lines represent PBPK model fits.

Source: Ward et al. (1997, 083652).

3.4.6. Human Model Calibration

3.4.6.1. *Inhalation Route*

1   The mouse model was scaled to humans by setting either a standard human body weight

2   (70 kg) or study-specific body weights and using human tissue compartment volumes and blood

3   flows, and then calibrated to fit the human inhalation exposure data available from the open

literature, which comprised data from four publications (Ernstgard et al., 2005, 088075);
(Batterman et al., 1998, 086797; Osterloh et al., 1996, 056314; Sedivec et al., 1981, 031154).

Since the human data included time-course data for urinary elimination, a first-order rate
of loss of methanol from the blood (K1) was used to provide an estimate of methanol elimination
to the bladder compartment in humans, and the rate of elimination from that compartment then
characterized by a second constant (KBL). Note that the total amount eliminated by this route
depends only on K1, while KBL affects the rate at which the material cleared from the blood
then appears in the urine. Inhalation-route urinary methanol kinetic data described by Sedivec
et al. (1981, 031154) (Figure 3-11) was used in the model calibration to inform this rate constant.
 Without use of the bladder compartment and rate constant, the fit of the model predictions to the
data in Figure 3-11 is quite poor (middle panel), and a statistical test on the improvement of fit
obtained by introducing the additional parameter (KBL) is significant ($p < 0.0001$). Conversion
between the PBPK-model-predicted rate of urinary excretion (mg/hours) or cumulative urinary
excretion (mg) and the urine methanol concentration data reported by the authors was achieved
by assuming 0.5 mL/hours/kg body weight total urinary output (Horton et al., 1992, 196222).
The resulting values of K1C and KBL, shown in Table 3-10, differ somewhat depending on
whether first-order or saturable liver metabolism is used. These are only calibrated against a
small dataset and should be considered an estimate. Urinary elimination is a minor route of
methanol clearance with little impact on blood methanol kinetics. However urine concentration
is an indirect indicator of the time-course in the blood and hence including this term in the model
is useful in overall model calibration.

Although the high doses used in the mouse studies clearly warrant the use of a second
metabolic pathway with a high K_m, the human exposure data all represent lower concentrations
and may not require or allow for accurate calibration of a second metabolic pathway. Horton
et al. (1992, 196222) employed two sets of metabolic rate constants to describe human methanol
disposition, similar to the description used for rats and mice, but in vitro studies using monkey
tissues with nonmethanol substrates were used as justification for this approach. Although
Bouchard et al. (2001, 030672) described their metabolism using Michaelis-Menten metabolism,
Starr and Festa (2003, 052598) reduced that to an effective first-order equation and showed
adequate fits. Perkins et al. (1995, 085259) estimated a K_m of 320 ± 1273 mg/L (mean $\pm$ S.E.)
by fitting a one-compartment model to data from a single estimated oral dose. In addition to the
extremely high standard error, the large standard error for the associated V_{max} (93 ± 87
mg/kg/hours) indicates that the set of Michaelis-Menten constants was not uniquely identifiable
using this data. Other Michaelis-Menten constants have been used to describe methanol
metabolism in various models for primates (Table 3-11).

Figure 3-11. Urinary methanol elimination concentration (upper panels) and cumulative amount (lower panel) following inhalation exposures to methanol in human volunteers. Middle panel shows that without a bladder compartment the shape of the urine time-course is quite discrepant from the data. Data points in lower panel represent estimated total urinary methanol elimination from humans exposed to 78 (diamonds), 157 (triangles), and 231 (circles) ppm methanol for 8 hours, and lines represent PBPK model simulations.

Source: Sedivec et al. (1981, 031154).

Table 3-11. Primate K_ms reported in the literature

K_m (mg/L)	Reference	Note
320 ±1273[a]	Jacobsen et al., (1988, 031808)	Human: oral poisoning, estimated dose
716 ± 489[a]	Noker et al., (1980, 030975)	Cynomolgus Monkey: 2 g/kg dose
278	Makar et al., (1968, 031109)	Rhesus Monkey: 0.05-1 mg/kg dose
252 ± 116[a]	Eells et al., (1983, 031053)	Cynomolgus Monkey: 1 g/kg dose
33.9	Horton et al. (1992, 196222)	PBPK model: adapted from rat K_m
0.66	Fisher et al., (2000, 009750)	PBPK model, Cynomolgus Monkey:10-900 ppm
23.7 ± 8.7[a,b]	(This analysis.)	PBPK model, human: 100-800 ppm

[a]The values reported are mean ± S.D.
[b]This K_m was optimized while varying V_{max}, K1C, and KBL, from all of the at-rest human inhalation data as a part of this project. The S.D. given for this analysis is based on the Optimize function of acslXtreme, which assumes all data points are discrete and not from sets of data obtained over time; therefore a true S.D. would be higher. The final value reported in Table B-1 (21 mg/L) was obtained by sequentially rounding and fixing these parameters, then re-optimizing the remaining ones.

Source: Perkins et al. (1995, 078067).

Table 3-12. Parameter estimate results obtained using acslXtreme to fit all human data using either saturable or first-order metabolism

Parameters	Optimized value	S.D.	Correlation coefficient	LLF
Michaelis-Menten (optimized)			-0.994	-24.1
K_m	23.7	8.9		
$V_{max}C$	33.1	10.1		
First order			NA	-31.0
KLLC	95.7	5.4		

Note. The S.D.s are based on the Optimize function of acslXtreme v2.3, which assumes all data points are discrete and not from sets of data obtained over time. Therefore a true S.D. would be a higher value.

1   To estimate both Michaelis-Menten and first-order rates, all human data under
2 nonworking conditions (Batterman et al., 1998, 086797; Osterloh et al., 1996, 056314; Sedivec
3 et al., 1981, 031154) were used (Table 3-12). The metabolic (first-order or saturable) and
4 urinary elimination constants were numerically fit to the human datasets, while holding the value
5 for FRACIN at 0.8655 (estimated from the results of Sedivec et al. [(1981, 031154)]) and
6 holding the ventilation rate constant at 16.5 L/hours/kg$^{0.75}$ and QPC at 24 L/hours/kg$^{0.75}$ (values

1   used by EPA [2000d] for modeling the inhalation-route kinetics of vinyl chloride). Other

2   human-specific physiological parameters were used, as reported in Table 3-10. Final fitted

3   parameters that have been used in the saturable model are given in Table 3-10. The resulting fits

4   of two different possible parameterizations, first-order ["linear"] (dashed lines) or optimized

5   K_m/V_{max} (solid lines), are shown in Figures 3-11 and 3-12.

Figure 3-12. Data showing the visual quality of the fit using optimized first-order or Michaelis-Menten kinetics to describe the metabolism of methanol in humans. Rate constants used for each simulation are given in Table 3-12.

Source: Batterman et al. (1998, 086797: top); Osterloh et al. (1996, 056314: bottom).

1   Use of a first-order rate has the advantage of resulting in a simpler (one fewer variable)
2 model, while providing an adequate fit to the data; however, the saturable model clearly fits
3 some of the data better. To discriminate the goodness-of-fit resulting of the inclusion of an
4 additional variable necessary to describe saturable metabolism versus using a single first-order
5 rate, a likelihood ratio test was performed.[14] The hypothesis that one metabolic description is
6 better than another is calculated using the likelihood functions evaluated at the maximum
7 likelihood estimates. Since the parameters are optimized in the model using the maximum log
8 likelihood function (LLF), the resultant LLF is used for the statistical comparison of the models.
9   The equation states that two times the log of the likelihood ratio follows a chi square (χ^2)
10 distribution with r degrees of freedom:

11
$$-2[\log(\lambda(\text{model1})/\lambda(\text{model 2}))] = -2[\log\lambda(\text{model1}) - \log\lambda(\text{model 2})] \cong \chi_r^2$$

12   The likelihood ratio test states that if the two times the difference between the maximum
13 LLFs of the two different descriptions of metabolism is greater than the χ^2 distribution then the
14 model fit has been improved (Devore, 1995, 196740; Steiner et al., 1990, 196738).
15   At greater than a 99.95% confidence level, using two metabolic rate constants (K_m and
16 $V_{max}C$) is preferred over using a single rate constant (Table 3-13). Forcing the model to use the
17 K_m calculated by Perkins et al. (1995, 078067) would result in model fits indistinguishable from
18 the first-order case (results not shown). While the correlation coefficients (Table 3-12) indicate
19 that $V_{max}C$, and K_m are highly correlated, that is not unexpected, and the S.D.s (Table B-3)
20 indicate that each is reasonably bounded. If the data were indistinguishable from a linear
21 system, K_m in particular would not be so bounded from above since the Michaels-Menten model
22 becomes indistinguishable from a linear model as $V_{max}C$ and K_m tend to infinity. Further, the
23 internal dose candidate points of departure (PODs), for example the $BMDL_{10}$ for the inhalation-
24 induced brain-weight changes from NEDO (1987, 064574) with methanol blood AUC as the
25 metric, is 90.9 mg-hr/L, which corresponds to an average blood concentration of 3.8 mg/L.
26 Therefore, the Michaelis-Menten metabolism rate equation appears to be sufficiently supported
27 by the existing data with values in a concentration range in which the nonlinearity has an impact.

---

[14] Models are considered to be nested when the model structures are identical except for the addition of complexity, such as the added metabolic rate. Under these conditions, the likelihood ratio can be used to compare the relative ability of the two models to describe the data, as described in "Reference Guide for Simusolv" (Steiner et al., 1990, 196738).

**Table 3-13. Comparison of LLFs for Michaelis-Menten and first-order
metabolism**

LLF (logλ) for M-M	LLF (logλ) for 1st order	LLF 1st versus M-M[a]	χ_r^2 (99% confidence)[b]	χ_r^2 (99.95% confidence)[b]
-24.1	-31.0	34.1	13.8	12.22

Note. Models were optimized for all human datasets under non working conditions. M-M: Michaelis-Menten
[a]obtained using this equation: $-2[\log \lambda(\text{model 1}) - \log \lambda(\text{model 2})]$
[b]significance level at r=1 degree of freedom.

1   While the use of Michaelis-Menten kinetics might allow predictions across a wide

2   exposure range (into the nonlinear region), extrapolation above 1,000 ppm is not suggested since

3   the highest human exposure data are for 800 ppm. Extrapolation to higher concentrations is

4   potentially misleading since the nonlinearity in the exposure-internal-dose relationship for

5   humans is uncertain above this point. However, the use of a BMDL should place the exposure

6   concentrations well within the linear range of the model.

7   The data from (Ernstgard et al., 2005, 088075) were used to assess the use of the first-

8   order metabolic rate constant to a dataset collected under conditions of light work. Historical

9   measures of QPC (52.6 L/hours/kg$^{0.75}$) and QCC (26 L/hours/kg$^{0.75}$) for individuals exposed

10 under conditions of 50 watts of work from that laboratory (52.6 L/hours/kg$^{0.75}$) (Ernstgard, 2005,

11 200750)(Corley et al., 1994, 041977; Johanson et al., 1986, 006760) were used for the 2-hour

12 exposure period (Figure. 3-13). Otherwise, there were no changes in the model parameters (no

13 fitting to these data). The results are remarkably good, given the lack of parameter adjustment to

14 data collected in a different laboratory and using different human subjects than those to which

15 the model was calibrated.

Figure 3-13. Inhalation exposures to methanol in human volunteers. Data points represent measured blood methanol concentrations from humans (4 males and 4 females) exposed to 100 ppm (open symbols) or 200 ppm (filled symbols) for 2 hours during light physical activity. Solid lines represent PBPK model simulations with no fitting of model parameters. For the first 2 hours, a QPC of 52.6 L/hours/kg$^{0.75}$ (Johanson et al., 1986, 006760), and a QCC of 26 L/hours/kg$^{0.75}$ (Corley et al., 1994, 041977) was used by the model.

Source: Ernstgard et al. (2005, 088075).

3.4.6.2. *Oral Route*

1   There were no methanol human data available for calibration or validation of the oral
2   route for the human model. In the absence of methanol data to estimate rate constants for oral
3   uptake, human oral absorption parameters reported values for ethanol (Sultatos et al., 2004,
4   090530) are set in the code, except that saturable absorption from the stomach was retained with
5   the KMASC equal to the mouse value. The maximum rate of absorption form the stomach,
6   VMASC, was then set such that for a 70-kg person, VMAS/KM (the effective first-order rate
7   constant at low doses) matched the first-order absorption rate from Sultatos et al. (0.21 hr^{-1}).
8   Also, while Sultatos et al. included a rate of metabolism for ethanol in the stomach, the
9   corresponding fecal elimination rate was set to zero here, effectively assuming 100% absorption
10 of methanol for humans. However, human oral dosimetry was described as zero-order uptake, in
11 which continuous infusion at a constant rate into the stomach equal to the daily dose/24 hours
12 was assumed and human internal doses were computed at steady state. Since absorption is 100%
13 for the human model, at steady state the net rate of absorption must equal the rate of infusion to

the stomach, irrespective of the other parameter values. (Changes in the absorption constants simply cause the amount of methanol in each GI compartment at steady state to change until the net rate of absorption from the stomach and intestine equals the rate of infusion.) Thus the human absorption constants were set to what is considered a reasonable estimate, given the lack of human oral PK data, but the simulations are conducted in a way that makes the result insensitive to their values; having human values set does allow for simulations of non-constant infusion, should such be desired. Since the AUC was computed for a continuous oral exposure, its value is just 24 hours times the steady-state blood concentration at a given oral uptake rate.

3.4.7. Monkey PK Data and Analysis

In order to estimate internal doses (blood AUCs) for the monkey health-effects study of Burbacher et al. (1999, 009753) and further elucidate the potential differences in methanol pharmacokinetics between NP and pregnant individuals (2nd and 3rd trimester), a focused reanalysis of the data of Burbacher et al. (1999, 009752) was performed. Individual blood concentration measurements prior to and following exposure are shown in scatter plots in Appendix B of Burbacher et al. (1999, 009752). More specifically, the monkeys in the study were exposed for 2.5 hours/day, with the methanol concentration raised to approximately the target concentration for the first 2 hours of each exposure and the last 30 minutes providing a chamber "wash-out" period, when the exposure chamber concentration was allowed to drop to 0.
  Blood samples were taken and analyzed for methanol concentration at 30 minutes, 1, 2, 3, 4, and 6 hours after removal from the chamber (or 1, 1.5, 2.5, 3.5, 4.5, and 6.5 hours after the end of active exposure). These data were analyzed to compare the PK in NP versus pregnant animals, and fitted with a simple PK model to estimate 24-hour blood AUC values for each exposure level. Dr. Burbacher graciously provided the original data, which were used in this analysis.

Two cohorts of monkeys were examined, but the data (plots) did not indicate a systematic difference between the two, so the data from the two cohorts were combined. The data from the scatter plots of Burbacher et al. (1999, 009752) for the NP (pre-pregnancy), first pregnancy (2nd trimester), and second pregnancy (3rd trimester) studies are compared in Figure 3-14, along with model simulations (explained below). Since the pregnancy time points were from animals that had been previously exposed for 87 days *plus* the duration of pregnancy to that time point, the pre-exposed NP animals were used for comparison, rather than naïve animals, with the expectation that effects due to changes in enzyme expression (i.e., induction) from the subchronic exposure would not be a distinguishing factor. Note that each exposure group included a pre-exposure baseline or background measurement, also shown. To aid in

distinguishing the data visually, the NP data are plotted at times 5 minutes prior to the actual blood draws and the 3rd trimester at 5 minutes after each blood draw.

Overall there appears to be no significant or systematic difference among the NP and pregnant groups. The solid lines are model simulations calibrated to only the 2nd trimester data (details below), but they just as adequately represent average concentrations for the NP and 3rd trimester data. Likewise, a PK model calibrated to the NP PK data adequately predicted the maternal methanol concentrations in the pregnant monkeys (results not shown). Since any maternal:fetal methanol differences are expected to be similar in experimental animals and humans (with the maternal:fetal ratio being close to one due to methanol's high aqueous solubility and relatively limited metabolism by the fetus), the predicted levels for the 2nd trimester maternal blood are used in place of measured or predicted fetal concentrations.

Figure 3-14. Blood methanol concentration data from NP and pregnant monkeys. NP and 3rd trimester data are plotted, respectively, at 5 minutes before and after actual collection times to facilitate comparison. Solid line is from simple PK model, fit to 2nd trimester data only.

Source: Burbacher et al. (1999, 009752; Figure B-4).

3.4.7.1. *PK Model Analysis for Monkeys*

1   To analyze and integrate the PK data of Burbacher et al. (1999, 009752), the one-

2   compartment model for Michaelis-Menten kinetics used by Burbacher et al. (1999, 009752;

3   1999, 009753) was extended by the addition of a chamber compartment to capture the kinetics of

concentration change in the exposure chamber, as shown in Figure 3-15. The data in Figure 3-15 (digitized from Figure 5 of Burbacher et al., (1999, 009752; 1999, 009753) show an exponential rise to and fall from the approximate target concentration during the exposure period. The use of a single-compartment model for the chamber allows this dynamic to be captured, so that the full concentration-time course is used in simulating the monkey internal concentration rather than an approximate step function (i.e. rather than assuming an instantaneous rise and fall). The pair of equations representing the time-course in the chamber and monkey are as follows (bolded parameters are fit to data):

$$\text{Chamber: } dC_{ch}/dt = [(C_{CM} \cdot S - C_{ch}) \cdot F_{ch} - R_{inh}]/V_{ch}$$

$$\text{Monkey: } dC_{mk}/dt = [R_{inh} - V_{max} \cdot C_{mk}/(K_m + C_{mk})]/(V_{mk} \cdot BW)$$

$$\text{with } R_{inh} = C_{ch} \cdot R_C \cdot (1000 \cdot BW)^{0.74} \cdot F \text{ and } C_{net} = C_{mk} + C_{bg}.$$

d: delta, change

C_{ch}: instantaneous chamber concentration (mg/L)

t: time (hour)

C_{CM}: chamber in-flow methanol concentration (mg/L), which was set to the concentrations corresponding to those reported in Table 2 of Burbacher et al. (1999, 009752), using the "Breeding" column for the NP (87 days pre-exposed; values in Table 3-14)

S: exposure switch, set to 1 when exposure is on (first 2 hours) and 0 when off

F_{ch}: chamber air-flow, 25,200 L/hours, as specified by Burbacher et al. (1999, 009752; 1999, 009753)

R_{inh}: net rate of methanol inhalation by the monkeys (mg/hr)

V_{ch} (1,220 L): chamber volume, initially set to 1,380 L ("accessible volume" stated by Burbacher et al. (1999, 009752; 1999, 009753), but allowed to vary below that value to account for volume taken by equipment, monkey, and to allow for imperfect mixing

C_{mk}: instantaneous inhalation-induced monkey blood methanol concentration (mg/L); this is added to the measured background/endogenous concentration before comparison to data

V_{max} (39.3 mg/hr): fitted (nonscaled) Michaelis-Menten maximum elimination rate

K_m (14.6 mg/L): fitted (nonscaled) Michaelis-Menten saturation constant

V_{mk} (0.75 L/kg): fitted volume of distribution for monkey

BW: monkey body weight (kg); for NP monkeys set to group average values in data of Burbacher et al. (1999, 009752; 1999, 009753; personal communication)

R_c: allometric scaling factor for total monkey respiration ($0.12 \text{ L/hours/g}^{0.74}$ = $2 \text{ mL/minute/g}^{0.74}$), as used by Burbacher et al. (1999, 009752; 1999, 009753) (note that scaling is to BW in g, not kg)

1   F: fractional absorption of inhaled methanol, set to 0.6 (60%), the (rounded) value measured
2   in humans by Sedivec et al. (1981, 031154); F and V_{mk} cannot be uniquely identified,
3   given the model structure, so F was set to the (approximate) human value to obtain a
4   realistic estimate of V_{mk}

5   C_{net}: net blood concentration, equal to sum of the inhalation-induced concentration (C_{mk}) and
6   the background blood level (C_{bg}) (mg/L)

7   C_{bg}: background (endogenous) methanol concentration, set to the pre-exposure group-
8   specific mean from the data of Burbacher et al. (1999, 009752; 1999, 009753; personal
9   communication)

Figure 3-15. Chamber concentration profiles for monkey methanol exposures. Lines are model simulations. Indicated concentrations are target concentrations; measured concentrations differed slightly (see Table 3-14).

Source: Burbacher et al. (1999, 009752).

10   The model was specifically fit to the 2nd trimester monkey data, assuming that the
11   parameters were the same for all the exposure groups and concentrations. While the discussion
12   above and data show little difference between the NP and two pregnancy groups, the 2nd
13   trimester group was presumed to be most representative of the average internal dosimetry over
14   the entire pregnancy. Further, the results of Mooney and Miller (2001, 196247) show that
15   developmental effects on the monkey brain stem following ethanol exposure are essentially
16   identical for monkeys exposed only during early pregnancy versus full-term, indicating that early
17   pregnancy is a primary window of vulnerability.
18   Model simulation results are the lines shown in Figures 3-14 and 3-15. The model
19   provides a good fit to the monkey blood and chamber air concentration data. While the chamber

1 volume was treated as a fitted parameter, which was not done by Burbacher et al. (1999,

2 009752), the chamber concentration data support this estimate. The model does an adequate job

3 of fitting the data for all exposure groups without group-specific parameters. In particular, the

4 data for all exposure levels can be adequately fit using a single value for the volume of

5 distribution (V_{mk}) as well as each of the metabolic parameters. While one may be able to show

6 statistically distinct parameters for different groups or exposure levels (by fitting the model

7 separately to each), as was done by Burbacher et al. (1999, 009752), it is unlikely that such

8 differences are biologically significant, given the fairly large number of data points and the large

9 variability evident in the blood concentration data. Thus, the single set of parameters listed with

10 the parameter descriptions above will be used to estimate internal blood concentrations for the

11 dose-response analysis. The chamber concentrations for "pregnancy" exposures recorded by

12 Burbacher et al. (1999, 009752; Table 2) and average body weights for each exposure group at

13 the 2nd trimester time point were used along with the model to calculate 24-hour blood methanol

14 AUCs (Table 3-14).

Table 3-14. Monkey group exposure characteristics

Exposure concentration (ppm)[a]	Group average BW (kg)[b]	24-hr blood methanol AUC (mg-hr/L)[c]
206	3.46	6.73
610	4.08	28.28
1,822	3.83	138.11

[a]From Burbacher et al. (1999, 009752; 1999, 009753), Table 2, "pregnancy" exposure.
[b]From Burbacher, original data (personal communication).
[c]Calculated using the two-compartment PK model as described above.

3.4.8. Summary and Conclusions

15 Mouse, rat, and human versions of a methanol PBPK model have been developed and

16 calibrated to data available in the open literature. The model simplifies the structure used by

17 Ward et al. (1997, 083652), while adding specific refinements such as a standard lung

18 compartment employed by Fisher et al. (2000, 009750) and a two-compartment GI tract.

19 Although the developmental endpoints of concern are effects which occur during in utero

20 and (to a lesser extent) lactational exposure, no pregnancy-specific PBPK model exists for

21 methanol and inadequate data exists for the development and validation of a

22 fetal/gestational/conceptus compartment. The fact that the unique physiology of pregnancy and

23 the fetus/conceptus are not represented in a methanol model would be important if methanol

pharmacokinetics differed significantly during pregnancy or if the observed partitioning of methanol into the fetus/conceptus versus the mother showed a concentration ratio significantly greater than or less than 1. Methanol pharmacokinetics during GD6–GD10 in the mouse are not different from NP mice (Pollack and Brouwer, 1996, 079812), and the maternal blood:fetus/conceptus partition coefficient is reported to be near 1 (Horton et al., 1992, 196222; Ward et al., 1997, 083652). At GD18 in the mouse, maternal blood levels are only modestly different from those in NP animals (see Figures B-4 and B-5 [Appendix B] for examples), and in general the PBPK model simulations for the NP animal match the pregnancy data as well as the nonpregnancy data. Likewise, maternal blood kinetics in monkeys differs little from those in NP animals (see Section 3.4.7 for details). Further, in both mice and monkeys, to the extent that late-pregnancy blood levels differ from NP for a given exposure, they are higher; i.e., the difference between model predictions and actual concentrations is in the same direction. These data support the assumption that the ratio of actual target-tissue methanol concentration to (predicted) NP maternal blood concentrations will be about the same across species, and hence, that using NP maternal blood levels in place of fetal concentrations will not lead to a systematic error when extrapolating risks.

The findings in the mouse (similar blood methanol kinetics between NP and pregnant animals prior to GD18 and a maternal blood:fetal partition coefficient close to 1) are assumed to be applicable to the rat. However, the critical gestational window for the reduced brain weight effect observed in the NEDO (1987, 064574) rat study is broader than for the mouse cervical rib effect. In addition, NEDO (1987, 064574) rats were exposed not only to methanol gestationally but also lactationally and via inhalation after parturition. The additional routes of exposure presented to the pups in this study present uncertainties (see additional discussion in Section 5.3.2) and suggest that average blood levels in pups might be greater than those of the dam.

Methanol is transported directly from the maternal circulation to fetal circulation via the placenta, but transfer via lactation involves distribution to the breast tissue, then milk, then uptake from the pup's GI tract. Therefore blood or target-tissue levels in the breast-feeding infant or pup are likely to differ more from maternal levels than do fetal levels. In addition, the health-effects data indicate that most of the effects of concern are due to fetal exposure, with a relatively small influence due to post birth exposures. Further, it would be extremely difficult to distinguish the contribution of post birth exposure from pre birth exposure to a given effect in a way that would allow the risk to be estimated from estimates of both exposure levels, even if one had a lactation/child PBPK model that allowed for prediction of blood (or target-tissue) levels in the offspring. Finally, one would still expect the target-tissue concentrations in the offspring to be closely related to maternal blood levels (which depend on ambient exposure and determine

the amount delivered through breast milk), with the relationship between maternal levels and those in the offspring being similar across species. Further, as discussed to a greater extent in Sections 5.1.2 and 5.3.2, it is likely that the difference in blood levels between rat pups and dams would be similar to the difference between mothers and human offspring. Therefore, it is assumed that the potential differences between pup and dam blood methanol levels do not have a significant impact on this risk assessment and the estimation of HECs.

Therefore, the development of a lactation/child PBPK model appears not to be necessary, given the minimal change that is likely to result in risk extrapolations, and use of (NP) maternal blood levels as a measure of risk in the offspring is considered preferable over use of default extrapolation methods. In particular, the existing human data allow for predictions of maternal blood levels, which depend strongly on the rate of maternal methanol clearance. Since bottle-fed infants do *not* receive methanol from their mothers, they are expected to have lower or, at most, similar overall exposures for a given ambient concentration than the breast-fed infant, so that use of maternal blood levels for risk estimation should also be adequately protective for that group.

The model fits to the mouse oral-route methanol kinetic data, using a consistent set of parameters (Figure B-4 in Appendix B), are fairly good for doses of 1,500 mg/kg but underpredict blood levels by 30% or more after a dose of 2,500 mg/kg. In particular, the oral mouse model consistently underpredicts the amount of blood methanol reported in two studies (1995, 077617; Ward et al., 1997, 083652). Ward et al. (1997, 083652) utilized a different V_{max} for each oral absorption dataset; the GD18 and the GD8 data from Dorman et al. (1995, 078081) were both fit using a V_{max} of ~80 mg/kg/hours (body weights were not listed; the model assumed that GD8 and GD18 mice were both 30 g; Ward et al. (1997, 083652) did not scale by body weight). Additionally, lower partition coefficients for placenta (1.63 versus 3.28) and embryonic fluid (0.0037 versus 0.77) were used for GD8 and GD18. The current refined model adequately fits the oral PK data using a single set of parameters that is not varied by dose or source of data.

The rat models were able to adequately predict the limited inhalation, oral and i.v. datasets available. Low-dose exposures were emphasized in model optimization due to their greater relevance to risk assessment. Based on a rat inhalation exposure to 500 ppm, the HEC would be 281 ppm (by applying an AUC of 201.3 [Figure B-12] to Equation 1 of Appendix B).

The final mouse, rat, and human methanol PBPK models fit multiple datasets for inhalation, oral, and i.v., from multiple research groups using consistent parameters that are representative of each species but are not varied within species or by dose or source of data. Also, a simple PK model calibrated to NP monkey data, which were shown to be essentially indistinguishable from pregnant monkey PK data, was used to estimate blood methanol AUC

1 values (internal doses) in that species. In Section 5, the models and these results are used to

2 estimate chronic human exposure concentrations from internal dose metrics.

4. HAZARD IDENTIFICATION

4.1. STUDIES IN HUMANS – CASE REPORTS, OCCUPATIONAL AND CONTROLLED STUDIES

4.1.1. Case Reports

1   An extensive library of case reports has documented the consequences of acute
2   accidental/intentional methanol poisoning. Nearly all have involved ingestion, but a few have
3   involved percutaneous and/or inhalation exposure. As many of the case reports demonstrate, the
4   association of Parkinson-like symptoms with methanol poisoning is related to the observation
5   that lesions in the putamen are a common feature both in Parkinson's disease and methanol
6   overexposure. These lesions are commonly identified using computed tomography (CT) or by
7   Magnetic Resonance Imaging (MRI). Other areas of the brain (e.g., the cerebrum, cerebellum,
8   and corpus callosum) also have been shown to be adversely affected by methanol overexposure.
9   Various therapeutic procedures (e.g., ethanol infusion, sodium bicarbonate or folic acid
10 administration, and hemodialysis) have been used in many of these methanol overexposures, and
11 the reader is referred to the specific case reports for details in this regard. The reader also is
12 referred to Kraut and Kurtz (2008, 196286) and Barceloux et al. (2002, 180477) for a more in-
13 depth discussion of the treatments in relation to clinical features of methanol toxicity. A brief
14 discussion of the terms cited in case report literature follows.

15   Basal ganglia, a group of interconnected subcortical nuclei in each cerebral hemisphere,
16 refers to various structures in the grey matter of the brain that are intimately involved, for
17 example, in coordinating motor function, maintaining ocular and respiratory function, and
18 consciousness. The connectivity within the basal ganglia involves both excitatory and inhibitory
19 neurotransmitters such as dopamine (associated with Parkinson's disease when production is
20 deficient).

21   The structures comprising the basal ganglia include but are not limited to: the putamen
22 and the globus pallidus (together termed the lentiform nuclei), the pontine tegmentum, and the
23 caudate nuclei. Dystonia or involuntary muscle contraction can result from lesions in the
24 putamina; if there are concomitant lesions in the globus pallidus, Parkinsonism can result (Bhatia
25 and Marsden, 1994, 076489). Bhatia and Marsden (1994, 076489) have discussed the various
26 behavioral and motor consequences of focal lesions of the basal ganglia from 240 case-study
27 reports. Lesions in the subcortical white matter adjacent to the basal ganglia often occur as well
28 (Airas et al., 2008, 196177; Bhatia and Marsden, 1994, 076489; Rubinstein et al., 1995, 077842).

In the case reports of Patankar et al. (1999, 196142), it was noted that the severity and extent of necrosis in the lenticular nuclei do not necessarily correlate with clinical outcome.

In one of the earliest reviews of methanol overexposure, Bennett et al. (1953, 031139) described a mass accidental poisoning when 323 persons, ranging in age from 10 to 78 years, in Atlanta, Georgia, consumed "whisky" adulterated with as much as 35–40% methanol. In all, 41 people died. Of the 323 individuals, 115 were determined to be acidotic with symptoms (visual impairment, headache [affecting ~62%], dizziness [affecting ~30%], nausea, abdominal pain and others) beginning around 24 hours post exposure. Visual impairment was mostly characterized by blurred or indistinct vision; some who were not acidotic experienced transient visual disturbances. The cardiovascular parameters were unremarkable. The importance of acidosis to outcome is shown in Table 4-1. Among the key pathological features were cerebral edema, lung congestion, gastritis, pancreatic necrosis, fatty liver, epicardial hemorrhages, and congestion of abdominal viscera.

In another early investigation of methanol poisoning (involving 320 individuals), Benton and Calhoun (1952, 030947) reported on methanol's visual disturbances.

Table 4–1. Mortality rate for subjects exposed to methanol-tainted whiskey in relation to their level of acidosis[a]

Subjects	Number	Percent deaths
All patients	323	6.2
Acidotic (CO_2 <20 mEq)	115	19
Acidotic (CO_2 <10 mEq)	30	50

[a]These data do not include those who died outside the hospital or who were moribund on arrival.

Source: Bennett et al. (1953, 031139).

Riegel and Wolf (1966, 196163), in a case report involving a 60-year-old woman who ingested methanol, noted that nausea and dizziness occurred within 30 minutes of ingestion. She subsequently passed out and remained unconscious for 3 days. Upon awakening she had paralysis of the vocal cords and was clinically blind in one eye after 4 months. Some aspects of Parkinson-like symptoms were evident. There was a pronounced hypokinesia with a mask-like face resembling a severe state of Parkinson's disease. The patient had difficulty walking and could only make right turns with difficulty. There was no memory loss.

Treatment of a 13-year-old girl who ingested an unspecified amount of a windshield-washer solution containing 60% methanol was described by Guggenheim et al. (1971, 037882). She displayed profound acidosis; her vital signs, once she was treated for acidosis, were normal

by 36 hours after hospital admission. During the ensuing 6 months after discharge from the hospital, visual acuity (20/400, both eyes) worsened, and she experienced muscle tremors, arm pain, and difficulty in walking. A regimen of levadopa treatment greatly improved her ability to function normally.

Ley and Gali (1983, 077133) also noted symptoms that are Parkinson like following methanol intoxication. In this case report respiratory support was needed; the woman was in a coma. Once stabilized, she exhibited symptoms similar to those noted in other case study reports, such as blurred vision, movement difficulty, and tremors. Computerized Axial Tomography scan findings highlighted the central nervous system (CNS) as an important site for methanol poisoning.

Rubinstein et al. (1995, 077842) presented evidence that a methanol blood level of 36 mg/dL (360 mg/L) is associated with a suite of CNS and ocular deficits that led to a 36-year-old man (who subsequently died) becoming comatose. CT scans at 1-2 days following ingestion were normal. However, MRI scans at day 4 revealed lesions in the putamen and peripheral white matter of the cerebral and cerebellar hemispheres. Bilateral cerebellar cortical lesions had been reported in an earlier case of methanol poisoning by Chen et al. (1991, 032295).

Finkelstein and Vardi (2002, 037357) reported that long-term inhalation exposure of a woman scientist to methanol without acute intoxication resulted in a suite of delayed neurotoxic symptoms (e.g., hand tremor, dystonia, bradykinesia, and other decrements in body movement). Despite treatment with levadopa, an increase in the frequency and severity of effects occurred. Exposure to bromine fumes was concomitant with exposure to methanol.

Hantson et al. (1997, 083446) found, in four cases, that MRI and brain CT scans were important tools in revealing specific brain lesions (e.g., in the putamina and white matter). The first subject was a 57-year-old woman who complained of blurred vision, diplopia, and weakness 24 hours after ingesting 250 mL of a methanolic antifreeze solution. Upon hospital admission she was comatose and in severe metabolic acidosis. An MRI scan at 9 days indicated abnormal hyperintense foci in the putamina (decreased in size by day 23) and subtle lesions (no change by day 23) in the white matter. Upon her discharge, bilateral deficits in visual acuity and color discrimination persisted.

Similar deficits (metabolic acidosis, visual acuity, and color discrimination) were seen in a man who ingested 300 mL of 75% methanol solution. His blood methanol level was 163 mg/dL (1,630 mg/L). An MRI administered 24 hours after hospital admission revealed abnormal hyperintense foci in the putamina, with less intense lesions in the white matter. Like the first subject, a subsequent MRI indicated the foci decreased in size over time, but visual impairments persisted.

The third individual, a male, ingested an unspecified amount of a methanolic solution. His blood methanol level was 1,290 mg/dL (12,900 mg/L), and he was in a coma upon hospital admission. An MRI revealed lesions in the putamina and occipital subcortical white matter. A follow-up CT scan was performed after 1 year and showed regression of the putaminal lesions but no change in the occipital lesions. Upon his discharge, severe visual impairment remained but no extrapyramidal signs were observed.

The last case was a man who became comatose 12 hours after ingesting 100 mL methanol. His blood methanol level at that time was 60 mg/dL (600 mg/L). An MRI revealed lesions in the putamina; at 3 weeks these lesions were observed to have decreased in size. Upon his discharge, the neurological signs had improved but optic neuropathy (in visual evoked potential) was observed.

In a separate publication, Hantson et al. (1997, 196137) reported a case of a 26-year-old woman who had ingested 250–500 mL methanol during the 38th week of pregnancy. Her initial blood methanol level was 230 mg/dL (2,300 mg/L) (formate was 33.6 mg/dL or 336 mg/L), yet only a mild metabolic acidosis was indicated. No distress to the fetus was observed upon gynecologic examination. Six days after therapy was initiated (methanol was not present in blood), she gave birth. No further complications with either the mother or newborn were noted.

There have been several case reports involving infant or toddler exposures to methanol (Brent et al., 1991, 032300; De et al., 2005, 196739; Kahn and Blum, 1979, 031423; Wu et al., 1995, 078112). The report by Wu et al. (1995, 078112) involved a 5-week-old infant with moderate metabolic acidosis and a serum methanol level of 1,148 mg/dL (11,480 mg/L), a level that is ordinarily fatal. However, this infant exhibited no toxic signs and survived without any apparent permanent problems. De Brabander et al. (2005, 196739) reported the case of a 3-year-old boy who ingested an unknown amount of pure methanol; at 3 hours after ingestion, the blood methanol level was almost 30 mg/dL (300 mg/L). Ethanol infusion as a therapeutic measure was not well tolerated; at 8 hours after ingestion, fomepizole was administered, and blood methanol levels stabilized below 20 mg/dL (200 mg/L), a level above which is considered to be toxic by the American Academy of Clinical Toxicology (Barceloux et al., 2002, 180477). Neither metabolic acidosis nor visual impairment was observed in this individual. Hantson et al. (1997, 083446), in their review, touted the efficacy of fomepizole over ethanol in the treatment of methanol poisoning

Bilateral putaminal lesions, suggestive of nonhemorrhagic necrosis in the brain of a man who accidentally ingested methanol, were reported by Arora et al. (2005, 196185). Approximately 10 hours after MRI examination, he developed blurred vision and motor dysfunction. After 5 months, visual deficits persisted along with extrapyramidal symptoms.

Persistent visual dysfunction was also reported in another methanol poisoning case (Arora et al., 2007, 092994); the vision problems developed ~46 hours subsequent to the incident.

Vara-Castrodeza et al. (2007, 093108) applied diffusion-weighted MRI on a methanol-induced comatose woman. Diffusion-weighted MRI provides an image contrast distinct from standard imaging in that contrast is dependent on the molecular motion of water (Schaefer et al., 2000, 196191). The neuroradiological findings were suggestive of bilateral putaminal hemorrhagic necrosis, cerebral and intraventricular hemorrhage, diffuse cerebral edema, and cerebellar necrosis. Diffusion-weighted MRI allows for differentiation of restricted diffusion which is indicative of nonviable tissue. In this case, treatment for acidosis (blood methanol levels had risen to 1,000 mg/L) was unsuccessful and the patient died.

Emergency treatment was unable to save the life of a 38-year-old man who presented with abdominal pain and convulsions after methanol intoxication (Henderson and Brubacher, 2002, 093106). A review of a head CT scan performed before the individual went into respiratory arrest revealed bilateral globus pallidus ischemia.

Discrete lesions of the putamen, cerebral white matter, and corpus callosum were observed upon MRI (8 days post ingestion) in a man exposed to methanol (blood level 370 mg/L) complaining of vision loss (Keles et al., 2007, 093115). Standard treatments corrected the acidosis (pH 6.8), and at 1-month follow-up, his cognitive function improved but blindness and bilateral optic atrophy were described as permanent. The follow-up MRI showed persistent putaminal lesions with cortical involvement.

Fontenot and Pelak (2002, 037256) described a case of a woman who presented with persistent blurred vision and a worsening mental status 36 hours after ingestion of an unspecified amount of methanol. The initial CT scan revealed mild cerebral edema. The blood methanol level at this time was 86 mg/dL (860 mg/L). A repeat CT scan 48 hours after presentation showed hypodensities in the putamen and peripheral white matter. One month after discharge, cognitive function improved, and the patient experienced only a mild lower-extremity tremor.

Putaminal necrosis and edema of the deep white matter (the corpus callosum was not affected) was found upon MRI examination of a 50-year-old woman who apparently ingested an unknown amount of what was believed to be pure laboratory methanol (Kuteifan et al., 1998, 196287). Her blood methanol level was 39.7 mM (127 mg/dL; 1,272 mg/L) upon hospital admission and dropped to 102 mg/dL (1,020 mg/L) at 10 hours and to 71 mg/dL (710 mg/L) at 34 hours. The woman, a chronic alcoholic, was in a vegetative state when found and did not improved over the course of a year.

MRI and CT scans performed on a 51-year-old man with generalized seizures who had a blood methanol level of 95 mM (304 mg/dL; 3,044 mg/L) revealed bilateral hemorrhagic

necrosis of the putamen and caudate nuclei (Gaul et al., 1995, 196131). In addition, there was extensive subcortical necrosis and bilateral necrosis of the pontine tegmentum and optic nerve. The patient died several hours after the scans were performed.

The relation of methanol overexposure to brain hemorrhage was a focus of the report by Phang et al. (1988, 031577), which followed the treatment of 7 individuals, 5 of whom died within 72 hours after hospital admission. In two of the deceased individuals, CT scans and autopsy revealed putaminal hemorrhagic necrosis. The investigators postulated that the association of methanol with hemorrhagic necrosis may be complicated by the use of heparin during hemodialysis treatment for acidosis

Treatment of two men who had drunk a solution containing 58% methanol and presented with impaired vision, coma, and seizures was discussed in a case report by Bessell-Browne and Bynevelt (2007, 093109). A CT scan on one individual revealed bilateral putaminal and cerebral lesions. Blood methanol levels were 21 mg/L. This individual, despite standard treatments, never regained consciousness. The second individual, upon MRI, showed scattered hemorrhage at the grey-white interface of the cerebral hemispheres.

There have been two case reports (Adanir et al., 2005, 196175; Downie et al., 1992, 196744) that involved percutaneous and inhalation exposure. Use of a methanol-containing emollient by a woman with chronic pain led to vision loss, hyperventilation and finally, coma (Adanir et al., 2005, 196175). Subsequent to standard treatment followed by hospital discharge, some visual impairment and CNS decrements remained. The methanol blood threshold for ocular damage and acidosis appeared to be ~20 mg/L. Dutkiewicz et al. (1980, 031082) have determined the skin absorption rate to be 0.192 mg/cm^2/minute. In the case report of Aufderheide et al. (1993, 032704), two firefighters were transiently exposed to methanol by inhalation and the percutaneous route. Both only complained of a mild headache and had blood methanol levels of 23 and 16 mg/dL (230 and 160 mg/L), respectively.

Bebarta et al. (2006, 090790) conducted a prospective observational study of seven men who had purposefully inhaled a methanol-containing product. Four had a blood methanol level upon hospital presentation of >24 mg/dL (240 mg/L); the mean formic acid level was 71 µg/dL. One individual had a blood methanol level of 86 mg/dL (860 mg/L) and a blood formic acid level of 250 µg/mL upon hospital admission. This latter individual was treated with fomepizole. No patient had an abnormal ophthalmologic examination. All seven stabilized quickly and acidosis was normalized in 4 hours.

Numerous other case reports documenting putaminal necrosis/hemorrhage and/or blindness have been reported (Blanco et al., 2006, 196161; Chen et al., 1991, 032295; Feany et al., 2001, 020604; Hsu et al., 1997, 196227; Pelletier et al., 1992, 032500).

Hovda et al. (2005, 087791) presented a combined prospective and retrospective case series study of 51 individuals in Norway (39 males and 12 females, many of whom were alcoholics) who were hospitalized after consuming tainted spirits containing 20% methanol and 80% ethanol. In general, serum methanol concentrations were highest among those most severely affected. The poor outcome was closely correlated with the degree of metabolic acidosis. It was noted by the investigators that the concomitant consumption of ethanol prevented more serious sequelae in 2/5 individuals who presented with detectable ethanol levels and were not acidotic despite 2 having the highest blood methanol levels. However, others with detectable levels of ethanol along with severe metabolic acidosis (two of whom died) presumably had subtherapeutic levels of ethanol in their system.

In a later report, Hovda et al. (2007, 092989) focused on formate kinetics in a 63-year-old male who died 6 days after being admitted to the hospital with headache, vomiting, reduced vision, and dizziness. The investigators speculated that the prolonged metabolic acidosis observed ($T^{1/2}$ for formic acid was 77 hours before dialysis, compared to a typical normal range of 2.5-12 hours) may have been related to retarded formate elimination.

Hovda and colleagues (Hunderi et al., 2006, 090791) found a strong correlation between blood methanol concentration and the osmolal gap ($R^2 = 0.92$) among 17 patients undergoing dialysis after consuming methanol-contaminated spirits. They concluded that the osmolal gap could be taken as a priori indication of methanol poisoning and be used to guide initiation and duration of dialysis. As they indicated, many hours of dialysis could be safely dispensed with. The osmolal gap pertains to the effect that methanol (and other alcohols) has on the depression of the freezing point of blood in the presence of normal solutes. Braden et al. (1993, 196164) demonstrated in case studies that the disappearance of the osmolal gap correlates with the correction of acidosis; they cautioned that methanol and ethanol should not be assumed to be the main factors in causing osmolal gap as glycerol and acetone and its metabolites can as well. A more detailed discussion of the anion and osmolal gap has been provided by Henderson and Brubacher (2002, 093106).

Hassanian-Moghaddam et al. (2007, 092987) compiled data on the prognostic factor relating to outcome in methanol-poisoning cases in Iran. They examined 25 patients, 12 of whom died; 3 of the survivors were rendered blind. There was a significant difference in mean pH of the first arterial blood gas measurements of those who subsequently died compared with survivors. It was concluded that poor prognosis was associated with pH <7, coma upon admission, and >24-hours delay from intake to admission.

The use of blood methanol levels as predictors of outcome is generally not recommended (Barceloux et al., 2002, 180477). These investigators cited differences in sampling time,

ingestion of ethanol, and levels of toxic (e.g., formic acid) metabolites among the complicating factors. As an illustration, the case report by Prabhakaran et al. (1993, 196154) cites two women who ingested a methanol solution (photocopying diluent) at about the same time, were admitted to the hospital about the same time (25-26 hours after ingestion) and had identical plasma methanol concentrations (83 mg/dL; 830 mg/L) upon admission, but different outcomes. Patient #1 was in metabolic acidosis and had an unstable conscious state even after treatment. Upon discharge at day 6, there were no apparent sequelae. Patient #2 had severe metabolic acidosis, fixed and dilated pupils, and no brain stem reflexes. This patient died at day 3 even though therapeutic measures had been administered.

In a discussion of 3 fatal methanol-overexposure cases, Andresen et al. (2008, 196179) found antemortem blood methanol levels of 540 and 740 mg/dL (5,400 and 7,400 mg/L) in two individuals. At autopsy brain stem blood levels were 738 and 1,008 mg/dL (7,380 and 10,080 mg/L), respectively. These brain levels were much higher than blood levels postmortem. Autopsy revealed brain and pulmonary edema in all three individuals; in the two who had the longer survival times, there was hemorrhagic necrosis of the putamen and hemorrhages of the tissue surrounding the optic nerve. In their study of 26 chronic users of methylated spirits, Meyer et al. (2000, 196237) found that the best predictor of death or a poor outcome in chronic abusers was a pH <7.0; there was no correlation between blood methanol levels and outcome. Mahieu et al. (1989, 196297) considered a latency period before treatment exceeding 10 hours and a blood formate level >50 mg/dL (500 mg/L) as predictive of possible permanent sequelae. Liu et al. (1998, 086518) in their examination of medical records of 50 patients treated for methanol poisoning over a 10-year period found that: (1) deceased patients had a higher mean blood methanol level than survivors; and (2) initial arterial pH levels <7.0 (i.e., severe metabolic acidosis). Coma or seizure was also associated with higher mortality upon hospital admission.

Numerous cases of methanol poisoning have been documented in a variety of countries. In Tunisia, 16 cases of methanol poisoning were discussed by Brahmi et al. (2007, 092993). Irreversible blindness occurred in two individuals, with others reporting CNS symptoms, GI effects, visual disturbances, and acidosis. Putaminal necrosis was also described in case reports from Iran (Sefidbakht et al., 2007, 093050). Of 634 forensic autopsies carried out in Turkey during 1992-2003, 18 appeared to be related to methanol poisoning (Azmak, 2006, 090781). Brain edema and focal necrosis of the optic nerve were among various sequelae noted. Dethlefs and colleagues (Dethlefs and Naraqi, 1978, 031038; Naraqi et al., 1979, 196252) described permanent ocular damage in 8/24 males who ingested methanol in Papua New Guinea.

In summary, most cases of accidental/intentional methanol poisoning reveal a common set of symptoms, many of which are likely to be presented upon hospital admission. These include:

- blurred vision and bilateral or unilateral blindness
- convulsions, tremors, and coma
- nausea, headache, and dizziness
- abdominal pain
- diminished motor skills
- acidosis
- dyspnea
- behavioral and/or emotional deficits
- speech impediments

Acute symptoms generally are nausea, dizziness, and headache. In the case reports cited above, the onset of symptom sets as well as their severity varies depending upon how much methanol was ingested, whether or not and when appropriate treatment was administered, and individual variability. A longer time between exposure and treatment, with few exceptions, results in more severe outcomes (e.g., convulsions, coma, blindness, and death). The diminution of some acute and/or delayed symptoms may reflect concomitant ingestion of ethanol or how quickly therapeutic measures (one of which includes ethanol infusion) were administered in the hospital setting.

Those individuals who are in a metabolic acidotic state (e.g., pH <7.0) are typically the individuals who manifest the more severe symptoms. Many case reports stress that, unlike blood pH levels <7.0, blood levels of methanol are not particularly good predictors of health outcome. According to a publication of the American Academy of Clinical Toxicology (Barceloux et al., 2002, 180477), "the degree of acidosis at presentation most consistently correlates with severity and outcome."

As the case reports demonstrate, those individuals who present with more severe symptoms (e.g., coma, seizures, severe acidosis) generally exhibit higher mortality (even after treatment) than those without such symptoms. In survivors of poisoning, persistence or permanence of vision decrements and particularly blindness often have been observed

Correlation of symptomatology with blood levels of methanol has been shown to vary appreciably between individuals. Blood methanol levels in the case reports involving ingestion ranged from values of 30 to over 1,000 mg/dL (300 to over 10,000 mg/L). The lowest value (20 mg/dL; 200 mg/L) reported (Adanir et al., 2005, 196175) involved a case of percutaneous absorption (with perhaps associated inhalation exposure) that led to vision and CNS deficits after

1 hospital discharge. In one case report (Rubinstein et al., 1995, 077842) involving ingestion,
2 coma and subsequent death were associated with an initial blood methanol level of 36 mg/dL
3 (360 mg/L).
4   Upon MRI and CT scans, the more seriously affected individuals typically have focal
5 necrosis in both brain white matter and more commonly, in the putamen. Bilateral hemorrhagic
6 and nonhemorrhagic necrosis of the putamen is considered by many radiologists as the most
7 well-known sequelae of methanol overexposure.

4.1.2. Occupational Studies

8   Occupational health studies have been carried out to investigate the potential effects of
9 chronic exposure to lower levels of methanol than those seen in acute poisoning cases such as
10 those described above. For example, Frederick et al. (1984, 031063) conducted a health hazard
11 evaluation on behalf of the National Institute for Occupational Safety and Health (NIOSH) to
12 determine if vapor from duplicating fluid (which contains 99% methanol) used in mimeograph
13 duplicating machines caused adverse health effects in exposed persons. A group of 84 teacher's
14 aides were selected for study, 66 of whom responded with a completed medical questionnaire. A
15 group of 297 teachers (who were not exposed to methanol vapors to the same extent as the
16 teacher's aides) completed questionnaires as a control group. A 15-minute breathing zone
17 sample was taken from 21 duplicators, 15 of which were greater than the NIOSH-recommended
18 short term ceiling concentration of 800 ppm (1048 mg/m^3). The highest breathing zone
19 concentrations were in the vicinity of duplicators for which no exhaust ventilation had been
20 provided (3,080 ppm [4,036 mg/m^3] was the highest value recorded). Upon comparison of the
21 self-described symptoms of the 66 teacher's aides with those of 66 age-matched teachers chosen
22 from the 297 who responded, the number of symptoms potentially related to methanol were
23 significantly higher in the teacher's aides. These included blurred vision (22.7 versus 1.5%),
24 headache (34.8 versus 18.1%), dizziness (30.3 versus 1.5%), and nausea (18 versus 6%). By
25 contrast, symptoms that are not usually associated with methanol exposure (painful urination,
26 diarrhea, poor appetite, and jaundice) were similar in incidence among the groups.
27   To further investigate these disparities, NIOSH physicians (not involved in the study)
28 defined a hypothetical case of methanol toxicity by any of the following four symptom
29 aggregations: (1) visual changes; (2) one acute symptom (headache, dizziness, numbness,
30 giddiness, nausea or vomiting) combined with one chronic symptom (unusual fatigue, muscle
31 weakness, trouble sleeping, irritability, or poor memory); (3) two acute symptoms; or (4) three
32 chronic symptoms. By these criteria, 45% of the teacher's aides were classified as being
33 adversely affected by methanol exposure compared to 24% of teachers ($p < 0.025$). Those

teacher's aides and teachers who spent a greater amount of time using the duplicators were affected at a higher rate than those who used the machines for a lower percentage of their work day.

Tanner (1992, 032549) reviewed the occupational and environmental causes of Parkinsonism, spotlighting the potential etiological significance of manganese, carbon monoxide, repeated head trauma (such as suffered by boxers), and exposure to solvents. Among the latter, Tanner (1992, 032549) discussed the effects of methanol and n-hexane on the nervous system. Acute methanol intoxication resulted in inebriation, followed within hours by GI pain, delirium, and coma. Tanner (1992, 032549) pinpointed the formation of formic acid, with consequent inhibition of cytochrome oxidase, impaired mitochondrial function, and decreased ATP formation as relevant biochemical and physiological changes for methanol exposure. Nervous system injury usually includes blindness, Parkinson-like symptoms, dystonia, and cognitive impairment, with injury to putaminal neurons most likely underlying the neurological responses.

Kawai et al. (1991, 032418) carried out a biomarker study in which 33 occupationally exposed workers in a factory making methanol fuel were exposed to concentrations of methanol of up to 3,577 ppm (4,687 mg/m^3), as measured by personal samplers of breathing zone air. Breathing zone exposure samples were correlated with the concentrations of methanol in urine at the end of the shift in 38 exposed individuals and 30 controls (r = 0.82). Eleven of 22 individuals who experienced high exposure to methanol (geometric mean of 459 ppm [601 mg/m^3]) complained of dimmed vision during work while 32% of this group of workers experienced nasal irritation. These incidences were statistically significant compared to those of persons who worked in low-exposure conditions (geometric mean of 31 ppm [41 mg/m^3]). One 38-year-old female worker who had worked at the factory for only 4 months reported that her visual acuity had undergone a gradual impairment. She also displayed a delayed light reflex.

Lorente et al. (2000, 056310) carried out a case control study of 100 mothers whose babies had been born with cleft palates. Since all of the mothers had worked during the first trimester, Lorente et al. (2000, 056310) examined the occupational information for each subject in comparison to 751 mothers whose babies were healthy. Industrial hygienists analyzed the work histories of all subjects to determine what, if any, chemicals the affected mothers may have been exposed to during pregnancy. Multivariate analysis was used to calculate odds ratios, with adjustments made for center of recruitment, maternal age, urbanization, socioeconomic status, and country of origin. Occupations with positive outcomes for cleft palate in the progeny were hairdressing (OR = 5.1, with a 95% confidence interval [CI] of 1.0-26) and housekeeping (OR = 2.8, with a 95% CI of 1.1-7.2). Odds ratios for cleft palate only and cleft lip with or without

cleft palate were calculated for 96 chemicals. There seemed to be no consistent pattern of
association for any chemical or group of chemicals with these impairments, and possible
exposure to methanol was negative for both outcomes.

4.1.3. Controlled Studies

Two controlled studies have evaluated humans for neurobehavioral function following
exposure to ~200 ppm (262 mg/m^3) methanol vapors in a controlled setting. The occupational
TLV established by the American Conference of Governmental Industrial Hygienists (ACGIH,
2000, 002886) is 200 ppm (262 mg/m^3). In a pilot study by Cook et al. (1991, 032367), 12
healthy young men (22-32 years of age) served as their own controls and were tested for
neurobehavioral function following a random acute exposure to air or 191 ppm (250 mg/m^3)
methanol vapors for 75 minutes. The majority of results in a battery of neurobehavioral
endpoints were negative. However, statistical significance was obtained for results in the P-200
and N1-P2 component of event-related potentials (brain wave patterns following light flashes
and sounds), the Sternberg memory task, and subjective evaluations of concentration and fatigue.
 As noted by the Cook et al. (1991, 032367), effects were mild and within normal ranges. Cook
et al. (1991, 032367) acknowledged limitations in their study design, such as small sample size,
exposure to only one concentration for a single duration time, and difficulties in masking the
methanol odor from experimental personnel and study subjects.

In a randomized double-blind study, neurobehavioral testing was conducted on 15 men
and 11 women (healthy, aged 26-51 years) following exposure to 200 ppm (262 mg/m^3)
methanol or water vapors for 4 hours (Chuwers et al., 1995, 081298); subjects served as their
own controls in this study. Exposure resulted in elevated blood and urine methanol levels (up to
peak levels of 6.5 mg/L and 0.9 mg/L, respectively) but not formate concentrations. The
majority of study results were negative. No significant findings were noted for visual,
neurophysiological, or neurobehavioral tests except for slight effects ($p < 0.05$) on P-300
amplitude (brain waves following exposure to sensory stimuli) and Symbol Digit testing (ability
to process information and psychomotor skills). Neurobehavioral performance was minimally
affected by methanol exposure at this level. Limitations noted by Chuwers et al. (1995, 081298)
are that studies of alcohol's affect on P-300 amplitude suggest that this endpoint may be biased
by unknown factors and some experimenters and subjects correctly guessed if methanol was
used.

Although the slight changes in P-200 and P-300 amplitude noted in both the Chuwers
et al. (1995, 081298) and Cook et al. (1991, 032367) studies may be an indication of moderate
alterations in cognitive function, the results of these studies are generally consistent and suggest

that the exposure concentrations employed were below the threshold for substantial neurological effects. This is consistent with the data from acute poisoning events which have pointed to a serum methanol threshold of 200 mg/L for the instigation of acidosis, visual impairment, and CNS deficits.

Mann et al. (2002, 034724) studied the effects of methanol exposure on human respiratory epithelium as manifested by local irritation, ciliary function, and immunological factors. Twelve healthy men (average age 26.8 years) were exposed to 20 and 200 ppm (26.2 and 262 mg/m^3, respectively) methanol for 4 hours at each concentration; exposures were separated by 1-week intervals. The 20 ppm (26.2 mg/m^3) concentration was considered to be the control exposure since previous studies had demonstrated that subjects can detect methanol concentrations of 20 ppm (26.2 mg/m^3) and greater. Following each single exposure, subclinical inflammation was assessed by measuring concentrations of interleukins (IL-8, IL-1β, and IL-6) and prostaglandin E2 in nasal secretions. Mucociliary clearance was evaluated by conducting a saccharin transport time test and measuring ciliary beat frequency. Interleukin and prostaglandin data were evaluated by a 1-tailed Wilcoxon test, and ciliary function data were assessed by a 2-tailed Wilcoxon test. Exposure to 200 (262 mg/m^3) versus 20 ppm (26.2 mg/m^3) methanol resulted in a statistically-significant increase in IL-1β (median of 21.4 versus 8.3 pg/mL) and IL-8 (median of 424 versus 356 pg/mL). There were no significant effects on IL-6 and prostaglandin E2 concentration, ciliary function, or on the self-reported incidence of subjective symptoms of irritation. The authors concluded that exposure to 200 ppm (262 mg/m^3) methanol resulted in a subclinical inflammatory response.

In summary, adult human subjects acutely exposed to 200 ppm (262 mg/m^3) methanol have experienced slight neurological (Chuwers et al., 1995, 081298) and immunological effects (increased subclinical biomarkers for inflammation) with no self-reported symptoms of irritation (Mann et al., 2002, 034724). These exposure levels were associated with peak methanol blood levels of 6.5 mg/L (Chuwers et al., 1995, 081298), which is approximately threefold higher than background methanol blood levels reported for adult human subjects on methanol-restrictive diets (Table 3-1). Nasal irritation effects have been reported by adult workers exposed to 459 ppm (601 mg/m^3) methanol (Kawai et al., 1991, 032418). Frank effects such as blurred vision, bilateral or unilateral blindness, coma, convulsions/tremors, nausea, headache, abdominal pain, diminished motor skills, acidosis, and dyspnea begin to occur as blood levels approach 200 mg methanol/L, while 800 mg/L appears to be the threshold for lethality. Data for subchronic, chronic or in utero human exposures are very limited and inconclusive.

4.2. ACUTE, SUBCHRONIC AND CHRONIC STUDIES AND CANCER BIOASSAYS IN ANIMALS – ORAL AND INHALATION

1   A number of studies in animals have investigated the acute, subchronic, and chronic

2   toxicity of methanol. Most are via the inhalation route. Presented below are summaries of these

3   investigations.

4.2.1. Oral Studies

4.2.1.1. *Acute Toxicity*

4   Although there are few studies that have examined the short-term toxic effects of

5   methanol via the oral route, a number of median lethal dose (LD_{50}) values have been published

6   for the compound. As listed in Lewis (1992, 001649), these include 5,628 mg/kg in rats, 7,300

7   mg/kg in mice, and 7,000 mg/kg in monkeys.

4.2.1.2. *Subchronic Toxicity*

8   An oral repeat dose study was conducted by the EPA (1986c) in rats. Sprague-Dawley

9   rats (30/sex/dose) were gavaged with 0, 100, 500, or 2,500 mg/kg-day of methanol. Six weeks

10 after dosing, 10 rats/sex/dose group were subjected to interim sacrifice, while the remaining rats

11 continued on the dosing regimen until the final sacrifice (90 days). This study generated data on

12 weekly body weights and food consumption, clinical signs of toxicity, ophthalmologic

13 evaluations, mortality, blood and urine chemistry (from a comprehensive set of hematology,

14 serum chemistry, and urinalysis tests), and gross and microscopic evaluations for all test animals.

15   Complete histopathologic examinations of over 30 organ tissues were done on the control and

16 high-dose rats. Histopathologic examinations of livers, hearts, and kidneys and all gross lesions

17 seen at necropsy were done on low-dose and mid-dose rats. There were no differences between

18 dosed animals and controls in body weight gain, food consumption, or upon gross or

19 microscopic evaluations. Elevated levels ($p \leq 0.05$ in males) of serum alanine transaminase

20 (ALT)[15] and serum alkaline phosphatase (SAP), and increased (but not statistically significant)

21 liver weights in both male and female rats suggest possible treatment-related effects in rats bolus

22 dosed with 2,500 mg methanol/kg-day despite the absence of supportive histopathologic lesions

23 in the liver. Brain weights of high-dose group (2,500 mg/kg-day) males and females were

24 significantly less than those of the control group at terminal sacrifice. Based on these findings,

25 500 mg/kg-day of methanol is considered an NOEL from this rat study.

---

[15] Also known as serum glutamate pyruvate transaminase (SGPT)

4.2.1.3. *Chronic Toxicity*

A report by Soffritti et al. (2002, 091004) summarized a European Ramazzini Foundation (ERF) chronic duration experimental study of methanol[16] in which the compound was provided to 100 Sprague-Dawley rats/sex/group ad libitum in drinking water at concentrations of 0, 500, 5,000, and 20,000 ppm (v/v). The animals were 8 weeks old at the beginning of the study. In general, ERF does not randomly assign animals to treatment groups, but assigns all animals from a given litter to the same treatment group (Bucher, 2002, 196169). All rats were exposed for up to 104 weeks, then maintained until they died naturally. Rats were housed in groups of 5 in Makrolon cages ($41 \times 25 \times 15$ cm) in a room that was maintained at $23 \pm 2°C$ and 50–60% relative humidity. The in-life portion of the experiment ended at 153 weeks with the death of the last animal. Mean daily drinking water, food consumption, and body weights were monitored weekly for the first 13 weeks, every 2 weeks thereafter for 104 weeks, then every 8 weeks until the end of the experiment. Clinical signs were monitored 3 times/day, and the occurrence of gross changes was evaluated every 2 weeks. All rats were necropsied at death then underwent histopathologic examination of organs and tissues.[17]

Soffritti et al. (2002, 091004) reported no substantial dose-related differences in survival, but no data were provided. Using individual animal data available from the ERF website,[18] Cruzan (2009, 196354) reports that male rats treated with methanol generally survived better than controls, with 50% survival occurring at day 629, 686, 639 and 701 in the 0, 500, 5,000, and 20, 000 mg/L groups, respectively. There were no significant differences in survival between female control and treatment groups, with 50% survival occurring at day 717, 691, 678 and 708 in the 0, 500, 5,000, and 20, 000 mg/L groups, respectively. Body weight and water and food consumption were monitored in the study, but the data were not documented in the published report. However, based on data available from the ERF website, average doses of 0, 53.2, 524, and 1,780 mg/kg-day in males and 0, 66.0, 624.1, and 2,177 mg/kg-day in females could be calculated (see Appendix E) from drinking water concentrations of 0, 500, 5,000, and 20,000 ppm.

---

[16] Soffritti et al. (2002, 091004) report that methanol was obtained from J.T. Baker, Deventer, Holland, purity grade 99.8%.

[17] Histopathology was performed on the following organs and tissues: skin and subcutaneous tissue, brain, pituitary gland, Zymbal glands, parotid glands, submaxillary glands, Harderian glands, cranium (with oral and nasal cavities and external and internal ear ducts) (5 sections of head), tongue, thyroid and parathyroid, pharynx, larynx, thymus and mediastinal lymph nodes, trachea, lung and mainstem bronchi, heart, diaphragm, liver, spleen, pancreas, kidneys, adrenal glands, esophagus, stomach (fore and glandular), intestine (four levels), urinary bladder, prostate, gonads, interscapular fat pad, subcutaneous and mesenteric lymph nodes, and any other organs or tissues with pathologic lesions.

[18] http://www.ramazzini.it/fondazione/foundation.asp.

Soffritti et al. (2002, 091004) reported that water consumption in high-dose females was reduced compared to controls between 8 and 56 weeks and that the mean body weight in high-dose males tended to be higher than that of control males. Overall, there was no pattern of compound-related clinical signs of toxicity, and the available data did not provide any indication that the control group was not concurrent with the treated group (Cruzan, 2009, 196354). Soffritti et al. (2002, 091004) further reported that there were no compound-related signs of gross pathology or histopathologic lesions indicative of noncancer toxicological effects in response to methanol.

Soffritti et al. (2002, 091004) reported a number of oncogenic responses to methanol (Table 4-2), principally hemolymphoreticular neoplasms, the majority of which were reported to be lympho-immunoblastic lymphomas. In ERF bioassays, including this methanol study, hemolymphoreticular neoplasms are generally divided into specific histological types (lymphoblastic lymphoma, lymphoblastic leukemia, lymphocytic lymphoma, lympho-immunoblastic lymphoma, myeloid leukemia, histocytic sarcoma, and monocytic leukemia) for identification purposes. According to Soffritti et al. (2007, 196366), the overall incidence of hemolymphoreticular tumors (lymphomas/leukemias) in ERF studies is 13.3% (range, 4.0–25.0%) in female historical controls (2,274 rats) and 20.6% (range, 8.0–30.9%) in male historical controls (2,265 rats). The high-dose responses, shown in Table 4-2, of 28% and 40% for females and males, respectively, are above their corresponding historical ranges.[19]

---

[19] While historical control data can be informative, for reasonably well-conducted studies, it should not take precedence over concurrent controls or appropriate statistical dose-response trend tests.

Table 4-2. Incidence of carcinogenic responses in Sprague-Dawley rats exposed to methanol in drinking water for up to 2 years

Tissues/affected sites	Dose (mg/kg-day)							
	Males				Females			
	0	53.2	524	1780	0	66.0	624.1	2177
Ear duct (carcinomas)	9/100	13/100	17/100	24/100[b]	9/100	8/100	16/100	19/100
Head (osteosarcomas)	6/100	6/100	13/100	11/100	1/100	4/100	3/100	6/100
Hemolymphoreticular tumors	28/100	35/100	36/100	40/100	13/100	24/100	24/100	28/100[a]
Liver (hepatocarcinomas)	0/100	2/100	2/100	3/100	0/100	0/100	1/100	0/100
Testis (interstitial cell adenomas)	12/100	9/100	13/100	17/100				
Total malignant tumors	50/100	55/100	64/100	70/100[b]	43/100	48/100	48/100	63/100[b]

[a]$p < 0.05$ using the χ^2 test.
[b]$p < 0.01$ using the χ^2 test.

Source: Soffritti et al. (2002, 091004).

The National Toxicology Program (NTP) does not routinely subdivide lymphomas into specific histological types as was done by the ERF. In 2004, a Pathology Working Group (PWG) of National Institute of Environmental Health Sciences (NIEHS) performed a limited review of about 75 slides provided by ERF as representative of lesions in Sprague-Dawley rats associated with aspartame exposure (EFSA, 2006, 196098; Hailey, 2004, 089842). The primary objective of this review was to "provide a second opinion for this set of lesions by a group of pathologists experienced in Toxicologic Pathology."[20] Eleven of the slides reviewed by the PWG were related to lymphomas, and three of these had been classified by ERF as lympho-immunoblastic. The PWG concluded that "The diagnoses of lymphatic and histocytic neoplasms in the cases reviewed were generally confirmed" (Hailey, 2004, 089842). In particular, the PWG accepted the more specific diagnoses of ERF when the lesions were considered to be consistent with a neoplasm of lymphocytic, histocytic, monocytic, and/or myeloid origin. The PWG noted, however, that while lymphoblastic lymphomas, lymphocytic lymphomas, lympho-immunoblastic lymphomas, and lymphoblastic leukemias as malignant lymphomas can be combined, myeloid leukemias, histocytic sarcomas, and monocytic leukemia should be treated as separate malignancies and not combined with the other lymphomas since they are of different cellular origin (Hailey, 2004, 089842). McConnell et al. (1986, 073655) and Cruzan (2009, 196354) have also noted that myeloid leukemia, histocytic sarcoma, and monocytic leukemia are of a

---

[20] This review was not considered a "peer review" of the pathology data from this study. As noted by Hailey (2004, 089842), "a peer review would necessitate a review of the study data by a second party, and selection and examination of lesions based upon that data review."

1 different cell line and are not typically combined with other lymphomas for statistical

2 significance or dose-response modeling. Consistent with these judgments, EPA has not included

3 the myeloid leukemia, histocytic sarcoma, and monocytic leukemia in combination with

4 lymphoblastic lymphoma, lymphoblastic leukemia, lymphocytic lymphoma, and lympho-

5 immunoblastic lymphoma in its consideration of tumorgenic responses reported by ERF (see

6 Section 5.4.1; Table 5-6). Thus, EPA's analysis of this tumorogenic response differs from the

7 lymphoreticular tumor response shown in Table 4-2 and reported by Soffritti et al. (2002,

8 091004). As described in Section 5.4.1.1, EPA's analysis indicates a significant increase in

9 tumor response at the two highest doses for males and across all doses for females (Fisher's

10 exact, $p < 0.05$), as well as a significant dose-response trend (Cochran Armitage trend test;

11 $p < 0.05$).

12   Schoeb et al. (2009, 196192) have suggested that the interpretation of lesions in ERF

13 studies, including the Soffritti et al. (2002, 091004) methanol study, may have been confounded

14 by a respiratory infection referred to as *Mycoplasma pulmonis (M. pulmonis)* disease and that

15 lesions of this disease were interpreted as lymphoma. They noted that lympho-immunoblastic

16 lymphoma is not listed as a lymphoma type in rats in available reference sources and that the

17 cellular morphology of the lung lympho-immunoblastic lymphomas reported by ERF for

18 aspartame (Soffritti et al., 2005, 087840) and MTBE (Belpoggi et al., 1999, 196209) studies are

19 more consistent with *M. pulmonis* disease. As noted above, an NIEHS PWG (Hailey, 2004,

20 089842) has confirmed the ERF diagnosis of the several lymphomas, including three lymphomas

21 from the lung, thymus and medullary lymph node and mesenteric lymph node that were

22 characterized by ERF as "lympho-immunoblastic." Hailey (2004, 089842) reports that the PWG

23 "accepted their [ERF's] more specific diagnosis if the lesion was considered to be consistent

24 with a neoplasm of lymphocytic, histocytic, monocytic, and/or myeloid origin." The concerns of

25 Schoeb et al. (2009, 196192) regarding the possibility of infection confounding the interpretation

26 of lung lesions in the ERF study are not unfounded. Chronic inflammatory changes are

27 apparently a common finding in ERF studies (Caldwell et al., 2008, 196182), probably caused by

28 the ERF bioassay design that does not employ specific pathogen-free (SPF) rats (EFSA, 2006,

29 196098) and allows the rats to live out their "natural life span" in the absence of disease barriers

30 (e.g., fully enclosed cages). However, the existence of an *M. pulmonis* infection in the rat colony

31 used for the ERF methanol study has not been confirmed (Caldwell et al., 2008, 196182) and the

32 existing indirect evidence for such an infection does not provide a sufficient basis for

33 discounting the ERF methanol study results. Further, even if the rats of the ERF methanol study

34 were suffering from a respiratory infection that confounded the interpretation of lung lesions,

35 60% of reported lymphoma incidences involved other organ systems, and the dose-response for

lymphomas in other organ systems is not remarkably different than for all lymphomas (see analysis in Section 5.4.3.2).

Another cancer response, reported by Soffritti et al. (2002, 091004), that is considered to be potentially related to methanol exposure was an increase in rare hepatocellular carcinomas in male rats. Although the increase was not statistically increased compared to concurrent controls, EPA has analyzed historical data for this tumor type in this species and determined that the incidence in all dose groups was significantly elevated relative to historical controls (Fisher's exact $p < 0.05$ for all doses and $p < 0.01$ for the high-dose group). The historical control group (n = 407) used was the combined control groups from ERF studies for which individual animal pathology data have been made available via the ERF website[21] and include data for methanol, formaldehyde, aspartame, MTBE, and TAME.

As noted in Table 4-2, increased incidences of carcinomas of the ear ducts and osteosarcomas of the head were reported for both female and male rats, with a statistically significant increase in only the high-dose male ear duct carcinomas. Ear duct carcinomas are a rare finding in Charles River rats and NTP historical databases of Sprague-Dawley rats (Cruzan, 2009, 196354). In their limited review of pathology slides from the ERF aspartame bioassay (2005, 087840; Soffritti et al., 2006, 196735), NTP pathologists interpreted a majority of such head pathologies, including in the ear duct, as being hyperplastic in nature, not carcinogenic (EFSA, 2006, 196098; Hailey, 2004, 089842). Soffritti et al. (2002, 091004) also noted an increased incidence of testicular hyperplasia in high-dose males and uterine sarcomas in high-dose females compared to controls. However, these increases were not statistically significant and were within historical control ranges for this species and strain (Haseman et al., 1998, 094054; NTP, 1999, 196291; NTP, 2007, 196299). The group-specific total number of malignant tumors was also shown to increase with dose in both sexes of rats.

Apaja (1980, 191208) performed dermal and drinking water chronic bioassays in which male and female Eppley Swiss Webster mice (25/sex/dose group; 8 weeks old at study initiation) were exposed 6 days per week until natural death to various concentrations of malonaldehyde and methanol. The stated purpose of the study was to determine the carcinogenicity of malonaldehyde, a product of oxidative lipid deterioration in rancid beef and other food products in advanced stages of degradation. However, due to its instability, malonaldehyde was obtained from the more stable malonaldehyde bis(dimethyacetal), which was hydrolyzed to malonaldehyde and methanol in dilute aqueous solutions in the presence of a strong mineral acid. In the drinking water portion of this study, mice were exposed to 3 different concentrations

---

[21] http://www.ramazzini.it/fondazione/foundation.asp.

of the malonaldehyde/methanol solution and three different control solutions of methanol alone, 0.222%, 0.444% and 0.889% methanol in drinking water (222, 444 and 889 ppm, assuming a density of 1 g/ml), corresponding to the stoichiometric amount of methanol liberated by hydrolysis of the acetal in the three test solutions. The methanol was described as Mallinckrodt analytical grade. No unexposed control groups were included in these studies. However, the author provided pathology data from historical records of untreated Swiss mice of the Eppley colony used in two separate chronic studies, one involving 100 untreated males and 100 untreated females (Toth et al., 1977, 196730) and the other involving 100 untreated females histopathological analyzed by Apaja (Apaja, 1980, 191208).

Mice in the Apaja (1980, 191208) study were housed five/plastic cage and fed Wayne Lab-Blox pelleted diet. Water was available ad libitum throughout life. Liquid consumption per animal was measured 3 times/week. The methanol dose in the dermal study (females only) was 21.3 mg (532 mg/kg-day using an average weight of 0.04 kg as approximated from Figure 4 of the study), three times/week. The methanol doses in the drinking water study were reported as 22.6, 40.8 and 84.5 mg/day (560, 1,000 and 2,100 mg/kg-day using an average weight of 0.04 kg as approximated from Figures 14-16 of the study) for females, and 24.6, 43.5 and 82.7 mg/day (550, 970, and 1,800 mg/kg-day using an average weight of 0.045 kg as approximated from Figures 14-16 of the study) for males, 6 days/week. The animals were checked daily and body weights were monitored weekly. The in-life portion of the experiment ended at 120 weeks with the death of the last animal. Like the Soffritti et al. (2002, 091004) study, test animals were sacrificed and necropsied when moribund.[22]

The authors reported that survival of the methanol exposed females of the drinking water study was lower than untreated historical controls ($p < 0.05$), but no significant differences in survival was noted for males. An increase in liver parenchymal cell necrosis was reported in the male and female high-dose groups, with the incidence in females (8%) being significant ($p < 0.01$) relative to untreated historical controls. Incidence of acute pancreatitis was higher in high-dose males ($p < 0.001$), but did not appear to be dose-related in females, increasing at the mid- ($p < 0.0001$) and low-doses ($p < 0.01$) when compared to historical controls but not appearing at all in the high-dose females. Significant increases relative to untreated historical controls were noted in amyloidosis of the spleen, nephropathy and pneumonia, but the increases did not appear to be dose related.

---

[22] The following tisues were fixed in 10% formalin (pH 7.5), embedded in paraffin, sectioned, stained routinely with hematoxylineosin (special stains used as needed) and histologically evaluated: skin, lungs, liver spleen, pancreas, kidneys, adrenal glands, esophagus, stomach, small and large intestines, rectum, urinary bladder, uterus and ovaries or testes, prostate glands and tumors or other gross pathological lesions.

1   The author reported incidences of malignant lymphoma in females of 15%, 16%, 36%,

2 and 40% for 532 mg/kg-day (dermal), 560, 1,000, and 2,100 mg/kg-day (drinking water),

3 respectively. Males from the drinking water study had incidences of malignant lymphoma of 4,

4 24, and 16% for 550, 970, and 1,800 mg/kg-day. The lymphomas were classified according to

5 Rappaport's classification (Rappaport, 1966, 196160), but location of the lymphoma (organ

6 system) was not reported. The distributions of lymphomas according to subclasses reported by

7 the author are shown in Table 4-3 for historical untreated and methanol exposed mice in the

8 drinking water studies. The author indicates that the incidences in both males and females were

9 "within the normal range of occurrence of malignant lymphomas in Eppley Swiss mice," but

10 provides no references or supporting data for this statement and reports elsewhere that the

11 response in high-dose females and mid-dose males were significantly different from unexposed

12 mice from "historical data of untreated controls (Table 9)" of Toth et al. (1977, 196730)

13 ($p < 0.05$). Though not statistically significant (Fishers exact p = 0.06), the malignant lymphoma

14 response in the mid-dose females was increased over untreated controls from an unpublished

15 study (Hinderer et al., 1979, 200845) for which the histopathology was also performed by Apaja

16 (Apaja, 1980, 191208).

Table 4-3. Incidence of malignant lymphoma responses in Eppley Swiss Webster mice exposed to methanol in drinking water for life (Apaja, 1980, 191208)

Malignant Lymphoma	Dose (mg/kg-day)								
	Males (%)				Females (%)				
	0[a] n=100	550 n=25	970 n=25	1800 n=24	0[a] n=100	0[b] n=100	560 n=25	1,000 n=25	2,100 n=25
Lymphocytic, well diff.						8		4	12
Lymphocytic moderately diff.			4			3		4	4
Lymphocytic, poorly diff.			4	8.3		7	4	4	4
Mixed cell type			4				4	4	8
Histocytic type		4	4	4.2			12	12	8
Unclassified			8	4.2				8	4
Total	8	4	24[c]	17	20	18	16	36[d]	40[c]

[a]Toth et al. (1977, 196730); Toth et al. (1977, 196730) did not report tumor classifications, only total incidence.
[b] Hinderer et al. (1979, 200845); the Hinderer et al. (1979) study was cited in (Apaja, 1980, 191208).
[c]p < 0.05 as reported by author compared with Toth et al. (1977, 196730); The high-dose female response is also significant (p < 0.05; Fishers exact test) versus untreated controls from Hinderer et al. (1979, 200845) and combined controls from both studies.
[d]p = 0.06 by Fishers exact test versus untreated controls from Hinderer et al. (1979, 200845) and combined controls from both studies.

4.2.2. Inhalation Studies

4.2.2.1. *Acute Toxicity*

Lewis (1992, 001649) reported a 4-hour median lethal concentration (LC_{50}) for methanol in rats of 64,000 ppm (83,867 mg/m^3).

Japan's NEDO sponsored a series of toxicological tests on monkeys (*M. fascicularis*), rats, and mice, using inhalation exposure.[23] These are unpublished studies; accordingly, they were externally peer reviewed by EPA in 2009.[24] A short-term exposure study evaluated monkeys (sex unspecified) exposed to 3,000 ppm (3,931 mg/m^3), 21 hours/day for 20 days (1 animal), 5,000 ppm (6,552 mg/m^3) for 5 days (1 animal), 5,000 ppm (6,552 mg/m^3) for 14 days (2 animals), and 7,000 and 10,000 ppm (9,173 and 13,104 mg/m^3, respectively) for up to 6 days (1 animal at each exposure level) (NEDO, 1987, 064574, unpublished report). Most of the experimental findings were discussed descriptively in the report, without specifying the extent of change for any of the effects in comparison to seven concurrent controls. However, the available data indicate that clinical signs of toxicity were apparent in animals exposed to 5,000 ppm (all exposure durations) or higher concentrations of methanol. These included reduced movement, crouching, weak knees, involuntary movements of hands, dyspnea, and vomiting. In the discussion section of the summary report, the authors stated that there was a sharp increase in the blood levels of methanol and formic acid in monkey exposed to >3,000 ppm (3,931 mg/m^3) methanol. They reported that methanol and formic acid concentrations in the blood of monkeys exposed to 3,000 ppm or less were 80 mg/L and 30 mg/L, respectively.[25] In contrast, monkeys exposed to 5,000 ppm or higher concentrations of methanol had blood methanol and formic acid concentrations of 5,250 mg/L and 1,210 mg/L, respectively. Monkeys exposed to 7,000 ppm and 10,000 ppm became critically ill and had to be sacrificed prematurely. Food intake was said to be little affected at 3,000 ppm, but those exposed to 5,000 ppm or more showed a marked reduction. Clinically, the monkeys exposed to 5,000 ppm or more exhibited reduced movement,

---

[23] In their bioassays, NEDO (1987, 064574) used inbred rats of the F344 or Sprague-Dawley strain, inbred mice of the B6C3F1 strain and wild-caught *M. fascicularis* monkeys imported from Indonesia. The possibility of disease among wild-caught animals is a concern, but NEDO (1987, 064574) state that the monkeys were initially quarantined for 9 weeks and measures were taken throughout the studies against the transmission of pathogens for infectious diseases. The authors indicated that "no infectious disease was observed in monkeys" and that "subjects were healthy throughout the experiment."

[24] An external peer review was conducted by EPA in 2009 to evaluate the accuracy of experimental procedures, results, and interpretation and discussion of the findings presented in these study reports. A report of this peer review is available through the EPA's IRIS Hotline at (202) 566-1676 (phone), (202) 566-1749 (fax), or hotline.iris@epa.gov (e-mail address) and on the IRIS website (www.epa.gov/iris).

[25] Note that Burbacher et al. (1999, 009752; 2004, 056018) measured blood levels of methanol and formic acid in control monkeys of 2.4 mg/L and 8.7 mg/L, respectively (see Table 3-3).

weak knees, and involuntary movement of upper extremities, eventually losing consciousness and dying.

There were no significant changes in growth, with the exception of animals exposed to the highest concentration, where body weight was reduced by 13%. There were few compound-related changes in hematological or clinical chemistry effects, although animals exposed to 7,000 and 10,000 ppm showed an increase in white blood cells. A marked change in blood pH values at the 7,000 ppm and 10,000 ppm levels (values not reported) was attributed to acidosis due to accumulation of formic acid. A range of histopathologic changes to the CNS was apparently related to treatment. Severity of the effects was increased with exposure concentration. Lesions included characteristic degeneration of the bilateral putamen, caudate nucleus, and claustrum, with associated edema in the cerebral white matter. Necrosis of the basal ganglia was noted following exposure to 5,000 ppm for 5 days (1 animal) and 14 days(1 animal). Exposure to 3,000 ppm was considered to be close to the threshold for these necrotic effects, as the monkeys exposed at this level experienced little more than minimal fibrosis of responsive stellate cells of the thalamus, hypothalamus and basal ganglion. The authors reported that no clinical or histopathological effects of the visual system were apparent, but that exposure to 3,000 ppm ($3,931 \text{ mg/m}^3$) or more caused dose-dependent fatty degeneration of the liver, and exposure to 5,000 ppm ($6,552 \text{ mg/m}^3$) or more caused vacuolar degeneration of the kidneys, centered on the proximal uniferous tubules.

4.2.2.2. *Subchronic Toxicity*

A number of experimental studies have examined the effects of subchronic exposure to methanol via inhalation. For example, Sayers et al. (1944, 031100) employed a protocol in which 2 male dogs were repeatedly exposed (8 times daily for 3 minutes/exposure) to 10,000 ppm ($13,104 \text{ mg/m}^3$) methanol for 100 days. One of the dogs was observed for a further 5 days before sacrifice; the other dog was observed for 41 days postexposure. There were no clinical signs of toxicity, and both gained weight during the study period. Blood samples were drawn on a regular basis to monitor hematological parameters, but few if any compound-related changes were observed. Ophthalmoscopic examination showed no incipient anomalies at any point during the study period. Median blood concentrations of methanol were 65 mg/L (range 0–280 mg/L) for one dog, and 140 mg/L (70–320 mg/L) for the other.

White et al. (1983, 064578) exposed 4 male Sprague-Dawley rats/group, 6 hours/day, 5 days/week to 0, 200, 2,000, or 10,000 ppm (0, 262, 2,621, and $13,104 \text{ mg/m}^3$) methanol for periods of 1, 2, 4, and 6 weeks. Additional groups of 6-week-exposure animals were granted a 6-week postexposure recovery period prior to sacrifice. The lungs were excised intact and lavaged 6 times with known volumes of physiological saline. The lavage supernatant was then

assayed for lactate dehydrogenase (LDH) and *N*-acetyl-*β*-*D*-glucosamidase (*β*-NAG) activities. Other parameters monitored in relation to methanol exposure included absolute and relative lung weights, lung DNA content, protein, acid RNase and acid protease, pulmonary surfactant, number of free cells in lavage/unit lung weight, surface protein, LDH, and *β*-NAG. As discussed by the authors, none of the monitored parameters showed significant changes in response to methanol exposure.

Andrews et al. (1987, 030946) carried out a study of methanol inhalation in 5 Sprague-Dawley rats/sex/group and 3 *M. fascicularis* monkeys/sex/group, 6 hours/day, 5 days/week, to 0, 500, 2,000, or, 5,000 ppm (0, 660, 2,620, and 6,552 mg/m^3) methanol for 4 weeks. Clinical signs were monitored twice daily, and all animals were given a physical examination once a week. Body weights were monitored weekly, and animals received an ophthalmoscopic examination before the start of the experiment and at term. Animals were sacrificed at term by exsanguination following i.v. barbiturate administration. A gross necropsy was performed, weights of the major organs were recorded, and tissues and organs taken for histopathologic examination. As described by the authors, all animals survived to term with no clinical signs of toxicity among the monkeys and only a few signs of irritation to the eyes and nose among the rats. In the latter case, instances of mucoid nasal discharges appeared to be dose related. There were no differences in body weight gain among the groups of either rats or monkeys, and overall, absolute and relative organ weights were similar to controls. The only exception to this was a decrease in the absolute adrenal weight of female high-concentration monkeys and an increase in the relative spleen weight of mid-concentration female rats. These changes were not considered by the authors to have biological significance. For both rats and monkeys, there were no compound-related changes in gross pathology, histopathology, or ophthalmoscopy. These data suggest a NOAEL of 5,000 ppm (6,600 mg/m^3) for Sprague-Dawley rats and monkeys under the conditions of the experiment.

Two studies by Poon et al. (1994, 074789; 1995, 085499) examined the effects of methanol on Sprague-Dawley rats when inhaled for 4 weeks. The effects of methanol were evaluated in comparison to those of toluene and toluene/methanol mixtures (Poon et al., 1994, 074789), and to gasoline and gasoline/methanol mixtures (Poon et al., 1995, 085499). In the first case (Poon et al., 1994, 074789), 10 Sprague-Dawley rats/sex/group were exposed via inhalation, 6 hours/day, 5 days/week to 0, 300, or 3,000 ppm (0, 393, 3,930 mg/m^3) methanol for 4 weeks. Clinical signs were monitored daily, and food consumption and body weight gain were monitored weekly. Blood was taken at term for hematological and clinical chemistry determinations. Weights of the major organs were recorded at necropsy, and histopathologic examinations were carried out. A 10,000 × g liver supernatant was prepared from each animal to

measure aniline hydroxylase, aminoantipyrine N-demethylase, and ethoxyresorufin-O-deethylase activities. For the most part, the responses to methanol alone in this experiment were unremarkable. All animals survived to term, and there were no clinical signs of toxicity among the groups. Body weight gain and food consumption did not differ from controls, and there were no compound-related effects in hematological or clinical chemistry parameters or in hepatic mixed function oxidase activities. However, the authors described a reduction in the size of thyroid follicles that was more obvious in female than male rats. The authors considered this effect to possibly have been compound related, although the incidence of this feature for the 0, 300, and 3,000 ppm-receiving females was 0/6, 2/6, and 2/6, respectively.

The second experimental report by Poon et al. (1995, 085499) involved the exposure of 15 Sprague-Dawley rats/sex/group, 6 hours/day, 5 days/week for 4 weeks to 0 or 2,500 ppm (0 and 3,276 mg/m^3) to methanol as part of a study on the toxicological interactions of methanol and gasoline. Many of the toxicological parameters examined were the same as those described in Poon et al. (1994, 074789) study. However, in this study urinalysis featured the determination of ascorbic and hippuric acids. Additionally, at term, the lungs and tracheae were excised and aspirated with buffer to yield bronchoalveolar lavage fluid that was analyzed for ascorbic acid, protein, and the activities of gamma-glutamyl transferase (γ-GT), AP and LDH. Few if any of the monitored parameters showed any differences between controls and those animals exposed to methanol alone. However, two male rats had collapsed right eyes, and there was a reduction in relative spleen weight in females exposed to methanol. Histopathologic changes in methanol-receiving animals included mild panlobular vacuolation of the liver in females and some mild changes to the upper respiratory tract, including mucous cell metaplasia. The incidence of the latter effect, though higher, was not significantly different than controls in rats exposed to 2,500 ppm (3,267 mg/m^3) methanol. However, there were also signs of an increased severity of the effect in the presence of the solvent. No histopathologic changes were seen in the lungs or lower respiratory tract of rats exposed to methanol alone.

4.2.2.3. *Chronic Toxicity*

Information on the chronic toxicity of inhalation exposure to methanol has come from NEDO (1987, 064574, unpublished report) which includes the results of experiments on 1) monkeys exposed for up to 3 years, 2) rats and mice exposed for 12 months, 3) mice exposed for

18 months, and 4) rats exposed for 2 years. These are unpublished studies; accordingly, they were externally peer reviewed by EPA in 2009.[26]

In the monkeys, 8 animals (sex unspecified) were exposed to 10, 100, or 1,000 ppm (13, 131, and 1,310 mg/m^3) methanol, 21 hours/day, for 7 months (2 animals), 19 months, (3 animals), or 29 months (3 animals). There was no indication in the NEDO (1987, 064574) report that this study employed a concurrent control group. One of the 3 animals receiving 100 ppm methanol and scheduled for sacrifice at 29 months was terminated at 26 months. Clinical signs were monitored twice daily, body weight changes and food consumption were monitored weekly, and all animals were given a general examination under anesthetic once a month. Blood was collected for hematological and clinical chemistry tests at term, and all animals were subject to a histopathologic examination of the major organs and tissues.

While there were no clinical signs of toxicity in the low-concentration animals, there was some evidence of nasal exudate in monkeys in the mid-concentration group. High-concentration (1,000 ppm) animals also displayed this response and were observed to scratch themselves over their whole body and crouch for long periods. Food and water intake, body temperature, and body weight changes were the same among the groups. NEDO (1987, 064574) reported that there was no abnormality in the retina of any monkey. When animals were examined with an electrocardiogram, there were no abnormalities in the control or 10 ppm groups. However, in the 100 ppm group, one monkey showed a negative change in the T wave. All 3 monkeys exposed to 1,000 ppm (1,310 mg/m^3) displayed this feature, as well as a positive change in the Q wave. This effect was described as a slight myocardial disorder and suggests that 10 ppm (13.1 mg/m^3) is a NOAEL for chronic myocardial effects of methanol and mild respiratory irritation. There were no compound-related effects on hematological parameters. However, 1 monkey in the 100 ppm (131 mg/m^3) group had greater than normal amounts of total protein, neutral lipids, total and free cholesterol, and glucose, and displayed greater activities of ALT and aspartate transaminase (AST). The authors expressed doubts that these effects were related to methanol exposure and speculated that the animal suffered from liver disease.[27]

Histopathologically, no degeneration of the optical nerve, cerebral cortex, muscles, lungs, trachea, tongue, alimentary canal, stomach, small intestine, large intestine, thyroid gland, pancreas, spleen, heart, aorta, urinary bladder, ovary or uterus were reported (neuropathological findings are discussed below in Section 4.4.2. Most of the internal organs showed no

---

[26] An external peer review was conducted by EPA in 2009 to evaluate the accuracy of experimental procedures, results, and interpretation and discussion of the findings presented in these study reports. A report of this peer review is available through the EPA's IRIS Hotline at (202) 566-1676 (phone), (202) 566-1749 (fax), or hotline.iris@epa.gov (e-mail address) and on the IRIS website (www.epa.gov/iris).

[27] Ordinarily, the potential for liver disease in test animals would be remote, but may be a possibility in this case given that these monkeys were captured in the wild.

compound-related histopathologic lesions. However, there were signs of incipient fibrosis and round cell infiltration of the liver in monkeys exposed to 1,000 ppm (1,310 mg/m^3) for 29 months. NEDO (1987, 064574) indicated that this fibrosis occurred in 2/3 monkeys of the 1,000 ppm group to a "strictly limited extent." They also qualitatively reported a dose-dependent increase in "fat granules" in liver cells "centered mainly around the central veins" at all doses, but did not provide any response data. The authors state that 1,000 ppm (1,310 mg/m^3) represents a chronic lowest-observed-adverse-effect level (LOAEL) for hepatic effects of inhaled methanol, suggesting that the no effect level would be 100 ppm (131 mg/m^3). However, this is a tenuous determination given the lack of information on the pathological progression and significance of the appearance of liver cell fat granules at exposures below 1,000 ppm and the lack detail (e.g., time of sacrifice) for the control group.

Dose-dependent changes were observed in the kidney; NEDO (1987, 064574) described the appearance of Sudan-positive granules in the renal tubular epithelium at 100 ppm (131 mg/m^3) and 1,000 (1,310 mg/m^3) and hyalinization of the glomerulus and penetration of round cells into the renal tubule stroma of monkeys exposed to methanol at 1,000 (1,310 mg/m^3). The former effect was more marked at the higher concentration and was thought by the authors to be compound-related. This would indicate a no effect level at 10 ppm (13.1 mg/m^3) for the chronic renal effects of methanol. The authors observed atrophy of the tracheal epithelium in four monkeys. However, the incidence of these effects was unrelated to dose and therefore, could not be unequivocally ascribed to an effect of the solvent. No other histopathologic abnormalities were related to the effects of methanol. Confidence in these determinations is considerably weakened by uncertainty over whether a concurrent control group was used in the chronic study.[28]

NEDO (1987, 064574) describes a 12-month inhalation study in which 20 F344 rats/sex/group were exposed to 0, 10, 100, or 1,000 ppm (0, 13.1, 131, and 1,310 mg/m^3) methanol, approximately 20 hours/day, for a year. Clinical signs of toxicity were monitored daily; body weights and food consumption were recorded weekly for the first 13 weeks, then monthly.   Blood samples were drawn at term to measure hematological and clinical chemistry parameters. Weights of the major organs were monitored at term, and a histopathologic examination was carried out on all major organs and tissues. Survival was high among the groups; one high-concentration female died on day 337 and one low-concentration male died on day 340. As described by the authors, a number of procedural anomalies arose during this study. For example, male controls in two cages lost weight because of an interruption to the water supply. Another problem was that the brand of feed was changed during the study. Fluctuations

---

[28] All control group responses were reported in a single table in the section of the NEDO (1987, 064574) report that describes the acute monkey study, with no indication as to when the control group was sacrificed.

1   in some clinical chemistry and hematological parameters were recorded. The authors considered

2   the fluctuations to be minor and within the normal range. Likewise, a number of histopathologic

3   changes were observed, which, in every case, were considered to be unrelated to exposure level

4   or due to aging.

5   A companion experiment featured the exposure of 30 B6C3F1 mice/sex/group for 1 year

6   to the same concentrations as the F344 rats (NEDO, 1987, 064574). Broadly speaking, the same

7   suite of toxicological parameters was monitored as described above, with the addition of

8   urinalysis. 10 mice/sex/group were sacrificed at 6 months to provide interim data on the

9   parameters under investigation. A slight atrophy in the external lacrimal gland was observed in

10 both sexes and was significant in the 1,000 ppm male group compared with controls. An

11 apparently dose-related increase in moderate fatty degeneration of hepatocytes was observed in

12 males (1/20, 4/20, 6/20 and 8/20 in the 0, 10, 100, and 1,000 ppm dose groups, respectively)

13 which was significantly increased over controls at the 1,000 ppm dose. However the incidence

14 of moderate to severe fatty degeneration was observed in untreated animals maintained outside

15 of the chamber. In addition, there was a clear correlation between fatty degeneration and body

16 weight (a change which was not associated with treatment at 12 months); heavier animals tended

17 to have more severe cases of fatty degeneration. The possibility of renal deficits due to methanol

18 exposure was suggested by the appearance of protein in the urine. However, this effect was also

19 seen in controls and did not display a dose-response effect. Therefore, it is unlikely to be a

20 consequence of exposure to methanol. NEDO (1987, 064574) reported other histopathologic and

21 biochemical (e.g., urinalysis and hematology) findings that do not appear to be related to

22 treatment, including a number of what were considered to be spontaneous tumors in both control

23 and exposure groups.

24   NEDO (1987, 064574; 2008, 196315)[29] exposed 52 male and 53 female B6C3F1

25 mice/group for 18 months at the same concentrations of methanol (0, 10, 100 and 1,000 ppm)

26 and with a similar experimental protocol to that described in the 12-month studies.[30]   The fact

27 that the duration of this study was only 18 months and not the more typical 2 years limits its

28 ability to detect carcinogenic responses with relatively long latency periods. Animals were

[29] This study is described in a summary report (NEDO, 1987, 064574) and a more detailed, eight volume translation
of the original chronic mouse study report (NEDO, 2008, 196315). The translation was submitted to EPA by the
Methanol Institute and has been certified by NEDO as accurate and complete (Hashimoto and NEDO, 2008,
201639). An external peer review was conducted by EPA in 2009 to evaluate the accuracy of experimental
procedures, results, and interpretation and discussion of the findings presented in these study reports. A report of this
peer review is available through the EPA's IRIS Hotline at (202) 566-1676 (phone), (202) 566-1749 (fax), or
hotline.iris@epa.gov (e-mail address) and on the IRIS website (www.epa.gov/iris).

[30] The authors reported that "[t]he levels of methanol turned out to be ~4 ppm in low level exposure group (10 ppm)
for ~11 weeks from week 43 of exposure due to the analyzer malfunction" and that "the average duration of
methanol exposure was 19.1 hours/day for both male and female mice."

sacrificed at the end of the 18-month exposure period. NEDO (2008, 196315) reported that "there was no microbiological contamination that may have influenced the result of the study" and that the study included an assessment of general conditions, body weight change, food consumption rate, laboratory tests (urinalysis, hematological, and plasma biochemistry) and pathological tests (pathological autopsy,[31] organ weight check and histopathology[32]). As stated in the summary report (NEDO, 1987, 064574), a few animals showed clinical signs of toxicity, but the incidence of these responses was not related to dose. Likewise, there were no compound-related changes in body weight increase, food consumption, [33] urinalysis, hematology, or clinical chemistry parameters. High-concentration males had lower testis weights compared to control males. Significant differences were detected for both absolute and relative testis weights. One animal in the high-dose group had severely atrophied testis weights, approximately 25% of that of the others in the dose group. Exclusion of this animal in the analysis still resulted in a significant difference in absolute testis weight compared to controls but resulted in no difference in relative testis weight. High-concentration females had higher absolute kidney and spleen weights compared to controls, but there was no significant difference in these organ weights relative to body weight. At necropsy, there were signs of swelling in spleen, preputial glands, and uterus in some animals. Some animals developed nodes in the liver and lung although, according to the authors, none of these changes were treatment-related. NEDO (2008, 196315) reported that all nonneoplastic changes were "nonspecific and naturally occurring changes that are often experienced by 18-month old B6C3F1 mice" and that fatty degeneration of liver that was suspected to occur dose-dependently in the 12-month NEDO (1987, 064574) study was not observed in this study. Similarly, though the study found various neoplastic changes across dose groups, there was no compound-related formation of tumors in any organ or tissue.

EPA reviewed the cancer findings documented in a recent translation of the original NEDO report on this chronic mouse study (NEDO, 2008, 196315) to identify possible compound-related effects. Hyperplastic and neoplastic histopathological findings have been tabulated and are as shown in Table 4-4.

---

[31] Autopsy was performed on all cases to look for gross lesions in each organ.
[32] Complete histopathological examinations were performed for the control group and high-dose (1,000 ppm) groups. Only histopathological examinations of the liver were performed on the low- and medium-level exposure groups because no chemical-related changes were found in the high-level exposure group and because liver changes were noted in the 12-month mouse study (NEDO, 1987, 064574).
[33] NEDO (NEDO, 2008, 196315) reports sporadic reductions in food consumption of the 1,000 ppm group, but no associated weight loss or abnormal test results.

Table 4-4. Histopathological changes in tissues of B6C3F1 mice exposed to methanol via inhalation for 18 months

Tissues/tumor type	Exposure concentration (ppm)							
	0	10	100	1,000	0	10	100	1,000
	Number of animals affected/number examined							
	Males				Females			
Lung								
Adenomatosis	0/52	0/3	0/3	0/52	0/53	0/0	0/5	1/53
Pulmonary adenoma	4/52	0/3	0/3	7/52	3/53	0/0	0/0	2/53
Liver								
Hepatocellular adenoma	3/52	2/52	2/52	4/52	1/53	1/52	1/53	4/53
Hepatocellular carcinoma	2/52	4/52	0/52	1/52	3/53	0/52	3/53	2/53
Neoplastic nodule	16/52	13/52	16/52	20/52	1/53	0/52	0/53	1/53

Source: (NEDO, 2008, 196315).

1   There is no clear evidence for treatment-related carcinogenic effects in the mice in this
2   study. However, the fact that the study duration was limited to 18 months rather than the
3   traditional 2-year bioassay makes it difficult to draw a definitive conclusion, particularly
4   regarding pulmonary adenomas, which were marginally increased in high-dose male mice of this
5   study and were also increased in male rats of the NEDO chronic rat study (NEDO, 1987,
6   064574; NEDO, 2008, 196316) In this study, the lack of adenomatosis in control or treated male
7   mice supports the conclusion of the authors that the observed tumors were probably unrelated to
8   methanol exposure. There was no apparent relationship to treatment in any neoplastic findings
9   in the liver. Of relevance to the findings of treatment-related lymphomas and leukemias in
10   Sprague-Dawley rats receiving methanol in drinking water in the Soffritti et al. (2002, 091004)
11   study, few lymphomas and leukemias were identified in the NEDO (1987, 064574; 2008,
12   196316) study reports, with no sign of a dose-related trend.
13   Another study reported in NEDO (1987, 064574; 2008, 196316)[34] was a 24-month
14   carcinogenicity bioassay in which 52 F344 rats/sex/group were kept in whole body inhalation
15   chambers containing 0, 10, 100, or 1,000 ppm (0, 13.1, 131, and 1,310 mg/m^3) methanol vapor.

---

[34] This study is described in a summary report (NEDO, 1987, 064574) and a more detailed, 10-volume translation of the original chronic rat study report (NEDO, 2008, 196316). The translation was submitted to EPA by the Methanol Institute and has been certified by NEDO as accurate and complete (Hashimoto and NEDO, 2008, 201639). An external peer review was conducted by EPA in 2009 to evaluate the accuracy of experimental procedures, results, and interpretation and discussion of the findings presented in these study reports. A report of this peer review is available through the EPA's IRIS Hotline at (202) 566-1676 (phone), (202) 566-1749 (fax), or hotline.iris@epa.gov (e-mail address) and on the IRIS website (www.epa.gov/iris).

Animals were maintained in the exposure chambers for approximately 19.5 hours/day for a total of 733-736 days (males) and 740-743 days (females). Animals were monitored once a day for clinical signs of toxicity, body weights were recorded once a week, and food consumption was measured weekly in a 24-animal subset from each group. Urinalysis was carried out on the day prior to sacrifice for each animal, the samples being monitored for pH, protein, glucose, ketones, bilirubin, occult blood, and urobilinogen. Routine clinical chemistry and hematological measurements were carried out and all animals were subject to necropsy at term, with a comprehensive histopathological examination of tissues and organs.[35]

There was some fluctuation in survival rates among the groups in the rat study, though apparently unrelated to exposure concentration. [36] In all groups, at least 60% of the animals survived to term. A number of toxicological responses were described by the authors, including atrophy of the testis, cataract formation, exophthalmia, small eye ball, alopecia, and paralysis of the hind leg. However, according to the authors, the incidence of these effects were unrelated to dose and more likely represented effects of aging. NEDO (2008, 196316) reported a mild, nonsignificant (4%) body weight suppression among 1,000 ppm females between 51 and 72 weeks, but that body weight gain was largely similar among the groups for the duration of the experiment. Food consumption was significantly lower than controls in high-concentration male rats during the day 210–365 time interval, but no corresponding weight loss was observed. Among hematological parameters, mid- and high-concentration females had a significantly ($p > 0.05$) higher differential leukocyte count than controls, but dose dependency was not observed. Serum total cholesterol, triglyceride, free fatty acid, and phospholipid concentrations were significantly ($p > 0.05$) lower in high-concentration females compared to controls. Likewise, serum sodium concentrations were significantly ($p > 0.05$) lower in mid- and high-concentration males compared to controls. High-concentration females had significantly lower ($p > 0.05$) serum concentrations of inorganic phosphorus but significantly ($p > 0.05$) higher concentrations of potassium compared to controls. Glucose levels were elevated in the urine of high-concentration male rats relative to controls, and female rats had lower pH values and higher bilirubin levels in mid- and high-concentration groups relative to controls. In general, NEDO (1987, 064574; 2008, 196316) reported that these variations in urinary, hematology, and clinical chemistry parameters were not related to chemical exposure.

[35] Complete histopathological examinations were performed on the cases killed on schedule (week 104) among the control and high-exposure groups, and the cases that were found dead/ killed in extremis of all the groups. Because effects were observed in male and female kidneys, male lungs as well as female adrenal glands of the high-level exposure group, these organs were histopathologically examined in the low- and mid-exposure groups.
[36]Survival at the time of exposure termination (24 months) was 69%, 65%, 81%, and 65% for males and 60%, 63%, 60% and 67% for females of the control, low-, mid- and high-exposure groups, respectively.

NEDO (1987, 064574) reported that there was little change in absolute or relative weights of the major organs or tissues. When the animals were examined grossly at necropsy, there were some signs of swelling in the pituitary and thyroid, but these effects were judged to be unrelated to treatment. The most predominant effect was the dose-dependent formation of nodes in the lung of males (2/52, 4/52, 5/52, and 10/52 [$p < 0.01$] for control, low-, mid-, and high-concentration groups, respectively). Histopathologic examination pointed to a possible association of these nodes with the appearance of pulmonary adenoma (1/52, 5/52, 2/52, and 6/52 for control, low-, mid- and high-concentration groups, respectively) and a single pulmonary adenocarcinoma in the high-dose group (1/52). Other examples of tumor formation that were increased in high-concentration animals versus controls included an increased incidence of pituitary adenomas in high-concentration males (17/52 compared to 12/52 controls), hyperplastic change in the testis in high-concentration males (10/52 compared to 4/52 controls), and chromaffinoma (pheochromocytomas)[37] in the adrenals of high-concentration females (7/52 compared to 2/52 controls). Individually, these changes did not achieve statistical significance, and in general, the authors concluded that few if any of the observed changes were effects of methanol.

EPA reviewed the cancer findings of this study that are documented in a recent translation of the original NEDO (2008, 196316) report to identify possible compound-related effects. High-dose incidences of pituitary adenomas (17/52; 33%) and hyperplastic change in testes (10/52; 19%) mentioned above were within historical incidences for this rat strain.[38] However, the observed incidence rate for pulmonary adenoma/adenocarcinoma in high-dose males of 13.5% (7/52) was significantly elevated (Fisher's exact test $p < 0.05$) over the concurrent control rate of 2% (1/52) and historical control rates of 2.5% ± 2.6% (n = 1054) and 3.84% ± 2.94% (n = 1199) reported by NTP for the pre-1995 control F344 male rats fed NIH-07 diet (NTP, 1999, 196291) and post-1994 control F344 male rats fed NTP-2000 diet (NTP, 2007, 196299), respectively. Also, the incidence of pulmonary adenoma/adenocarcinoma in male rats exhibited a dose-response trend (Cochrane-Armitage $p < 0.05$). While the observed incidence rate for pheochromocytomas in high-dose females of 13.7% (7/51) was not significantly elevated over the concurrent control rate of 4% (2/50), it was significantly elevated (Fisher's exact test

---

[37] There were some differences in nomenclature used in the NEDO (2008, 196316) report translation versus those used in the older summary report (NEDO, 1987, 064574). For example, it is probable that the adrenal chromaffinoma referred to in NEDO (1987, 064574) are the same lesions as the pheochromocytoma referred to in NEDO (2008, 196316).

[38] NTP reports high incidences in historical control male F344 rats of pituitary gland adenomas, ranging from 45.4% ± 20.19% (NTP, 2007, 196299) to 63.4% ± 18.3% (NTP, 1999, 196291). While control incidences for testicular hyperplasia are not reported, historical incidences of testicular ademoma ranged from 70.1% ±11.2% (NTP, 1999, 196291) to 86.32% ±9.34% (NTP, 2007, 196299) in this rat strain.

1 *p* < 0.05) over NTP historical control rates for total (benign, complex and malignant)

2 pheochromocytomas of 2.5% ± 2.6% (n = 1054) and 3.84% ± 2.94% (n = 1199) reported by NTP

3 for pre-1995 control F344 female rats fed NIH-07 diet (NTP, 1999, 196291) and post-1994

4 control F344 female rats fed NTP-2000 diet (NTP, 2007, 196299), respectively.[39] Also, the

5 incidence of pheochromocytomas in female rats exhibited a dose-response trend (Cochrane-

6 Armitage *p* < 0.05). The histopathological incidences for pulmonary and adrenal effects reported

7 by NEDO (1987, 064574; 2008, 196316) are shown in Table 4-5.

Table 4-5. Histopathological changes in lung and adrenal tissues of F344 rats exposed to methanol via inhalation for 24 months

Tissues/ tumor type	Exposure concentration (ppm)							
	0	10	100	1000	0	10	100	1000
	Number of animals affected/number examined							
	Males				Females			
Lung								
Pulmonary adenoma	1/52	5/50	2/52	6/52	2/52	0/19	0/20	0/52
Pulmonary adenocarcinoma	0/52	0/50	0/52	1/52	0/52	0/19	0/20	0/52
Combined pulmonary adenoma/adenocarcinoma	1/52	5/50	2/52	7/52 [a,b]	2/52	0/19	0/20	0/52
Adenomatosis	4/52	1/50	5/52	4/52	3/52	2/19	1/20	1/52
Epithelial swelling	3/52	2/50	1/52	1/52	0/52	0/19	0/20	0/52
Adrenal glands								
Pheochromocytoma	7/52	2/16	2/10	4/51	2/50	3/51	2/49	7/51 [b,c]
Medullary hyperplasia	0/52	0/16	0/10	2/51	2/50	3/51	7/49	2/51

[a]*p* < 0.05 over concurrent controls using the Fisher's Exact test.
[b]*p* < 0.05 for Cochrane-Armitage test of overall dose-response trend.
[c]*p* < 0.05 over NTP historical controls for total (benign, complex and malignant) pheochromocytomas using the Fisher's Exact test

Source: NEDO (1987, 064574; 2008, 196316).

8 In contrast to the conclusions of the NEDO (1987, 064574) summary report that there

9 were no compound-related changes in F344 rats exposed to methanol via inhalation, EPA

10 identifies potential treatment-related changes in the lungs of male rats and the adrenal medulla of

11 female rats in the more detailed translation of the original report (NEDO, 2008, 196316). The

12 NEDO (1987, 064574) summary report did not report the statistically significant combined

---

[39] NEDO (1987, 064574; 2008, 196316) does not categorize reported chromoffinoma (pheochromocytomas) as benign, complex or malignant. The historical rates for complex and malignant tumors are much lower, ranging from 0.1% to 0.7 % for female F344 rats (Haseman et al., 1998, 094054; NTP, 1999, 196291; NTP, 2007, 196299).

pulmonary adenoma and adenocarcinoma finding in the high-dose group of male rats. Table 6 (page 146) of the NEDO (1987, 064574) summary reports only "Tumural changes occurring at a rate of over 5%." The lung response of the male rats as shown in Table 4-5 suggests a proliferative change in cells of the alveolar epithelium involving a progression towards adenoma and adenocarcinoma that appears to be more pronounced with increasing methanol exposure and considerably elevated over historical controls. Similarly, for female rats, the observed increase in medullary hyperplasia in the 100 ppm dose group, in conjunction with a higher incidence of pheochromocytoma in the adrenal gland is suggestive of a methanol-induced progressive change leading to a carcinogenic response.

4.3. REPRODUCTIVE AND DEVELOPMENTAL STUDIES – ORAL AND INHALATION

Many studies have been conducted to investigate the reproductive and developmental toxicity of methanol. The purpose of these studies was principally to determine if methanol has a similar toxicology profile to another widely studied teratogen, ethanol.

4.3.1. Oral Studies

Three studies were identified that investigated the reproductive and developmental effects of methanol in rodents via the oral route (Fu et al., 1996, 080957; Rogers et al., 1993, 032696; Sakanashi et al., 1996, 056308). Two of these studies also investigated the influence of folic acid-deficient (FAD) diets on the effects of methanol exposures (Fu et al., 1996, 080957; Sakanashi et al., 1996, 056308).

Rogers et al. (1993, 032696) conducted a developmental toxicity study in which methanol in water was administered to pregnant female CD-1 mice via gavage on GD6–GD15. Eight test animals received 4 g/kg-day methanol given in 2 daily doses of 2g/kg; 4 controls received distilled water. By analogy to the protocol of an inhalation study of methanol that was described in the same report, it is assumed that dams were sacrificed on GD17, at which point implantation sites, live and dead fetuses, resorptions/litter, and the incidences of external and skeletal anomalies and malformations were determined. In the brief summary of the findings provided by the authors, it appears that cleft palate (43.5% per litter versus 0% in controls) and exencephaly (29% per litter versus 0% in controls) were the prominent external defects following maternal methanol exposure by gavage. Likewise, an increase in totally resorbed litters and a decrease in the number of live fetuses per litter were evident. However, it is possible that these effects may have been caused or exacerbated by the high bolus dosing regimen employed. It is also possible that effects were not observed due to the limited study

size. The small number of animals in the control group relative to the test group limits the power of this study to detect treatment-related responses.

Sakanashi et al. (1996, 056308) tested the influence of dietary folic acid intake on various reproductive and developmental effects observed in CD-1 mice exposed to methanol. Starting 5 weeks prior to breeding and continuing for the remainder of the study, female CD-1 mice were fed folic acid free diets supplemented with 400 (low), 600 (marginal) or 1,200 (sufficient) nmol folic acid/kg. After 5 weeks on their respective diets, females were bred with CD-1 male mice. On GD6–GD15, pregnant mice in each of the diet groups were given twice-daily gavage doses of 2.0 or 2.5 g/kg-day methanol (total dosage of 4.0 or 5.0 g/kg-day). On GD18, mice were weighed and killed, and the liver, kidneys and gravid uteri removed and weighed. Maternal liver and plasma folate levels were measured, and implantation sites, live and dead fetuses, and resorptions were counted. Fetuses were weighed individually and examined for cleft palate and exencephaly. One third of the fetuses in each litter were examined for skeletal morphology. They observed an approximate 50% reduction in liver and plasma folate levels in the mice fed low versus sufficient folic acid diets in both the methanol exposed and unexposed groups. Similar to Rogers et al. (1993, 032696), Sakanashi et al. (1996, 056308) observed that an oral dose of 4-5 g/kg-day methanol during GD6-GD15 resulted in an increase in cleft palate in mice fed sufficient folic acid diets, as well as an increase in resorptions and a decrease in live fetuses per litter. They did not observe an increase in exencephaly in the FAS group at these doses, and the authors suggest that this may be due to diet and the source of CD-1 mice differing between the two studies.

In the case of the animals fed the folate deficient diet, there was a 50% reduction in maternal liver folate concentration and a threefold increase in the percentage of litters affected by cleft palate (86.2% versus 34.5% in mice fed sufficient folic acid) and a 10-fold increase in the percentage of litters affected by exencephaly (34.5% versus 3.4% in mice fed sufficient folic acid) at the 5 g/kg methanol dose. Sakanashi et al. (1996, 056308) speculate that the increased methanol effect from the FAD diet could have been due to an increase in tissue formate levels (not measured) or to a critical reduction in conceptus folate concentration following the methanol exposure. Plasma and liver folate levels at GD18 within each dietary group were not significantly different between exposed versus unexposed mice. However, these measurements were taken 3 days after methanol exposure. Dorman et al. (1995, 078081) observed a transient decrease in maternal red blood cells (RBCs) and conceptus folate levels within 2 hours following inhalation exposure to 15,000 ppm methanol on GD8.   Thus, it is possible that short-term reductions in available folate during GD6-GD15 may have affected fetal development.

Fu et al. (1996, 080957) also tested the influence of dietary folic acid intake on reproductive and developmental effects observed in CD-1 mice exposed to methanol. This study was performed by the same laboratory and used a similar study design and dosing regimen as Sakanashi et al. (1996, 056308), but exposed the pregnant mice to only the higher 2.5 g/kg-day methanol (total dosage of 5.0 g/kg-day) on GD6-GD10. Like Sakanashi et al. (1996, 056308), Fu et al. (1996, 080957) measured maternal liver and plasma folate levels on GD18 and observed similar, significant reductions in these levels for the FAD versus FAS mice. However, Fu et al. (1996, 080957) also measured fetal liver folate levels at GD18. This measurement does not address the question of whether methanol exposure caused short-term reductions in fetal liver folate because it was taken 8 days after the GD6-GD10 exposure period. However, it did provide evidence regarding the extent to which a maternal FAD diet can impact fetal liver folate levels in this species and strain. Significantly, the maternal FAD diet had a greater impact on fetal liver folate than maternal liver folate levels. Relative to the FAS groups, fetal liver folate levels in the FAD groups were reduced 2.7-fold for mice not exposed to methanol (1.86 ± 0.15 nmol/g in the FAD group versus 5.04 ± 0.22 nmol/g in the FAS group) and 3.5-fold for mice exposed to methanol (1.69 ± 0.12 nmol/g in the FAD group versus 5.89 ± 0.39 nmol/g in the FAS group). Maternal folate levels in the FAD groups were only reduced twofold both for mice not exposed (4.65 ± 0.37 versus 9.54 ± 0.50 nmol/g) and exposed (4.55 ± 0.19 versus 9.26 ± 0.42 nmol/g). Another key finding of the Fu et al. (1996, 080957) study is that methanol exposure during GD6-GD10 appeared to have similar fetotoxic effects, including cleft palate, exencephaly, resorptions, and decrease in live fetuses, as the same level of methanol exposure administered during GD6-GD15 (Rogers et al., 1993, 032696; Sakanashi et al., 1996, 056308). This is consistent with the hypothesis made by Rogers et al. (1993, 032696) that the critical period for methanol-induced cleft palate and exencephaly in CD-1 mice is within GD6-GD10. As in the studies of Sakanashi et al. (1996, 056308) and Rogers et al. (1993, 032696), Fu et al. (1996, 080957) reported a higher incidence of cleft palate than exencephaly.

4.3.2. Inhalation Studies

Nelson et al. (1985, 064573) exposed 15 pregnant Sprague-Dawley rats/group to 0, 5,000, 10,000, or 20,000 ppm (0, 6,552, 13,104, and 26,209 mg/m^3) methanol (99.1% purity) for 7 hours/day. Exposures were conducted on GD1–GD19 in the two lower concentration groups and GD7-GD15 in the highest concentration group, apparently on separate days. Two groups of 15 control rats were exposed to air only. Day 1 blood methanol levels measured 5 minutes after the termination of exposure in NP rats that had received the same concentrations of methanol as those animals in the main part of the experiment were 1.00 ± 0.21, 2.24 ± 0.20, and 8.65 ± 0.40

mg/mL for those exposed to 5,000, 10,000 and 20,000 ppm methanol, respectively. Evidence of
maternal toxicity included a slightly unsteady gait in the 20,000 ppm group during the first few
days of exposure. Maternal bodyweight gain and food intake were unaffected by methanol.
Dams were sacrificed on GD20, and 13-30 litters/group were evaluated. No effect was observed
on the number of corpora lutea or implantations or the percentage of dead or resorbed fetuses.
Statistical evaluations included analysis of variance (ANOVA) for body weight effect, Kruskal-
Wallis test for endpoints such as litter size and viability and Fisher's exact test for
malformations. Fetal body weight was significantly reduced at concentrations of 10,000 and
20,000 ppm by 7% and 12–16%, respectively, compared to controls. An increased number of
litters with skeletal and visceral malformations were observed at ≥10,000 ppm, with statistical
significance obtained at 20,000 ppm.   Numbers of litters with visceral malformations were 0/15,
5/15, and 10/15 and with skeletal malformations were 0/15, 2/15, and 14/15 at 0, 10,000, and
20,000 ppm, respectively. Visceral malformations included exencephaly and encephaloceles.
The most frequently observed skeletal malformations were rudimentary and extra cervical ribs.
The developmental and maternal NOAELs for this study were identified as 5,000 ppm (6,552
mg/m^3) and 10,000 ppm (13,104 mg/m^3), respectively.

NEDO (1987, 064574) sponsored a teratology study in Sprague-Dawley rats that
included an evaluation of postnatal effects in addition to standard prenatal endpoints. Thirty-six
pregnant females/group were exposed to 0, 200, 1,000, or 5,000 ppm (0, 262, 1,310, and 6,552
mg/m^3) methanol vapors (reagent grade) on GD7–GD17 for 22.7 hours/day. Statistical
significance of results was evaluated by t-test, Mann-Whitney U test, Fisher's exact test, and/or
Armitage's χ^2 test.

Contrary to the Nelson et al. (1985, 064573) report of a 10,000 ppm NOAEL for this rat
strain, in the prenatal portion of the NEDO (1987, 064574) study, reduced body weight gain and
food and water intake during the first 7 days of exposure were reported for dams in the
5,000 ppm group. However, it was not specified if these results were statistically significant.
One dam in the 5,000 ppm group died on GD19, and one dam was sacrificed on GD18 in
moribund condition. On GD20, 19-24 dams/group were sacrificed to evaluate the incidence of
reproductive deficits and such developmental parameters as fetal viability, weight, sex, and the
occurrence of malformations. As summarized in Table 4-6, adverse reproductive and fetal
effects were limited to the 5,000 ppm group and included an increase in late-term resorptions,
decreased live fetuses, reduced fetal weight, and increased frequency of litters with fetal
malformations, variations, and delayed ossifications. Malformations or variations included
defects in ventricular septum, thymus, vertebrae, and ribs.

1   Postnatal effects of methanol inhalation were evaluated in the remaining 12 dams/group

2   that were permitted to deliver and nurse their litters. Effects were only observed in the

3   5,000 ppm group, and included a 1-day prolongation of the gestation period and reduced post-

4   implantation survival, number of live pups/litter, and survival on PND4 (Table 4-7). When the

5   delay in parturition was considered, methanol treatment had no effect on attainment of

6   developmental milestones such as eyelid opening, auricle development, incisor eruption, testes

7   descent, or vaginal opening. There were no adverse body weight effects in offspring from

8   methanol treated groups. The weights of some organs (brain, thyroid, thymus, and testes) were

9   reduced in 8-week-old offspring exposed to 5,000 ppm methanol during prenatal development.

Table 4-6. Reproductive and developmental toxicity in pregnant Sprague-Dawley rats exposed to methanol via inhalation during gestation

Effect	Exposure concentration (ppm)			
	0	**200**	**1,000**	**5,000**
Reproductive effects				
Number of pregnant females examined	19	24	22	20
Number of corpora lutea	17.0 ± 2.6	17.2 ± 2.7	16.4 ± 1.9	16.5 ± 2.4
Number of implantations	15.7 ± 1.6	15.0 ± 3.0	15.5 ± 1.2	14.5 ± 3.3
Number of resorptions	0.79 ± 0.85	0.71 ± 1.23	0.95 ± 0.65	1.67 ± 2.03
Number of live fetuses	14.95 ± 1.61	14.25 ± 3.54	14.55 ± 1.1	12.86 ± 4.04[a]
Sex ratio (M/F)	144/140	177/165	164/156	134/136
Fetal weight (male)	3.70 ± 0.24	3.88 ± 0.23	3.82 ± 0.29	3.02 ± 0.27[c]
Fetal weight (female)	3.51 ± 0.19	3.60 ± 0.25	3.60 ± 0.30	2.83 ± 0.26[c]
Total resorption rate (%)	11.2 ± 9.0	15.6 ± 21.3	10.6 ± 8.4	23.3 ± 22.7[a]
Soft tissue malformations				
Number of fetuses examined	136	165	154	131
Abnormality at base of right subclavian	0.7 ± 2.87 (1)	0	0	0
Excessive left subclavian	0	0	0	3.5 ± 9.08 (3)
Ventricular septal defect	0	0.6 ± 2.96 (1)	0	47.6 ± 36.51 (16)[b]
Residual thymus	2.9 ± 5.91 (4)	2.4 ± 5.44 (4)	2.6 ± 5.73 (4)	53.3 ± 28.6 (20)[b]
Serpengious urinary tract	43.0 ± 24.64 (18)	35.2 ± 31.62 (19)	41.8 ± 38.45 (15)	22.1 ± 22.91 (13)

Effect	Exposure concentration (ppm)			
	0	**200**	**1,000**	**5,000**
Skeletal abnormalities				
Number of fetuses examined	148	177	165	138
Atresia of foramen costotransversarium	23.5 ± 5.47 (3)	7.7 ± 1.3 (8)	3.5 ± 8.88 (4)	45.2 ± 25.18 (20)[b]
Patency of foramen costotransversium	0	0	0.6 ± 2.67 (1)	13.7 ± 20.58 (7)
Cleft sternum	0	0	0	5.6 ± 14.14 (3)
Split sternum	0	0	0	7.0 ± 14.01 (5)
Bifurcated vertebral center	0.8 ± 3.28 (1)	1.6 ± 5.61 (2)	3.0 ± 8.16 (3)	14.5 ± 16.69 (11)[b]
Cervical rib	0	0	0	65.2 ± 25.95 (19)[b]
Excessive sublingual neuropore	0	0	0	49.9 ± 27.31 (19)
Curved scapula	0	0	0	0.7 ± 3.19 (1)
Waved rib	0	0	0	6.1 ± 11.84 (5)
Abnormal formation of lumbar vertebrae	0	0	0	0.7 ± 3.19 (1)

[a]$p < 0.05$, [b]$p < 0.01$, [c]$p < 0.001$, as calculated by the authors.
Values are means ± S.D. Values in parentheses are the numbers of litters.

Source: NEDO (1987, 064574).

Table 4-7. Reproductive parameters in Sprague-Dawley dams exposed to methanol during pregnancy then allowed to deliver their pups

Effect	Exposure concentration (ppm)			
	0	**200**	**1,000**	**5,000**
Number of dams	12	12	12	12
Duration of gestation (days)	21.9 ± 0.3	21.9 ± 0.3	21.9 ± 0.3	22.6 ± 0.5[c]
Number of implantations	15.8 ± 1.6	14.8 ± 1.2	15.3 ± 1.3	14.6 ± 1.1[a]
Number of pups	15.2 ± 1.6	14.4 ± 1.3	14.5 ± 1.4	13.1 ± 2.2[a]
Number of live pups	15.2 ± 1.6	14.1 ± 1.4	14.3 ± 1.4	12.6 ± 2.5[b]
Number of live pups on PND4	15.0 ± 1.7 (2)	13.8 ± 1.5 (3)	14.2 ± 1.6 (1)	10.3 ± 2.8 (9)[c]
Sex ratio (M/F)	88/94	87/85	103/70[a]	75/81
Postimplantation embryo survival rate	96.3 ± 4.2	94.9 ± 5.1	93.6 ± 6.1	86.2 ±16.2[a]

[a]$p < 0.05$, [b]$p < 0.01$, [c]$p < 0.001$, as calculated by the authors.
Values are means ± S.D. Values in parentheses are the numbers of litters.

Source: NEDO (1987, 064574).

1   NEDO (1987, 064574) contains an account of a two-generation reproductive study that
2   evaluated the effects of pre- and postnatal methanol (reagent grade) exposure (20 hours/day) on
3   reproductive and other organ systems of Sprague-Dawley rats. The F_0 generation (30 males and

30 females per exposure group)[40] was exposed to 0, 10, 100, and 1,000 ppm (0, 13.1, 131, and 1,310 mg/m^3) from 8 weeks old to the end of mating (males) or to the end of lactation period (females). The F_1 generation was exposed to the same concentrations from birth to the end of mating (males) or to weaning of F_2 pups 21 days after delivery (females). Males and females of the F_2 generation were exposed from birth to 21 days old (one animal/sex/litter was exposed to 8 weeks of age). NEDO (1987, 064574) noted reduced brain, pituitary, and thymus weights, and early testicular descent in the offspring of F_0 and F_1 rats exposed to 1,000 ppm methanol. The early testicular descent is believed to be an indication of earlier fetal development as indicated by the fact that it was correlated with increased pup body weight. However, no histopathologic effects of methanol were observed. As discussed in the report, NEDO (1987, 064574) sought to confirm the possible compound-related effect of methanol on the brain by carrying out an additional study in which Sprague-Dawley rats were exposed to 0, 500, 1,000, and 2,000 ppm (0, 655, 1,310, and 2,620 mg/m^3) methanol from the first day of gestation through the F_1 generation (see Section 4.4.2).

Rogers et al. (1993, 032696) evaluated development toxicity in pregnant female CD-1 mice exposed to air or 1,000, 2,000, 5,000, 7,500, 10,000, or 15,000 ppm (0, 1,310, 2,620, 6,552, 9,894, 13,104, and 19,656 mg/m^3) methanol vapors ($\geq$ 99.9% purity) in a chamber for 7 hours/day on GD6-GD15 in a 3-block design experiment. The numbers of mice exposed at each dose were 114, 40, 80, 79, 30, 30, and 44, respectively. During chamber exposures to air or methanol, the mice had access to water but not food. In order to determine the effects of the chamber exposure conditions, an additional 88 control mice were not handled and remained in their cages; 30 control mice were not handled but were food deprived for 7 hours/day on GD6-GD15. Effects in dams and litters were statistically analyzed using the General Linear Models procedure and multiple *t*-test of least squares means for continuous variables and the Fisher's exact test for dichotomous variables. An analysis of plasma methanol levels in 3 pregnant mice/block/treatment group on GD6, GD10, and GD15 revealed a dose-related increase in plasma methanol concentration that did not seem to reach saturation levels, and methanol plasma levels were not affected by gestation stage or number of previous exposure days. Across all 3 days, the mean plasma methanol concentrations in pregnant mice were approximately 97, 537, 1,650, 3,178, 4,204, and 7,330 μg/mL in the 1,000, 2,000, 5,000, 7,500, 10,000, and 15,000 ppm exposure groups, respectively.

The dams exposed to air or methanol in chambers gained significantly less weight than control dams that remained in cages and were not handled. There were no methanol-related

---

[40] A second control group of 30 animals/sex was maintained in a separate room to "confirm that environmental conditions inside the chambers were not unacceptable to the animals."

reductions in maternal body weight gain or overt signs of toxicity. Dams were sacrificed on GD17 for a comparison of developmental toxicity in methanol-treated groups versus the chamber air-exposed control group. Fetuses in all exposure groups were weighed, assessed for viability, and examined for external malformations. Fetuses in the control, 1,000, 2,000, 5,000, and 15,000 ppm groups were also examined for skeletal and visceral defects. Incidence of developmental effects is listed in Table 4-8. A statistically significant increase in cervical ribs/litter was observed at concentrations of 2,000, 5,000, and 15,000 ppm. At doses of ≥5,000 ppm the incidences of cleft palates/litter and exencephaly/litter were increased with statistical significance achieved at all concentrations with the exception of exencephaly which increased but not significantly at 7,500 ppm.[41] A significant reduction in live pups/litter was noted at ≥ 7,500 ppm, with a significant increase in fully resorbed litters occurring at ≥ 10,000 ppm. Fetal weight was significantly reduced at ≥ 10,000 ppm. Rogers et al. (1993a) identified a developmental NOAEL and LOAEL of 1,000 ppm and 2,000 ppm, respectively. They also provide BMD maximum likelihood estimates (benchmark concentration [BMC]; referred to by the authors as MLE) and estimates of the lower 95% confidence limit on the BMC (benchmark concentration, 95% lower bound [BMCL]; referred to as benchmark dose [BMD] by Rogers et al. (1993, 032696) for 5% and 1% added risk, by applying a log-logistic dose-response model to the mean percent/litter data for cleft palate, exencephaly and resorption. The BMC_{05} and $BMCL_{05}$ values for added risk estimated by Rogers et al. (1993, 032696) are listed in Table 4-9. From this analysis, the most sensitive indicator of developmental toxicity was an increase in the proportion of fetuses per litter with cervical rib anomalies. The most sensitive BMCL and BMC from this effect for 5% added risk were 305 ppm (400 mg/m^3) and 824 ppm (1,080 mg/m^3), respectively.[42]

---

[41] Due to the serious nature of this response and the relative lack of a response in controls, all incidence of exenceaphaly reported in this study at 5,000 ppm or higher are considered biologically significant.

[42] The BMD analysis of the data described in Section 5 was performed similarly using, among others, a similar nested logistic model. However, the Rogers et al. (1993, 032696) analysis was performed using added risk and external exposure concentrations, whereas the analyses in Section 5 used extra risk and internal dose metrics that were then converted to human equivalent exposure concentrations.

Table 4-8. Developmental effects in mice after methanol inhalation

Endpoint	Exposure concentration (ppm)						
	0	**1,000**	**2,000**	**5,000**	**7,500**	**10,000**	**15,000**
No. live pups/litter	9.9	9.5	12.0	9.2	8.6[b]	7.3[c]	2.2[c]
No. fully resorbed litters	0	0	0	0	3	5[a]	14[c]
Fetus weight (g)	1.20	1.19	1.15	1.15	1.17	1.04[c]	0.70[c]
Cleft palate/ litter (%)	0.21	0.65	0.17	8.8[b]	46.6[c]	52.7[c]	48.3[c]
Exencephaly/litter (%)	0	0	0.88	6.9[a]	6.8	27.4[c]	43.3[c]
Anomalies							
Cervical ribs/litter (%)	28	33.6	49.6[b]	74.4[c]	ND	ND	60.0[a]
Sternebral defects/litter (%)	6.4	7.9	3.5	20.2[c]	ND	ND	100[c]
Xiphoid defects/litter (%)	6.4	3.8	4.1	10.9	ND	ND	73.3[c]
Vertebral arch defects/litter (%)	0.3	ND	ND	1.5	ND	ND	33.3[c]
Extra lumbar ribs/litter (%)	8.7	2.5	9.6	15.6	ND	ND	40.0[c]
Ossifications (values are means of litter means)							
Sternal	5.96	5.99	5.94	5.81	ND	ND	5.07[c]
Caudal	5.93	6.26	5.71[a]	5.42	ND	ND	3.20[a]
Metacarpal	7.96	7.92	7.96	7.93	ND	ND	7.60[b]
Proximal phalanges	7.02	7.04	7.04	6.12	ND	ND	3.33[c]
Metatarsals	9.87	9.90	9.87	9.82	ND	ND	8.13[c]
Proximal phalanges	7.18	7.69	6.91	5.47	ND	ND	0[c]
Distal phalanges	9.64	9.59	9.57	8.46[b]	ND	ND	4.27[c]
Supraoccipital score+	1.40	1.65	1.57	1.48	ND	ND	3.20[c]

ND = Not determined. [+] = on a scale of 1–4, where 1 is fully ossified and 4 is unossified.
Statistical significance: [a]$p < 0.05$, [b]$p < 0.01$, [c]$p < 0.001$, as calculated by the authors.

Source: Rogers et al. (1993, 032696).

Table 4-9. Benchmark doses at two added risk levels

Endpoint	BMC$_{05}$ (ppm)	BMCL$_{05}$ (ppm)	BMC$_{01}$ (ppm)	BMCL$_{01}$ (ppm)
Cleft Palate (CP)	4,314	3,398	2,717	1,798
Exencephaly (EX)	5,169	3,760	2,122	784
CP and EX	3,713	3,142	2,381	1,816
Resorptions (RES)	5,650	4,865	3,749	2,949
CP, EX, and RES	3,667	3,078	2,484	1,915
Cervical ribs	824	305	302	58

Source: Rogers et al. (1993, 032696).

1 Rogers and Mole (1997, 009755) investigated the critical period of sensitivity to the

2 developmental toxicity of inhaled methanol in the CD-1 mouse by exposing 12-17 pregnant

females to 0 or 10,000 ppm (0 and 13,104 mg/m^3), 7 hours/day on 2 consecutive days during GD6–GD13, or to a single exposure to the same methanol concentration during GD5-GD9. Another group of mice received a single 7-hour exposure to methanol at 10,000 ppm. The latter animals were sacrificed at various time intervals up to 28 hours after exposure. Blood samples were taken from these animals to measure the concentration of methanol in the serum. Serum methanol concentrations peaked at ~4 mg/mL 8 hours after the onset of exposure. Methanol concentrations in serum had declined to pre-exposure levels after 24 hours. All mice in the main body of the experiment were sacrificed on GD17, and their uteri removed. The live, dead, and resorbed fetuses were counted, and all live fetuses were weighed, examined externally for cleft palate, and then preserved. Skeletal abnormalities were determined after the carcasses had been cleaned and eviscerated. Cleft palate, exencephaly, and skeletal defects were observed in the fetuses of exposed dams. For example, cleft palate was observed following 2-day exposures to methanol on GD6-GD7 through GD11-GD12. These effects also were apparent in mice receiving a single exposure to methanol on GD5-GD9. This effect peaked when the dams were exposed on GD7. Exencephaly showed a similar pattern of development in response to methanol exposure. However, the data indicated that cleft palate and exencephaly might be competing malformations, since only one fetus displayed both features. Skeletal malformations included exoccipital anomalies, atlas and axis defects, the appearance of an extra rudimentary rib on cervical vertebra No.7, and supernumerary lumbar ribs. In each case, the maximum time point for the induction of these defects appeared to be when the dams were exposed to methanol on or near GD7. When dams were exposed to methanol on GD5, there was also an increased incidence of fetuses with 25 presacral vertebrae (26 is normal). However, an increased incidence of fetuses with 27 presacral vertebrae was evident when dams were exposed on GD7. These results indicate that gastrulation and early organogenesis is a period of increased embryonic sensitivity to methanol.

Burbacher et al. (1999, 009752; 1999, 009753) carried out toxicokinetic and reproductive/developmental studies of methanol in *M. fascicularis* monkeys that were published by the Health Effects Institute (HEI) in a two-part monograph. Some of the data were subsequently published in the open scientific literature (Burbacher et al., 2004, 059070; Burbacher et al., 2004, 056018). The experimental protocol featured exposure to 2 cohorts of 12 monkeys/group to low exposure levels (relative to the previously discussed rodent studies) of 0, 200, 600, or 1,800 ppm (0, 262, 786, and 2,359 mg/m^3) methanol vapors (99.9% purity), 2.5 hours/day, 7 days/week, during a premating period and mating period (−180 days combined) and throughout the entire gestation period (−168 days). The monkeys were 5.5–13 years old and were a mixture of feral-born and colony-bred animals. The study included an evaluation of

maternal reproductive performance and tests to assess infant postnatal growth and newborn health, reflexes, behavior, and development of visual, sensorimotor, cognitive, and social behavioral function (see Section 4.4.2 for a review of the developmental neurotoxicity findings from this study). Blood methanol levels, clearance, and the appearance of formate were also examined and are discussed in Section 3.2.

With regard to reproductive parameters, there was a statistically significant decrease ($p = 0.03$) in length of pregnancy in all treatment groups, as shown in Table 4-10. Maternal menstrual cycles, conception rate, and live birth index were all unaffected by exposure. There were also no signs of an effect on maternal weight gain or clinical toxicity among the dams. The decrease in pregnancy length was largely due to complications of pregnancy requiring Cesarean section (C-section) deliveries in the methanol exposure groups. The C-section deliveries were performed in response to signs of difficulty in the pregnancy and thus may serve as supporting evidence of reproductive dysfunction in the methanol-exposed females.

While pregnancy duration was virtually the same in all exposure groups, there were some indications of increased pregnancy duress only in methanol-exposed monkeys. C-sections were done in 2 monkeys from the 200 ppm group and 2 from the 600 ppm group due to vaginal bleeding, presumed, but not verified, to be from placental detachment.[43] A monkey in the 1,800 ppm group also received a C-section after experiencing nonproductive labor for 3 nights. In addition, signs of prematurity were observed in 1 infant from the 1,800 ppm group that was born after a 150-day gestation period. The authors speculated that the shortened gestation length could be due to a direct effect of methanol on the fetal hypothalamus-pituitary-adrenal (HPA) axis or an indirect effect of methanol on the maternal uterine environment. Other fetal parameters such as crown-rump length and head circumference were unchanged among the groups. Infant growth and tooth eruption were unaffected by prenatal methanol exposure.

---

[43] Burbacher et al. (2004, 059070; 2004, 056018) note, however, that in studies of pregnancy complication in alcohol- exposed human subjects, an increased incidence of uterine bleeding and abrutio placenta has been reported.

Table 4-10. Reproductive parameters in monkeys exposed via inhalation to methanol during prebreeding, breeding, and pregnancy

Exposure (ppm)	Conception rate	Weight gain (kg)	Pregnancy duration (days)[a]	Live born delivery rate
0	9/11	1.67 ± 0.07	168 ± 2	8/9
200	9/12	1.27 ± 0.14	160 ± 2[b]	9/9
600	9/11	1.78 ± 0.25	162 ± 2[b]	8/9
1,800	10/12	1.54 ± 0.20	162 ± 2[b]	9/10

Values are means ± SE.;
[a]Live-born offspring only; [b]$p < 0.05$, as calculated by the authors.

Source: Burbacher et al. (2004, 059070).

In later life, 2 females out of the total of 9 offspring in the 1,800 ppm group experienced a wasting syndrome at 12 and 17 months of age. Food intake was normal and no cause of the syndrome could be determined in tests for viruses, hematology, blood chemistry, and liver, kidney, thyroid, and pancreas function. Necropsies revealed gastroenteritis and severe malnourishment. No infectious agent or other pathogenic factor could be identified. Thus, it appears that a highly significant toxicological effect on postnatal growth can be attributed to prenatal methanol exposure at 1,800 ppm (2,300 mg/m^3).

In summary, the Burbacher et al. (1999, 009753; 2004, 059070; 2004, 056018) studies suggest that methanol exposure can cause reproductive effects, manifested as a shortened mean gestational period due to pregnancy complications that precipitated delivery via a C-section, and developmental neurobehavioral effects which may be related to the shortened gestational period (see Section 4.4.2). The low exposure of 200 ppm may signify a LOAEL for reproductive effects. However, the decrease in gestational length was marginally significant and largely the result of human intervention (C-section) for reasons (presumably pregnancy complications) that were not objectively confirmed with clinical procedures (e.g., placental ultrasound). Also, this effect did not appear to be dose related, the greatest gestational period decrease having occurred at the lowest (200 ppm) exposure level. Thus, a clear NOAEL or LOAEL cannot be determined from this study.

In a study of the testicular effects of methanol, Cameron et al. (1984, 064567) exposed 5 male Sprague-Dawley rats/group to methanol vapor, 8 hours/day, 5 days/week for 1, 2, 4, and 6 weeks at 0, 200, 2,000, or 10,000 ppm (0, 262, 2,620, and 13,104 mg/m^3). The authors examined the possible effects of methanol on testicular function by measuring blood levels of testosterone, luteinizing hormone (LH), and follicular stimulating hormone (FSH) using radioimmunoassay. When the authors tabulated their results as a percentage of the control value for each duration

series, the most significant changes were in blood testosterone levels of animals exposed to 200 ppm methanol, the lowest concentration evaluated. At this exposure level, animals exposed for 6 weeks had testosterone levels that were 32% of those seen in controls. However, higher concentrations of methanol were associated with testosterone levels that were closer to those of controls. However, the lack of a clear dose-response is not necessarily an indication that the effect is not related to methanol. The higher concentrations of methanol could be causing other effects (e.g., liver toxicity) which can influence the results. Male rats exposed to 10,000 ppm methanol for 6 weeks displayed blood levels of LH that were about 3 times higher (mean ± S.D.) than those exposed to air ($311 \pm 107\%$ versus $100 \pm 23\%$). In discussing their results, the authors placed the greater emphasis on the fact that an exposure level equal to the ACGIH TLV (200 ppm) had caused a significant depression in testosterone formation in male rats.

A follow-up study report by the same research group (Cameron et al., 1985, 064568) described the exposure of 5 male Sprague-Dawley rats/group, 6 hours/day for either 1 day or 1 week, to methanol, ethanol, n-propanol, or n-butanol at their respective TLVs. Groups of animals were sacrificed immediately after exposure or after an 18-hour recovery period, and the levels of testosterone, LH, and corticosterone measured in serum. As shown in Table 4-11, the data were consistent with the ability of these aliphatic alcohols to cause a transient reduction in the formation of testosterone. Except in the case of n-butanol, rapid recovery from these deficits can be inferred from the 18-hour postexposure data.

Table 4-11. Mean serum levels of testosterone, luteinizing hormone, and corticosterone (± S.D.) in male Sprague-Dawley rats after inhalation of methanol, ethanol, n-propanol or n-butanol at threshold limit values

		Single-day exposure		One-week exposure	
Condition	**TLV (ppm)**	**End of exposure**	**18 hr postexposure**	**End of exposure**	**18 hr postexposure**
Testosterone (as a percentage of control)					
Control		100 ± 17	100 ± 20	100 ± 26	100 ± 17
Methanol	200	41 ± 16^a	98 ± 18	81 ± 22	82 ± 27
Ethanol	1,000	64 ± 12^a	86 ± 16	88 ± 14	101 ± 13
n-Propanol	200	58 ± 15^a	81 ± 13	106 ± 28	89 ± 17
n-Butanol	50	37 ± 8^a	52 ± 22^a	73 ± 34	83 ± 18
Luteinizing hormone					
Control		100 ± 30	100 ± 35	100 ± 28	100 ± 36
Methanol	200	86 ± 32	110 ± 40	78 ± 13	70 ± 14
Ethanol	1,000	110 ± 22	119 ± 54	62 ± 26	81 ± 17
n-Propanol	200	117 ± 59	119 ± 83	68 ± 22	96 ± 28
n-Butanol	50	124 ± 37	115 ± 28	78 ± 26	98 ± 23
Corticosterone					
Control		100 ± 20	ND	100 ± 21	ND
Methanol	200	115 ± 18	ND	74 ± 26	ND
Ethanol	1,000	111 ± 32	ND	60 ± 25	ND
n-Propanol	200	112 ± 21	ND	79 ± 14	ND
n-Butanol	50	143 ± 11^a	ND	85 ± 26	ND

ND = No data.;
[a]$p < 0.05$, as calculated by the authors.

Source: Cameron et al. (1985, 064568).

1 In a series of studies that are relevant to the reproductive toxicity of methanol in males,
2 Lee et al. (1991, 032419) exposed 8-week-old male Sprague-Dawley rats (9-10/group) to 0 or
3 200 ppm (0 and 262 mg/m^3) methanol, 8 hours/day, 5 days/week, for 1, 2, 4, or 6 weeks to
4 measure the possible treatment effects on testosterone production. Study results were evaluated
5 by one factor ANOVA followed by Student's t-test. In the treated rats, there was no effect on
6 serum testosterone levels, gross structure of reproductive organs, or weight of testes and seminal
7 vesicles. Lee et al. (1991, 032419) also studied the in vitro effect of methanol on testosterone
8 production from isolated testes, but saw no effect on testosterone formation either with or
9 without the addition of human chorionic gonadotropin hormone.

In a third experiment from the same report, Lee et al. (1991, 032419) examined testicular histopathology to determine if methanol exposure produced lesions indicative of changing testosterone levels; the effects of age and folate status were also assessed. This is relevant to the potential toxicity of methanol because folate is the coenzyme of tetrahydrofolate synthetase, an enzyme that is rate limiting in the removal of formate. Folate deficiency would be expected to cause potentially toxic levels of methanol, formaldehyde, and formate to be retained. The same authors examined the relevance of folate levels, and by implication, the overall status of formate formation and elimination in mediating the testicular functions of Long-Evans rats. Groups of 4-week-old male Long-Evans rats were given diets containing either adequate or reduced folate levels plus 1% succinylsulfathiazole, an antibiotic that, among other activities, [44] would tend to reduce the folate body burden. At least 9 rats/dietary group/dose were exposed to 0, 50, 200, or 800 ppm (0, 66, 262, and 1,048 mg/m^3) methanol vapors starting at 7 months of age while 8-12 rats/dietary group/dose were exposed to 0 or 800 ppm methanol vapors at 15 months of age. The methanol exposures were conducted continuously for 20 hours/day for 13 weeks. Without providing details, the study authors reported that visual toxicity and acidosis developed in rats fed the low folate diet and exposed to methanol. No methanol-related testicular lesions or changes in testes or body weight occurred in rats that were fed either the folate sufficient or deficient diets and were 10 months old at the end of treatment. Likewise, no methanol-lesions were observed in 18-month-old rats that were fed diets with adequate folate. However, the incidence but not severity of age-related testicular lesions was increased in the 18-month-old rats fed folate-deficient diets. Subcapsular vacuoles in germinal epithelium were noted in 3/12 control rats and 8/13 rats in the 800 ppm group. One rat in the 800 ppm group had atrophied seminiferous tubules and another had Leydig cell hyperplasia. These effects, as well as the transient decrease in testosterone levels observed by Cameron et al. (1984, 064567; 1985, 064568), could be the result of chemically-related strain on the rat system as it attempts to maintain hormone homeostasis.

Dorman et al. (1995, 078081) conducted a series of in vitro and in vivo studies of developmental toxicity in ICR BR (CD-1) mice associated with methanol and formate exposure. The studies used HPLC grade methanol and appropriate controls. PK and developmental toxicity parameters were measured in mice exposed to a 6-hour methanol inhalation (10,000 or 15,000 ppm), methanol gavage (1.5 g/kg) or sodium formate (750 mg/kg by gavage) on GD8. In the in vivo inhalation study, 12-14 dams/group were exposed to 10,000 ppm methanol for

---

[44] Succinylsulfathiazone antibiotic may have a direct impact on the effects being measured, the extent of which was not addressed by the authors of this study.

6 hours on GD8,[45] with and without the administration of fomepizole (4-methylpyrazole) to inhibit the metabolism of methanol by ADH1. Dams were sacrificed on GD10, and folate levels in maternal RBC and conceptus (decidual swelling) were measured, as well as fetal neural tube patency (an early indicator of methanol-induced dysmorphogenic response). The effects observed included a transient decrease in maternal RBC and conceptus folate levels within 2 hours following exposure and a significant ($p < 0.05$) increase in the incidence of fetuses with open neural tubes (9.65% in treated versus 0 in control). These responses were not observed following sodium formate administration, despite peak formate levels in plasma and decidual swellings being similar to those observed following the 6-hour methanol inhalation of 15,000 ppm. This suggests that these methanol-induced effects are not related to the accumulation of formate. As this study provides information relevant to the identification of the proximate teratogen associated with developmental toxicity in rodents, it is discussed more extensively in Section 4.6.1.

4.3.3. Other Reproductive and Developmental Toxicity Studies

Additional information relevant to the possible effects of methanol on reproductive and developmental parameters has been provided by experimental studies that have exposed experimental animals to methanol during pregnancy via i.p. injections (Rogers et al., 2004, 056010). Relevant to the developmental impacts of the chemical, a number of studies also have examined the effects of methanol when included in whole-embryo culture (Andrews et al., 1993, 032687; Andrews et al., 1995, 077672; Andrews et al., 1998, 079068; Hansen et al., 2005, 196135; Harris et al., 2003, 047369).

Pregnant female C57BL/6J mice received 2 i.p. injections of methanol on GD7 (Rogers et al., 2004, 056010). The injections were given 4 hours apart to provide a total dosage of 0, 3.4, and 4.9 g/kg. Animals were sacrificed on GD17 and the litters were examined for live, dead, and resorbed fetuses. Rogers et al. (2004, 056010) monitored fetal weight and examined the fetuses for external abnormalities and skeletal malformations. Methanol-related deficits in maternal and litter parameters observed by Rogers et al. (2004, 056010) are summarized in Table 4-12.

---

[45] Dorman et al. (1995, 078081) state that GD8 was chosen because it encompasses the period of murine neurulation and the time of greatest vulnerability to methanol-induced neural tube defects.

Table 4-12. Maternal and litter parameters when pregnant female C57BL/6J mice were injected i.p. with methanol

Parameter	Methanol dose (g/kg)		
	0	**3.4**	**4.9**
No. pregnant at term	43	13	24
Wt gain GD7–GD8 (g)	0.33 ± 0.10	0.37 ± 0.15	-0.24 ± 0.14[a]
Wt gain GD7–GD10 (g)	1.63 ± 0.18	2.20 ± 0.20	1.50 ± 0.20
Live fetuses/litter	7.5 ± 0.30	6.3 ± 0.5[a]	3.7 ± 0.4[a]
Resorbed fetuses/litter	0.4 ± 0.1	1.3 ± 0.4[a]	4.4 ± 0.4[a]
Dead fetuses/litter	0.1 ± 0.1	0	0.1 ± 0.1
Fetal weight (g)	0.83 ± 0.02	0.82 ± 0.03	0.70 ± 0.02[a]

Values are means ± SEM.
[a]$p < 0.05$, as calculated by the authors.

Source: Rogers et al. (2004, 056010).

Rogers et al. (2004, 056010) used a number of sophisticated imaging techniques, such as confocal laser scanning and fluorescence microscopy, to examine the morphology of fetuses excised at GD7, GD8, and GD9. They identified a number of external craniofacial abnormalities, the incidence of which was, in all cases, significantly increased in the high-dose group compared to controls. For some responses, such as microanophthalmia and malformed maxilla, the incidence was also significantly increased in animals receiving the lower dose. Fifteen compound-related skeletal malformations were tabulated in the report. In most cases, a dose-response effect was evident, resulting in statistically significant incidences in affected fetuses and litters, when compared to controls. Apparent effects of methanol on the embryonic forebrain included a narrowing of the anterior neural plate, missing optical vesicles, and holoprosencephaly (failure of the embryonic forebrain to divide). The authors noted that there was no sign of incipient cleft palate or exencephaly, as had been observed in CD-1 mice exposed to methanol via the oral and inhalation routes (Rogers et al., 1993, 032696).

In order to collect additional information on cell proliferation and histological changes in methanol-treated fetuses, Degitz et al. (2004, 056021) used an identical experimental protocol to that of Rogers et al. (2004, 056010) by administering 0, 3.4, or 4.9 g methanol/kg in distilled water i.p. (split doses, 4 hours apart) to C57BL/6J mice on GD7. Embryos were collected at various times on GD8 and GD10. Embryos from dams exposed to 4.9 g/kg and examined on GD8 exhibited reductions in the anterior mesenchyme, the mesenchyme subjacent to the mesencephalon and the base of the prosencephalon (embryonic forebrain), and in the forebrain epithelium. The optic pits were often lacking; where present their epithelium was thin and there were fewer neural crest cells in the mid- and hindbrain regions.

At GD9, there was extensive cell death in areas populated by the neural crest, including the forming cranial ganglia. Dose-related abnormalities in the development of the cranial nerves and ganglia were seen on GD7. In accordance with an arbitrary dichotomous scale devised by the authors, scores for ganglia V, VIII, and IX were significantly (not otherwise specified) reduced at all dose levels, and ganglia VII and X were reduced only at the highest dose. At the highest dose (4.9 g/kg), the brain and face were poorly developed and the brachial arches were reduced in size or virtually absent. Flow cytometry of the head regions of the embryos from the highest dose at GD8 did not show an effect on the proportion of cells in S-phase.

Cell growth and development were compared in C57BL/6J and CD-1 mouse embryos cultured in methanol (Degitz et al., 2004, 056020). GD8 embryos, with 5-7 somites, were cultured in 0, 1, 2, 3, 4, or 6 mg methanol/mL for 24 hours and evaluated for morphological development. Cell death was increased in both strains in a developmental stage- and region-specific manner at 4 and 6 mg/mL after 8 hours of exposure. The proportions of cranial region cells in S-phase were significantly ($p < 0.05$) decreased at 6 mg/mL following 8- and 18-hour exposures to methanol. After 24 hours of exposure, C57BL/6J embryos had significantly ($p < 0.05$) decreased total protein at 4 and 6 mg/kg. Significant ($p < 0.05$) developmental effects were seen at 3, 4, and 6 mg/kg, with eye dysmorphology being the most sensitive endpoint. CD-1 embryos had significantly decreased total protein at 3, 4, and 6 mg/kg, but developmental effects were seen only at 6 mg/kg. It was concluded that the C57BL/6J embryos were more severely affected by methanol in culture than the CD-1 embryos.

Andrews et al. (1993, 032687) carried out a comparative study of the developmental toxicity of methanol in whole Sprague-Dawley rat or CD-1 mouse embryos. Nine-day rat embryos were explanted and cultured in rat serum containing 0, 2, 4, 8, 12, or 16 mg/mL methanol for 24 hours then transferred to rat serum alone for a further 24 hours. Eight-day mouse embryos were cultured in 0, 2, 4, 6, or 8 mg/mL methanol in culture medium for 24 hours. At the end of the culture period, embryos were examined for growth, development and dysmorphogenesis. For the rats, doses of 8 mg/mL and above resulted in a concentration-related decrease in somite number, head length, and developmental score. Some lethality was seen in embryos incubated at 12 mg/mL methanol. For the mouse embryos, incubation concentrations of 4 mg/mL methanol and above resulted in a significant decrease in developmental score and crown-rump length. The high concentration (8 mg/mL) was associated with embryo lethality. These data suggest that mouse embryos are more sensitive than rat embryos to the developmental effects of methanol. Using a similar experimental system to examine the developmental toxicity of formate and formic acid in comparison to methanol, Andrews et al. (1995, 077672) showed that the formates are embryotoxic at doses that are four times lower than

equimolar doses of methanol. Andrews et al. (1998, 079068) showed that exposure to combinations of methanol and formate was less embryotoxic than would be expected based on simple toxicity additivity, suggesting that the embryotoxicity observed following low-level exposure to methanol is mechanistically different from that observed following exposure to formate.

A study by Hansen et al. (2005, 196135) determined the comparative toxicity of methanol and its metabolites, formaldehyde and sodium formate, in GD8 mouse (CD-1) and GD10 rat (Sprague-Dawley) conceptuses. Incubation of whole embryos was for 24 hours in chemical-containing media (mouse: 4-12 mg/mL methanol, 1-6 μg/mL formaldehyde, 0.5-4 mg/mL sodium formate; rat: 8-20 mg/mL, 1-8 μg/mL, 0.5-8 mg/mL). Subsequently, the visceral yolk sac (VYS) was removed and frozen for future protein and DNA determination. The embryos were examined morphologically to determine growth and developmental parameters such as viability, flexure and rotation, crown-rump length, and neuropore closure. In other experiments, the chemicals were injected directly into the amniotic space. For each response, Table 4-13 provides a comparison of the concentrations or amounts of methanol, formaldehyde, and formate that resulted in statistically significant changes in developmental abnormalities compared to controls.

For a first approximation, these concentrations or amounts may be taken as threshold-dose ranges for the specific responses under the operative experimental conditions. The data show consistently lower threshold values for the effects of formaldehyde compared to those of formate and methanol. The mouse embryos were more sensitive towards methanol toxicity than rat embryos, consistent with in vivo findings, whereas the difference in sensitivity disappeared when formaldehyde was administered. Hansen et al. (2005, 196135) hypothesized that, while the MOA for the initiation of the organogenic defects is unknown, the relatively low threshold levels of formaldehyde for most measured effects suggest formaldehyde involvement in the embryotoxic effects of methanol. By contrast, formate, the putative toxicant for the acute effects of methanol poisoning (acidosis, neurological deficits), did not appear to reproduce the methanol-induced teratogenicity in these whole embryo culture experiments.

Table 4-13. Reported thresholds concentrations (and author-estimated ranges) for the onset of embryotoxic effects when rat and mouse conceptuses were incubated in vitro with methanol, formaldehyde, and formate

Parameter	Mouse			Rat		
	Methanol	Formaldehyde	Formate	Methanol	Formaldehyde	Formate
In vitro incubation (mg/mL)						
Viability (%)	8.0	0.004	NS	16.0	0.006	2.0
Normal rotation (%)	4.0	0.003	0.5	8.0	0.003	4.0
CR[a] length	No change	No change	No change	No change	No change	No change
Neural tube closure (%)	8.0	0.001	2.0	12.0	No change	No change
Reduced embryo protein	8.0	0.003	4.0	8.0	0.004	2.0
Reduced VYS[b] protein	10.0	0.004	4.0	12.0	0.004	NR
Reduced embryo DNA	8.0	0.003	No change	12.0	0.003	NR
Reduced VYS DNA	4.0	0.001	0.5	12.0	0.003	NR
Microinjection (author-estimated dose ranges in μg)						
Viability (%)	46-89	0.003-0.5	1.01-1.5	46-89	1.01-1.5	1.51-4.0
Normal rotation (%)	1-45	0.003-0.5	0.03-0.5	46-89	1.01-1.5	0.51-1.0
CR[a] length	No change	No change	No change	No change	No change	No change
Neural tube closure (%)	1-45	0.003-0.5	1.01-1.5	No change	No change	1.01-1.5
Reduced embryo protein	1-45	0.501-1.0	No change	No change	1.51-2.0	0.51-1.0
Reduced VYS[b] protein	135-178	1.01-1.5	No change	No change	No change	1.01-1.5
Reduced embryo DNA	46-89	0.501-1.0	No change	No change	No change	0.51-1.0
Reduced VYS[b] DNA	1-45	0.003-0.5	0.03-0.5	No change	No change	0.51-1.0

[a]CR = crown-rump length,
[b]VYS = visceral yolk sac.
NR = not reported

Source: Hansen et al. (2005, 196135); Harris et al. (2004, 059082) (adapted).

Harris et al. (2003, 047369) provided biochemical evidence consistent with the concept that formaldehyde might be the ultimate embryotoxicant of methanol by measuring the activities of enzymes that are involved in methanol metabolism in mouse (CD-1) and rat (Sprague-Dawley) whole embryos at different stages of development. Specific activities of the enzymes ADH1, ADH3, and CAT, were determined in rat and mouse conceptuses during the organogenesis period of 8-25 somites. Activities were measured in heads, hearts, trunks, and VYS from early- and late-stage mouse and rat embryos. While CAT activities were similar between rat and mouse embryos, mouse ADH1 activities in the VYS were significantly lower throughout organogenesis when compared to the rat VYS or embryos of either species. ADH1 activities of heads, hearts, and trunks from mouse embryos were significantly lower than those from rats at the 7-12 somite stage. However, these interspecies differences were not evident in embryos of 20-22 somites. ADH3 activities were lower in mouse versus rat VYS, irrespective of

1 the stage of development. However, while ADH3 activities in mouse embryos were markedly
2 lower than those of rats in the early stages of development, the levels of activity were similar to
3 at the 14-16 somite stage and beyond. A lower capacity to transform formaldehyde to formate
4 might explain the increased susceptibility of mouse versus rat embryos to the toxic effects of
5 methanol. The hypothesis that formaldehyde is the ultimate embryotoxicant of methanol is
6 supported by the demonstration of diminished ADH3 activity in mouse versus rat embryos and
7 by the demonstration by Hansen et al. (2005, 196135) that formaldehyde has a far greater
8 embryotoxicity than either formate or methanol itself.

9 That formate can induce similar developmental lesions in whole rat and mouse
10 conceptuses was demonstrated by Andrews et al. (1995, 077672), who evaluated the
11 developmental effects of sodium formate and formic acid in rodent whole embryo cultures in
12 vitro. Day 9 rat (Sprague-Dawley) embryos were cultured for 24 or 48 hours and day 8 mouse
13 (CD-1) cultures were incubated for 24 hours. As tabulated by the authors, embryos of either
14 species showed trends towards increasing lethality and incidence of abnormalities with exposure
15 concentration. Among the anomalies observed were open anterior and posterior neuropores, plus
16 rotational defects, tail anomalies, enlarged pericardium, and delayed heart development.

4.4. NEUROTOXICITY

17 A substantial body of information exists on the toxicological consequences to humans
18 who consume or are exposed to large amounts of methanol. As discussed in Section 4.1,
19 neurological consequences of acute methanol intoxication in humans include Parkinson-like
20 responses, visual impairment, confusion, headache, and numerous subjective symptoms. The
21 occurrence of these symptoms has been shown to be associated with necrosis of the putamen
22 when neuroimaging techniques have been applied (Salzman, 2006, 196172). Such profound
23 changes have been linked to tissue acidosis that arises when methanol is metabolized to
24 formaldehyde and formic acid through the actions of ADH1 and ADH3. However, the well-
25 documented impact of the substantial amounts of formate that are formed when humans and
26 animals are exposed to large amounts of methanol may obscure the potentially harmful effects
27 that may arise when humans and animals exposed to smaller amounts. Human acute exposure
28 studies (Chuwers et al., 1995, 081298; Cook et al., 1991, 032367) (See Section 4.1.3) at TLV
29 levels of 200 ppm would indicate that some measures of neurological function (e.g., sensory
30 evoked potentials, memory testing and psychomotor testing) were impaired in the absence of
31 measureable formate production.

4.4.1. Oral Studies

1   Two rodent studies investigated the neurological effects of developmental methanol
2 exposure via the oral route (Aziz et al., 2002, 034481; Infurna and Weiss, 1986, 064572). One of
3 these studies also investigated the influence of FAD diets on the effects of methanol exposures
4 (Aziz et al., 2002, 034481). In the first, Infurna and Weiss (1986, 064572) exposed 10 pregnant
5 female Long-Evans rats/dose to 2% methanol (purity not specified) in drinking water on either
6 GD15-GD17 or GD17-GD19. Daily methanol intake was calculated at 2,500 mg/kg-day by the
7 study authors. Dams were allowed to litter and nurse their pups. Data were analyzed by
8 ANOVA with the litter as the statistical unit. Results of the study were equivalent for both
9 exposure periods. Treatment had no effect on gestational length or maternal bodyweight.
10 Methanol had no effect on maternal behavior as assessed by the time it took dams to retrieve
11 pups after they were returned to the cage following weighing. Litter size, pup birth weight, pup
12 postnatal weight gain, postnatal mortality, and day of eye opening did not differ from controls in
13 the methanol treated groups. Two neurobehavioral tests were conducted in offspring. Suckling
14 ability was tested in 3-5 pups/treatment group on PND1. An increase in the mean latency for
15 nipple attachment was observed in pups from the methanol treatment group, but the percentage
16 of pups that successfully attached to nipples did not differ significantly between treatment
17 groups. Homing behavior, the ability to detect home nesting material within a cage containing
18 one square of shavings from the pup's home cage and four squares of clean shavings, was
19 evaluated in 8 pups/group on PND10. Pups from both of the methanol exposure groups took
20 about twice as long to locate the home material and took less direct paths than the control pups.
21 Group-specific values differed significantly from controls. This study suggests that
22 developmental toxicity can occur at this drinking water dose without readily apparent signs of
23 maternal toxicity.
24   Aziz et al. (2002, 034481) investigated the role of developmental deficiency in folic acid
25 and methanol-induced developmental neurotoxicity in PND45 rat pups. Wistar albino female
26 rats (80/group) were fed FAD[46] and FAS diets separately. Following 14-16 weeks on the diets,
27 liver folate levels were estimated and females exhibiting a significantly low folic acid level were
28 mated. Throughout their lactation period, dams of both the FAD and the FAS group were given
29 0, 1, 2, or 4% v/v methanol via drinking water, equivalent to approximately 480, 960 and

---

[46] Along with the FAD diet, 1% succinylsulphathiazole was also given to inhibit folic acid biosynthesis from
intestinal bacteria.

1,920 mg/kg-day.[47] Pups were exposed to methanol via lactation from PND1-PND21. Litter size was culled to 8 with equal male/female ratios maintained as much as possible. Liver folate levels were determined at PND21 and neurobehavioral parameters (motor performance using the spontaneous locomotor activity test and cognitive performance using the conditioned avoidance response [CAR] test), and neurochemical parameters (dopaminergic and cholinergic receptor binding and dopamine levels) were measured at PND45. The expression of growth-associated protein (GAP 43), a neuro-specific protein in the hippocampus that is primarily localized in growth cone membranes and is expressed during developmental regenerative neurite outgrowth, was examined using immunohistochemistry and western blot analysis.

A loss in body weight gain was observed at PND7, PND14, and PND21 in animals exposed to 2% (11, 15 and 19% weight gain reduction) and 4% (17, 24 and 29% weight gain reduction) methanol in the FAD group and only at 4% (9, 14 and 17% weight gain reduction) methanol in the FAS group. No significant differences in food and water intake were observed among the different treatment groups. Liver folate levels in the FAD group were decreased by 63% in rats prior to mating and 67% in pups on PND21.

Based on reports of Parkinson-like symptoms in survivors of severe methanol poisoning (see Section 4.1), Aziz et al. (2002, 034481) hypothesized that methanol may cause a depletion in dopamine levels and degeneration of the dopaminergic nigrostriatal pathway.[48] Consistent with this hypothesis, they found dopamine levels were significantly decreased (32% and 51%) in the striatum of rats in the FAD group treated with 2% and 4% methanol, respectively. In the FAS group, a significant decrease (32%) was observed in the 4% methanol-exposed group.

Methanol treatment at 2% and 4% was associated with significant increases in activity, in the form of distance traveled in a spontaneous locomotor activity test, in the FAS group (13% and 39%, respectively) and more notably, in the FAD group (33% and 66%, respectively) when compared to their respective controls. Aziz et al. (2002, 034481) suggest that these alterations in locomotor activity may be caused by a significant alteration in dopamine receptors and disruption in neurotransmitter availability. Dopamine receptor (D_2) binding in the hippocampus of the FAD group was significantly increased (34%) at 1% methanol, but was significantly decreased at 2% and 4% methanol exposure by 20% and 42%, respectively. In the FAS group,

---

[47] Assuming that Wistar rat drinking water consumption is 60 mL/kg-day (Rogers et al., 2002, 196167), 1% methanol in drinking water would be equivalent to 1% x 0.8 g/mL x 60 mL/kg-day = 0.48 g/kg-day = 480 mg/kg-day.

[48] The nigrostriatal pathway is one of four major dopamine pathways in the brain that are particularly involved in the production of movement. Loss of dopamine neurons in the substantia nigra is one of the pathological features of Parkinson's disease (Kim et al., 2003),

1   D_2 binding was significantly increased by 22% and 54% in the 2% and 4% methanol-exposed

2   groups.

3   At PND45, the CAR in FAD rats exposed to 2% and 4% methanol was significantly

4   decreased by 48% and 52%, respectively, relative to nonexposed controls. In the FAS group, the

5   CAR was only significantly decreased in the 4% methanol-exposed animals and only by 22% as

6   compared to their respective controls. Aziz et al. (2002, 034481) suggest that the impairment in

7   CAR of the methanol-exposed FAD pups may be due to alterations in the number of cholinergic

8   (muscarinic) receptor proteins in the hippocampal region of the brain. Muscarinic receptor

9   binding was significantly increased in the 2% (20%) and 4% (42%) methanol-exposed group in

10 FAD animals, while FAS group animals had a significant increase in cholinergic binding only in

11 the 4% methanol exposed group (21%). High concentrations of methanol may saturate the

12 body's ability to remove toxic metabolites, including formaldehyde and formate, and this may be

13 exacerbated in FAD pups having a low store of folate.

14   Immunohistochemistry showed an increase in the expression of GAP-43 protein in the

15 dentate granular and pyramidal cells of the hippocampus in 2% and 4% methanol-exposed

16 animals in the FAD group. The FAS group showed increased expression only in the 4%

17 methanol-exposed group. The Western blot analysis also confirmed a higher expression of

18 GAP-43 in the 2% and 4% methanol-exposed FAD group rats. Aziz et al. (2002, 034481)

19 suggested that up-regulation of GAP-43 in the hippocampal region may be associated with

20 axonal growth or protection of the nervous system from methanol toxicity.

21   The Aziz et al. (2002, 034481) study provides evidence that hepatic tetrahydrofolate is an

22 important contributing factor in methanol-induced developmental neurotoxicity in rodents. The

23 immature blood-brain barrier and inefficient drug-metabolizing enzyme system make the

24 developing brain a particularly sensitive target organ to the effects of methanol exposure.

4.4.2. Inhalation Studies

25   A review by Carson et al. (1981, 031176) has summarized a number of older reports of

26 studies on the toxicological consequences of methanol exposure. In one example relevant to

27 neurotoxicity, the review cites a research report of Chen-Tsi (1959, 196193) who exposed 10

28 albino rats/group (sex and strain unstated) to 1.77 and 50 mg/m^3 (1.44 and 40.7 ppm) methanol

29 vapor, 12 hours/day, for 3 months. Deformation of dendrites, especially the dendrites of

30 pyramidal cells, in the cerebral cortex was included in the description of histopathological

31 changes observed in adult animals following exposure to 50 mg/m^3 (40.7 ppm) methanol vapor.

32 One out of ten animals exposed to the lower methanol concentration also displayed this feature.

Information on the neurotoxicity of methanol inhalation exposure in adult monkeys (*M. fascicularis*) has come from NEDO (1987, 064574) which describes the results of a number of experiments. The study included an acute study, a chronic study monkeys, and a repeated exposure experiment (of variable duration depending upon exposure level), followed by recovery period (1-6 months), and an experiment looking at chronic formaldehyde exposure (1 or 5 ppm), a combustion product of methanol. This last experiment was apparently only a pilot and included only one monkey per exposure condition.

In the chronic experiment 8 monkeys were included per exposure level (control, 10, 100, 1,000 ppm or 13, 131, and 1,310 mg/m^3, respectively, for 21 hours/day); however, animals were serially sacrificed at 3 time points: 7 months, 19 months, or >26 months. This design reduced the number of monkeys at each exposure level to 2 subjects at 7 months and 3 subjects at the subsequent time points (see Section 4.2.2). One of the 3 animals receiving 100 ppm methanol and scheduled for sacrifice at 29 months was terminated at 26 months.

Histopathologically, no overt degeneration of the retina, optical nerve, cerebral cortex, or other potential target organs (liver and kidney) was reported in the chronic experiment. Regarding the peripheral nervous system, 1/3 monkeys exposed to 100 ppm (131 mg/m^3) and 2/3 exposed to 1,000 ppm (1,310 mg/m^3) for 29 months showed slight but clear changes in the peroneal nerves. There was limited evidence of CNS degeneration inside the nucleus of the thalamus of the brain at exposure to 100 ppm (131 mg/m^3) or 1,000 ppm (1,310 mg/m^3) for 7 months or longer. Abnormal appearance of stellate cells (presumed astroglia) within the cerebral white matter was also observed in a high proportion (7/8 in both mid- and high-exposure groups) of monkeys exposed to 100 ppm and 1,000 ppm for 7 months or more. All monkeys that had degeneration of the inside nucleus of the thalamus also had degeneration of the cerebral white matter. According to NEDO (1987, 064574), the stellate cell response was transient and "not characteristic of degeneration." The authors also noted that the stellate cell response was "nearly absent in normal monkeys in the control group" and "in the groups exposed to a large quantity of methanol or for a long time their presence tended to become permanent, so a relation to the long term over which the methanol was inhaled is suspected." However, all control group responses are reported in a single table in the section of the NEDO (1987, 064574) report that describes the acute monkey study, with no indication as to when the control group was sacrificed.

In the recovery experiment, monkeys were exposed to 1,000, 2,000, 3,000, or 5,000 ppm methanol, followed by recovery periods of various duration. Monkeys exposed to 3,000 ppm for 20 days followed by a 6-month recovery period experienced relatively severe fibrosis of responsive stellate cells and lucidation of the medullary sheath. However, resolution of some of the glial responses was noted in the longer duration at lower exposure levels, with no effects observed on the cerebral white matter in monkeys exposed for 7 months to 1,000 ppm methanol

followed by a 6-month recovery period. In general, the results from the recovery experiment corroborated results observed in the chronic experiment. NEDO (1987, 064574) interpreted the lack of glial effects after a 6-month recovery as an indication of a transient effect. The authors failed to recognize that glial responses to neural damage do not necessarily persist following resolution of neurodegeneration (Aschner and Kimelberg, 1996, 076190).

The limited information available from the NEDO (1987, 064574) summary report suggests that 100 ppm (131 mg/m^3) may be an effect level following continuous, chronic exposure to methanol. However, the current report does not indicate a robust dose response for the neurodegenerative changes in the thalamus and glial changes in the white matter. The number of animals at each exposure level for each serial sacrifice also limits statistical power (2-3 monkeys/time point/exposure level). Confidence in this study is also weakened by the lack of documentation for a concurrent control group.

Weiss et al. (1996, 079211) exposed 4 cohorts of pregnant Long-Evans rats (10-12 dams/ treatment group/cohort) to 0 or 4,500 ppm (0 and 5,897 mg/m^3) methanol vapor (high-performance liquid chromatography [HPLC] grade), 6 hours/day, from GD6 to PND21. Pups were exposed together with the dams during the postnatal period. Average blood methanol levels in pups on PND7 and PND14 were about twice the level observed in dams. However, methanol exposure had no effect on maternal gestational weight gain, litter size, or postnatal pup weight gain up to PND18[49]. Neurobehavioral tests were conducted in neonatal and adult offspring; the data generated from those tests were evaluated by repeated measures ANOVA. Three neurobehavioral tests conducted in 13-26 neonates/group included a suckling test, conditioned olfactory aversion test, and motor activity test. In contrast to earlier test results reported by Infurna and Weiss (1986, 064572), methanol exposure had no effect on suckling and olfactory aversion tests conducted on PND5 and PND10, respectively. Results of motor activity tests in the methanol group were inconsistent, with decreased activity on PND18 and increased activity on PND25. Tests that measured motor function, operant behavior, and cognitive function were conducted in 8-13 adult offspring/group. Some small performance differences were observed between control and treated adult rats in the fixed wheel running test only when findings were evaluated separately by sex and cohort. The test requires the adult rats to run in a wheel and rotate it a certain amount of times in order to receive a food reward. A stochastic spatial discrimination test examined the rats' ability to learn patterns of sequential responses. Methanol exposure had no effect on their ability to learn the first pattern of sequential responses, but methanol-treated rats did not perform as well on the reversal test. The result indicated possible

---

[49] The fact that this level of exposure caused effects in the Sprague-Dawley rats of the NEDO (1987, 064574) study but did not cause a readily apparent maternal effect in Long-Evans rats of this study could be due to diffences in strain susceptibility.

subtle cognitive deficits as a result of methanol exposure. A morphological examination of offspring brains conducted on PND1 and PND21 indicated that methanol exposure had no effect on neuronal migration, numbers of apoptotic cells in the cortex or germinal zones, or myelination. However, neural cell adhesion molecule (NCAM) 140 and NCAM 180 gene expression in treated rats was reduced on PND4 but not 15 months after the last exposure. NCAMs are glycoproteins required for neuron migration, axonal outgrowth, and establishing mature neuronal function patterns.

Stanton et al. (1995, 085231) exposed 6-7 pregnant female Long-Evans rats/group to 0 or 15,000 ppm (0 and 19,656 mg/m^3) methanol vapors ($\geq$ 99.9% purity) for 7 hours/day on GD7-GD19. Mean serum methanol levels at the end of the 1st, 4th, 8th, and 12th days of exposure were 3,836, 3,764, 3,563, and 3,169 µg/mL, respectively. As calculated by authors, dams received an estimated methanol dose of 6,100 mg/kg-day. A lower body weight on the first 2 days of exposure was the only maternal effect; there was no increase in postimplantation loss. Dams were allowed to deliver and nurse litters. Parameters evaluated in pups included mortality, growth, pubertal development, and neurobehavioral function. Examinations of pups revealed that two pups from the same methanol-exposed litter were missing one eye; aberrant visually evoked potentials were observed in those pups. A modest but significant reduction in body weight gain on PND1, PND21, and PND35 was noted in pups from the methanol group. For example, by PND35, male pups of dams exposed to methanol had a mean body weight of 129 grams versus 139 grams in controls ($p < 0.01$). However, postnatal mortality was unaffected by exposure to methanol. The study authors did not consider a 1.7-day delay in vaginal opening in the methanol group to be an adverse effect. Preputial separation was not affected by prenatal methanol exposure. Neurobehavioral status was evaluated using 8 different tests on specific days up to PND160. Tests included motor activity on PND13-PND21, PND30, and PND60, olfactory learning and retention on PND18 and PND25, behavioral thermoregulation on PND20-21, T-maze delayed alternation learning on PND23-PND24, acoustic startle reflex on PND24, reflex modification audiometry on PND61-PND63, passive avoidance on PND73, and visual evoked potentials on PND160. A single pup/sex/litter was examined in most tests, and some animals were subjected to multiple tests. The statistical significance of neurobehavioral testing was assessed by one-way ANOVA, using the litter as the statistical unit. Results of the neurobehavioral testing indicated that methanol exposure had no effect on the sensory, motor, or cognitive function of offspring under the conditions of the experiment. However, given the comparatively small number of animals tested for each response, it is uncertain whether the statistical design had sufficient power to detect small compound-related changes.

1   NEDO (1987, 064574) sponsored a teratology study that included an evaluation of
2   postnatal effects in addition to standard prenatal endpoints in Sprague-Dawley rats. Thirty-six
3   pregnant females/group were exposed to 0, 200, 1,000, or 5,000 ppm (0, 262, 1,310, and 6,552
4   mg/m^3) methanol vapors (reagent grade) on GD7-GD17 for 22.7 hours/day. Statistical
5   significance of results was evaluated by t-test, Mann-Whitney U test, Fisher's exact test, and/or
6   Armitage's χ^2 test.

7   Postnatal effects of methanol inhalation were evaluated in the remaining 12 dams/group
8   that were permitted to deliver and nurse their litters. Effects were only observed in the
9   5,000 ppm. There were no adverse effects on offspring body weight from methanol exposure.
10   However, the weights of some organs (brain, thyroid, thymus, and testes) were reduced in
11   8-week-old offspring following prenatal-only exposure to 5,000 ppm methanol. An unspecified
12   number of offspring were subjected to neurobehavioral testing or necropsy, but results were
13   incompletely reported.

14   NEDO (1987, 064574) also contains an account of a two-generation reproductive study
15   that evaluated the effects of pre- and postnatal methanol (reagent grade) exposure (20 hours/day)
16   on reproductive and other organ systems of Sprague-Dawley rats and in particular the brain. The
17   F_0 generation (30 males and 30 females per exposure group)[50] was exposed to 0, 10, 100, and
18   1,000 ppm (0, 13.1, 131, and 1,310 mg/m^3) from 8 weeks old to the end of mating (males) or to
19   the end of lactation period (females). The F_1 generation was exposed to the same concentrations
20   from birth to the end of mating (males) or to weaning of F_2 pups 21 days after delivery (females).
21   Males and females of the F_2 generation were exposed from birth to 21 days old (1
22   animal/sex/litter was exposed to 8 weeks of age). NEDO (1987, 064574) noted reduced brain,
23   pituitary, and thymus weights, in the offspring of F_0 and F_1 rats exposed to 1,000 ppm methanol.
24   As discussed in the report, NEDO (1987, 064574) sought to confirm the possible compound-
25   related effect of methanol on the brain by carrying out an additional study in which Sprague-
26   Dawley rats were exposed to 0, 500, 1,000, and 2,000 ppm (0, 655, 1,310, and 2,620 mg/m^3)
27   methanol from the first day of gestation through the F_1 generation. Brain weights were measured
28   in 10-14 offspring/sex/group at 3, 6, and 8 weeks of age. As illustrated in Table 4-14, brain
29   weights were significantly reduced in 3-week-old males and females exposed to $\geq$ 1,000 ppm.
30   At 6 and 8 weeks of age, brain weights were significantly reduced in males exposed to
31    $\geq$ 1,000 ppm and females exposed to 2,000 ppm. Due to the toxicological significance of this
32   postnatal effect and the fact that it has not been measured or reported elsewhere in the peer-

---

[50] A second control group of 30 animals/sex was maintained in a separate room to "confirm that environmental conditions inside
the chambers were not unacceptable to the animals."

1 reviewed methanol literature, the brain weight changes observed by NEDO (1987, 064574)

2 following gestational and postnatal exposures and following gestation-only exposure (in the

3 teratology study discussed above) are evaluated quantitatively and discussed in more detail in

4 Section 5 of this review.

Table 4-14. Brain weights of rats exposed to methanol vapors during gestation and lactation

| Offspring age | Sex | Brain weight (g) (% control) at each exposure level | | | | | |
		0 ppm	200 ppm	500 ppm	1,000 ppm	2,000 ppm	5,000 ppm
3 wk[a]	Male	1.45 ± 0.06	--	1.46 ± 0.08 (101%)	1.39 ± 0.05^{c} (96%)	1.27 ± 0.06^{e} (88%)	--
	Female	1.41 ± 0.06	--	1.41 ± 0.07 (100%)	1.33 ± 0.07^{d} (94%)	1.26 ± 0.09^{e} (89%)	--
6 wk[a]	Male	1.78 ± 0.07	--	1.74 ± 0.09 (98%)	1.69 ± 0.06^{d} (95%)	1.52 ± 0.07^{e} (85%)	--
	Female	1.68 ± 0.08	--	1.71 ± 0.08 (102%)	1.62 ± 0.07 (96%)	1.55 ± 0.05^{e} (92%)	--
8 wk[a]	Male	1.99 ± 0.06	--	1.98 ± 0.09 (99%)	1.88 ± 0.08^{d} (94%)	1.74 ± 0.05^{e} (87%)	--
	Female	1.85 ± 0.05	--	1.83 ± 0.07 (99%)	1.80 ± 0.08 (97%)	1.67 ± 0.06^{e} (90%)	--
8 wk[b]	Male	2.00 ± 0.05	2.01 ± 0.08 (100%)	--	1.99 ± 0.07 (100%)	--	1.81 ± 0.16^{d} (91%)
	Female	1.86 ± 0.08	1.91 ± 0.06 (103%)	--	1.90 ± 0.08 (102%)	--	1.76 ± 1.09 (95%)

[a]Exposed throughout gestation and F_1 generation.
[b]Exposed on gestational days 7-17 only.
[c]$p < 0.05$, [d]$p < 0.01$, [e]$p < 0.001$, as calculated by the authors.
Values are means ± S.D.

Source: NEDO (1987, 064574).

5 Burbacher et al. (1999, 009752; 1999, 009753) carried out toxicokinetic, reproductive,

6 developmental and postnatal neurological and neurobehavioral studies of methanol in *M.*

7 *fascicularis* monkeys that were published by HEI in a two-part monograph. Some of the data

8 were subsequently published in the open scientific literature (Burbacher et al., 2004, 059070;

9 Burbacher et al., 2004, 056018). The experimental protocol featured exposure to 2 cohorts of 12

10 monkeys/group to low-exposure levels (relative to the previously discussed rodent studies) of 0,

11 200, 600, or 1,800 ppm (0, 262, 786, and 2,359 mg/m^3) methanol vapors (99.9% purity),

12 2.5 hours/day, 7 days/week, during a premating period and mating period (−180 days combined)

13 and throughout the entire gestation period (−168 days). The monkeys were 5.5-13 years old and

were a mixture of feral-born and colony-bred animals. The outcome study included an evaluation of maternal reproductive performance (discussed in Section 4.3.2) and tests to assess infant postnatal growth and newborn health, neurological outcomes included reflexes, behavior, and development of visual, sensorimotor, cognitive, and social behavioral function. Blood methanol levels, elimination, and the appearance of formate were also examined and are discussed in Section 3.2. The effects observed were in the absence of appreciable increases in maternal blood formate levels.

Neurobehavioral function was assessed in 8-9 infants/group during the first 9 months of life (Burbacher et al., 1999, 009753; Burbacher et al., 2004, 059070). Although results in 7/9 tests were negative, 2 effects were possibly related to methanol exposure. The Visually Directed Reaching (VDR) test is a measure of sensorimotor development and assessed the infants' ability to grasp for a brightly colored object containing an applesauce-covered nipple. Beginning at 2 weeks after birth, infants were tested 5 times/day, 4 days/week. Performance on this test, measured as age from birth at achievement of test criterion (successful object retrieval on 8/10 consecutive trials over 2 testing sessions), was reduced in all treated male infants. The times (days after birth) to achieve the criteria for the VDR test were 23.7 ± 4.8 (n = 3), 32.4 ± 4.1 (n = 5), 42.7 ± 8.0 (n = 3), and 40.5 ± 12.5 (n = 2) days for males and 34.2 ± 1.8 (n = 5), 33.0 ± 2.9 (n = 4), 27.6 ± 2.7 (n = 5), and 40.0 ± 4.0 (n = 7) days for females in the control to 1,800 ppm groups, respectively. Statistical significance was obtained in the 1,800 ppm group when males and females were evaluated together ($p = 0.04$) and in the 600 ppm ($p = 0.007$) for males only. However, there was no significant difference between responses and/or variances among the dose levels for males and females combined ($p = 0.244$), for males only ($p = 0.321$) and for males only, excluding the high-dose group ($p = 0.182$). Yet there was a significant dose-response trend for females only ($p = 0.0265$). The extent to which VDR delays were due to a direct effect of methanol on neurological development or a secondary effect due to the methanol-induced decrease in length of pregnancy and subsequent prematurity is not clear. Studies of reaching behavior have shown that early motor development in pre-term human infants without major developmental disorders differs from that of full-term infants (Fallang et al., 2003, 196118). Clinical studies have indicated that the quality of reaching and grasping behavior in pre-term infants is generally less than that in full-term infants (Fallang et al., 2003, 196118; Plantinga et al., 1997, 196151). For this reason, measures of human infant development generally involve adjustment of a child's "test age" if he or she had a gestational age of fewer than 38 weeks, often by subtracting weeks premature from the age measured from birth (Wilson and Cradock, 2004, 196726). When this type of adjustment is made to the Burbacher et al. (1999, 009753; 2004, 059070) VDR data, the dose-response trend for males only becomes worse ($p = 0.448$) and the

dose-response trend for the females only is improved ($p = 0.009$), though the variance in the data could not be modeled adequately. Thus, only the unadjusted VDR response for females only exhibited a dose response that could be adequately modeled for the purposes of this assessment (see Appendix C).

At 190-210 days of age, the Fagan Test of infant intelligence was conducted. The paradigm makes use of the infant's proclivity to direct more visual attention to novel stimuli rather than familiar stimuli. The test measures the time infants spend looking at familiar versus novel items. Deficits in the Fagan task can qualitatively predict deficits in intelligence quotient (IQ) measurements assessed in children at later ages (Fagan and Singer, 1983, 196116). Control monkey infants in the Burbacher et al. (1999, 009753; 2004, 059070) study spent more than 62% $\pm$ 4% (mean for both cohorts) of their time looking at novel versus familiar monkey faces, while none of the treated monkeys displayed a preference for the novel faces (59% $\pm$ 2%, 54% $\pm$ 2% and 59% $\pm$ 2% in 200, 600 and 1,800 ppm groups, respectively). Unlike the VDR results discussed previously, results of this test did not appear to be gender specific and were neither statistically significant (ANOVA $p = 0.38$) nor related to exposure concentration. The findings indicated a cohort effect which appeared to reduce the statistical power of this analysis. The authors' exploratory analysis of differences in outcomes between the 2 cohorts indicated an effect of exposure in the second cohort and not the first cohort due to higher mean performance in controls of cohort 2 (70% $\pm$ 5% versus 55% $\pm$ 4% for cohort 1). In addition, this latter finding could reflect the inherent constraints of this endpoint. If the control group performs at the 60% level and the most impaired subjects perform at approximately the 50% chance level (worse than chance performance would not be expected), the range over which a concentration-response relationship can be expressed is limited. Because of the longer latency between assessment and birth, these results would not be confounded with the postulated methanol-induced decrease in gestation length of the exposed groups of this study. Negative results were obtained for the remaining seven tests that evaluated early reflexes, gross motor development, spatial and concept learning and memory, and social behavior. Infant growth and tooth eruption were unaffected by methanol exposure.

4.4.3. Studies Employing In Vitro, S.C. and I.P. Exposures

There is some experimental evidence that the presence of methanol can affect the activity of acetylcholinesterase (Tsakiris et al., 2006, 196731). Although these experiments were carried out on erythrocyte membranes in vitro, the apparent compound-related changes may have implications for possible impacts of methanol and/or its metabolites on acetylcholinesterase at other centers, such as the brain. Tsakiris et al. (2006, 196731) prepared erythrocyte ghosts from

blood samples of healthy human volunteers by repeated freezing-thawing. The ghosts were
incubated for 1 hour at $37^{\circ}C$ in 0, 0.07, 0.14, 0.6 or 0.8 mmol/L methanol and the specific
activities of acetylcholinesterase monitored. Respective values (in change of optical density
units/minute-mg protein) were 3.11 ± 0.15, 2.90 ± 0.10, 2.41 ± 0.10 ($p < 0.05$), 2.05 ± 0.11 ($p <$
0.01), and 1.81 ± 0.09 ($p < 0.001$). More recently, Simintzi et al. (2007, 092988) carried out an in
vitro experiment to investigate the effects of aspartame metabolites, including methanol, on 1) a
pure preparation of acetylcholinesterase, and 2) the same activity in homogenates of frontal
cortex prepared from the brains of (both sexes of) Wistar rats. The activities were measured after
incubations with 0, 0.14, 0.60, or 0.8 mmoles/L (0, 4.5, 19.2, and 25.6 mg/L) methanol, and with
methanol mixed with the other components of aspartame metabolism, phenylalanine and aspartic
acid. After incubation at $37^{\circ}C$ for 1 hour, the activity of acetylcholinesterase was measured
spectrophotometrically. As shown in Table 4-15, the activities of the acetylcholinesterase
preparations were reduced dose dependently after incubation in methanol. Similar results were
also obtained with the other aspartame metabolites, aspartic acid, and phenylalanine, both
individually or as a mixture with methanol. While the implications of this result to the acute
neurotoxicity of methanol are uncertain, the authors speculated that methanol may bring about
these changes through either interactions with the lipids of rat frontal cortex or perturbation of
proteinaceous components.

Table 4-15. Effect of methanol on Wistar rat acetylcholinesterase activities

Methanol concentration (mmol/L)	Acetylcholinesterase activity (ΔOD/min-mg)	
	Frontal cortex	Pure enzyme
Control	0.269 ± 0.010	1.23 ± 0.04
0.14	0.234 ± 0.007[a]	1.18 ± 0.06
0.60	0.223 ± 0.009[b]	1.05 ± 0.04[b]
0.80	0.204 ± 0.008[b]	0.98 ± 0.05[b]

Values are means ± S.D. for four experiments. The average value of each experiment was derived from three
determinations of each enzyme activity.
[a]$p < 0.01$.
[b]$p < 0.001$.

Source: Simintzi et al. (2007, 092988).

In another experiment of relevance to neurotoxicity, the impact of repeat methanol
exposure on amino acid and neurotransmitter expression in the retina, optic nerve, and brain was
examined by Gonzalez-Quevedo et al. (2002, 037282). The goal of the study was to determine
whether a sustained increase in formate levels, at concentrations below those known to produce
toxic effects from acute exposures, can induce biochemical changes in the retina, optical nerve,

or certain regions of the brain. Male Sprague-Dawley rats (5-7/group; 100-150 g) were divided into 6 groups and treated for 4 weeks according to the following plan. Four groups of animals received tap water ad libitum as drinking water for 1 week. During the second week, groups 1 and 2 (control and methanol respectively) received saline subcutaneously, (s.c.) and groups 3 and 4 (methotrexate[51] [MTX] and methotrexate-methanol [MTX-methanol], respectively) received MTX s.c. (0.2 mg/kg-day). During the 3rd week, MTX was reduced to 0.1 mg/kg and 20% methanol (2g/kg-day) was given i.p. to groups 2 (methanol) and 4 (MTX-methanol). Groups 1 (control) and 3 (MTX) received equivalent volumes of saline administered i.p. The treatment was continued until the end of the fourth week. Groups 5, (taurine[52] [Tau]) and 6, (Tau-MTX-methanol) received 2% Tau in their drinking water ad libitum during the first 4 weeks, after which they were treated in the same manner as groups 1 and 4, respectively. Weights were documented weekly on all animals. Blood for formate and amino acid determinations and biopsy samples of retina, optic nerve, hippocampus, and posterior cortex of each animal were collected at the end of the experiment. Formate levels were not affected by Tau alone or MTX alone. While methanol alone increased blood formate levels, MTX-methanol, and Tau-MTX-methanol produced a threefold increase in blood formate levels as compared to controls and a twofold increase as compared to methanol alone. The amino acids aspartate, glutamate, asparagine, serine, histidine, glutamine, threonine, glycine, arginine, alanine, hypotaurine, gamma-aminobutyric acid (which is also a neurotransmitter), and tyrosine were measured in blood, brain, and retinal regions.

None of the amino acids measured were altered in the blood of methanol-, MTX-, or MTX-methanol-treated animals. Tau was increased in the blood of animals treated with taurine in the drinking water (Tau and Tau-MTX-methanol) and histidine was increased in the Tau group but not in the Tau-MTX-methanol group.

The levels of aspartate, Tau, glutamine, and glutamate were found to be altered by treatment in various areas of the brain. Aspartate was increased in the optic nerve of animals treated with MTX-methanol and Tau-MTX-methanol, indicating a possible relation to formate accumulation. The authors note that L-aspartate is a major excitatory amino acid in the brain and that increased levels of excitatory amino acids can trigger neuronal cell damage and death (Albin and Greenamyre, 1992, 196178). Aspartate, glutamine and Tau were found to be increased with respect to controls in the hippocampus of the three groups receiving methanol. Glutamate was significantly increased in the hippocampus in the methanol and the Tau-MTX-methanol groups

---

[51] Methotrexate depletes folate stores (resulting in an increase in the formate levels of methanol exposed animals) by interfering with tetrahydrofolate(THF) regeneration (Dorman et al., 1994, 196743).
[52] Taurine plays and important role in the CNS, especially in the retina and optical nerve, and was administered here to explore its possible protective effect (Gonzalez-Quevado et al., 2002, 037282).

with respect to controls, but no statistically significant difference was found in the MTX-methanol group when compared to controls, methanol alone, or the Tau-MTX-methanol groups. The authors suggest that increased levels of aspartate and glutamine in the hippocampus could provide an explanation for some of the CNS symptoms observed in methanol poisonings on the basis of their observed impact on cerebral arteries (Huang et al., 1994, 196230). The fact that these increases resulted primarily from methanol without MTX is significant in that it indicates methanol can cause excitotoxic effects without formate mediation. The treatments used did not produce any significant changes in amino acid levels in the posterior cortex.

The neurotransmitters serotonin (5-HT) and dopamine (DA) and their respective metabolites, 5-hydroxyindolacetic acid (5-HIAA) and dihydroxyphenylacetic acid (DOPAC), were measured in the brain regions described. The levels of these monoamines were not affected by formate accumulation, as the only increases were observed for 5-HT and 5-HIAA following methanol-only exposure. 5-HT was increased in the retina and hippocampus of methanol-only treated animals, and the metabolite 5-HIAA was increased in the hippocampus of methanol-only treated animals; DA and DOPAC levels were not altered by the treatments in any of the areas measured. The posterior cortex did not show any changes in monoamine levels for any treatment group.

Rajamani et al. (2006, 196157) examined several oxidative stress parameters in male Wistar rats following methotrexate-induced folate deficiency. Animals (6/group) were divided into 3e groups: saline controls, methotrexate (MTX) controls, and MTX-methanol treated animals. Animals in the MTX-only group were treated with 0.2 mg/kg-day MTX s.c. injection for 7 days and following confirmation of folate deficiency, received either saline for MTX control and saline controls or a single dose of 3 g/kg methanol (20% w/v in saline) i.p. on day 8. On the 9th day, all animals were sacrificed and blood and tissue samples were collected. The optic nerve, retina, and brain were collected and the brain was dissected into the following regions: cerebral cortex, cerebellum, mid-brain, pons medulla, hippocampus and hypothalamus. Each region was homogenized, then centrifuged at $300 \times g$ for 15 minutes and the supernatant was examined for indicators of oxidative stress including the free radical scavengers superoxide dismutase (SOD), CAT, glutathione peroxidase, and reduced GSH levels. The levels of protein thiols, protein carbonyls, and amount of lipid peroxidation were also measured. Compared to controls the levels of SOD, CAT, GSH peroxidase, oxidized GSH, protein carbonyls and lipid peroxidation were elevated in all of the brain regions where it was measured, with greater increases observed in the MTX-methanol treated animals than in the MTX alone group. The level of GSH and protein thiols was decreased in all regions of the brain, with a greater decrease observed in the MTX-methanol-treated animals than MTX-treated animals. In addition,

expression of HSP70, a biomarker of cellular stress, was increased in the hippocampus. Overall, these results suggest that methanol treatment of folate-deficient rats results in increased oxidative stress in the brain, retina and optic nerve.

To determine the effects of methanol intoxication on the HPA axis, a combination of oxidative stress, immune and neurobehavioral parameters were observed (Parthasarathy et al., 2006a). Adult male Wistar albino rats (6 animals/group) were treated with either 0 or 2.37g/kg-day methanol i.p. for 1, 15 or 30 days. Oxidative stress parameters examined included SOD, CAT, GSH peroxidase, GSH, and ascorbic acid (Vitamin C). Plasma corticosterone levels were measured, and lipid peroxidation was measured in the hypothalamus and the adrenal gland. An assay for DNA fragmentation was conducted in tissue from the hypothalamus, the adrenal gland and the spleen. Immune function tests conducted included the footpad thickness test for delayed type hypersensitivity (DTH), a leukocyte migration inhibition assay, the hemagglutination assay (measuring antibody titer), the neutrophil adherence test, phagocytosis index, and a nitroblue tetrazolium (NBT) reduction and adherence assay used to measure the killing ability of polymorphonuclear leukocytes (PMNs). The open field behavior test was used to measure general locomotor and explorative activity during methanol treatment in the 30-day treatment group, with tests conducted on days 1, 4, 8, 12, 16, 20, 24, and 28. All enzymatic (SOD, CAT, and GSH peroxidase) and nonenzymatic antioxidants (GSH and Vitamin C) were significantly increased in the 1-day methanol-exposed group as compared to controls. However, with increasing time of treatment, all of the measured parameters were significantly decreased when compared with control animals. Lipid peroxidation was significantly increased in both the hypothalamus and the adrenal gland at 1, 15, and 30 days, with the 30-day treated animals also significantly increased when compared to the 15-day methanol-treated animals.

Leukocyte migration and antibody titer were both significantly increased over controls for all time points, while footpad thickness was significantly decreased in 15- and 30-day treated animals. Neutrophil adherence was significantly decreased after 1 and 30 days of exposure. A significant decrease in the NBT reduction and adherence was found when comparing PMNs from the 30-day treated animals with cells from the 15-day methanol-treated group.

The open field behavior tests showed a significant decrease in ambulation from the 4th day on and significant decreases in rearing and grooming from the 20th day on. A significant increase was observed in immobilization from the 8th day on and in fecal bolus from the 24th day on in methanol-exposed animals.

While corticosterone levels were significantly increased following 1 or 15 days of methanol treatment, they were significantly decreased after 30 days of treatment, as compared to controls. Following 30 days of methanol treatment, DNA from the hypothalamus, the adrenal

gland, and the spleen showed significant fragmentation. The authors conclude that exposure to methanol-induced oxidative stress, disturbs HPA-axis function, altering corticosterone levels and producing effects in several nonspecific and specific immune responses.

4.5. IMMUNOTOXICITY

Parthasarathy et al. (2005, 090783) provided data on the impact of methanol on neutrophil function in an experiment in which 6 male Wistar rats/group were given a single i.p. exposure of 2,370 mg/kg methanol mixed 1:1 in saline. Another group of 6 animals provided blood samples that were incubated with methanol in vitro at a methanol concentration equal to that observed in the in vivo-treated animals 30 and 60 minutes postexposure. Total and differential leukocyte counts were measured from these groups in comparison to in vivo and in vitro controls. Neutrophil adhesion was determined by comparing the neutrophil index in the untreated blood samples to those that had been passed down a nylon fiber column. The cells' phagocytic ability was evaluated by their ability to take up heat-killed *Candida albicans*. In another experiment, neutrophils were assessed for their killing potential by measuring their ability to take up then convert NBT to formazan crystals.[53] One hundred neutrophils/slides were counted for their total and relative percent formazan-positive cells.

The blood methanol concentrations 30 and 60 minutes after dosing were $2,356 \pm 162$ and $2,233 \pm 146$ mg/L, respectively. The mean of these values was taken as the target concentration for the in vitro methanol incubation. In the in vitro studies, there were no differences in total and differential leukocyte counts, suggesting that no lysis of the cells had occurred at this methanol concentration. This finding contrasts with the marked difference in total leukocytes observed as a result of methanol incubation in vivo, in which, at 60 minutes after exposure, $16,000 \pm 1,516$ cells/mm^3 were observed versus $23,350 \pm 941$ in controls ($p < 0.001$). Some differences in neutrophil function were observed in blood samples treated with methanol in vitro and in vivo. These differences are illustrated for the 60-minute postexposure samples in Table 4-16.

---

[53] Absence of NBT reduction indicates a defect in some of the metabolic pathways involved in intracellular microbial killing.

Table 4-16. Effect of methanol on neutrophil functions in in vitro and in vivo studies in male Wistar rats

Parameter	In vitro studies (60 minutes)		In vivo studies (60 minutes)	
	Control	Methanol	Control	Methanol
Phagocytic index (%)	89.8 ± 3.07	81.6 ± 2.2^a	66.0 ± 4.8	84.0 ± 7.0^b
Avidity index	4.53 ± 0.6	4.47 ± 0.7	2.4 ± 0.1	3.4 ± 0.3^a
NBT reduction (%)	31.6 ± 4.6	48.6 ± 4.3^b	4.6 ± 1.2	27.0 ± 4.6^b
Adherence (%)	50.2 ± 5.1	39.8 ± 2.4^a	49.0 ± 4.8	34.6 ± 4.0^b

Values are means ± S.D. for six animals.
[a]$p < 0.01$.
[b]$p < 0.001$.

Source: Parthasarathy et al. (2005, 090783).

Parthasarathy et al. (2005, 090783) observed differences in the neutrophil functions of cells exposed to methanol in vitro versus in vivo, most notably in the phagocytic index that was reduced in vitro but significantly increased in vivo. However, functions such as adherence and NBT reduction showed consistency in the in vitro and in vivo responses. The authors noted that, by and large, the in vivo effects of methanol on neutrophil function were more marked than those in cells exposed in vitro.

Another study by Parthasarathy et al. (2005, 196306) also exposed 6 male Wistar rats/group i.p. to methanol at approximately 1/4 the LD_{50} (2.4 g/kg). The goal was to further monitor possible methanol-induced alterations in the activity of isolated neutrophils and other immunological parameters. The exposure protocol featured daily injections of methanol for up to 30 days in the presence or absence of sheep RBCs. Blood samples were assessed for total and differential leukocytes, and isolated neutrophils were monitored for changes in phagocytic and avidity indices, NBT reduction, and adherence. In the latter test, blood samples were incubated on a nylon fiber column, then eluted from the column and rechecked for total and differential leukocytes. Phagocytosis was monitored by incubating isolated buffy coats from the blood samples with heat-killed *C. albicans*. NBT reduction capacity examined the conversion of the dye to formazan crystals within the cytoplasm. The relative percentage of formazan-positive cells in each blood specimen gave a measure of methanol's capacity to bring about cell death. As tabulated by the authors, there was a dose-dependent reduction in lymphoid organ weights (spleen, thymus, and lymph node) in rats exposed to methanol for 15 and 30 days via i.p. injection, irrespective of the presence of sheep RBCs. Methanol also appeared to result in a reduction in the total or differential neutrophil count. These and potentially related changes to neutrophil function are shown in Table 4-17.

Table 4-17. Effect of intraperitoneally injected methanol on total and differential leukocyte counts and neutrophil function tests in male Wistar rats

Parameter	Without sheep red blood cell treatment			With sheep red blood cell treatment		
	Control	15-day methanol	30-day methanol	Control	15-day methanol	30-day methanol
Organ weights (mg)						
Spleen	1223 ± 54	910 ± 63[a]	696 ± 83[a,b]	1381 ± 27	1032 ± 39[a]	839 ± 35[a,b]
Thymus	232 ± 12	171 ± 7[a]	121 ± 10[a,b]	260 ± 9	172 ± 10[a]	130 ± 24[a,b]
Lymph node	32 ± 2	24 ± 3[a]	16 ± 2[a,b]	39 ± 2	28 ± 1[a]	23 ± 1[a,b]
Leukocyte counts						
Total leukocytes	23,367 ± 946	16,592 ± 1219[a]	13,283 ± 2553[a,b]	18,633 ± 2057	16,675 ± 1908	14,067 ± 930[a,b]
% neutrophils	24 ± 8	21 ± 3	16 ± 3[a]	8 ± 3	23 ± 4[a]	15 ± 5[a,b]
% Lymphocytes	71 ± 7	76 ± 3	79 ± 5	89 ± 4	78.5 ± 4[a]	82 ± 6
Neutrophil function tests						
Phagocytic index (%)	91.0 ± 2.0	80.0 ± 4.0[a]	79.0 ± 2.0[a]	87.0 ± 4.0	68.0 ± 3.0[a]	63.0 ± 4.0[a]
Avidity index	2.6 ± 0.3	3.2 ± 0.5[a]	3.2 ± 0.1[a]	4.1 ± 0.1	2.6 ± 0.3[a]	2.1 ± 0.3[a]
NBT reduction (%)	6.3 ± 2.0	18.2 ± 2.0[a]	15.0 ± 1.0[a,b]	32.0 ± 3.3	22.0 ± 3.0[a]	19.0 ± 2.4[a]
Adherence (%)	49.0 ± 5.0	44.0 ± 5.0	29.5 ± 5.0[a,b]	78.0 ± 9.2	52.0 ± 9.0[a]	30.0 ± 4.3[a,b]

Values are means ± S.D. (n = 6).
[a]$p < 0.05$ from respective control.
[b]$p < 0.05$ between 15-and 30-day treatment groups.

Source: Parthasarathy et al. (2005, 196306).

The study provided data that showed altered neutrophil functions following repeated daily exposures of rats to methanol for periods up to 30 days. This finding is indicative of a possible effect of methanol on the immunocompetence of an exposed host.

Parthasarathy et al. (2006, 196309) reported on additional immune system indicators as part of a study to determine the effects of methanol intoxication on the HPA axis. As described in Section 4.4.3, immune function tests conducted included the footpad thickness test for DTH, a leukocyte migration inhibition assay, the hemagglutination assay (measuring antibody titer), the neutrophil adherence test, phagocytosis index, and a NBT reduction and adherence assay used to measure the killing ability of PMNs.

Leukocyte migration and antibody titer were both significantly increased over controls for all time points, while footpad thickness was significantly deceased in 15- and 30-day treated animals. Neutrophil adherence was significantly decreased after 1 and 30 days of exposure. A

significant decrease in the NBT reduction and adherence was found when comparing PMNs from the 30-day treated animals with cells from the 15-day methanol-treated group.

Parthasarathy et al. (2007, 092996) reported the effects of methanol on a number of specific immune functions. As before, 6 male Wistar rats/group were treated with 2,370 mg/kg methanol in a 1:1 mixture in saline administered intraperitoneally for 15 or 30 days. Animals scheduled/designated for termination on day 15 were immunized intraperitoneally with 5×10^9 sheep RBCs on the 10th day. Animals scheduled for day 30 termination were immunized on the 25th day. Controls were animals that were not exposed to methanol but immunized with sheep RBCs as described above. Blood samples were obtained from all animals at sacrifice and lymphoid organs including the adrenals, spleen, thymus, lymph nodes, and bone marrow were removed. Cell suspensions were counted and adjusted to 1×10^8 cells/mL. Cell-mediated immune responses were assessed using a footpad thickness assay and a leucocyte migration inhibition (LMI) test, while humoral immune responses were determined by a hemagglutination assay, and by monitoring cell counts in spleen, thymus, lymph nodes, femoral bone marrow, and in splenic lymphocyte subsets. Plasma levels of corticosterone were measured along with levels of such cytokines as TNF-α, IFN-γ, IL-2, and IL-4. DNA damage in splenocytes and thymocytes was also monitored using the Comet assay.

Table 4-18 shows decreases in the animal weight/organ weight ratios for spleen, thymus, lymph nodes and adrenal gland as a result of methanol exposure. However, the splenocyte, thymocyte, lymph node, and bone marrow cell counts were time-dependently lower in methanol-treated animals.

Table 4-18. Effect of methanol exposure on animal weight/organ weight ratios and on cell counts in primary and secondary lymphoid organs of male Wistar rats.

Organ	Immunized		
	Control	15 days	30 days
Animal weight/organ weight ratio			
Spleen	3.88 ± 0.55	2.85 ± 0.36[a]	2.58 ± 0.45[a]
Thymus	1.35 ± 0.29	0.61 ± 0.06[a]	0.63 ±0.04[a]
Lymph node	0.10 ± 0.01	0.08 ± 0.01[a]	0.06 ± 0.02[a]
Adrenal	0.14 ± 0.01	0.15 ± 0.01	0.12 ± 0.01[a, b]
Cell counts			
Splenocytes ($\times 10^8$)	5.08 ± 0.06	3.65 ±0.07[a]	3.71 ± 0.06[a]
Thymocytes ($\times 10^8$)	2.66 ± 0.09	1.95 ± 0.03[a]	1.86 ± 0.09[a]
Lymph node ($\times 10^7$)	3.03 ± 0.04	2.77 ± 0.07[a]	2.20 ± 0.06[a, b]
Bone marrow ($\times 10^7$)	4.67 ± 0.03	3.04 ± 0.09[a]	2.11 ± 0.05[a,b]

Values are means ± six animals. [a]$p < 0.05$ versus control groups. [b]$p < 0.05$ versus 15-day treated group.

Organ	Immunized		
	Control	**15 days**	**30 days**

Source: Parthasarathy et al. (2007, 092996).

Parthasarathy et al. (2007, 092996) also documented their results on the cell-mediated and humoral immunity induced by methanol. Leucocyte migration was significantly increased compared to control animals, an LMI of 0.82 ± 0.06 being reported in rats exposed to methanol for 30 days. This compares to an LMI of 0.73 ± 0.02 in rats exposed for 15 days and 0.41 ± 0.10 in controls. By contrast, footpad thickness and antibody titer were decreased significantly in methanol-exposed animals compared to controls (18.32 ± 1.08, 19.73 ± 1.24, and $26.24 \pm 1.68\%$ for footpad thickness; and 6.66 ± 1.21, 6.83 ± 0.40, and 10.83 ± 0.40 for antibody titer in 30-day, 15-day exposed rats, and controls, respectively).

Parthasarathy et al. (2007, 092996) also provided data in a histogram that showed a significant decrease in the absolute numbers of Pan T cells, CD4, macrophage, major histocompatibility complex (MHC) class II molecule expressing cells, and B cells of the methanol-treated group compared to controls. The numbers of CD8 cells were unaffected. Additionally, as illustrated in the report, DNA single strand breakage was increased in immunized splenocytes and thymocytes exposed to methanol versus controls. Although some fluctuations were seen in corticosterone levels, the apparently statistically significant change versus controls in 15-day exposed rats was offset by a decrease in 30-day exposed animals. Parthasarathy et al. (2007, 092996) also tabulated the impacts of methanol exposure on cytokine levels; these values are shown in Table 4-19.

Table 4-19. The effect of methanol on serum cytokine levels in male Wistar rats

Cytokines (pg/mL)	Immunized		
	Control	**15 days**	**30 days**
IL-2	1810 ± 63.2	1303.3 ± 57.1^a	$1088.3 \pm 68.8^{a,b}$
IL-4	44.8 ± 2.0	74.0 ± 5.1^a	78.8 ± 4.4^a
TNF-α	975 ± 32.7	578.3 ± 42.6^a	585 ± 45^a
IFN-γ	1380 ± 55.1	$961\ 6 \pm 72.7^a$	950 ± 59.6^a

Values are means ± six animals.
[a]$p < 0.05$ versus control groups.
[b]$p < 0.05$ versus 15-day treated group.

Source: Parthasarathy et al. (2007, 092996).

1   Drawing on the results of DNA single strand breakage in this experiment, the authors
2 speculated that methanol-induced apoptosis could suppress specific immune functions such as
3 those examined in this research report. Methanol appeared to suppress both humoral and cell-
4 mediated immune responses in exposed Wistar rats.

4.6. MECHANISTIC DATA AND OTHER STUDIES IN SUPPORT OF THE MOA

5   While the role of the methanol metabolite, formate, in inducing the toxic consequences of
6 acute exposure to methanol, including ocular toxicity and metabolic acidosis, is well established
7 in humans (see Section 4.1), there is controversy over the possible roles of the parent compound,
8 metabolites, and folate deficiency (potentially associated with methanol metabolism) in the
9 developmental neurotoxicity of methanol. Experiments that have attempted to address these
10 issues are reviewed in the following paragraphs.

4.6.1. Role of Methanol and Metabolites in the Developmental Toxicity of Methanol

11   Dorman et al. (1995, 078081) conducted a series of in vitro and in vivo studies that
12 provide information for identifying the proximate teratogen associated with developmental
13 toxicity in CD-1 mice. The studies used CD-1 ICR BR (CD-1) mice, HPLC grade methanol, and
14 appropriate controls. PK and developmental toxicity parameters were measured in mice exposed
15 to sodium formate (750 mg/kg by gavage), a 6-hour methanol inhalation (10,000 or 15,000 ppm),
16 or methanol gavage (1.5 g/kg). In the in vivo inhalation study, 12-14 dams/ group were exposed
17 to 10,000 ppm methanol for 6 hours on GD8,[54] with and without the administration of
18 fomepizole (4-methylpyrazole) to inhibit the metabolism of methanol by ADH1. Dams were
19 sacrificed on GD10, and fetuses were examined for neural tube patency. As shown in
20 Table 4-20, the incidence of fetuses with open neural tubes was significantly increased in the
21 methanol group (9.65% in treated versus 0 in control) and numerically but not significantly
22 increased in the group treated with methanol and fomepizole (7.21% in treated versus 0 in
23 controls). These data should not be interpreted to suggest that a decrease in methanol
24 metabolism is protective. As discussed in Section 3.1, rodents metabolize methanol via both
25 ADH1 and CAT. This fact and the Dorman et al. (1995, 078081) observation that maternal
26 formate levels in blood and decidual swellings (swelling of the uterine lining) did not differ in
27 dams exposed to methanol alone or methanol and fomepizole suggest that the role of ADH1
28 relative to CAT and nonenzymatic methanol clearance is not of great significance in adult
29 rodents.

---

[54] Dorman et al. (1995, 078081) state that GD8 was chosen because it encompasses the period of murine neurulation
and the time of greatest vulnerability to methanol-induced neural tube defects.

Table 4-20. Developmental outcome on GD10 following a 6-hour 10,000 ppm (13,104 mg/m³) methanol inhalation by CD-mice or formate gavage (750 mg/kg) on GD8

Treatment	No. of litters	Open neural tubes (%)	Head length (mm)	Body length (mm)
Air	14	2.29 ± 1.01	3.15 ± 0.03	5.89 ± 0.07
Air/fomepizole	14	2.69 ± 1.19	3.20 ± 0.05	5.95 ± 0.09
Methanol	12	9.65 ± 3.13[a]	3.05 ± 0.07	5.69 ± 0.13
Methanol/fomepizole	12	7.21 ± 2.65	3.01 ± 0.05	5.61 ± 0.11
Water	10	0	3.01 ± 0.07	5.64 ± 0.11
Formate	14	2.02 ± 1.08	2.91 ± 0.08	5.49 ± 0.12

Values are means ± S.D.
[a]$p < 0.05$, as calculated by the authors.

Source: Dorman et al. (1995, 078081) (adapted).

1   The data in Table 4-20 suggest that the formate metabolite is not responsible for the
2   observed increase in open neural tubes in CD-1 mice following methanol exposure. Formate
3   administered by gavage (750 mg/kg) did not increase this effect despite the fact that this formate
4   dose produced the same toxicokinetic profile as a 6-hour exposure to 10,000 ppm methanol
5   vapors (1.05 mM formate in maternal blood and 2.0 mmol formate/kg in decidual swellings).
6   However, the data are consistent with the hypotheses that the formaldehyde metabolite of
7   methanol may play a role. Both CAT and ADH1 activity are immature at days past conception
8   (DPC)8 (Table 4-21). If fetal ADH1 is more mature than fetal CAT, it is conceivable that the
9   decrease in the open neural tube response observed for methanol combined with fomepizole
10   (Table 4-20) may be due to fomepizole having a greater effect on the metabolism of fetal
11   methanol to formaldehyde than is observed in adult rats. Unfortunately, the toxicity studies were
12   carried out during a period of development where ADH1 expression and activity are just starting
13   to develop (Table 4-21); therefore, it is uncertain whether any ADH1 was present in the fetus to
14   be inhibited by fomepizole.

Table 4-21. Summary of ontogeny of relevant enzymes in CD-1 mice and humans

	CD-1 Mouse						Human		
	Days Past Conception (DPC)						Trimesters		
	6.5	7.5		8.5		9.5	1	2	3
Somites			(8-12)		(13-20)	(21-29)			

CAT
  mRNA
  activity[a]
    embryo
    VYS
			
			1
			10
					
					10
					15
						
						20
						20
							N/A	N/A	N/A

ADH1
  mRNA
  activity
    embryo
    VYS
	–
	
		–
		
			320
			240
				–
				
					460
					280
						+
						
						450
						290
							+	+	+

ADH3
  mRNA
  activity
    embryo
    VYS
	+
	
		+
		
			300
			500
				+
				
					490
					500
						+
						
						550
						550
							–	–	+

[a]Activity of CAT and ADH1 are expressed as nmol/minute/mg and pmol/minute/mg, respectively.

Source: Harris et al. (2003, 047369).

1   Dorman et al. (1995, 078081) provide additional support for their hypothesis that
2 methanol's developmental effects in CD-1 mice are not caused by formate in an in vitro study
3 involving the incubation of GD8 whole CD-1 mouse embryos with increasing concentrations of
4 methanol or formate. Developmental anomalies were observed on GD9, including cephalic
5 dysraphism, asymmetry and hypoplasia of the prosencephalon, reductions of brachial arches I
6 and II, scoliosis, vesicles on the walls of the mesencephalon, and hydropericardium (Table 4-22).
7   The concentrations of methanol used for embryo incubation (0-375 mM) were chosen to be
8 broadly equivalent to the peak methanol levels in plasma that have been observed
9 (approximately 100 mM) after a single 6-hour inhalation exposure to 10,000 ppm (13,104
10 mg/m^3). As discussed above, these exposure conditions induced an increased incidence of open
11 neural tubes on GD10 embryos when pregnant female CD-1 mice were exposed on GD8.
12 (Table 4-20). Embryonic lesions such as cephalic dysraphism, prosencephalic lesions, and
13 brachial arch hypoplasia were observed with 250 mM (8,000 mg/L) methanol and 40 mM (1,840
14 mg/L) formate. The study authors noted that a formate concentration of 40 mM (1,840 mg/L)

greatly exceeds blood formate levels in mice inhaling 15,000 ppm methanol (0.75 mM = 35

mg/L), a teratogenic dose.

Table 4-22. Dysmorphogenic effect of methanol and formate in neurulating CD-1 mouse embryos in culture (GD8)

Treat-ment	Concen-tration (mM)	Live embryos		Cephalic dysraphism			Prosencephalic lesions			Bra-chial arch- hypo-plasia
		Total	No. abnor-mal	Severe	Mode-rate	Total	Hypo-plasia	Asym-metry	Total	
Vehicle		20	3	0	2	2	2	0	2	0
Methanol	62	13	1	0	0	0	1	0	1	0
	125	14	5	1	0	2	2	2	4	1
	187	13	7	2	4	6	3	1	4	1
	250	15	7	2	5	7	7[a]	1	8	6[a]
	375	12	7	6[a]	5	11[a]	9[a]	1	10[a]	8[a]
Formate	4	12	2	0	0	0	2	0	2	1
	8	13	5	1	5	6	4	2	6	0
	12	9	5	0	5	5	1	2	3	0
	20	16	7	2	5	7	2	1	3	1
	40	16	14[a]	10[a]	4	14[a]	3	5[a]	8	13[a]

[a] $p < 0.05$, as calculated by the authors.

Source: Dorman et al. (1995, 078081) (adapted).

As discussed in Section 4.3.3, a series of studies by Harris et al. (2003, 047369; 2004, 059082) also provide evidence as to the moieties that may be responsible for methanol-induced developmental toxicity. Harris et al. (2004, 059082) have shown that among methanol and its metabolites, viability of cultured rodent embryos is most affected by formate. In contrast, teratogenic endpoints (of interest to this risk assessment) in cultured rodent embryos are more sensitive to methanol and formaldehyde than formate. Data from these studies indicate that developmental toxicity may be more related to formaldehyde than methanol, as formaldehyde-induced teratogenicity occurs at several orders of magnitude lower than methanol (Table 4-14) (Hansen et al., 2005, 196135; Harris et al., 2004, 059082). It should also be noted that CAT, ADH1, and ADH3 activities are present in both the rat embryo and VYS at stages as early as 6-12 somites (Harris et al., 2003, 047369); thus, it is presumable that in these ex vivo studies methanol is metabolized to formaldehyde and formaldehyde is subsequently metabolized to S-formylglutathione.

Studies involving GSH also lend support that formaldehyde may be a key proximal teratogen. Inhibition of GSH synthesis with butathione sulfoximine (BSO) has little effect on developmental toxicity endpoints, yet treatment with BSO and methanol or formaldehyde

increases developmental toxicity (Harris et al., 2004, 059082). Among the enzymes involved in methanol metabolism, only ADH3-mediated metabolism of formaldehyde is GSH dependent. This hypothesis that ADH3-mediated metabolism of formaldehyde is important for the amelioration of methanol's developmental toxicity is also supported by the diminished ADH3 activity in the mouse versus rat embryos, which is consistent with the greater sensitivity of the mouse to methanol developmental toxicity (Harris et al., 2003, 047369) (Section 4.3.3). Similarly reasonable explanations for this greater mouse sensitivity are not readily apparent for the two MOAs described below that attribute methanol toxicity to methanol metabolism per se, either through the depletion of folate (Section 4.6.2) or the generation of reactive oxidant species (Section 4.6.3). Mouse livers actually have considerably higher hepatic tetrahydrofolate and total folate than rat or monkey liver. Harris et al. (2003, 047369) and Johlin et al. (1987, 032236) have shown that CAT activity in the embryo and VYS of rats and mice appear similar..

Without positive identification of the actual moiety responsible for methanol-induced teratogenicity, MOA remains unclear. If the moiety is methanol, then it is possible that generation of NADH during methanol oxidation creates an imbalance in other enzymatic reactions. Studies have shown that ethanol intake leads to a >100-fold increase in cellular NADH, presumably due to ADH1-mediated reduction of the cofactor NAD^+ to NADH (Cronholm, 1987, 196350; Smith and Newman, 1959, 196208). This is of potential importance because, for example, ethanol intake has been shown to increase the in vivo and in vitro enzymatic reduction of other endogenous compounds (e.g., serotonin) in humans (Davis et al., 1967, 196356; Svensson et al., 1999, 196732). In rodents, CAT-mediated methanol metabolism may obviate this effect; in humans, however, methanol is primarily metabolized by ADH1.

If the teratogenic moiety of methanol is formaldehyde, then reactivity with protein sulfhydryls and nonprotein sulfhydryls (e.g., GSH) or DNA protein cross-links may be involved. Metabolic roles ascribed to ADH3, particularly regulation of S-nitrosothiol biology (Foster and Stamler, 2004, 196126), could also be involved in the MOA. Recently, Staab et al. (2008, 196368) have shown that formaldehyde alters other ADH3-mediated reactions through cofactor recycling and that formaldehyde alters levels of cellular S-nitrosothiol, which plays a key role in cellular signaling and many cellular functions and pathways (Hess et al., 2005).

Studies such as those by Harris et al. (2003, 047369; 2004, 059082) and Dorman et al. (1995, 078081) suggest that formate is not the metabolite responsible for methanol's teratogenic effects. The former researchers suggest that formaldehyde is the proximate teratogen, and provide evidence in support of that hypothesis. However, questions remain. Researchers in this area have not yet reported using a sufficient array of enzyme inhibitors to conclusively identify formaldehyde as the proximate teratogen. Studies involving other inhibitors or toxicity studies

1 carried out in genetically engineered mice, while not devoid of confounders, might further

2 inform regarding the methanol MOA for developmental toxicity. Even if formaldehyde is

3 ultimately identified as the proximate teratogen, methanol would likely play a prominent role, at

4 least in terms of transport to the target tissue. The high reactivity of formaldehyde would limit

5 its unbound and unaltered transport as free formaldehyde from maternal to fetal blood (Thrasher

6 and Kilburn, 2001, 196728), and, as has been discussed, the capacity for the metabolism of

7 methanol to formaldehyde is likely lower in the fetus and neonate versus adults (Section 3.3).

4.6.2. Role of Folate Deficiency in the Developmental Toxicity of Methanol

8 As discussed in Sections 3.1 and 4.1, humans and other primates are susceptible to the

9 effects of methanol exposure associated with formate accumulation because they have lower

10 levels of hepatic tetrahydrofolate-dependent enzymes that help in formate oxidation.

11 Tetrahydrofolate-dependent enzymes and critical pathways that depend on folate, such as purine

12 and pyrimidine synthesis, may also play a role in the developmental toxicity of methanol.

13 Studies of rats and mice fed folate-deficient diets have identified adverse effects on reproductive

14 performance, implantation, fetal growth and developmental defects, and the inhibition of folate

15 cellular transport has been associated with several developmental abnormalities, ranging from

16 neural tube defects to neurocristopathies such as cleft-lip and cleft-palate, cardiacseptal defects,

17 and eye defects (Antony, 2007, 196184). Folate deficiency has been shown to exacerbate some

18 aspects of the developmental toxicity of methanol in mice (see discussion of (Fu et al., 1996,

19 080957), and (Sakanashi et al., 1996, 056308), in Section 4.3.1) and rats (see discussion of (Aziz

20 et al., 2002, 034481), in Section 4.4.1).

21 The studies in mice focused on the influence of FAD on the reproductive and skeletal

22 malformation effects of methanol. Sakanashi et al. (1996, 056308) showed that dams exposed to

23 5 g/kg-day methanol on GD6-GD15 experienced a threefold increase in the percentage of litters

24 affected by cleft palate and a 10-fold increase in the percentage of litters affected by exencephaly

25 when fed a FAD (resulting in a 50% decrease in liver folate) versus a FAS diet. They speculated

26 that the increased methanol effect from FAD diet could have been due to an increase in tissue

27 formate or a critical reduction in conceptus folate concentration immediately following the

28 methanol exposure. The latter appears more likely, given the high levels of formate needed to

29 cause embryotoxicity (Section 4.3.3) and the decrease in conceptus folate that is observed within

30 2 hours of GD8 methanol exposure (Dorman et al., 1995, 078081). Fu et al. (1996, 080957)

31 confirmed the findings of Sakanashi et al. (1996, 056308) and also determined that the maternal

32 FAD diet had a much greater impact on fetal liver folate than maternal liver folate levels.

The rat study of Aziz et al. (2002, 034481) focused on the influence of FAD on the developmental neurotoxicity of methanol. Experiments by Aziz et al. (2002, 034481) involving Wistar rat dams and pups exposed to methanol during lactation provide evidence that methanol exposure during this postnatal period affects the developing brain. These effects (increased spontaneous locomotor activity, decreased conditioned avoidance response, disturbances in dopaminergic and cholinergic receptors and increased expression of GAP-43 in the hippocampal region) were more pronounced in FAD as compared to FAS rats. This suggests that folic acid may play a role in methanol-induced neurotoxicity. These results do not implicate any particular proximate teratogen, as folate deficiency can increase levels of both methanol, formaldehyde and formate (Medinsky et al., 1997, 084177). Further, folic acid is used in a number of critical pathways such as purine and pyrimidine synthesis. Thus, alterations in available folic acid, particularly to the conceptus, could have significant impacts on the developing fetus apart from the influence it is presumed to have on formate removal.

4.6.3. Methanol-Induced Formation of Free Radicals, Lipid Peroxidation, and Protein Modifications

Oxidative stress in mother and offspring has been suggested to be part of the teratogenic mechanism of a related alcohol, ethanol. Certain reproductive and developmental effects (e.g., resorptions and malformation rates) observed in Sprague-Dawley rats following ethanol exposure were reported to be ameliorated by antioxidant (Vitamin E) treatment (Wentzel and Eriksson, 2006, 196723; Wentzel et al., 2006, 196377). A number of studies have examined markers of oxidative stress associated with methanol exposure.

Skrzydlewska et al. (2005, 196205) provided inferential evidence for the effects of methanol on free radical formation, lipid peroxidation, and protein modifications, by studying the protective effects of N-acetyl cysteine and the Vitamin E derivative, U83836E, in the liver of male Wistar rats exposed to the compound via gavage. Forty-two rats/group received a single oral gavage dose of either saline or 50% methanol. This provided a dose of approximately 6,000 mg/kg, as calculated by the authors. Other groups of rats received the same concentration of methanol, but were also injected intraperitoneally with either N-acetylcysteine or U-83836E. N-acetylcysteine and U-83836E controls were also included in the study design. Animals in each group were sacrificed after 6, 14, and 24 hours or after 2, 5, or 7 days. Livers were rapidly excised for electron spin resonance (ESR) analysis, and $10,000 \times g$ supernatants were used to measure GSH, malondialdehyde, a range of protein parameters, including free amino and sulfhydryl groups, protein carbonyls, tryptophan, tyrosine, and bityrosine, and the activity of cathepsin B.

Skrzydlewska et al. (2005, 196205) provided data that showed an increase in an ESR signal at g = 2.003 in livers harvested 6 and 12 hours after methanol exposure. The signal, thought to be indicative of free radical formation, was opposed by N-acetylcysteine and U83836E. Other compound-related changes included: 1) a significant decrease in GSH levels that was most evident in rats sacrificed 12 and 24 hours after exposure; 2) increased concentrations in the lipid peroxidation product, malondialdehyde (by a maximum of 44% in the livers of animals sacrificed 2 days after exposure); 3) increased specific concentrations of protein carbonyl groups and bityrosine; but 4) reductions in the specific level of tryptophan. Given the ability of N-acetylcysteine and U83836E to oppose these changes, at least in part, the authors speculated that a number of potentially harmful changes may have occurred as a result of methanol exposure. These include free radical formation, lipid peroxidation, and disturbances in protein structure. However, it is unclear whether or not the metabolites of methanol, formaldehyde, and/or formate, were involved in any of these changes.

Rajamani et al. (Rajamani et al., 2006, 196157) examined several oxidative stress parameters in male Wistar rats following methotrexate-induced folate deficiency. Compared to controls, the levels of free radical scavengers SOD, CAT, GSH peroxidase, oxidized GSH, protein carbonyls, and lipid peroxidation were elevated in several regions of the brain, with greater increases observed in the MTX-methanol-treated animals than in the MTX-alone group. The level of GSH and protein thiols was decreased in all regions of the brain, with a greater decrease observed in the MTX-methanol-treated animals than MTX-treated animals.

Dudka (2006, 090784) measured the total antioxidant status (TAS) in the brain of male Wistar rats exposed to a single oral gavage dose of methanol at 3 g/kg. The animals were kept in a nitrous oxide atmosphere (N_2O/O_2) throughout the experiment to reduce intrinsic folate levels, and various levels of ethanol and/or fomepizole (as ADH antidotes) were administered i.p. after 4 hours. Animals were sacrificed after 16 hours, the brains homogenized, and the TAS determined spectrophotometrically. As illustrated graphically by the author, methanol administration reduced TAS in brain irrespective of the presence of ADH antidotes. The author speculated that, while most methanol is metabolized in the liver, some may also reach the brain. Metabolism to formate might then alter the $NADH/NAD^+$ ratio resulting in an increase in xanthine oxidase activity and the formation of the superoxide anion.

Parthasarathy et al. (2006, 089721) investigated the extent of methanol-induced oxidative stress in rat lymphoid organs. Six male Wistar rats/group received 2,370 mg/kg methanol (mixed 1:1 with saline) injected i.p. for 1, 15 or 30 days. A control group received a daily i.p. injection of saline for 30 days. At term, lymphoid organs such as the spleen, thymus, lymph nodes, and bone marrow were excised, perfused with saline, then homogenized to obtain supernatants in

1 which such indices of lipid peroxidation as malondialdehyde, and the activities of CAT, SOD,

2 and GSH peroxidase were measured. Parthasarathy et al. (2006, 089721) also measured the

3 concentrations of GSH and ascorbic acid (nonenzymatic antioxidants) and the serum

4 concentrations of a number of indicators of liver and kidney function, such as ALT, AST, blood

5 urea nitrogen (BUN), and creatinine.

6   Table 4-23 shows the time-dependent changes in serum liver and kidney function

7 indicators that resulted from methanol administration. Treatment with methanol for increasing

8 durations resulted in increased serum ALT and AST activities and the concentrations of BUN and

9 creatinine.

Table 4-23. Time-dependent effects of methanol administration on serum liver and kidney function, serum ALT, AST, BUN, and creatinine in control and experimental groups of male Wistar rats

Parameters	Methanol administration (2,370 mg/kg)			
	Control	Single dose	15 days	30 days
ALT (μmoles/min-mg)	29.0 ± 2.5	31.4 ± 3.3	53.1 ± 2.3[a]	60.4 ± 2.8[a]
AST (μmoles/min-mg)	5.8 ± 0.4	6.4 ± 0.3	9.0 ± 1.2[a]	13.7 ± 1.2[a]
BUN (mg/L)	301 ± 36	332 ± 29	436 ± 35[a]	513 ± 32[a]
Creatinine (mg/L)	4.6 ± 0.3	4.8 ± 0.3	5.6 ± 0.2[a]	7.0 ± 0.4[a]

Values are means ± S.D. of 6 animals.
[a]$p < 0.05$ versus controls.

Source: Parthasarathy et al. (2006, 089721) (adapted).

Table 4-24. Effect of methanol administration on male Wistar rats on malondialdehyde concentration in the lymphoid organs of experimental and control groups and the effect of methanol on antioxidants in spleen

Parameters	Methanol administration (2,370 mg/kg)			
	Control	Single dose	15 days	30 days
Malondialdehyde in lymphoid organs				
Spleen	2.62 ± 0.19	4.14 ± 0.25^a	7.22 ± 0.31^a	9.72 ± 0.52^a
Thymus	3.58 ± 0.35	5.76 ± 0.36^a	9.23 ± 0.57^a	11.6 ± 0.33^a
Lymph nodes	3.15 ± 0.25	5.08 ± 0.24^a	8.77 ± 0.57^a	9.17 ± 0.67^a
Bone marrow	3.14 ± 0.33	4.47 ± 0.18^a	7.20 ± 0.42^a	9.75 ± 0.56^a
Antioxidant levels in spleen				
SOD (units/mg protein)	2.40 ± 0.16	4.06 ± 0.19^a	1.76 ± 0.09^a	1.00 ± 0.07^a
CAT (μmoles H_2O_2 consumed/min-mg protein	35.8 ± 2.77	52.5 ± 3.86^a	19.1 ± 1.55^a	10.8 ± 1.10^a
GPx (μg GSH consumed/min-mg protein)	11.2 ± 0.60	20.0 ± 1.0^a	7.07 ± 0.83^a	5.18 ± 0.45^a
GSH (μg/mg protein)	2.11 ± 0.11	3.75 ± 0.15^a	1.66 ± 0.09^a	0.89 ± 0.04^a
Vit C (μg/mg protein)	0.45 ± 0.04	0.73 ± 0.05^a	0.34 ± 0.18^a	0.11 ± 0.03^a

Values are means ± S.D. of six animals.
[a] $p < 0.05$, versus controls.

Source: Parthasarathy et al. (2006, 089721) (adapted).

Table 4-24 gives the concentration of malondialdehyde in the lymphoid organs of control and experimental groups, and, as an example of all tissue sites examined, the levels of enzymatic and nonenzymatic antioxidants in spleen. The results show that malondialdehyde concentrations were time-dependently increased at each tissue site and that, in spleen as an example of all the lymphoid tissues examined, increasing methanol administration resulted in lower levels of all antioxidants examined compared to controls. Parthasarathy et al. (2006, 089721) concluded that exposure to methanol may cause oxidative stress by altering the oxidant/antioxidant balance in lymphoid organs in the rat.

4.6.4. Exogenous Formate Dehydrogenase as a Means of Detoxifying the Formic Acid that Results from Methanol Exposure

In companion reports, Muthuvel et al. (2006, 196250; 2006, 090786) used 6 male Wistar rats/group to test the ability of exogenously-administered formate dehydrogenase (FD) to reduce the serum levels of formate that were formed when 3 g/kg methanol was administered i.p. to rats in saline. In the first experiment, purified FD (from *Candida boitinii*) was administered by i.v. conjugated to the N-hydroxysuccinimidyl ester of monomethoxy polyethylene glycol propionic acid (PEG-FD) (Muthuvel et al., 2006, 196250). In the second, rats were administered FD-

loaded erythrocytes (Muthuvel et al., 2006, 090786). In the former case, some groups of rats were made folate deficient by means of a folate-depleted diet; in the latter, folate deficiency was brought about by i.p. administration of methotrexate. In some groups, the rats received an infusion of an equimolar mixture of carbonate and bicarbonate (each at 0.33 mol/L) to correct the formate-induced acidosis. As illustrated by the authors, methanol-exposed rats receiving a folate-deficient diet showed significantly higher levels of serum formate than those receiving a folate-sufficient diet. However, administration of native or PEG-FD reduced serum formate in methanol-receiving folate-deficient rats to levels seen in animals receiving methanol and the folate-sufficient diet.

In the second report, Muthuvel et al. (2006, 090786) carried out some preliminary experiments to show that hematological parameters of normal, reconstituted but unloaded, and reconstituted and FD-loaded erythrocytes, were similar. In addition, they showed that formate levels of serum were reduced in vitro in the presence of FD-loaded erythrocytes. Expressing blood formate concentration in mmol/L at the 1-hour time point after carbonate/bicarbonate and enzyme-loaded erythrocyte infusion via the tail vein, the concentration was reduced from 10.63 $\pm$ 1.3 (mean $\pm$ S.D.) in methanol and methotrexate-receiving controls to 5.83 ± 0.97 (n = 6). This difference was statistically significant at the $p < 0.05$ level. However, FD-loaded erythrocytes were less efficient at removing formate in the absence of carbonate/bicarbonate. Effective elimination of formate appears to require an optimum pH for the FD activity in the enzyme-loaded erythrocytes.

4.6.5. Mechanistic Data Related to the Potential Carcinogenicity of Methanol

4.6.5.1. *Genotoxicity*

The genotoxicity/mutagenicity of methanol has not been extensively studied, but the results of those studies that have thus far have been mostly negative. For example, in a survey of the capacity of 71 drinking water contaminants to induce gene reversion in the Ames test, Simmon et al. (1977, 029451) listed methanol as one of 45 chemicals that gave negative results with *Salmonella typhimurium* strains TA 98, 100, 1535, 1537, and 1538, irrespective of the presence or absence of metabolic activation (an S9 microsomal fraction). This result was confirmed by DeFlora et al. (1984, 017980) and in NEDO (1987, 064574) for the same strains of Salmonella. DeFlora et al. (1984, 017980) also found methanol to be negative for induction of DNA repair in *E. coli* strains WP2, WP2 (*uvrA⁻, polA⁻*), and CM871 (*uvrA⁻, recA⁻, lexA⁻*), again irrespectively of the presence or absence of S9.

Abbondandolo et al. (1980, 031009) used a *ade6-60/rad10-198,h⁻* strain of *Schizosaccharomyces pombe* (P1 strain) to determine the capacity of methanol and other solvents

to induce forward mutations. Negative results were obtained for methanol, irrespective of metabolic activation status. In other genotoxicity/mutagenicity studies of methanol using fungi, Griffiths (1981, 180469) reported methanol to be negative for the induction of aneuploidy in *Neurospora crassa*. By contrast, weakly positive results for the compound were obtained by Crebelli et al. (1989, 032119) for the induction of chromosomal malsegregation in the diploid strain P1 of *Aspergillus nidulans*.

In an extensive review of the capacity of a wide range of compounds to induce transformation in mammalian cell lines, Heidelberger et al. (1983, 088310) reported methanol to be negative in Syrian hamster embryo (SHE) cells. It also did not enhance the transformation of SHE cells by Simian adenovirus. However, McGregor et al. (1985, 196231) reported in an abstract that a statistically significant increase in forward mutations in the mouse lymphoma L5178Y tk$^+$/tk$^-$ cell line occurred at a concentration of 7.9 mg/mL methanol in the presence of S9.

The capacity of methanol to bring about genetic changes in human cell lines was examined by Ohno et al. (2005, 196301), who developed a system in which the chemical activation of the *p53R2* gene was assessed by the incorporation of a *p53R2*-dependent luciferase reporter gene into two human cell lines, MCF-7 and HepG2. Methanol, among 80 chemicals tested in this system, gave negative results. NEDO (1987, 064574) used Chinese hamster lung (CHL) cells to monitor methanol's capacity to induce 1) forward mutations to azaguanine, 6-thioguanine, and ouabain resistance, and 2) chromosomal aberrations (CA) though with negative results throughout. However, methanol did display some capacity to induce sister chromatid exchanges (SCE) in CHL cells, since the incidence of these lesions at the highest concentration (28.5 mg/mL) was significantly greater than in controls (9.41 ± 0.416 versus 6.42 ± 0.227 [mean ± SE per 100 cells]).

In an in vivo experiment examining the genotoxicity/mutagenicity of methanol, Campbell et al. (1991, 032354) exposed 10 male C57BL/6J mice/group to 0, 800, or 4,000 ppm (0, 1,048, and 5,242 mg/m^3) methanol, 6 hours/day, for 5 days. At sacrifice, blood cells were examined for the formation of micronuclei (MN). Excised lung cells for SCE, CA and MN, and excised testicular germ cells were examined for evidence of synaptonemal damage, in each case with negative results.

There was no evidence of methanol-induced formation of MN in the blood of fetuses or pregnant CD-mice when the latter were gavaged twice daily with 2,500 mg/kg methanol on GD6-GD10 (Fu et al., 1996, 080957). The presence of marginal or adequate amounts of folic acid in the diet of the dams did not affect MN formation. NEDO (1987, 064574) carried out an in vivo MN test in 6 male SPF mice/group who received a single gavage dose of 1,050, 2,110,

4,210, and 8,410 mg/kg methanol. Twenty-four hours later, 1,000 cells were counted for MN in

bone marrow smears. No compound-related effects on MN incidence were observed. Table 4-

25 provides a summary of the genotoxicity/mutagenicity studies of methanol.

Table 4-25. Summary of genotoxicity studies of methanol

Test system	Cell/strain	Result	Reference	Comments
In vitro tests				
Gene reversion/ *S. typhimurium*	TA98; TA100; TA1535, TA1537, TA1538	- (+S9); - (-S9)	Simmon et al. (1977, 029451)	
	TA98; TA100; TA1535, TA1537, TA1538	- (+S9); - (-S9)	De Flora et al. (1984, 017980)	
	TA98; TA100; TA1535, TA1537, TA1538	- (+S9); - (-S9)	NEDO (1987, 064574)	
DNA repair/*E. coli*	WP2, WP2 *(uvrA⁻, polA⁻)*,CM871*(uvrA⁻, recA⁻, lexA⁻)*	- (+S9), - (-S9)	DeFlora et al. (1984, 017980)	
Forward mutations/ *S. pombe*	P1 (*ade6-60/rad10-198,h⁻*)	- (+S10), - (-S10)	Abbondandolo et al. (1980, 031009)	Molecular activation used a 10,000 × g (S10) supernatant from liver of induced Swiss mice
Aneuploidy/ *N. crassa*	*(arg-1, ad-3A, ad-3B, nic-2, tol, C/c, D/d, E/e)*	- (S9 status not reported)	Griffiths (1981, 180469)	
Chromosomal malsegregation/ *A. nidulans*	P1 (diploid)	+ (S9 status not reported)	Crebelli et al. (1989, 032119)	
Forward mutations/Mouse lymphoma cells	L5178Y tk⁺/tk⁻	+ (+S9), ND (-S9)	McGregor et al. (1985, 196231)	Results reported in an abstract
Forward mutations/Chinese hamster lung cells	to azaguanine, 6-thioguanine and ouabain resistance	- (-S9), ND (+S9)	NEDO (1987, 064574)	
Chromosomal aberrations/Chinese hamster lung cells		- (-S9), ND (+S9)	NEDO (1987, 064574)	
Sister chromatid exchanges/Chinese hamster lung cells		+ (-S9), ND (+S9)	NEDO (1987, 064574)	
Genetic activation/ human cell lines	MCF-7 and HepG2 containing a *p53R2-*dependent luciferase reporter gene	- (-S9), ND (+S9)	Ohno et al. (2005, 196301)	
Cell transformation/ Syrian hamster embryo cells	with/without transformation by Simian adenovirus	- (-S9), ND (+S9) - (-S9), ND (+S9)	Heidelberger et al. (1983, 088310)	Review

Test system	Cell/strain	Result	Reference	Comments
In vivo tests				
Mouse/MN formation	C57BL/6J (Blood cells)	–	Campbell et al. (1991, 032354)	Molecular activation not applicable
	C57BL/6J (Lung cells)	–	Campbell et al. (1991, 032354)	Molecular activation not applicable
Mouse/SCEs	C57BL/6J (Lung cells)	–	Campbell et al. (1991, 032354)	Molecular activation not applicable
Mice/CA	C57BL/6J (Lung cells)	–	Campbell et al. (1991, 032354)	Molecular activation not applicable
Mouse/synaptonemal damage	C57BL/6J (Testicular germ cells)	–	Campbell et al. (1991, 032354)	Molecular activation not applicable
Mouse/MN formation	CD-1 (Blood cells)	–	Fu et al. (1996, 080957)	Molecular activation not applicable
	SPF (Bone marrow cells)	–	NEDO (1987, 064574)	Molecular activation not applicable

ND = not determined.

4.6.5.2. *Lymphoma Responses Reported in ERF Life span Bioassays of Compounds Related to Methanol, Including an Analogue (Ethanol), Precursors (Aspartame and Methyl Tertiary Butyl Ether), and a Metabolite (Formaldehyde)*

1   The ERF or the European Foundation of Oncology and Environmental Sciences have
2   conducted nearly 400 experimental bioassays on over 200 compounds/agents, using some
3   148,000 animals over nearly 4 decades. Of the over 200 compounds tested by ERF,[55] 8 have
4   been associated with an increased incidence of hemolymphoreticular tumors in Sprague-Dawley
5   rats, suggesting that it may be a rare and potentially species/strain-specific finding. These eight
6   chemicals are: methanol, formaldehyde, aspartame, MTBE, DIPE, TAME, mancozeb, and
7   toluene. Methanol, formaldehyde, aspartame, and MTBE share a common metabolite,
8   formaldehyde, and DIPE, TAME, methanol and MTBE are all gasoline-oxygenate additives
9   (Caldwell et al., 2008, 196182).
10   With the exception of a positive study for malignant lymphomas in Swiss Webster mice
11   exposed to methanol (Apaja, 1980, 191208), lymphoma responses have not been reported by
12   other institutions performing long-term testing of these chemicals in various strains of rats,
13   including formaldehyde inhalation studies in F344 (Kamata et al., 1997, 198505; Kerns et al.,

---

[55] While ERF has tested over 200 chemicals in 398 long-term ERF bioassays, only 112 of their bioassays have been published to date (Caldwell et al., 2008, 196182). The extent to which the unpublished studies are documented varies.

1983, 007031)[56] and Sprague-Dawley (Albert et al., 1982, 065679; Sellakumar et al., 1985, 065689) rats, formaldehyde oral studies in Wistar rats (Til et al., 1989, 031957; 1989, 196729), toluene oral studies in F344 rats (NTP, 1990, 065618), MTBE inhalation studies in F344 rats (Chun et al., 1992 068400), aspartame oral studies in Wistar (Ishii et al., 1981, 196255) and Sprague-Dawley (Molinary, 1984, 198504) rats, and methanol inhalation studies in F344 rats (NEDO, 1987, 064574; NEDO, 2008, 196316). Several differences in study design may contribute to the differences in responses observed across institutions, particularly study duration and test animal strain. Fischer-344 rats have a high background of mononuclear cell leukemia (20% in control females)[57] and a very low background rate of ''lymphoma'' (0% in control females) at 104 weeks (NTP, 2006, 196296). In contrast, Sprague-Dawley rats from NTP studies exhibit a low background rate of "leukemias" (0.8% in control females) and a higher background rate of "lymphomas" (1.08% in control females) at 104 weeks (NTP, 2006, 196296). Similarly, Chandra et al. (1992, 020535) report a background level of 1.6% for malignant lymphocytic lymphomas in female control Sprague-Dawley rats for 17 2-year carcinogenicity studies.

In lifetime studies of Sprague-Dawley rats at ERF, the overall incidence of lymphomas/leukemias has been reported to be 13.3% (range, 4.0-25.0%) in female historical controls (2,274 rats) and 20.6% (range, 8.0-30.9%) in male historical controls (2,265 rats) (Soffritti et al., 2007, 196366). The difference in background rates reported by ERF versus other labs for this tumor type could be due to differences in study duration, differences in tumor classification systems, and/or misdiagnoses due to confounding effects (see discussion in Section 4.2.1.3). A high background incidence can increase the difficulty of detecting chemically related responses (Melnick et al., 2007, 196236), and the background rate reported by ERF for this tumor type is considered to be high relative to other tumor types and relative to the background rate for this tumor type in Sprague-Dawley rats from other laboratories (Cruzan, 2009, 196354; EFSA, 2006, 196098).[58] However, it is in a range that can be considered reasonable for studies that employ a large number of animals (Caldwell et al., 2009, 196183; Leakey et al., 2003, 196288).

---

[56] Though Kerns et al. (1983, 007031) did not report a positive response for lymphoma, a survival-adjusted analysis of the data from this study indicates a statistically significant trend in female rat mononuclear cell leukemia (p = 0056) and a nearly significant increase in female mouse lymphoma (p = 0.06). In the Kamata et al., (1997, 198505) study, only a small percentage of the original 32 rats/group survived to the end of the study (28 months) due largely to interim sacrifices (5/group) at 12, 18 and 24 months.

[57] Due to this and other health concerns, NTP transitioned to the use of Wistar rats in 2008, and more recently has adopted Sprague-Dawley rats as the rat model for NTP studies due to the reproductive capability and size of Wistar rats (http://ntp.niehs.nih.gov/go/29502).

[58] Cruzan (2009, 196354) reports that the incidences of total cancers derived from bloodforming cells, designated as hemolymphoreticular tumors by Ramazzini pathologists, is consistently about four times higher than the incidences of such tumors in SD rats recorded in the Charles River Laboratory historical database (CRL database).

Thus, with respect to the identification of hemolymphoreticular carcinogenic responses, life span studies of Sprague-Dawley rats performed by ERF may be more sensitive than the 2-year studies of Fischer 344 (F344) strain of rats used by NTP (1990, 065618) and NEDO (1987, 064574; 2008, 196316). The results of ERF studies of the carcinogenic potential of methanol, MTBE, and formaldehyde and related chemicals, ethanol and aspartame, are summarized in this section. This does not represent a critical review of the findings of these study authors, but a brief overview of their reported results.

4.6.5.2.1. *Ethanol.* In a study that was reported in the same article that described the carcinogenic responses of Sprague-Dawley rats to methanol, Soffritti et al. (2002, 091004) exposed 110 Sprague-Dawley rats/sex/group to ethanol in drinking water at concentrations of 0 or 10% (v/v) beginning at 39 weeks of age and ending at natural death, and including a single breeding cycle. Various numbers of the offspring (30 male controls, 39 female controls, 49 exposed males, and 55 exposed females) were exposed to ethanol in drinking water at the same concentrations as their parents. The experiment concluded with the death of the last offspring at 179 weeks of age. Animals were examined for the same toxicological parameters as those described for methanol, and organs and tissues were grossly and histopathologically examined at necropsy. Soffritti et al. (2002, 091004) reported that food and drinking water intake were lower in exposed animals compared to controls but that body weight changes were similar among the groups. [59] There were no compound-related clinical signs of toxicity and no differences in survival rates among the groups. While there were apparently no nononcogenic pathological changes evident on gross inspection or histopathologic examination, a number of benign and malignant tumors were considered by the authors to be compound-related. Compared to controls, these included increased incidences of: 1) total malignant tumors in male and female breeders (145/220 versus 99/220) and offspring (49/69 versus 54/104); 2) total malignant tumors per 100 animals in female breeders (130 versus 60.9) and offspring (164.1 versus 96.4); 3) carcinomas of the head and neck, especially to the oral cavity, lips and tongue in male and female breeders (27/220 versus 5/220) and offspring (26/69 versus 5/104); 4) squamous cell carcinomas of the forestomach in male and female breeders (5/220 versus 0/220) and offspring (2/69 versus 0/104); 5) interstitial cell adenomas of the testis in male breeders (23/110 versus 9/110) and offspring (4/30 versus 4/49); 6) Sertoli-Leydig cell tumors in ovaries of female offspring (3/39 versus 1/55); 7) adenocarcinomas of the uterus in female breeders (9/110 versus 2/110) and offspring (8/39 versus 6/55); 8) pheochromoblastomas in male and female breeders (13/220 versus 4/220) and offspring (4/69 versus 2/104); and 9) osteosarcomas in male and

---

[59] Test animals were likely receiving calories from ethanol exposure.

1 female breeders ([for the head] 14/220 versus 4/220) and offspring ([for the head] 10/69 versus

2 7/104). Notably, Soffritti et al. (2002, 091004) did not observe increases in any of the lymphoma

3 responses reported in their methanol bioassay. Incidence data for these responses and their

statistical significance compared to controls are shown in Table 4-26.

Table 4-26. Incidence of carcinogenic responses in Sprague-Dawley rats exposed to ethanol in drinking water for up to 2 years

Tissues/affected sites	Concentration in percent (v/v)							
	Male (breeders)		Female (breeders)		Male (offspring)		Female (offspring)	
	0	10	0	10	0	10	0	10
Total malignant tumors	51/110	66/110	48/110	79/110[b]	23/49	23/30[a]	31/55	26/39
Oral cavity (carcinomas)	3/110	15/110[b]	2/110	12/110	2/49	10/30[b]	3/55	16/39[b]
Forestomach (squamous cell carcinomas)	0/110	2/110	0/110	3/110	0/49	1/30	0/55	1/39
Testis (interstitial cell adenomas)	9/110	23/110[d]			4/49	4/30		
Sertoli-Leydig cell tumors (ovary)			1/110	2/110			0/55	3/39
Uterus (adenocarcinomas)			2/110	9/110[c]			6/55	8/39
Head (osteosarcomas)	0/110	8/110	4/110	6/110	4/49	6/30	3/55	4/39
Adrenal gland (pheochromoblastomas)	3/110	9/110	1/110	4/110	1/49	4/30	1/55	0/39
Total malignant tumors per 100 animals	61.8	89.1[b]	60.9	130[b]	61.2	136.7[b]	96.4	164.1[b]

[a]$p < 0.05$ using the χ^2 test, as calculated by the authors.
[b]$p < 0.01$ using the χ^2 test, as calculated by the authors.
[c]$p < 0.05$ using Fisher's exact test, as calculated by the reviewers.
[d]$p < 0.01$ using Fisher's exact test, as calculated by the reviewers.

Source: Soffritti et al. (2002, 091004).

5 **4.6.5.2.2. *Aspartame.*** Soffritti et al. (2005, 087840; 2006, 196735) reported the results of a

6 cancer bioassay on the artificial sweetener aspartame. The study has potential relevance to the

7 carcinogenicity of methanol because aspartame has been shown to be metabolized to aspartic

8 acid, phenylalanine, and methanol in the GI tract prior to absorption into systemic circulation. In

9 the study, aspartame (>98% purity) was given to 100 or 150 Sprague-Dawley rats/sex/group in

10 feed at dietary concentrations of 0, 80, 400, 2,000, 10,000, 50,000, and 100,000 ppm. The

11 authors reported these concentrations to be equivalent to approximate daily doses of 0, 4, 20,

12 100, 500, 2,500, and 5,000 mg/kg-day, respectively, under the conditions of the study. Animals

13 were maintained until their "natural death," with the in-life phase of the experiment concluding

with the death of the last animal at 151 weeks. All animals were monitored for body weight,
food and water consumption. At death, animals were examined grossly and given a complete
histopathological examination.

Soffritti et al. (2005, 087840; 2006, 196735) reported that there were no differences
among the groups in mean body weight, survival, or daily water consumption. However, there
appeared to be a dose-related reduction in food consumption in both male and female rats.

The principal histopathological finding was an increased incidence of lymphomas and
leukemias in female rats, a response reported by the authors to be statistically significant
compared to concurrently exposed controls (Table 4-27) and greater than the range of overall
incidence of lymphomas and leukemias in historical controls at the ERF (13.4% [range, 7.0-18.4]
in females and 21.8% [range, 8.0-30.9] in males). Among the hemolymphoreticular neoplasms
observed, the most frequent type observed was lympho-immunoblastic lymphoma. The authors
concluded that aspartame causes a "dose-related statistically significant increase in lymphomas
and leukemias in females at dose levels very near those to which humans can be exposed." They
postulated that an increase in the incidence of lymphomas and leukemias could be associated
with the formation of either methanol or formaldehyde. Other potentially compound-related
effects of aspartame were (1) an increase in combined dysplastic hyperplasias, papillomas, and
carcinomas of the renal pelvis and ureter, and (2) an increasing trend in the formation of
malignant schwannomas in peripheral nerves (Table 4-28).

The European Commission asked the European Food Safety Authority (EFSA) to assess
the study and review all ERF findings related to aspartame. An EFSA review panel assessed the
study and considered additional unpublished data provided to it by the ERF. In their report,
EFSA (2006, 196098) concluded that the Soffritti et al. (2005, 087840; 2006, 196735) study had
flaws that brought into question the reported findings. The review panel noted the high
background of chronic inflammatory changes in the lung and other vital organs. These
background inflammatory changes were thought to contribute significant uncertainty to the
interpretations of the study. In fact, the review panel concluded that most of the documented
changes, in particular, the apparent compound-related increase in lymphomas and leukemias,
may have been incidental findings and, therefore, unrelated to aspartame.

Table 4-27. Incidence of lymphomas and leukemias in Sprague-Dawley rats exposed to aspartame via the diet

Group	ppm in feed	Dose (mg/kg-day)	Lymphomas/leukemias (incidence and %) Male	Lymphomas/leukemias (incidence and %) Female
I	0	0	31/150 (21)	13/150 (9)
II	80	4	23/150 (15)	22/150 (15)
III	400	20	25/150 (17)	30/150[b] (20)
IV	2,000	100	33/150 (22)	28/150[a] (19)
V	10,000	500	15/100 (15)	19/100[a] (19)
VI	50,000	2,500	20/100 (20)	25/100[b] (25)
VII	100,000	5,000	29/100 (29)	25/100[b] (25)

[a]$p < 0.05$ using the poly-k test.
[b]$p < 0.01$ using the poly-k test.

Source: Soffritti et al. (2005, 087840; 2006, 196735).

Table 4-28. Incidence of combined dysplastic hyperplasias, papillomas and carcinomas of the pelvis and ureter and of malignant schwannomas in peripheral nerve in Sprague-Dawley rats exposed to aspartame via the diet

Group	ppm in feed	Dose (mg/kg-day)	Combined hyperplasias, papillomas and carcinomas of the pelvis and ureter Male	Combined hyperplasias, papillomas and carcinomas of the pelvis and ureter Female	Peripheral nerve malignant schwannomas Male	Peripheral nerve malignant schwannomas Female
I	0	0	1/150 (0.7)	2/150[c] (1.3)	1/150[c] (0.7)	0/150 (0)
II	80	4	3/149 (2)	6/150 (4)	1/150 (0.7)	2/150 (1.3)
III	400	20	5/149 (3)	9/150[a] (6)	3/150 (2)	0/150 (0)
IV	2,000	100	5/150 (3)	10/150[a] (7)	2/150 (1.3)	3/150 (2)
V	10,000	500	3/100 (3)	10/100[b] (10)	2/100 (2)	1/100 (1)
VI	50,000	2,500	3/100 (3)	10/99[b] (10)	3/100 (3)	1/100 (1)
VII	100,000	5,000	4/100 (4)	15/100[b] (15)	4/100 (4)	2/100 (2)

[a]$p < 0.05$ using the poly-k test.
[b]$p < 0.01$ using the poly-k test.
[c]$p < 0.05$ using the Cochran-Armitage test for trend.

Source: Soffritti et al. (2006, 196735).

1   In their conclusions, the EFSA review panel took note of negative results of 2-year
2   carcinogenic studies of aspartame (Ishii, 1981, 196254; Ishii et al., 1981, 196255; NTP, 2003,
3   196295) and of the findings of a recent epidemiological study carried out by the US National
4   Cancer Institute (NCI, 2006, 196256).

In an effort to further clarify these issues, Soffritti et al. (2007, 196366) reported the results of another lifetime study of aspartame in which 95 controls and 70 Sprague-Dawley rats/sex/group were exposed, first in utero, then via the diet, to aspartame at concentrations of 0, 400, or 2,000 ppm (mg/kg) of feed. The authors assumed an average food consumption of 20 g/day and an average body weight (males and females) of 400 g, thereby deriving average target doses of 0, 40, and 200 mg/kg-day. Soffritti et al. (2007, 196366) began administering the aspartame-supplemented feed to the dams on GD12; and offspring received feed containing aspartame at the appropriate concentration from weaning until natural death. Animals were observed three times daily Monday-Friday, and twice daily on Saturdays, Sundays, and holidays. This regimen was both to monitor clinical signs and to reduce the possibility of decedents undergoing autolysis before discovery. As described by the authors, all deceased animals were refrigerated, then necropsied no more than 19 hours after discovery.

Food and drinking water consumption was monitored once/day. Beginning at 6 weeks of age, individual body weights were recorded once a week for 13 weeks, then every 2 weeks until natural death. All animals were examined grossly every 2 weeks. After necropsy, tissues and organs were sampled for histopathological processing and microscopic examination (including skin and subcutaneous tissue, mammary gland, brain, pituitary, Zymbal's gland, salivary gland, Harderian gland, cranium, tongue, thyroid, parathyroid, pharynx, larynx, thymus and mediastinal lymph nodes, trachea, lung and main stem bronchi, heart, diaphragm, liver, spleen, pancreas, kidney, adrenal gland, esophagus, stomach, intestine, urinary bladder, prostate, vagina, gonads, interscapular brown fat pads, subcutaneous and mesenteric lymph nodes), as were all pathological lesions identified on gross necropsy.

There were no differences in food and water consumption or in body weights among the dose groups. As illustrated graphically by the authors, there was little change in overall survival rates. Discussion of the histopathological findings focused exclusively on the cancer outcomes. The incidence of total malignant tumors was increased significantly in high-dose males compared to controls ($p < 0.01$). The slight increase in the incidence of total malignant tumors in females was not statistically significant (Table 4-29). With regard to the incidence of type- or site-specific neoplasms, Soffritti et al. (2007, 196366) reported statistically significant increases (calculated using the Cox regression model) in combined lymphomas and leukemias in both sexes of Sprague-Dawley rats. In males, the most frequently observed histiotypes were lymphoblastic lymphomas involving the lung and mediastinal peripheral nodes, while in females, the most commonly observed lesions were lymphocytic lymphomas and lympho-immunoblastic lymphomas involving the thymus, spleen, lung and peripheral nodes. There was also an increase in the incidence of mammary gland carcinomas in female Sprague-Dawley rats. The incidences

1   of total malignant, mammary, and lymphocytic and leukocytic tumors, in comparison to

2   concurrent and the range of historical controls for combined lymphomas and leukemias and

3   mammary gland tumors observed at the ERF, are shown in Table 4-29.

Table 4-29. Incidence of tumors in Sprague-Dawley rats exposed to aspartame from GD12 to natural death

Dose (mg/kg-day)	Malignant tumors		Lymphomas/leukemias	Mammary carcinomas
	Tumor-bearing animals (percent)	Tumors/100 animals	Tumor-bearing animals (percent)	Tumor-bearing animals (percent)
Males				
0	23/95 (24.2)	27.4	9/95 (9.5)	0/95 (0)
20	18/70 (25.7)	27.1	11/70 (15.7)	0/70 (0)
100	28/70 (40.0)[a]	44.3	12/70 (17.1)[b]	2/70 (2.9)
Historical controls	ND	ND	8-31%	NR
Females				
0	42/95 (44.2)	50.5	12/95 (12.6)	5/95 (5.3)
20	31/70 (44.3)	62.9	12/70 (17.1)	5/70 (7.1)
100	37/70 (52.9)	85.7	22/70 (33.4)[a]	11/70 (15.7)[b]
Historical controls	ND	ND	7-18%	4-14%

[a]$p < 0.01$ versus concurrent controls, as calculated by the authors using the Cox regression model.
[b]$p < 0.05$ versus concurrent controls, as calculated by the authors using the Cox regression model.
ND = no data.; NR = not reported.

Source: Soffritti et al. (2007, 196366).

4   With regard to target organs and tissues susceptible to aspartame carcinogenicity, Soffritti

5   et al. (2007, 196366) drew attention to the similar outcome of these results to those reported by

6   Soffritti et al. (2005, 087840; 2006, 196735). The authors suggested that the increased incidence

7   in combined lymphomas and leukemias in female Sprague-Dawley rats as compared to the

8   earlier study was likely due to the earlier exposure to aspartame experienced by the animals in

9   the Soffritti et al. (2007, 196366) study (prenatal and postnatal versus postnatal only). The

10 authors provided a direct comparison of the incidence of lymphomas/leukemias between the

11 studies, as summarized in Table 4-30.

Table 4-30. Comparison of the incidence of combined lymphomas and leukemias in female Sprague-Dawley rats exposed to aspartame in feed for a lifetime, either pre- and postnatally or postnatally only

Dose (mg/kg-day)	Percent with lymphomas/leukemias	
	Pre-and postnatal exposure[A]	Postnatal exposure only[B]
0	12.6	8.7
20	17.1	20.0
100	31.4	18.7

Source: [a] Soffritti et al. (2007, 196366); [b] Soffritti et al. (2005, 087840; 2006, 196735).

1   An EFSA (2009, 196103) review of the Soffritti et al. (2007, 196366) study notes that the

2   ratio between the incidence in the low-dose group and the incidence in the concurrent control in

3   Table 4-30 is considerably lower in the animals exposed prenatally (1.4:1) compared to those

4   exposed postnatally (2.3:1). The ratio in the groups exposed to 100 mg/kg bw/day relative to the

5   respective concurrent controls is only slightly higher in animals exposed prenatally (2.5:1)

6   compared to those exposed postnatally (2.2:1). EFSA also notes that the incidence of

7   lymphomas and leukemias in aspartame-receiving males of the Soffritti et al. (2007, 196366)

8   study was within the range of historical controls for these responses in Sprague-Dawley rats at

9   the ERF. For example, the percent incidence of combined lymphomas and leukemias in males

10   exposed pre- and postnatally to 100 mg/kg-day aspartame (17.1%) was within the range of

11   historical controls for this response (8-31%, with an overall mean of 20.6%). Soffritti et al.

12   (2007, 196366) acknowledge this fact, but reason that comparisons of potentially compound-

13   associated incidences of tumor formation to incidences in concurrent controls provide a more

14   scientifically valid indicator of the tumorogenic impact of a chemical under investigation than

15   comparisons to historical control data.[60] Furthermore, the incidence of combined lymphomas

16   and leukemias in the female rats in the high-dose group is well above the historical control

17   range. Therefore, Soffritti et al. (2007, 196366) concluded that their second experiment

18   confirmed the carcinogenic potential of aspartame in Sprague-Dawley rats observed in Soffritti

19   et al. (2005, 087840; 2006, 196735). The high and variable incidence of this tumor type in ERF

20   controls remains a concern. However, the results provide support for studies suggesting similar

21   effects from methanol (Soffritti et al., 2002, 091004) since methanol is one of the degradation

22   products of aspartame and appears to have carcinogenic potential at some of the same target

23   organs and tissues.

---

[60] There are also potential problems with the use of historical control information from a colony that has been maintained for over three decades. Population sensitivity can and does change over time.

1   **4.6.5.2.3. *MTBE.***   In an experiment that also may be relevant to the carcinogenicity of

2   methanol, scientists at the ERF carried out a cancer bioassay on MTBE, in which the compound

3   was administered to 60 Sprague-Dawley rats/sex/group by gavage in olive oil at 0, 250, and

4   1,000 mg/kg-day, 4 days/week, for 104 weeks (Belpoggi et al., 1995, 075825). Doses adjusted

5   to daily dose were 0, 143, and 571 mg/kg-day. This experiment and its findings may relate to the

6   carcinogenicity of methanol, since methanol is one of several metabolites of MTBE (ATSDR,

7   1997). At the end of the exposure period, the animals were allowed to live out their "natural"

8   life, the last animal dying 166 weeks after the start of the experiment (at 174 weeks of age).

9   Mean daily feed and drinking water consumption were determined weekly for the first

10   13 weeks of the experiment, then every 2 weeks until 112 weeks of age. Individual body

11   weights were measured according to the same protocol, then every 8 weeks until the end of the

12   experiment. All animals were examined for gross lesions weekly for the first 13 weeks, then

13   every 2 weeks until term. All animals were examined grossly at death, then histopathologically

14   examined for a full suite of organs and tissues.

15   As described by the authors, there were no differences among the groups in body weight

16   and clinical signs of toxicity. Survival was dose-dependently reduced in female rats after

17   16 weeks of exposure. Paradoxically, survival was improved in high-dose males compared to

18   controls after 80 weeks. Although there were no noncarcinogenic effects of MTBE reported, a

19   number of benign and malignant tumors were identified, including tumor types that were not

20   observed in the ERF methanol study such as an increased incidence of testicular Leydig tumors

21   in high-dose males and as determined by the authors, as well as a dose-related statistically

22   significant increase in lymphomas and leukemias in females. The incidences of these tumors

23   compared to the initial number of animals exposed and compared to those at risk at the time of

24   the first observed tumor formation are shown in Table 4-31.

Table 4-31. Incidence of Leydig cell testicular tumors and combined lymphomas and leukemias in Sprague-Dawley rats exposed to MTBE via gavage for 104 weeks

Duration-adjusted dose	Leydig cell tumors			Combined lymphomas and leukemias					
	Number of males			Number of males			Number of females		
	Affected	Initial	At risk[C]	Affected	Initial	At Risk[D]	Affected	Initial	At Risk[E]
0	2	60	26	10	60	59	2	60	58
143	2	60	25	9	60	59	6[b]	60	51
571	11[a]	60	32	7	60	58	12[b]	60	47

[a] $p < 0.05$ using prevalence analysis.
[b] $p < 0.01$ using a log-ranked test.
[c] Alive male rats at 96 weeks of age, when first Leydig cell tumor was observed.
[d] Alive male rats at 32 weeks of age, when first leukemia was observed.
[e] Alive female rats at 56 weeks of age, when first leukemia was observed.

Source: Belpoggi et al. (1995, 075825).

1　　　The possible contribution of the metabolite methanol to the reported responses cannot be
2　quantified. It is also possible that the parent compound and/or one or more of MTBE's other
3　metabolites (e.g., tertiary butanol or formaldehyde) may be etiologically linked to the formation
4　of the identified neoplasms (Blancato et al., 2007, 091278).

5　**4.6.5.2.4. *Formaldehyde.*** Scientists at the ERF have performed two long-term drinking water
6　experiments on the potential carcinogenicity of formaldehyde, which is itself a metabolite of
7　methanol, aspartame and MTBE. While the tumorogenic effects at the portal-of-entry (such as in
8　the oral cavity and GI tract, for oral studies) may lack relevance to the possible effects of
9　metabolites formed *in situ* following methanol exposure, systemic neoplasms such as lymphomas
10　and leukemias have been described for formaldehyde as well (Soffritti et al., 1989, 081120;
11　Soffritti et al., 2002, 196211). This suggests that formaldehyde metabolized from methanol,
12　aspartame and MTBE may be etiologically important in the formation of lymphomas and
13　leukemias in animals exposed to these compounds.

14　　　In the first formaldehyde study (designated BT 7001; (Soffritti et al., 1989, 081120)), 50
15　Sprague-Dawley rats/sex/group (starting at 7 weeks of age) were exposed to formaldehyde in
16　drinking water at concentrations of 10, 50, 500, 1,000, and 1,500 mg/L for 104 weeks. Another
17　50 Sprague-Dawley rats/sex received methanol in drinking water at 15 mg/L, and 100 rats/sex
18　received water only, as controls. Body weight and water and food consumption were monitored
19　weekly for the first 13 weeks, then every 2 weeks thereafter. All animals were allowed to live
20　out their "natural" life, at which point they were subjected to necropsy and a complete
21　histopathological examination.

1   The final results of the BT 7001 Soffritti et al. (1989, 081120) experiment were reported

2   by Soffritti et al. (2002, 196211). Water consumption was reduced compared to controls in high-

3   dose males and in females at the three highest doses. However, there appeared to be no evidence

4   of compound-related body weight changes, clinical signs of toxicity among the groups, nor

5   nononcogenic histopathological effects of formaldehyde. The authors noted statistically

6   significant increases in the incidence of tumor-bearing males at 1500 ppm ($p<0.01$) and in total

7   malignant tumors in females at 100, 1000 and 1500 ppm ($p<0.01$) and in males at 500 ppm

8   ($p<0.05$) and 1500 ppm ($p<0.01$). They reported statistically significant increases in malignant

9   mammary tumors in females at 100 ppm ($p<0.01$) and 1500 ppm ($p<0.05$), and in testicular

10 interstitial cell adenomas in the 1000 ppm males ($p<0.05$). They also noted sporadic incidences

11 in the treatment groups only (primarily at the highest dose) of leiomyosarcomas of the stomach

12 and intestine considered to be very rare for the ERF rat colony. As for methanol and the other

13 compounds discussed in this section, they reported increases in the number of

14 hemolymphoreticular tumors for both sexes. The incidence of hemolymphoreticular neoplasms

15 among the dose groups is shown in Table 4-32.

**Table 4-32. Incidence of hemolymphoreticular neoplasms on Sprague-Dawley
rats exposed to formaldehyde in drinking water for 104 weeks**

Concentration in drinking water (mg/L)	Males	Females
0	8/100	7/100
0 (15 mg/L methanol)	10/50	5/50
10	4/50	5/50
50	10/50	7/50
100	13/50[b]	8/50
500	12/50[a]	7/50
1,000	11/50[a]	11/50[a]
1,500	23/50[b]	10/50[b]

[a]$p < 0.05$ using the χ^2 test; [b]$p < 0.01$ using the χ^2 test.

Source: Soffritti et al. (2002, 196211).

16 Soffritti et al. (1989, 081120) also described the results of another experiment (BT 7005)

17 in which approximately 20 Sprague-Dawley rats/sex/group were exposed to either regular

18 drinking water or 2,500 mg/L formaldehyde, beginning at 25 weeks of age for 104 weeks. These

19 animals were allowed to mate and approximately 40-60 of the F_0 pups were likewise exposed to

20 0 or 2,500 ppm formaldehyde in drinking water (after weaning) for 104 weeks. As before,

21 parents and progeny lived out their normal life span but then were subjected to a complete

22 histopathological examination. Incidence of leukemias in exposed breeders and offspring is

1 shown in Table 4-33. The authors considered this data to indicate a "slight" increase in

2 leukemias in breeders at 2,500 ppm, but the changes did not achieve statistical significance.

Table 4-33. Incidence of leukemias in breeder and offspring Sprague-Dawley rats exposed to formaldehyde in drinking water for 104 weeks (Test BT 7005)

Concentration (ppm)	Incidence of leukemias			
	Breeder		Offspring	
	Males	Females	Males	Females
0	0/20	1/20	3/59	3/49
2,500	2/18	2/18	4/36	0/37

Source: Soffritti et al. (1989, 081120).

4.7. SYNTHESIS OF MAJOR NONCANCER EFFECTS

4.7.1. Summary of Key Studies in Methanol Toxicity

3   A substantial body of information exists on the toxicological consequences to humans

4 who consume or are acutely exposed to large amounts of methanol. Neurological and

5 immunological effects have been noted in adult human subjects acutely exposed to as low as

6 200 ppm (262 mg/m^3) methanol (Chuwers et al., 1995, 081298; Mann et al., 2002, 034724).

7 Nasal irritation effects have been reported by adult workers exposed to 459 ppm (601 mg/m^3)

8 methanol. Frank effects such as blurred vision and bilateral or unilateral blindness, coma,

9 convulsions/tremors, nausea, headache, abdominal pain, diminished motor skills, acidosis, and

10 dyspnea begin to occur as blood levels approach 200 mg methanol/L, and 800 mg/L appears to

11 be the threshold for lethality. Data for subchronic, chronic or in utero human exposures are very

12 limited. Determinations regarding longer term effects of methanol are based primarily on animal

13 studies.

14   An end-point-by-end-point survey of the primary effects of methanol in experimental

15 animals is given in the following paragraphs. Tabular summaries of the principal toxicological

16 studies that have examined the impacts of methanol when experimental animals were exposed to

17 methanol via the oral or inhalation routes are provided in Tables 4-34 and 4-35. Most studies

18 focused on developmental and reproductive effects. A large number of the available studies were

19 performed by routes of exposure (e.g., i.p.) that are less relevant to the assessment. The data are

20 summarized separate sections that address oral exposure (Section 4.7.1.1) and inhalation

21 exposure (Section 4.7.1.2).

Table 4-34. Summary of studies of methanol toxicity in experimental animals (oral)

Species, strain, number/sex	Dose/duration	NOAEL (mg/kg-day)	LOAEL (mg/kg-day)	Effect	Reference
Rat Sprague-Dawley 30/sex/group	0, 100, 500, and 2,500 mg/kg-day for 13 wk	500	2,500	Reduction of brain weights, increase in the serum activity of ALT and AP. Increased liver weights	U.S. EPA (1986c)
Rat Sprague-Dawley 100/sex/group	0, 500, 5,000, or 20,000 ppm (v/v) in drinking water, for 104 wk. Doses were approx. 0, 46.6, 466, and 1,872 mg/kg-day (male) and 0, 52.9, 529, and 2101 mg/kg-day (female)	466-529	1,872-2,101	Increased incidence of ear duct[a] carcinomas, lymphoreticular tumors, and total malignant tumors. No noncancer effects	Soffritti et al. (2002a)
Mouse Swiss	560, 1000 and 2100 mg/kg/d (female) and 550, 970, and 1800 mg/kg/d (male), 6 days/wk for life	ND	1,800-2,100	Increased incidence of liver parenchymal cell necrosis and malignant lymphomas	Apaja (1980)
Reproductive/developmental toxicity studies					
Rat Long-Evans 10 pregnant females/group	0 and 2,500 mg/kg-day on either GD15-GD17 or GD17-GD19.	NA	2,500	Neurobehavioral deficits (such as homing behavior, suckling ability	Infurna and Weiss (1986)
Mouse CD-1 8 pregnant females and 4 controls	4 g/kg-day in 2 daily doses on GD6-GD15	NA	4,000	Increased incidence of totally resorbed litters, cleft palate and exencephaly. A decrease in the number of live fetuses/litter	Rogers, et al. (1993a)

NA = Not applicable; ND = Not determined; M= male, F=female.
[a]In an NTP evaluation of pathology slides from another bioassay from this laboratory in which a similar ear duct carcinoma finding was reported (Soffritti et al., 2005, 087840; Soffritti et al., 2006, 196735), NTP pathologists interpreted a majority of these ear duct responses as being hyperplastic, not carcinogenic, in nature (EFSA, 2006, 196098; Hailey, 2004, 089842).

Table 4-35. Summary of studies of methanol toxicity in experimental animals (inhalation exposure)

Species, strain, number/sex	Dose/duration	NOAEL (ppm)	LOAEL (ppm)	Effect	Reference
Monkey *M. fascicularis*, 1 or 2 animals/group	0, 3,000, 5,000, 7,000, or 10,000 ppm, 21 hr/day, for up to 14 days	ND	ND	Clinical signs of toxicity, CNS changes, including degeneration of the bilateral putamen, caudate nucleus, and claustrum. Edema of cerebral white matter.	NEDO (1987, 064574)
Dog (2)	10,000 ppm for 3 min, 8 times/day for 100 days	NA	NA	None	Sayers et al. (1944, 031100)
Rat Sprague-Dawley 5 males/ group	0, 200, 2000, or 10,000 ppm, 8 hr/day, 5 days/wk for up to 6 wk	NA	200	Transient reduction in plasma testosterone levels	Cameron et al. (1984, 064567)
Rat Sprague-Dawley 5 males/ group	0, or 200 ppm, 6 hr/day, for either 1 or 7 days	NA	200	Transient reduction in plasma testosterone levels	Cameron et al. (1985, 064568)
Rat Sprague-Dawley 5/sex/group	0, 500, 2,000, or 5,000 ppm, 5 days/wk for 4 wk	5,000	NA	No compound-related effects	Andrews et al. (1987, 030946)
Monkey *M. fascicularis* 3/sex/group	0, 500, 2,000, or 5,000 ppm, 5 days/wk for 4 wk	5,000	NA	No compound-related effects	
Rat Sprague-Dawley 10/sex/group	0, 300, or 3,000 ppm, 6 hr/day, 5 days/wk for 4 wk	NA	300	Reduction in size of thyroid follicles	Poon et al. (1994, 074789)
Rat Sprague-Dawley 15/sex/group	0 or 2,500 ppm, 6 hr/day, 5 days/wk for 4 wk	NA	2,500	Reduction of relative spleen weight in females, histopathologic changes to the liver, irritation of the upper respiratory tract	Poon et al. (1995, 085499)
Monkey *M. fascicularis* 2 or 3 animals/ group/time point	0, 10, 100, or 1,000 ppm, 21 hr/day for either 7, 19, or 29 mo	ND / ND	ND / ND	Limited fibrosis of the liver / Possible myocardial and renal effects	NEDO (1987, 064574)
Rat F344 20/sex/group	0, 10, 100, or 1,000 ppm, 20 hr/day, for 12 mo	NA	NA	No compound-related effects	
Mouse B6C3F$_1$ 30/sex/group	0, 10, 100, or 1000 ppm, 20 hr/day, for 12 mo	NA	NA	No clear-cut compound-related effects	
Mouse B6C3F$_1$ 52-53/sex/group	0, 10, 100, or 1,000 ppm, 20 hr/day, for 12 mo	100	1,000	Increase in kidney weight, decrease in testis and spleen weights	

Species, strain, number/sex	Dose/duration	NOAEL (ppm)	LOAEL (ppm)	Effect	Reference
Rat F344 52/sex/group	0, 10, 100, or 1,000 ppm, ~20 hr/day for 2 yr	100	1,000	Fluctuations in a number of urinalysis, hematology, and clinical chemistry parameters. Development of pulmonary adenoma/ adenocarcinoma (males), pheochromocytomas (females)	
Reproductive/developmental toxicity studies					
Rat Sprague-Dawley 15/pregnant females/group	0, 5,000, 10,000, or 20,000 ppm, 7 hr/day on either GD1-GD19 or GD7-GD15.	5,000	10,000	Reduced fetal body weight, increased incidence of visceral and skeletal abnormalities, including rudimentary and extra cervical ribs	Nelson et al. (1985, 064573)
Rat Sprague-Dawley 36/pregnant females/group	0, 200, 1,000, or 5000 ppm, 22.7 hr/day, on GD7-GD17	1,000	5,000	Late-term resorptions, reduced fetal viability, increased frequency of fetal malformations, variations and delayed ossifications.	NEDO (1987, 064574)
Rat Sprague-Dawley F_1 and F_2 generations of a two-generation study	0, 10, 100, or 1000 ppm, 20 hr/day; F_1- birth to end of mating (M) or weaning (F); F2- birth to 8 wks	100	1,000	Reduced weight of brain, pituitary, and thymus at 8, 16 and 24 wk postnatal in F_1 and at 8 wk in F_2	
Rat Sprague-Dawley Follow-up study of brain weights in F_1 generation of 10-14/sex/group in F_1 generation	0, 500, 1,000, and 2,000 ppm; GD0 through F_1 generation	500	1,000	Reduced brain weight at 3 wk and 6 wk (males only). Reduced brain and cerebrum weight at 8 wk (males only)	
Mouse CD-1 30-114 pregnant females/group	0, 1,000, 2,000, 5,000, 7,500, 10,000, or 15,000 ppm, 7 hr/day on GD6-GD15.	1,000	2,000	Increased incidence of extra cervical ribs, cleft palate, exencephaly; reduced fetal weight and pup survival, Delayed ossification	Rogers et al. (1993, 032696)
Mouse CD-1 12-17 pregnant females/group	0 and 10,000 ppm on two consecutive days during GD6-GD13 or on a single day during GD5-GD9	NA	10,000	Cleft palate, exencephaly, skeletal malformations	Rogers and Mole (1997, 009755)
Rat Long-Evans 6-7 pregnant females/group	0 or 15,000 ppm, 7 hr/day on GD7-GD19	NA	15,000	Reduced pup weight	Stanton et al. (1995, 085231)
Rat Long-Evans 10-12 pregnant females/group	0 or 4,500 ppm from GD10 to PND21.	NA	4,500	Subtle cognitive deficits	Weiss et al. (1996, 079211)

Species, strain, number/sex	Dose/duration	NOAEL (ppm)	LOAEL (ppm)	Effect	Reference
Monkey *M. fascicularis* 12 monkeys/group	0, 200, 600, or 1800 ppm, 2.5 hr/day, 7 days/wk, during premating, mating and gestation	ND	ND[a]	Shortened period of gestation; may be related to exposure (no dose-response), neurotoxicological deficits including reduced performance in the VDR test; may be related to premature births.	Burbacher et al. (1999, 009752; 1999, 009753; 2004, 059070; 2004, 056018)

ND = Not determined due to study limitations such as small number of animals /time point/ exposure level
NA = Not applicable.
[a]Gestation resulted in a shorter period of gestation in dams exposed to as low as 200 ppm (263 mg/m^3). However, because of uncertainties associated with these results, including clinical intervention and the lack of a dose-response, EPA was not able to identify a definitive NOAEL or LOAEL from this study.

4.7.1.1. *Oral*

1   There have been very few subchronic, chronic, or in utero experimental studies of oral
2 methanol toxicity. In one such experiment, an EPA-sponsored 90-day gavage study in Sprague-
3 Dawley rats suggested a possible effect of the compound on the liver (U.S., 1986, 196737). In
4 the absence of gross or histopathologic evidence of toxicity, fluctuations on some clinical
5 chemistry markers of liver biochemistry and increases in liver weights at the highest
6 administered dose (2,500 mg/kg-day) justify the selection of the mid-dose level (500 mg/kg-day)
7 as a NOAEL for this effect under the operative experimental conditions. That the bolus effect
8 may have been important in the induction of those few effects that were apparent in the
9 subchronic study is suggested by the outcome of lifetime drinking water study of methanol that
10 was carried out in Sprague-Dawley rats by Soffritti et al. (2002, 091004). According to the
11 authors, no noncancer toxicological effects of methanol were observed at drinking water
12 concentrations of up to 20,000 ppm (v/v). Based on default assumptions on drinking water
13 consumption and body weight gain assumptions, the high concentration was equivalent to a dose
14 of 1,780 mg/kg-day in males and 2,177 mg/kg-day in females. In the stated absence of any
15 changes to parameters reflective of liver toxicity in the Soffritti et al. (2002, 091004) study, the
16 slight impacts to the liver observed in the subchronic study at 2,500 mg/kg-day suggest the latter
17 dose to be a minimal LOAEL. Logically, the true but unknown threshold would at the high end
18 of the range from 500 (the default NOAEL) to 2,500 mg/kg-day for liver toxicity via oral
19 gavage.
20   Two studies have pointed to the likelihood that oral exposure to methanol is associated
21 with developmental neurotoxicity or developmental deficits. When Infurna and Weiss (1986,
22 064572) exposed pregnant Long-Evans rats to 2% methanol in drinking water (providing a dose
23 of approximately 2,500 mg/kg-day), they observed no reproductive or developmental sequelae
24 other than from 2 tests within a battery of fetal behavioral tests (deficits in suckling ability and

homing behavior). In the oral section of the Rogers et al. (1993, 032696) study, such
teratological effects as cleft palate and exencephaly and skeletal malformations were observed in
fetuses of pregnant female mice exposed to daily gavage doses of 4,000 mg/kg methanol during
GD6-GD15. Likewise, an increase in totally resorbed litters and a decrease in the number of live
fetuses/litter appear likely to have been an effect of the compound. Similar skeletal
malformations were observed by Rogers and Mole (1997, 009755), Rogers et al. (1993, 032696),
and Nelson et al. (1985, 064573) following inhalation exposure.

4.7.1.2. *Inhalation*

Some clinical signs, gross pathology, and histopathological effects of methanol have been
seen in experimental animals including adult nonhuman primates exposed to methanol vapor.
Results from an unpublished study (NEDO, 1987, 064574) of *M. fascicularis* monkeys,
chronically exposed to concentrations as low as 10 ppm for up to 29 months, resulted in
histopathological effects in the liver, kidney, brain and peripheral nervous system. These results
were generally reported as subtle and do not support a robust dose response over the range of
exposure levels used. Confidence in the methanol-induced findings of effects in adult nonhuman
primates is limited because this study utilized a small number (2-3) of animals/dose level/time of
sacrifice and inadequately reporting of results (i.e., lack of clear documentation of a concurrent
control group). In addition, the monkeys used in this study were all wild-caught. All of these
concerns limit the study's utility in derivation of an RfC.

A number of studies have examined the potential toxicity of methanol to the male
reproductive system (Cameron et al., 1984, 064567; Cameron et al., 1985, 064568; Lee et al.,
1991, 032419). The data from Cameron et al. (1984, 064567; 1985, 064568) showed a transient
but not necessarily dose-related decrease in serum testosterone levels of male Sprague-Dawley
rats. Lee et al. (1994, 032712) reported the appearance of testicular lesions in 18-month-old
male Long-Evans rats that were exposed to methanol for 13 weeks and maintained on folate-
deficient diets. Taken together, the Lee et al. (1994, 032712) and Cameron et al. (1984, 064567;
1985, 064568) study results could indicate chemically-related strain on the rat system as it
attempts to maintain hormone homeostasis. However, the available data are insufficient to
definitively characterize methanol as a toxicant to the male reproductive system.

When Sprague-Dawley rats were exposed to methanol, 6 hours/day for 4 weeks, there
were some signs of irritation to the eyes and nose. Mild changes to the upper respiratory tract
were also described in Sprague-Dawley rats that were exposed for 4 weeks to up to 300 ppm
methanol (Poon et al., 1995, 085499). Other possible effects of methanol in rats included a
reduction in size of thyroid follicles (Poon et al., 1994, 074789), panlobular vacuolation of the
liver, and a decrease in spleen weight (Poon et al., 1995, 085499). NEDO (1987, 064574)

1 reported dose-related increases in moderate fatty degeneration in hepatocytes of male mice
2 exposed via inhalation for 12 months, but this finding was not observed in the NEDO (1987,
3 064574) 18-month mouse inhalation study. Nodes reported in the liver of mice from the 18-
4 month study may have been precancerous, but the 18-month study duration was not of sufficient
5 duration to make a determination.

6 One of the most definitive and quantifiable toxicological impacts of methanol when
7 administered to experimental animals via inhalation is related to the induction of developmental
8 abnormalities in fetuses exposed to the compound in utero. Developmental effects have been
9 demonstrated in a number of species, including monkeys, but particularly rats and mice. Most
10 developmental teratological effects appear to be more severe in the latter species. For example,
11 in the study of Rogers et al. (1993, 032696) in which pregnant female CD-1 mice were exposed
12 to methanol vapors on GD6-GD15 at a range of concentrations, reproductive and fetal effects
13 included an increase in the number of resorbed litters, a reduction in the number of live pups,
14 and increased incidence of exencephaly, cleft palate, and the number of cervical ribs. While the
15 biological significance of the cervical rib effect has been the subject of much debate (See
16 discussion of Chernoff and Rogers (2004, 069993) in Section 5), it appears to be the most
17 sensitive indicator of developmental toxicity from this study, with a NOAEL of 1,000 ppm
18 (1,310 mg/m^3). In rats, however, the most sensitive developmental effect, as reported in the
19 NEDO (1987, 064574) two-generation inhalation studies, was a postnatal reduction in brain
20 weight at 3, 6 and 8 weeks postnatally, which was significantly lower than controls when pups
21 and their dams were exposed to 1,000 ppm (1,310 mg/m^3) during gestation and throughout
22 lactation. The NOAEL reported in this study was 500 ppm (655 mg/m^3).

23 Rogers and Mole (1997, 009755) addressed the question of which period of gestation was
24 most critical for the adverse developmental effects of methanol in CD-1 rats. Such
25 malformations and anomalies as cleft palate, exencephaly, and a range of skeletal defects,
26 appeared to be induced with a greater incidence when the dams were exposed on or around GD6.
27 These findings were taken to indicate that methanol is most toxic to embryos during gastrulation
28 and in the early stages of organogenesis. However, NEDO (1987, 064574) gestation-only and
29 two-generation studies showed that significant reductions in brain weight were observed at a
30 lower exposure levels when pups and their dams were exposed during lactation as well as
31 gestation, indicating that exposure during the later stages of organogenesis, including postnatal
32 development, can significantly contribute to the severity of the effects in this late-developing
33 organ system.

34 In comparing the toxicity (NOAELs and LOAELs) for the onset of developmental effects
35 in mice and rats exposed in utero, there is suggestive evidence from the above studies that mice

1   may be more susceptible to methanol than rats. Supporting evidence for this proposition has

2   come from in vitro studies in which rat and mouse embryos were exposed to methanol in culture

3   (Andrews et al., 1993, 032687). Further evidence for species-by-species variations in the

4   susceptibility of experimental animals to methanol during organogenesis has come from

5   experiments on monkeys (Burbacher et al., 1999, 009752; Burbacher et al., 1999, 009753;

6   Burbacher et al., 2004, 059070; Burbacher et al., 2004, 056018). In these studies, exposure of

7   monkeys to methanol during premating, mating, and throughout gestation resulted in a shorter

8   period of gestation in dams exposed to as low as 200 ppm (263 mg/m^3). The shortened gestation

9   period was largely the result of C-sections performed in the methanol-exposure groups "in

10   response to signs of possible difficulty in the maintenance of pregnancy," including vaginal

11   bleeding. Though statistically significant, the finding of a shortened gestation length may be of

12   limited biological significance. Gestational age, birth weight and infant size observations in all

13   exposure groups were within normal ranges for *M. fascicularis* monkeys, and vaginal bleeding

14   1-4 days prior to delivery of a healthy infant does not necessarily imply a risk to the fetus (as

15   cited in CERHR, (2004, 091201)). An ultrasound examination could have substantiated fetal or

16   placental problems arising from presumptive pregnancy duress (see Section 4.3.2). As discussed

17   in Section 4.4.2, there is also evidence from this study that methanol caused neurobehavioral

18   effects in exposed monkey infants that may be related to the gestational exposure. However, the

19   data are not conclusive, and a dose-response trend is not robust. There is insufficient evidence to

20   determine if the primate fetus is more or less sensitive than rodents to methanol teratogenesis.

21   Several other uncertainties contributed to decreased confidence in the use of this primate in

22   quantitative estimates of risk. These included: a mixture of wild- and colony-derived monkey

23   mothers used in the study; the use of a cohort design necessitated by the complexity of this study

24   also seemingly resulted in limitations in power to detect effects (e.g., Fagan test results for

25   controls); and no apparent adjustment in statistical analysis for results from the neurobehavioral

26   battery of tests employed leading to concern about inflation of type 1 error. Because of the

27   uncertainties associated with these results, including the fact that the decrease in gestational

28   length was not exacerbated with increasing methanol exposure, EPA was not able to identify a

29   definitive NOAEL or LOAEL from this study. This study does support the weight of evidence

30   for developmental neurotoxicity in the hazard characterization of low-level methanol exposure.

31   Weiss et al. (1996, 079211) and Stanton et al. (1995, 085231) evaluated the

32   developmental and developmental neurotoxicological effects of methanol exposure on pregnant

33   female Long-Evans rats and their progeny. In the former study, exposure of dams to 15,000 ppm

34   (19,656 mg/m^3), 7 hours/day on GD7-GD19 resulted in reduced weight gain in pups, but

35   produced little other evidence of adverse developmental effects. The authors subjected the pups

to a number of neurobehavioral tests that gave little if any indication of compound-related changes. This study, while using high exposure levels, was limited in its power to detect effects due to the small number of animals used. In the Weiss et al. (1996, 079211) study, exposure of pregnant female Long-Evans rats to 0 or 4,500 (0 and 5,897 mg/m^3) methanol from GD6 to PND21 likewise provided fluctuating and inconsistent results in a number of neurobehavioral tests that did not necessarily indicate any compound-related impacts. The finding of this study indicated subtle cognitive defects not on the learning of an operant task but in the reversal learning. This study also reported exposure-related changes in neurodevelopmental markers of NCAMs on PND4. NCAMs are a family of glycoproteins that is needed for migration, axonal outgrowth, and establishment of the pattern for mature neuronal function.

Taking all of these findings into consideration reinforces the conclusion that the most appropriate endpoints for use in the derivation of an RfC for methanol are associated with developmental neurotoxicity and developmental toxicity. Among an array of findings indicating developmental neurotoxicity and developmental malformations and anomalies that have been observed in the fetuses and pups of exposed dams, an increase in the incidence of cervical ribs of gestationally exposed mice (Rogers et al., 1993, 032696) and a decrease in the brain weights of gestationally and lactationally exposed rats (NEDO, 1987, 064574) appear to be the most robust and most sensitive effects.

4.8. NONCANCER MOA INFORMATION

A review by Jacobsen and McMartin (1986, 031514) has provided a comprehensive summary of the mechanism by which methanol brings about its acute toxic effects. Overwhelmingly, the evidence points to methanol poisoning being a consequence of formate accumulation. This compound is formed from formaldehyde under the action of ADH3. Formaldehyde itself is formed from methanol under the action of ADH1. Evidence for the involvement of formate comes from the delay in the onset of harmful symptoms, detection of formate in the blood stream, and the profound acidosis that develops 12-24 hours after exposure to methanol. Treatments for methanol poisoning include the i.v. administration of buffer to correct the acidosis, hemodialysis to remove methanol from the blood stream, and i.v. administration of either ethanol or fomepizole to inhibit the activity of ADH1. Therapies to increase endogenous levels of folate may enhance the activity of THF synthetase, an enzyme that catalyzes the oxidation of formate to CO_2. Jacobsen and McMartin (1986, 031514) have drawn attention to the accumulation of lactate in advanced stages of severe methanol poisoning, a possible consequence of formate inhibition of mitochondrial respiration and tissue hypoxia. The

additional decrease in blood pH is likely to enhance the nonionic diffusion of formic acid across
cell membranes, with resulting CNS-depression, hypotension, and further lactate production.

Jacobsen and McMartin (1986, 031514) summarized a body of evidence that also points
to the formate-related acidosis as the etiologically important factor in ocular damage. The
hypothesis suggests that ocular toxicity is due to the inhibition of cytochrome oxidase in the
optic nerve by formate. This would cause inhibition of ATP formation and consequent disruption
of optic nerve function.

While it is well established that the toxic consequences of acute methanol poisoning arise
from the action of formate, there is less certainty on how the toxicological impacts of longer-
term exposure to lower levels of methanol are brought about. For example, since developmental
effects in experimental animals appear to be significant adverse effects associated with in utero
methanol exposure, it is important to determine potential MOAs for how these specific effects
are brought about.

As described in Section 4.6.1, data from experiments carried out by Dorman et al. (1995,
078081), formate is not the probable proximate teratogen in pregnant CD-1 mice exposed to high
concentrations of methanol vapor. This conclusion is based on the fact that there appeared to be
little, if any, accumulation of formate in the blood of methanol-exposed mice, and exencephaly
did not occur until formate levels were grossly elevated. Another line of argument is based on
the observation that treatment of pregnant mice with a high oral dose of formate did not induce
neural tube closure defects at media concentrations comparable to those observed in uterine
decidual swelling after maternal exposure to methanol. Lastly, methanol- but not formate-
induced neural tube closure defects in mouse embryos in vitro at media concentrations
comparable to the levels of methanol detected in blood after a teratogenic exposure.

Harris et. al (Hansen et al., 2005, 196135; Harris et al., 2003, 047369; Harris et al., 2004,
059082) carried out a series of physiological and biochemical experiments on mouse and rat
embryos exposed to methanol, formaldehyde and formate, concluding that the etiologically
important substance for embryo dysmorphogenesis and embryolethality was likely to be
formaldehyde rather than the parent compound or formate. Specific activities for enzymes
involved in methanol metabolism were determined in rat and mouse embryos during the
organogenesis period of 8-25 somites (Harris et al., 2003, 047369). The experiment was based
on the concept that differences in the metabolism of methanol to formaldehyde and formic acid
by the enzymes ADH1, ADH3, and CAT may contribute to hypothesized differences in species
sensitivity that were apparent in toxicological studies. A key finding was that the activity of
ADH3 (converting formaldehyde to formate) was lower in mouse VYS than that of rats
throughout organogenesis, consistent with the greater sensitivity of the mouse to the

developmental effects of methanol exposure. Another study (Harris et al., 2004, 059082) which

showed that the inhibition of GSH synthesis increases the developmental toxicity of methanol

also lends support to this hypothesis because ADH3-mediated metabolism of formaldehyde is the

only enzyme involved in methanol metabolism that is GSH-dependent. These findings provide

inferential evidence for the proposition that formaldehyde may be the ultimate teratogen through

diminished ADH3 activity. This concept is further supported by the demonstration that the

LOAELs for the embryotoxic effects of formaldehyde in rat and mouse embryos were much

lower than those for formate and methanol (Hansen et al., 2005, 196135). Taking findings from

both sets of experiments together, Harris et. al. (Hansen et al., 2005, 196135; Harris et al., 2003,

047369; Harris et al., 2004, 059082) concluded that the demonstrable lower capacity of mouse

embryos to transform formaldehyde to formate (by ADH3) could explain the increased

susceptibility of mouse versus rat embryos to the toxic effects of methanol.

While studies such as those by Harris et al. (2003, 047369; 2004, 059082) and Dorman

et al. (1996, 095723; 1995, 078081) strongly suggest that formate is not the metabolite

responsible for methanol's teratogenic effects, there are still questions regarding the relative

involvement of methanol versus formaldehyde. In vitro evidence suggests that formaldehyde is

the more embryotoxic moiety, but methanol would likely play a prominent role, at least in terms

of transport to the target tissue. The high reactivity of formaldehyde would limit its unbound and

unaltered transport as free formaldehyde from maternal to fetal blood (Thrasher and Kilburn,

2001, 196728), and the capacity for the metabolism of methanol to formaldehyde is likely lower

in the fetus and neonate versus adults (see discussion in Section 3.3)

In humans, metabolism of methanol occurs primarily through ADH1, whereas in rodents

methanol metabolism involves primarily CAT, as well as ADH1. There are no known studies

that compare enzyme activities of human ADH1 and rodent CAT. Assuming that relative

expression and activity of ADH1 is comparable across species, rodents are expected to clear

methanol more rapidly than humans due to involvement of CAT. In fact, even among rodents the

metabolism of methanol may be quite different, as one study has demonstrated that the rate of

methanol oxidation in mice is twice the rate in rats, as well as nonhuman primates (Mannering et

al., 1969, 031429). Despite a faster rate of methanol metabolism, mice have consistently shown

higher blood methanol levels than rats following exposure to equivalent concentrations

(Tables 3-4 and 3-5). A faster respiration rate and increased fraction of absorption by mice is

thought to be the reason for the higher blood methanol levels compared to rats (Perkins et al.,

1995, 085259). Using the exposure conditions of Horton et al. (1992, 196222) for rats, when the

respiration rate scaling coefficient (QPC) was increased from the rat value of 16.4 to the mouse

value of 25.4 while holding all other parameters constant, peak blood concentrations were

predicted by the PBPK model to increase by 1.4-fold at 200 ppm and 1.8-fold at 2,000 ppm (where metabolism is becoming saturated).   Because smaller species generally have faster breathing rates than larger species (in the PBPK model, the respiration rate/BW is 3 times slower in humans versus rats and almost 10 times slower versus mice), humans would be expected to accumulate less methanol than rats or mice inhaling equivalent concentrations and given the same metabolism rate. However, Horton et al. (1992, 196222) measured a blood concentration in rats exposed to 200 ppm methanol of about 3.7 mg/L after 6 hours of exposure while Sedevic et al. (1981, 031154) measured around 5.5 mg/L in human volunteers after 6 hours of exposure to 231 ppm. Correcting for the higher exposure, human blood concentrations would be around 4.8 mg/L if exposed at 200 ppm. Simulations with the mouse model predict a blood level of 5.7 mg/L after 6 hours of exposure to 200 ppm, only 20% higher than this interpolated human value.   Thus the slower inhalation rate in humans is offset by the slower metabolic rate, leading to equivalent blood concentrations. (If the same rate of metabolism/BW as mice is used, human blood concentrations are predicted to decrease by approximately fivefold.). These differences are considered in Section 5 for the characterization of human and rodent PBPK models used for the derivation of human equivalent concentrations (HECs).

4.9. EVALUATION OF CARCINOGENICITY

4.9.1. Summary of Overall Weight-of-Evidence

Under the *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005, 086237) (U.S. EPA, 2005, 088823), methanol is likely to be carcinogenic to humans by all routes of exposure based on dose-dependent trends in multiple tumors in both sexes of two strains of rats by inhalation and oral routes of exposure, and increases in malignant lymphoma in both sexes of Eppley Swiss Webster mice by oral exposure. Specifically, EPA's analysis of the Soffritti et al. (2002, 091004) lifespan study of Sprague-Dawley rats exposed to methanol in drinking water for 104 weeks indicates a statistically significant increase in the incidence of lymphoma[61] in lung and other organs at the two highest doses for males and across all doses for females (Fisher's exact, $p < 0.05$) and a statistically significant increase in relatively rare hepatocellular carcinomas in males compared to historical controls (n=407)[62] (Fisher's exact $p < 0.05$ for all

---

[61] Combining lymphoblastic lymphomas, lymphocytic lymphomas, lympho-immunoblastic lymphomas and/or lymphoblastic leukemias as malignant lymphomas but excluding myeloid leukemias, histocytic sarcomas and monocytic leukemia as tumors of different origin (Cruzan, 2009, 196354; Hailey, 2004, 089842; McConnell et al., 1986, 073655).

[62] Obtained by combining control data from ERF studies of methanol, formaldehyde, aspartame, MTBE, and TAME.available from the ERF website at http://www.ramazzini.it/fondazione/foundation.asp).

doses and $p < 0.01$ for the high-dose group). Statistically significant increases in the incidence
of malignant lymphomas relative to historical controls (Fisher's exact, $p < 0.05$) have also been
observed in another rodent species, Eppley Swiss Webster mice, following similar mg/kg-day
exposures to methanol in drinking water for life (Apaja, 1980, 191208). The available chronic
inhalation studies of methanol (NEDO, 2008, 196315; NEDO, 2008, 196316) reported slight but
statistically significant tumor responses in F344 rats at 24 months, and no evidence of
carcinogenicity in B6C3F$_1$ mice at 18 months. EPA's analysis of the NEDO (2008, 196316)
inhalation study of F344 rats indicates a dose-response trend (Cochrane-Armitage $p < 0.05$) and
an increased incidence over concurrent controls at the high dose (Fisher's exact $p < 0.05$) of
pulmonary adenomas/adenocarcinomas in male rats. This analysis also indicates a statistically
significant dose-response trend (Cochrane-Armitage $p < 0.05$) and a statistically significant
increased incidence over NTP historical controls at the high-dose (Fisher's exact $p < 0.05$) of
pheochromocytomas in female rats.

This WOE conclusion is supported by the results of other studies performed by ERF that
have shown tumorogenic responses similar to that of methanol in male and female Sprague-
Dawley rats exposed to formaldehyde (via drinking water), a metabolite of methanol, and to
aspartame (via feed) and MTBE (via olive oil gavage), substances that hydrolyze to release
methanol and formaldehyde. Confidence in the designation of methanol as a likely human
carcinogen is strengthened by the fact that methanol is metabolized to formaldehyde, a chemical
that has been associated with increased incidences of lymphoma and leukemia in humans (IARC,
2004, 196244). As discussed below and in Section 5.4.3, there are uncertainties in the
interpretation of these findings. All of the key studies have design and reporting limitations.
EPA has reanalyzed the reported data from both the ERF (Soffritti et al., 2002, 091004) and
NEDO (1987, 064574; 2008, 196315; 2008, 196316) studies. In reassessing the ERF study data,
EPA decided to combine only those lymphomas considered to have originated from the same cell
type. In the case of the NEDO data, the significance of the tumor findings was incompletely
reported in the original NEDO (1987, 064574) summary. Hence, EPA used translations of the
original, detailed Japanese study reports provided by NEDO and the Methanol Institute (NEDO,
2008, 196315; NEDO, 2008, 196316) and reanalyzed the individual animal data.

The "likely to be carcinogenic to humans" descriptor is appropriate when the weight of
the evidence is adequate to demonstrate carcinogenic potential to humans but does not reach the
weight of evidence for the descriptor "carcinogenic to humans." An example provided in the
EPA cancer guidelines (U.S. EPA, 2005, 086237) is "an agent that has tested positive in animal
experiments in more than one species, sex, strain, site, or exposure route, with or without
evidence of carcinogenicity in humans." However, Section 2.5 of the EPA cancer guidelines

(U.S. EPA, 2005, 086237) emphasizes that WOE descriptors represent "points along a continuum of evidence." As is discussed in Sections 4.9.2 and 5.4.3 of this assessment, though there are indications from several rodent bioassays that methanol can cause cancer in more than one species, sex, strain, site, and exposure route, there are also uncertainties associated with the interpretation of the tumor responses reported in these laboratory studies. Further, despite human evidence for the association of lymphomas with a methanol metabolite, there is no information available in the literature regarding the observation of cancer in humans following chronic administration of methanol. As a consequence, though the overall WOE supports the determination that methanol is likely to be carcinogenic to humans, evidence supporting the proximate descriptor, in this case "suggestive evidence of carcinogenic potential," was also considered (U.S. EPA, 2005, 086237).

Two examples that are considered representative of suggestive evidence of carcinogenic potential (U.S. EPA, 2005, 086237) are potentially relevant to methanol. The first example is a chemical that causes "a small increase in a tumor with a high background rate in that sex and strain, when there is some but insufficient evidence that the observed tumors may be due to intrinsic factors that cause background tumors and not due to the agent being assessed." Consistent with this example, intrinsic factors (e.g., respiratory infection) have been suggested to cause or confound the interpretation of tumor findings reported in the Soffritti et al. (2002, 091004) rat drinking water study. The second example is a chemical that causes a "positive response in a study whose power, design, or conduct limits the ability to draw a confident conclusion (but does not make the study fatally flawed), but where the carcinogenic potential is strengthened by other lines of evidence (such as structure-activity relationships)." Limitations in each of the individual methanol rodent bioassays affecting EPA's ability to draw conclusions have been documented and are discussed in several sections of this assessment, including sections 4.9.2 and 5.4.3.

As is detailed elsewhere in this assessment, particularly Sections 4.9.2, 5.4.3.1 and 5.4.3.2, EPA has weighed the evidence that the Soffritti et al. (2002, 091004) study was confounded by intrinsic or inherent biological factors and concluded that the evidence is not sufficient to discount the study results. Further EPA has determined that while limitations in each of the key bioassays exist, the value of these individual studies is considerably enhanced by (1) the breadth of evidence for methanol's carcinogenic potential across more than one species, sex, strain, site, and exposure route and (2) strong evidence in rodents and humans for the carcinogenicity of formaldehyde, a methanol metabolite. In addition, the organizations responsible for two of the key rodent studies have provided additional study details beyond that which is normally available from published journal articles, including quality assurance reports

1 and individual animal data. Based on an in-depth review of this detailed information and after

2 consideration of all pertinent issues, EPA has concluded that the currently information is most

3 consistent with a determination that methanol is likely to be carcinogenic to humans.

4.9.2. Synthesis of Human, Animal, and Other Supporting Evidence

4 Evidence of the carcinogenic potential of methanol arises from drinking water studies in

5 Sprague-Dawley rats (Soffritti et al., 2002, 091004) and in Eppley Swiss Webster mice (Apaja,

6 1980, 191208), and an inhalation study in F344 rats (NEDO, 2008, 196316), with no information

7 available in humans. As is described in Section 4.2.1.3 (Table 4-2), Soffritti et al. (2002,

8 091004) reported a number of tumors in methanol-exposed Sprague-Dawley rats. EPA

9 reanalyzed the tumor findings from this study using individual animal pathology available from

10 the ERF website (see Section 5.4.1.1).[63] As indicated above, the increase in a relatively rare

11 hepatocellular carcinoma in males compared to historical controls (Fisher's exact $p < 0.05$ for all

12 doses and $p < 0.01$ for the high-dose group) is potentially related to methanol dosing. A

13 significant increase in the incidence of ear duct carcinoma was also reported by Soffritti et al.

14 (2002, 091004). However, the high incidence for this tumor in controls of the Soffritti et al.

15 (2002, 091004) study relative to other studies of Sprague-Dawley rats (Cruzan, 2009, 196354)

16 and the results of an NTP evaluation of pathology slides from another bioassay (EFSA, 2006,

17 196098; Hailey, 2004, 089842) raise questions about the ear duct pathological determinations of

18 Soffritti et al. (2002, 091004).[64]

19 As is described in Section 4.2.1.3 (Table 4-3), Apaja (1980, 191208) found an increase in

20 malignant lymphomas in mid-dose (p = 0.06) and high-dose (p < 0.05) female and mid-dose

21 (p < 0.05) male Eppley Swiss Webster mice exposed for life via drinking water. The lack of a

22 concurrent unexposed control data limit the confidence that can be placed on the relevance of the

23 increased lymphoma responses noted in this study. However, while controls were not

24 concurrent, they were from proximate (within 3 years) generations of the same mouse colony,

25 lymphomas were evaluated via the same classification criteria and, in the case of the Hinderer

26 (1979) controls, the histopathological analysis was performed by the same author (Apaja, 1980,

27 191208). In addition, this is a late developing tumor, as noted by the author, suggesting the

28 possibility of a higher tumor response in the females of all exposure groups had their survival not

---

[63] ERF provided the EPA with the detailed, individual animal data via reports available through their web portal (http://www.ramazzini.it/fondazione/foundation.asp). This allowed the EPA to combine lymphomas of similar histopathological origins and confirm the tumor incidences reported in the Soffritti et al. (2002, 091004) paper.

[64] In an NTP evaluation of pathology slides from another bioassay from this laboratory in which a similar ear duct carcinoma finding was reported (2005, 087840)(2006, 196735), NTP pathologists interpreted a majority of these ear duct responses as being hyperplastic, not carcinogenic, in nature (EFSA, 2006, 196098)(Hailey, 2004, 089842).

been significantly lower than untreated historical controls. Further, additional support for these study results comes from the fact that Soffritti et al. (2002, 091004) subsequently reported increased lymphomas in rats following similar levels of mg/kg-day methanol drinking water doses which resulted in similar estimates of internal benchmark doses associated with 10% extra risk of a lymphoma response (see dose-response analyses in Appendix E).

Chronic inhalation bioassays have been conducted in monkeys, mice, and F344 rats (NEDO, 1987, 064574; NEDO, 2008, 196315; NEDO, 2008, 196316). No exposure-related carcinogenic responses were observed in the monkey or mouse studies. As is described in Section 4.2.2.3, individual tumor responses from the rat study were not significantly increased over concurrent controls, but the response in the high-dose (1,000 ppm) group for pulmonary adenomas/adenocarcinomas in male rats was increased over concurrent controls (Fisher's exact $p < 0.05$), and the dose-response for both pulmonary adenomas/adenocarcinomas in male rats and pheochromocytomas in female rats represent increasing trends (Cochran-Armitage trend test $p < 05$). Further, the high-dose responses for both of these tumor types were elevated ($p < 0.05$) over historical control incidences within their respective sex and strain. As can be seen from Table 4-5, the severity and combined incidence of effects reported in the alveolar epithelium of male rat lungs (epithethial swelling, adenomatosis, pulmonary adenoma and pulmonary adenocarcinoma) and the adrenal glands of female rats (hyperplasia and pheochromocytoma) were increased over controls and lower exposure groups. This pathology and the appearance of a rare adenocarcinoma in the high-dose group are suggestive of a progressive effect associated with methanol exposure. The increased pheochromocytoma response in female rats is considered to be potentially treatment related because this is a historically rare tumor type for female F344 rats (Haseman et al., 1998, 094054; NTP, 1999, 196291; NTP, 2007, 196299)[65] and because, when viewed in conjunction with the increased medullary hyperplasia observed in the mid-exposure (100 ppm) group females, it is indicative of a proliferative change with increasing methanol exposure.

Additional support for the designation of methanol as a likely carcinogen is provided by the fact that methanol is metabolized to formaldehyde, which has been associated with increased incidences of lymphoma and leukemia in humans (IARC, 2004, 196244). Furthermore, lymphomas similar to those noted in Sprague-Dawley rats following exposure to methanol in drinking water and following a similar dose-response pattern were noted in a bioassay for formaldehyde in drinking water conducted by the same laboratory (Soffritti et al., 1989, 081120;

---

[65] Haseman et al. (1998, 094054) report rates for spontaneous pheochromocytomas in 2-year NTP bioassays of 5.7% (benign) and 0.3% (malignant) in male F344 rats and 0.3% (benign) and 0.1% (malignant) in female (n = 1517) F344 rats.

Soffritti et al., 2002, 196211) (Section 4.9.3). These shared endpoints suggests that the carcinogenic effects of methanol may result from its conversion to formaldehyde, though the moiety and MOA responsible for methanol-associated tumor formation have not been identified.

Significant increases in the incidence of lymphoreticular tumors have also been reported for other chemicals that convert in the body to methanol and/or formaldehyde including aspartame (Soffritti et al., 2005, 087840; Soffritti et al., 2006, 196735; Soffritti et al., 2007, 196366) and MTBE (Belpoggi et al., 1995, 075825; Belpoggi et al., 1997, 047984). In contrast, no such tumors have been reported in a similar study conducted with a structurally similar alcohol, ethanol (Soffritti et al., 2002, 091004). In addition, epidemiological studies have associated formaldehyde exposure with increases in the incidence of related lymphohematopoietic tumors. While lymphomas are a rare finding in chronic laboratory bioassays, NCI (Hauptmann et al., 2003, 093083) and NIOSH (Pinkerton et al., 2004, 093085) have reported increased lymphohematopoietic cancer risk, principally leukemia, in humans from occupational exposure to formaldehyde.[66] The similarities in tumor response across these chemicals, as well as a similar shape in the dose-response curve, supports the hypothesis that the common carcinogenic moiety for these compounds is the generation or presence of formaldehyde. The dose-response analysis discussed in Section 5 provides additional evidence supporting a role for the formaldehyde metabolite of methanol. When "total metabolites in blood" predicted by a PBPK model was used as the dose metric, model fit to the dose-response data was significantly improved.

As discussed in Sections 4.2.1.3 and 4.6.5.2, there are challenges relative to the interpretation of the observed lymphoreticular tumors because of the potential for *M. pulmonis* lung infection and the use of rats that were not specific pathogen-free (SPF) (Schoeb et al., 2009, 196192), and the protocol for the studies conducted by the ERF (Soffritti et al., 2002, 196736) is different from 2-year bioassays conducted by NTP and NEDO and cancer bioassay guidelines developed by EPA (1998, 006378) and FDA (2000, 200770). A distinct characteristic of the protocol for long-term bioassays conducted by the ERF is to maintain animals until spontaneous death, rather than sacrificing them at the end of exposure at 104 weeks. This difference in protocol may have an impact on the tumors observed compared to a 2-year bioassay (Melnick et al., 2007, 196236). The ERF methanol and ethanol studies (Soffritti et al., 2002, 091004), as well as the aspartame studies (Soffritti et al., 2006, 196735; Soffritti et al., 2007, 196366) described in Section 4.6.5.2, employed a large number of animals (100 or more per dose group) compared to a typical (e.g., NTP) cancer bioassay. In addition, the Sprague-Dawley rats used by

---

[66] IARC (2004, 196244) concluded that there was sufficient epidemiological evidence that formaldehyde causes nasopharyngeal cancer in humans but, also, that there was strong evidence for a causal association between formaldehyde and the development of leukemia in humans.

ERF appear to have increased sensitivity to certain lymphoma responses relative to F344 rats that have been typically used in NTP studies (Caldwell et al., 2008, 196182).[67] According to Soffritti et al. (2006, 196735; 2007, 196366), the overall incidence of lymphomas/leukemias in ERF studies is 13.3% (range, 4.0-25.0%) in female historical controls (2,274 rats) and 20.6% (range, 8.0-30.9%) in male historical controls (2,265 rats). This background rate is considered to be high relative to other tumor types and relative to the background rate for this tumor type in Sprague-Dawley rats from other laboratories (Cruzan, 2009, 196354; EFSA, 2006, 196098),[68] However, it is in a range that can be considered reasonable for studies that employ a large number of animals (Caldwell et al., 2009, 196183; Leakey et al., 2003, 196288). These characteristics of ERF studies (i.e., lifetime observation, large number of animals, and test strain sensitive to endpoint but with a relatively low control background rate and mortality) may give them the sensitivity needed to detect a chemically related lymphoma response.

Other aspects of ERF studies may impede their ability to reliably detect a chemically related response (EFSA, 2006, 196098; EFSA, 2009, 196103). Chronic inflammatory responses have been reported in test animals of some ERF studies (EFSA, 2006, 196098; EFSA, 2009, 196103), which may be the result of infections in test animals resulting from a bioassay design that does not employ SPF rats (Schoeb et al., 2009, 196192) and allows the rats to live out their "natural life span" in the absence of disease barriers (e.g., fully enclosed cages). In fact, the ERF has acknowledged that the primary cause of spontaneous death in their rats is respiratory infection (Caldwell et al., 2008, 196182; Ramazzini Foundation, 2006, 196158; Soffritti et al., 2006, 196735). Cruzan (2009, 196354) has suggested that respiratory infections in test animals of the Soffritti et al. (2002, 091004) methanol study were not specific to older rats, as findings of lung pathology were reported as often in rats dying prior to 18 months as in rats dying at or after 24 months.[69]

In their reviews of the recently published ERF studies on aspartame (Soffritti et al., 2006, 196735; Soffritti et al., 2007, 196366), the European Food Safety Authority (EFSA) have suggested that the increased incidence of lymphomas/leukemias reported in treated rats was related to chronic respiratory disease in the rat colony (EFSA, 2006, 196098; EFSA, 2009,

---

[67] F344 rats have a high mortality rate due to late-developing mononuclear cell leukemia, but the lymphoblastic and immunoblastic lymphomas reported in the Sprague-Dawley rat by ERF following methanol, MTBE, formaldehyde and aspartame administration are rarely diagnosed in the F344 rat (Caldwell et al., 2008, 196182).

[68] Cruzan (2009, 196354) reports that the incidences of total cancers derived from bloodforming cells, designated as hemolymphoreticular tumors by Ramazzini pathologists, is consistently about four times higher than the incidences of such tumors in SD rats recorded in the Charles River Laboratory historical database (CRL database).

[69] The infection rate did not have a significant impact on survival, however. The 2-year survival rate was 40–50% in the ERF methanol bioassay (see Appendix E, Figures E-1 and E-2), which is above the average 2-year NTP study survival rate of 41.5% for Sprague-Dawley rats (Caldwell et al., 2008, 196182).

196103), which they suggest was caused by a *Mycoplasma pulmonis* (*M. pulmonis*) infection. EFSA felt that the increased incidence of these tumors was unrelated to aspartame, given the high background incidence of chronic inflammatory changes such as bronchopneumonia in the lungs of treated and untreated rats, and the concern that such tumors might arise as a result of abundant lymphoid hyperplasia in the lungs of rats suffering from chronic respiratory disease. The scientific evidence to support the EFSA opinion that lymphomas/leukemias can result from chronic infection is limited (Caldwell et al., 2008, 196182; Schoeb et al., 2009, 196192). Epithelial hyperplasias and lymphoid accumulations are commonly found in the larynx and trachea of rats infected with *M. pulmonis*, but induction of lymphoma has not been noted (Everitt and Richter, 1990, 196113; Lindsey et al., 1985, 196292). Further, the lung, not the larynx or trachea, has been reported as the site of respiratory tract hemolymphoreticular tumors in ERF studies of MTBE (Belpoggi et al., 1995, 075825; Belpoggi et al., 1998, 086776) and methanol (Soffritti et al., 2002, 091004).[70] In their review of the molecular biology and pathogenicity of *M. pulmonis*, Razin et al. (1998, 196162) note that further study is needed before any conclusion can be reached regarding a relationship between *M. pulmonis* and neoplasia. In addition, if the increased incidence of lymphoreticular tumors in the ERF methanol study was strictly the consequence of an incipient respiratory infection in the ERF rat colony, one would expect this to be a common finding across ERF studies. However, as discussed in Section 4.6.5.2, of the 200 compounds tested by ERF, only 8, which includes methanol, have been associated with an increased incidence of hemolymphoreticular tumors. Further, the chemicals for which hemolymphoreticular tumors have been reported have chemical characteristics or physical properties in common,[71] consistent with the hypothesis that the increased response is chemical-related.

   While evidence for a causal association between respiratory infections and lymphomas is limited, there is evidence that respiratory infections may have confounded the interpretation of lung lesions in the ERF studies. Schoeb et al. (2009, 196192) state that lymphomas illustrated in two ERF studies (Figure 10 of Soffritti et al. (2005, 087840) and Figures 1-5 of Belpoggi et al. (1999, 196209)) do not demonstrate the lymphoma type, cellular morphology, and organ distribution typical of lymphoma in rats, but are consistent with "lymphocyte and plasma cell accumulation in the lung that is characteristic of *M. pulmonis* disease." They suggest that, because *M. pulmonis* disease can be exacerbated by chemical treatment, a plausible alternative explanation for the dose-related response reported in the MTBE, aspartame and methanol ERF

---

[70] ERF provided EPA with the detailed, individual animal data for the Soffritti et al. (2002, 091004) via reports available through their web portal (http://www.ramazzini.it/fondazione/foundation.asp).

[71] Methanol, formaldehyde, aspartame, and MTBE, have common metabolites (e.g., formaldehyde); DIPE, TAME, methanol, and MTBE are all gasoline-oxygenate additives.

bioassays is that the studies were confounded by *M. pulmonis* disease and that lesions of the disease were interpreted as lymphoma. However, several ERF lymphoma diagnoses in multiple rat organ systems, including the lung, have been confirmed by an independent panel of six NIEHS pathologists (Hailey, 2004, 089842). Further, 60% of the lymphoma incidences reported in the ERF methanol study involved organ systems other than the lungs (Schoeb et al., 2009, 196192). The incidence of "lung-only" lymphomas is evenly distributed across the control and dose groups of the methanol study such that removing "lung-only" lympho-immunoblastic lymphomas from consideration (i.e., using only lymphomas from other organ systems) does not significantly alter the dose-response for this lesion (see Section 5.4.3.2).

Based on the NEDO (1987, 064574) summary report, IPCS (1997, 196253) concluded that "no evidence of carcinogenicity was found in either species [F344 rats and B6C3F$_1$ mice]." This determination was made based on Fisher's exact test results which indicated that the reported high-dose pulmonary adenoma response in male rats and the high-dose pheochromocytoma response in female rats were not statistically significant. However, IPCS did not have translations of the original NEDO mouse and rat chronic studies (NEDO, 2008, 196315; NEDO, 2008, 196316), which provided additional detail for EPA's analysis and reported combined lung adenoma and adenocarcinoma results for high-dose male rats. In addition, IPCS did not consider trend test results or historical tumor data for F344 rats, both of which indicate a positive result for lung adenoma/adenocarcinoma (males) and pheochromocytomas (females) from the NEDO rat study.

4.9.3. MOA Information

As discussed in Section 4.6.5.1, the results of genotoxicity/mutagenicity studies have been largely negative, irrespective of the presence or absence of metabolic activation (an S9 microsomal fraction). Studies that investigate the MOA for methanol, particularly with respect to its developmental effects, have been discussed extensively in Sections 4.6. and 4.8. Studies such as those by Harris et al. (2003, 047369; 2004, 059082) suggest that formaldehyde is the proximate teratogen and provide evidence in support of that hypothesis. It is reasonable to hypothesize that the highly reactive molecule, formaldehyde, has a role in the carcinogenicity of methanol, given the ability of formaldehyde to bind to proteins and DNA, induce DNA-protein cross-links, and possibly participate in reactions leading to free radical formation and the formation of lipid peroxidation products. As discussed in Section 4.6.3, evidence of oxidative stress following methanol exposure has been reported in several organ systems. Studies of Wistar rats suggest that methanol exposure can cause the production of free radical formation, lipid peroxidation, and protein modifications in the liver (Skrzydlewska et al., 2005, 196205) and

brain (Rajamani et al., 2006, 196157), and adversely impact the oxidant/antioxidant balance in the brain (Dudka, 2006, 090784) and lymphoid organs (Parthasarathy et al., 2006, 089721).

As discussed in Section 4.6.5.2, ERF studies of a number of compounds that have formaldehyde as a metabolic product have been reported to cause lymphomas in Sprague-Dawley rats. As described in Section 4.6.5.2.4, the ERF has conducted a formaldehyde drinking water study (Soffritti et al., 1989, 081120) that is comparable in its design to the methanol drinking water study of Soffritti et al. (2002, 196211). The mg/kg-day doses of metabolized methanol in Sprague-Dawley rats from the ERF methanol study estimated from the PBPK model described in Section 3.4 and mg/kg-day doses of formaldehyde reported in the ERF formaldehyde study were plotted together versus the hemolymphoreticular neoplasm incidences in their respective studies (Figure 4-1).   Separate linear models were fit to the male and female rat data from these studies. The model fits shown in Figure 4-1 demonstrate that when metabolized methanol is used as the dose metric for the methanol study data, the dose-response data from these two studies can be adequately fit by two separate linear dose-response functions for the combined male ($R^2 = 0.6832$) and combined female ($R^2 = 0.7592$) responses. Even if it is true that formaldehyde is the common moiety responsible for these tumors, one would not expect this approach to result in perfect dose-response alignment because the metabolized methanol estimate is not an accurate representation of formaldehyde distribution, and formaldehyde from methanol administration would not be expected to distribute the same as orally administered formaldehyde. However, the similarities in the dose-response data for male and female rats from these studies are consistent with the hypothesis that formaldehyde is key to methanol's carcinogenic MOA.

Figure 4-1. Hemolymphoreticular neoplasms in male and female Sprague-Dawley rats in formaldehyde and methanol drinking water studies versus mg formaldehyde/kg/day or mg metabolized methanol/kg/day (predicted by EPA PBPK model).

Source: Soffritti et al. (2002, 196211).

1   As discussed above, methanol is metabolized to formaldehyde, which has been associated

2 with increased incidences of lymphoma and leukemia in humans by both the oral and inhalation

3 routes (IARC, 2004, 196244), and there are readily apparent similarities between the dose-

4 response data from oral studies of rats exposed to formaldehyde and methanol. In addition, the

5 dose-response model fit for the lymphoma response observed in the Soffritti et al. (2002,

6 091004) study is improved when predicted total metabolites is used as the dose-metric (Section

7 5.4.1.2). However, the database of information available concerning methanol's carcinogenic

8 MOA is limited, and the extent to which the parent or a metabolite such as formaldehyde is

9 responsible for the carcinogenic effects observed in the studies conducted by Soffritti et al.

10 (2002, 091004) or NEDO (1987, 064574; 2008, 196316) is not clear.

4.10. SUSCEPTIBLE POPULATIONS AND LIFE STAGES

4.10.1. Possible Childhood Susceptibility

Studies in animals have identified the fetus as being more sensitive than adults to the toxic effects of methanol; the greatest susceptibility occurs during gastrulation and early organogenesis (CERHR, 2004, 091201). Table 4-21 summarizes some of the data regarding the relative ontogeny of CAT, ADH1, and ADH3 in humans and mice. Human fetuses have limited ability to metabolize methanol as ADH1 activity in 2-month-old and 4-5 month-old fetuses is 3-4% and 10% of adult activity, respectively (Pikkarainen and Raiha, 1967, 056315). ADH1 activity in 9-22 week old fetal livers was found to be 30% of adult activity (Smith et al., 1971, 053549). Likewise, ADH1 activity is ~20-50% of adult activity during infancy (Pikkarainen and Raiha, 1967, 056315; Smith et al., 1971, 053549). Activity continues to increase until reaching adult levels at 5 years of age (Pikkarainen and Raiha, 1967, 056315). However, no difference between blood methanol levels in 1-year-old infants and adults was observed following ingesting the same doses of aspartame, which releases 10% methanol by weight during metabolism (Stegink et al., 1983, 056316). Given that the exposure was aspartame as opposed to methanol, it is difficult to draw any conclusions from this study vis-à-vis ontogeny data and potential influences of age differences in aspartame disposition. With regard to inhalation exposure, increased breathing rates relative to adults may result in higher blood methanol levels in children compared to adults (CERHR, 2004, 091201). It is also possible that metabolic variations resulting in increased methanol blood levels in pregnant women could increase the fetus' risk from exposure to methanol. In all, unresolved issues regarding the identification of the toxic moiety increase the uncertainty with regards to the extent and pathologic basis for early life susceptibility to methanol exposure.

The prevalence of folic acid deficiency has decreased since the United States and Canada introduced a mandatory folic acid food fortification program in November 1998. However, folate deficiency is still a concern among pregnant and lactating women, and factors such as smoking, a poor quality diet, alcohol intake, and folic antagonist medications can enhance deficiency (CERHR, 2004, 091201). Folate deficiency could affect a pregnant woman's ability to clear formate, which has also been demonstrated to produce developmental toxicity in rodent in in vitro studies at high-doses (Dorman et al., 1995, 078081). It is not known if folate-deficient humans have higher levels of blood formate than individuals with adequate folate levels. A limited study in folate-deficient monkeys demonstrated no formate accumulation following an endotracheal exposure of anesthetized monkeys to 900 ppm methanol for 2 hours (Dorman et al., 1994, 196743). The situation is obscured by the fact that folic acid deficiency during pregnancy

1 by itself is thought to contribute to the development of severe congenital malformations (Pitkin,

2 2007, 196150).

4.10.2. Possible Gender Differences

3 There is limited information on potential differences in susceptibility to the toxic effects

4 of methanol according to gender. However, one study reported a higher background blood

5 methanol level in human females versus males (Batterman and Franzblau, 1997, 056331). In

6 rodents, fetuses exposed in utero were found to be the most sensitive subpopulation. One study

7 suggested a possible increased sensitivity of male versus female rat fetuses and pups. When rats

8 were exposed to methanol pre- and postnatally, 6- and 8-week-old male progeny had

9 significantly lower brain weights at 1,000 ppm, compared to those in females that demonstrated

10 the same effect only at 2,000 ppm (NEDO, 1987, 064574). In general, there is little evidence for

11 substantial disparity in the level or degree of toxic response to methanol in male versus female

12 experimental animals or humans. However, it is possible that the compound-related deficits in

13 fetal brain weight that were evident in the pups of F_1 generation Sprague-Dawley rats exposed to

14 methanol in the NEDO (1987, 064574) study may reflect a threshold neurotoxicological

15 response to methanol. It is currently unknown whether higher levels of exposure would result in

16 brain sequelae comparable to those observed in acutely exposed humans.

4.10.3. Genetic Susceptibility

17 Polymorphisms in enzymes involved in methanol metabolism may affect the sensitivity

18 of some individuals to methanol. For example, as discussed in Chapter 3, data summarized in

19 reviews by Agarwal (2001, 056332), Burnell et al. (1989, 088308), Bosron and Li (1986,

20 056330), and Pietruszko (1980, 056337) discuss genetic polymorphisms for ADH. Class I ADH,

21 the primary ADH in human liver, is a dimer composed of randomly associated polypeptide units

22 encoded by three genetic loci (ADH1A, ADH1B, and ADH1C). Polymorphisms are observed at

23 the ADH1B (ADH1B*2, ADH1B*3) and ADH1C (ADH1C*2) loci. The ADH1B*2 phenotype

24 is estimated to occur in ~15% of Caucasians of European descent, 85% of Asians, and less that

25 5% of African Americans. Fifteen percent of African Americans have the ADH1B*3 phenotype,

26 while it is found in less than 5% of Caucasian Europeans and Asians. The only reported

27 polymorphisms in ADH3 occur in the promoter region, one of which reduces the transcriptional

28 activity in vitro nearly twofold (Hedberg et al., 2001, 196206). While polymorphisms in ADH3

29 are described in more than one report (Cichoz-Lach et al., 2007, 196229; Hedberg et al., 2001,

30 196206), the functional consequence(s) for these polymorphisms remains unclear.

5. DOSE-RESPONSE ASSESSMENTS AND CHARACTERIZATION

5.1. INHALATION REFERENCE CONCENTRATION (RfC)[72]

1   In general, the RfC is an estimate of a daily exposure of the human population (including
2 susceptible subgroups) that is likely to be without an appreciable risk of adverse health effects
3 over a lifetime. It is derived from a POD, generally the statistical lower confidence limit on the
4 BMCL or BMDL, with uncertainty/variability factors applied to reflect limitations of the data
5 used. The inhalation RfC considers toxic effects for both the respiratory system (portal-of-entry)
6 effects and systems peripheral to the respiratory system (extra-respiratory or systemic effects). It
7 is generally expressed in mg/m^3. EPA performed an IRIS assessment of methanol in 1991 and
8 determined that the database was inadequate for derivation of an RfC. While some limitations
9 still exist in the database (see Sections 5.1.3.2 and 5.3), the experimental toxicity database has
10 expanded and newer methods and models have been developed to analyze the results. In this
11 update, the PBPK model, described in Section 3.4, was developed by EPA and is used to estimate
12 HECs and HEDs from inhalation study data for the derivation of both the RfC and RfD. In both
13 cases, the use of a PBPK model replaces part of the UF adjustments traditionally used for
14 species-to-species extrapolation.

15   Additionally, this assessment uses the BMD method in its derivation of the POD.[73] The
16 suitability of these methods to derive a POD is dependent on the nature of the toxicity database
17 for a specific chemical. Details of the BMD analyses are found in Appendix C. The use of the
18 BMD approach for determining the POD improves the assessment by including consideration of
19 shape of the dose-response curve, independence from experimental doses, and estimation of the
20 uncertainty pertaining to the calculated dose response. However, the methanol database still has
21 limitations and uncertainties associated with it, in particular, those uncertainties associated with
22 human variability, animal-to-human differences, and limitations in the database influence
23 derivation of the RfC.

---

[72] The RfC discussion precedes the RfD discussion in this assessment because the inhalation database ultimately serves as the basis for the RfD. The RfD development would be difficult to follow without prior discussion of inhalation database and PK models used for the route-to-route extrapolation.

[73] Use of BMD methods involves fitting mathematical models to dose-response data and using the results to select a POD that is associated with a predetermined benchmark response (BMR), such as a 10% increase in the incidence of a particular lesion or a 10% decrease in body weight gain (see Section 5.1.2.2).

5.1.1. Choice of Principal Study and Critical Effect(s)

5.1.1.1. *Key Inhalation Studies*

1   While a substantial body of information exists on the toxicological consequences to
2   humans exposed to large amounts of methanol, no human studies exist that would allow for
3   quantification of subchronic, chronic, or in utero effects of methanol exposure. Table 4-35
4   summarizes available experimental animal inhalation studies of methanol. Several of these
5   studies, including the monkey chronic (NEDO, 1987, 064574) and developmental (Burbacher et
6   al., 1999, 009752; Burbacher et al., 1999, 009753; Burbacher et al., 2004, 059070; Burbacher et
7   al., 2004, 056018) studies, the male rat reproductive studies (Cameron et al., 1984, 064567;
8   Cameron et al., 1985, 064568; Lee et al., 1991, 032419), and the 4-week rat studies (Poon et al.,
9   1994, 074789), are lacking in key attributes (e.g., documented dose response, documented
10   controls, and duration of exposure) necessary for their direct use in the quantification of a
11   chronic RfC. These studies will be considered in this chapter for their contributions to the
12   overall RfC uncertainty. Several inhalation reproductive or developmental studies were
13   adequately documented and are of appropriate size and design for quantification and derivation
14   of an RfC. These studies are considered for use in the derivation of an RfC and are summarized
15   below.

5.1.1.2. *Selection of Critical Effect(s)*

16   Developmental effects have been assessed in a number of toxicological studies of
17   monkeys, rats, and mice. The findings of Rogers and Mole (1997, 009755) indicate that
18   methanol is toxic to mouse embryos in the early stages of organogenesis, on or around GD7. In
19   the study of Rogers et al. (1993, 032696), in which pregnant female CD-1 mice were exposed to
20   methanol vapors (1,000, 2,000, and 5,000 ppm) on GD6-GD15, reproductive and fetal effects
21   included an increase in the number of resorbed litters, a reduction in the number of live pups,
22   and increased incidences of exencephaly, cleft palate, and the number of cervical ribs. They
23   reported a NOAEL for cervical rib malformations at 1,000 ppm (1,310 mg/m^3) and a LOAEL of
24   2,000 ppm (2,620 mg/m^3, 49.6% per litter versus 28.0% per litter in the control group).
25   Increased incidence of cervical ribs was also observed in the rat organogenesis study (NEDO,
26   1987, 064574) in the 5,000 ppm dose group (65.2% per litter versus 0% in the control group),
27   indicating that the endpoint is significant across species.
28   The biological significance of the cervical rib endpoint within the regulatory arena has
29   been the subject of much debate (Chernoff and Rogers, 2004, 069993). Previous studies have
30   classified this endpoint as either a malformation (birth defect of major importance) or a variation
31   (morphological alternation of minor significance). There is evidence that incidence of

supernumerary ribs (including cervical ribs) is not just the addition of extraneous, single ribs but rather is related to a general alteration in the development and architecture of the axial skeleton as a whole. In CD-1 mice exposed during gestation to various types of stress, food and water deprivation, and the herbicide dinoseb, supernumerary ribs were consistently associated with increases in length of the 13th rib (Branch et al., 1996, 196166). This relationship was present in all fetal ages examined in the study. The authors concluded that these findings are consistent with supernumerary ribs being one manifestation of a basic alteration in the differentiation of the thoraco-lumbar border of the axial skeleton. The biological significance of this endpoint is further strengthened by the association of supernumerary ribs with adverse health effects in humans. The most common effect produced by the presence of cervical ribs is thoracic outlet disease (Fernandez et al., 1996, 196121; Henderson, 1914, 196216; Nguyen et al., 1997, 196258). Thoracic outlet disease is characterized by numbness and/or pain in the shoulder, arm, or hands. Vascular effects associated with this syndrome include cerebral and distal embolism (Bearn et al., 1993, 196194; Connell et al., 1980, 196342; Short, 1975, 196198), while neurological symptoms include extreme pain, migraine, and symptoms similar to Parkinson's (Evans, 1999, 196110; Fernandez et al., 1996, 196121; Saxton et al., 1999, 196189). Schumacher et al. (1992, 196196) observed 242 rib anomalies in 218 children with tumors (21.8%) and 11 (5.5%) in children without malignancy, a statistically significant ($p < 0.001$) difference that indicates a strong association between the presence of cervical ribs and childhood cancers. Specific cancers associated with statistically significant increases in anomalous ribs included leukemia, brain, tumor, neuroblastoma, soft tissue sarcoma, and Wilm's tumor.

A number of rat studies have confirmed the toxicity of methanol to embryos during organogenesis (NEDO, 1987, 064574; Nelson et al., 1985, 064573; Weiss et al., 1996, 079211). NEDO (1987, 064574) reported reduced brain, pituitary, and thymus weights in F_1 and F_2 generation Sprague-Dawley rats at 1,000 ppm methanol. In a follow-up study of the F_1 generation brain weight effects, NEDO (1987, 064574) reported decreased brain, cerebellum, and cerebrum weights in F_1 males exposed at 1,000 ppm methanol from GD0 through the F_1 generation. The exposure levels used in these studies are difficult to interpret because dams were exposed prior to gestation, and dams and pups were exposed during gestation and lactation. However, it is clear that postnatal exposure increases the severity of brain weight reduction. In another experiment in which NEDO (1987, 064574) exposed rats only during organogenesis (GD7-GD17), the observed decreases in brain weights in offspring at 8 weeks of age were less severe than in the studies for which exposure was continued postnatally. This finding is not unexpected, given that the brain undergoes tremendous growth beginning early in gestation and continuing in the postnatal period. Rats are considered altricial (i.e., born at relatively

underdeveloped stages), and many of their neurogenic events occur postnatally (Clancy et al., 2007, 196224). Brain effects from postnatal exposure are also relevant to humans given that, in humans, gross measures of brain growth increase for at least 2-3 years after birth, with the growth rate peaking approximately 4 months after birth (Rice and Barone, 2000, 020837).

A change in brain weight is considered to be a biologically significant effect (U.S. EPA, 1998, 030021). This is true regardless of changes in body weight because brain weight is generally protected during malnutrition or weight loss, unlike many other organs or tissues (U.S. EPA, 1998, 030021). Thus, change in absolute brain weight is an appropriate measure of effects on this critical organ system. Decreases in brain weight have been associated with simultaneous deficits in neurobehavioral and cognitive parameters in animals exposed during gestation to various solvents, including toluene and ethanol (Coleman et al., 1999, 196341; Gibson et al., 2000, 196133; Hass et al., 1995, 196199). NEDO (1987, 064574) reports that brain, cerebellum, and cerebrum weights decrease in a dose-dependant manner in male rats exposed to methanol throughout gestation and the F_1 generation.

Developmental neurobehavioral effects associated with methanol inhalation exposure have been investigated in monkeys. Burbacher et al. (1999, 009752; 1999, 009753; 2004, 059070; 2004, 056018) exposed *M. fascicularis* monkeys to 0, 262, 786, and 2,359 mg/m^3 methanol, 2.5 hours/day, 7 days/week during premating/mating and throughout gestation (approximately 168 days). In these studies, exposure of monkeys to up to 1,800 ppm (2,359 mg/m^3) methanol during premating, mating, and throughout gestation resulted in no changes in reproductive parameters other than a shorter period of gestation in all exposure groups that did not appear to be dose related. The shortened gestation period was largely the result of C-sections performed in the methanol exposure groups "in response to signs of possible difficulty in the maintenance of pregnancy," including vaginal bleeding. As discussed in Section 4.7.1.2, though statistically significant, the shortened gestation finding may be of limited biological significance given questions concerning its relation to the methanol exposure. Developmental parameters, such as fetal crown-rump length and head circumference, were unaffected, but there appeared to be neurotoxicological deficits in methanol-exposed pups. VDR was significantly reduced in the 786 mg/m^3 group for males and the 2,359 mg/m^3 group for both sexes. However, a dose-response trend for this endpoint was only exhibited for females. In fact, this is the only effect reported in the Burbacher et al. (1999, 009752; 1999, 009753; 2004, 059070; 2004, 056018) studies for which a significant dose-response trend is evident. As discussed in Section 4.4.2, confidence may have been increased by statistical analyses to adjust for multiple testing (CERHR, 2004, 091201). Yet it is worth noting that the dose-response trend for VDR in females remained significant with ($p = 0.009$) and without ($p = 0.0265$) an adjustment for the shortened

1 gestational periods, and it is a measure of functional deficits in sensorimotor development that is
2 consistent with early developmental CNS effects (brain weight changes discussed above) that
3 have been observed in rats.

4   Another test, the Fagan test of infant intelligence, indicated small but not significant
5 deficits of performance (time spent looking at novel faces versus familiar faces) in treated
6 monkeys. Although not statistically significant and not quantifiable, the results of this test are
7 also important when considered in conjunction with the brain weight changes noted in the
8 NEDO (1987, 064574) rat study. As discussed in Section 4.7.1.2, the monkey data are not
9 conclusive, and there is insufficient evidence to determine if the primate fetus is more or less
10 sensitive than rodents to methanol teratogenesis. Taken together, however, the NEDO (1987,
11 064574) rat study and the Burbacher et al. (1999, 009752; 1999, 009753; 2004, 059070; 2004,
12 056018) monkey study suggest that prenatal exposure to methanol can result in adverse effects
13 on developmental neurology pathology and function, which can be exacerbated by continued
14 postnatal exposure.

15   A number of studies described in Section 4.3.2 and summarized in Section 4.7.1.2 have
16 examined the potential toxicity of methanol to the male reproductive system (Cameron et al.,
17 1984, 064567; Cameron et al., 1985, 064568; Lee et al., 1991, 032419). Some of the observed
18 effects, including a transient decrease in testosterone levels, could be the result of chemically
19 related strain on the rat system as it attempts to maintain hormone homeostasis. However, the
20 data are insufficient to definitively characterize methanol as a toxicant to the male reproductive
21 system.

22   The studies considered for use in the derivation of an RfC are summarized in Table 5-1.
23 As discussed in Sections 5.1.3.1 and 5.3, there is uncertainty associated with the selection of an
24 effect endpoint from the methanol database for use in the derivation of an RfC. Taking into
25 account the limitations of the studies available for quantification purposes, decreased brain
26 weight at 6 weeks in male Sprague-Dawley rats exposed throughout gestation and the postnatal
27 period (NEDO, 1987, 064574) was chosen as the critical effect for the purposes of this dose-
28 response assessment as it can be reliably quantified and represents both a sensitive organ system
29 and a key period of development. RfC derivations utilizing alternative endpoints (e.g., cervical
30 rib effects in mice and delayed sensorimotor development in monkeys) and alternative methods
31 (e.g., use of different BMRs) are summarized in Appendix C and in Section 5.1.3.1.

Table 5-1. Summary of studies considered most appropriate for use in derivation of an RfC

REFERENCE	Species (strain)	Sex	Number/ dose group	Exposure Duration	Critical Effect	NOAEL (ppm)	LOAEL (ppm)
NEDO (1987, 064574) Two-generation study	Rat Sprague-Dawley	M,F	Not specified - F_1 and F_2 generation	F_1-Birth to end of mating (M) or weaning (F); F_2-birth to 8 wk	Reduced weight of brain, pituitary, and thymus at 8, 16, and 24 wk postnatal in F_1 and at 8 wk in F_2	100	1,000
NEDO (1987, 064574) Follow-up study of F_1 generation			10-14/ sex/ group- F_1 generation	GD0 through F_1 generation	Reduced brain weight at 3 wk and 6 wk (males only). Reduced brain and cerebrum weight at 8 wk (males only)	500	1,000
NEDO (1987, 064574) Teratology study	Rat Sprague-Dawley	M,F	10-12/sex/ group	GD7-GD17	Reduced brain, pituitary, thyroid, thymus, and testis weights at 8 wk postnatal.	1,000	5,000
Nelson et al. (1985, 064573)	Rat Sprague-Dawley	F	15 pregnant dams/group	GD1-GD19 or GD7-GD15	Reduced fetal body weight, increased incidence of visceral and skeletal abnormalities, including rudimentary and extra cervical ribs	5,000	10,000
Rogers et al. (1993, 032696)	Mouse CD-1	F	30-114 pregnant dams/ group	GD6-GD15	Increased incidence of extra cervical ribs, cleft palate, exencephaly; reduced fetal weight and pup survival, delayed ossification	1,000	2,000
Burbacher et al. (1999, 009752; 1999, 009753; 2004, 059070; 2004, 056018)	*M. fascicularis*		12 pregnant monkeys/group	2.5 hr/day, 7 days/wk, during premating, mating and gestation	Shortened period of gestation; may be related to exposure (no dose response), neurotox. deficits including reduced performance in the VDR test	-	-[b]

[a]Animals were dosed 20-21 hr/day. NS = Not Specified
[b]Gestational exposure resulted in a shorter period of gestation in dams exposed to as low as 200 ppm (263 mg/m³). However, because of uncertainties associated with these results, including clinical intervention and the lack of a dose-response, EPA was not able to identify a definitive NOAEL or LOAEL from this study.

5.1.2. Methods of Analysis for the POD—Application of PBPK and BMD Models

Potential PODs for the RfC derivation, described here and in Appendix C, have been calculated via the use of monkey, rat and mouse PBPK models, described in Section 3.4. First, the doses used in an experimental bioassay were converted to an internal dose metric that is most appropriate for the endpoint being assessed. The PBPK models are capable of calculating several measures of dose for methanol, including the following:

- Cmax – The peak concentration of methanol in the blood during the exposure period;
- AUC – Area under the curve, which represents the cumulative product of concentration and time for methanol in the blood; and
- Total metabolism – The production of metabolites of methanol, namely formaldehyde and formate.

As described in Section 3.4.3.2, the focus of model development is on obtaining accurate predictions of increased body burdens over endogenous background levels of methanol and its metabolites. The PBPK models do not describe or account for background levels of methanol, formaldehyde or formate.

Although there remains uncertainty surrounding the identification of the proximate teratogen of importance (methanol, formaldehyde, or formate), the dose metric chosen for derivation of an RfC was based on blood methanol levels. This decision was primarily based on evidence that the toxic moiety is not likely to be the formate metabolite of methanol (CERHR, 2004, 091201) and evidence that levels of the formaldehyde metabolite following methanol maternal and/or neonate exposure would be much lower in the fetus and neonate than in adults. While recent in vitro evidence indicates that formaldehyde is more embryotoxic than methanol and formate, the high reactivity of formaldehyde would limit its unbound and unaltered transport as free formaldehyde from maternal to fetal blood (Thrasher and Kilburn, 2001, 196728), and the capacity for the metabolism of methanol to formaldehyde is likely lower in the fetus and neonate versus adults (see discussion in Section 3.3). Thus, even if formaldehyde is identified as the proximate teratogen, methanol would likely play a prominent role, at least in terms of transport to the target tissue. Further discussions of methanol metabolism, dose metric selection, and MOA issues are covered in Sections 3.3, 4.6, 4.8 and 4.9.2.

A BMDL was then derived in terms of the internal dose metric utilized. Finally, the BMDL values were converted to HECs via the use of a PBPK model parameterized for humans. The next section describes the rationale for and application of the benchmark modeling methodology for the RfC derivation.

5.1.2.1. *Application of the BMD/BMDL Approach*

1   Several developments over the past few years impact the derivation of the RfC: (1) EPA
2   has developed draft BMD assessment methods (U.S. EPA, 1995, 005992; U.S. EPA, 2000,
3   052150) and supporting software (Appendix C) to improve upon the previous NOAEL/LOAEL
4   approach; (2) MOA studies have been carried out that can give more insight into methanol
5   toxicity; and (3) EPA has refined PBPK models for methanol on the basis of the work of Ward
6   et al. (1997, 083652) (see Section 3.4. for description of the EPA model). The EPA PBPK model
7   provides estimates of HECs from rodent exposures that are supported by pharmacokinetic
8   information available for rodents and humans. The following sections describe how the
9   BMD/BMDL approach, along with the EPA PBPK model, is used to obtain a POD for use in the
10 derivation of an RfC for methanol in accordance with current draft BMD technical guidance
11 (U.S. EPA, 2000, 052150).

12 The BMD approach attempts to fit models to the dose-response data for a given endpoint.
13   It has the advantage of taking more of the dose-response data into account when determining the
14 POD, as well as estimating the dose for which an effect may have a specific probability of
15 occurring. The BMD approach also accounts, in part, for the quality of the study (e.g., study
16 size) by estimating a BMDL, the 95% lower bound confidence limit on the BMD. The BMDL is
17 closer to the BMD (higher) for large studies and further away from the BMD (lower) for small
18 studies. Because the BMDL approach will account, in part, for a study's power, dose spacing,
19 and the steepness of the dose-response curve, it is generally preferred over the NOAEL
20 approach.

21 When possible, all experimental data points are included in this assessment to ensure
22 adequate fit of a BMD model and derivation of a BMDL. A summary of the POD values
23 determined by BMD analysis for the critical endpoint (as well as other considered endpoints)
24 (see Appendix C for modeling results), application of UFs, and conversion to HECs using the
25 BMD and PBPK approach, is included in Section 5.1.3.1.

Use of the BMD approach has uncertainty associated with it. An element of the BMD approach is the use of several models to determine which best fits the data.[74] In the absence of an established MOA or a theoretical basis for why one model should be used over another, model selection is based on best fit to the experimental data selection. Model fit was determined by statistics (AIC and χ^2 residuals of individual dose groups) and visual inspection recommended by EPA (U.S. EPA, 2000, 052150).[75]

The PBPK model developed by EPA for methanol (described in Section 3.4) was applied for the estimation of methanol blood levels in the exposed dams (NEDO, 1987, 064574). When using PBPK models, it is very important to determine what estimate of internal dose (i.e., dose metric) can serve as the most appropriate dose metric for the health effects under consideration.

The results of NEDO (1987, 064574), described in Section 4.4.2 and shown in Table 4-14, indicate that there is not an obvious cumulative effect of ongoing exposure on brain-weight decrements in rats exposed postnatally; i.e., the dose response in terms of percent of control is about the same at 3 weeks postnatal as at 8 weeks postnatal in rats exposed throughout gestation and the F_1 generation. However, there does appear to be a greater brain-weight effect in rats exposed postnatally versus rats exposed only during organogenesis (GD7-GD17). In male rats exposed during organogenesis only, there is no statistically significant decrease in brain weight at 8 weeks after birth at the 1,000 ppm exposure level. Conversely, in male rats exposed to the same level of methanol throughout gestation and the F_1 generation, there was an approximately 5% decrease in brain weights (statistically significant at the $p < 0.01$ level). The fact that male rats exposed to 5,000 ppm methanol only during organogenesis experienced a decrease in brain weight of 10% at 8 weeks postnatal indicates that postnatal exposure is not necessary for the observation of persistent postnatal effects. However, the fact that this decrease was less than the 13% decrease observed in male rats exposed to 2,000 ppm methanol throughout gestation and the 8 week postnatal period indicates that both exposure concentration and duration are important components of the ability of methanol to cause this effect. The extent to which the observation of the increased effect is due to a cumulative effect in rats exposed postnatally versus recovery in rats for which exposure was discontinued at birth is not clear.

---

[74]USEPA's BMDS 2.1.1 (U.S. EPA, 2009, 200772) was used for this assessment as it provides data management tools for running multiple models on the same dose-response data set. At this time, BMDS offers over 30 different models that are appropriate for the analysis of dichotomous, continuous, nested dichotomous and time-dependent toxicological data. Results from all models include a reiteration of the model formula and model run options chosen by the user, goodness-of-fit information, the BMD, and the estimate of the lower-bound confidence limit on the BMD (BMDL).

[75]Akaike's Information Criterion (AIC) (Akaike, 1973, 000591) is used for model selection and is defined as -2L + 2P where L is the log-likelihood at the maximum likelihood estimates for the parameters and P is the number of model degrees of freedom.

1   The fact that brain weight is susceptible to both the level and duration of exposure
2 suggests that a dose metric that incorporates a time component would be the most appropriate
3 metric to use. For these reasons, and because it is more typically used in internal-dose-based
4 assessments and better reflects total exposure within a given day, daily AUC (measured for
5 22 hours exposure/day) was chosen as the most appropriate dose metric for modeling the effects
6 of methanol exposure on brain weights in rats exposed throughout gestation and continuing into
7 the F_1 generation.

8   Application of the EPA methanol PBPK model (described in Section 3.4) to the NEDO
9 (1987, 064574) study, in which developing rats were exposed during gestation and the postnatal
10 period, presents complications that need to be discussed. The neonatal rats in this study were
11 exposed to methanol gestationally before parturition as well as lactationally and inhalationally
12 after parturition. The PBPK model developed by EPA only estimates internal dose metrics for
13 methanol exposure in NP adult mice and rats. Experimental data indicate that inhalation-route
14 blood methanol kinetics in NP mice and pregnant mice on GD6-GD10 are similar (Dorman et al.,
15 1995, 078081; Perkins et al., 1995, 078067; Rogers et al., 1993, 032696; Rogers et al., 1993,
16 032697). In addition, experimental data indicate that the maternal blood:fetal partition
17 coefficient for mice is approximately 1 (see Sections 3.4.1.2 and 3.4.4). Assuming that these
18 findings apply for rats, the data indicate that PBPK estimates of PK and blood dose metrics for
19 NP rats are better predictors of fetal exposure during gestation than would be obtained from
20 default extrapolations from external exposure concentrations. However, as is discussed to a
21 greater extent in Section 5.3, the additional routes of exposure presented to the pups in this study
22 (lactation and inhalation) present uncertainties that suggest the average blood levels in pups in
23 the NEDO (1987, 064574) report might be greater than those of the dam. The assumption made
24 in this assessment is that, if such differences exist between human mothers and their offspring,
25 they are not expected to be significantly greater than that which has been postulated for rats.
26 Thus, the PBPK model-estimated adult blood methanol level is considered to be an appropriate
27 dose metric for the purpose of this analysis and HEC derivation.

5.1.2.2. *BMD Approach Applied to Brain Weight Data in Rats*

28   The NEDO (1987, 064574) study reported decreases in brain weights in developing rats
29 exposed during gestation only (GD7-GD17) or during gestation and the postnatal period, up to
30 8 weeks (see Section 4.4.2). Because of the biological significance of decreases in brain weight
31 as an endpoint in the developing rat and because this endpoint was not evaluated in other peer-
32 reviewed studies, BMD analysis was performed using these data. For the purposes of deriving
33 an RfC for methanol from developmental endpoints using the BMD method and rat data,
34 decreases in brain weight at 6 weeks of age in the more sensitive gender, males, exposed

1 throughout gestation and continuing into the F_1 generation (both through lactation and inhalation

2 routes) were utilized. Decreases in brain weight at 6 weeks (gestational and postnatal exposure),

3 rather than those seen at 3 and 8 weeks, were chosen as the basis for the RfC derivation because

4 they resulted in lower estimated BMDs and BMDLs. Decreased brain weights in male rats at 8

5 weeks age after gestation-only exposure were not utilized because they were less severe at the

6 same dose level (1,000 ppm) compared to gestation and postnatal exposure.

7   The first step in the current BMD analysis is to convert the inhalation doses, given

8 as ppm values from the studies, to an internal dose metric using the EPA PBPK model (see

9 Section 3.4). For decreased brain weight in male rats, AUC of methanol in blood (hr × mg/L) is

10 chosen as the appropriate internal dose metric for the reasons discussed in Section 5.1.2.1.

11 Predicted AUC values for methanol in the blood of rats are summarized in Table 5-2. These

12 AUC values are then used as the dose metric for the BMD analysis of response data shown in

13 Table 5-2 for decreased brain weight at 6 weeks in male rats following gestational and postnatal

14 exposure.[76] The full details of this analysis are reported in Appendix C. More details

15 concerning the PBPK modeling were presented in Section 3.4.

16

**Table 5-2. The EPA PBPK model estimates of methanol blood levels (AUC)[a]
in rat dams following inhalation exposures and reported brain weights of 6
week old male pups.**

Exposure level (ppm)	Methanol in blood AUC (hr × mg/L)[A] in Rats	Mean male rat (F_1 generation) brain weight at 6 weeks[B]
0	0	1.78 ± 0.07
500	79.1	1.74 ± 0.09
1,000	226.5	1.69 ± 0.06[c]
2,000	966.0	1.52 ± 0.07[d]

[a]AUC values were obtained by simulating 22 hr/day exposures for 5 days and calculated for the last 24 hours of that period.
[b]Exposed throughout gestation and F_1 generation. Values are means ± S.D.
[c]$p < 0.01$, [d]$p < 0.001$, as calculated by the authors.

Source: NEDO (1987, 064574).

17   The current draft BMD technical guidance (U.S. EPA, 2000, 052150) suggests that, in the

18 absence of knowledge as to what level of response to consider adverse, a change in the mean

19 equal to one S.D. from the control mean can be used as a BMR for continuous endpoints.

---

[76]All BMD assessments in this review were performed using BMDS version 2.1.1 (U.S. EPA, 2009, 200772).

1   However, it has been suggested that other BMRs, such as 5% change relative to estimated

2   control mean, are also appropriate when performing BMD analyses on fetal weight change as a

3   developmental endpoint (Kavlock et al., 1995, 075837). Therefore, both a one S.D. change from

4   the control mean and a 5% change relative to estimated control mean were considered (see

5   Appendix C for RfC derivations using alternative BMRs). For this endpoint, a one S.D. change

6   from the control mean returned the lowest BMDL estimates and was considered the most

7   suitable BMR for use in the RfC derivation. All models were fit using restrictions and option

8   settings suggested in the draft EPA BMD Technical Guidance Document (U.S. EPA, 2000,

9   052150).

10   A summary of the results most relevant to the development of a POD using the BMD

11   approach (BMD, BMDL, and model fit statistics) for decreased brain weight at 6 weeks in male

12   rats exposed to methanol throughout gestation and continuing into the F_1 generation is provided

13   in Table 5-3. BMDL values in Table 5-3 represent the 95% lower-bound confidence limit on the

14   AUC estimated to result in a mean that is one S.D. from the control mean. There is a 2.5-fold

15   range of BMDL estimates from adequately fitting models, indicating considerable model

16   dependence. In addition, the fit of the Hill and more complex Exponential models is better than

17   the other models in the dose region of interest as indicated by a lower scaled residual at the dose

18   group closest to the BMD (0.09 versus -0.67 or -0.77) and visual inspection. In accordance with

19   draft EPA BMD Technical Guidance (2000, 052150), the BMDL from the Hill model (bolded), is

20   selected as the most appropriate basis for an RfC derivation because it results in the lowest

21   BMDL from among a broad range of BMDLs and provides a superior fit in the low dose region

22   nearest the BMD. The Hill model dose-response curve for decreased brain weight in male rats is

23   presented in Figure 5-1, with response plotted against the chosen internal dose metric of AUC of

24   methanol in rats. The $BMDL_{1SD}$ was determined to be 90.9 hr × mg/L using the 95% lower

25   confidence limit of the dose-response curve expressed in terms of the AUC for methanol in

26   blood.

Table 5-3. Comparison of benchmark dose modeling results for decreased brain weight in male rats at 6 weeks of age using modeled AUC of methanol as a dose metric

Model	BMD$_{1SD}$ (AUC, hr × mg/L) [A]	BMDL$_{1SD}$ (AUC, hr × mg/L) [A]	*p*-value	AIC[C]	Scaled residual[D]
Linear	277.75	224.85	0.5387	-203.84	-0.77
2nd degree polynomial	277.75	224.85	0.5387	-203.84	-0.77
3rd degree polynomial	277.75	224.85	0.5387	-203.84	-0.77
Power	277.75	224.85	0.5387	-203.84	-0.77
Hill[b]	**170.43**	**90.86**	**0.836**	**-203.04**	**0.09**
Exponential 2	260.42	208.68	0.613	-204.10	-0.67
Exponential 3	260.42	208.68	0.613	-204.10	-0.67
Exponential 4	171.95	96.85	0.82	-203.03	0.09
Exponential 5	171.95	96.85	0.82	-203.03	0.09

[a]The BMDL is the 95% lower confidence limit on the AUC estimated to decrease brain weight by 1 control mean S.D. using BMDS 2.1.1 (U.S. EPA, 2009, 200772) and model options and restrictions suggested by EPA BMD technical guidance (U.S. EPA, 2000, 052150).

[b]In accordance with draft EPA BMD Technical Guidance guidance (2000, 052150), the BMDL from the Hill model (bolded) is chosen for us in an RfC derivation because it is the lowest of a broad range of BMDL estimates from adequately fitting models and because the Hill model provides good fit in the dose region of interest as indicated by a relatively low scaled residual at the dose group closest to the BMD (0.09 versus -0.67 or -0.77).

[c]AIC = Akaike Information Criterion = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters, and P is the number of modeled degrees of freedom (usually the number of parameters estimated).

[d]χ^2d residual (measure of how model-predicted responses deviate from the actual data) for the dose group closest to the BMD scaled by an estimate of its S.D. Provides a comparative measure of model fit near the BMD. Residuals that exceed 2.0 in absolute value should cause one to question model fit in this region.

Source: NEDO (1987, 064574).

Figure 5-1. Hill model BMD plot of decreased brain weight in male rats at 6 weeks age using modeled AUC of methanol in blood as the dose metric, 1 control mean S.D.

1

2   Once the $BMDL_{1SD}$ was obtained in units of hr × mg/L, it was used to derive a chronic

3   RfC. The first step is to calculate the HEC using the PBPK model described in Appendix B. An

4   algebraic equation is provided (Equation 1 of Appendix B) that describes the relationship

5   between predicted methanol AUC and the human equivalent inhalation exposure concentration

6   (HEC) in ppm.

7       $BMDL_{HEC}$ (ppm) = 0.0224*BMDL1SD+(1334*BMDL1SD)/(794+ BMDL1SD)

8       $BMDL_{HEC}$ (ppm) = 0.0224*90.9+(1334*90.9)/(794+ 90.9) = 139 ppm

9   Next, because RfCs are typically expressed in units of mg/m^3, the HEC value in ppm was

10   converted using the conversion factor specific to methanol of 1 ppm = 1.31 mg/m^3:

11   HEC (mg/m^3) = 1.31 × 139 ppm = 182 mg/m^3

12

5.1.3. RfC Derivation – Including Application of Uncertainty Factors

5.1.3.1. *Comparison between Endpoints and BMDL Modeling Approaches*

1   A summary of the PODs for the various developmental endpoints and BMD modeling

2 approaches considered for the derivation of an RfC, along with the UFs applied[77] and the

3 conversion to an HEC, are presented in Table 5-4 and graphically compared in Figure 5-2 (see

4 Appendix C for details). Information is presented that compares the use of different endpoints

5 (i.e., cervical rib, decreased brain weight, and increased latency of VDR) and different methods

6 (i.e., different BMR levels) for estimating the POD. These comparisons are presented to inform

7 the analysis of uncertainty surrounding these choices. Each approach considered for the

8 determination of the POD has strengths and limitations, but when considered together for

9 comparative purposes they allow for a more informed determination for the POD for the

10 methanol RfC.

11   A 10% extra risk BMR is adequate for most traditional bioassays using 50 animals per

12 dose group. A smaller BMR of 5% extra risk can sometimes be justified for developmental

13 studies (e.g., Rogers et al., 1993, 032696) because they generally involve a larger number of

14 subjects. Reference values estimated for cervical rib incidence in mice using C_{max} as the dose

15 metric were 13.6 and 10.4 mg/m^3 using $BMDL_{10}$ and $BMDL_{05}$ PODs, respectively (see

16 Appendix D for discussion of choice of C_{max} as the appropriate dose metric for incidence of

17 cervical rib in mice). The reference value estimated for alterations in sensorimotor development

18 and performance as measured by the VDR test in female monkeys using AUC as the dose metric

19 was 1.7 mg/m^3 using the $BMDL_{SD}$ as the POD. As discussed in Section 4.4.2, confidence in this

20 endpoint is reduced by a marginal dose-response trend in one sex (females) and a limited sample

21 size. Although the VDR test demonstrates that prenatal and continuing postnatal exposure to

22 methanol can result in neurotoxicity, the use of such statistically borderline results is not

23 warranted in the derivation of the RfC, given the availability of better dose-response data in

24 other species. Decreases in brain weight at 6 weeks of age in male rats exposed during gestation

25 and throughout the F_1 generation using AUC as the dose metric yield the reference values of 1.8

26 and 2.4 mg/m^3 for BMRs of one S.D. from the control mean and 5% change relative to control

27 mean, respectively. Because decreases in brain weight in male rats at 6 weeks postbirth resulted

28 in a clear dose response and returned RfC estimates lower than or approximate to the other

29 endpoints considered, it was chosen as the critical endpoint. One S.D. from the control mean

30 was chosen as the appropriate level of response (BMR) for the calculation of the RfC because it

---

[77] The rationale for the selection of these UFs is discussed later in Section 5.1.3.

1　is the standard recommended by EPA's draft technical guidance (2000, 052150) and yields a

2　lower BMDL than 5% relative deviance for this data set. Thus, the RfC is:

3　　　　$RfC = POD_{HEC} \div UF = 182 \text{ mg/m}^3 \div 100 = 2 \text{ mg/m}^3$ (rounded to one significant figure)

Table 5-4. Summary of PODs for critical endpoints, application of UFs and conversion to HEC values using BMD and PBPK modeling

	Rogers et al. (1993, 032696)		Burbacher et al. (1999, 009752; 1999, 009753)	NEDO (1987, 064574)	
	$BMDL_{10}$ mouse cervical rib C_{max}	$BMDL_{05}$ mouse cervical rib C_{max}	$BMDL_{1SD}$ female monkey VDR[a] AUC	$BMDL_{05}$ rat brain wt.[b] AUC	$BMDL_{1SD}$ rat brain wt.[b] AUC
BMDL	94.3 mg/L	44.7 mg/L	81.7 hr×mg/L	123.8 hr×mg/L	**90.9 hr×mg/L**
HEC (mg/m^3)[c]	1360	1036	165	240	**182**
UF_H[d]	10	10	10	10	**10**
UF_A[e]	3	3	3	3	**3**
UF_D	3	3	3	3	**3**
UF_S	1	1	1	1	**1**
UF_L	1	1	1	1	**1**
UF_{TOTAL}	100	100	100	100	**100**
RfC (mg/m^3)	13.6	10.4	1.7	2.4	**1.8**

[a]VDR = test of sensorimotor development as measured by age from birth at achievement of test criterion for grasping a brightly colored object.
[b]Brain weight at 6 weeks postbirth, multiple routes of exposure (whole gestation, lactation, inhalation)
[c]The PBPK model used for this HEC estimate is described in Appendix B. An algebraic equation (Equation 1 of Appendix B) describes the relationship between predicted methanol AUC and the human equivalent inhalation exposure concentration (HEC) in ppm. This equation can also be used to estimate model predictions for HECs from C_{max} values because C_{max} values and AUC values were estimated at steady-state for constant 24 hours exposures (i.e., AUC = 24 x C_{max}). The ppm HEC estimate is then converted to mg/m^3 by multiplying by 1.31.
[d]The rationale for the selection of these UFs is discussed in Section 5.1.3 below.
[e]These uncertainty factor (UF) acronyms are defined in Sections 5.1.3.2.1 to 5.1.3.2.4.
[f]This endpoint (bolded) was used for the derivation of the RfC.

Figure 5-2. PODs (in mg/m³) for selected endpoints with corresponding applied UFs (chosen RfC value is circled)

5.1.3.2. *Application of UFs*

1   UFs are applied to the POD, identified from the rodent data, to account for recognized
2   uncertainties in extrapolation from experimental conditions to the assumed human scenario (i.e.,
3   chronic exposure over a lifetime). A composite UF of 100-fold (10-fold for interindividual
4   variation, 3-fold for residual toxicodynamic differences associated with animal-to-human
5   extrapolation, and 3-fold for database uncertainty) was applied to the POD for the derivation of
6   the RfC, as described below.

7   **5.1.3.2.1. *Interindividual variation UF$_H$.*** A factor of 10 was applied to account for variation in
8   sensitivity within the human population (UF$_H$). The UF of 10 is commonly considered to be
9   appropriate in the absence of convincing data to the contrary. The data from which to determine
10 the potential extent of variation in how humans respond to chronic exposure to methanol are
11 limited, given the complex nature of the developmental endpoint employed and uncertainties
12 surrounding the importance of metabolism to the observed teratogenic effects. Susceptibility to
13 methanol is likely to involve intrinsic and extrinsic factors. Some factors may include alteration

of the body burden of methanol or its metabolites, sensitization of an individual to methanol effects, or augmentation of underlying conditions or changes in processes that share common features with methanol effects. Additionally, inherent differences in an individual's genetic make-up, diet, gender, age, or disease state may affect the pharmacokinetics and pharmacodynamics of methanol, influencing susceptibility intrinsically. Co-exposure to a pollutant that alters metabolism or other clearance processes, or that adds to background levels of metabolites may also affect the pharmacokinetics and pharmacodynamics of methanol, influencing susceptibility extrinsically (see Section 4.9). The determination of the UF for human variation is supported by several types of information, including information concerning background levels of methanol in humans, variation in pharmacokinetics revealed through human studies and from PBPK modeling, variation of methanol metabolism in human tissues, and information on physiologic factors (including gender and age), or acquired factors (including diet and environment) that may affect methanol exposure and toxicity.

In using the AUC of methanol in blood as the dose metric for derivation of health benchmarks for methanol, the assumption is made that concentrations of methanol in blood over time are related to its toxicity, either through the actions of the parent or it subsequent metabolism. However, the formation of methanol's metabolites has been shown in humans to be carried out by enzymes that are inducible, highly variable in activity, polymorphic, and to also be involved in the metabolism of other drugs and environmental pollutants. Hence, differences in the metabolism of methanol that are specific for target tissue, gender, age, route of administration, and prior exposure to other environmental chemicals may give a different pattern of methanol toxicity if metabolism is required for that toxicity. Eighty-five percent of Asians carry an atypical phenotype of ADH that may affect their ability to metabolize methanol (Agarwal, 2001, 056332; Bosron and Li, 1986, 056330; Pietruszko, 1980, 056337). Also, polymorphisms in ADH3 occurring in the promoter region reduce the transcriptional activity in vitro nearly twofold, although no studies have reported differences in ADH3 enzyme activity in humans (Hedberg et al., 2001, 196206).

Although data on the specific potential for increased susceptibility to methanol are lacking, there is information on PK and pharmacodynamic factors suggesting that children may have differential susceptibility to methanol toxicity (see Section 4.10.1). Thus, there is uncertainty in children's responses to methanol that should be taken into consideration for derivation of the UF for human variation that is not available from either measured human data or PBPK modeling analyses. The enzyme primarily responsible for metabolism of methanol in humans, ADH, has been reported to be reduced in activity in newborns. Differences in pharmacokinetics include potentially greater pollutant intake due to greater ventilation rates,

1 activity, and greater intake of liquids in children. In terms of differences in susceptibility to
2 methanol due to pharmacodynamic considerations, the substantial anatomical, physiologic, and
3 biochemical changes that occur during infancy, childhood, and puberty suggest that there are
4 developmental periods in which the endocrine, reproductive, immune, audiovisual, nervous, and
5 other organ systems may be especially sensitive.

6   There are some limited data from short-term exposure studies in humans and animal
7 experiments that suggest differential susceptibility to methanol on the basis of gender. Gender
8 can provide not only different potential targets for methanol toxicity but also differences in
9 methanol pharmacokinetics and pharmacodynamics. NEDO (1987, 064574) reported that in rats
10 exposed to methanol pre- and postnatally, 6- and 8-week-old male progeny had significantly
11 lower brain weights at 1,000 ppm, whereas females only showed decreases at 2,000 ppm. In
12 general, gender-related differences in distribution and clearance of methanol may result from the
13 greater muscle mass, larger body size, decreased body fat, and increased volumes of distribution
14 in males compared to females.

15 **5.1.3.2.2. *Animal-to-human extrapolation UF_A.*** A factor of 3 was applied to account for
16 uncertainties in extrapolating from rodents to humans. Application of a full UF of 10 would
17 depend on two areas of uncertainty: toxicokinetic and toxicodynamic uncertainty. In this
18 assessment, the toxicokinetic component is largely addressed by the determination of a HEC
19 through the use of PBPK modeling. Given the chosen dose metric (AUC for methanol blood),
20 uncertainties in the PBPK modeling of methanol are not expected to be greater for one species
21 than another. The analysis of parameter uncertainty for the PBPK modeling performed for
22 human, mouse, and rat data gave similar results as to how well the model fit the available data.
23 Thus, the human and rodent PBPK model performed similarly using this dose metric for
24 comparisons between species. As discussed in Section 5.3 below, uncertainty does exist
25 regarding the relation of maternal blood levels estimated by the model to fetal and neonatal
26 blood levels that would be obtained under the (gestational, postnatal and lactational) exposure
27 scenario employed in the critical study. However, at environmentally relevant exposure levels, it
28 is assumed that the ratio of the difference in blood concentrations between a human infant and
29 mother would be similar to and not significantly greater than the difference between a rat dam
30 and its fetus. Key parameters and factors which determine the ratio of fetal or neonatal human
31 versus mother methanol blood levels either do not change significantly with age (partition
32 coefficients, relative blood flows) or scale in a way that is common across species
33 (allometrically). For this reason and because EPA has confidence in the ability of the PBPK
34 model to accurately predict adult blood levels of methanol, the PK uncertainty is reduced and a
35 value of 1 was applied. Rodent-to-human pharmacodynamic uncertainty is covered by a factor

of 3, as is the practice for deriving RfCs (U.S. EPA, 1994, 006488). Therefore, a factor of 3 is
used for interspecies uncertainty.

5.1.3.2.3. *Database UF_D.* A database UF of 3 was applied to account for deficiencies in the
toxicity database. The database for methanol toxicity is quite extensive: there are chronic and
developmental toxicity studies in rats, mice, and monkeys, a two-generation reproductive
toxicity study in rats, and neurotoxicity and immunotoxicity studies. However, there is
uncertainty regarding which test species is most relevant to humans. In addition, limitations of
the developmental toxicity database employed in this assessment include gaps in testing and
imperfect study design, reporting, and analyses. Developmental studies were conducted at levels
inducing maternal toxicity, a full developmental neurotoxicity test (DNT) in rodents has not been
performed and is warranted given the critical effect of decreased brain weight, there are no
chronic oral studies in mice, and chronic and developmental studies in monkeys were generally
inadequate for quantification purposes, for reasons discussed in Section 5.1.1.1. Problems of
interpretation of developmental and reproductive studies also arise given the dose spacing
between lowest and next highest level. For these reasons, an UF of 3 was applied to account for
deficiencies in the database.

**5.1.3.2.4. *Extrapolation from subchronic to chronic and LOAEL-to-NOAEL extrapolation
UFs.*** A UF was not necessary to account for extrapolation from less than chronic results because
developmental toxicity (cervical rib and decreased brain weight) was used as the critical effect.
The developmental period is recognized as a susceptible lifestage where exposure during certain
time windows is more relevant to the induction of developmental effects than lifetime exposure
(U.S. EPA, 1991, 008567).

A UF for LOAEL-to-NOAEL extrapolation was not applied because BMD analysis was
used to determine the POD, and this factor was addressed as one of the considerations in
selecting the BMR. In this case, a BMR of one S.D. from the control mean in the critical effect
was selected based on the assumption that it represents a minimum biologically significant
change.

5.1.4. Previous RfC Assessment

The health effects data for methanol were assessed for the IRIS database in 1991 and
were determined to be inadequate for derivation of an RfC.

5.2. ORAL REFERENCE DOSE (RfD)

In general, the RfD is an estimate of a daily exposure to the human population (including
susceptible subgroups) that is likely to be without an appreciable risk of adverse health effects

1 over a lifetime. It is derived from a POD, generally the statistical lower confidence limit on the

2 BMDL, with uncertainty/variability factors applied to reflect limitations of the data used. The

3 RfD is expressed in terms of mg/kg-day of exposure to an agent and is derived by a similar

4 methodology as is the RfC. Ideally, studies with the greatest duration of exposure and conducted

5 via the oral route of exposure give the most confidence for derivation of an RfD. For methanol,

6 the oral database is currently more limited than the inhalation database. With the development of

7 PBPK models for methanol, the inhalation database has been used to help bridge data gaps in the

8 oral database to derive an RfD.

5.2.1. Choice of Principal Study and Critical Effect–with Rationale and Justification

9 No studies have been reported in which humans have been exposed subchronically or

10 chronically to methanol by the oral route of exposure and thus, would be suitable for derivation

11 of an oral RfD. Data exist regarding effects from oral exposure in experimental animals, but

12 they are more limited than data from the inhalation route of exposure (see Sections 4.2, 4.3, and

13 4.4).

14 Only 2 oral studies of 90-days duration or longer in animals have been reported (Soffritti

15 et al., 2002, 091004; U.S., 1986, 196737) for methanol. EPA (1986, 196737) reported that there

16 were no differences in body weight gain, food consumption, or gross or microscopic evaluations

17 in Sprague-Dawley rats gavaged with 100, 500, or 2,500 mg/kg-day versus control animals.

18 Liver weights in both male and female rats were increased, although not significantly, at the

19 2,500 mg/kg-day dose level, suggesting a treatment-related response despite the absence of

20 histopathologic lesions in the liver. Brain weights of high-dose group males and females were

21 significantly less than control animals at terminal (90 days) sacrifice. The data were not reported

22 in adequate detail for dose-response modeling and BMD estimation. Based primarily on the

23 qualitative findings presented in this study, the 500 mg/kg-day dose was deemed to be a

24 NOAEL.[78]

25 The only lifetime oral study available was conducted by Soffritti et al. (2002, 091004) in

26 Sprague-Dawley rats exposed to 0, 500, 5,000, 20,000 ppm (v/v) methanol, provided ad libitum

27 in drinking water. Based on default, time-weighted average body weight estimates for Sprague-

28 Dawley rats (U.S. EPA, 1988, 064560), average daily doses of 0, 46.6, 466, and 1,872 mg/kg-day

29 for males and 0, 52.9, 529, 2,101 mg/kg-day for females were reported by the study authors. All

30 rats were exposed for up to 104 weeks, and then maintained until natural death. The authors

31 report no substantial changes in survival nor was there any pattern of compound-related clinical

---

[78] U.S. EPA (1986, 196737) did not report details required for a BMD analysis such as standard deviations for mean responses.

signs of toxicity. The authors did not report noncancer lesions, and there were no reported compound-related signs of gross pathology or histopathologic lesions indicative of noncancer toxicological effects in response to methanol.

Five oral studies investigated the reproductive and developmental effects of methanol in rodents (Aziz et al., 2002, 034481; Fu et al., 1996, 080957; Infurna and Weiss, 1986, 064572; Rogers et al., 1993, 032696; Sakanashi et al., 1996, 056308), including three studies that investigated the influence of FAD diets on the effects of methanol exposures (Aziz et al., 2002, 034481; Fu et al., 1996, 080957; Sakanashi et al., 1996, 056308). Infurna and Weiss (1986, 064572)exposed pregnant Long-Evans rats to 2,500 mg/kg-day in drinking water on either GD15-GD17 or GD17-GD19. Litter size, pup birth weight, pup postnatal weight gain, postnatal mortality, and day of eye opening were not different in treated animals versus controls. Mean latency for nipple attachment and homing behavior (ability to detect home nesting material) were different in both methanol treated groups. These differences were significantly different from controls. Rogers et al. (1993, 032696) exposed pregnant CD-1 mice via gavage to 4 g/kg-day methanol, given in 2 equal daily doses. Incidence of cleft palate and exencephaly was increased following maternal exposure to methanol. Also, an increase in totally resorbed litters and a decrease in the number of live fetuses per litter were observed.

Aziz et al. (2002, 034481), Fu et al. (1996, 080957), and Sakanashi et al. (1996, 056308) investigated the role of folic acid in methanol-induced developmental neurotoxicity. Like Rogers et al. (1993, 032696), the former 2 studies observed that an oral gavage dose of 4–5 g/kg-day during GD6-GD15 or GD6-GD10 resulted in an increase in cleft palate in mice fed sufficient folic acid diets, as well as an increase in resorptions and a decrease in live fetuses per litter.   Fu et al. (1996, 080957) also observed an increase in exencephaly in the FAS group. Both studies found that an approximately 50% reduction in maternal liver folate concentration resulted in an increase in the percentage of litters affected by cleft palate (as much as threefold) and an increase in the percentage of litters affected by exencephaly (as much as 10-fold). Aziz et al. (2002, 034481) exposed rat dams throughout their lactation period to 0, 1, 2, or 4% v/v methanol via the drinking water, equivalent to approximately 480, 960 and 1,920 mg/kg-day.[79] Pups were exposed to methanol via lactation from PND1–PND21. Methanol treatment at 2% and 4% was associated with significant increases in activity (measured as distance traveled in a spontaneous locomotor activity test) in the FAS group (13 and 39%, respectively) and most notably, in the FAD group (33 and 66%, respectively) when compared to their respective controls. At PND45,

---

[79] Assuming that Wistar rat drinking water consumption is 60 mL/kg-day (Rogers et al., 2002, 196167), 1% methanol in drinking water would be equivalent to 1% x 0.8 g/mL x 60 mL/kg-day = 0.48 g/kg-day = 480 mg/kg-day.

1 the CAR in FAD rats exposed to 2% and 4% methanol was significantly decreased by 48% and

2 52%, respectively, relative to nonexposed controls. In the FAS group, the CAR was only

3 significantly decreased in the 4% methanol-exposed animals and only by 22% as compared to

4 their respective controls.

5.2.1.1. *Expansion of the Oral Database by Route-to-Route Extrapolation*

5 Given the oral database limitations, including the limited reporting of noncancer findings

6 in the subchronic (U.S., 1986, 196737) and chronic studies (Soffritti et al., 2002, 091004) of rats

7 and the high-dose levels used in the two rodent developmental studies, EPA has derived an RfD

8 by using relevant inhalation data and route-to-route extrapolation with the aid of the EPA PBPK

9 model (see Sections 3.4 and 5.1). Several other factors support use of route-to-route

10 extrapolation for methanol. The limited data for oral administration indicate similar effects as

11 reported via inhalation exposure (e.g., the brain and fetal skeletal system are targets of toxicity).

12 Methanol has been shown to be rapidly and well-absorbed by both the oral and inhalation routes

13 of exposure (CERHR, 2004, 091201; Kavet and Nauss, 1990, 032274). Once absorbed,

14 methanol distributes rapidly to all organs and tissues according to water content, regardless of

15 route of exposure.

16 As with the species-to-species extrapolation used in the development of the RfC, the dose

17 metric used for species-to-species and route-to-route extrapolation of inhalation data to oral data

18 is the AUC of methanol in blood. Simulations for human oral methanol exposure were

19 conducted using the model parameters as previously described for human inhalation exposures,

20 with human oral kinetic/absorption parameters from Sultatos et al. (2004, 090530) (i.e., KAS =

21 0.2, KSI = 3.17, and KAI = 3.28). Human oral exposures were assumed to occur during six

22 drinking episodes during the day, at times 0, 3, 5, 8, 11, and 15 hours from the first ingestion of

23 the day. For example, if first ingestion occurred at 7 am, these would be at 7 am, 10 am, 12

24 noon, 3 pm, 6 pm, and 10 pm. Each ingestion event was treated as occurring over 3 minutes,

25 during which the corresponding fraction of the daily dose was infused into the stomach lumen

26 compartment. The fraction of the total ingested methanol simulated at each of these times was

27 25%, 10%, 25%, 10%, 25%, and 5%, respectively. Six days of exposure were simulated to allow

28 for any accumulation (visual inspection of plots showed this to be finished by the 2nd or 3rd

29 day), and the results for the last 24 hours were used. Dividing the exposure into more and

30 smaller episodes would decrease the estimated peak concentration but have little effect on AUC.

31 This dose metric was used for dose-response modeling to derive the POD, expressed as a

32 BMDL. The BMDL was then back-calculated using the EPA PBPK model to obtain an

33 equivalent oral drinking water dose in terms of mg/kg-day.

5.2.2. RfD Derivation–Including Application of UFs

5.2.2.1. *Consideration of Inhalation Data*

1   Inhalation studies considered for derivation of the RfC are used to supplement the oral
2   database using the route-to-route extrapolation, as previously described. BMD approaches were
3   applied to the existing inhalation database, and the EPA PBPK model was used for species-to-
4   species extrapolations. The rationale and approach for determining the RfC is described above
5   (Section 5.1), and the data used to support the derivation of the RfC were extrapolated using the
6   EPA PBPK model to provide an oral equivalent POD.

5.2.2.2. *Selection of Critical Effect(s) from Inhalation Data*

7   Methanol-induced effects on the brain in rats (weight decrease) and fetal axial skeletal
8   system in mice (cervical ribs and cleft palate) were consistently observed at lower levels, than
9   other targets, in the oral and inhalation databases. Analysis of inhalation developmental toxicity
10   studies shows lower BMDLs for decreased male brain weight in rats exposed throughout
11   gestation and the F_1 generation (NEDO, 1987, 064574) than BMDLs associated with the fetal
12   axial skeletal system in mice (see Section 5.1.3.1). Therefore, the BMDL for decreases in brain
13   weight in male rats is chosen to serve as the basis for the route-to-route extrapolation and
14   calculation of the RfD.

5.2.2.3. *Selection of the POD*

15   The BMDL chosen for the RfC is used to determine the POD for the RfD. This value is
16   based on a developmental toxicity dataset that includes in utero and postnatal exposures and is
17   below the range of estimates for other developmental datasets consisting of exposure only
18   throughout organogenesis. The neonatal brain is the target organ chosen for derivation of the
19   RfC. The BMDL for the RfC (AUC of 90.9 hr × mg/L methanol in blood) is converted using the
20   EPA model to a human equivalent oral exposure of 38.6 mg/kg-day.[80]

5.2.3. RfD Derivation–Application of UFs

21   In an approach consistent with the RfC derivation, UFs are applied to the oral POD of
22   38.6 mg/kg-day to address interspecies extrapolation, intraspecies variability, and database
23   uncertainties for the RfD. Because the same dataset, endpoint, and PBPK model used to derive
24   the RfC were also used to calculate the oral POD, the total UF of 100 is applied to the BMDL of
25   38.6 mg/kg-day to yield an RfD of 0.4 mg/kg-day for methanol.

---

[80] The PBPK model used for this HEC estimate is described in Appendix B. An algebraic equation is provided
(Equation 2) that describes the relationship between predicted methanol AUC and the HED in mg/kg-day.

1   RfD = 38.6 mg/kg-day ÷ 100 = 0.4 mg/kg-day (rounded to one significant figure)

5.2.4. Previous RfD Assessment

2   The previous IRIS assessment for methanol included an RfD of 0.5 mg/kg-day that was
3   derived from a EPA (1986, 196737) subchronic oral study in which Sprague-Dawley rats
4   (30/sex/dose) were gavaged daily with 0, 100, 500, or 2,500 mg/kg-day of methanol. There were
5   no differences between dosed animals and controls in body weight gain, food consumption, gross
6   or microscopic evaluations. Elevated levels of SGPT, serum alkaline phosphatase (SAP), and
7   increased but not statistically significant liver weights in both male and female rats suggest
8   possible treatment-related effects in rats dosed with 2,500 mg methanol/kg-day, despite the
9   absence of supportive histopathologic lesions in the liver. Brain weights of both high-dose group
10   males and females were significantly less than those of the control group. Based on these
11   findings, 500 mg/kg-day of methanol was considered a NOAEL in this rat study. Application of
12   a 1,000-fold UF (interspecies extrapolation, susceptible human subpopulations, and subchronic
13   to chronic extrapolation) yielded an RfD of 0.5 mg/kg-day.

5.3. UNCERTANTIES IN THE INHALATION RFC AND ORAL RFD

14   The following is a more extensive discussion of the uncertainties associated with the RfC
15   and RfD for methanol beyond that which is addressed quantitatively in Sections 5.1.2, 5.1.3, and
16   5.2.2. A summary of these uncertainties is presented in Table 5-5.

Table 5-5. Summary of uncertainties in methanol noncancer risk assessment

Consideration	Potential Impact	Decision	Justification
Choice of endpoint	Use of other endpoint could ↑ RfC by up to ~5-fold (see Table 5-4 and Section 5.3.1)	RfC is based on the most sensitive and quantifiable endpoint, decreased brain weight in male rats exposed pre- and postnatally	Chosen endpoint is considered the most relevant due to its biological significance, and consistency across a developmental and a subchronic study in rats and with the observation of other developmental neurotoxicities reported in monkeys.
Choice of dose metric	Alternatives could ↑ or ↓ RfC/D (e.g., use of C_{max} increased RfC by ~20%)	AUC for methanol in arterial blood	AUC was selected as the most appropriate dose metric because it incorporates time (brain weight is sensitive to both the level and duration of exposure) and better reflects exposure within a given day.
Choice of model for BMDL derivation	Use of a linear model could ↑ RfC by ~2.5-fold (see Table 5-3)	Hill model used	Hill model gave lowest of a broad range of BMDL estimates from adequate models and provides good fit in low dose region.
Choice of animal-to-human extrapolation method	Alternatives could ↑ or ↓ RfC/D (e.g., use of standard dosimetry assumption would ↑ RfC by ~2-fold; see Section 5.3.4)	A PBPK model was used to extrapolate animal to human concentrations	Use of a PBPK model reduced uncertainty associated with the animal to human extrapolation. AUC blood levels of methanol is an appropriate dose metric and a peer-reviewed PBPK model that estimates this metric was verified by EPA using established (U.S. EPA, 2006, 194566) methods and procedures
Statistical uncertainty at POD (sampling variability due to bioassay size)	POD would be ~90% higher if BMD were used	A BMDL was used as the POD	Lower bound is 95% CI of administered exposure
Choice of bioassay	Alternatives could ↑ RfC/D	NEDO (1987, 064574)	Alternative bioassays were available, but the chosen bioassay was adequately conducted and reported and resulted in the most sensitive and reliable BMDL for derivation of the RfC.
Choice of species/gender	RfC would be ↑ or ↓ if based on another species/gender	RfC is based on the most sensitive and quantifiable endpoint (↓ brain weight) in the most sensitive species and gender adequately evaluated (male rats).	Choice of female rats would have resulted in a higher RfC/D. Effects in mice also yield higher RfCs. Qualitative evidence from NEDO (1987, 064574) and Burbacher et al. (2004, 059070; 2004, 056018). suggest that monkeys may be a more sensitive species, but data are not as reliable for quantification.
Human population variability	RfC could ↓ or ↑ if another value of the UF was used	10-fold uncertainty factor applied to derive the RfC/RfD values	10-fold UF is applied because of limited data on human variability or potential susceptible subpopulations, particularly pregnant mothers and their neonates.

5.3.1. Choice of Endpoint

1   The impact of endpoint selection (on brain weight decrease in male rats) the derivation of
2   the RfC and RfD was discussed in Sections 5.1.3.1 and 5.2.2.2. Potential RfC values considered
3   ranged from 1.7 to 13.6 mg/m^3, depending on whether neurobehavioral function in male
4   monkeys, brain weight decrease in male rats, or cervical ribs incidence in mice was chosen as the
5   critical effect for derivation of the POD, with the former endpoint representing the lower end of
6   the RfC range. The use of other endpoints, particularly pre-term births identified in the
7   Burbacher et al. (1999, 009752; 1999, 009753; 2004, 059070; 2004, 056018) monkey study,
8   would potentially result in lower reference values, but significant uncertainties associated with
9   those studies preclude their use as the basis for an RfC.
10 Burbacher et al. (1999, 009752; 1999, 009753; 2004, 059070; 2004, 056018) exposed *M.*
11 *fascicularis* monkeys to 0, 262, 786, and 2,359 mg/m^3 methanol 2.5 hours/day, 7 days/week
12 during premating/mating and throughout gestation (approximately 168 days). They observed a
13 slight but statistically significant gestation period shortening in all exposure groups that was
14 largely due to C-sections performed in the methanol exposure groups "in response to signs of
15 possible difficulty in the maintenance of pregnancy," including vaginal bleeding. As discussed
16 in Sections 4.3.2 and 5.1.1.2, there are questions concerning this effect and its relationship to
17 methanol exposure. An ultrasound was not done to confirm the existence of real fetal or
18 placental problems. Neurobehavioral function was assessed in infants during the first 9 months
19 of life. Two tests out of nine, returned positive results possibly related to methanol exposure.
20 VDR performance was reduced in all treated male infants, and was significantly reduced in the
21 2,359 mg/m^3 group for both sexes and the 786 mg/m^3 group for males. However, an overall
22 dose-response trend for this endpoint was only observed in females. As discussed in Section
23 4.4.2, confidence in this endpoint may have been increased by statistical analyses to adjust for
24 multiple testing (CERHR, 2004, 091201), but it is a measure of functional deficits in
25 sensorimotor development that is consistent with early developmental CNS effects (brain weight
26 changes discussed above) that have been observed in rats. The Fagan test of infant intelligence
27 indicated small but not significant deficits of performance (time spent looking a novel faces
28 versus familiar faces) in treated infants. Although these results indicate that prenatal and
29 continuing postnatal exposure to methanol can result in neurotoxicity to the offspring, especially
30 when considered in conjunction with the gross morphological effects noted in NEDO (1987,
31 064574), the use of such statistically borderline results is not warranted in the derivation of the
32 RfC, given the availability of better dose-response data in other species.
33 NEDO (1987, 064574) also examined the chronic neurotoxicity of methanol in *M.*
34 *fascicularis* monkeys exposed to 13.1, 131, or 1,310 mg/m^3 for up to 29 months. Multiple

effects were noted at 131 mg/ m^3, including slight myocardial effects (negative changes in the T wave on an EKG), degeneration of the inside nucleus of the thalamus, and abnormal pathology within the cerebral white tissue in the brain. The results support the identification of 13.1 mg/m^3 as the NOAEL for neurotoxic effects in monkeys exposed chronically to inhaled methanol. However, as discussed in Section 4.2.2.3, there exists significant uncertainty in the interpretation of these results and their utility in deriving an RfC for methanol. These uncertainties include lack of appropriate control group data, limited nature of the reporting of the neurotoxic effects observed, and use of wild-caught monkeys in the study. Thus, while the NEDO (1987, 064574) study suggests that monkeys may be a more sensitive species to the neurotoxic effects of chronic methanol exposure than rodents, the substantial deficits in the reporting of data preclude the quantification of data from this study for the derivation of an RfC.

The increased incidence of cervical ribs was identified as a biologically significant, potential co-critical effect based on the findings of Rogers et al. (1993, 032696). Mice were exposed to 1,000, 2,000, or 5,000 ppm, and incidence of cervical ribs was statistically increased at 2,000 ppm. However, given that the reference values for the increased incidence of cervical ribs are estimated to be approximately five times higher than the reference values calculated using decreases in brain weight in male rats (NEDO, 1987, 064574) decreased brain weight was chosen as the basis for the derivation of the RfC.

5.3.2. Choice of Dose Metric

A recent review of the reproductive and developmental toxicity of methanol by a panel of experts concluded that methanol, not its metabolite formate, is likely to be the proximate teratogen and that blood methanol level is a useful biomarker of exposure (CERHR, 2004, 091201; Dorman et al., 1995, 078081). The CERHR Expert Panel based their assessment of potential methanol toxicity on an assessment of circulating blood levels (CERHR, 2004, 091201). In contrast to the conclusions of the NTP-CERHR panel, in vitro data from Harris et al. (2003, 047369; 2004, 059082) suggest that the etiologically important substance for embryo dysmorphogenesis and embryolethality was likely to be formaldehyde rather than the parent compound or formate. Although there remains uncertainty surrounding the identification of the proximate teratogen of importance (methanol, formaldehyde, or formate), the dose metric chosen for derivation of an RfC was based on blood methanol levels. This decision was primarily based on evidence that the toxic moiety is not likely to be the formate metabolite of methanol (CERHR, 2004, 091201), and evidence that levels of the formaldehyde metabolite following methanol maternal and/or neonate exposure would be lower in the fetus and neonate than in adults. While recent in vitro evidence indicates that formaldehyde is more embryotoxic

than methanol and formate, the high reactivity of formaldehyde would limit its unbound and unaltered transport as free formaldehyde from maternal to fetal blood (Thrasher and Kilburn, 2001, 196728) (see discussion in Section 3.3). Thus, even if formaldehyde is ultimately identified as the proximate teratogen, methanol would likely play a prominent role, at least in terms of transport to the target tissue. Further discussions of methanol metabolism, dose metric selection, and MOA issues are in Sections 3.3, 4.6, 4.8 and 4.9.2.

There exists some concern in using the F_1 generation NEDO (1987, 064574) rat study as the basis from which to derive the RfC. This concern mainly arises from issues related to the low confidence that the PBPK model is accurately predicting dose metrics for neonates exposed through multiple and simultaneous routes. The PBPK model was structured to predict internal dose metrics for adult NP animals and was optimized using adult metabolic and physiological parameters. Young animals have very different metabolic and physiological profiles than adults (enzyme activities, respiration rates, etc.). This fact, coupled with multiple routes of exposure, make it likely that the PBPK did not accurately predict the internal dose metrics for the offspring. Stern et al. (1996, 081114) reported that when rat pups and dams were exposed together during lactation to 4,500 ppm methanol in air, methanol blood levels in pups from GD6–PND21 were approximately 2.25 times greater than those of dams. This discrepancy persisted until PND48, when postnatal exposure continued to PND52. It is logical to assume that similar differences in blood methanol levels would also be observed in the NEDO (1987, 064574) F_1 study, as the exposure scenario is similar to that of Stern et al. (1996, 081114). Differences between pup and dam blood methanol levels might be expected to be slightly greater than twofold in the NEDO (1987, 064574) F_1 study as the exposure was continuous (versus 6 hours/day in the Stern et al. (1996, 081114) paper) and lasted for a longer duration (~64 days versus 37). Under a similar scenario, human newborns may experience higher blood levels than their mothers as a result of breast feeding. As has been discussed in Chapter 3, children have a limited capacity to metabolize methanol via ADH; however, there is some evidence that human infants are able to efficiently eliminate methanol at high-exposure levels, possibly via CAT (Tran et al., 2007, 196724). At environmentally relevant exposure levels, it is assumed that the ratio of the difference in blood concentrations between infant and mother would not be significantly greater than the twofold difference that has been observed in rats.[81] For this reason and because EPA has confidence in the ability of the PBPK model to accurately predict adult blood levels of

---

[81] Key parameters and factors which determine the ratio of fetal or neonatal human versus mother methanol blood levels either do not change significantly with age (partition coefficients, relative blood flows) or scale in a way that is common across species (allometrically).

methanol, the maternal blood methanol levels for the estimation of HECs from the NEDO (1987, 064574) study were used as the dose metric.

5.3.3. Choice of Model for BMDL Derivations

The Hill model adequately fit the dataset for the selected endpoint (goodness-of-fit p-value = 0.84). Data points were well predicted near the BMD (scaled residual = 0.09) (see Figure 5-1). There is a 2.5-fold range of BMDL estimates from adequately fitting models, indicating considerable model dependence. The BMDL from the Hill model was selected, in accordance with EPA BMD Technical Guidance (2000, 052150), because it results in the lowest BMDL from among a broad range of BMDLs and provides a superior fit in the low dose region nearest the BMD.

5.3.4. Choice of Animal-to-Human Extrapolation Method

A PBPK model developed by the EPA, adapted from Ward et al. (1997, 083652), was used to extrapolate animal-to-human concentrations. An AUC blood level of methanol (90.9 hr x mg/L) associated with a one S.D. change from the control mean for brain weights in rats was estimated using the rat PBPK model. Then the human PBPK model was used to convert back to a human equivalent exposure concentration or a $BMCL_{HEC/1SD}$ of 182 mg/m^3. If no PBPK models were available, a $BMCL_{HEC/1SD}$ of 424 mg/m^3 would have been derived by adjusting the 556.5 mg/m^3 $BMCL_{1SD}$ for external exposure concentration for duration and the animal-to-human standard adjustment factor for systemic effects (the ratio of animal and human blood:air partition coefficients). This value is approximately twofold higher than the value derived using the PBPK model. However, as discussed above, use of PBPK-estimated maternal blood methanol levels for the estimation of HECs allows for the use of data-derived extrapolations rather than standard methods for extrapolations from external exposure levels.

As discussed in Section 3.4, the PBPK models do not describe or account for background levels of methanol, formaldehyde or formate, and background levels were subtracted from the reported data before use in model fitting or validation (if not already subtracted by study authors), as described below. This approach was taken because the relationship between background doses and background responses is not known, because the primary purpose of this assessment is for the determination of noncancer and cancer risk associated with increases in the levels of methanol or its metabolites (e.g., formate, formaldehyde) over background, and because the subtraction of background levels is not expected to have a significant impact on PBPK model parameter estimates (see further discussion in Section 3.4.3.2).

5.3.5. Route-to-Route Extrapolation

1   To estimate an oral dose POD for decrease in brain weight in rats, a route-to-route
2 extrapolation was performed on the inhalation exposure POD used to derive the RfC. One way
3 to characterize the uncertainty associated with this approach is to compare risk levels (BMDL
4 values) using the dose metric, AUC methanol, for developmental decreases in brain weight
5 derived from 1) an existing oral subchronic study and 2) from a model estimating this metric
6 from an existing inhalation subchronic study. There are currently no oral developmental studies
7 investigating decreases in brain weight available to compare to the risk values estimated using
8 the second procedure. However, the fact that the oral BMDL of 38.6 mg/kg-day estimated in this
9 assessment from the NEDO (1987, 064574) inhalation study of neonate rats via a PBPK model is
10 lower than the NOAEL of 500 mg/kg-day identified in EPA (1986, 196737) methanol study of
11 adult rats is consistent with other studies which suggest that fetal/neonatal organisms are a
12 sensitive subpopulation.

5.3.6. Statistical Uncertainty at the POD

13   There is uncertainty in the selection of the BMR level. For decreased brain weight in
14 rats, no established standard exists, so a BMR of one S.D. change from the control mean was
15 used. Parameter uncertainty can be assessed through CIs. Each description of parameter
16 uncertainty assumes that the underlying model and associated assumptions are valid. For the
17 Hill model applied to the data for decreased brain weight in rats, there is a degree of uncertainty
18 at the one S.D. level (the POD for derivation of the RfC), with the 95% one-sided lower
19 confidence limit (BMDL) being ~50% below the maximum likelihood estimate of the BMD.

5.3.7. Choice of Bioassay

20   The NEDO (1987, 064574) study was used for development of the RfC and RfD because
21 it resulted in the lowest BMDL. It was also a well-designed study, conducted in a relevant
22 species with an adequate number of animals per dose group, and with examination of appropriate
23 developmental toxicological endpoints. Developmental (Burbacher et al., 1999, 009752;
24 Burbacher et al., 1999, 009753; Burbacher et al., 2004, 059070; Burbacher et al., 2004, 056018)
25 and chronic studies (NEDO, 1987, 064574) of methanol have been performed in monkeys. As
26 discussed above in Section 5.3.1 and other sections of this assessment, while the monkey may be
27 a sensitive species for use in the determination of human risk, reporting deficits and study
28 uncertainties preclude their use in the derivation of an RfC.

5.3.8. Choice of Species/Gender

The RfC and RfD were based on decreased brain weight at 6 weeks postbirth in male rats (the gender most sensitive to this effect) (NEDO, 1987, 064574). This decrease in brain weight also occurs in female rats; however, if the decreased brain weight in female rats had been used, higher RfC and RfD values would have been derived (approximately 66% higher than the male derived values).

5.3.9. Human Population Variability

The extent of interindividual variation of methanol metabolism in humans has not been well characterized. As discussed in Section 4.9, there are a number of issues that may lead to sensitive human subpopulations. Potentially sensitive subpopulations would include individuals with polymorphisms in the enzymes involved in the metabolism of methanol and individuals with significant folate deficiencies. Sensitive lifestages would include children and neonates, as they have increased respiration rates compared to adults, which may increase their methanol blood levels compared to adults. Also, children have been shown to have decreased ADH activity relative to adults, thus decreasing their ability to metabolize and eliminate methanol. As demonstrated by these examples, there exists considerable uncertainty pertaining to human population variability in methanol metabolism, which provides justification for the 10-fold intraspecies UF used to derive the RfC and RfD.

5.4. CANCER ASSESSMENT

5.4.1. Oral Exposure

5.4.1.1. *Choice of Study/Data—with Rationale and Justification*

No human data exist that would allow for quantification of the cancer risk of chronic methanol exposure. Table 4-34 summarizes the available experimental animal oral exposure studies of methanol. The Soffritti et al. (2002, 091004) and Apaja (1980, 191208) oral studies report effects that show a statistically significant increase in incidence of cancer endpoints in the treated groups versus the control group (pair-wise comparison). As detailed in Section 4.2.1.3, Soffritti et al. (2002, 091004) exposed Sprague-Dawley rats via drinking water to 500–20,000 ppm methanol for 104 weeks. Exposure ended at 104 weeks, but the animals were not euthanized and were followed until their natural death. Increased lymphoma responses in multiple organs of male and female rats were the only carcinogenic effects reported in the Soffritti et al. (2002, 091004) methanol drinking water study that are considered dose related and quantifiable. Hepatocellular carcinomas observed in male rats are considered potentially dose

related (relative to historical controls) but are not quantifiable due to the lack of a statistically significant dose-response trend. Significant increases reported for head and ear duct carcinomas in male rats were not used because NTP pathologists interpreted a majority of these ear duct responses as being hyperplastic, not carcinogenic, in nature (EFSA, 2006, 196098; Hailey, 2004, 089842). Apaja (1980, 191208) observed significant increases in malignant lymphomas relative to untreated, historical controls in Eppley Swiss Webster mice exposed to methanol in drinking water for life. Due to the lack of a concurrent control, the Apaja (1980, 191208) study was not considered adequate for derivation of an oral slope factor. However, the quantitative analysis of the dose-response data from this study in Appendix E resulted in similar estimates of internal benchmark doses associated with 10% extra risk of a lymphoma response.

5.4.1.2. *Dose-Response Data*

The tumor incidence data selected for modeling were the lympho-immunoblastic lymphomas and the combined lympho-immunoblastic, lymphoblastic and lymphocytic lymphomas in both male and female rats of the Soffritti et al. (2002, 091004) study. These lymphomas were combined at the recommendation of NTP pathologists due to their similar histological origin (see discussion in Section 4.2.1.3). The incidence of histiocytic sarcomas and myeloid leukemias was not significantly increased in either sex, and the data for these tumors was not combined with the lymphoblastic lymphomas because they are of a different cell line and the combination is not typically evaluated either for statistical significance or dose-response modeling (Hailey, 2004, 089842; McConnell et al., 1986, 073655). Table 5-6 gives the lymphoma incidence data from the study which differs slightly from the data reported in Soffritti et al. (2002, 091004) in the incidence of lympho-immunoblastic lymphomas in the male 5,000 ppm group.[82]

---

[82] EPA obtained detailed, individual animal data via an interagency agreement with NIEHS which supported the development of reports made available through the Ramazzini Foundation (ERF) web portal (http://www.ramazzini.it/fondazione/foundation.asp). This allowed EPA to combine lymphomas of similar histopathological origin and confirm the tumor incidences reported in the Soffritti et al. (2002, 091004) paper.

Table 5-6. Incidence data for lymphoma, lympho-immunoblastic, and all lymphomas in male and female Sprague-Dawley rats

Dose (ppm)	Dose rate (mg/kg-day)	Internal dose $(mg/kg^{0.75}\text{-day})$ [a]	Number of animals examined	Lymphoma lympho-immunoblastic	All lymphomas combined
Female rats					
0	0	0	100	9	9
500	66.0	42.2	100	17	19[b]
5,000	624.1	291.0	100	19[b]	20[b]
20,000	2,177	318.0	100	21[b]	22[c]
Male rats					
0	0	0	100	16	17
500	53.2	37.3	100	24	27
5,000	524	284.0	100	28[b]	29[b]
20,000	1,780	317.5	99	37[c]	38[c]

[a] Allometrically scaled metabolized methanol metabolized (mg/kg0.75-day)
Statistically significant by Fisher's Exact test: [b] $p < 0.05$, [c] $p < 0.01$

Source: Soffritti et al. (2002, 091004) and ERF web portal
(http://www.ramazzini.it/fondazione/foundation.asp).

5.4.1.3. *Dose Adjustments and Extrapolation Method*

1   As with the extrapolations used in the development of the RfC and RfD, the PBPK model
2 was used for species-to-species extrapolation of the doses to be used in the cancer dose-response
3 analysis. Three dose metrics were considered for use in the dose-response analysis: total
4 metabolized methanol; maximum blood concentration of the parent (C_{max}); and area under the
5 blood concentration time curve (AUC) for the parent. Internal dose estimates (above
6 background) corresponding to the administered doses from the animal bioassay were determined
7 for each of these metrics with the PBPK model (see Appendix E, Table E-5). To help inform the
8 selection of the most appropriate dose metric, dose-response analyses were performed using
9 these PBPK model results to assess which dose metric best corresponded to the observed
10 incidence data in Table 5-6 (see Appendix E, Tables E-6 and E-7). Figures 5-3, 5-4, and 5-5
11 show the fit of the multistage model to the all lymphoma incidence data for female and males,
12 using each dose metric as the dose input.

Figure 5-3. All lymphomas versus allometrically scaled metabolized methanol metabolized (mg/kg$^{0.75}$-day) for female and male rats.

Figure 5-4. All lymphomas versus C_{max} (mg/L) for female and male rats.

Figure 5-5. All lymphomas versus AUC (hr x mg/L) for male and female rats.

The dose-response modeling suggests that allometrically scaled metabolized methanol is a better dose metric than the parent compound metrics as indicated by improved model fit to responses reported by Soffritti et al. (2002, 091004) for both lympho-immunoblastic lymphoma (see Appendix E, Table E-7) and all lymphoma (see Figures 5-3 to 5-5 and Appendix E, Table E-7), and also for malignant lymphoma responses reported by Apaja (1980, 191208) (see Appendix E, Table E-18). Chi-square p values for the total metabolite dose metric ranged from 0.18 to 0.55 and were consistently higher than for the other dose metrics. This could be an indication of the importance of metabolite formation, which is likely to be more rapid at low doses, to the carcinogenic response. The allometrically scaled metabolized methanol dose metric was selected as the dose metric for use in the dose-response assessment to derive the POD because it provided the best fit to the response data. With the allometric scaling, the equivalent human dose is assumed to be identical to the derived POD (from animal data); this scaling adjusts for the fact that the rate of metabolism is effectively a dose-rate for the key metabolite and the elimination of that metabolite is expected to scale allometrically across species and among individuals. The estimated human applied-dose BMDL was then back-calculated from the scaled metabolized POD using the EPA human PBPK model to obtain a human equivalent oral drinking water dose in terms of mg/kg-day (see Appendix E, Table E-8).

Multistage and multistage Weibull time-to-tumor models were applied to the lymphoma data obtained from ERF for the Soffritti et al. (2002, 091004) drinking water study and considered for determining the POD to be used in the derivation of the oral cancer slope factor (see Appendix E, Table 3-8). Appendix E gives the details and justification for the various approaches used. As described in Appendix E, time-to-tumor modeling and multistage quantal modeling gave similar results, and the tumor responses modeled did not exhibit significant time dependence on dose. The EPA multistage cancer model fit the response data adequately and was used to derive the oral cancer slope factor (CSF) (see Appendix E, Tables E-7, E-8, and Figure E-10).

BMDs and BMDLs were estimated for the combined lymphomas in male and female rats. The BMR selected was the standard value of 10% extra risk recommended for dichotomous models (U.S. EPA, 2000, 052150).[83] The 95% one-sided lower confidence limit defined the BMDL. The dose terms in the fitting were set equal to the estimated total metabolized doses derived using the PBPK model for methanol for each of the administered doses in the bioassay.

---

[83] The use of lower BMR values was determined not to have a significant impact on the CSF derivation.

1   Application of the multistage model to the incidence data for all lymphomas in male rats

2   (Table 5-6) resulted in the BMD and $BMDL_{10}$ values presented in Table 5-7. The results for the

3   male rat were used in the derivation of the CSF because the female data for this endpoint yielded

4   slightly higher values (see Appendix E, Tables E-7 and E-8). As stated above, since an

5   allometrically scaled dose-rate ($mg/kg^{0.75}$-day) was used, the human equivalent internal dose for

6   the $BMDL_{10}$ is the assumed to be identical to the male rat $BMDL_{10}$. The human PBPK model

7   (Appendix B) was then used to convert this scaled methanol metabolic rate ($BMDL_{10}$) to a

8   human equivalent methanol oral dose $HED(BMDL_{10})$ of 36.6 mg/kg-day for lymphomas in the

9   male rat (see Appendix E, Table E-8).[84]

Table 5-7. BMD results and oral CSF using all lymphoma in male rats

Allometrically scaled metabolic rates ($mg/kg^{0.75}$-d)		Human equivalent $HED(BMDL_{10})$ (mg/kg-day)	Oral CSF $(mg/kg\text{-}day)^{-1}$
BMD_{10}	Rat $BMDL_{10}$ =Estimated human $BMDL_{10}$		
	104.4	36.6	2.7E-03

Source: Soffritti et al. (2002, 091004).

10   In the case of methanol, there is no information to inform the MOA for carcinogenicity.

11   As recommended in the *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005, 086237),

12   "when the weight of evidence evaluation of all available data is insufficient to establish the MOA

13   for a tumor site and when scientifically plausible based on the available data, linear extrapolation

14   is used as a default approach." Accordingly, for the derivation of a quantitative estimate of

15   cancer risk for ingested methanol, a linear extrapolation was performed to determine the CSF.

5.4.1.4. *Oral Slope Factor*

16   The oral slope factor was derived based on a linear extrapolation from this

17    $HED(POD_{internal})$ (36.6 mg/kg-day for lymphomas in the male rat) to the estimated background

18   response level:

19    $$0.1/ HED(BMDL_{10}) = 0.1/36.6 \text{ mg/kg-day} = 3E\text{-}03 \ (mg/kg\text{-}day)^{-1}$$

(rounded to one significant figure)

---

[84] The following algebraic equation is provided in Appendix B (Equation 4) to describe the relationship between predicted human $mg/kg^{0.75}$-day methanol metabolized ("$dose_{internal}$") and the human equivalent oral dose (HED) in mg/kg-day:

$$HED = (4.286 \text{ mg/kg-d*}dose_{internal})/(860.0 \text{ mg/kg}^{0.75}\text{-d} - dose_{internal}) + (0.3448/kg^{0.25}\text{*}dose_{internal})$$

5.4.2. Inhalation Exposure

5.4.2.1. *Choice of Study/Data–with Rationale and Justification*

1   No human data exist that would allow for quantification of the cancer risk associated
2 with chronic methanol exposure. Table 4-35 summarizes the available experimental animal
3 inhalation exposure studies of methanol. The NEDO (1987, 064574; 2008, 196316) 24-month
4 rat study is the only inhalation bioassay available that reports an increase in incidence of any
5 cancer endpoints (see Section 4.2.2.3). This NEDO (1987, 064574; 2008, 196316) study was of
6 high quality and was based on standard OECD guidelines (OECD, 2007, 196300).   F344 rats
7 were exposed for 104 weeks to air concentrations of 0, 10, 100 and 1,000 ppm methanol. Rats
8 were sacrificed and necropsied at the end of the 104-week exposure period. The NEDO (1987,
9 064574; 2008, 196316) study reports increased pulmonary adenomas/adenocarcinomas and
10 pheochromocytomas in high-dose (1,000 ppm) male and female rats, respectively. The
11 combined incidence of pulmonary adenomas and adenocarcinomas was significantly increased in
12 the high-dose males (see Tables 4-5 and 5-8), and both tumor types were considerably elevated
13 at the high-dose over historical control incidences within their respective sex and strain (see
14 discussion in Section 4.2.2.3). As shown in Table 4-5, the severity and combined incidence of
15 potential precursor effects in the alveolar epithelium of male rat lungs (epithethial swelling,
16 adenomatosis, pulmonary adenoma, and pulmonary adenocarcinoma) and the adrenal glands of
17 female rats (hyperplasia and pheochromocytoma) were increased in the higher exposure groups
18 compared with the controls and lower exposure groups. While the incidence of male rat
19 pulmonary adenomas was also high in the lowest (10 ppm) exposure group, the appearance of a
20 rare adenocarcinoma in the high-dose group is suggestive of a progressive effect associated with
21 methanol exposure. While the increased pheochromocytoma response in female rats is not
22 statistically increased over controls, it is considered to be potentially treatment related because
23 this is a historically rare tumor type for female F344 rats (Haseman et al., 1998, 094054; NTP,
24 1999, 196291; NTP, 2007, 196299),[85] and when viewed in conjunction with the increased
25 medullary hyperplasia observed in the mid-exposure (100 ppm) group females, it is suggestive of
26 a proliferative change with increasing methanol exposure.

---

[85] Haseman et al. (1998, 094054) report rates for spontaneous pheochromocytomas in 2-year NTP bioassays of 5.7% (benign) and 0.3% (malignant) in male F344 rats and 0.3% (benign) and 0.1% (malignant) in female (n=1517) F344 rats.

5.4.2.2. *Dose-Response Data*

1 The tumor incidence data selected for modeling are the NEDO (1987, 064574; 2008,

2 196316) reported incidences of adenoma/adenocarcinoma in male rats and pheochromocytoma

3 in female rats. These data are presented in Table 5-8.

Table 5-8. Incidence data for tumor responses in male and female F344 rats

Concentration (ppm)	Internal Dose $(mg/kg^{0.75}$-d) [a]	Number of animals affected/number examined	
		Pheochromocytoma	Pulmonary adenoma/adenocarcinoma
Female rats			
0	0	2/50	2/52
10	0.79	3/51	0/19
100	7.91	2/49	0/20
1000	78.38	7/51[b,c]	0/52
Male rats			
0	0	7/52	1/52
10	0.79	2/16	5/50
100	7.91	2/10	2/52
1000	78.38	4/51	7/52[c,d]

[a] Allometrically scaled metabolized methanol metabolized (mg/kg0.75-day)
[b] $p < 0.05$ over NTP historical controls for total (benign, complex and malignant) pheochromocytomas using the Fisher's Exact test
[c] $p < 0.05$ for Cochrane-Armitage test of overall dose-response trend.
[d] $p < 0.05$ over concurrent controls using the Fisher's Exact test.

Source: NEDO (1987, 064574; 2008, 196316).

5.4.2.3. *Dose Adjustments and Extrapolation Method*

4 As with the extrapolations used in the development of the RfC and RfD, the PBPK model

5 was used for species-to-species extrapolation of the doses to be used in the cancer dose-response

6 analysis. Three dose metrics were considered for use in the dose-response analysis:

7 allometrically scaled metabolized methanol, maximum blood concentration of the parent (C_{max}),

8 and area under the blood concentration time curve (AUC) for the parent. Each of the dose

9 metrics corresponding to the administered dose from the animal bioassay was determined with

10 the PBPK model (see Appendix E, Table E-10). To help inform the selection of the most

11 appropriate dose metric, dose-response analyses were performed using these PBPK model results

12 to assess which dose metric best corresponded to the observed incidence data in Table 5-8 (see

13 Table E-11). All of the dose metrics resulted in similar fit to the incidence data for both

endpoints, with the total metabolites metric providing a slightly improved fit to the female pheochromocytoma response data.

Unlike the oral data discussed in Section 5.4.1.2, dose-response modeling of the inhalation data from NEDO (1987, 064574; 2008, 196316) does not suggest the use of any one dose metric over the other. However, since the pheochromocytoma response likely involves systemically distributed, metabolized methanol, and to be consistent with the oral CSF, analysis the scaled methanol metabolic rate dose metric is selected as the dose metric for use in the dose-response assessment to derive the inhalation POD. The estimated BMDL for the methanol metabolized dose metric was then back-calculated using the EPA PBPK model to obtain a human equivalent air exposure concentration in terms of mg/m3 (see Table E-12).

The EPA multistage model was applied to the data in Table 5-8 obtained from the NEDO (1987, 064574; 2008, 196316) inhalation study and considered for determining POD to be used in the derivation of the inhalation cancer unit risk (Table E-11). Appendix E gives the details and justification for the various approaches used. As described in Appendix E, time-to-tumor and quantal modeling gave similar results, and the tumor responses modeled did not exhibit significant time dependence on dose. The EPA multistage cancer model fit the response data adequately and was used to derive the IUR (Tables E-11, E-12, and Figure E-13).

BMDs and BMDLs were estimated for tumor responses in male and female rats shown in Table 5-8. The BMR selected was the standard value of 10% extra risk recommended for quantal models (U.S. EPA, 2000, 052150).[86] The 95% one-sided lower confidence limit defined the BMDL. The dose terms in the fitting were set equal to the estimated total metabolized doses derived using the PBPK model for methanol for each of the administered doses in the bioassay.

Application of the multistage model to the incidence data for pheochromocytomas in female rats (Table 5-8) resulted in the BMD and $BMDL_{10}$ values presented in Table 5-9. The results for the female rat were used because the female data for pheochromocytoma yielded slightly lower BMDL values (Table E-11). Assuming that the key methanol metabolite is cleared (i.e., metabolized) from the body by a rate that scales across species and among individuals according to body weight to the ¾ power, the human $BMDL_{10}$ is identical to the female rat $mg/kg^{0.75}$-day $BMDL_{10}$. The human PBPK model (Appendix B) was then used to convert this human $mg/kg^{0.75}$-day value for scaled methanol metabolized back to a human equivalent

---

[86] The use of lower BMR values was determined not to have a significant impact on the IUR derivation.

1 methanol inhalation concentration, HEC(BMCL$_{10}$), of 80.5 mg/m^3 or 80,500 μg/m^3 for

2 pheochromocytomas in the female rat (see Appendix E, Table E-12).[87]

Table 5-9. BMD results and IUR using pheochromocytoma in female rats

Allometrically scaled metabolic rate (mg/kg$^{0.75}$/day)		Human equivalent BMCL$_{10}$ (mg/m^3)	IUR (μg/m^3)$^{-1}$
BMC$_{10}$	BMDL$_{10}$=Estimated human BMCL$_{10}$		
	39.4	80.5	1.24E-06

Source: NEDO (1987, 064574; 2008, 196316).

5.4.2.4. *IUR*

3 The IUR in terms of (μg/m^3)$^{-1}$ was then derived based on a linear extrapolation from this

4 POD to the estimated background response level:

5 $$0.1/ \text{HEC(BMCL}_{10}) = 0.1/(80{,}500 \text{ μg/m}^3) = 1\text{E-06 (μg/m}^3)^{-1}$$

(rounded to one significant figure)

5.4.3. Uncertainties in Cancer Risk Assessment

6 The following is a discussion of the uncertainties associated with the cancer potency

7 estimate for methanol beyond that which can be addressed with the quantitative approach

8 applied. A summary of these uncertainties is presented in Table 5-10.

---

[87] The following algebraic equation is provided in Appendix B (Equation 3) to describe the relationship between predicted human mg-/kg$^{0.75}$-day methanol scaled metabolic rate (dose$_{internal}$) and the human equivalent inhalation concentration (HEC) in mg/m^3:

HEC = (19.75 mg/m^3 x dose$_{internal}$)/(996 (mg/kg$^{0.75}$-day) - dose$_{internal}$) + (1.5361 (kg$^{0.75}$-day/m^3) x dose$_{internal}$)

Table 5-10. Summary of uncertainty in the methanol cancer risk assessment

Consideration	Potential impact	Decision	Justification
Quality of the studies relied upon for the determination of the PODs	Key chronic studies not always well reported; could lead to ↑ or ↓ of risks	Utilize re-analyses of the Soffritti et al. (2002, 091004) and NEDO (2008, 196316; 2008, 196315) chronic studies	Consideration of all available information resulted in the determination that the Soffritti et al. (2002, 091004) and NEDO (2008, 196315; 2008, 196316) chronic studies are adequate (see discussion of individual studies in Sections 4.2.1.3 and 4.2.2.3 and summaries in Sections 4.9.1 and 4.9.2).
Interpretation of results from study relied upon for the determination of the POD	Differences in tumor classification can lead to over or underestimate of risk	Derive POD based on incidence of combined lymphomas as suggested by NTP pathologists; Assume proper classification of lung and adrenal tumors by NEDO	Both NTP and EFSA recommend that only lymphomas of the same cellular origin be combined for dose-response analysis. With respect to lung and adrenal tumors, examination of concurrent alveolar and adrenal noncancer hyperplastic endpoints supports a proliferative change in these organ systems consistent with the appearance of carcinogenic responses.
Consistency of results across chronic studies	If effects not relevant to humans, risk is overestimated.	Derive PODs based on Soffritti et al. (2002, 091004) and NEDO (2008, 196316).	Though tissue concordance across species, strains and routes of exposure is not assumed, lymphomas have been observed in more than one species by oral route. Also there is evidence that the observed lymphomas are relevant to humans (see discussions in Section 4.9. concerning human studies of methanol metabolite formaldehyde).
Choice of endpoint for POD derivation	Route-to-route extrapolation from Soffritti et al. (2002, 091004) study would ↑ inhalation POD by about 4-fold	Derive oral CSF from lymphoma data and inhalation IUR from adrenal effects.	Oral POD was based on the only tumor type from Soffritti et al. (2002, 091004) drinking water study significantly increased (all lymphomas); Inhalation POD based on most sensitive tumor response from NEDO (2008, 196316) study, increased pheochromocytoma in female rats.
Choice of species/gender	CSF and IUR would be ↓ if based on another gender	CSF and IUR are based on the most sensitive and reliably quantifiable species/gender	Choice of female rat lymphoma and male rat adenoma/adenocarcinoma would have resulted in lower CSF and IUR values, respectively. Use of the Apaja (1980, 191208) mouse data would have resulted in a higher, but less reliable CSF due to study problems, including a lack of concurrent controls
Choice of model for POD derivation	Use of other models could ↑ or ↓ POD, but not significantly	Derive cancer potency factor based on multistage model.	Use of the multistage model is consistent with EPA guidance (U.S. EPA, 2005, 086237). The multistage model provides adequate fit to the data, which is not improved by a time-to-tumor modeling.
Choice of animal-to-human extrapolation method	Traditional method could ↑ the HEC(BMCL$_{10}$) estimate by 4-fold.	A PBPK model was used to extrapolate animal–to–human concentrations.	Use of a PBPK model reduces uncertainty associated with the animal to human extrapolation. Total metabolites normalized by body weight is an appropriate dose metric and a verified PBPK model exists that estimates this metric.

5.4.3.1. *Quality of Studies that are the Basis for the PODs*

1   The protocols used at the laboratories that have performed cancer bioassays of methanol,
2 particularly those of the ERF, differ from the more commonly used (e.g., NTP) protocols. The
3 unique features of the ERF study design and their implications to a methanol cancer risk
4 assessment are discussed in Section 4.9.2. Separate from these experimental design issues are
5 considerations relative to the quality of the cancer bioassays and any associate uncertainties.

6   The number of animals per dose group in ERF studies is often higher than the 50 animals
7 per sex per dose group typically used in EPA and NTP studies, increasing the statistical power of
8 the ERF cancer bioassay. However, ERF sometimes shares controls across concurrent studies
9 (Belpoggi et al., 1995, 075825; Cruzan, 2009, 196354). In contrast, EPA requires (U.S. EPA,
10 1998, 030021) and NTP generally uses (Melnick et al., 2007, 196236) concurrent, matched
11 controls for each carcinogen bioassay. The use shared controls does not necessarily compromise
12 a study, but the use of a concurrent, matched control is generally preferred as a means of further
13 avoiding confounding factors and increasing the reliability of a study regarding the interpretation
14 of findings in treated animals.

15   The published report of the methanol bioassay (Soffritti et al., 2002, 091004) indicates
16 that the experiment was performed according to good laboratory practice (GLP) and standard
17 operating procedures (SOP) of the ERF. Further, an independent review of ERF (Huff, 2002,
18 090326) suggests that quality control procedures associated with GLP were in place. However,
19 questions have been raised about the quality of studies at the ERF by European Food Safety
20 Authority (EFSA, 2006, 196098) in regards to the aspartame bioassays conducted by the ERF
21 (Soffritti et al., 2006, 196735); by extension this EFSA report has raised issues for consideration
22 in regards to methanol. EFSA (2006, 196098) has suggested that an inspection by the Italian
23 GLP compliance monitoring authority (Ministry of Health) necessary to confirm GLP had not
24 been conducted.[88] The EFSA (2006, 196098) report also identifies specific deviations from
25 OECD guidelines (OECD, 2007, 196300), including a lack of a complete analysis of the test
26 substance, no clear information on the stability of the substance, a lack of clinical observations
27 or macroscopic changes, a lack of hematological assays, a lack of serology (e.g., to confirm the
28 presence of infection) and limited histopathology reports. While these details may be recorded
29 internally by the ERF as part of their standard protocol, because there is no documentation of
30 these details available for consideration, there remains some uncertainty regarding the level at
31 which they were performed. There is limited evidence, however, that these factors had a

---

[88] Since the publication of the EFSA (2006, 196098) report, the EPA has confirmed through communication with the
ERF laboratory (Knowles, 2008, 200774) that ERF is in the process of obtaining this certification.

significant impact on the adequacy of the study for assessing carcinogenic potential (see Sections 4.2.1.3, 4.9.2 and 5.4.3.2).

EFSA (2006, 196098) also expresses concern over the possibility of compromised pathological diagnosis in the ERF aspartame study (Soffritti et al., 2006, 196735) due to extensive autolysis. ERF performs pathological examinations on "dying animals undergoing necropsy" (Soffritti et al., 2002, 091004). This creates difficulties in pathological examinations associated with cell autolysis that can occur when pathology slides are prepared after natural death. The NTP (Hailey, 2004, 089842) commented on the increased prevalence of autolysis in slides from the ERF (Soffritti et al., 2006, 196735) aspartame study. EPA conducted a detailed analysis of the individual animal tissue data obtained from ERF for their chronic methanol, MTBE, formaldehyde, and aspartame studies, and determined that autolysis and other causes of tissue loss did not substantially impact tissue denominators. For most of the tissues evaluated there were more than 96 (individual animal) samples available for microscopic evaluation, and for all sites and dose groups, denominators were larger than for routine NTP bioassays (i.e., >50). Thus, missing tissues does not appear to have been a serious problem in the methanol study. While this analysis does not completely rule out the possibility that pathology slides and diagnoses were impacted by autolysis, it does indicate that this possibility would be offset by the large group size (response denominator) employed. Further, even if autolysis was a confounding factor, its presence would not negate positive cancer findings as autolysis would tend to decrease, not increase, the power to observe an effect.

There were no differences in survival among the methanol dose groups of the Soffritti et al. (2002, 091004) study. However, Cruzan (2009, 196354) has suggested that "While the survival at 104 weeks was within the normal, but widespread, range for Sprague-Dawley rats, there was significant early mortality among all groups, including the controls" and that "the control group from an inhalation study (Cruzan et al., 1998, 051380) had much better survival through 104 weeks than seen in the RF methanol study." Yet, according to Table 12 of the Cruzan (2009, 196354) article, 104-week survival in male (~40%) and female (~50%) control rats of the Cruzan et al. (1998, 051380) study was not discernibly different from the 104 week survival of male (~40%) and female (~50%) control rats of the Soffritti et al. (2002, 091004) methanol study (see Appendix E, Figures E-1 and E-2). Survival of male and female Sprague-Dawley rats in the Soffritti et al. (2002, 091004) study at 104 weeks was greater than 40% in all but the female 5,000 ppm group. At the NTP (2006, 196296), the 104-week survival of 353 control female Sprague-Dawley rats was 41.5% (range of 28.3%–51% in 7 studies) using NTP's new diet and corn oil gavage.

Studies such as the Soffritti et al. (2002, 091004) methanol study that allow test animals to live a full life span can be difficult to interpret due to the need to distinguish between age-related and chemical-related effects. Full life-span studies may have advantages. Huff et al. (2008, 196234) note that "studies truncated after 2 years of exposure do not allow sufficient latency periods for late-developing tumors, such as the 80% of all human cancers that occur after 60 years of age." Several recent publications have noted deficiencies with the 2-year study design used at the NTP and have recommended extending the duration of rodent studies to increase the sensitivity of their bioassays (Bucher, 2002, 196169; Huff and LaDou, 2007, 196233; Huff et al., 2008, 196234; Maronpot et al., 2004, 196228).

While arguments have been documented related to the possible confounding influence of infection and autolysis on the results obtained from the ERF, available evidence does not indicate that these factors significantly influenced the observed lymphoma/leukemia response in the methanol or other bioassays conducted at ERF. In addition, for the purposes of this assessment and at the request of the EPA, the ERF and NEDO have provided additional study details beyond that which is normally available from published journal articles, including quality assurance reports and individual animal data. Based on a review of this information, consideration of the issues, and absent additional data to the contrary, EPA has determined that both studies were sufficient for use in the assessment of risk from methanol exposure.

5.4.3.2. *Interpretation of Results of the Studies that are the Basis for the PODs*

There are a number of uncertainties regarding the interpretation of both the lymphoma response in male Sprague-Dawley rats (Soffritti et al., 2002, 091004) that forms the basis of the oral CSF and the pheochromocytoma response in F344 rats (NEDO, 2008, 196316) that forms the basis for the inhalation IUR.

There is also a wide range in the background incidence of hemolymphoreticular tumors reported in control groups of ERF studies. Between 1984 and 1997, incidence rates of hemolymphoreticular neoplasms in control rats at ERF increased by 38% among male rats and decreased by 12% among female rats (Caldwell et al., 2008, 196182). Soffritti et al. (2006, 196735; 2007, 196366) reports that among 2,265 untreated males and 2,274 untreated females the average incidence of lymphomas and leukemias is 20.6% (range, 8.0-30.9%) in males and 13.3% (range, 4.0-25%) in females. Caldwell et al. (2008, 196182) noted that for the incidences of these lesions for the ERF colony are relatively low and stable across studies. EFSA (2006, 196098) and Cruzan (2009, 196354) consider it to be high relative to other tumor types and relative to the background rate for this tumor type in Sprague-Dawley rats from other laboratories (see Section 4.9.2 for further discussion).

In the ERF bioassays, including methanol, hemolymphoreticular neoplasms were divided into specific histological types (lymphoblastic lymphoma, lymphoblastic leukemia, lymphocytic lymphoma, lympho-immunoblastic lymphoma, myeloid leukemia, histocytic sarcoma, and monocytic leukemia) for identification purposes. Upon examining slides from the aspartame study conducted by the ERF, a PWG of the NTP at the NIEHS (Hailey, 2004, 089842) found that "The diagnoses of lymphatic and histocytic neoplasms in the cases reviewed were generally confirmed. The NTP does not routinely subdivide lymphomas into specific histological types as was done by the ERF, however the PWG accepted their more specific diagnosis if the lesion was considered to be consistent with a neoplasm of lymphocytic, histocytic, monocytic, and/or myeloid origin." The NTP PWG also noted that while lymphoblastic lymphomas, lymphocytic lymphomas, lympho-immunoblastic lymphomas and lymphoblastic leukemias as malignant lymphomas can be combined, myeloid leukemias, histocytic sarcomas and monocytic leukemia should be treated as separate malignancies and not combined with the other lymphomas for statistical evaluation since they are of different cellular origin (Hailey, 2004, 089842). Other researchers have also noted this distinction between myeloid leukemias and histiocytic sarcomas and other lymphomas (McConnell et al., 1986, 073655). To decrease the uncertainty in the combination of tumors relied upon for dose-response modeling, the current dose-response modeling conducted for methanol did not include myeloid leukemia, histocytic sarcoma, monocytic leukemia, alone or in combination with lymphoblastic lymphoma, lymphoblastic leukemia, lymphocytic lymphoma, and lympho-immunoblastic lymphoma.

As expressed by EFSA (2006, 196098) and others (Cruzan, 2009, 196354; Schoeb et al., 2009, 196192), there is concern that the lympho-immunoblastic lymphoma response in the ERF aspartame study (Soffritti et al., 2005, 087840; Soffritti et al., 2006, 196735) was caused by or confused with sequelae of a *M. pulmonis* infection. Infection of the ERF colony with *M. pulmonis* has not been confirmed (Caldwell et al., 2008, 196182) and, as discussed in Section 4.9.2, a link between *M. pulmonis* infection and induction of lymphoma in rats has not been established in the literature. As noted in Section 4.9.2, there is evidence suggesting that respiratory infections may have confounded the interpretation of lung lesions in ERF studies. Lymphoma illustrations in 2 ERF studies (Figure 10 of Soffritti et al. (2005, 087840) and Figures 1-5 of Belpoggi et al. (1999, 196209)), suggest that ERF MTBE and aspartame bioassays may have been confounded by a respiratory infection such as *M. pulmonis* and that lesions associated with this infection may have been interpreted as lymphoma (Schoeb et al., 2009, 196192). However, other ERF lymphoma diagnoses in multiple rat organ systems, including the lung, have been confirmed by an independent working group panel of six NIEHS pathologists (Hailey, 2004, 089842). In addition, the incidence of "lung-only" lympho-immunoblastic lymphomas

1 was evenly distributed across the control and 0, 500 5000, 20,000 ppm dose groups for male (9,

2 10, 14 and 13) and female (3, 5, 6 and 7) rats of the Soffritti et al. (2002, 091004) methanol study

3 (Schoeb et al., 2009, 196192). Consequently, removing "lung-only" lympho-immunoblastic

4 lymphomas from consideration and using only lymphomas from organ systems not likely to be

5 confounded by a respiratory infection (i.e., subtracting the lung-only incidence from lympho-

6 immunoblastic lymphomas reported in Table 5-6) still results in increasing dose-response curves

7 for this lesion with p values for model fit of 0.06 and 0.20 for males and females, respectively

8 (see Figure 5-6). The $BMDL_{10}$ estimates of 134 (males) and 213 (females) mg metabolized

9 methanol/$kg^{0.75}$-day are about 30% higher than metabolized methanol $BMDL_{10}$ estimates for this

10 endpoint when "lung-only" responses are included (Appendix E, Table E-7).

Figure 5-6. Lympho-immunoblastic Lymphoma minus "lung-only" response in rats of Soffritti et al. (2002, 091004) methanol study versus methanol metabolized (mg/kg$^{0.75}$-day).

1   For increases in 2 other tumor types (ear duct and head/oral cavity tumors) reported in

2   the ERF methanol study (Table 4-2), an independent review of the 75 pathology slides from the

3   ERF aspartame study has suggested differences in interpretation. After reviewing these slides,

the NTP PWG noted that "about half" of hyperplastic and neoplastic lesions in the ear duct or oral cavity were more severely classified by ERF study pathologists, compared with diagnosis from the PWG (EFSA, 2006, 196098). Though a similar review has not been conducted of the Soffritti et al. (2002, 091004) ERF methanol bioassay results, there is uncertainty regarding the ERF interpretation of these lesions. For this reason, these lesions were not considered in the derivation of the oral CSF.

Another uncertainty that confounds the interpretation of some ERF studies is the possibility of litter effects in ERF test groups. Bucher (2002, 196169) has reported that ERF does not randomize the assignment of animals to treatment groups, but generally "assigns all animals from a given litter to the same treatment group, recording which litter each animal came from." This approach would make it more difficult to distinguish the relative contributions of the chemical and genetics to the effect of concern. In response to an EPA query regarding this matter (Knowles, 2008, 200774), ERF has stated that "the assignment of test animals to dose groups will vary in ERF studies according to the experimental protocol and aims of the research" and "in the case of experiments in which exposure begins at 6-8 weeks of age (for example BT960, methanol), randomization is performed so as to have no more than one female and one male from each litter in each experimental group." For other experiments in which exposure begins during prenatal life, [89] "randomization is performed on the breeders," but the offspring are not randomized across dose groups in order to "..simulate as much as possible the human situation in which all descendents are part of a population."

There is uncertainty regarding the pheochromocytoma response observed in the NEDO (2008, 196316) study with respect to both its relation to exposure and to its pathology. As discussed in Section 4.2.2.3, the incidence of pheochromocytomas in female rats exhibited a dose-response trend (Cochrane-Armitage $p < 0.05$). While the incidence of 13.7% (7/51) in the high-dose group was significantly elevated ($p < 0.05$) over NTP historical controls, it was not significantly elevated over the concurrent control rate of 4% (2/50). Much of the uncertainty is inherent in difficulties associated with the characterization of this lesion. According to NTP (2000, 196293), the primary criterion used to distinguish pheochromocytomas from nonneoplastic adrenal medullary hyperplasia, the presence of mild-to-moderate compression of the adjacent tissue, can be a difficult determination. Further, while NEDO (2008, 196316) reported adrenal effects as "hyperplasia of medullary cells" and "pheochromocytoma," NTP pathologists categorize pheochromocytomas into three types: benign, complex and malignant

---

[89] For some chemicals such as vinyl chloride (Maltoni et al., 1988, 196225) and aspartame (Soffritti et al., 2006, 196735), ERF has started exposure as early as *in utero,* This early exposure study design can markedly increase the sensitivity of a cancer bioassay (Maltoni et al., 1988, 196225)(Soffritti et al., 2006, 196735)(Melnick et al., 2007, 196236).

(NTP, 1999, 196291; NTP, 2006, 196296). This is an important distinction as complex and malignant pheochromocytomas are a rare tumor type, occurring spontaneously in female F344 rats at rates ranging from 0.1% to 0.7% (Haseman et al., 1998, 094054; NTP, 1999, 196291; NTP, 2007, 196299) and with cell proliferation activity that is much higher than benign pheochromocytomas (Pace et al., 2002, 196304).   Thus, severity of the pheochromocytoma response reported by NEDO (2008, 196316) is uncertain, potentially ranging from mischaracterized hyperplasia to highly proliferative and potentially metastatic malignancies. Finally, the NEDO study was a two-year study, and these lesions, which include diffuse hyperplasia, nodular hyperplasia, and pheochromocytoma, progress with age. Thus, it is possible that a life-span study would have detected a more severe carcinogenic response (e.g., progression of the mid-dose group hyperplastic responses as reported in Table 4-5).

5.4.3.3. *Consistency across Chronic Bioassays for Methanol*

The observation of a lymphoma response in rats (Soffritti et al., 2002, 091004) and mice (Apaja, 1980, 191208), along with reported associations between lymphomas and human exposure to methanol's metabolite, formaldehyde (see Section 4.9), contributes significantly to the cancer weight-of-evidence determination. This was the only carcinogenic response that was observed in more than one animal bioassay. However, tissue concordance across species, strains and routes of exposure is not assumed, and a lack of such concordance does not negate the validity of individual findings nor the potential relevance of such findings to humans.

Besides the Soffritti et al. (2002, 091004) drinking water study of rats (2 years) reported by ERF, the only other chronic studies available are the Apaja (1980, 191208) lifespan drinking water study in Eppley Swiss Webster mice which did not include a concurrent untreated control group, and those reported in the Japanese NEDO (1987, 064574; 2008, 196315; 2008, 196316) study of monkeys (7–29 months), mice (18 months), and F344 rats (2 years). None of the NEDO studies involved lifetime evaluations, and only the rat study can be said to cover a significant portion of the test species life span. The only organ system that exhibited an increase in effects in both inhalation and drinking water studies was the testes. High-dose rats of the Soffritti et al. (2002, 091004) methanol study exhibited an increase in testicular interstitial cell adenomas, and the incidence of testicular hyperplasia was increased in high-dose rats of the NEDO (1987, 064574; 2008, 196316) study. However, neither effect was statistically increased over controls, and both effects were well within their historical control ranges. An increase in lymphomas was the only carcinogenic effect reported in the Soffritti et al. (2002, 091004) and Apaja (1980, 191208) drinking water studies that is considered dose related and quantifiable, and male pulmonary adenoma/adenocarcinoma and female pheochromocytoma were the only carcinogenic

effects from the NEDO (1987, 064574; 2008, 196316) inhalation study that are considered exposure related and quantifiable.

As discussed in Section 4.9.2, there are several differences between the NEDO (1987, 064574; 2008, 196316) and Soffritti et al. (2002, 091004) studies conducted in rats which limit their direct comparison and may explain some of the differences in response. These include route of exposure, lifetime evaluation period, and strain of species used. Pulmonary adenomas observed in the NEDO inhalation study could be portal-of-entry effects associated with the inhalation route of exposure. Differences in systemic effects observed in the two studies such as the pheochromocytoma response in the NEDO (1987, 064574; 2008, 196316) study and the lymphoma responses observed in the Soffritti et al. (2002, 091004) study are systemic responses and differences would not be expected based on route of exposure. Differences in the evaluation period between the two studies may have contributed to the lack of endpoint concordance. In the Soffritti et al. (2002, 091004) study, the animals were administered methanol for 104 weeks and then followed until the completion of their natural lifetime. The average life span for these animals was 94 and 96 weeks for males and females, respectively, with animals living as long as 153 weeks (female). However, this does not explain the difference in lymphoma response between the studies as many of the lympho-immunoblastic lymphomas (most common type observed) were observed prior to 104 weeks (control – 5/9; 500 ppm – 7/17; 5,000 ppm – 13/19; 20,000 ppm – 11/21). The NEDO (1987, 064574; 2008, 196316) study was conducted in F344 rats versus the Sprague-Dawley rats used in the Soffritti et al. (2002, 091004) ERF study. More importantly, the background rates of selected types of lymphomas and leukemias are very different between the two strains of rats. In the F344 rat, there is a high background rate of mononuclear cell leukemia, while there is a much lower background rate of this leukemia type in the Sprague-Dawley rat (Caldwell et al., 2008, 196182). The types of lymphoma reported in the Sprague-Dawley rat by Soffritti et al. (2002, 091004) following methanol administration are rarely diagnosed in the F344 rat. Thus, the strain difference between the two studies is a likely explanation for the fact that lymphomas were only increased in the Soffritti et al. (2002, 091004) rat study. NTP (1999, 196291; 2007, 196299), reports do not suggest a significant difference between F344 and Sprague-Dawley rats with respect to pulmonary adenomas and pheochromocytomas. Another possible explanation for this difference includes a different profile of circulating metabolites associated with oral first-pass liver metabolism.

5.4.3.4. *Choice of Endpoint for POD Derivation*

Keeping in mind the aforementioned uncertainties associated with the interpretation of the Soffritti et al. (2002, 091004) and NEDO (2008, 196316) study results, the choice of tumors to use for the derivation of the oral CSF and inhalation IUR was made on the basis of the

appearance of a dose-related increase in response rates for the selected tumor categories. Analysis of lymphomas used a pair-wise statistical comparison (Fisher's Exact test) and a trend test (Cochran Armitage trend test) to determine whether the slope of that trend was statistically significantly greater than 0. The Fisher's Exact result for the male rat high-dose group and the results of the Cochran Armitage Trend Test were both $p < 0.01$. The decision not to include the liver tumors in the dose-response analysis was made based on a lack of dose response according to pair-wise and a trend test results versus concurrent controls This is not to say that the slight increase in the incidence of this tumor type observed in all dose groups of male rats was not related to methanol exposure (this is a relatively rare Sprague-Dawley rat tumor), only that the increase was not statistically significant and did not contribute significantly to the overall tumor response.

As discussed in Sections 4.2.2.3 and 4.9.2, the high-dose incidences for pulmonary adenomas/adenocarcinomas were increased over concurrent controls ($p < 0.05$). While the high-dose incidences of pheochromocytomas in the NEDO (2008, 196316) study were not statistically increased over concurrent controls, the dose-response for both tumor types represents increasing trends (Cochran Armitage trend test; $p < 0.05$), and in both cases, the high-dose response incidences were considerably elevated over historical control incidences ($p < 0.05$) within their respective sex and strain. Further, both tumor responses are accompanied by proliferative changes (e.g., hyperplastic responses) in their respective cell types that suggest tumor progression.

5.4.3.5. *Choice of Species/Gender*

The oral CSF was based on male rat lymphomas rather than female rat lymphomas. The inhalation IUR was based on female rat pheochromocytomas rather than male rat adenoma/carcinomas. In both cases, the gender that exhibited the steeper dose response and the higher risk estimate was chosen.

Both the CSF and IUR were based on rat studies. Use of the Apaja (1980, 191208) mouse data would have resulted in slightly higher oral CSF. However, this study was not used due to a high level of uncertainty associated with the Apaja (1980, 191208) study, which contained limited experimental detail and did not include a concurrent control group (see Section 4.2.1.3).

5.4.3.6. *Choice of Model for POD Derivation*

The multistage-cancer model contained in EPA's BMDS version 2.1.1 (U.S. EPA, 2009, 200772) was used to derive both the CSF and IUR estimates for methanol. When no biologically-based cancer model exists and evidence for a nonlinear cancer MOA is lacking, as is the case for methanol, the preference within the EPA's IRIS program is for the use of a multistage model. There is uncertainty associated with whether the multistage model is the most

appropriate choice, but in the absence of a biologically based model, dose-response modeling is largely a curve-fitting exercise, and the multistage model is sufficiently flexible for most cancer bioassay data. In the case of the oral CSF, individual animal response data was obtained from the authors of the principal study (Soffritti et al., 2002, 091004) and a multistage-Weibull time-to-tumor model was applied to determine whether the lifespan study design of the study had an appreciable impact on the dose-response analysis. As described in Appendix E, time-to-tumor modeling and multistage quantal modeling gave similar results, and the tumor responses modeled did not exhibit significant time dependence on dose.

5.4.3.7. *Choice of Dose Metric*

The allometrically scaled methanol metabolized was selected over AUC or the C_{max} as the most appropriate dose metric for derivation of the oral cancer slope factor and inhalation unit risk primarily because it provided the best fit to response data, particularly lymphoma incidence from Soffritti et al. (2002, 091004) (see Figures 5-3 through 5-5 and Table E-7 of Appendix E) and Apaja (1980, 191208) (see Table E-18 of Appendix E). Also, lymphomas and respiratory effects have been observed in studies conducted with formaldehyde, and lymphomas have been observed in chronic bioassays conducted with other compounds that convert to formaldehyde (i.e., MTBE and aspartame). As discussed in Section 4.9.3, metabolites of methanol, particularly formaldehyde, may play a role in the MOA.

In considering the dose-response relationship for methanol-induced carcinogenesis, a key factor is the saturation of metabolism since metabolic transformation to formaldehyde and generation of oxidative stress are considered likely candidates in the mode of action. Cruzan (2009, 196354) indicates that saturation occurs at dose of "600 mg/kg," but saturation depends on the dose rate, not the total administered dose. For example, if 600 mg/kg is given in a single bolus, the internal concentration immediately following that bolus could well be high enough to saturate metabolism, while the same total dose ingested over the course of a day might not.

To aid in interpretation of the Soffritti et al. (2002, 091004) bioassay, water ingestion in rats was assumed to shift between nocturnal (high activity) and diurnal (low activity) periods, each lasting 12 hours. Rats were assumed to consume 20% of their daily water ingestion during the diurnal period and 80% during the nocturnal period. Ingestion in each period was assumed to occur in "bouts" which were treated as periods of continuous (zero-order) infusion to the stomach. During the nocturnal period each bout was assumed to last 45 minutes, followed by 45 minutes without ingestion (overall period is 1.5 hours) and during the diurnal period the bout was assumed to last on 3 hours followed by 2.5 hours without ingestion (overall period is 3 hours).

1   Given this exposure pattern, the amount metabolized per day (after periodicity is

2 reached) in a 420 g rat (average weight in Soffritti et al., (2002, 091004)) was estimated using

3 the PBPK model, with the results shown in Figure 5-7. The amount increases almost linearly

4 with exposure until ~ 400 mg/kg/d, but continues to increase above that point, becoming almost

5 completely saturated by 2,200 mg/kg/d. This pattern occurs in part because of the circadian

6 ingestion pattern. The more rapid ingestion rate during the dark cycle leads to the highest

7 internal concentrations and hence the initial metabolic saturation during that part of the day. But

8 the lower ingestion (light) period, internal concentrations drop, allowing for an exposure range

9 (400-1,600 mg/kg/d) where nocturnal metabolism is saturated but diurnal metabolism is not.

Figure 5-7. Scaled amount metabolized per day (after periodicity is reached) in a 420 g rat.

10   While, based on this exposure-dose pattern, one might expect a similar exposure-

11 response relationship, this pattern does not include detoxification mechanisms. If such

12 mechanisms also saturate, then it is possible for the slower increase in total metabolism above

13 400 mg/kg/d to result in a significant increase in effect, though full metabolic saturation at

14 ~2,000 mg/kg/d would still be expected to result in a maximal effect at that exposure level.

5.4.3.8. *Choice of Animal-to-Human Extrapolation Method*

15   A PBPK model was used to extrapolate animal-to-human concentrations. The estimated

16 methanol metabolized for each dose administered to the animals in NEDO (2008, 196316) and

17 Soffritti et al. (2002, 091004) were determined using the animal PBPK model, and then the

18 BMDL$_{10}$ determined by the methods described previously (Sections 5.4.1 and 5.4.2); the value

1   for male rats for oral exposure was $BMDL_{10} = 104.4$ mg/kg$^{0.75}$-day and the value for female rats

2   for inhalation exposure was $BMDL_{10} = 39.4$ mg/kg$^{0.75}$-day. Assuming that key methanol

3   metabolites are cleared (metabolized) from the body at a rate that scales across species and

4   among individuals according to body weight to the ¾ power, the human mg/kg$^{0.75}$ $BMDL_{10}$

5   values are expected to equal those in the rat. The human PBPK model (Appendix B) was then

6   used to convert these human mg/kg$^{0.75}$-day values for total methanol metabolized back to a

7   human equivalent methanol oral dose HED($BMDL_{10}$) of 36.6 mg/kg-day for lymphomas in the

8   male rat, and a human equivalent methanol inhalation concentration HEC($BMCL_{10}$) of

9   80.5 mg/m^3 for pheochromocytomas in the female rat. If traditional dosimetry assumptions are

10   used, the HED($BMDL_{10}$) and HEC($BMCL_{10}$) estimates would have been approximately 4-fold

11   higher than the value derived using the PBPK model.

12   As discussed in Sections 3.4 and 5.3.4, the PBPK models do not describe or account for

13   background levels of methanol, formaldehyde or formate, and background levels were subtracted

14   from the reported data before use in model fitting or validation (if not already subtracted by

15   study authors), as described below. This approach was taken because the relationship between

16   background doses and background responses is not known, because the primary purpose of this

17   assessment is for the determination of noncancer and cancer risk associated with increases in the

18   levels of methanol or its metabolites (e.g., formate, formaldehyde) over background, and because

19   including background levels in the PBPK modeling was found to have an insignificant impact on

20   the estimation of risk due to increased methanol exposure over background (see Section

21   3.4.3.2.1). However, there is uncertainty associated with the relationship between background

22   levels of methanol or its metabolites and adverse effects. Adequate human data are not available

23   to evaluate this relationship and, while inconclusive, the results of dose-response analysis of

24   tumor data from rat cancer bioassays using "background dose" modeling (see discussion in

25   Appendix E, Section E.5) does not rule out the possibility of a relationship between background

26   doses and background cancer, particularly for doses characterized as allometrically scaled

27   metabolized methanol (mg/kg$^{0.75}$-day).

5.4.3.9. *Human Relevance of Cancer Responses Observed in Rats and Mice*

28   As discussed in Sections 4.9.2, there is human evidence for the association of lymphomas

29   with a metabolite of methanol, formaldehyde. However, there is no information available in the

30   literature regarding the observation of cancer in humans following chronic administration of

31   methanol. The only observations in animals were noted in the chronic studies of methanol

32   conducted by Apaja (1980, 191208), Soffritti et al. (2002, 091004) and NEDO (2008, 196316)

33   and there is uncertainty associated with the interpretation of the tumor responses reported in

34   these studies. As a consequence, the overall WOE, while convincing, is not strong.

6. MAJOR CONCLUSIONS IN CHARACTERIZATION OF HAZARD AND DOSE RESPONSE

6.1. HUMAN HAZARD POTENTIAL

1 Methanol is the smallest member of the family of aliphatic alcohols. Also known as
2 methyl alcohol or wood alcohol, among other synonyms, it is a colorless, very volatile, and
3 flammable liquid that is widely used as a solvent in many commercial and consumer products. It
4 is freely miscible with water and other short-chain aliphatic alcohols but has little tendency to
5 distribute into lipophilic media. Methanol can be formed in the mammalian organism as a
6 metabolic byproduct and can be ingested with foodstuffs, such as fruits or vegetables. A
7 potential for human exposure exists today in the form of the artificial sweetener, aspartame,
8 which is a methyl ester of the dipeptide aspartyl-phenylalanine. Methanol is the major anti-
9 freeze constituent of windshield washer fluid. Its use as a fuel additive for internal combustion
10 engines is, as yet, limited by its corrosive properties.

11 Because of its very low oil:water partition coefficient, methanol is taken up efficiently by
12 the lung or the intestinal tract and distributes freely in body water without any tendency to
13 accumulate in fatty tissues. It can be metabolized completely to CO_2, but may also, as a regular
14 byproduct of metabolism, enter the C_1-pool and become incorporated into biomolecules. Animal
15 studies indicate that blood methanol levels increase with the breathing rate and that metabolism
16 becomes saturated at high exposure levels. Because of its volatility it can also be excreted
17 unchanged via urine or exhaled air.

18 The acute toxicity in laboratory animals in response to high levels of exposure results
19 from CNS depression. NEDO (1987, 064574) reported that methanol blood levels around
20 5,000 mg/L were necessary to cause clinical signs and CNS changes in monkeys. In humans,
21 however, acute toxicity can result from relatively low doses due to metabolic acidosis that
22 appears to affect predominantly the nervous system, with potentially lasting effects such as
23 blindness, Parkinson-like symptoms, and cognitive impairment. These effects can be observed
24 in humans when blood methanol levels exceed 200 mg/L. The species differences in toxicity
25 from acute exposures appear to be the result of a limited ability of humans to metabolize formic
26 acid.

27 Despite the existence of many case reports on acute human exposures, the knowledge
28 base for long-term, low-level exposure of humans to methanol is limited. The current TLV for
29 methanol is 200 ppm (262 mg/m^3) (American, 2000, 002886). Controlled experiments with
30 human volunteers indicate that only minor neurobehavioral changes occur following 4-hour

exposure to this concentration. A limited study on self-reported health effects in 66 persons
exposed to methanol at levels that came close to or exceeded the NIOSH short-term ceiling of
800 ppm (1048 mg/m^3), in comparison with an age-matched group of 66 less or not exposed
persons, suggested a statistically significant increase in the incidence of CNS-related symptoms,
such as dizziness, nausea, headache, and blurred vision (Frederick et al., 1984, 031063).
Impaired vision and nasal irritation were observed in a study of 33 methanol-exposed workers
(Kawai et al., 1991, 032418). None of the case reports or human studies have investigated cancer
as a potential outcome of methanol exposure.

A number of reproductive, developmental, subchronic and chronic exposure duration
studies have been conducted in mice, rats, and monkeys. This summary will focus primarily on
reproductive and developmental toxicity, and cancer as the main endpoints of concern. Sections
4.7, 5.1.1 and 5.2.1 contain more extensive summaries that consider the dose-related effects that
have been observed in other organ systems following subchronic or chronic exposure.

Although there is no evidence in humans, methanol has shown to be a reproductive and
developmental toxicant in several animal studies. No studies have been reported in which
humans have been exposed subchronically or chronically to methanol by the oral route of
exposure, and thus would be suitable for derivation of an oral RfD. Data exist regarding effects
from oral exposure in experimental animals, but they are more limited than data from the
inhalation route of exposure (see Sections 4.2, 4.3, and 4.4). Two oral studies in rats (Soffritti et
al., 2002, 091004) (U.S., 1986, 196737), one oral study in mice (Apaja, 1980, 191208) and
several inhalation studies in monkeys, rats and mice (NEDO, 1987, 064574; NEDO, 2008,
196315; NEDO, 2008, 196316) of 90-days duration or longer have been reported. While some
noncancer effects of methanol exposure were noted in these studies, principally in the liver and
brain, they were either not quantifiable due to study limitations or occurred at high doses relative
to reproductive/developmental effects. As discussed below, the results of inhalation
reproductive/developmental toxicity studies in rats (NEDO, 1987, 064574), mice (Rogers et al.,
1993, 032696), and monkeys (Burbacher et al., 1999, 009752; Burbacher et al., 1999, 009753;
Burbacher et al., 2004, 059070; Burbacher et al., 2004, 056018) are the principal considerations
for both the RfD and RfC values derived in this assessment.

A larger number of studies have used the inhalation route to assess the potential of
reproductive or developmental toxicity of methanol in mice, rats, and monkeys, with
concentrations ranging from 200 to 20,000 ppm (blood levels reaching as high as 8.65 mg/mL).
To sum up the findings, rat dams survived even the highest doses without gross signs of toxicity,
but their offspring were severely affected (Nelson et al., 1985, 064573). Two more inhalation
studies, Rogers et al. (1993, 032696; 1993, 032697) and Rogers and Mole (1997, 009755),

confirmed that methanol causes exencephaly and cleft palate in mice, the most sensitive days
being GD6 and GD7 (i.e., early organogenesis). These severe malformations were observed at
exposure concentrations of 5,000 ppm or above. Nelson et al. (1985, 064573) and Rogers et al.
(1993, 032696) also observed an increased occurrence of ossification disturbances and skeletal
anomalies at methanol concentrations ≥ 2,000 ppm, of which cervical ribs in mouse fetuses is
considered the critical effect for toxicity value derivation in this review. A study conducted in
pregnant cynomolgus monkeys that were exposed to 200-600 ppm methanol for 2.5 hours/day
throughout premating, mating, and gestation showed no signs of maternal or fetal toxicity. The
potential compound-related effects noted were a shortening of the gestation period by less than
5% and developmental neurotoxicity, particularly delayed sensorimotor development monkeys
(Burbacher et al., 1999, 009752; Burbacher et al., 1999, 009753; Burbacher et al., 2004, 059070;
Burbacher et al., 2004, 056018).

While all of the above studies were conducted with exposure durations of 7 hours/day or
less, NEDO (1987, 064574) conducted a series of developmental/reproductive studies in rats that
used exposure times of 20 hours/day or more at concentrations between 500 and 5,000 ppm. A
two-generation study by these researchers that exposed the dams throughout pregnancy and the
pups through 8 weeks of age, demonstrated dose-dependent reductions in brain weights that
forms the basis for the RfC derived in this review.

Carcinogenic effects following methanol exposure were observed in a chronic drinking
water study in Eppley Swiss Webster mice (Apaja, 1980, 191208) and two chronic rat studies: a
drinking water study of Sprague-Dawley rats (Soffritti et al., 2002, 091004) and an inhalation
study of F344 rats (NEDO, 2008, 196316). Following administration via drinking water, both
Apaja (1980, 191208) and Soffritti et al. (2002, 091004) observed positive dose-response trends
for increases in the incidence of lymphomas in both test animal genders. Soffritti et al. (2002,
091004) characterized the lymphomas in their study as lymphoreticular, principally lympho-
immunoblastic. EPA re-analyzed the lymphoma data from the Soffritti et al. (2002, 091004)
study for quantification purposes, combining only tumors of the same cell type origin. There
was a slight increase in hepatocellular carcinomas in male rats of all exposure groups of this
study that was not statistically elevated over controls in any group, but potentially this tumor is
related to methanol exposure given the low historical background rate for this tumor in this rat
strain. As discussed in Section 5.4.1.1, the other tumor increases reported by Soffritti et al.
(2002, 091004) are not quantifiable or were considered hyperplastic rather than carcinogenic
following a review by NTP pathologists (EFSA, 2006, 196098; Hailey, 2004, 089842). No
tumor responses were significantly increased over controls in the chronic inhalation bioassays
performed by NEDO (1987, 064574) in monkeys, and mice, but the high-dose incidences for

pulmonary adenomas/adenocarcinomas in male rats was elevated over concurrent controls and
pheochromocytomas in female rats were significantly elevated over historical control incidences
for these tumor types within their respective sex and strain. The dose response for both of these
tumor types represents increasing trends (Cochran Armitage trend test; $p < 0.05$). Further, both
tumor responses are accompanied by proliferative changes (e.g., hyperplastic responses) in their
respective cell types.

6.2. DOSE RESPONSE

As described in Chapter 3, background levels of methanol and its metabolites are
produced through endogenous metabolic processes. Potential risks resulting from these
endogenous levels are not determined in this IRIS assessment. This assessment focuses on the
determination of noncancer and cancer risk associated with exogenous methanol exposures that
increase the body burden of methanol or its metabolites (e.g., formate, formaldehyde) above
endogenous background levels. Average background blood levels in healthy adults following
restriction of methanol-producing foods from the diet are reported in Section 3.1 (Table 3-1).
The mouse, rat and human PBPK models developed for this assessment predict increased blood
levels of methanol and its metabolites over background following oral or inhalation exposure to
methanol (see further discussion in Section 3.4.3.2). Consequently, this assessment provides
estimates of noncancer and cancer risk from oral and inhalation exposures above sources of
methanol that contribute to background blood levels.

6.2.1. Noncancer/Inhalation

Clearly defined toxic endpoints at moderate exposure levels have been observed only in
reproductive and developmental toxicity studies. Three endpoints from developmental toxicity
studies were considered for derivation of the RfC: formation of cervical ribs in CD-1 mice
exposed to methanol during organogenesis (Rogers et al., 1993, 032696), deficits in
sensorimotor development as measured by VDR tests administered to monkeys exposed to
methanol monkeys (Burbacher et al., 1999, 009752; 1999, 009753; 2004, 059070; 2004,
056018), and reduced brain weights in rats exposed to methanol from early gestation through 8
weeks of postnatal life (NEDO, 1987, 064574). For the purpose of comparability and to better
illustrate methodological uncertainty, reference values were derived for all of these endpoints
using a BMD modeling approach which evaluated several models and various measures of risk.
In the present review, mostly because of a paucity of adequate long-term or developmental oral
studies and the existence of several inhalation studies that examined sensitive subpopulations
(pregnant mothers, developing fetuses and neonates) in various species, it was decided to use the

critical effect from an inhalation study to derive an RfD. Thus, the criteria and rationales on which the RfC assessment is based also form the basis for the RfD derivation.

The Rogers et al. (1993, 032696) inhalation study is a multidose developmental study that was considered for use in the derivation of a reference value. The exposure concentrations in this study were 0, 1,000, 2,000, and 5,000 ppm administered for 7 hours/day on GD7–GD17. The BMD evaluation, based on the nested log-logistic model of BMDS version 2.1.1 (U.S. EPA, 2009, 200772), produced BMD/BMDL values in terms of internal peak blood methanol (C_{max}). PBPK modeling was used to convert the internal animal dose metrics to HECs, and a UF of 100 was applied to yield RfCs of 10.4 mg/m^3 and 13.6 mg/m^3 for 5 and 10% extra risk, respectively.

Reproductive and developmental neurobehavioral effects observed in monkeys following methanol inhalation exposure monkeys (Burbacher et al., 1999, 009752; 1999, 009753; 2004, 059070; 2004, 056018) were also considered for use in the derivation of a reference value. *M. fascicularis* monkeys were exposed to 0, 262, 786, and 2,359 mg/m^3 methanol 2.5 hours/day, 7 days/week during premating/mating and throughout gestation (approximately 168 days). Delayed sensorimotor development as measured by a VDR test was the only effect in this study that exhibited a dose-response and is a measure of a functional deficit that is consistent with early developmental CNS effects (e.g., brain weight changes) that have been observed in rats (NEDO, 1987, 064574). Though there is uncertainty associated with this effect and its relation to methanol exposure, a BMD analysis was performed for comparative purposes. BMD/BMDL values for the VDR endpoint were estimated using AUCs derived from a monkey PBPK model of blood methanol data reported in the Burbacher et al. (1999, 009752) monkeys study. A human methanol PBPK modeling was then used to convert the internal AUC BMDL to an HEC, and a UF of 100 was applied to yield a reference value estimate of 1.7 mg/m^3.

Reduced brain weight was evaluated based on the results of a two-generation study by NEDO (1987, 064574) in which fetal rats and their dams were exposed from the first day of gestation until 8 weeks of age, and brain weights were determined at 3, 6, and 8 weeks of age. To obtain reference value estimates from these studies, a rat PBPK model was used to predict PODs in terms of internal doses, which were converted to HEC values via a human PBPK model and divided by UFs (see Table 5-4). BMD modeling was executed using two different BMRs, one S.D. (as is usual with continuous data) and 5% relative (to control response) risk. The resulting reference value estimates were 2.4 and 1.8 mg/m^3 (5% relative risk and 1 S.D., respectively) for reduced brain weight at 6 weeks of age following gestational and postnatal exposure.

Despite the variety of approaches, different critical effects, and different data sources, all reference value estimates fell within a narrow range. The reference value associated with the

BMD estimate of the dose corresponding to a one S.D. decrease in brain weight in male rats at 6 weeks post-birth observed in the NEDO (1987, 064574) developmental toxicity study is considered most suitable for derivation of the methanol chronic RfC due to the relevance of the exposure scenario/study design and endpoint (see Sections 5.1.2.2 and 5.3) to the potential for developmental effects in neonatal humans, the relative robustness of the dose response data and because it resulted in one of the lowest reference values of the BMD derivations (see Table 5-4). Thus, the proposed chronic RfC for exposure to methanol is 2 mg/m^3, an evaluation that includes a UF_H of 10 for intraspecies variability, a UF_A of 3 to address the pharmacodynamic component of interspecies variability, and a UF_D of 3 for database uncertainty.

The confidence in this RfC is medium to high. Confidence in the NEDO (1987, 064574) developmental studies is medium to high. While there are issues with the lack of reporting detail, the critical effect (brain weight reduction) has been reproduced in an oral study of adult rats (U.S., 1986, 196737), and the exposure regimen involving pre- and postnatal exposures addresses a potentially sensitive human subpopulation. Confidence in the database is medium. Despite the fact that skeletal and brain effects have been demonstrated and corroborated in multiple animal studies in rats, mice, and monkeys, some study results were not quantifiable, there is uncertainty regarding which is the most relevant test species, and there is limited data regarding reproductive or developmental toxicity of methanol in humans. There is also uncertainty regarding the potential active agent—the parent compound, methanol, formaldehyde, or formic acid. There are deficiencies in our knowledge of the metabolic pathways of methanol in the human fetus during early organogenesis, when the critical effects can be induced in animals. Thus, the medium-to-high confidence in the critical study and the medium confidence in the database together warrant an overall confidence descriptor of medium to high.

6.2.2. Noncancer/Oral

There is a paucity of scientific data regarding the outcomes of chronic oral exposure to methanol. No data exist for long-term methanol exposure of humans. A subchronic (90-day) oral study in Sprague-Dawley rats reported brain and liver weight changes, with some evidence for minor liver damage at 2,500 mg/kg-day that was not supported by histopathologic findings (U.S., 1986, 196737). Liver necrosis was reported in Eppley Swiss Webster mice that consumed approximately 2000 mg/kg-day (Apaja, 1980, 191208). In the only other study that administered methanol chronically to animals by the oral route, Soffritti et al. (2002, 091004) reported that, overall, there was no pattern of compound-related clinical signs of toxicity in Sprague-Dawley rats exposed to up to approximately 2,000 mg/kg-day. The authors further reported that there

were no compound-related signs of gross pathology nor histopathologic lesions indicative of noncancer toxicological effects in response to methanol; however, they did not provide any detailed data to illustrate these findings.

As discussed above and in Section 5.1.1, reproductive and developmental effects are considered the most sensitive and quantifiable effects reported in studies of methanol. Oral reproductive and developmental studies employed single doses that were too high to be of use. In the absence of suitable reproductive or developmental data from oral exposure studies, it was decided to conduct a route-to-route extrapolation and to use the critical effect from the inhalation study (brain weight) to derive an RfD. Thus, the POD (in terms of AUC methanol in blood) used for the derivation of the RfC was also used for the derivation of the RfD. This POD was converted to an HED via a human PBPK model and divided by a UF of 100 to obtain an RfD value of 0.4 mg/kg-day. As for the RfC, the 100-fold UF includes a UF_H of 10 for intraspecies variability, a UF_A of 3 to address pharmacodynamic uncertainty, and a UF_D of 3 for database uncertainty.

The confidence in the RfD is medium to high. Despite the relatively high confidence in the critical studies, all limitations to confidence as presented for the RfC also apply to the RfD. Confidence in the RfD is slightly lower than for the RfC due to the lack of adequate oral studies for the RfD derivation, necessitating a route-to-route extrapolation.

6.2.3. Cancer/Oral and Inhalation

Under the current *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005, 086237; U.S. EPA, 2005, 088823), methanol fulfils the criteria to be described as *likely to be a human carcinogen* by all routes of exposure. This descriptor is based principally on findings of dose-related, statistically significant increases in the incidence of: lymphoreticular tumors in lifetime studies of both sexes of Eppley Swiss Webster mice (Apaja, 1980, 191208) and both sexes of Sprague-Dawley rats (Soffritti et al., 2002, 091004), a slight but significant (compared to historical controls) increase in relatively rare hepatocellular carcinomas in male Sprague-Dawley rats following oral exposure (Soffritti et al., 2002, 091004), and dose-related occurrences of pulmonary adenomas/adenocarcinomas and pheochromocytomas in F344 rats by inhalation exposure (NEDO, 2008, 196316). This determination is supported by the results of other studies that have shown tumorogenic responses similar to those observed by Soffritti et al. (2002, 091004) in rats exposed to formaldehyde, a metabolite of methanol, and to the metabolic precursors of methanol and formaldehyde, aspartame and MTBE. In addition, epidemiological studies have associated exposure to formaldehyde with increases in the incidence of both leukemias and lymphomas (IARC, 2004, 196244). However, the key studies, Soffritti et al.

1　(2002, 091004), NEDO (2008, 196316) and Apaja (1980, 191208), have associated uncertainties

2　(see below and discussions in Sections 4.9.2 and 5.4.3) that reduce confidence in the chosen

3　descriptor.

4　　　The statistically significant increase in the incidence of lymphoreticular tumors observed

5　in the Soffritti et al. (2002, 091004) drinking water study of Sprague-Dawley rats was used in the

6　determination of the POD for estimating the methanol oral CSF. A PBPK model was developed,

7　and several model predictions of internal dose metrics were considered for use in the dose-

8　response analysis and derivation of the human equivalent dose. Methanol metabolized was

9　selected as the dose metric best suited for derivation of the oral POD because of its superior fit to

10　the response data and consistency with the hypothesis that formaldehyde may be the

11　carcinogenic agent associated with methanol exposure. The EPA multistage cancer model was

12　used to derive a $BMDL_{10}$ for the male rat in terms of mg methanol metabolized/day. Assuming

13　that key methanol metabolites are cleared from the body at rates that scale across species and

14　among individuals according to body weight to the ¾ power, the human $BMDL_{10}$ is identical to

15　the rat $BMDL_{10}$ of 104.4 $mg/kg^{0.75}$-day.   The human PBPK model was then used to convert this

16　human mg-day value for total methanol metabolized back to a human equivalent methanol oral

17　dose HED ($BMDL_{10}$) of 36.6 mg/kg-day for lymphomas in the male rat. The oral CSF of 3E-03

18　$(mg/kg-day)^{-1}$ was then derived based on a linear extrapolation from this POD to estimated

19　background levels.

20　　　Pulmonary adenomas/adenocarcinomas in male F344 rats and pheochromocytomas in

21　female F344 rats observed in the chronic inhalation study of NEDO (2008, 196316) were

22　considered in the determination of the POD for estimating the inhalation IUR. In this case, all

23　dose metrics estimated by the PBPK model provided a similar acceptable fit to the tumor

24　response data. Methanol metabolized was selected as the dose metric for derivation of the

25　inhalation POD for consistency with the approach used for the derivation of the oral POD and

26　with the hypothesis that formaldehyde may be the carcinogenic agent associated with methanol

27　exposure. As for the oral POD, the EPA multistage cancer model was used to derive a $BMDL_{10}$

28　for the rat in terms of mg methanol metabolized/day. Assuming that key methanol metabolites

29　are cleared from the body at rates that scale across species and among individuals according to

30　body weight to the ¾ power, the human $BMDL_{10}$ is identical to the rat $BMDL_{10}$ of 39.4

31　$mg/kg^{0.75}$-day. The human PBPK model was then used to convert this human mg-day value for

32　total methanol metabolized back to a human equivalent methanol inhalation concentration

33　HEC($BMCL_{10}$) of 80,500 $\mu g/m^3$ for pheochromocytomas in the female rat. The inhalation

34　cancer unit risk of 1E-06 $(\mu g/m^3)^{-1}$ was then derived based on a linear extrapolation from this

35　POD to estimated background levels.

1   Section 5.4.3 of this assessment documents several uncertainties with the quantification

2   of cancer risk. The main uncertainties can be grouped into issues related to study quality, the

3   interpretation of study results, and the consistency of the results with other laboratories. Other

4   uncertainties discussed in Section 5.4.3 include the choice of tumor endpoint, the choice of dose-

5   response model, the PBPK model and dose metric used for the animal to human extrapolations,

6   and the human relevance of the carcinogenic responses in rats and mice.

7. REFERENCES

Abbondandolo A; Bonatti S; Corsi C; Corti G; Fiorio R; Leporini C; Mazzaccaro A; Nieri R; Barale R; Loprieno N. (1980). The use of organic solvents in mutagenicity testing. DNA Repair (Amst), 79: 141-150. 031009

Adanir J; Ozkalkanti MY; Aksun M. (2005). Percutaneous methanol intoxication: Case report. Eur J Anaesthesiol, 22: 560-561. 196175

Agarwal DP. (2001). Genetic polymorphisms of alcohol metabolizing enzymes. Pathol Biol, 49: 703-709. 056332

Airas L; Paavilainen T; Marttila RJ; Rinne J. (2008). Methanol intoxication-induced nigrostriatal dysfunction detected using 6-[18F]fluoro-L-dopa PET. Neurotoxicology, 29: 671-674. 196177

Akaike H. (1973). Information theory and an extension of the maximum likelihood principle. Presented at In: Petrov, B. N.; Csaki, F., eds. 2nd International symposium on information theory; September 1971; Tsahkadsor, Armenia, USSR. Budapest, Hungary: Akademiai Kiado; pp. 267-281., Budapest, Hungary. 000591

Albert RE; Sellakumar AR; Laskin S; Kuschner M; Nelson N; Snyder CA. (1982). Gaseous formaldehyde and hydrogen chloride induction of nasal cancer in the rat. J Natl Cancer Inst, 68: 597-603. 065679

Albin RL; Greenamyre JT. (1992). Alternative excitotoxic hypotheses. Neurology, 42: 733-738. 196178

Allen BC; Kavlock RJ; Kimmel CA; Faustman EM. (1994). Dose-response assessment for developmental toxicity II: comparison of generic benchmark dose estimates with no observed adverse effect levels. Toxicol Sci, 23: 487-495. 197125

American Conference of Governmental Industrial Hygienists. (2000). 2000 TLVs"R" and BEIs"R": based on the documentations of the threshold limit values for chemical substances and physical agents and biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists. 002886

Andresen H; Schmoldt H; Matschke J; Flachskampfc FA; Turka EE. (2008). Fatal methanol intoxication with different survival times -morphological findings and postmortem methanol distribution. Forensic Sci Int, 179: 206-210. 196179

Andrews JE; Ebron-McCoy M; Kavlock RJ; Rogers JM. (1995). Developmental toxicity of formate and formic acid in whole embryo culture: a comparative study with mouse and rat embryos. Teratology, 51: 243-251. 077672

Andrews JE; Ebron-McCoy M; Logsdon TR; Mole LM; Kavlock RJ; Rogers JM. (1993). Developmental toxicity of methanol in whole embryo culture: a comparative study with mouse and rat embryos. Toxicology, 81: 205-215. 032687

Note. Hyperlinks to the reference citations throughout this document will take you to the NCEA HERO database (Health and Environmental Research Online) at http://epa.gov/hero. HERO is a database of scientific literature used by U.S. EPA in the process of developing science assessments such as the Integrated Science Assessments (ISAs) and the Integrated Risk Information System (IRIS).

Andrews JE; Ebron-McCoy M; Schmid JE; Svensgaard D. (1998). Effects of combinations of methanol and formic acid on rat embryos in culture. Birth Defects Res A Clin Mol Teratol, 58: 54-61. 079068

Andrews LS; Clary JJ; Terrill JB; Bolte HF. (1987). Subchronic inhalation toxicity of methanol. J Toxicol Environ Health, 20: 117-124. 030946

Ang HL; Deltour L; Hayamizu TF; Žgombic-Knight M; Duester G. (1996). Retinoic acid synthesis in mouse embryos during gastrulation and craniofacial development linked to class IV alcohol dehydrogenase gene expression. J Biol Chem, 271: 9526-9534. 196181

Antony AC. (2007). In utero physiology: role of folic acid in nutrient delivery and fetal development. Am J Clin Nutr, 85 (suppl.): 598S- 603S. 196184

Apaja M. (1980). Evaluation of toxicity and carcinogenicity of malonaldehyde: An experimental study in Swiss mice. Acta Universitatis Ouluensis, Series D, Medica 55. Finland: Anat Pathol Microbiol. 191208

Arora V; Nijjar IBS; Multani AS; Singh JP; Abrol R; Chopra R; Attri R. (2007). MRI findings in methanol intoxication: a report of two cases. Br J Radiol, 80: 243-6. 092994

Arora, V; Nijjar, IS; Thukral, H; Roopa. (2005). Bilateral putaminal necrosis caused by methanol intoxication- a case report. Neuroradiology, 15: 341-342. 196185

Aschner M; Kimelberg HK eds. (1996). The role of glia in neurotoxicity. Boca Raton, FL: CRC Press. 076190

Aufderheide TP; White SM; Brady WJ; Stueven HA. (1993). Inhalational and percutaneous methanol toxicity in two firefighters. Ann Emerg Med, 22: 1916-1918. 032704

Aziz MH; Agrawal AK; Adhami VM; Ali MM; Baig MA; Seth PK. (2002). Methanol-induced neurotoxicity in pups exposed during lactation through mother; role of folic acid. Neurotoxicol Teratol, 24: 519-527. 034481

Azmak D. (2006). Methanol related deaths in Edirne. Leg Med, 8: 39-42. 090781

Barceloux DG; Bond GR; Krenzelok EP; Cooper H; Vale JA. (2002). American academy of clinical toxicology practice guidelines on the treatment of methanol poisoning. Clin Toxicol, 40: 415-446. 180477

Batterman SA; Franzblau A. (1997). Time-resolved cutaneous absorption and permeation rates of methanol in human volunteers. Int Arch Occup Environ Health, 70: 341-351. 056331

Batterman SA; Franzblau A; D'Arcy JB; Sargent NE; Gross KB; Schreck RM. (1998). Breath, urine, and blood measurements as biological exposure indices of short-term inhalation exposure to methanol. Int Arch Occup Environ Health, 71: 325-335. 086797

Bearn P; Patel J; O'Flynn WR. (1993). Cervical ribs: a cause of distal and cerebral embolism. Postgrad Med J, 69: 65-68. 196194

Bebarta VS; Heard K; Dart RC. (2006). Inhalational abuse of methanol products: elevated methanol and formate levels without vision loss. Am J Emerg Med, 24: 725-728. 090790

Belpoggi F; Soffritti M; Filippini F; Maltoni C. (1997). Results of long-term experimental studies on the carcinogenicity of methyl tert-butyl ether. In Bingham, E.; Rall, D. P. (Ed.),Preventive strategies for living in a chemical world: a symposium in honor of Irving J. Selikoff (pp. 77-95). Ann. N. Y.: Acad. Sci. 047984

Belpoggi F; Soffritti M; Maltoni C. (1995). Methyl-tertiary-butyl ether (MTBE)--a gasoline additive--causes testicular and lymphohaematopoietic cancers in rats. Toxicol Ind Health, 11: 119-149. 075825

Belpoggi F; Soffritti M; Maltoni C. (1998). Pathological characterization of testicular tumours and lymphomas-leukaemias, and of their precursors observed in Sprague-Dawley rats exposed to methyl-tertiary-butyl-ether (MTBE). Giornale Europeo di Oncologia (Italian), 3: 201-206. 086776

Belpoggi F; Soffritti M; Maltoni C. (1999). Immunoblastic lymphomas in Sprague-Dawley rats following exposure to the gasoline oxygenated additives Methyl-Tertiary-Butyl Ether (MTBE) and Ethyl-Tertiary-Butyl Ether (ETBE): early observations on their natural history. Giornale Europeo di Oncologia (Italian), 4: 563-572. 196209

Bennett IL Jr; Cary FH; Mitchell GL Jr; Cooper MN. (1953). Acute methyl alcohol poisoning: A review based on experiences in an outbreak of 323 cases. Medicine (Baltimore), 32: 431-463. 031139

Benton CD Jr; Calhoun FP Jr. (1952). The ocular effects of methyl alcohol poisoning: Report of a catastrophe involving three hundred and twenty persons. Trans Am Acad Ophthalmol Otolaryngol, 56: 875-885. 030947

Bessell-Browne RJ; Bynevelt M. (2007). Two cases of methanol poisoning: CT and MRI features. Australasian Radiology, 51: 175-178. 093109

Bhatia KP; Marsden CD. (1994). The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain, 117: 859-876. 076489

Black KA; Eells JT; Noker PE; Hawtrey CA; Tephly TR. (1985). Role of hepatic tetrahydrofolate in the species difference in methanol toxicity. PNAS, 82: 3854-3858. 094937

Blancato JN; Evans MV; Power FW; Caldwell JC. (2007). Development and use of PBPK modeling and the impact of metabolism on variability in dose metrics for the risk assessment of methyl tertiary butyl ether (MTBE). J Environ Prot Sci, 1: 29-51. 091278

Blanco M; Casado R; Vázquez F; Pumar JM. (2006). CT and MR imaging findings in methanol intoxication. Am J Neuroradiol, 27: 452-454. 196161

Bosron WF; Li T-K. (1986). Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism. Hepatology, 6: 502-510. 056330

Bouchard M; Brunet RC; Droz P-O; Carrier G. (2001). A biologically based dynamic model for predicting the disposition of methanol and its metabolites in animals and humans. Toxicol Sci, 64: 169-184. 030672

Braden GL; Strayhorn CH; Germain MJ; Mulhern JG; Skutches CL. (1993). Increased osmolal gap in alcoholic acidosis. Arch Intern Med, 153: 2377-2380. 196164

Brahmi N; Blel Y; Abidi N; Kouraichi N; Thabet H; Hedhili A; Amamou M. (2007). Methanol poisoning in Tunisia: Report of 16 cases. Clin Toxicol, 45: 717-20. 092993

Branch S; Rogers JM; Brownie CF; Chernoff N. (1996). Supernumerary lumbar rib: Manifestation of basic alteration in embryonic development of ribs. J Appl Toxicol, 16: 115-119. 196166

Brent J; Lucas M; Kulig K; Rumack BH. (1991). Methanol poisoning in a six-week-old infant. J Paediatr Child Health, 118: 644-646. 032300

Brien JF; Clarke DW; Richardson B; Patrick J. (1985). Disposition of ethanol in maternal blood, fetal blood, and amniotic fluid of third-trimester pregnant ewes. Am J Obstet Gynecol, 152: 583-590. 031551

Brown RP; Delp MD; Lindstedt SL; Rhomberg LR; Beliles RP. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health, 13: 407-484. 020304

Bucher JR. (2002). The National Toxicology Program rodent bioassay: Designs, interpretations, and scientific contributions. Ann N Y Acad Sci, 982: 198-207. 196169

Burbacher T; Grant K; Shen D; Damian D; Ellis S; Liberato N. (1999). Reproductive and offspring developmental effects following maternal inhalation exposure to methanol in nonhuman primates Part II: developmental effects in infants exposed prenatally to methanol. Health Effects Institute. Cambridge, MA. 009753

Burbacher T; Shen D; Grant K; Sheppard L; Damian D; Ellis S; Liberato N. (1999). Reproductive and offspring developmental effects following maternal inhalation exposure to methanol in nonhuman primates Part I: methanol disposition and reproductive toxicity in adult females. Health Effects Institute. Cambridge, MA. 009752

Burbacher TM; Grant KS; Shen DD; Sheppard L; Damian D; Ellis S; Liberato N. (2004). Chronic maternal methanol inhalation in nonhuman primates (Macaca fascicularis): reproductive performance and birth outcome. Neurotoxicol Teratol, 26: 639-650. 059070

Burbacher TM; Shen DD; Lalovic B; Grant KS; Sheppard L; Damian D; Ellis S; Liberato N. (2004). Chronic maternal methanol inhalation in nonhuman primates (Macaca fascicularis): exposure and toxicokinetics prior to and during pregnancy. Neurotoxicol Teratol, 26: 201-221. 056018

Burnell JC; Li T-K; Bosron WF. (1989). Purification and steady-state kinetic characterization of human liver b3b3 alcohol dehydrogenase. Biochemistry, 28: 6810-6815. 088308

Burwell RD; Whealin J; Gallagher M. (1992). Effects of aging on the diurnal pattern of water intake in rats. Behav Neural Biol, 58: 196-203. 196176

Butchko HH; Stargel WW; Comer CP; Mayhew DA; Benninger C; Blackburn GL; De Sonneville LMJ; Geha RS; Hertelendy Z; Koestner A; Leon AS; Liepa GU; McMartin KE; Mendenhall CL; Munro IC; Novotny EJ; Renwick AG; Schiffman SS; Schomer DL; Shaywitz BA; Spiers PA; Tephly TR; Thomas JA; Trefz FK. (2002). Aspartame: Review of safety. Regul Toxicol Pharmacol, 35: S1-S93. 034722

Caldwell J; Jinot J; Devoney D; Gift JS. (2008). Evaluation of evidence for infection as a mode of action for induction of rat lymphoma. Environ Mol Mutagen, 49: 155-164. 196182

Caldwell J; Jinot J; Devoney D; Gift JS. (2009). Author reply to comment on "Evaluation of evidence for infection as the mode of action for induction of rat lymphoma" . Environ Mol Mutagen, 50: 6-9. 196183

Cameron AM; Nilsen OG; Haug E; Eik-Nes KB. (1984). Circulating concentrations of testosterone, luteinizing hormone and follicle stimulating hormone in male rats after inhalation of methanol. Arch Toxicol, 7: 441-443. 064567

Cameron AM; Zahlsen K; Haug E; Nilsen OG; Eik-Nes KB. (1985). Circulating steroids in male rats following inhalation of n-alcohols. Arch Toxicol, 8: 422-424. 064568

Campbell JA; Howard DR; Backer LC; Allen JW. (1991). Evidence that methanol inhalation does not induce chromosome damage in mice. DNA Repair (Amst), 260: 257-264. 032354

Carson BL; McCann JL; Ellis HV III; Herndon BL; Baker LH. (1981). Methanol health effects [final task 7 report]. U.S. EPA. Ann Arbor, MI. 031176

Caspi R; Foerster H; Fulcher CA; Hopkinson R; Ingraham J; Kaipa P; Krummenacker M; Paley S; Pick J; Rhee SY; Tissier C; Zhang P; Karp PD. (2006). MetaCyc: a multiorganism database of metabolic pathways and enzymes. Nucleic Acids Res, 34: D511-D516. 196186

CERHR. (2004). NTP-CERHR expert panel report on the reproductive and developmental toxicity of methanol. Reprod Toxicol, 18: 303-390. 091201

Chandra M; Riley MG; Johnson DE. (1992). Spontaneous neoplasms in aged Sprague-Dawley rats. Arch Toxicol, 66: 496-502. 020535

Chen JC; Schneiderman JF; Wortzman G. (1991). Methanol poisoning: Bilateral putaminal and cerebellar cortical lesions on CT and MR. J Comput Assist Tomogr, 15: 522-524. 032295

Chen-Tsi, C. (1959). [Materials on the hygienic standardization of the maximally permissible concentration of methanol vapors in the atmosphere]. Gig Sanit, 24: 7-12. 196193

Chernoff N; Rogers JM. (2004). Supernumerary ribs in developmental toxicity bioassays and in human populations: Incidence and biological significance. J Toxicol Environ Health B Crit Rev, 7: 437-449. 069993

Chun JS; Burleigh-Flayer HD; Kintigh WJ. (1992). Methyl tertiary butyl ether: vapor inhalation oncogenicity study in Fischer 344 rats. 068400

Chuwers P; Osterloh J; Kelly T; D'Alessandro A; Quinlan P; Becker C. (1995). Neurobehavioral effects of low-level methanol vapor exposure in healthy human volunteers. Environ Res, 71: 141-150. 081298

Cichoz-Lach H; Partycka J; Nesina I; Wojcierowski J; Slomka M; Celinski K. (2007). Genetic polymorphism of alcohol dehydrogenase 3 in digestive tract alcohol damage. Hepatogastroenterology, 54: 1222-1227. 196229

Clancy B; Finlay BL; Darlington RB; Anand KJ. (2007). Extrapolating brain development from experimental species to humans. Neurotoxicology, 28: 931-937. 196224

Clarke DW; Steenaart NAE; Brien JF. (1986). Disposition of ethanol and activity of hepatic and placental alcohol dehydrogenase and aldehyde dehydrogenases in the third-trimester pregnant guinea pig for single and short-term oral ethanol administration. Alcohol Clin Exp Res, 10: 330-336. 031223

Clary JJ. (2003). Methanol, is it a developmental risk to humans?. Regul Toxicol Pharmacol, 37: 83-91. 047003

Clewell HJ III; Gentry PR; Gearhart JM; Covington TR; Banton MI; Andersen ME. (2001). Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. Toxicol Sci, 63: 160-172. 030673

Coleman CN; Mason T; Hooker EP; Robinson SE. (1999). Developmental effects of intermittent prenatal exposure to 1,1,1-trichloroethane in the rat. Neurotoxicol Teratol, 21: 699-708. 196341

Collins AS; Sumner SCJ; Borghoff SJ; Medinsky MA. (1999). A physiological model for tert-amyl methyl ether and tert-amyl alcohol: hypothesis testing of model structures. Toxicol Sci, 49: 15-28. 012383

Connell JL; Doyle JC; Gurry JF. (1980). The vascular complications of cervical ribs. Aust New Zeal J Surg, 50: 125-130. 196342

Cook MR; Bergman FJ; Cohen HD; Gerkovich MM; Graham C; Harris RK; Siemann LG. (1991). Effects of methanol vapor on human neurobehavioral measures. Health Effects Institute. Boston, MA. Research Report Number 42. 032367

Cook RJ; Champion KM; Giometti CS. (2001). Methanol toxicity and formate oxidation in NEUT2 mice. Arch Biochem Biophys, 393: 192-198. 019564

Cooper RL; Molea ML; Rehnberga GL; Goldmana JM; McElroya WK; Heina J; Stoker TE. (1992). Effect of inhaled methanol on pituitary and testicular hormones in chamber acclimated and nonacclimated rats. Toxicology, 71: 69-81. 196348

Corley RA; Bormett GA; Ghanayem BI. (1994). Physiologically-based pharmacolinetics of 2-butoxyethanol and its major metabolite 2-butoxyacetic acid, in rats and humans. Toxicol Appl Pharmacol, 129: 61-79. 041977

Crebelli R; Conti G; Conti L; Carere A. (1989). A comparative study on ethanol and acetaldehyde as inducers of chromosome malsegregation in Aspergillus nidulans. Mutat Res, 215: 187-195. 032119

Cronholm T. (1987). Effect of ethanol on the redox state of the coenzyme bound to alcohol dehydrogenase studied in isolated hepatocytes. Biochem J, 248: 567-572. 196350

Cruzan G. (2009). Assessment of the cancer potential of methanol. Crit Rev Toxicol, 39: 347-363. 196354

Cruzan G; Cushman JR; Andrews LS; Granville GC; Johnson KA; Hardy CJ; Coombs DW; Mullins PA; Brown WR. (1998). Chronic toxicity/oncogenicity study of styrene in CD rats by inhalation exposure for 104 weeks. Toxicol Sci, 46: 266-281. 051380

Cumming ME; Ong BY; Wade JG; Sitar DS. (1984). Maternal and fetal ethanol pharmacokinetics and cardiovascular responses in near-term pregnant sheep. Can J Physiol Pharmacol, 62: 1435-1439. 031556

d'Alessandro A; Osterloh JD; Chuwers P; Quinlan PJ; Kelly TJ; Becker CE. (1994). Formate in serum and urine after controlled methanol exposure at the threshold limit value. Environ Health Perspect, 102: 178-181. 077257

Davis VE; Brown H; Huff JA; Cashaw JL. (1967). The alteration of serotonin metabolism to 5-hydroxytryptophol by ethanol ingestion in man. J Lab Clin Med, 69: 132-140. 196356

Davoli E; Cappellini L; Airoldi L; Fanelli R. (1986). Serum methanol concentrations in rats and in men after a single dose of aspartame. Food Chem Toxicol, 24: 187-189. 056313

De Brabander N; Wojciechowski M; De Decker K; De Weerdt A; Jorens PG. (2005). Fomepizole as a therapeutic strategy in paediatric methanol poisoning: a case report and review of the literature. Eur J Pediatr, 164: 158-161. 196739

Degitz SJ; Rogers JM; Zucker RM; Hunter ES III. (2004). Developmental toxicity of methanol: pathogenesis in CD-1 and C57BL/6J mice exposed in whole embryo culture. Birth Defects Res A Clin Mol Teratol, 70: 179-184. 056020

Degitz SJ; Zucker RM; Kawanishi CY; Massenburg GS; Rogers JM. (2004). Pathogenesis of methanol-induced craniofacial defects in C57BL/6J mice. Birth Defects Res A Clin Mol Teratol, 70: 172-178. 056021

Deltour L; Foglio MH; Duester G. (1999). Metabolic deficiencies in alcohol dehydrogenase Adh1, Adh3, and Adh4 null mutant mice - overlapping roles of Adh1 and Adh4 in ethanol clearance and metabolism of retinol to retinoic acid. J Biol Chem, 274: 16,796-16,801. 056397

Dethlefs R; Naraqi S. (1978). Ocular manifestations and complications of acute methyl alcohol intoxication. Med J Aust, 2: 483-485. 031038

Devore JL. (1995). Probability and statistics for engineering and the sciences. Belmont, CA: Duxbury Press. 196740

De Flora S; Zanacchi P; Camoirano A; Bennicelli C; Badolati GS. (1984). Genotoxic activity and potency of 135 compounds in the Ames reversion test and in a bacterial DNA-repair test. Mutat Res, 133: 161-198. 017980

Dicker E; Cedebaum AI. (1986). Inhibition of the low-Km mitachondrial aldehyde dehydrogenase by diethyl maleate and phorone in vivo and in vitro: implications for formaldehyde metabolism. Biochem J, 240: 821-827. 196741

Dikalova AE; Kadiiska MB; Mason RP. (2001). An in vivo ESR spin-trapping study: free radical generation in rats from formate intoxication-role of the Fenton reaction. PNAS, 98: 13549-13553. 196742

Dorman DC; Bolon B; Struve MF; LaPerle KMD; Wong BA; Elswick B; Welsch F. (1995). Role of formate in methanol-induced exencephaly in CD-1 mice. Teratology, 52: 30-40. 078081

Dorman DC; Moss OR; Farris GM; Janszen D; Bond JA; Medinsky MA. (1994). Pharmacokinetics of inhaled [14C]methanol and methanol-derived [14C]formate in normal and folate-deficient cynomolgus monkeys. Toxicol Appl Pharmacol, 128: 229-238. 196743

Dorman DC; Welsch F. (1996). Developmental toxicity of methanol in rodents. , 16: 1-7. 095723

Downie A; Khattab TM; Malik MI; Samara IN. (1992). A case of percutaneous industrial methanol toxicity. Occup Med (Lond), 42: 47-49. 196744

Dudka J. (2006). The total antioxidant status in the brain after ethanol or 4-methylpyrazole administration to rats intoxicated with methanol. Exp Toxicol Pathol, 57: 445-448. 090784

Dutkiewicz B; Konczalik J; Karwacki W. (1980). Skin absorption and per os administration of methanol in men. Int Arch Occup Environ Health, 47: 81-88. 031082

Eells JT; Black KA; Tedford CE; Tephly TR. (1983). Methanol toxicity in the monkey: effects of nitrous oxide and methionine. J Pharmacol Exp Ther, 227: 349-353. 031053

EFSA. (2006). Opinion of the scientific panel on food additives, flavourings, processing aids and materials in contact with food (AFC) on a request from the commission related to a new long-term carcinogenicity study on aspartame. EFSA J, 356: 1-44. 196098

EFSA. (2009). Updated scientific opinion of the panel on food additives and nutrient sources added to food on a request from the European commission related to the 2nd ERF carcinogenicity study on aspartame, taking into consideration study data submitted by the Ramazzini foundation in February 2009. EFSA J, 1015: 1-18. 196103

Ernstgard L; Shibata E; Johanson G. (2005). Uptake and disposition of inhaled methanol vapor in humans. Toxicol Sci, 88: 30-38. 088075

Ernstgard. (2005). E-mail correspondance from Lena Ernstgàrd to Torka Poet. 200750

Estonius M; Svensson S; Høøg JO. (1996). Alcohol dehydrogenase in human tissues: localization of transcripts coding for five classes of the enzyme. FEBS Lett, 397: 338-342. 196107

Evans AL. (1999). Pseudoseizures as a complication of painful cervical ribs. Dev Med Child Neurol, 41: 840-842. 196110

Everitt JI; Richter CB. (1990). Infectious diseases of the upper respiratory tract: Implications for toxicology studies. Environ Health Perspect, 85: 239-247. 196113

Fagan JF; Singer LT. (1983). Infant recognition memory as a measure of intelligence. In LP Lipsitt (Ed.), (Ed.),Advances in infancy research (pp. 31-78). New York, NY: Ablex. 196116

Fallang B; Saugstad OD; Grøgaard J; Hadders-Algra M. (2003). Kinematic quality of reaching movements in preterm infants. Pediatr Res, 53: 836-842. 196118

FDA. (2000). Redbook 2000 chapter IV.C.6.: Carcinogenicity studies with rodents. Retrieved 09-OCT-09, from http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIn gredientsandPackaging/Redbook/ucm078388.htm. 200770

Feany MB; Anthony DC; Frosch MP; Zane W; De Girolami U. (2001). August 2000: two cases with necrosis and hemorrhage in the putamen and white matter. Brain Pathol, 11: 125. 020604

Fernandez Noda EI; Nuñez-Arguelles J; Perez Fernandez J; Castillo J; Perez Izquierdo M; Rivera Luna H. (1996). Neck and brain transitory vascular compression causing neurological complications, results of surgical treatment on 1300 patients. J Cardiovasc Surg (Torino), 37: 155-166. 196121

Finkelstein Y; Vardi J. (2002). Progressive parkinsonism in a young experimental physicist following long-term exposure to methanol. Neurotoxicology, 23: 521-525. 037357

Fiserova-Bergerova V; Diaz ML. (1986). Determination and prediction of tissue-gas partition coefficients. Int Arch Occup Environ Health, 58: 75-87. 064569

Fisher JW; Dorman DC; Medinsky MA; Welsch F; Conolly RB. (2000). Analysis of respiratory exchange of methanol in the lung of the monkey using a physiological model. Toxicol Sci, 53: 185-193. 009750

Fontenot AP; Pelak VS. (2002). Development of neurologic symptoms in a 26-year-old woman following recovery from methanol intoxication. Chest, 122: 1436-1439. 037256

Foster MW; Stamler J. (2004). New insights into protein s-nitrosylation-mitochondria as a model system. J Biol Chem, 279: 25891-25897. 196126

Frederick LJ; Schulte PA; Apol A. (1984). Investigation and control of occupational hazards associated with the use of spirit duplicators. J Occup Environ Hyg, 45: 51-55. 031063

Fu SS; Sakanashi TM; Rogers JM; Hong. (1996). Influence of dietary folic acid on the developmental toxicity of methanol and the frequency of chromosomal breakage in the CD-1 mouse. Reprod Toxicol, 10: 455-463. 080957

Gannon KS; Smith JC; Henderson R; Hendrick P. (1992). A system for studying the microstructure of ingestive behavior in mice. Physiol Behav, 51: 515-521. 090532

Gaul HP; Wallace CJ; Auer RN; Chen Fong T. (1995). MRI findings in methanol intoxication. Am J Neuroradiol, 16: 1783-1786. 196131

Gentry PR; Covington TR; Andersen ME; Clewell HJ III. (2002). Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul Toxicol Pharmacol, 36: 51-68. 034904

Gentry PR; Covington TR; Clewell HJ 3rd. (2003). Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul Toxicol Pharmacol, 38: 1-16. 194592

Gibson MAS; Butters NS; Reynolds JN; Brien JF. (2000). Effects of chronic prenatal ethanol exposure on locomotor activity, and hippocampal weight, neurons, and nitric oxide synthase activity of the young postnatal guinea pig. Neurotoxicol Teratol, 22: 183-182. 196133

Gonzalez-Quevado A; Obregon FUrbina M; Rousso T; Lima L. (2002). Effect of chronic methanol administration on amino-acids and monoamines in retina, optic nerve, and brain of the rat. Toxicol Appl Pharmacol, 185: 77-84. 037282

Griffiths AJF. (1981). Neurospora and environmentally induced aneuploidy. In HF Stich; RHC San (Ed.),Short-Term Tests for Chemical Carcinogens (pp. 187-199). New York: Springer-Verlag. 180469

Guerri C; Sanchis R. (1985). Acetaldehyde and alcohol levels in pregnant rats and their fetuses. Alcohol, 2: 267-270. 005706

Guggenheim MA; Couch JR; Weinberg W. (1971). Motor dysfunction as a permanent complication of methanol ingestion. Arch Neurol, 24: 550-554. 037882

Hailey JR. (2004). Lifetime study in rats conducted by the Ramazzini Foundation Pathology Working Group Chairperson's report. NIEHS. RTP, NC. 089842

Hansen JM; Contreras KM; Harris C. (2005). Methanol, formaldehyde, and sodium formate exposure in rat and mouse conceptuses: A potential role of the visceral yolk sac in embryotoxicity. Birth Defects Res A Clin Mol Teratol, 73: 72-82. 196135

Hantson P; Duprez T; Mahieu P. (1997). Neurotoxicity to the basal ganglia shown by magnetic resonance imaging (MRI) following poisoning by methanol and other substances. Clin Toxicol, 35: 151-161. 083446

Hantson P; Lambermont JY; Mahieu P. (1997). Methanol poisoning during late pregnancy. Clin Toxicol, 35: 187-191. 196137

Hanzlik RP; Fowler SC; Eells JT. (2005). Absorption and elimination of formate following oral administration of calcium formate in female human subjects. Drug Metab Dispos, 33: 282-286. 030632

Harris C; Dixon M; Hansen JM. (2004). Glutathione depletion modulates methanol, formaldehyde and formate toxicity in cultured rat conceptuses. Cell Biol Toxicol, 20: 133-145. 059082

Harris C; Wang S-W; Lauchu JJ; Hansen JM. (2003). Methanol metabolism and embryotoxicity in rat and mouse conceptuses : comparisons of alcohol dehydrogenase (ADH1), formaldehyde dehydrogenase (ADH3), and catalase. Reprod Toxicol, 17: 349-357. 047369

Haseman JK; Hailey JR; Morris RW. (1998). Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: A National Toxicology Program update. Toxicol Pathol, 26: 428-441. 094054

Hashimoto M; NEDO. (2008). Report letter from Masahiro Hashimoto, Director General of the Policy Planning and Coordination Department of NEDO, to John Lynn, CEO of Methanol Institute, certifying the English translations of the 1985 NEDO (New Energy and Industrial Technology Development Organization) original Japanese methanol test reports are accurate and complete. New Energy and Industrial Technology Development Organization. Kawasaki City, Japan. 201639

Hass U; Lund SP; Simonsen L; Fries AS. (1995). Effects of prenatal exposure to xylene on postnatal development and behavior in rats. Neurotoxicol Teratol, 17: 341-349. 196199

Hassanian-Moghaddam H; Pajoumand A; Dadgar SM; Shadnia SH. (2007). Prognostic factors in methanol poisoning. Hum Exp Toxicol, 26: 583-586. 092987

Hauptmann M; Lubin Jay H; Stewart PA; Hayes RB; Blair A. (2003). Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries. J Natl Cancer Inst, 95: 1615-1623. 093083

Health Research Committee. (1987). Automotive methanol vapors and human health: An evaluation of existing scientific information and issues for future research. Health Effects Institute. Boston, MA. 031207

Hedberg JJ; Backlund M; Strömberg P; Lönn S; Dahl ML; Ingelman-Sundberg M; Höög JO. (2001). Functional polymorphism in the alcohol dehydrogenase 3 (ADH3) promoter. Pharmacogenetics, 11: 815-824. 196206

Heidelberger C; Freeman AE; Pienta RJ; Sivak A; Bertram JS; Casto BC; Dunkel VC; Francis MW; Kakunaga T; Little JB; Schechtman LM. (1983). Cell transformation by chemical agents--a review and analysis of the literature A report of the US Environmental Protection Agency Gene-Tox Program. DNA Repair (Amst), 114: 283-385. 088310

Henderson MS. (1914). Cervical rib: Report of thirty-one cases. J Bone Joint Surg Am, 11: 408-430. 196216

Henderson WR; Brubacher J. (2002). Methanol and ethylene glycol poisoning: A case study and review of current literature. C J E M, 4: 34-40. 093106

Hinderer RK; Johnson MN; Seppala A; Jacobs MM; Patil KD; Shubik P. (1979). Toxicity and carcinogenicity of Agerite Resin D (ARD), trimethyldihydroquinoline polymer. J Environ Pathol Toxicol, 2: submitted, as cited by Apaja 1980. 200845

Hines RN; McCarver DG. (2002). The ontogeny of human drug-metabolizing enzymes: Phase I. Oxidative enzymes. J Pharmacol Exp Ther, 300: 355-360. 196221

Horton VL; Higuchi MA; Rickert DE. (1992). Physiologically based pharmacokinetic model for methanol in rats, monkeys, and humans. Toxicol Appl Pharmacol, 117: 26-36. 196222

Hovda KE; Hunderi OH; Tafjord A-B; Dunlop O; Rudberg N; Jacobsen D. (2005). Methanol outbreak in Norway 2002-2004: epidemiology, clinical features and prognostic signs. J Intern Med, 258: 181-190. 087791

Hovda KE; Mundal H; Urdal P; McMartin K; Jacobsen D. (2007). Extremely slow formate elimination in severe methanol poisoning: A fatal case report. Clin Toxicol, 45: 516-521. 092989

HSDB. (2009). Methanol: Human health effects. Retrieved 22-DEC-09, from http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~XKgvsM:1. 200738

Hsu HH; Chen CY; Chen FH; Lee CC; Chou TY; Zimmerman RA. (1997). Optic atrophy and cerebral infarcts caused by methanol intoxication: MRI. Neuroradiology, 39: 192-194. 196227

Huang QF; Gebrewold A; Zhang A; Altura BT; Altura BM. (1994). Role of excitatory amino acids in regulation of rat pial microvasculature. Am J Physiol, 266: R158-R163. 196230

Huff J. (2002). Chemicals studied and evaluated in long-term carcinogenesis bioassays by both the Ramazzini Foundation and the National Toxicology Program: In tribute to Cesare Maltoni and David Rall. Ann N Y Acad Sci, 982: 208-230. 090326

Huff J; Jacobson MF; Davis DL. (2008). The limits of two-year bioassay exposure regimens for identifying chemical carcinogens. Environ Health Perspect, 116: 1439-1442. 196234

Huff J; LaDou J. (2007). Aspartame bioassay findings portend human cancer hazards. Int J Occup Environ Health, 13: 446-448. 196233

Hunderi OH; Hovda KE; Jacobsen D. (2006). Use of the osmolal gap to guide the start and duration of dialysis in methanol poisoning. Scand J Urol Nephrol, 40: 70-74. 090791

IARC. (2004). IARC monographs on the evaluation of carcinogenic risks to humans: Formaldehyde, 2 butoxyethanol and 1-tert-butoxy-2-propanol. Lyon, France: International Agency for Research on Cancer. 196244

Infurna R; Weiss B. (1986). Neonatal behavioral toxicity in rats following prenatal exposure to methanol. Teratology, 33: 259-265. 064572

IPCS (International Programme on Chemical Safety). (1997). Methanol. World Health Organization. Geneva, Switzerland. 196253

Ishii H. (1981). Incidence of brain tumors in rats fed aspartame. Toxicol Lett, 7: 433-437. 196254

Ishii H; Koshimizu T; Usami S; Fujimoto T. (1981). Toxicity of aspartame and its diketopiperazine for Wistar rats by dietary administration for 104 weeks. Toxicology, 21: 91-94. 196255

Jacobsen D; McMartin KE. (1986). Methanol and ethylene glycol poisonings. Mechanisms of toxicity, clinical course, diagnosis and treatment. Med Toxicol, 1: 309-334. 031514

Jacobsen D; Webb R; Collins TD; McMartin KE. (1988). Methanol and formate kinetics in late diagnosed methanol intoxication. Med Toxicol, 3: 418-423. 031808

Johanson G; Kronborg H; Naslund PH; Nordqvist MB. (1986). Toxicokinetics of inhaled 2-butoxyethanol (ethylene glycol monobutyl ether) in man. Scand J Work Environ Health, 12: 594-602. 006760

Johlin FC; Fortman CS; Nghiem DD; Tephly TR. (1987). Studies on the role of folic acid and folate-dependent enzymes in human methanol poisoning. Mol Pharmacol, 31: 557-561. 032236

Kahn A; Blum D. (1979). Methyl alcohol poisoning in an 8-month-old boy: An unusual route of intoxication. J Paediatr Child Health, 94: 841-843. 031423

Kamata E; Nakadate M; Uchida O; Ogawa Y; Suzuki S; Kaneko T; Saito M; Kurokawa Y. (1997). Results of a 28-month chronic inhalation toxicity study of formaldehyde in male Fisher-344 rats. J Toxicol Sci, 22: 239-254. 198505

Kavet R; Nauss KM. (1990). The toxicity of inhaled methanol vapors. Crit Rev Toxicol, 21: 21-50. 032274

Kavlock RJ; Allen BC; Faustman EM; Kimmel CA. (1995). Dose-response assessments for developmental toxicity. IV. Benchmark doses for fetal weight changes. Toxicol Sci, 26: 211-222. 075837

Kawai T; Yasugi T; Mizunuma K; Horiguchi S; Hirase Y; Uchida Y; Ikeda M. (1991). Methanol in urine as a biological indicator of occupational exposure to methanol vapor. Int Arch Occup Environ Health, 63: 311-318. 032418

Keles GT; Orguc S; Toprak B; Ozaslan S; Sakarya M. (2007). Methanol poisoning with necrosis corpus callosum. Clin Toxicol, 45: 307-308. 093115

Kerns W II; Tomaszewski C; McMartin K; Ford M; Brent J; the META Study Group. (2002). Formate kinetics in methanol poisoning. Clin Toxicol, 40: 137-143. 035438

Kerns WD; Pavkov KL; Donofrio DJ; Gralla EJ; Swenberg JA. (1983). Carcinogenicity of formaldehyde in rats and mice after long-term inhalation exposure. Cancer Res, 43: 4382-4392. 007031

Keys DA; Schultz IR; Mahle DA; Fisher JW. (2004). A quantitative description of suicide inhibition of dichloroacetic acid in rats and mice. Toxicol Sci, 82: 381-393. 196283

Knowles K. (2008). E-mail correspondance from Kathryn Knowles to Jeff Gift dated July 9, 2008. 200774

Kraut JA; Kurtz I. (2008). Toxic alcohol ingestions: Clinical features, diagnosis, and management. Clin J Am Soc Nephrol, 3: 208-225. 196286

Kuteifan K; Oesterlé H; Tajahmady T; Gutbub AM; Laplatte G. (1998). Necrosis and haemorrhage of the putamen in methanol poisoning shown on MRI. Neuroradiology, 40: 158-160. 196287

Leakey JE; Seng JE; Allaben WT. (2003). Body weight considerations in the B6C3F1 mouse and the use of dietary control to standardize background tumor incidence in chronic bioassays. Toxicol Appl Pharmacol, 193: 237-265. 196288

Lee E; Brady AN; Brabec MJ; Fabel T. (1991). Effects of methanol vapors on testosterone production and testis morphology in rats. Toxicol Ind Health, 7: 261-275. 032419

Lee EW; Garner CD; Terzo TS. (1994). Animal model for the study of methanol toxicity: Comparison of folate-reduced rat responses with published monkey data. J Toxicol Environ Health, 41: 71-82. 032712

Lee EW; Terzo TS; D'Arcy JB; Gross KB; Schreck RM. (1992). Lack of blood formate accumulation in humans following exposure to methanol vapor at the current permissible exposure limit of 200 ppm. J Occup Environ Hyg, 53: 99-104. 032629

Lewis RJ Sr. (1992). Sax's dangerous properties of industrial materials: v III. New York, NY: Van Nostrand Reinhold. 001649

Ley CO; Gali FG. (1983). Parkinsonian syndrome after methanol intoxication. Eur Neurol, 22: 405-409.
077133

Lindsey JR; Davidson MK; Schoeb TR; Cassell GH. (1985). Mycoplasma pulmonis-host relationships in a breeding colony of Sprague-Dawley rats with enzootic murine respiratory mycoplasmosis. Lab Anim Sci, 35: 597-608. 196292

Liu JJ; Daya MR; Carrasquillo O; Kales SN. (1998). Prognostic factors in patients with methanol poisoning. Clin Toxicol, 36: 175-181. 086518

Lorente C; Cordier S; Bergeret A; De Walle HEK; Goujard J; Ayme S; Knill-Jones R; Calzolari E; Bianchi F. (2000). Maternal occupational risk factors for oral clefts. Scand J Work Environ Health, 26: 137-145. 056310

Mahieu P; Hassoun A; Lauwerys R. (1989). Predictors of methanol intoxication with unfavorable outcome. Hum Toxicol, 8: 135-137. 196297

Makar AB; Tephly TR; Mannering GJ. (1968). Methanol metabolism in the monkey. Mol Pharmacol, 4: 471-483. 031109

Maltoni C; Ciliberti A; Cotti G; Perino G. (1988). Long-term carcinogenicity bioassays on acrylonitrile administered by inhalation and by ingestion to Sprague-Dawley rats. Ann N Y Acad Sci, 534: 179-202. 196225

Mann WJ; Muttray A; Schaefer D; Klimek L; Faas M; Konietzko J. (2002). Exposure to 200 ppm of methanol increases the concentrations of interleukin-1beta and interleukin-8 in nasal secretions of healthy volunteers. Ann Otol Rhinol Laryngol, 111: 633-638. 034724

Mannering GJ; Van Harken DR; Makar AB; Tephly TR; Watkins WD; Goodman JI. (1969). Role of the intracellular distribution of hepatic catalase in the peroxidative oxidation of methanol. Ann N Y Acad Sci, 168: 265-280. 031429

Maronpot RR; Flake G; Huff J. (2004). Relevance of animal carcinogenesis findings to human cancer predictions and prevention. Toxicol Pathol, 32: 40-48. 196228

McConnell EE; Solleveld HA; Swenberg JA; Boorman GA. (1986). Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. J Natl Cancer Inst, 76: 283-289. 073655

McGregor DB; Martin R; Riach CG; Caspary WG. (1985). Optimization of a metabolic activation system for use in the mouse lymphoma L5178Y tk+tk- system. Environ Mutagen, 7: 10. 196231

Medinsky MA; Dorman DC; Bond JA; Moss OR; Janszen DB; Everitt JI. (1997). Pharmacokinetics of methanol and formate in female cynomolgus monkeys exposed to methanol vapors. Health Effects Institute. Boston, MA. 084177

Meister A; Anderson ME. (1983). Glutathione. Annu Rev Biochem, 52: 711-760. 001404

Melnick RL; Thayer KA; Bucker JR. (2007). Conflicting views on chemical carcinogenesis arising from the design and evaluation of rodent carcinogenicity studies. Environ Health Perspect, 116: 130-135. 196236

Methanol Institute. (2009). Biodiesel: A growing market for methanol. Retrieved 18-DEC-09, from http://www.methanol.org/pdfFrame.cfm?pdf=Biodiesel2.pdf. 200744

Methanol Institute. (2009). Frequently asked questions. Retrieved 18-DEC-09, from
http://www.methanol.org/pdfFrame.cfm?pdf=faqs.pdf. 200739

Meyer RJ; Beard ME; Ardagh MW;. (2000). Methanol poisoning. N Z Med J, 113: 11-13. 196237

Molinary VS. (1984). Preclinical studies of aspartame in nonprimate animals. In Aspartame: Physiology
and biochemistry (pp. 289-306). New York: Marcel Dekker, Inc. 198504

Montserrat CA; Field MS; Perry C; Ghandour H; Chiang E; Selhub J; Shane B; Stover PJ. (2006).
Regulation of folate-mediated one-carbon metabolism by 10-formyltetrahydrofolate
dehydrogenase. J Biol Chem, 281: 18335-18342. 196243

Mooney SM; Miller MW. (2001). Episodic exposure to ethanol during development differentially affects
brainstem nuclei in the macaque. J Neurocytol, 30: 973-982. 196247

Muthuvel A; Rajamani R; Manikandan S; Sheeladevi R. (2006). Detoxification of formate by formate
dehydrogenase-loaded erythrocytes and carbicarb in folate-deficient methanol-intoxicated rats.
Clin Chim Acta, 367: 162-169. 090786

Muthuvel A; Rajamani R; Senthilvelan M; Manikandan S; Sheeladevi R. (2006). Modification of
allergenicity and immunogenicity of formate dehydrogenase by conjugation with linear mono
methoxy poly ethylene glycol: Improvement in detoxification of formate in methanol poisoning. Clin
Chim Acta, 374: 122-128. 196250

Naraqi S; Dethlefs RF; Slobodniuk RA; Sairere JS. (1979). An outbreak of acute methyl alcohol
intoxication. Aust. N. Z. J. Med., 9: 65-68. 196252

NCI. (2006). Prospective study of aspartame-containing beverages and risk of hematopoietic and brain
cancers. Abstract no. 4010. Presented at 97th AACR Annual Meeting, Washington, DC. 196256

NEDO. (1987). Toxicological research of methanol as a fuel for power station: summary report on tests
with monkeys, rats and mice. New Energy Development Organization. Tokyo, Japan. 064574

NEDO. (2008). Test report: 18-month inhalation carcinogenicity study on methanol in B6C3F1 mice (test
no. 4A-223). Mitsubishi Kasei Institute of Toxicology and Environmental Sciences. Tokyo, Japan
(Original work published 1985). 196315

NEDO. (2008). Test report: 24-month inhalation carcinogenicity study on methanol in Fischer rats (Test No.
5A-268). Mitsubishi Kasei Institute of Toxicology and Environmental Sciences. Toyko, Japan
(Original work published 1985). 196316

Nelson BK; Brightwell WS; MacKenzie DR; Khan A; Burg JR; Weigel WW; Goad PT. (1985). Teratological
assessment of methanol and ethanol at high inhalation levels in rats. Toxicol Sci, 5: 727-736.
064573

Nguyen T; Baumgartner F; Nelems B. (1997). Bilateral rudimentary first ribs as a cause of thoracic outlet
syndrome. J Natl Med Assoc, 89: 69-73. 196258

Noker PE; Eells JT; Tephly TR. (1980). Methanol toxicity: treatment with folic acid and 5-formyl
tetrahydrofolic acid. Alcohol Clin Exp Res, 4: 378-383. 030975

NRC (National Research Council). (1983). Risk assessment in the federal government: managing the
process. National Academy Press. Washington, DC. 194806

NTP. (1990). National Toxicology Program technical report on the toxicology and carcinogenesis studies of toluene (CAS no 108-88-3) in F344/N rats and B6C3F1 mice (inhalation studies). National Institute of Environmental Health Science. Research Triangle Park, NC. 065618

NTP. (1999). Toxicology data management system, historical control tumor incidence summary - inhalation studies of Fischer 344 rats. National Toxicology Program. RTP, NC. 196291

NTP. (2000). NTP technical report on the toxicology and carcinogenesis studies of 2 butoxyethanol (CAS No. 111 76 2) in F344/N rats and B6C3F1 mice (inhalation studies). National Institute of Environmental Health Sciences. RTP, NC. 196293

NTP. (2003). Toxicity studies of aspartame in FVB/N-TgN(v-Ha-ras)Led (Tg.AC) hemizygous mice and carcinogenicity studies of aspartame in B6.129-Trp53m&Brd (N5) haploinsufficient mice. National Institute of Environmental Health Sciences. RTP, NC. 196295

NTP. (2006). Specifications for the conduct of studies to evaluate the toxic and carcinogenic potential of chemical, biological and physical agents in laboratory animals for the national toxicology program (NTP). National Institute of Environmental Health Science. RTP, NC. 196296

NTP. (2007). NTP historical controls report, all routes and vehicles, rats. National Institute of Environmental Health Sciences. RTP, NC. 196299

OECD. (2007). Establishment and control of archives that operate in compliance with the principles of GLP. OECD Environment Directorate. Paris, France. 196300

Ohno K; Tanaka-Azuma Y; Yoneda Y; Yamada T. (2005). Genotoxicity test system based on p53R2 gene expression in human cells: Examination with 80 chemicals. Mutat Res, 588: 47-57. 196301

Osterloh JD; D'Alessandro A; Chuwers P; Mogadeddi H; Kelly TJ. (1996). Serum concentrations of methanol after inhalation at 200 ppm. J Occup Environ Med, 38: 571-576. 056314

Pace V; Perentes E; Germann P-G. (2002). Pheochromocytomas and ganglioneuromas in the aging rats: Morphological and immunohistochemical characterization. Toxicol Pathol, 30: 492-500. 196304

Parthasarathy NJ; Kumar RS; Devi RS. (2005). Effect of methanol intoxication on rat neutrophil functions. J Immunotoxicol, 2: 115-211. 196306

Parthasarathy NJ; Kumar RS; Karthikeyan P; Sheela Devi R. (2005). In vitro and in vivo study of neutrophil functions after acute methanol intoxication in albino rats. Toxicol Environ Chem, 87: 559-566. 090783

Parthasarathy NJ; Kumar RS; Manikandan S; Devi RS. (2006). Methanol-induced oxidative stress in rat lymphoid organs. J Occup Health, 48: 20-27. 089721

Parthasarathy NJ; Kumar RS; Manikandan S; Narayanan GS; Kumar RV; Devi RS. (2006). Effect of methanol-induced oxidative stress on the neuroimmune system of experimental rats. Chem Biol Interact, 161: 14-25. 196309

Parthasarathy NJ; Srikumar R; Manikandan S; Narayanan GS; Devi RS. (2007). Effect of methanol intoxication on specific immune functions of albino rats. Cell Biol Toxicol, 23: 177-187. 092996

Pastino GM; Conolly RB. (2000). Application of a physiologically based pharmacokinetic model to estimate the bioavailability of ethanol in male rats: distinction between gastric and hepatic pathways of metabolic clearance. Toxicol Sci, 55: 256-265. 006128

Patankar T; Bichile L; Karnad D; Prasad S; Rathod K. (1999). Methanol poisoning: computed tomography scan findings in four patients. Australasian Radiology, 43: 526-528. 196142

Pelletier J; Habib MH; Khalil R; Salamon G; Bartoli D; Jean P. (1992). Putaminal necrosis after menhanol intoxication [letter]. J Neurol Neurosurg Psychiatry, 55: 234-235. 032500

Peng M-T; Chen Y-T; Hung S-H; Yaung C-L. (1990). Circadian rhythms of feeding and drinking behavior of rats aged from 3 to 21 months. Proc Natl Sci Council China B, 14: 98-104. 056797

Perkins RA; Ward KW; Pollack GM. (1995). A pharmacokinetic model of inhaled methanol in humans and comparison to methanol disposition in mice and rats. Environ Health Perspect, 103: 726-733. 078067

Perkins RA; Ward KW; Pollack GM. (1995). Comparative toxicokinetics of inhaled methanol in the female CD-1 mouse and Sprague-Dawley rat. Toxicol Sci, 28: 245-254. 085259

Perkins RA; Ward KW; Pollack GM. (1996). Methanol inhalation: site and other factors influencing absorption, and an inhalation toxicokinetic model for the rat. Pharm Res, 13: 749-755. 196147

Phang PT; Passerini L; Mielke B; Berendt R; King EG. (1988). Brain hemorrhage associated with methanol poisoning. Crit Care Med, 16: 137-140. 031577

Pietruszko R. (1980). Alcohol and aldehyde dehydrogenase isozymes from mammalian liver--their structural and functional differences. Isozymes Current Top Biology Med Res, 4: 107-130. 056337

Pikkarainen PH; Raiha NCR. (1967). Development of alcohol dehydrogenase activity in the human liver. Pediatr Res, 1: 165-168. 056315

Pinkerton LE; Hein MJ; Stayner LT. (2004). Mortality among a cohort of garment workers exposed to formaldehyde: an update. Occup Environ Med, 61: 193-200. 093085

Pitkin RM. (2007). Folate and neural tube defects. Am J Clin Nutr, 85: 285S-288S. 196150

Plantinga Y; Perdock J; de Groot L. (1997). Hand function in low-risk preterm infants: Its relation to muscle power regulation. Dev Med Child Neurol, 39: 6-11. 196151

Poet TS; Teeguarden JG; Hinderliter PM. (2006). Final Report: Development, calibration and application of a methanol PBPK model. Battelle Pacific Northwest National Laboratory. Richland, WA. 196152

Pollack GM; Brouwer KLR. (1996). Maternal-fetal pharmacokinetics of methanol. Health Effects Institute. Boston, MA. 74. 079812

Pollack GM; Brouwer KLR; Kawagoe JL. (1993). Toxicokinetics of intravenous methanol in the female rat. Toxicol Sci, 21: 105-110. 032685

Pollack GM; Kawagoe JL. (1991). Determination of methanol in whole blood by capillary gas chromatography with direct on-column injection. J Chromatogr A, 570: 406-411. 032412

Poon R; Chu I; Bjarnason S; Potvin M; Vincent R; Miller RB; Valli VE. (1994). Inhalation toxicity study of methanol, toluene, and methanol/toluene mixtures in rats: effects of 28-day exposure. Toxicol Ind Health, 10: 231-245. 074789

Poon R; Chu I; Bjarnason S; Vincent R; Potvin M; Miller RB; Valli VE. (1995). Short-term inhalation toxicity of methanol, gasoline, and methanol/gasoline in the rat. Toxicol Ind Health, 11: 343-361. 085499

Prabhakaran V; Ettler H; Mills A. (1993). Methanol poisoning: Two cases with similar plasma methanol concentrations but different outcomes. Can Med Assoc J, 148: 981-984. 196154

Rajamani R; Muthuvel A; Senthilvelen M; Sheeladevi R. (2006). Oxidative stress induced by methotrexate alone and in the presence of methanol in discrete regions of the rodent brain, retina and optic nerve. Toxicol Lett, 165: 265-273. 196157

Ramazzini Foundation. (2006). European Ramazzini foundation stands behind aspartame study results, announces ongoing research on artificial sweeteners. Ramazzini Foundation. Bologna, Italy. 196158

Ramsey JC; Andersen ME. (1984). A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol Appl Pharmacol, 73: 159-175. 063020

Rappaport H. (1966). Tumors of the hematopoietic system. In Atlas of tumor pathology (pp. 49-64). Washington, DC: Armed Forces Institute of Pathology. 196160

Razin S; Yogev D; Naot Y. (1998). Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev, 62: 1094-1156. 196162

Rice D; Barone S Jr. (2000). Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect, 108: 511-533. 020837

Riegel H; Wolf G. (1966). Severe neurological deficiencies as a consequence of methyl alcohol poisoning. Fortschr Neurol Psychiatr, 34: 346-351. 196163

Rogers JM; Barbee BD; Mole ML. (1995). Exposure concentration and time (CxT) relationships in the developmental toxicity of methanol in mice. Toxicologist, 15: 164. 196165

Rogers JM; Barbee BD; Rehnberg BF. (1993). Critical periods of sensitivity for the developmental toxicity of inhaled methanol. Teratology, 47: 395. 032697

Rogers JM; Brannen KC; Barbee BD; Zucker RM; Degitz SJ. (2004). Methanol exposure during gastrulation causes holoprosencephaly, facial dysgenesis, and cervical vertebral malformations in C57BL/6J mice. Birth Defects Res B Dev Reprod Toxicol, 71: 80-88. 056010

Rogers JM; Mole ML. (1997). Critical periods of sensitivity to the developmental toxicity of inhaled methanol in the CD-1 mouse. Teratology, 55: 364-372. 009755

Rogers JM; Mole ML; Chernoff N; Barbee BD; Turner CI; Logsdon TR; Kavlock RJ. (1993). The developmental toxicity of inhaled methanol in the CD-1 mouse, with quantitative dose-response modeling for estimation of benchmark doses. Teratology, 47: 175-188. 032696

Rogers VV; Wickstrom M; Liber K; MacKinnon MD. (2002). Acute and subchronic mammalian toxicity of naphthalenic acids from oil sands tailings. Toxicol Sci, 66: 347-355. 196167

Rubinstein D; Escott E; Kelly JP. (1995). Methanol intoxication with putaminal and white matter necrosis: MR and CT findings. Am J Neuroradiol, 16: 1492-1494. 077842

Sakanashi TM; Rogers JM; Fu SS; Connelly LE; Keen CL. (1996). Influence of maternal folate status on the developmental toxicity of methanol in the CD-1 mouse. Teratology, 54: 198-206. 056308

Salzman M. (2006). Methanol neurotoxicity. Clin Toxicol, 44: 89-90. 196172

Saxton EH; Miller TQ; Collins JD. (1999). Migraine complicated by brachial plexopathy as displayed by MRI and MRA: Aberrant subclavian artery and cervical ribs. J Natl Med Assoc, 91: 333-341. 196189

Sayers RR; Yant WP; Schrenk HH; Chornyak J; Pearce SJ; Patty FA; Linn JG. (1944). Methanol poisoning II Exposure of dogs for brief periods eight times daily to high concentrations of methanol vapor in air. J Ind Hyg Toxicol, 26: 255-259. 031100

Schaefer PW; Grant PE; Gonzalez RG. (2000). Diffusion-weighted MR imaging of the brain. Radiology, 217: 331-345. 196191

Schoeb TR; Mcconnell EE; Juliana MM; Davis JK; Davidson MK; and Lindsey JR. (2009). Mycoplasma pulmonis and lymphoma in bioassays in rats. Vet Pathol, 46: 952-959. 196192

Schumacher R; Mai A; Gutjahr P. (1992). Association of rib abnormalities and malignancy in childhood. Eur J Pediatr, 151: 432-434. 196196

Sedivec V; Mraz M; Flek J. (1981). Biological monitoring of persons exposed to methanol vapours. Int Arch Occup Environ Health, 48: 257-271. 031154

Sefidbakht S; Rasekhi AR; Kamali K; Borhani HA; Salooti A; Meshksar A; Abbasi HR; Moghadami M; Nabavizadeh SA. (2007). Methanol poisoning: acute MR and CT findings in nine patients. Neuroradiology, 49: 427-435. 093050

Sellakumar AR; Snyder CA; Solomon JJ; Albert RE. (1985). Carcinogenicity of formaldehyde and hydrogen chloride in rats. Toxicol Appl Pharmacol, 81: 401-406. 065689

Short DW. (1975). The subclavian artery in 16 patients with complete cervical ribs. J Cardiovasc Surg (Torino), 16: 135-141. 196198

Simintzi I; Schulpis KH; Angelogianni P; Liapi C; Tsakiris S. (2007). The effect of aspartame metabolites on the suckling rat frontal cortex acetylcholinesterase An in vitro study. Food Chem Toxicol, 45: 2397-2401. 092988

Simmon VF; Kauhanen K; Tardiff RG. (1977). Mutagenic activity of chemicals identified in drinking water. In D Scott, B Bridges, F Sobel (Eds.), (Ed.),Progress in Genetic Toxicology (pp. 249-268). New York; Amsterdam: Elsevier/North Holland Press. 029451

Siragusa RJ; Cerda JJ; Baig MM; Burgin CW; Robbins FL. (1988). Methanol production from the degradation of pectin by human colonic bacteria. Am J Clin Nutr, 47: 848-851. 031610

Skrzydlewska E; Elas M; Ostrowska J. (2005). Protective effects of N-acetylcysteine and vitamin E derivative U83836E on proteins modifications induced by methanol intoxication. Toxicol Mech Meth, 15: 263-270. 196205

Smith M; Hopkinson DA; Harris H. (1971). Developmental changes and polymorphism in human alcohol dehydrogenase. Ann Hum Genet, 34: 251-271. 053549

Smith ME; Newman HW. (1959). The rate of ethanol metabolism in fed and fasting animals . J Biol Chem, 234: 1544-1549. 196208

Soffritti M; Belpoggi F; Cevolani D; Guarino M; Padovani M; Maltoni C. (2002). Results of long-term experimental studies on the carcinogenicity of methyl alcohol and ethyl alcohol in rats. Ann N Y Acad Sci, 982: 46-69. 091004

Soffritti M; Belpoggi F; Degli Esposti D; Lambertini L; Tibaldi T; Rigano A. (2006). First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environ Health Perspect, 114: 379-385. 196735

Soffritti M; Belpoggi F; Esposti DD; Lambertini L. (2005). Aspartame induces lymphomas and leukaemias in rats. Giornale Europeo di Oncologia (Italian), 10: 107-116. 087840

Soffritti M; Belpoggi F; Lambertin L; Lauriola M; Padovani M; Maltoni C. (2002). Results of long-term experimental studies on the carcinogenicity of formaldehyde. Ann N Y Acad Sci, 982: 87-105. 196211

Soffritti M; Belpoggi F; Minardi F; Maltoni C. (2002). Ramazzini Foundation cancer program: history and major projects, life-span carcinogenicity bioassay design, chemicals studied, and results. Ann N Y Acad Sci, 982: 26-45. 196736

Soffritti M; Belpoggi F; Tibaldi E; Esposti DD; Lauriola M. (2007). Life span exposure to low doses of aspartame beginnig during prenatal life increases cancer effects in rats. Environ Health Perspect, 115: 1293-1297. 196366

Soffritti M; Maltoni C; Maffei F; Biagi R. (1989). Formaldehyde: an experimental multipotential carcinogen. Toxicol Ind Health, 5: 699-730. 081120

Spiteri NJ. (1982). Circadian patterning of feeding, drinking and activity during diurnal food access in rats. Physiol Behav, 28: 139-147. 196363

Staab Ca; Lander J; Brandt M; Lengqvist J; Morgenstern R; Grafström RC; Höög J-O. (2008). Reduction of S-nitrosoglutathione by alcohol dehydrogenase 3 is facilitated by substrate alcohols via direct cofactor recycling and leads to GSH-controlled formation of glutathione transferase inhibitors. Biochem J, 413: 493–504. 196368

Staats DA; Fisher JW; Connolly RB. (1991). Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models: a two-compartment description. Drug Metab Dispos, 19: 144-148. 065129

Stanton ME; Crofton KM; Gray LE; Gordon CJ; Boyes WK; Mole ML; Peele DB; Bushnell PJ. (1995). Assessment of offspring development and behavior following gestational exposure to inhaled methanol in the rat. Toxicol Sci, 28: 100-110. 085231

Starr TB; Festa JL. (2003). A proposed inhalation reference concentration for methanol. Regul Toxicol Pharmacol, 38: 224-231. 052598

Stegink LD; Brummel MC; Filer LJ Jr; Baker GL. (1983). Blood methanol concentrations in one-year-old infants administered graded doses of aspartame. J Nutr, 113: 1600-1606. 056316

Stegink LD; Brummel MC; McMartin K; Martin-Amat G; Filer LJ Jr; Baker GL; Tephly TR. (1981). Blood methanol concentrations in normal adult subjects administered abuse doses of aspartame. J Toxicol Environ Health, 7: 281-290. 030982

Stegink LD; Filer LJ; Bell EF; Ziegler EE; Tephly TR. (1989). Effect of repeated ingestion of aspartame-sweetened beverage on plasma amino acid, blood methanol, and blood formate concentrations in normal adults. Metabolism, 38: 357-363. 031945

Steiner EC; Rey TD; McCroskey PS. (1990). Reference Guide for Simusolv. Midland, MI: Dow Chemical Company. 196738

Stern S; Reuhl K; Soderholm S; Cox C; Sharma A; Balys M; Gelein R; Yin C; Weiss B. (1996). Perinatal methanol exposure in the rat I Blood methanol concentration and neural cell adhesion molecules. Toxicol Sci, 34: 36-46. 081114

Sultatos LG; Pastino GM; Rosenfeld CA; Flynn EJ. (2004). Incorporation of the genetic control of alcohol dehydrogenase into a physiologically based pharmacokinetic model for ethanol in humans. Toxicol Sci, 78: 20-31. 090530

Svensson S; Some M; Lundsjö A; Helander A; Cronholm T; Höög J-O;. (1999). Activities of human alcohol dehydrogenases in the metabolic pathways of ethanol and serotonin. Eur J Biochem, 262: 324-329. 196732

Tanner CM. (1992). Occupational and environmental causes of parkinsonism. Occup Environ Med, 7: 503-513. 032549

Teeguarden JG; Deisinger PJ; Poet TS; English JC; Faber WD; Barton HA; Corley RA; Clewell HJ III. (2005). Derivation of a human equivalent concentration for n-butanol using a physiologically based pharmacokinetic model for n-butyl acetate and metabolites n-butanol and n-butyric acid. Toxicol Sci, 85: 429-446. 194624

Teng S; Beard K; Pourahmad J; Moridani M; Easson E; Poon R; O'Brien PJ. (2001). The formaldehyde metabolic detoxification enzyme systems and molecular cytotoxic mechanism in isolated rat hepatocytes. Chem Biol Interact, 130-132: 285-296. 017289

Tephly TR; McMartin KE. (1984). Methanol metabolism and toxicity. Food Sci Technol Bull Func Food, 12: 111-140. 031035

Thomas DG; Breslow N; Gart JJ. (1977). Trend and homogeneity analyses of proportions and life table data. Comput Biomed Res, 10: 373-381 . 196727

Thrasher JD; Kilburn KH. (2001). Embryo toxicity and teratogenicity of formaldehyde. Arch Environ Health, 56: 300-311. 196728

Til HP; Woutersen RA; Feron VJ; Hollanders VHM; Falker HE; Clary JJ. (1989). Two-year drinking-water study of formaldehyde in rats. Food Chem Toxicol, 27: 77-87. 031957

Tobe M; Naito K; Kurokawa Y. (1989). Chronic toxicity study on formaldehyde administered orally to rats. Toxicology, 56: 79-86. 196729

Toth BA; Wallcave L; Patil K; Schmeltz I; and Hoffmann D. (1977). Induction of tumors in mice with the herbicide succinic acid 2,2-dimethylhydrazide. Cancer Res, 37: 3497-3500. 196730

Tran MN; Wu AH; Hill DW. (2007). Alcohol dehydrogenase and catalase content in perinatal infant and adult livers: potential influence on neonatal alcohol metabolism. Toxicol Lett, 169: 245-252. 196724

Tsakiris T; Giannoulia-Karantana A; Simintzi I; Schulpis KH. (2006). The effect of aspartame metabolites on human erythrocyte membrane acetylcholinesterase activity . Pharmacol Res, 53: 1-5. 196731

Turner C; Spanel P; Smith D. (2006). A longitudinal study of methanol in the exhaled breath of 30 healthy volunteers using selected ion flow tube mass spectrometry, SIFT-MS. Physiol Meas, 27: 637-648 . 196733

U.S. EPA. (1986). Rat oral subchronic toxicity study with methanol. U.S. Environmental Protection Agency. Washington, DC. TRL No. 032-005. 196737

U.S. EPA. (2004). Integrated risk information system: Vinyl chloride. U.S. Environmental Protection
Agency. Washington, D.C..www.epa.gov/iris/subst/1001.htm. 196369

U.S. EPA. (1986). Guidelines for mutagenicity risk assessment. Federal Register. Washington, DC.
001466

U.S. EPA. (1986). Guidelines for the health risk assessment of chemical mixtures. Federal Register.
Washington, DC. 001468

U.S. EPA. (1988). Recommendations for and documentation of biological values for use in risk
assessment. Environmental Criteria and Assessment Office. Cincinnati, OH. 600/6-87/008.
064560

U.S. EPA. (1991). Guidelines for developmental toxicity risk assessment. Federal Register 56(234):63798-
63826 . U.S. Environmental Protection Agency, Risk Assessment Forum. Washington, DC.
EPA/600/FR-91/001. http://oaspub.epa.gov/eims/eimscomm.getfile?p_download_id=4560. 008567

U.S. EPA. (1994). Interim policy for particle size and limit concentration issues in inhalation toxicity
studies. U.S. Environmental Protection Agency, Health Effects Division. Washington,
DC.http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=186068. 076133

U.S. EPA. (1994). Methods for derivation of inhalation reference concentrations and application of
inhalation dosimetry. Office of Research and Development. Washington, DC. EPA/600/8-90/066F .
http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=71993. 006488

U.S. EPA. (1995). The use of the benchmark dose approach in health risk assessment. U.S.
Environmental Protection Agency. Washington, DC. EPA/630/R-94/007.
http://cfpub.epa.gov/ncea/raf/recordisplay.cfm?deid=42601. 005992

U.S. EPA. (1996). Guidelines for reproductive toxicity risk assessment. Office of Research and
Development. Washington, DC. 030019

U.S. EPA. (1998). Guidelines for neurotoxicity risk assessment. Federal Register 63(93):26926-26954.
National Center for Environmental Assessment; Office of Research and Development; U.S.
Environmental Protection Agency. Washington, DC. EPA/630/R-95/001Fa.
http://oaspub.epa.gov/eims/eimscomm.getfile?p_download_id=4555 . 030021

U.S. EPA. (1998). Health effects test guidelines: OPPTS 870.4200 Carcinogenicity. U.S. Environmental
Protection Agency. Washington, DC. EPA 712-C-98-211. 006378

U.S. EPA. (2000). Benchmark dose technical guidance document [draft]. Risk Assessment Forum.
Washington, DC. 052150

U.S. EPA. (2000). Science policy council handbook: Risk characterization. Office of Research and
Development. Washington, DC. EPA 100-B-00-002. http://www.epa.gov/iris/backgr-d.htm. 052149

U.S. EPA. (2000). Supplementary guidance for conducting health risk assessment of chemical mixtures.
Risk Assessment Forum. Washington, DC. 004421

U.S. EPA. (2002). A review of the reference dose and reference concentration processes. Risk
Assessment Forum. Washington, DC. EPA/630/P-02/0002F. 088824

U.S. EPA. (2005). Guidelines for carcinogen risk assessment, Risk Assessment Forum Report. U.S.
Environmental Protection Agency. Washington, DC. EPA/630/P-03/001F.
http://cfpub.epa.gov/ncea/index.cfm. 086237

U.S. EPA. (2005). Guidelines for carcinogen risk assessment. Risk Assessment Forum. Washington, DC. EPA/630/P-03/001B. http://www.epa.gov/cancerguidelines. 194126

U.S. EPA. (2005). Supplemental guidance for assessing susceptibility from early-life exposure to carcinogens. Risk Assessment Forum. Washington, DC. EPA/630/R-03/003F. http://www.epa.gov/iris/backgr-d.htm. 088823

U.S. EPA. (2006). A framework for assessing health risk of environmental exposures to children. National Center for Environmental Assessment. Washington, DC. EPA/600/R-05/093F. http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=158363. 194567

U.S. EPA. (2006). Science policy council handbook. Science Policy Council. Washington, DC. EPA/100/B-06/002. http://www.epa.gov/iris/backgr-d.htm. 194566

U.S. EPA. (2009). Benchmark dose software (BMDS) version 2.1.1 [build: 11/06/2009]. Retrieved 19-DEC-09, from http://www.epa.gov/NCEA/bmds. 200772

U.S. EPA. (2009). Section E - Quantities of TRI chemicals in waste, 2008. Retrieved 18-DEC-09, from http://www.epa.gov/tri/tridata/tri08/national_analysis/index.htm. 200741

U.S. EPA. (2009). The Toxics Release Inventory (TRI) and factors to consider when using TRI data. Retrieved 18-DEC-09, from http://www.epa.gov/tri/triprogram/FactorsToConPDF.pdf. 200746

U.S. EPA. (2009). TRI on-site and off-site reported disposed of or otherwise released in pounds for facilities in all industries for hazardous air pollutant chemicals U.S. 2008. Retrieved 18-DEC-09, from http://www.epa.gov/triexplorer/. 200742

Vara-Castrodeza A; Perez-Castrillon JL; Duenas-Laita A. (2007). Magnetic resonance imaging in methanol poisoning. Clin Toxicol, 45: 429-430. 093108

Ward KW; Blumenthal GM; Welsch F; Pollack GM. (1997). Development of a physiologically based pharmacokinetic model to describe the disposition of methanol in pregnant rats and mice. Toxicol Appl Pharmacol, 145: 311-322. 083652

Ward KW; Perkins RA; Kawagoe JL; Pollack GM. (1995). Comparative toxicokinetics of methanol in the female mouse and rat. Toxicol Sci, 26: 258-264. 077617

Ward KW; Pollack GM. (1996). Comparative toxicokinetics of methanol in pregnant and nonpregnant rodents. Drug Metab Dispos, 24: 1062-1070. 025978

Weiss B; Stern S; Soderholm SC; Cox C; Sharma A; Inglis GB; Preston R; Balys M; Reuhl KR; Gelein R. (1996). Developmental neurotoxicity of methanol exposure by inhalation in rats. Health Effects Institute. Boston, MA . HEI Research Report Number 73. 079211

Wentzel P; Eriksson UJ. (2006). Ethanol-induced fetal dysmorphogenesis in the mouse is diminished by high antioxidative capacity of the mother. Toxicol Sci, 2: 416-22. 196723

Wentzel P; Rydberg U; Eriksson UJ. (2006). Antioxidative treatment diminishes ethanol-induced congenital malformations in the rat. Alcohol Clin Exp Res, 30: 1752-1760. 196377

White LR; Marthinsen ABL; Richards RJ; Eik-Nes KB; Nilsen OG. (1983). Biochemical and cytological studies of rat lung after inhalation of methanol vapour. Toxicol Lett, 17: 1-5. 064578

Wilson SL; Cradock MM. (2004). Review: Accounting for prematurity in developmental assessment and the use of age-adjusted scores. J Pediatr Psychol, 29: 641-649. 196726

Wu AHB; Kelly T; McKay C; Ostheimer D;. (1995). Definitive identification of an exceptionally high methanol concentration in an intoxication of a surviving infant: Methanol metabolism by first-order elimination kinetics. J Forensic Sci, 40: 315-320. 078112

Yuan JH. (1993). Modeling blood/plasma concentrations in dosed feed and dosed drinking water toxicology studies. Toxicol Appl Pharmacol, 119: 131-141. 050215

Zorzano A; Herrera E. (1989). Disposition of ethanol and acetaldehyde in late pregnant rats and their fetuses. Pediatr Res, 25: 102-106. 095202

APPENDIX A. SUMMARY OF EXTERNAL PEER REVIEW AND PUBLIC COMMENTS AND DISPOSITION

1
2
3
4   [page intentionally left blank]

APPENDIX B. DEVELOPMENT, CALIBRATION AND APPLICATION OF A METHANOL PBPK MODEL

B.1. SUMMARY

1   This appendix describes the development, calibration, and approach for application of
2   mouse, rat, and human PBPK models to extrapolate mouse and rat methanol inhalation-route
3   internal dose metrics to human inhalation exposure concentrations that result in the same internal
4   dose (HEC). The human oral methanol dose(s) yielding internal dose(s) equivalent to the mouse
5   or rat internal dose at the (HED) is also presented.

6   A PBPK model was developed to describe the blood kinetics of methanol (MeOH) in
7   mice and humans. The model includes compartments for lung/blood MeOH exchange, liver, fat,
8   and the rest of the body. To describe blood MeOH kinetics, the model employs two saturable
9   descriptions of MeOH metabolism in mice and SD rats, one saturable metabolic pathway in F344
10   rats and humans, and a first-order description of renal clearance (from blood) in humans. Renal
11   clearance is a minor pathway and does not appreciably affect MeOH blood kinetics, but
12   methanol concentrations in urine are an important indicator of the corresponding blood levels.

13   This model is a revision of the model reported by Ward et al. (1997, 083652), reflecting
14   significant simplifications (removal of compartments for placentae, embryo/fetus, and
15   extraembrionic fluid) and two elaborations (addition of an intestine lumen compartment to the
16   existing stomach lumen compartment and addition of a bladder compartment which impacts
17   simulations for human urinary excretion.), while maintaining the ability to describe MeOH blood
18   kinetics. The model reported here uses a single consistent set of parameters; the Ward et al.
19   model employed a number of data-set specific parameters. Other biokinetic MeOH models that
20   were considered as starting points for the current model also used varied parameters by dataset to
21   achieve model fits to the data. For example, the model of Bouchard et al. (2001, 030672) used
22   different respiratory rates and fractional inhalation absorbed for different human exposures.

23   The mouse model was calibrated against inhalation-route blood MeOH kinetic data and
24   verified using intravenous-route blood MeOH kinetic data. The rat model was calibrated against
25   low-dose intravenous data and validated with inhalation-route data. The human model was
26   calibrated against inhalation-route MeOH kinetic data. The models accurately described the
27   inhalation route pharmacokinetics of MeOH. Mouse model simulations of oral- and i.v.-route
28   kinetics compare well to some but not all the experimental data.

29   The MeOH HECs predicted by the human model (based on 1,000 ppm inhalation
30   exposure in mice) were >1,000 ppm using either blood AUC or C_{max} as the dose metrics. The
31   MeOH HED derived by cross-route extrapolation of this inhalation-route HEC was 110 mg/kg-

1 day, based on MeOH blood AUC following zero order uptake of MeOH (a constant rate of
2 delivery). Because of the lack of human data from high-dose exposures, it was not possible to
3 calibrate the human model for inhalation exposures above 1,000 ppm or oral exposures above
4 110 mg/kg-day. However, application of the human PBPK model to the internal experimental
5 animal doses estimated via the BMD approach resulted in RfC and RfD PODs that are below
6 1,000 ppm or 110 mg/kg-day, respectively (see Sections 5.1.3.1 and 5.2.2).

B.2. MODEL DEVELOPMENT

B.2.1. Model Structure

7 This model is a revision of the model reported by Ward et al. (1997, 083652), reflecting
8 significant simplifications and two elaborations, while maintaining the ability to describe MeOH
9 blood kinetics in mice, rats, and humans (Figure B-1). The kidney, pregnancy and the fetal
10 compartment have been removed. The kidney was lumped with the body compartment because
11 the blood:tissue partition coefficients for these tissues were similar. The elaborate time-
12 dependent descriptions of pregnancy were removed because analysis of the available
13 pharmacokinetic data indicates that blood MeOH kinetics in NP and pregnant mice are not
14 different enough to warrant separate descriptions. Because the maternal blood:fetal blood
15 partition coefficients were near 1, there was no need to explicitly model fetal kinetics; they will
16 be equivalent to maternal blood kinetics. Further supporting data exist for ethanol, which is
17 quite similar to MeOH in its partitioning and transport properties. In rats (Guerri and Sanchis,
18 1985, 005706; Zorzano and Herrera, 1989, 095202), sheep (Brien et al., 1985, 031551;
19 Cumming et al., 1984, 031556), and guinea pigs (Clarke et al., 1986, 031223), fetal and maternal
20 blood concentrations of ethanol are virtually superimposable; maternal to fetal blood ratios are
21 very close to 1, including during late gestation. Also, fetal brain concentrations in guinea pigs
22 (Clarke et al., 1986, 031223) were also very similar to the mothers'.
23 In addition to the absolute maternal-fetal concentration similarity noted above, it is
24 common practice to use blood concentrations as an appropriate metric for risk extrapolation via
25 PBPK modeling for effects in various tissues, based on the reasonable expectation that any
26 tissue:blood differences will be similar in both the test species and humans. For example, even if
27 the brain:blood ratio was around 1.2 in the mouse or rat, the similar biochemical make-up of
28 brain tissue and blood in rats and humans leads to the expectation that the brain:blood levels in
29 humans (which depend on the biochemical make-up) will also be close to 1.2, and so the relative
30 "error" that might occur by using blood instead of brain concentration in evaluating the dose-
31 response in rats will be cancelled out by using blood instead of brain concentration in the human.
32 The fact that measured fetal blood levels are virtually identical to maternal levels for methanol

1 (and ethanol) tells us that the rate of metabolism in the fetus is not sufficient to significantly

2 reduce the fetal concentration versus maternal, and use of a PBPK model to predict maternal

3 levels will give a *better* estimate of fetal exposure than use of the applied dose or exposure,

4 because there *are* animal-human differences in adult PK of MeOH for which the model accounts,

5 based on PK data from humans as well as rodents.

Figure B-1. Schematic of the PBPK model used to describe the inhalation, oral, and i.v. route pharmacokinetics of MeOH. KAS, first-order oral absorption rate from stomach; KAI, first-order uptake from the intestine; KSI, first-order transfer between stomach and intestine; Vmax, Km, Vmax2, and Km2, Michaelis-Menten rate constants for high affinity/low capacity and low affinity/high capacity metabolism of MeOH; KLL, alternate first-order rate constant; KBL, rate constant for urinary excretion from bladder. Both metabolic pathways were used to describe MeOH metabolism in the mouse and SD rat, while a single pathway describes metabolism in the F344 rat and human.

6   A lung compartment was added to describe delivery of MeOH to blood as a function of

7 ventilation, partitioning, and blood flow rather than the less standard approach used by Ward

8 et al. (1997, 083652). A term was added to the gas uptake equations to describe the fractional

9 respiratory bioavailability of MeOH. A fat compartment was included because it is the only

10 tissue with a tissue:blood partitioning coefficient appreciably different than unity, and the liver is

11 included because it is the primary site of metabolism. A bladder compartment was added to

better describe the kinetics of human urinary data, where the drop in excretion rate is slower than the predicted decline in blood methanol and hence rate of metabolite production. Also, to best describe the observed rat dosimetry after oral exposure while maintaining metabolic parameters fit to data from inhalation and IV exposure, a small rate of elimination from the intestine (lumen) compartment to feces. (The mouse data could be adequately fit with this rate set to zero, corresponding to 100% absorption; humans were assumed to have zero fecal elimination, like the mouse.) The final models thus include compartments for fat, liver, the rest of the body, bladder (only used for humans), and lung. The mouse and rat models describe inhalation, oral, and intravenous route dosing and the human model describes inhalation and oral route dosing and the rat model includes a non-zero rate of fecal elimination. Although there is an endogenous background level of both MeOH and formate (See Section 3.3), the model does not explicitly describe or account for background levels of MeOH or formate. In this analysis, when non-zero background levels have been measured (in blood), that background was simply subtracted from the concentrations measured during exposure. However, a zero-order rate of infusion could be added to the liver, blood, or stomach compartments to mimic background levels if that was considered necessary.

MeOH is well absorbed by the inhalation and oral routes, and is readily metabolized to formaldehyde, which is rapidly converted to formate in both rodents and humans. Although the enzymes responsible for metabolizing formaldehyde are different in rodents (CAT) and humans (ALD) the metabolite, formate, is the same, and the metabolic rates are similar (Clary, 2003, 047003). Most of the published rodent kinetic models for MeOH describe the metabolism of MeOH to formaldehyde as a saturable process but differ in the handling of formate metabolism and excretion (Bouchard et al., 2001, 030672; Fisher et al., 2000, 009750; Horton et al., 1992, 196222; Ward et al., 1997, 083652). Ward et al. (1997, 083652) used one saturable and one first-order pathway for mice, and Horton et al. (1992, 196222) applied two saturable pathways of metabolism to describe MeOH elimination in rats. Bouchard et al. (2001, 030672) employed one metabolic pathway and a second pathway described as urinary elimination in rats and humans. The need for two saturable metabolic pathways in the mouse model was confirmed through simulation and optimization. High exposure (>2,000 ppm MeOH) and low exposure (1,000 ppm MeOH) blood data could not be adequately fit either visually or by more formal optimization without the second saturable metabolic pathway. The optimization approach and results are found below and in the Additional Materials at the end of this appendix.

While the PPK model explicitly describes the concentration of methanol, it only describes the rate of metabolism or conversion of MeOH to its metabolites. Distribution and metabolism of formaldehyde is not considered by the model, and this model tracks neither formate nor formaldehyde. (The data that would be needed to parameterize or validate a specific

1 description of either of these metabolites is not available). Since the metabolic conversion of

2 formaldehyde to formate is rapid (< 1 minute) in all species (Kavet and Nauss, 1990, 032274),

3 the MeOH metabolism rate should approximate a formate production rate, though this has not

4 been verified. Thus the rate of MeOH metabolism predicted by the model can be used as a dose

5 metric for either or both of these metabolites, but scaling of that metabolic rate metric to humans

6 requires that the rate be normalized to $BW^{0.75}$, (i.e., scaled rate = $mg/kg^{0.75}$-time) to account for

7 the general expectation metabolic elimination of the metabolites scales as $BW^{0.75}$, hence is

8 slower in humans.

9   The model was initially coded in acslXtreme v1.4 and updated in acslXtreme v 2.3. Most

10 procedures used to generate this report, except those for the optimization, may be run by

11 executing the corresponding .m files. The model code (acslXtreme .csl file) and supporting .m

12 files are available electronically and as text in the Additional Materials at the end of this

13 appendix. A key identifying .m files associated with figures and tables in this report is also

14 provided in the Additional Materials.

B.2.2. Model Parameters

15   Physiological parameters such as tissue volumes, blood flows, and ventilation rates were

16 obtained from the open literature (Table B-1). Parameters for blood flow, ventilation, and

17 metabolic capacity were scaled as a function of body weight raised to the 0.75 power, according

18 to the methods of Ramsey and Andersen (1984, 063020).

Table B-1. Parameters used in the mouse and human PBPK models

	Mouse	Rat SD | F344	Human	Source
Body weight (kg)	0.03^a	0.275^b	70	Measured/estimated
Tissue volume (% body weight)				
Liver	5.5	3.7	2.6	(Brown et al., 1997, 020304)
Blood arterial	1.23	1.85	1.98	
venous	3.68	4.43	5.93	
Fat	7.0	7.0	21.4	
Lung	0.73	0.50	0.8	
Rest of body	72.9	73.9	58.3	Calculated^c
Flows (L/hr/kg$^{0.75}$)				
Alveolar ventillation^d	25.4	16.4	16.5	(Brown et al., 1997, 020304; Perkins et al., 1995, 085259; U.S., 2004, 196369)
Cardiac output	25.4	16.4	24.0	
Percentage of cardiac output				
Liver	25.0	25.0	22.7	(Brown et al., 1997, 020304)

	Mouse	Rat SD | F344		Human		Source
				1st order	**saturable**	
Fat	5.0	7.0		5.2		
Rest of body	70.0	68		72.1		Calculated
Biochemical constants[e]						
$V_{max}C$ (mg/hr/kg$^{0.75}$)	19	5.0	0	NA	33.1	Fitted
Km (mg/L)	5.2	6.3	NA	NA	23.7	
$V_{max}2C$ (mg/hr/kg$^{0.75}$)	3.2	8.4	22.3	NA		
Km2 (mg/L)	660	65	100	NA		
K1C (BW$^{0.25}$/hr)	NA	NA		0.0373	0.0342	
KLLC (BW$^{0.25}$/hr)[f]	NA	NA		95.7	NA	
Oral absorption						
VmASC (mg/hr/kg$^{0.75}$)	1830	5570		377		Mouse and rat fitted (mouse and human KMASC assumed = rat); other human values are those for ethanol from (Sultatos et al., 2004, 090530), with VmASC set so that for a 70-kg person VmAS/KM = the first-order constant of Sultatos et al.
KMASC (mg/kg)	620	620		620		
KSI (hr^{-1})	2.2	7.4		3.17		
KAI (hr^{-1})	0.33	0.051		3.28		
Kfec (hr^{-1})	0	0.029		0		
Partition coefficients						
Liver:Blood	1.06	1.06		0.583[h]		(Fiserova-Bergerova and Diaz, 1986, 064569; Ward et al., 1997, 083652)
Fat:Blood	0.083	0.083		0.142		
Blood:Air	1350[i]	1350		1626		(Fiserova-Bergerova and Diaz, 1986, 064569; Horton et al., 1992, 196222)
Body:Blood	0.66	0.66		0.805		Rodent: estimated; human: (Fiserova-Bergerova and Diaz, 1986, 064569) (human "body" assumed = muscle)
Lung:Blood	1	1		1.07		
Bladder time-constant (KBL, hr^{-1})[j]	NA			0.564	0.612	Fitted (human)
Inhalation fractional availability (%)	0.665	0.20		0.866[k]		Rodent: fitted; human (Ernstgard et al., 2005, 088075)

	Mouse	Rat SD | F344	Human	Source

NA - Not applicable for that species

[a]Both sources of mouse data report body weights of approximately 30 g

[b]The midpoints of rat weights reported for each study was used and ranged from 0.22 to 0.33 kg

[c]The volume of the other tissues was subtracted from 91% (whole body minus a bone volume of approximately 9%) to get the volume of the remaining tissues

[d]Minute ventilation was measured and reported for much of the data from (Perkins et al., 1996, 196147) and the average alveolar ventilation (estimated as 2/3 minute ventilation) for each exposure concentration was used in the model. When ventilation rates were not available, a mouse QPC (Alveolar Ventilation/$BW^{0.75}$) of 25.4 was used (average from (Perkins et al., 1995, 085259)). The QPC used to fit the human data was obtained from U.S. EPA (2004, 196369). This QPC was somewhat higher than calculated from Brown et al. (1997, 020304) (~13 $L/hr/kg^{0.75}$)

[e]V_{max}, Km, and $V_{max}2$, Km2 represent the two saturable metabolic processes assumed to occur solely in the liver. The V_{max} used in the model = $V_{max}C$ ($mg/kg^{0.75} \cdot hr$)$\times BW^{0.75}$. K1C is the first-order loss from the blood for human simulations that represents urinary elimination. Allometric scaling for first-order clearance processes was done as previously described (Teeguarden et al., 2005, 194624); The K1 used in the model= K1C / $BW^{0.25}$

[f]KLLC – alternate human first-order metabolism rate (used only when $V_{max}C = V_{max}2C = 0$)

[g]Human oral simulations used a zero order dose rate equal to the mg/kg-day dose

[h]Human liver:blood estimated from correlation to (measured) fat:blood, based on data from 28 other solvents

[i]Rat partition coefficient used for mice as done by Ward et al. (1997, 083652)

[j]KBL – a first-order rate constant for elimination from the bladder compartment, used to account for the difference between blood kinetics and urinary excretion data as observed in humans

[k]For human exposures, the fractional availability was from Šedivec et al. (1981, 031154), corrected for the fact that alveolar ventilation is 2/3 of total respiration rate

1   Mouse model partition coefficients were used as reported (liver, fat, blood:air) or

2 estimated (lung, body). The mouse body compartment partition coefficient was set

3 approximately equal to the measured value for muscle (Ward et al., 1997, 083652). The mouse

4 lung partition coefficient was assumed to be 1.0, similar to the liver partition coefficient. This

5 parameter has no numerically significant impact on modeled blood dose metrics.

6   Human partition coefficients were reported by Horton et al. (1992, 196222), but were in

7 fact measured in rat tissues. The reported rat fat partition coefficient was considerably closer to

8 unity than reported for MeOH or ethanol by other researchers (Pastino and Conolly, 2000,

9 006128; Ward et al., 1997, 083652) and assumed to be in error. Human partition coefficients

10 were obtained from Fiserova-Bergerova and Diaz (1986, 064569).

B.2.3. Mouse Model Calibration

B.2.3.1. Inhalation-Route Calibration

11   For purposes of conducting interspecies extrapolations of MeOH dosimetry, the

12 inhalation route was the most important route requiring calibration for the mouse model. The

13 critical endpoint and NOEL, which are the basis for the HEC estimation, are from inhalation-

14 route studies. The ability to predict blood MeOH concentrations from inhalation exposures was

15 therefore a priority. Pharmacokinetic data from other routes, i.v. and oral, were used to verify

16 elimination terms derived by fitting to the inhalation data or to estimate a MeOH oral uptake rate

1 constants. Holding other parameters constant, the mouse PBPK model was calibrated against
2 inhalation-route blood pharmacokinetic data (Figure B-2) by fitting five parameters: Michaelis-
3 Menten constants for one high affinity/low capacity and one low-affinity high-capacity enzyme
4 and the inhalation fractional availability term.

Figure B-2. Model fits to data sets from GD6, GD7, and GD10 mice for 7-hour inhalation exposures to 1,000–15,000 ppm MeOH. Maximum concentrations are from Table 2 in Rogers et al. (1993, 032696). The complete data set for GD7 mice exposed to 10,000 ppm is from Rogers et al. (1997, 009755) and personal communication (Additional Materials). Symbols are concentration means of a minimum of n = 4 mice/concentration. Default ventilation rates (Table B-1) were used to simulate these data.

5 For these mouse simulations, pulmonary ventilation was set to 25.4 (L/hr/kg$^{0.75}$), the
6 average value measured by Perkins et al. (1995, 085259), which is similar to the value of 29
7 (L/hr/kg$^{0.75}$) reported in Brown et al. (1997, 020304). Where ventilation rates were reported for
8 individual exposure concentrations by Perkins et al. (1995, 085259), they were used directly in
9 the model and a notation was made in the figure legend. Reported ventilation rates varied from
10 592 to 857 L/kg x 8 hr, depending on exposure concentration (Perkins et al., 1995, 085259).
11 Adjusting these values to 2/3 total (for alveolar ventilation) and allometrically scaling by BW$^{0.75}$,
12 values used in the model for these exposures ranged from 20.5 to 29.7 (L/hr/kg$^{0.75}$) (See Table B-
13 1). A fractional availability of 73% of alveolar ventilation was visually optimized to best
14 describe the inhalation-route blood MeOH pharmacokinetic data. This percentage of uptake for
15 inhalation exposures is similar to values reported for other alcohols in rodents (Teeguarden et al.,
16 2005, 194624), but considerably lower than the value reported by Perkins et al. (1995, 085259)
17 of 126% of alveolar ventilation (85% of total ventilation).

1   The calibrated model predicted blood MeOH concentration time-course agreed well with
2   measured values in adult mice in the inhalation studies of Rogers et al. (1997, 009755)(1993,
3   032696) (Figure B-2), and Perkins et al. (1995, 085259), as well as in NP and early gestation
4   (GD8) mice of Dorman et al. (1995, 078081) (Figure B-3). Parameter values used in the
5   calibrated model are given in Table B-1.

Figure B-3. Simulation of inhalation exposures to MeOH in NP mice from Perkins et al. (1995, 085259) (8-hour exposures) and Dorman et al. (1995, 078081), (6-hour exposures). Data points represent measured blood MeOH concentrations and lines represent PBPK model simulations. Note: data was obtained using DigitizIt (SharIt! Inc. Greensburg, PA) to digitize data from Figure 2 of Perkins et al. (1995, 085259) and Figure B-2 from Dorman et al. (1995, 078081). Default ventilation rates (Table B-1) were used to simulate the Dorman data. The alveolar ventilation rate for each data set from Perkins et al. (1995, 085259) was set equal to the measured value reported in that manuscript. For the 2,500, 5,000, and 10,000 ppm exposure groups, the alveolar ventilation rates were 29, 24, and 21 (L/hr/kg0.75), respectively. The cardiac output for these simulations was set equal to the alveolar ventilation rate.

B.2.3.2. Oral-Route Calibration

6   The mouse model was calibrated for the oral route by fitting the rate constants for oral
7   uptake of MeOH. Calibration of the oral route was not required for interpretation of the critical
8   toxicology studies. This exercise was undertaken to estimate the rate constants for oral uptake so

1 it could be used to make dose-route extrapolations for calculating human oral-route exposures

2 equivalent to mouse exposures at the NOEL.

3   Ward et al. (1997, 083652) described MeOH uptake as the sum of a fast and slow

4 process (two rate constants), with a fraction of the administered dose attributed to each process.

5 The rate constants and the fraction of the dose attributed to each process were varied to describe

6 oral-route blood MeOH kinetics for each GD. For instance, the fraction of the total oral dose

7 assigned to the fast absorption process varied from 54 to 71%, depending on the data set. An

8 alternative approach with uptake attributed to stomach and intestine, which allows for greater

9 flexibility in fitting the data (Staats et al., 1991, 065129), was compared to a simpler one

10 utilizing a single rate of uptake. In both the current model and the model of Ward et al. (1997,

11 083652), orally ingested MeOH was assumed to be 100 % absorbed.

12   Initially, a single oral absorption rate constant (KAS, hr^{-1}) was fitted to oral-route blood

13 MeOH kinetics reported by Ward et al. (1995, 077617; 1997, 083652). Using these data, an

14 average KAS (0.62 hr^{-1}) was estimated that provides adequate fits to MeOH blood kinetics

15 following 2,500 mg/kg dose in NP and GD18 mice and 1,500 mg/kg in GD8 mice up to ~8

16 hours. At later time points, however, a model using a single oral uptake rate constant

17 consistently under predicts blood concentrations of MeOH (results not shown). Fits were

18 improved by using the two compartment GI tract model (Figure B-4). However, when fitting the

19 oral data in rats, it was found that the fits were significantly improved if the uptake from the

20 stomach was treated as a saturable process. V_{max} (VMASC) was scaled as $BW^{0.75}$, as is done for

21 other V_{max}s, and the Km (KMASC) was scaled as BW^1 to reflect that the variable used is the

22 total amount in the stomach, whose volume is expected to scale with BW^1. For the mouse,

23 model fits were not significantly improved when KMASC was allowed to vary (change from the

24 value fitted to rats, 1830 mg/kg), so it was kept at the rat value.

25   Using the two-compartment oral absorption model and adjusting only the absorption

26 parameters resulted in a good fit to the lower oral dose (1,500 mg/kg) (Dorman et al., 1995,

27 078081), but consistently under-prediction of the 2,500 mg/kg oral dosing blood levels (Ward et

28 al., 1997, 083652). When the metabolic constants (V_{max}C values) were decreased, the data from

29 the higher dose were fit, but the fit of the data for the 1,500 mg/kg dose was lost (see Additional

30 Materials, Figure B-19). Also, when using the lower clearance required to fit the data of Ward

31 et al. (1997, 083652), the inhalation data of Rogers et al. (1993, 032696) could no longer be fit

32 by the model (see Additional Materials, Figure B-20). The two-compartment GI tract approach

33 (with parameters that better fit the low dose data) was retained in the model and used for all final

34 mouse oral route simulations.

Figure B-4. Oral exposures to MeOH in pregnant mice on GD8 (Dorman et al., 1995, 078081) or NP and GD18. Data points represent measured blood concentrations and lines represent PBPK model estimations for NP mice.

1   Using the two-compartment oral absorption model and adjusting only the absorption

2   parameters resulted in a good fit to the lower oral dose (1,500 mg/kg) (Dorman et al., 1995,

3   078081), but consistently under-prediction of the 2,500 mg/kg oral dosing blood levels (Ward et

4   al., 1997, 083652). When the metabolic constants ($V_{max}C$ values) were decreased, the data from

5   the higher dose were fit, but the fit of the data for the 1,500 mg/kg dose was lost (see Additional

6   Materials, Figure B-19). Also, when using the lower metabolic rate constants required to fit the

7   data of Ward et al. (1997, 083652), the inhalation data of Rogers et al. (1993, 032696) could no

8   longer be fit by the model (see Additional Materials, Figure B-20). The two-compartment GI

9   tract approach (with parameters that better fit the low dose data) was retained in the model and

10   used for all final mouse oral route simulations.

B.2.3.3. Intravenous Route Simulation

11   The parameterization of MeOH metabolism (high-and-low affinity metabolic pathways)

12   was verified by simulation of data sets describing the intravenous-route pharmacokinetics of

13   MeOH. MeOH blood kinetics data in NP mice are only available for a single i.v. dose of

14   2,500 mg/kg (Ward et al., 1997, 083652). MeOH blood kinetics are also reported in GD18 mice

15   following administration of a broader range of doses: 100, 500, and 2,500 mg/kg. Because

16   MeOH kinetics appear similar for NP and pregnant mice after administration of 2,500 mg/kg

17   prior to 20 hours, the model is expected to fit data for both pregnant and NP mice using the same

set of parameters, and hence, data for both life stages were used to verify overall clearance
(including metabolism) of MeOH.

Initial blood concentrations of MeOH following i.v. administration were not proportional
to administered dose in the data from Ward et al. (1997, 083652), but were approximately 1.5-
fold lower in the 100 mg/kg dose group than expected if a dose-independent volume of
distribution (V_D) is assumed (Figure B-5A). Initial blood concentrations were, however,
proportional to administered dose between 2,500 and 500 mg/kg. To account for this unexpected
nonproportionality, Ward et al. (1997, 083652) used higher partition coefficients for placenta and
embryonic fluid and a lower V_{max} for the metabolism of MeOH for the 100 and 500 mg/kg doses
than for the 2,500 mg/kg dose. These adjustments to partition coefficients effectively make the
volume of distribution (V_D) dose-dependent. However, the PBPK model obtained here, with
measured partition coefficients and otherwise calibrated to inhalation data as described above,
was capable of simulating both the 500 and 2,500 mg/kg data without adjustment or varying
parameters between those 2 doses.

From a physico-chemical (mechanistic) basis, V_D should only depend on the tissue:blood
partitioning, which for small organic (non-polar) molecules such as methanol is not expected to
have any concentration- or dose-dependence. Hence the V_D should be adequately predicted by
the PBPK model with the independently measured partition coefficients. If there were some
dose-dependence one would expect the value at 500 mg/kg to be intermediate between the values
at 100 and 2,500 mg/kg doses, but that was not the case. Further, no biochemical mechanism has
been suggested (by Ward et al. or others) which could explain such dose-dependence. Thus the
apparent change in V_D at 100 mg/kg is highly unlikely, based on mechanistic considerations and
past experience with similar organic compounds. Finally, the data at the nominal dose of 100
mg/kg could also be adequately fit without other parameter adjustment simply by simulating a
dose of 200 mg/kg (dotted line, Figure B-5B). The fact that this alternate simulation differs in
dose by a factor of 2 suggests another possibility: a dilution error occurred in the preparation of
the dosing solution by Ward et al. (1997, 083652) (i.e., one serial dilution step was skipped).

Figure B-5. Mouse intravenous route MeOH blood kinetics. A) MeOH was infused over 1.5 minutes into female CD-1 mice at target doses of 100 (circles), 500 (triangles) or 2,500 (squares) mg/kg. Mice were NP, GD9 or GD18 at the time of dosing. Data points represent measured blood concentrations and lines represent PBPK model simulations. B) Comparison of the 100 mg/kg dose data (points) and PBPK model simulations assuming a 100 mg/kg dose as reported (solid line) or to a presumed 200 mg/kg dose (dashed lines). Note: the 24-hour time point data from the 500 mg/kg NP and GD 9 mice are below the reported detection limit (2 μg/ml) and so are not shown.

Source: Adapted from Ward et al. (1997, 083652).

1   Given these considerations and observations regarding dosimetry and distribution, the

2   ability of the model to fit the high- (2,500 mg/kg) and mid-dose (500 mg/kg) intravenous-route

pharmacokinetic data without adjustment was considered sufficient to validate the parameters

calibrated from the inhalation studies for the metabolic elimination of MeOH. Metabolic

constants reasonably predict blood MeOH kinetics following a 2,500 mg/kg dose in NP animals

until 12 hours postexposure, but under predict blood MeOH in GD9 and GD18 mice at 8 hours

of exposure and beyond, and under-predict levels in both NP and pregnant mice at 15 hours and

beyond. At this high-dose, where blood kinetics of MeOH were reported in NP, GD9, and GD18

mice, the data for the GD18 mice was inconsistent with the GD9 and NP animals. The GD9 data

at 12 hours appears inconsistent with the NP data, but then the 2 are nearly identical again at 15

hours, so it is not clear if that difference at 12 hours is real or just due to experimental variability.

Blood levels of MeOH were ~500 mg/L in GD18 mice at 24 hours, but were nondetectable after

18 hours in the other groups (detection limit 2 mg/L). Blood concentrations were accurately

predicted following administration of 500 mg/kg MeOH (Figure B-5A). The model predictions

did not match the 100 mg/kg data unless one assumed an error in dose preparation, as described

above (Figure B-5B). While it is very unusual to suggest such an error in published, peer-

reviewed experimental data, since no other adequate explanation (mechanism) is available, such

dose-dependence in V_D has not been observed for similar organic compounds, and the error

suggested is a fairly simple one, this seems a far more likely explanation than the alternative.

The calibration of the MeOH PBPK model is consistent with both the available inhalation and

oral-route data.

B.2.3.4. Total methanol metabolism

Quantifying production of formaldehyde following MeOH exposure for use as an

alternative dose metric is of particular interest because formaldehyde is also undergoing toxicity

assessment. However, it is important to understand that because the model was developed to

describe blood MeOH kinetics, metabolism of MeOH to neither formaldehyde nor formate is

specifically described; the model tracks neither of these metabolites. While the metabolism of

MeOH described by the model may be presumed to equate with formaldehyde production, this

metabolic flux simply leaves the computational model system without specific attribution. Since

the metabolic conversion of formaldehyde to formate is rapid in all species (< 1 minute) (Kavet

and Nauss, 1990, 032274), the MeOH clearance rate may also approximate a formate production

as well as a formaldehyde production rate, though this has not been verified.

Thus, production of formaldehyde or formate following exposure to MeOH can only be

estimated by summing the total amount of MeOH eliminated by metabolic processes. If used,

this metric of formaldehyde or formate dose should be scaled by $BW^{0.75}$ to adjust for expected

species differences in the clearance of these two metabolites (this is scaling reflects the generally

accepted assumption that metabolic elimination [of formaldehyde or formate] scales as $BW^{0.75}$;

if the metabolic rate is scaled this way, then equal scaled rates in animals and humans is expected

1   to result in equal body burdens or concentrations of the toxic metabolites). The total rate of

2   MeOH metabolism is assumed to equal the total amount of metabolites produced. Values of total

3   MeOH metabolism as a function of exposure in mice and humans are presented in the Additional

4   Materials (Tables B-6, B-7, and B-8).

B.2.3.5. Formal optimization of mouse model parameters

5   Formal optimization of five parameters (inhalation fractional availability and the V_{max}

6   and Kms for high and low affinity MeOH metabolism) was attempted using optimization

7   routines in acslXtreme v2.01.1.2. Under the best circumstances, formal optimizations offer the

8   benefit of repeatability and confirmation that global optima have not been significantly missed

9   by user-guided visual optimization. Incorporating judgments regarding the value of specific data

10 sets, while possible when visually fitting, is more difficult when using optimization routines.

11 This is an important distinction between these approaches for this modeling exercise.

12   The mouse inhalation route NOEL was less than 1,000 ppm MeOH. The model is

13 calibrated against inhalation-route data because of the importance of this exposure route in the

14 assessment. Unfortunately, the vast majority of the MeOH data came from much higher

15 exposure concentrations. As expected, various attempts at formal optimization lead to improved

16 fits for some but never all data sets. This is to be expected when there is significant variability in

17 the underlying data. Various data-weighting schemes were included to improve overall

18 optimization while maintaining a good fit to the lowest concentration (1,000 ppm) data. In the

19 end, formal optimization provided no significant improvement over the fractional availability

20 and metabolic parameter values obtained by visual optimization, so these were retained in the

21 final version of the model.

22   Further details on the approach and results from the formal optimization are found in the

23 Additional Materials in outline format with supporting figures. More complete documentation

24 was not developed because the products of the optimizations were not used in the final model.

25 The documentation is intended only to demonstrate that appropriate optimizations were

26 conducted and what the results of those optimizations were.

B.2.4. Mouse Model Sensitivity Analysis

27   An evaluation of the importance of selected parameters on mouse model estimates of

28 blood MeOH AUC was performed by conducting a sensitivity analysis using the subroutines

29 within acslXtreme. Files for reproducing the sensitivity analysis are available in the model as

30 described in the additional materials. The analysis was conducted by measuring the change in

31 model output corresponding to a 1% change in a given model parameter when all other

32 parameters were held fixed. A normalized sensitivity coefficient of 1 indicates that there is a

33 one-to-one relationship between the fractional change in the parameter and model output; values

1   close to zero indicate a small effect on model output. A positive value for the normalized

2   sensitivity coefficient indicates that the output and the corresponding model parameter are

3   directly related while a negative value indicates they are inversely related.

4   Sensitivity analyses were conducted for the inhalation and oral routes. The

5   inhalation-route analysis was conducted under the exposure conditions of Rogers and Mole

6   (1997, 009755) and Rogers et al. (1993, 032696), 7-hour inhalation exposures at the NOEL

7   concentration of 1,000 ppm. The oral route sensitivity analysis was conducted for an oral dose

8   of 1,000 mg/kg.

9   Parameters with sensitivity coefficients less than 0.1 are not reported. The parameters

10 with the largest sensitivity coefficients for the inhalation route at 1,000 ppm were pulmonary

11 ventilation, $V_{max}C$, and partitioning to the body compartment (Figures B-6 [metabolism] and B-7

12 [flows and partition coefficients]). MeOH AUC was also sensitive to KM2 and $V_{max}C$. The

13 sensitivity coefficient for pulmonary ventilation increases from 1 to ~1.75 during the exposure

14 period as metabolism begins to saturate. The sensitivity coefficient is 1 for concentrations 100

15 ppm MeOH or less or when hepatic elimination is nonlimiting.

16   Oral-route mouse blood MeOH AUC was sensitive to the rate constants for uptake.

17 Blood AUC was most sensitive to the first-order rate constant for uptake from the stomach, KAS,

18 during the first hour after exposure, becoming less important over time (Figure B-8). Blood

19 MeOH AUC was also modestly sensitive to KAI, and KSI, the rate constants for uptake from the

20 intestine and transfer rates between compartments, respectively.

Figure B-6. Mouse model inhalation route sensitivity coefficients for metabolic parameters. Sensitivity coefficients calculated for an exposure of 1,000 ppm MeOH are reported for blood MeOH AUC. Note: Km, Vmax refer to the high-affinity, low-capacity pathway and Km2, Vmax2 refer to the low-affinity, high-capacity pathway.

Figure B-7. Mouse model inhalation route sensitivity coefficients for flow rates (QCC: cardiac output; QPC: alveolar ventilation), and partitioning to the body (PR) compartment are reported for blood MeOH AUC. Sensitivity coefficients calculated for an exposure to 1,000 ppm MeOH.

Figure B-8. Mouse model sensitivity coefficients for oral exposures to MeOH. The sensitivity of blood MeOH AUC to oral absorption rate constants (KAS: stomach; KAI: intestine; KSI: transfer between compartments) is reported.

B.2.5. Mouse drinking water ingestion pattern

1   To simulate exposures of mice via drinking water under bioassay conditions, an ingestion
2   pattern first used by Keys et al. (2004, 196283), based on data from Yuan (1993, 050215) was
3   used. The pattern specifies a fraction of percent of total daily ingestion consumed in each half-
4   hour interval. The first interval was shifted to correspond to the beginning of the active (dark)
5   period, for consistency with patterns used for humans and rats. A Table function was used in
6   acslXtreme to interpolate an instantaneous rate between the measured (30-min) values, with
7   normalization so that the 24-hour integral equals 100%. The daily pattern is shown in Figure B-
8   9A and the resulting blood concentration for a mouse exposed for 6 days per week (2100 mg/kg)
9   is shown in Figure B-9B.

Figure B-9. Mouse daily drinking water ingestion pattern (A) and resulting predicted blood concentration for a 6 d/wk exposure (B). Mouse drinking water exposures were simulated by multiplying the fractional rate (1/h) as a function of clock time by the daily total dose ingested (mg) to obtain a rate of addition of methanol into the stomach lumen compartment (mg/h).

Source: Yuan (1993, 050215); Keys et al. (2004, 196283)

B.2.6. Rat model calibration

1   The model was initially calibrated-to-fit data from intravenous, inhalation, and oral
2   exposures in Sprague-Dawley (SD) rats using the 100 and 2500 mg/kg intravenous (IV) data
3   provided in the command file of Ward et al. (1997, 083652). Holding other parameters constant,
4   the rat PBPK model was calibrated against the Ward et al. (1997, 083652) IV-route blood

pharmacokinetic data (Figure B-10) by fitting Michaelis-Menten constants for one high affinity/low capacity and one low-affinity, high-capacity enzyme, using the optimization routines in acslXtreme v2.3. Also shown for comparison in Figure B-10A are the 100 mg/kg IV data of Horton et al. (1992, 196222), obtained using Fischer 344 (F344) rats (data extracted from figures using DigitizIt), with a model simulation (heavy red line) which differs from that for the SD rat only due to the predicted effect of know body weight differences. While the fit to the Ward et al. (1997, 083652) data for SD rats is excellent, especially for the lower dose, the rate of clearance (disappearance from the blood, mostly due to metabolism) is over-predicted for the F344 rat when parameters fit to SD rat data are used. The 100 mg/kg IV data, with an alternate simulation for the F344 rat obtained with distinct parameters (see below) is expanded in Figure B-10B, emphasizing the difference in clearance between the two strains.

We then attempted to fit the model to the inhalation data of Horton et al. (1992, 196222) by adjusting only the inhalation fractional uptake (FRACIN). The results, shown in Figure B-11A, are clearly poor. While the model does match the uptake portion of the inhalation data for the 1200 and 2000 ppm exposures, it under-predicts the peak concentration reached at 200 ppm. Further, the post-exposure clearance predicted by the model is much more rapid than indicated by the data, as occurred with the IV kinetics (Figure B-10). (Since the peak concentration for the 2000 ppm inhalation exposure actually occurred at 7 hr, we also simulated a 7-hr exposure, shown by the thin black line. The result indicates that the data are more consistent with and better predicted by the longer exposure duration, but clearance is still over-predicted post-exposure.) Therefore we concluded that the data show a clear strain difference in metabolism, and should support at least a partially independent set of parameters for SD and F344 rats.

We then combined the 100 mg/kg IV and inhalation data of Horton et al. (1992, 196222) (for F344 rats) and attempted to simultaneously identify the four metabolic parameters (Vmax and Km for two pathways) and FRACIN. However when this was done the resulting values for the two Km's were ~ 90 ± 50 mg/L and 70 ± 40 mg/L (Km and Km2, respectively), which are clearly indistinguishable from a statistical standpoint. If instead the Km's were fixed at the more distinct values identified from the SD rat IV data (6.3 and 65 mg/L), the optimization routine tended to set the Vmax associated with the lower Km to zero. Thus the F344 rat data of Horton et al. (1992, 196222) appear to be most consistent with a single metabolic pathway, even though the observed concentrations spanned almost 2 orders of magnitude. Therefore those data (including the 100 mg/kg IV data) were simultaneously fit by adjusting a single Vmax and Km, along with the inhalation fraction, FRACIN, with the second metabolic pathway set to zero (Figures B-10B and B-11B).

Figure B-10. NP rat i.v.-route methanol blood kinetics. MeOH was infused into: female Sprague-Dawley rats (275 g) at target doses of 100 (open squares and thin black line) or 2,500 (filled squares and heavy blue line) mg/kg; or (filled diamonds and heavy red lines) male F-344 rats (220 g) at target doses of 100 mg/kg. Data points represent measured blood concentrations and lines represent PBPK model simulations with (A) metabolic parameters fit to the Sprague-Dawley rat data or (B) metabolic parameters fit to F-344 data (see text for further details).

Source: Ward et al. (1997, 083652; squares); Horton et al. (1992, 196222; diamonds).

Figure B-11. Model fits to data sets from inhalation exposures to 200 (triangles), 1,200 (diamonds), or 2,000 (squares) ppm MeOH in male F-344 rats. (A) Model fits with metabolic parameters set to values obtained from IV data for Sprague-Dawley rats, with only the inhaled fraction (FRACIN) adjusted. (B) Model fits obtained by fitting metabolic parameters (Vmax and Km) for a single pathway, along with FRACIN, to these data as well as the 100 mg/kg IV data from F-344 rats (Figure B-9B).

Symbols are concentrations obtained using DigitizIt!. Lines represent PBPK model fits. As the 7-hour data point at 2,000 ppm is higher than the 6-hour data point (more evident on a linear scale) and appears more consistent with a 7-hour exposure, a model simulation for a 7-hour exposure at 2,000 ppm is also shown (lighter line).

Source: Horton et al. (1992, 196222)

1   Model simulations of the F344 rat data with the F344-specific parameters are shown in
2   Figure B-10B (heavy red line) and Figure B-11B. Unfortunately we were unable to

simultaneously fit the inhalation data for all exposure levels, although a wide range of metabolic saturation (Km) values were tested. We could obtain a better fit of the high-concentration data by constraining FRACIN to a higher value, for example, but then the fits to the lower concentration data were compromised (not shown). Examining Figure 2 of Horton et al. (1992, 196222), the experimental variability (indicated by the error bars) on the 2000 ppm data was much larger than the 200 or 1200 ppm data, and as indicated by the simulations in Figure B-11 here, there is at least the appearance that the exposure was actually for 7 hr instead of 6 hr. (To be clear, the 2000 ppm data were used in the optimization with the duration of inhalation set to 6 hr, but the routine selected parameters which only poorly fit those data.) Since our greatest concern is in predicting dosimetry at lower exposure levels, near to the points of departure, we decided to retain the fits shown here. The corresponding parameters are listed in Table B-1. The fractional absorption (20%) was lower than that estimated for mice (66.5%), but Perkins et al. (1995, 085259) also found lower fractional absorption of inhaled methanol in rats vs. mice.

Finally, first-order oral absorption parameters were first fit to the lower dose (100 mg/kg) oral absorption data reported by Ward et al. (1997, 083652), using the optimization routines in acslXtreme v2.3 (Figure B-12, heavy/solid lines). (Since the animals used were SD rats, the SD-specific metabolic parameters were used.) While the fit to the low-concentration data was quite good (Figure B-12, lower panel), the fit to the 2500 mg/kg data (Figure B-12, upper panel) exhibited a much faster and higher peak than shown by the data. Even when the model was fit to both the high- and low-concentration data simultaneously, the fit to the high-concentration data could not be significantly improved without completely degrading the low-concentration fit (not shown). Also note that the 2500 mg/kg linear simulation completely over-estimates all the data points; i.e., the area-under-the-curve for this dose is higher than indicated by the data, indicating that the assumption of 100% absorption is not valid. Therefore, an alternative model using a saturable (Michaelis-Menten) equation for absorption from the stomach and fecal elimination (linear term) from the intestine was considered (thin lines) and found to significantly improve the high-concentration simulation, with a nearly identical fit the low-concentration data. While methanol absorption is not known to be regulated by transporters or other processes that would give rise to rate saturation, it is clear form the discrepancy between the linear model and the 2500 mg/kg data that uptake is slower than predicted by such a model and its use would lead to an over-prediction of internal concentrations. Therefore parameters for the saturable uptake model are reported in Table B-1 and the KMASC applied to mice and humans. Note that since the saturation constant corresponds to a fairly large dose (620 mg/kg), the model is still effectively linear at low- to moderate dose rates.

Figure B-12. Model fits to data sets from oral exposures to 100 (squares) or 2,500 (diamonds) mg/kg MeOH in female Sprague-Dawley rat (Expanded scale in lower panel). Symbols are concentrations obtained from the command file. The thick lines represent PBPK model fits using a linear (first-order) equation for absorption from the stomach compartment with no fecal elimination, while the thin lines use a Michaelis-Menton equation with a small fraction eliminated in the feces. All other GI rates, including absorption from the intestine, are first order.

Source: Ward et al.(1997, 083652).

B.2.7. Rat model simulations

1   A range of adverse developmental effects was noted in rat pups exposed to methanol
2 throughout embryogenesis (NEDO, 1987, 064574). SD rats were exposed in utero over different
3 periods of pregnancy and as neonates via inhalation or in drinking water. Inhalation exposures to
4 methanol were carried out for 18–22 hours, depending on the exposure group. Simulations of
5 predicted C_{max}, AUC, and total metabolized from 22-hour exposures to 500, 1,000, and 5,000
6 ppm MeOH are shown in Figure B-13. Simulations of oral exposures of SD rats to 65.9, 624.1,
7 or 2,177 mg/kg-day (500, 5,000, 20,000 ppm in drinking water), daily dose estimations from the
8 study of Soffritti et al. (2002, 091004), based on measured water consumption, kindly provided
9 by Cynthia Van Landingham, Environ International, Ruston, Louisiana, are shown in Figure B-
10 13. Although the exposures in these studies are to rats over long periods and in some cases
11 exposures of the newborn pups, the model simulations are to NP adult rats only, using the dose-
12 group specific average body weights of 0.33-0.34 kg BW from the study of Soffritti et al. (2002,
13 091004) and do not take into account changes is body weight or composition. These simulated
14 values are presumed to be a better surrogate for and predictor of target-tissue concentrations in
15 developing rats, and the corresponding estimated human concentrations a better predictor of
16 developmental risk in humans than would be obtained using the applied concentration or dose
17 and default extrapolations. The logic here is simply that the ratio of actual target tissue
18 concentration (in the developing rat pup or human) to the simulated concentration in the NP
19 adult is expected to be the same in both species and hence, that proportionality drops out in
20 calculating a HEC.

21   Figure B-13 depicts simulations run to determine internal doses for 22 hours/day
22 inhalation exposures at 500, 1,000, or 2,000 ppm. Simulation results for continuous inhalation
23 exposures are shown for contrast. The simulations show that for all but the highest dose (2,000
24 ppm) steady state is reached within 22 hours, and that "periodicity," where the concentration
25 time course is the same for each subsequent day, is reached by the 2nd day of exposure. At
26 2,000 ppm, however, steady state is not reached until after 48 hours for the continuous exposure.
27   Therefore, the C_{max}, 24-hour AUC and amount metabolized per day (AMET) were by simulating
28 22 hours/day exposures for 5 days and calculating values of AUC and AMET over the last day
29 (24 hours) of that period.

Exposure concentration (ppm)	C_{max} (mg/L)	AUC (hr·mg/L)	AMET (mgEq)
500	3.6	79	17.6
1,000	10.6	227	34.8
2000	48.5	968	67.2

Figure B-13. Simulated Sprague-Dawley rat inhalation exposures to 500, 1,000, or 2,000 ppm MeOH. Rat BW was set to 0.33 kg. Simulations are shown for both continuous (thin, dashed/dotted lines in plot) and 22 hours/day exposures (thick, solid lines in plot). Cmax, AUC, and amount metabolized (AMET) are determined from the 22 hour/day simulations, run for a total of 5 days (120 hours), with the AUC and AMET calculated for the last 24 hours of the simulation.

1   Figure B-14 depicts simulations run to mimic a single oral exposure, treated as a

2 continuous infusion for 12 hours (assuming 12-hour period when rats are awake and active).

3 Total AUC and AMET and AUC24 and AMET24 for the first 24 hours after start of exposure

4 were calculated.

Exposure dose (mg/kg·day)	Body weight (kg)	C_{max} (mg/L)	AUC (hr·mg/L)	AUC24 (hr·mg/L)	AMET (mgEq)	AMET24 (mgEq)
66.0	0.33	9.3	104.8	104.8	21.2	21.2
624.1	0.33	631.6	9,525	8,817	155.6	122.6
177	0.34	2,832.4	72,617	45,138	347.4	138.4

Figure B-14. Simulated rat oral exposures of Sprague-Dawley rats to 65.9, 624.2, or 2,177 mg MeOH/kg/day. Dosing was simulated as a 12-hour, zero-order infusion to the liver compartment. The AUC and total amount metabolized are given for a period sufficient for the MeOH to clear (84 hours), and the AUC24 and AMET24 values represent just the first 24 hours of exposure. (Results shown for illustrative purposes. Dosimetry used in assessment was simulated using a more realistic water ingestion pattern.)

1   To simulate ingestion of methanol in drinking water by rats under bioassay conditions, an
2 ingestion pattern based on the observations of Spiteri (1982, 196363) and Peng et al. (1990, 056797).
3 While mice ingest water in frequent, small bouts (Gannon et al., 1992, 090532) that are reasonably
4 described as a continuous delivery to the stomach, rats exhibit clear periods of ingestion
5 alternating with periods where no ingestion occurs (Peng et al., 1990, 056797; Spiteri, 1982, 196363).
6 Based on those data a reasonable representation of rat water ingestion can be described as
7 serious of pulses. During the dark/active period of each day (first 12 hr) each bout of drinking
8 was assumed to last 45 min followed by 45 min without ingestion (total of 8 bouts). During the
9 light/inactive period (next 12 hr) drinking bouts were assumed to last only 30 min followed by
10 2.5 hr (150 min) without drinking (4 bouts). An equal amount was assumed to be consumed in

1 each bout within the dark period, likewise within each light-period bout, with the respective

2 amounts adjusted such that 80% of the total ingestion occurs during the dark and 20% during the

3 light (Burwell et al., 1992, 196176). The resulting absorption pattern is shown in Figure B-15A and a

4 simulated blood concentration time-curve (for 50 mg/kg/day dosing) is shown in Figure B-15B.

Figure B-15. Rat daily drinking water ingestion pattern (A) and resulting predicted blood concentration for a 2-day exposure (B).Rat drinking water exposures were simulated by multiplying the fractional absorption rate (1/hr) as a function of clock time by the daily total dose ingested (mg) to obtain a rate of addition of methanol into the stomach lumen compartment (mg/h).

B.2.8. Human Model Calibration

B.2.8.1. Inhalation Route

1   The mouse model was scaled to human body weight (70 kg or study-specific average),

2 using human tissue compartment volumes and blood flows, and calibrated to fit the human

3 inhalation-exposure data available from the open literature, which comprised data from four

4 publications (Batterman et al., 1998, 086797; Ernstgard et al., 2005, 088075; Osterloh et al.,

5 1996, 056314; Sedivec et al., 1981, 031154).

6   A first-order rate of loss of MeOH from the blood, K1C, and a first-order bladder

7 compartment time constant, KBL, were used to provide an estimate of urinary MeOH

8 elimination. The inhalation-route urinary MeOH kinetic data described by Sedivec et al. (1981,

9 031154) (Figure B-16) were used to inform these parameters. The urine MeOH concentration

10 data reported by the authors were converted to amount in urine by assuming 0.5 mL/hr/kg total

11 urinary output (Horton et al., 1992, 196222). Sedivec et al. (1981, 031154) measured a

12 fractional uptake of 57.7%, based on total amount inhaled. Since the PBPK model uses alveolar

13 rather than total ventilation and this is typically assumed to be 2/3 of total ventilation the

14 fractional uptake of Sedivec et al. (1981, 031154) was corrected by dividing by 2/3 to obtain a

15 value for FRACIN of 0.8655. The resulting values of K1C and KBL, shown in Table B-1, differ

16 somewhat depending on whether first-order or saturable liver metabolism is used. These are

17 only calibrated against a small data set and should be considered an estimate. Urine is a minor

18 route of MeOH clearance with little impact on blood MeOH kinetics.

19   Although the high-doses used in the mouse studies warrant the use of a second metabolic

20 pathway with a high Km, the human exposure data all represent lower concentrations and may

21 not require or allow for accurate calibration of a second metabolic pathway. Horton et al. (1992,

22 196222) employed two sets of metabolic rate constants to describe human MeOH disposition,

23 similar to the description used for rats and mice, but in vitro studies using monkey tissues with

24 non-MeOH substrates were used as justification for this approach. Although Bouchard et al.

25 (2001, 030672) described their metabolism using Michaelis-Menten metabolism, Starr and Festa

26 (2003, 052598) reduced that to an effective first-order equation and showed adequate fits.

27 Perkins et al. (1995, 085259) estimated a Km of 320 ± 1273 mg/L (mean ± S.E.) by fitting a one-

28 compartment model to data from a single oral poisoning to an estimated dose. In addition to the

29 extremely high standard error, the large standard error for the associated Vmax (93 ± 87

30 mg/kg/hr) indicates that the set of Michaelis-Menten constants was not uniquely identifiable

31 using this data. Other Michaelis-Menten constants that have been used to describe MeOH

32 metabolism in various models for primates are given in Table B-2. Because the Km calculated

33 by Perkins et al. (1995, 085259) from the high-dose oral exposure is 320 mg/L, while the highest

1 observed concentration in the data sets considered here is 14 mg/L (Batterman et al., 1998,
2 086797), forcing the model to use this higher Km would simply result in fits that are effectively
3 indistinguishable from the linear model. A simple, linear model is preferred over the use of a
4 Km value that high.

Figure B-16. Urinary MeOH elimination concentration (upper panel) and cumulative amount (lower panel), following inhalation exposures to MeOH in human volunteers. Data points in lower panel represent estimated total urinary MeOH elimination from humans exposed to 78 (diamonds), 157 (triangles), and 231 (circles) ppm MeOH for 8 hours, and lines represent PBPK model simulations. Solid lines are model results with the saturable equation for hepatic metabolism while dashed lines show results for liner metabolism. Data digitized from Sedivec et al. (1981, 031154) and provided for modeling by the EPA.

Source: Sedivec et al. (1981, 031154).

Table B-2. Primate kms reported in the literature

Km (mg/L)	Reference	Note
320 ±1273	(Perkins et al., 1995, 085259)	Human: oral poisoning, estimated dose
716 ± 489	(Perkins et al., 1995, 085259)	Cynomolgus monkey: 2 g/kg dose
278	(Perkins et al., 1995, 085259)	Rhesus monkey: 0.05-1 mg/kg dose
252 ± 116	(Perkins et al., 1995, 085259)	Cynomolgus monkey: 1 g/kg dose
33.9	(Horton et al., 1992, 196222)	PBPK model: adapted from rat Km
0.66	(Fisher et al., 2000, 009750)	PBPK model, Cynomolgus monkey:10-900 ppm
23.7 ± 8.7[a]	(This analysis.)	PBPK model, human: 100-800 ppm

Note- the values from Perkins et al. (1995b), are ± S.E.

[a]Mean ± S.D. This Km was optimized while also varying V_{max}, K1C, and KBL, from all of the at-rest human inhalation data as a part of this project. The S.D. given for this analysis is based on the Optimize function of acslXtreme, which assumes all data points are discrete and not from sets of data obtained over time and therefore a true S.D. would be a higher value. The final value reported in Table B-1 (21 mg/L) was obtained by sequentially rounding and fixing these parameters, then re-optimizing the remaining ones. For more detail, see text and Table B-3.

1   To estimate both the Michaelis-Menten and first-order rates, all human data under
2   nonworking conditions (Batterman et al., 1998, 086797; Osterloh et al., 1996, 056314; Sedivec et al., 1981,
3   031154) were used. Before discussing the parameter estimation, however, adjustments were made
4   to one of these data sets (Osterloh et al., 1996, 056314). Batterman et al., (1998, 086797) and Sedivec
5   et al. (1981, 031154) both subtracted background levels before reporting their results. However,
6   Osterloh et al. (1996, 056314) measured and reported (plotted) blood methanol in nonexposed
7   controls (data shown in Figure B-17). The data for Osterloh et al. (1996, 056314) clearly show a
8   time-dependent trend which is close to linear, and a linear regression is also included. However,
9   the blood concentration (average) in the exposed group of that study was ~1.2 mg/L, whereas the
10   data and regression in Figure B-17 indicate a value of ~ 0.9 mg/L. Therefore, the exposure data
11   for Osterloh et al (1996, 056314) were corrected by subtracting time-zero value for the exposed
12   group *plus* a time-dependent factor obtained by multiplying the slope of this regression (0.093
13   mg/L-hr) by the measurement time.
14   The metabolic (first-order or saturable) and urinary elimination constants were
15   numerically fit to the nonworking human data sets while holding the value for FRACIN at
16   0.8655 (estimated from the results of Sedivec et al. as described above) and holding the

1   ventilation rate constant at 16.5 L/hr/kg$^{0.75}$ and QPC at 24 L/hr/kg$^{0.75}$ (values used by EPA

2   [2000d] for modeling the inhalation-route kinetics vinyl chloride). Other human-specific

3   physiological parameters were set as reported in Table B-1.

Figure B-17. Control (nonexposed) blood methanol concentrations

Source: Ernstgard et al. (2005, 088075); Osterloh et al. (1996, 056314).

4   Either (a) the set of $V_{max}C$, Km, K1C, and KBL were simultaneously varied while fitting

5   the entire data set or (b) KLLC, K1C, and KBL were so varied and fit. Thus the two model fits

6   are separated by a single degree of freedom (one additional parameter in case [a]). Statistical

7   results given in Tables B-2 and B-3 are from these global fitting exercises. Final fitted

8   parameters that have been used in the model for the risk assessment are given in Table B-1. The

9   resulting fits of the two parameterizations (1st order or optimized Km/V_{max}) are shown in

10   Figures B-16 and B-18.

11   Use of a first-order rate has the advantage of resulting in one fewer variable in the model

12   and results in an adequate fit to the data, but the saturable model clearly fits some of the data

13   better (Figures B-16 and B-18). To discriminate the goodness-of-fit resulting from the inclusion

14   of an additional variable necessary to describe saturable metabolism versus using a single first-

15   order rate, a likelihood ratio test was performed. Models are considered to be nested when the

16   basic model structures are identical except for the addition of complexity, such as the added

17   metabolic rate. Under these conditions, the likelihood ratio can be used to statistically compare

18   the relative ability of the two different metabolism scenarios to describe the same data, as

19   described by Collins et al. (1999, 012383). The hypothesis that one metabolic description is

20   better than another is calculated using the likelihood functions evaluated at the maximum

1   likelihood estimates. Since the parameters are optimized in the model using the maximum LLF,

2   the resultant LLF is used for the statistical comparison of the models. The equation states that

3   two times the log of the likelihood ratio follows a χ2 distribution with r degrees of freedom:

4    $$-2\big[\log(\lambda(\text{model 1})/\lambda(\text{model 2}))\big] = -2\big[\log \lambda(\text{model 1}) - \log \lambda(\text{model 2})\big] \cong \chi_r^2$$

5   The likelihood ratio test states that if twice the difference between the maximum LLF of

6   the two different descriptions of metabolism is greater than the χ2 distribution, then the model fit

7   has been improved (Collins et al., 1999, 012383; Devore, 1995, 196740; Steiner et al., 1990,

8   196738)

Figure B-18. Data showing the visual quality of the fit using optimized first-order or Michaelis-Menten kinetics to describe the metabolism of MeOH in humans. The rate constants used for each simulation are given in Table B-3.

Source: Batterman et al. (1998, 086797: top); Osterloh et al. (1996, 056314: bottom).

Table B-3. Parameter estimate results obtained using acslXtreme to fit all human data using either saturable or first-order metabolism

Parameters	Optimized value	S.D.	Correlation matrix	LLF
Michaelis-Menten (optimized)			-0.994	-24.1
Km	23.8	8.8		
$V_{max}C$	33.2	10.1		
First Order			NA	-31.0
KLLC	95.7	5.4		

Note: The S.D.s are based on the Optimize function of acslXtreme, which assumes all data points are discrete and not from sets of data obtained over time and therefore a true S.D. would be a higher value.

1 At greater than a 99.95% confidence level, using 2 metabolic rate constants (Km and
2 VmaxC) is preferred over utilizing a single rate constant (Table B-4). While the correlation
3 coefficients (Table B-3) indicate that Vmax and Km are highly correlated, that is not unexpected,
4 and the S.D.s (Table B-3) indicate that each is reasonably bounded. If the data were
5 indistinguishable from a linear system, Km in particular would not be so bounded from above,
6 since the Michaels-Menten model becomes indistinguishable from a linear model as VmaxC and
7 Km tend to infinity. Moreover, the internal dose candidate POD, for example the BMDL10 for
8 the inhalation-induced brain-weight changes from NEDO (1987, 064574), with methanol blood
9 AUC as the metric, is 374.67 mg-hr/L, which corresponds to an average blood concentration of
10 15.6 mg/L. Therefore the Michaelis-Menten metabolism rate equation appears to be sufficiently
11 supported by the existing data, and its use is expected to improve the accuracy of the HEC
12 calculations, since those are being conducted in a concentration range in which the nonlinearity
13 has an impact.

Table B-4. Comparison of LLF for Michaelis-Menten and first-order metabolism

LLF (logλ) for M-M	LLF (logλ) for 1st order	LLF 1st versus M-M [a]	χ_r^2 (99% confidence) [b]	χ_r^2 (99.95% confidence) [b]
-24.1	-31.0	34.1	13.8	12.22

Note: The models were optimized for all of the human data sets under non working conditions. M-M: Michaelis-Menten
[a]obtained using this equation: $-2[\log \lambda(\text{model1}) - \log \lambda(\text{model2})]$
[b]significance level at r = 1 degree of freedom.

1   While the use of Michaelis-Menten kinetics might allow predictions across a wide

2   exposure range (into the nonlinear region), extrapolation above 1,000 ppm is not suggested since

3   the highest human exposure data are for 800 ppm. Extrapolations to higher concentrations are

4   potentially misleading since the nonlinearity in the exposure-internal-dose relationship for

5   humans is uncertain above this point. The use of a BMD or internally applied UFs should place

6   the exposure concentrations within the range of the model.

7   The data from Ernstgard et al. (2005, 088075) was used to assess the use of the first-order

8   metabolic rate constant to a dataset collected under conditions of light work. Historical

9   measures of QPC (52.6 L/hr/kg0.75) and QCC (26 L/hr/kg0.75) for individuals exposed under

10   conditions of 50 w of work from that laboratory (52.6 L/hr/kg0.7) (Ernstgard, 2005, 200750)(Corley et

11   al., 1994, 041977; Johanson et al., 1986, 006760) were used for the 2-hour exposure period (Figure B-

12   19). Otherwise, there were no changes in the model parameters (no fitting to these data). The

13   results are remarkably good, given the lack of parameter adjustment to data collected in a

14   different laboratory, using different human subjects than those to which the model was

15   calibrated.

Figure B-19. Inhalation exposures to MeOH in human volunteers. Data points represent measured blood MeOH concentrations from humans (4 males and 4 females) exposed to 100 ppm (open symbols) or 200 ppm (filled symbols) for 2 hours during light physical activity. Solid lines represent PBPK model simulations with no fitting of model parameters. For the first 2 hours, a QPC of 52.6 L/hr/kg0.75 (Johanson et al., 1986, 006760), and a QCC of 26 L/hr/kg0.75 (Corley et al., 1994, 041977) were used by the model.

Source: Ernstgard et al..(2005, 088075)

B.2.8.2. Oral Route

1   There were no human data available for calibration or validation of the oral route for the
2   human model. In the absence of data to estimate rate constants for oral uptake, the 'humanset.m'
3   file which sets parameters for human simulations applies the KMAS for the mouse with the other
4   absorption parameters set to match those identified for ethanol in humans by Sultatos et al. (2004,
5   090530); VmASC was set such that for a 70-kg person, VMAS/KMAS matches the first-order
6   uptake constant of Sultatos et al. (2004, 090530) (0.21 hr-1). While Sultatos et al. (2004, 090530)
7   include a term for ethanol metabolism in the stomach, no such term is included here and the rate
8   of fecal elimination is set to zero, corresponding to 100% absorption. However zero-order
9   ingestion, a continuous infusion at a constant rate into the stomach lumen equal to the daily
10   dose/24 hours, was assumed for all human simulations. Since absorption was assumed to be
11   100% of administered MeOH, at steady state the rate of uptake from the stomach and intestine
12   compartments (combined) must equal the rate of infusion to the stomach. Since Cmax is driven
13   by the oral absorption rate, which was assumed rather than fitted and verified, Cmax was not
14   used as a dose metric for human oral route simulations. AUC, which is less dependent on rate of
15   uptake, was used as the dose metric and for estimation of HEDs. Since the AUC was computed
16   for a continuous oral exposure, its value is just 24-hours times the steady-state blood
17   concentration at a given oral uptake rate.

B.2.8.3. Inhalation Route HECs and Oral Route HEDs

18   The atmospheric MeOH concentration resulting in a human daily average blood MeOH
19   AUC (hr×mg/L) or C_{max} (mg/L) equal to that occurring in experimental animals following
20   exposure at the POD concentration is termed the HEC. Similarly, the oral dose (rate) resulting in
21   human daily average blood MeOH AUC (hr×mg/L) equivalent to that occurring in an
22   experimental animal at the POD concentration is termed the HED.
23   To determine the HEC for specific exposures in mice, the mouse PBPK model is first
24   used to determine the daily blood MeOH 24-hours AUC and C_{max} associated with 7 hour/day
25   inhalation exposures. Mice were exposed each day for 10 days, so the full 10-day exposure was
26   simulated and an average 24-hours AUC calculated over that time, so no other duration
27   adjustment was needed. The human AUC was determined for the last 24 hours of a continuous
28   1,000-hour exposure, to assure steady state was achieved. The human C_{max} was determined at
29   steady state and so is equivalent to the steady state blood MeOH concentration. Results are given
30   in Table B-5 and for inhalation shown in Figure B-20.
31   For example, for a 1,000 ppm exposure this resulted in model-predicted peak blood of
32   133 mg/L and an AUC of 770 (hr×mg/L). The human model can then be used to determine the
33   human MeOH exposure concentration leading to the same daily average AUC or C_{max} under

1 continuous exposure conditions. Based on AUC, the HEC of the 1,000-ppm exposure is

2 684 ppm, while based on peak (human steady-state) concentration, the HEC is predicted to be

3 1110 ppm. The parameters used in the human model for these simulations are listed in Table B-1

4 for saturable kinetics.

5   The HED was calculated by using the human model to find the oral dose (mg/kg-day)

6 that gave a blood MeOH AUC equivalent to the mouse AUC following an exposure at the POD.

7 Zero-order absorption was assumed. For example, the human oral exposure equivalent to a

8 1,000-ppm inhalation exposure in mice (i.e., with an AUC of 770 mg-hr/L) is 165 mg/kg-day.

9 Since a 200 mg/kg-day oral exposure gave a human AUC of 1,284 mg-hr/L, which falls between

10 the values predicted for inhalation exposures at 800 ppm (1,090 mg-hr/L) and 1,000 ppm (2,090

11 mg-hr/L), this oral exposure rate was taken to be the upper end for the model to accurately

12 estimate an HED.

Table B-5. PBPK model predicted C_{max} and 24-hour AUC for mice and humans exposed to MeOH

| Exposure concentration (ppm) | Inhalation Route | | | | Oral Route | |
| | Mouse[a] | | Human[b] | | Human | |
	AUC (mg-hr/L)	C_{max} (mg/L)	AUC (mg-hr/L)	Css (mg/L)	Dose (mg/kg-day)	AUC (mg-hr/L)
1	0.15	0.021	0.59	0.025	0.1	0.204
10	1.52	0.22	5.97	0.25	1	2.05
50	7.98	1.14	30.6	1.28	10	21.2
100	17.0	2.45	63.3	2.64	50	124
250	53.4	7.77	177	7.36	100	315
500	170	26.1	447	18.6	200	1320
1,000	770	133	2090	87.2	500	39400
2,000	3310	524	31100	1300	1,000	125000
5,000	17300	2000	147000	6130	2000	297000
10,000	51200	4710	341,000	14200	5000	814000

[a]The mouse 24-hour average AUC were calculated under the conditions of the bioassay: 10 days of exposure with 7 hours of exposure during each 24 hour period.
[b]Human simulation results are considered unreliable above 1,000 ppm (inhalation) or 200 mg/kg-day (oral), but are included for comparison

13   Again, since the available human exposure data is to, at most, 800 ppm, the model could

14 not be calibrated for higher exposures that approximate most of the mouse and rat exposure

15 concentrations. The AUC in humans for similar exposure levels is ~3 times greater than in the

1   mouse, primarily because human exposure estimates are expected to result from 24-hour
2   exposures and the mice were exposed for 7 hours.

Figure B-20. Predicted 24-hour AUC (upper left), Cmax (upper right), and amount metabolized (lower) for MeOH inhalation exposures in the mouse (average over a 10-day exposure at 7 hours/day) and humans (steady-state values for a continuous exposure). C_{max} for human exposures is equal to the steady-state blood concentration. For humans, the long-dashed lines are model predictions using Michaelis-Menten metabolism (optimized Km of 23.8 mg/L) and the short-dashed lines are model predictions using first-order kinetics. Amount metabolized normalized to BW$^{0.75}$ to reflect cross-species scaling (Human simulation results above 1,000 ppm are not considered reliable but are shown for comparison).

3   While the PBPK computational code can be used in the future to derive HECs or HEDs
4   for other exposures, an alternative approach was developed that allows non-PBPK model users
5   to estimate MeOH HECs and HEDs from benchmark doses in the form of AUCs. This approach
6   uses algebraic equations describing the relationship between predicted MeOH 24-hour AUC or
7   scaled daily metabolic rate in the liver (MET, mg/kg$^{0.75}$-day) (constant 24-hour exposure) and the

1 inhalation exposure level (i.e., an HEC in ppm) (Equations 1, 1b, 3 or 3b) or oral exposure rate

2 (i.e., an HED in mg/kg-day) (Equations 2, 2b, 4 or 4b). To use the equations to derive an HEC or

3 HED, the target human AUC is applied to the appropriate equation. Since these relationships are

4 for continuous exposures, blood concentration is constant, and hence extrapolation for a C_{max} is

5 obtained by simply using AUC = 24*C_{max}.

6

7
$$HEC(ppm_{<1000}) = 0.02525 \times AUC \; + \; \frac{1290 \times AUC}{765.5 + AUC} \qquad \text{Equation 1}$$

8
$$HED(\text{mg/kg-day}_{<200}) = 0.00606 \times AUC \; + \; \frac{280.5 \times AUC}{579.0 + AUC} \qquad \text{Equation 2}$$

9
$$HEC(ppm_{<1000}) = 1.5361 \times MET \; + \; \frac{19.75 \times MET}{996 - MET} \qquad \text{Equation 3}$$

10
$$HED(\text{mg/kg-day}_{<200}) = 0.3448 \times MET \; + \; \frac{4.286 \times MET}{860.0 - MET} \qquad \text{Equation 4}$$

11
12 Once the HEC or HED is calculated from the appropriate equation above (depending on which internal metric is
13 being used), the RfC or RfD is then just calculated by dividing with the extrapolation uncertainty factor (UF).
14

15
$$RfC(ppm) = HEC(ppm)/UF \qquad \text{Equation 5}$$
16
$$RfD(mg/kg\text{-}day) = HED(mg/kg\text{-}day)/UF \qquad \text{Equation 6}$$

B.2.9. Conclusions and Discussion

17   Mouse, rat, and human MeOH PBPK models have been developed and calibrated to data

18 in the open literature. The EPA chose to develop its own model because none of the existing

19 models satisfactorily fulfilled all of the criteria specified in Section 3.4.1 of Chapter 3. Further,

20 none of the existing models had been calibrated or tested against the larger collection of data

21 considered for each species here. As a result, while each model may fit the subset of the data to

22 which it had been calibrated better than the final model described here, without adjustment of

23 parameters from those published, each model either had features which made it incompatible

24 with risk extrapolation (e.g., parameters which vary with dose in an unpredictable way) or had an

25 inadequate fit to other data considered critical for establishing overall model soundness. The

26 EPA model simplifies the structure used by Ward et al. (1997, 083652) in some aspects while

27 adding specific refinements (e.g., a standard lung compartment and a two-compartment GI tract).

28   Although the developmental endpoints of concern are effects which occur during in utero

29 and (to a lesser extent) lactational exposure, it is not necessary for a MeOH PBPK model to

30 specifically describe pregnancy (i.e., specify a fetal/gestational/conceptus compartment) and

31 lactation in order for it to provide better cross-species extrapolation of risk than default methods.

32 Representation of the unique physiology of pregnancy and the fetus/conceptus would be

necessary if MeOH pharmacokinetics differed significantly during pregnancy or if the observed partitioning of MeOH into the fetus/conceptus versus the mother showed a concentration ratio significantly greater than or less than 1. MeOH pharmacokinetics GD6–GD10 in the mouse, are not different from NP mice (Pollack and Brouwer, 1996, 079812), and the maternal blood:fetus/conceptus partition coefficient is reported to be near 1 (Horton et al., 1992, 196222; Ward et al., 1997, 083652). At GD18 in the mouse, maternal blood levels are only modestly different from those in NP animals (see Figures B-4 and B-5 for examples), and in general the PBPK model simulations for the NP animal match the pregnancy data as well as the NP data. Likewise maternal blood kinetics in monkeys differs little from those in NP animals (see Section 3.4.7). Further, in both mice and monkeys, to the extent that late-pregnancy blood levels differ from NP for a given exposure, they are higher; i.e., the difference between model predictions and actual concentrations is in the same direction. These data support the assumption that the ratio of actual target-tissue methanol concentration to (predicted) NP maternal blood concentrations will be about the same across species, and hence that using NP maternal blood levels in place of fetal concentrations will not lead to a systematic error when extrapolating risks. Thus, a full representation of pregnancy and the fetal/conceptus compartment appears to be unnecessary.

While lactational exposure is less direct than fetal exposure and blood or target-tissue levels in the breast-feeding infant or pup are likely to differ more from maternal levels, the health-effects data indicate that most of the effects of concern are due to fetal exposure, with only a small influence due to postbirth exposures. Separating out the contribution of postbirth exposure from pre-birth exposure to a given endpoint in a way that would allow the risk to be estimated from estimates of both exposure levels would be extremely difficult, even if one had a lactation/child PBPK model that allowed for prediction of blood (or target-tissue) levels in the offspring. And one would still expect the target-tissue concentrations in the offspring to be closely related to maternal blood levels (which depend on ambient exposure and determine the amount delivered through breast milk), with the relationship between maternal levels and those in the offspring being similar across species.

Therefore, the development of a lactation/child PBPK model appears not to be supported, given the minimal change that is likely to result in risk extrapolations and use of (NP) maternal blood levels as a measure of risk in the offspring is still considered preferable over use of default extrapolation methods. In particular, the existing human data allow for accurate predictions of maternal blood levels, which depend strongly on the rate of maternal methanol clearance. Failing to use the existing data (via PBPK modeling) for human methanol clearance (versus that in other species) would be to ignore this very important determinant of exposure to breast-fed infants. And since bottle-fed infants do *not* receive methanol from their mothers, they are expected to have lower or, at most, similar overall exposures for a given ambient concentration

than the breast-fed infant, so that use of maternal blood levels for risk estimation should also be adequately protective for that group.

During model development, several inconsistencies between experimental blood MeOH kinetic data embedded in the Ward et al. (1995, 077617) model and the published figures first reporting these data were discovered. Therefore, data were digitized from the published literature when a figure was available, and the digitized data was compared to the provided data. When the digitized data and the data embedded in the computational files (i.e., provided to Battelle under contract from the EPA) were within 3% of each other, the provided data was used; when the difference was greater than 3%, the digitized data was used. Often, using the published figures as a data source resulted in substantial improvements of the fit to the data in the cases where the published figures were different from the embedded data.

The final MeOH PBPK model fits well inhalation-route blood kinetic data from separate laboratories in rodents and humans. Intravenous-route blood MeOH kinetic data in NP mice were only available for a single i.v. dose of 2,500 mg/kg, but were available for GD18 mice following administration of a broader range of doses: 100, 500, and 2,500 mg/kg. Up to 20 hours postexposure, blood MeOH kinetics appear similar for NP and pregnant mice after administration of 2,500 mg/kg. The intravenous pharmacokinetic data in GD18 mice showed an unexpected dose-dependent nonlinearity in initial blood concentrations, suggesting either a dose dependence on the volume distribution, which is unlikely, or some source of experimental variability. To account for this nonlinearity, Ward et al. (1997, 083652) used dose-specific partition coefficients for placenta and embryonic fluid and Vmax for the metabolism of MeOH. The current model uses a consistent set of parameters that are not varied by dose and therefore does not fit these 100 mg/kg dose intravenous data. The model does fit the 500 and 2,500 mg/kg doses, and if a presumed i.v. dose of 200 mg/kg (twice the reported 100 mg/kg) is employed, is able to predict initial blood concentrations for the lowest dose data, as expected. The i.v. data from the Ward et al. (1995, 077617) model does match the corresponding published figures.

The model fits to the mouse oral-route MeOH kinetic data using a consistent set of parameters (Figure B-4) are reasonably good but not as good as fits to the inhalation data. The model consistently underpredicts the amount of blood MeOH reported in two studies (1995, 077617; Ward et al., 1997, 083652). Ward et al. (1997, 083652) utilized a different Vmax for each oral absorption data set. In the report by Ward et al. (1997, 083652) the GD18 and the GD8 data from Dorman et al. (1995, 078081) were both fit using a Vmax of ~80 mg/kg/hr (body weights were not listed, the model assumed that GD8 and GD18 mice were both 30 g; Ward et al. (1997, 083652) did not scaled by body weight), but lower partition coefficients for placenta (1.63 versus 3.28) and embryonic fluid (0.0037 versus 0.77). The current model adequately fits

the oral pharmacokinetic data using a single set of parameters that is not varied by dose or source of data.

The fits of the rat model to the limited dataset readily available were quite good. The low-dose exposures of all routes were emphasized in model optimization since they were the doses most relevant to risk assessment. Based on a rat inhalation exposure to 500 ppm, the human HEC would be 300 ppm (by applying an AUC of 226 [Figure B-12] to Equation 1).

The mouse, rat, and human models fit multiple datasets from multiple research groups using consistent parameters that are representative of each species, but are not varied within species. Using the model, it will be possible to ascertain chronic human exposure concentrations that are likely to be without an appreciable risk of deleterious effects.

B.3. ADDITIONAL MATERIAL

- Results from Optimizations
- acslXtreme Program (.csl) File (Electronic Attachment)
- acslXtreme procedure (.cmd) file
- Key to .m files for reproducing the results in this report
- Code for .m files
- Personal communication from Lena Ernstgard regarding human exposures reported in the Ernstgard and Johanson, 2005 SOT poster
- Personal communication from Dr. Rogers regarding mouse exposures to MeOH
- Data and simulations for MeOH Metabolism/Total Metabolites Produced
- Multiple daily oral dosing for humans

B.3.1. Results From Optimizations

B.3.1.1. Approach for and Results of the Optimization of Metabolic Parameters and Inhalation Route Fractional Availability in Mice

The approach and results are presented below in outline format with supporting figures. More complete documentation was not developed because the products of the optimizations were not used in the final model. The documentation here is intended only to demonstrate that appropriate optimizations were conducted and what the results of those optimizations were.

1. The Vmax for the low affinity pathway was set to 0 and the remaining VmaxC, Km, and fractional availability were optimized using inhalation data only.
    a. The optimizer was unable to find a value for Km that was greater than 0.
    b. The resulting metabolic parameters essentially represented a zero order loss process.
2. The Vmax for the low affinity pathway was set to 0 and the remaining VmaxC and Km were optimized using all (oral, intravenous and inhalation) data.

1   a. The optimized single Km, 135 mg/L, was equal to the average of the 2 original

2   Kms.

3   b. Fits to the MeOH blood levels following inhalation exposures > 2,000 ppm are

4   slightly improved, but the model fits to the 1,000 ppm exposure concentration

5   overpredict reported values by 20%.

6 3. Parameters for both metabolic pathways were optimized using all (oral,   intravenous

7   and inhalation) data.

8   a. The fit to the high-dose intravenous data from Ward et al. (1997, 083652) (2,500

9   mg/kg) was improved (Figure B-21).

10   b. The fit to the high-dose oral data, also from Ward et al. (1997, 083652), (2,500

11   mg/kg) was improved (Figure B-22).

12   c. The fit to the mid-dose i.v. data (500 mg/kg) dose was not as good as using the

13   visually fit parameters (Figure B-21)

14   d. The fit to the low-dose oral data (1,500 mg/kg) was not as good when the visually

15   fit parameters were used (Figure B-22). The low-dose data was from Dorman

16   et al. (1995, 078081).

17   e. Neither set of parameters resulted in an adequate fit to the low-dose intravenous

18   data (100 mg/kg; Figure B-21).

19   f. Fits to the inhalation data following exposures to < 5,000 ppm MeOH were

20   substantially worse than when using the visually fit parameters (Figure B-23)

Figure B-21. Fit of the model to i.v. data using different metabolism and uptake parameter optimizations. Solid blue lines - visually optimized; dashed red lines - metabolic parameters (Km, Km2, VmaxC, Vmax2C) optimized using all inhalation data sets; dash/dot green lines - metabolic parameters optimized using all data sets (inhalation, oral, and intravenous).

Figure B-22. Fit of the model to oral data using different metabolism and uptake parameter optimizations. Solid blue lines - visually optimized; dashed red lines - metabolic parameters (Km, Km2, $V_{max}C$, $V_{max}2C$) optimized using all inhalation data sets; dash/dot green lines - metabolic parameters optimized using all data sets (inhalation, oral, and intravenous).

Source: Ward et al. (1997, 083652); Dorman et al. (1995, 078081).

Figure B-23. Fit of the model to inhalation data using different metabolism and uptake parameter optimizations. Dotted black lines - model optimized fractional inhalation, solid blue lines - visually optimized; dashed red lines - metabolic parameters (Km, Km2, VmaxC, Vmax2C) optimized using all inhalation data sets; dash/dot green lines - metabolic parameters optimized using all data sets (inhalation, oral, and intravenous).

B.3.1.2. Conclusion

Under the best circumstances, formal optimizations offer the benefit of repeatability and confirmation that global optima have not been missed by user-guided visual optimization. Incorporating judgments regarding the value of specific data sets while easy when visually fitting, is difficult at best when using optimization routines. This is an important distinction between these approaches for this modeling exercise.

The mouse NOEL was 1,000 ppm MeOH. Fitting the blood MeOH concentration data at this exposure drove our modeling exercises because of the importance of this exposure group in the risk assessment. Unfortunately, the vast majority of the blood MeOH data came from much higher exposures. As expected, our various attempts at optimization led to fits that were better for some, but never all, data sets. This is to be expected when there is clearly significant variability in the underlying data. Various data weighting schemes were included to improve overall optimization while maintaining a good fit to the 1,000 ppm data. In the end, optimization offered no significant improvement over the fractional uptake and metabolic parameter values obtained by visual optimization, so these were retained in the final version of the model.

B.3.1.3. acslXtreme Program (.csl) File

```
PROGRAM MeOH -- PBPK Model for Methanol
PROGRAM MeOH -- PBPK Model for Methanol
! Based on MeOH Model by Ward et al (1997, 083652) with these revisions:
! TS Poet, P Hinderliter and J Teeguarden (2006, 196152),
! Center for Biological Monitoring and Modeling   4/16/05
! Pacific Northwest National Laboratory
! Model contains inhalation, iv, and oral (multiple patterns).
! 1) Removed fetal compartment and other tissues that could be lumped
! based on similarity of partition coefficients or did not need to be
! specified directly (Bone, mammary tissue) for the modeling purposes here.
! 2) Changed day to hr.
! 3) Flows (scaled to BW or BW**0.75), Metabolism (BW**0.75) and
! tissue volumes (BW) are scaled in the model.
! Final has stomach and intestine compartments which provide fast and
! slow absorption rates, respectively.
! 4) Bladder compartment (for human simulations) added by Paul
! Schlosser, U.S. EPA, Oct. 2008
! 5) "Sipping" drinking water exposure code for rats, to match data
! from Peng et al. (1990, 056797)
! 6) Time-variable drinking pattern for mice from Keys et al. (2004, 196283)
! added by Paul Schlosser, U.S. EPA, Aug. 2009
! Version is final version used for simulations
! 7) Code for incorporating endogenous/background MeOH, where the "source"
! is a continuous infusion term in the liver was added.  A set of equations
! in the initial section sets the infusion rate based on other model parameters
! such that when the endogenous background blood level is set by CVBBG = X mg/L
```

```
1   ! (or VCVBBG can be adjusted in a parameter estimation when INCBG = 1, otherwise
2   ! set INCBG = 0), or DCVBBG = X mg/L (the later to be used when dosing and
3   ! data analysis are for radiolabled methanol), the appropriate infusion rate
4   ! initial concentration in all tissues is set.  Alternately one can set the
5   ! and endogenous urine concentration RUR0 = Y mg/L and the initial calculations
6   ! will set the other parameters appropriately.  Finally, setting RINCBG > 0
7   ! with INCBG = 1 gives a linear increase in the zero-order infusion with time.
8   ! Code added by Paul Schlosser, U.S. EPA, Dec. 2009
9   ! Version is final version used for simulations
10  ! ************ MODEL UNITS *****************
11  !        Concentration, mg/L
12  !        Mass of Chemical, mg
13  !        Volume, L
14  !        Flow, L/hr
15  !        Body Weight Kg
16  !=========================72 Character Line=========================!
17  INITIAL
18  ! Initialize some Variables before start
19  Integer IDS, MULTE
20  REAL DRT(6), DRP(6)   !store drink water times, percents in array!
21
22  CONSTANT    BW = 0.030      ! Body weight (kg)
23  CONSTANT    QPC = 15.       ! Alveolar ventilation (L/hr/kg**0.75)
24
25  ! Blood Flows (fraction of cardiac output)
26          CONSTANT    QCC = 15.0      ! Cardiac output (L/hr/kg**0.75)
27          CONSTANT    QFC = 0.05      ! Fat
28          CONSTANT    QLC = 0.25      ! Liver
29  ! Blood flow to rest of body Calculated by Flow Balance!
30          QRC = 1.0 - (QFC + QLC)
31          QC = QCC*BW**0.75
32          QP = QPC*BW**0.75
33
34  ! Tissue Volumes for mice (fraction of body weight)
35          CONSTANT    VAC = 0.0123   ! Arterial blood
36          CONSTANT    VFC = 0.07     ! Fat
37          CONSTANT    VLC = 0.055    ! Liver
38          CONSTANT    VLuC = 0.0073  ! Lung tissue
39          CONSTANT    VVBC = 0.0368  ! Venous blood
40          VRC = 0.91 - (VAC+VFC+VLC+VLuC+VVBC)
41
42  ! Partition Coefficients (Mouse values from Ward et al. (1997, 083652) used as default)
43          CONSTANT    PB = 1350      ! MeOH Blood:Air; Use Horton value!
44          CONSTANT    PF = 0.08      ! MeOH Fat:Blood
45          CONSTANT    PL = 1.1       ! MeOH Liver:Blood
46          CONSTANT    PLU = 1.0      ! MeOH Lung:Blood, compartment for dosing only
47          CONSTANT    PR = 0.8       ! MeOH Rest of body:Blood
48
49  ! Hepatic Metabolism of MeOH
50          CONSTANT    KM = 45.0      ! mg/L
51          CONSTANT    VMAXC = 15.0   ! mg/hr/BW**0.75
52          VMAX = VMAXC*BW**0.75      ! mg/hr
53          CONSTANT    VMAX2C = 15.0! 2nd saturable pathway
54          VMAX2 = VMAX2C*BW**0.75
55          CONSTANT    KM2= 45.0
```

```
        CONSTANT KLLC = 0.0! First-order metabolism
! Set VMAXC = VMAX2C = 0, when KLLC > 0
        KLL = KLLC/BW**0.25


! MeOH Clearance from Blood!
        CONSTANT    K1C = 0.01        ! First-order clearance, BW**0.25/hr
        K1 = K1C/BW**0.25       ! Scaled blood elimination, hr-1
! This lumped term was used in the WARD model an accounted for
! renal elimination and "additional" non-hepatic metabolism of
! MeOH associated only with high dose i.v. data.
! A 1st-order term should not be used to represent two processes
! with different dose-dependencies.
! This has not been used for mouse data (set=0), but was used to
! approximate human urinary data!

! Bladder compartment added by Paul Schlosser, October 2008
        CONSTANT KBL=0.0    ! Bladder constant, 1/hr

! Fractional Absorption of MeOH
        CONSTANT    FRACin = 0.85  ! Inhalation, value from Perkins et al (1996, 196147)
        CONSTANT    KFEC = 0.0      ! Fecal elimination constant, 1/hr
                ! KFEC determines oral bioavailability

! Molecular Weight of MeOH
        CONSTANT    MWMe = 32.0   ! mol wt, g/mol!

! Closed Chamber Parameters
        CONSTANT    VChC = 100.0   ! Volume of closed chamber (L)
        CONSTANT    Rats = 0.0       ! Number of rats in chamber
        CONSTANT    kLoss = 0.0      ! Chamber loss rate /hr
        ! Set RATS = 0.0 and KLOSS = 0.0 for open chamber

! Blood Flows (L/hr)
        QF = QFC*QC  ! Fat
        QL = QLC*QC  ! Liver
        QR = QRC*QC  ! Rest of Body

! Tissue Volumes (mL)
        VAB = VAC*BW! Arterial blood volume
        VF = VFC*BW            ! Fat
        VL = VLC*BW            ! Liver
        VLu = VLuC*BW          ! Lung
        VR = VRC*BW            ! Rest of the body
        VVB = VVBC*BW          ! Venous blood
        VBL = VAB + VVB        ! Total blood

!----------Timing commands------------!
        CONSTANT    TCHNG = 6.0           ! End of exposure!
        CONSTANT    TSTOP = 24.0          ! End of experiment/simulation!
        CONSTANT    POINTS = 1000.0       ! No. points for simulation output!
        CONSTANT    REST = 100000.0       ! End of work period for human exercise
        CONSTANT    WORK = 100000.0       ! Start of work period for human exercise
        SCHEDULE DS1.AT.REST      ! Change from work to rest conditions
        SCHEDULE DS2.AT.WORK      ! Change from rest to work conditions
        ! Human Rest/Work (changes in blood-flow fractions to fat/liver not currently used0
```

```
 1          CONSTANT QPCHR=15.0, QCCHR=15.0, QLCHR=0.25, QFCHR=0.05  ! Rest
 2          CONSTANT QPCHW=52.0, QCCHW=26.0, QLCHW=0.16, QFCHW=0.06          ! Work
 3
 4    !---------Simulation Control------------!
 5    ! Exposure Conditions Based on User Defined Initial Amounts of
 6    ! Chemical (mg)
 7          CONSTANT CONCppm = 0.0     ! Air Concentration in ppm
 8          VCh = VChC-(Rats*BW)           ! Volume of Occupied Chamber
 9          CONCmg = CONCppm*MWMe/24451    ! Convert ppm to mg/Liter!
10          ACHO = CONCmg*VCH                      ! Init Amt in Chamber, mg!
11
12    ! Background levels, added by Paul M. Schlosser, U.S. EPA, 12/8/09
13    ! CVBbg (CVBBG) is the constant to be set to the background blood
14    ! concentration when dosing is with *non*-radio-labeled methanol, so
15    ! exogenous and endogenous methanol are indistinguishable.
16    ! dCVBbg (DCVBBG) is the constant to be set to the background blood
17    ! concentration when dosing is with *radio-labeled* methanol.
18    CONSTANT CVBbg = 1.6        ! Value from Rogers et al (1993) for CD-1 mice
19    constant vCVBbg = 0.0  ! Value for use as an adjustable variable
20    constant RINCBG=0.113          ! Relative increase in background appearance of
21                        ! methanol per hour (multiplies time T and time-zero appearance)
22                        ! Paul M. Schlosser, U.S. EPA, 12/2009
23    constant INCBG=0.0     ! Set to 1.0 when fitting vCVBbg and RINCBG
24    constant dCVBbg = 0.0  ! "Cold" (not-radiolabeled) background, for 14C data
25    constant RUR0 = 0.0     ! Initial urine concentration; used to set CVBBG when > 0
26
27    IF (K1C.EQ.0.0) THEN
28          CVBG = CVBBG + incbg*vCVBbg
29    ELSE
30          CVBG = CVBBG + incbg*vCVBbg + RUR0*BW^0.25*0.5e-3/(K1C*VVBC)
31    ENDIF
32
33    ! Following are calculations of initial conditions given an endogenouse
34    ! background blood concentration, CVBBG or VCVBBG, or urine concentration, RUR0.
35    CVLbg = ((QF+QR)*QP/(QP+QC*PB) + QL + K1*VVB)*cvbg/QL
36    RAObg = (VMAX/(KM + CVLbg) + VMAX2/(KM2 + CVLbg) + KLL)*CVLbg + ...
37          (QC*QP/(QP+QC*PB) + K1*VVB)*cvbg
38    CAB0=QC*cvbg/(QC+QP/PB)
39    AAB0=CAB0*VAB
40    AF0=VF*CAB0*PF
41    AL0=VL*CVLbg*PL
42    ALu0=VLu*CAB0*PLu
43    AR0=VR*CAB0*PR
44    AVB0=VVB*cvbg
45    ABL0=K1*cvbg*VVB/KBL
46
47    ! Following are calculations of initial conditions given an endogenouse
48    ! background blood concentration, DCVBBG, set > 0 (with CVBBG, etc. = 0)
49    ! when dosing is with radio-labelled MeOH.  Currently does not allow one
50    ! to use the equivalent of fitted background (VCVBBG), time-dependent
51    ! (RINCBG), or urine concntration (RUR0) to set the background.
52    dCVLbg = ((QF+QR)*QP/(QP+QC*PB) + QL + K1*VVB)*dCVBbg/QL
53    dRAObg = (VMAX/(KM + dCVLbg) + VMAX2/(KM2 + dCVLbg) + KLL)*dCVLbg + (QC*QP/(QP+QC*PB) +
54    K1*VVB)*dCVBbg
55    dCAB0=QC*dCVBbg/(QC+QP/PB)
```

```
1   dAAB0=dCAB0*VAB
2   dAF0=VF*dCAB0*PF
3   dAL0=VL*dCVLbg*PL
4   dALu0=VLu*dCAB0*PLu
5   dAR0=VR*dCAB0*PR
6   dAVB0=VVB*dCVBbg
7
8   ! Oral dosing
9           CONSTANT    KAS = 0.1        ! 1st order oral abs, hr-1
10          CONSTANT    KMASC = 550   ! Saturable oral abs Kmasc [=] mg/kg
11                  KMAS = KMASC*BW
12          CONSTANT    VASC  = 1740 ! Saturable oral ab VmaxC, mg/hr/kg^0.75
13                  VAS = VASC*BW**0.75 ! Saturable oral ab Vmax, mg/hr
14          CONSTANT    KAI = 0.1        ! 1st order oral abs from intestine, hr-1
15          CONSTANT    KSI = 0.5        ! 1st order transfer stom to intes hr-1
16          CONSTANT    DOSE = 0.0       ! Oral dose in mg/kg BW
17          CONSTANT    ODS = 0.0        ! Switch for zero order oral uptake
18          ! (Set to 1 for zero order, set to 0 for first order)
19          ODOSE = DOSE*BW*(1.0-ODS)         ! Convert mg/kg to mg total (oral)
20          RAOZ = DOSE*BW*ODS/24.0   ! mg/hr for zero order dosing
21
22          ! Daily dose for steady drinking water by "sipping" (by rats)
23                  CONSTANT DWDOSE = 0       ! mg/kg/d by periodic sipping
24                  CONSTANT PER1 = 1.5          ! Period between sipping episodes (hr) during dark
25          ! "Between" means from the start of 1 to the start of the next episode
26                  CONSTANT DUR1 = 0.75        ! Duration of sipping episodes during dark (hr)
27                  CONSTANT PER2 = 3.0            ! Period during light (hr) between sipping episodes
28                  CONSTANT DUR2 = 0.5            ! Duration of sipping episodes during light (hr)
29                  CONSTANT FNIGHT = 0.8         ! Fraction of drinking during night
30                  constant days = 7.0       ! days/week of oral exposure
31                  constant metd = 7.0       ! number of days at end over which AUCBF and AMETF
32                                            ! are averaged
33                  tmetf = metd*24.0
34                  dayon=24.0*days
35          ! Night sipping rate (mg/h) during episodes
36                  DWRNIGHT = DWDOSE*BW*FNIGHT*PER1/(12.0*DUR1)
37          ! Day sipping rate (mg/h) during episodes
38                  DWRDAY = DWDOSE*BW*(1-FNIGHT)*PER2/(12.0*DUR2)
39          IDOSE=0
40          ! Above assumes 12-hr each for day/night
41
42   ! Drinking Table from Deborah Keys for mice, as used in
43   ! A quantitative description of suicide inhibition of dichloroacetic acid in rats and mice.
44   ! Keys DA, Schultz IR, Mahle DA, Fisher JW.
45   ! Toxicol Sci. 2004 Dec;82(2):381-93 (2004, 196283).
46   ! Based on data of Yuan, J.. Modeling blood/plasma concentrations in dosed feed and dosed
47   ! drinking water toxicology studies. Toxicol. Appl. Pharmacol. 119, 131-141 (1993, 050215).
48   constant rdrink = 1.0 ! Default for use of sipping w/ DWDOSE abopve
49          ! set rdrink = 0.0 to use pattern below
50   table mdrinkp,1,49 / 0., .5, 1., 1.5, 2., 2.5, 3., 3.5, &
51        4., 4.5, 5., 5.5, 6., 6.5, 7., 7.5, &
52        8., 8.5, 9., 9.5, 10., 10.5, 11., 11.5,  &
53        12., 12.5, 13., 13.5, 14., 14.5, 15., 15.5,  &
54        16., 16.5, 17., 17.5, 18., 18.5, 19., 19.5,  &
55        20., 20.5, 21., 21.5, 22., 22.5, 23., 23.5, 24.0,  &
```

```
1        0.12 , 0.9, 1.6, 1.8, 1.9, 2.9, 4.0, 4.5, 4.9, 4.9,  &
2        4.8, 4.4, 4.0, 5.0, 5.9, 5.3, 4.5, 3.9,  &
3        3.2, 3.0, 2.7, 2.5, 2.3, 2.3, 2.3, 1.9,  &
4        1.4, 1.4, 1.3, 1.3, 1.3, 1.1, 0.8, 0.8,  &
5        0.8, 0.6, 0.5, 0.7, 0.8, 0.6, 0.4, 0.2,  &
6        0.05, 0.08, 0.14, 0.07, 0.06, 0.08, 0.12 /
7
8            ! Larger bolus dosing
9                 CONSTANT DRDOSE=0.0        ! Total dose by drinking water in boluses, mg/kg day
10           ! Times for multiple oral drinks/day *after* 0
11                ! Must be ascending, 0 <= times < 24 hr
12                ! CONSTANT DRT=0, 2, 4, 6, 8, 10       ! Rat values
13                Constant DRT = 0.0, 3.0, 5.0, 8.0, 11.0, 15.0       ! Human values
14                ! DRTIME(1) assumed = 0 and not used
15           ! Fraction consumed by drinking at those times
16                CONSTANT DRP = 0.25, 0.1, 0.25, 0.1, 0.25, 0.05
17
18           !Total oral bolus dose; initial value given at t=0 via initial condition
19                TODOSE = DRP(1)*DRDOSE*BW*(1.0-ODS) + ODOSE
20
21    ! IV dosing
22           CONSTANT IVDOSE = 0.0        ! IV dose, mg/kg
23           CONSTANT TINF = 0.025        ! Length of exposure (hrs), default = 1.5 min (bolus)
24                ! 1.5 min reported by Ward and Pollack, (DMB 1996, 025978)
25           TIV = IVDOSE*BW       ! Expected amt infused, mg
26           IV1 = TIV/TINF  ! Rate of infusion, mg/hg
27
28    ! For I.V. Runs, control step size if necessary by changing MaxT, not POINTs or CINT
29           MAXT = 1.0      ! Maximum Step Size, Hours
30           !IF (IVDOSE.GE.1.0E-4) MAXT = 1.0E-4
31
32    ! Liver infusion
33           CONSTANT LIVR0 = 0.0         ! Zero-order liver total, mg/kg/day
34           RLIV0 = LIVR0*BW/TCHNG       ! Rate in mg/hr
35
36    !--------Dose Scheduling-----------------
37           CONSTANT MULTE=0                      ! Default is *no* repeated dosing/inhalation
38           CIZONE = 1.0   ! Start with inhalation on
39           IVZONE = 1.0   ! Start with IV on
40           schedule ON.AT.24.0
41           SCHEDULE OFF.AT.TCHNG     ! Turn off exposure at TCHNG
42           DAY = 0;
43           NEWDAY = 0; IDS = 2   ! First dose given as initial condition
44           IF (MULTE) SCHEDULE ORALDOSE.AT.DRT(2)
45    ALGORITHM IALG = 2  ! Gear algorithm
46    END     ! END OF INITIAL
47
48    DYNAMIC
49
50    DERIVATIVE
51    !***********************  MeOH  *************************
52           IVR = IVZONE*IV1        ! IV dosing; IVR = ate of infusion, mg/hg
53    ! Oral Dosing
54           DWING = ( (DWRNIGHT*PULSE(0.0,PER1,DUR1)*PULSE(0.0,24.0,12.0) + &
55                DWRDAY*PULSE(0.0,PER2,DUR2)*(1-PULSE(0.0,24.0,12.0)) )*rdrink + &
```

```
1              (1-rdrink)*mdrinkp(mod(T,24.0))*0.02*DWDOSE*BW )*PULSE(0.0,168,dayon)
2         RAS = KAS*STOM + VAS*STOM/(KMAS+STOM)
3         RSTOM = DWING + RAOZ - RAS - KSI*STOM   ! Change in stomach (mg/hr)
4         RINT = KSI*STOM - RFEC - KAI*AINTEST       ! Change in intestines (mg/hr)
5         RLZ = RLIV0*CIZONE   ! Zero-order to liver
6         RAO = RAS + KAI*AINTEST + RLZ + RAObg*(1.0+incbg*Rincbg*T)
7              ! Oral absorption (mg/hr); last term is endogenous background rate
8         RFEC = KFEC*AINTEST
9         FEC = INTEG(RFEC, 0.0)
10        STOM = INTEG(RSTOM, TODOSE)      ! Amt in stomach (mg)
11        AINTEST = INTEG(RINT, 0.0)    ! Amt in intestines (mg)
12        OralDoseCheck = INTEG(RAO, 0.0)
13
14   ! Arterial Blood
15        RAAB = QC*(CVLU - CAB)
16        AAB = INTEG(RAAB, AAB0)     ! Amount, mg
17        CAB = AAB/VAB                  ! Concentration, mg/L
18        AAUCB = INTEG(CAB, 0.0)      ! AUC, hr*mg/L
19
20        dRAAB = QC*(dCVLU - dCAB)  ! non-radio-labelled background equations
21        dAAB = INTEG(dRAAB, dAAB0)        ! Amount, mg
22        dCAB = dAAB/VAB               ! Concentration, mg/L
23
24   ! Fat
25        RF = QF*(CAB - CVF)
26        AF = INTEG(RF, AF0)   ! Amount, mg
27        CF = AF/VF      ! Concentration, mg/L
28        CVF = CF/PF    ! AUC, hr*mg/L
29
30        dRF = QF*(dCAB - dCVF)        ! non-radio-labelled background equations
31        dAF = INTEG(dRF, dAF0)       ! Amount, mg
32        dCF = dAF/VF   ! Concentration, mg/L
33        dCVF = dCF/PF! AUC, hr*mg/L
34
35   ! Liver
36        RAL = QL*(CAB - CVL) + RAO - RMETL - RMETL2 - RMETL3
37        AL = INTEG(RAL, AL0)  ! Amount, mg
38        CL = AL/VL               ! Concentration, mg/L
39        CVL = CL/PL              ! Concentration, mg/L
40        AUCL = INTEG(CL, 0.0)! AUC, hr*mg/L
41
42              ! non-radio-labelled background equations ...
43        dRAL = QL*(dCAB - dCVL) + dRAObg*(1.0+incbg*Rincbg*T) - dRMETL - dRMETL2 - dRMETL3
44        dAL = INTEG(dRAL, dAL0)       ! Amount, mg
45        dCL = dAL/VL            ! Concentration, mg/L
46        dCVL = dCL/PL           ! Concentration, mg/L
47
48   tCVL = CVL + dCVL
49   ! tCVL = total of labelled and non-radio-labelled liver venous bloood, used
50   ! in metabolic saturation terms to account for mutual inhibition of both forms.
51
52   ! Liver Metabolism
53        RMETL = VMAX*CVL/(KM + tCVL)
54        METL = INTEG(RMETL, 0.0)
55        RMETL2 = VMAX2*CVL/(KM2 + tCVL)
```

```
1        METL2 = INTEG(RMETL2, 0.0)
2        RMETL3 = KLL*CVL
3        METL3 = INTEG(RMETL3, 0.0)
4
5        dRMETL = VMAX*dCVL/(KM + tCVL)     ! non-radio-labelled background equations
6        dRMETL2 = VMAX2*dCVL/(KM2 + tCVL)
7        dRMETL3 = KLL*dCVL
8
9
10    ! Total Amount Metabolized (Formate and Formaldehyde)
11    ! Does not include K1C for human MeOH excretion estimate
12        AMET = METL + METL2 + METL3
13        AMET24 = AMET*24.0/TSTOP
14    ! Total amount metabolized in last tmetf hr of exposure, averaged per day
15        AMETF = INTEG((RMETL+RMETL2+RMETL3)*PULSE(TSTOP-
16    tmetf,TSTOP,tmetf),0.0)*24.0/tmetf
17        ! (tmetf = 24.0*metd)
18    ! Chamber concentration (mg/L)
19        RACh = (Rats*QP*CLEx) - (FRACinh*Rats*QP*CCh) - (kLoss*ACh)
20        ACh = INTEG(RACh, AChO)
21
22    ! The following calculation yields an air concentration equal to the
23    ! closed chamber value if a closed chamber run is in place and a
24    ! specified constant air concentration if an open chamber run is in place
25        CCh = ACh*Cizone/VCh
26        CCPPM = CCh*24451/MWMe
27        CLoss = INTEG(kLoss*ACh, 0.0)
28
29    ! Lungs
30        RALu = QP*(FRACinh*CCh - CLEx) + QC*(CVB - CVLu)
31        ALu = INTEG(RALu, ALu0)
32        CLu = ALu/VLu ! Concentration, mg/L
33        CVLu = CLu/PLu          ! Exiting Concentration, mg/L
34
35        dRALu = QC*(dCVB - dCVLu) - QP*dCLEx         ! non-radio-labelled background eqns
36        dALu = INTEG(dRALu, dALu0)
37        dCLu = dALu/VLu          ! Concentration, mg/L
38        dCVLu = dCLu/PLu         ! Exiting Concentration, mg/L
39
40    ! Amount Inhaled
41        RInh = FRACinh*QP*CCh
42        AInh = INTEG(RInh, 0.0)          ! mg per rat
43        AInhC = AInh*Rats        ! mg for a group of rats
44
45    ! Amount Exhaled
46        CLEx = CVLu/PB          ! Concentration, mg/L
47        dCLEx = dCVLu/PB                ! non-radio-labelled background equations
48    ! changed from CVB/PB to CVLu/PB by Paul Schlosser, U.S. EPA, 12/8/09
49    ! This makes it a standard venous equilibrium gas exchange model!
50        RAEx = QP*CLEx
51        AEx = INTEG(RAEx, 0.0)*PULSE(0,TCHNG,TSTOP)       ! Amount, mg per rat
52        AExC = AEx*Rats          ! Amount, mg, for a group of rats
53        AxF = INTEG(RAEx*PULSE(TCHNG,24,24), 0.0)          ! Amount exhaled post-exposure
54
55    ! Rest of Body
```

```
1              RAR = QR*(CAB - CVR)
2              AR = INTEG(RAR, AR0)          ! Amount, mg
3              CR = AR/VR              ! Concentration, mg/L
4              CVR = CR/PR   ! Exiting Venous Concentration, mg/L
5              AUCR = INTEG(CR, 0.0)          ! AUC, hr*mg/L
6
7              dRAR = QR*(dCAB - dCVR)        ! non-radio-labelled background equations
8              dAR = INTEG(dRAR, dAR0)       ! Amount, mg
9              dCR = dAR/VR              ! Concentration, mg/L
10             dCVR = dCR/PR           ! Exiting Venous Concentration, mg/L
11
12   ! Venous Blood (mg)
13             RURB = K1*CVB*VVB                ! Lumped Clearance from Blood
14             RAVB = QF*CVF + QL*CVL + QR*CVR + IVR - QC*CVB - RURB
15             AVB = INTEG(RAVB, AVB0)      ! Amount, mg
16             CVB = AVB/VVB                     ! Concentration, mg/L
17
18             dRURB = K1*dCVB*VVB               ! non-radio-labelled background equations
19             dRAVB = QF*dCVF + QL*dCVL + QR*dCVR - QC*dCVB - dRURB
20             dAVB = INTEG(dRAVB, dAVB0)! Amount, mg
21             dCVB = dAVB/VVB                   ! Concentration, mg/L
22
23             AUCB = INTEG(CVB, 0.0)         ! AUC, hr*mg/L (total over entire exposure)
24             AUCBB = AUCB*24.0/TSTOP     ! Average over exposure, hr*mg/(L*day)
25             AUCBF = INTEG(CVB*PULSE(TSTOP-tmetf,TSTOP,tmetf),0)*24.0/tmetf
26                    ! AUCBF = Last tmetf AUC averaged/day (tmetf = 24.0*metd)
27                    ! For "steady state" AUC in blood over a day, set exposures to
28                    ! several weeks to reach "periodicity", then use AUCBF w/ metd = 7
29
30   ! Bladder compartment, added by PS, U.S. EPA, 10/2008
31             RBL = KBL*ABL           ! Rate of clearance from bladder (mg/hr)
32             ABL = INTEG((RURB-RBL),ABL0)         ! Amount in bladder (mg)
33             RUR= RBL/(BW*0.5e-3)! Urine concentration = rate/[BW*(0.5e-3 L/h/kg BW)]
34             URB = INTEG(RBL, 0.0) ! Amount cleared to urine, mg
35             URBF = INTEG(RURB*PULSE(TSTOP-tmetf,TSTOP,tmetf),0)*24.0/tmetf
36                    ! Amount cleared to urine in last tmetf averaged/day (tmetf = 24.0*metd)
37
38   !*********************  Mass Balance   *************************
39             Tbody = AAB + AF + AL + ALU + AR + AVB + ABL + STOM + AINTEST
40             MetabORClrd = URB + METL + METL2 + METL3 + AEX + FEC
41             TMass = Tbody + MetabORClrd
42             TDose = AinH + INTEG(IVR+DWING+RAOZ+RLZ,0.0) + TODOSE
43             MassBal=100*(TDose-TMass)/(TMass+1e-12)
44             !compare to TIV, ODOSE, or AINHC
45   ! Check Blood Flows
46             QTOT = QF + QL + QR
47             QRECOV = 100.0*QTOT/QC
48   END    ! End of Derivative
49   TERMT(T.GE.TStop)
50
51   !-------Exposure Control------------
52   DISCRETE ORALDOSE           ! Stom is amount in stomach
53             IDOSE = DRP(IDS)*DRDOSE*BW
54             STOM = STOM + IDOSE          ! Drinking percent
55             TODOSE = TODOSE + IDOSE
```

```
1              IF (IDS.EQ.1) THEN
2                      STOM = STOM + ODOSE
3                      TODOSE = TODOSE + ODOSE
4              ENDIF
5              IDS = IDS+1
6              IF (IDS.EQ.7) THEN      ! For 6 doses
7                      IDS = 1
8                      NEWDAY = NEWDAY + 24
9                      SCHEDULE ORALDOSE.AT.NEWDAY  ! Go to start of the next day
10             ELSE
11                     SCHEDULE ORALDOSE.AT.(NEWDAY+DRT(IDS)) ! Go to next drink time
12             ENDIF
13     END    ! OF DISCRETE ORALDOSE
14
15     DISCRETE OFF           ! Turn INHAL exposure off
16             CIZONE = 0.0
17             IVZONE = 0.0
18             DAY=DAY+1
19             IF (MULTE) SCHEDULE ON.AT.(DAY*24.0)
20     END    ! OF DISCRETE OFF
21
22     DISCRETE ON
23             CIZONE=1.0
24             SCHEDULE OFF.AT.(T+TCHNG)
25     END    ! OF DISCRETE ON
26
27     DISCRETE DS1          ! Human at rest
28             ! Equations scheduled for change during simulation repeated here
29             QC = QCCHR*BW**0.75
30             QP = QPCHR*BW**0.75
31             QF = QFC*QC  ! QFCHR*QC    ! Equations for alternate flow fractions
32             QL = QLC*QC  ! QLCHR*QC    ! But QFC and QLC taken to be 'at rest' values
33             QRC = 1.0 - (QFC + QLC)
34             QR = QRC*QC
35             FRACINH = FRACIN
36     END    ! OF DISCRETE DS1
37
38     DISCRETE DS2          ! Human at work (50W)
39             ! Equations scheduled for change during simulation repeated here
40             QC = QCCHW*BW**0.75
41             QP = QPCHW*BW**0.75
42             QF = QFC*QC  ! QFCHW*QC   ! Equations for alternate flow fractions
43             QL = QLC*QC  ! QLCHW*QC   ! But don't seem to work (fit data) well
44             QRC = 1.0 - (QFC + QLC)
45             QR = QRC*QC
46             FRACINH=FRACINW
47     END    ! OF DISCRETE DS2
48
49     END    ! End of Dynamic
50     END    ! End of Program
```

B.3.2. acslXtreme procedure (.cmd) file

```
51     ! File MEOHCBMMfinal.CMD - FOR PBPK MODEL FOR METHANOL
52     ! taken from .cmd file from Ward et al. (1997, 083652) , Edited by KWW - 06/02/96
```

```
1    ! Developed for this (CBMM) model - 4/15/15
2    ! Final with Digitized Data - 5/25/05
3    ! Final Version has fast and slow rates of oral absorption
4    ! Version 4 is final version used for simulations
5    ! Final Version 1.10.06
6    ! Beyond this comment, this file is left "as is" for archival purposes.  But most if not all of
7    ! the functions and data sets defined here are replicated and/or replaced in the .m files below.
8    ! Only use these when there is no corresponding .m file.
9    ! – Edited by Paul Schlosser (U.S. EPA), October 2008
10   !------------------------------------------------------------
11   PREPARE T,CVB,MetB
12
13   ! Procedural blocks for general mouse/rat data
14   PROCED CDMICE          ! Anatomic/physiologic data for mice
15   SET BW=0.03, TSTOP=1.5
16   SET IVDose=0, DOSE=0, CONCppm=0
17   SET PL=1.06, PF=0.083, PR=0.66, PB=1350
18   SET QPC=25.4,QCC=25.4,fracin=0.73
19   SET QLC = 0.25,QFC=0.05
20   SET KM=12,VmaxC=14.3,KLC=0.0,KAS=2
21   SET Vmax2c=19,km2=210,KAI=0.22,KSI=1.1
22   SET VAC = 0.0123,VFC = 0.07,VLC = 0.055
23   SET VLuC = 0.0073, VVBC = 0.0368
24   !Volumes from Brown et al (1997, 020304)
25   !Mouse QPC avg from Brown 29, 24 used in Corley et al. (1994, 041977) and others
26   !AVG of measured vent rates by Perkins et al  (1995, 085259) 25.4 L/hr/kg^0.75
27   !Blood volume 4.9% total. As per Brown 25:75 split art:ven
28   !Metab originally from Ward et al (1997, 083652)- KldC for mice =0
29   END
30
31   PROCED HUMAN
32   SET BW=70
33   SET IVDose=0, DOSE=0, CONCppm=0
34   SET PL=1.06, PR=0.66, fracin=0.75
35   SET VFC=0.214, VLC=0.026,VLUC=0.008
36   SET VAC= 0.0198,VVBC=0.0593
37   SET QPC=18.5, QCC=18.5, QLC=0.227, QFC=0.052
38   SET KM=12,VmaxC=11,KLC=0.044,KAS=2.0
39   SET KAI=0.22,KSI=1.1
40   SET PB = 1626, PF=0.14
41   SET Vmax2c=0
42   !Volumes from Brown et al (1997, 020304)
43   !QPC from Brown et al (1997, 020304), upper end 13.4 L/hr/kg^0.75
44   !Need higher for data, 15 L/hr/kg^0.75 used in several published human models
45   !Blood volume 7.9% total. As per Brown 25:75 split art:ven
46   !Frac absorbed from Ernstgard SOT poster + personal communication
47   !Human Partition Coef. equal to mice. Horton et al. (1992, 196222) used rat
48   !Except Human Partition Coef blood and fat - from Fiserova-Bergerova and Diaz, (1986, 064569)
49   ! - but rat values are inconsistent with expected fat partitioning for an alcohol like this
50   ! - for example Pastino and Conolly (2000, 006128) EtOH model, fat PC =0.1
51   END
52
53   PROCED SDRAT          !Anatomic/physiologic data for rats
54   SET BW=0.3, TSTOP=1.5
55   SET IVDose=0, DOSE=0, CONCppm=0
56   SET PL=1.6, PF=0.1, PR=1.3
57   SET KM=45,VmaxC=15,KLC=0.1,KAS=5
```

```
1    SET VAC = 0.0185, VFC=0.07, VLC= 0.034, VLuC=0.005, VVBC=0.0555
2    !Volumes from Brown et al (1997, 020304)
3    !PC from horton et al. (1992, 196222), PF reduced to 0.1 from Horton's 1.1
4    !Blood volume 7.4% total. As per Brown 25:75 split art:ven
5    !Metab originally from Ward et al (1997, 083652) - KldC for mice =0
6    !Rat model not calibrated
7    END
8
9    PROCED PREG
10   !For GD 18 mice, BW increased as estimated from Rogers et al (1993, 032696)
11   !Increased VFC as per Corley CRT development review
12   !This just to give a WAG as to how data might change from BW and different volume of distribution
13   !Not invoked for any PROCs below as the default
14   !Liver to 140% of NP
15   SET BW = 0.055, VFC=0.08,VLC=0.11,VVBC=0.05
16   END
17
18   PROCED CLEARIT
19   SET IVDose=0, DOSE=0, CONCppm=0
20   END
21
22   PROCED SHOWIT
23   display V_maxc,km,klc,pb,pf,pr,pl,kas,fracin
24   END
25
26   !Procedural blocks for all non-pregnant mouse data
27   ! IV
28   PROCED MWARDIV25
29   !Ward et al., (TAP 1997, 083652)
30   !Figure 2, data from Ward model cmd
31   !Data was checked via digitizit - within +/-5% of cmd file
32   CLEARIT
33   CDMICE
34   SET TSTOP=24.0
35   SET IVDOSE=2500., tchng=0.025
36   END
37
38   PROCED PMWARDIV25
39   PLOT /D=MWARDIV25, CVB
40   END
41
42   DATA MWARDIV25(T,CVB)
43   0.08    4481.8
44   0.25    4132.2
45   0.5     3888
46   1.00    3164.8
47   2.0     2303.5
48   4.00    1921.5
49   6       1883.8
50   8       1620
51   12      838
52   18      454.7
53   24      NaN
54   END
55
56   PROCED MWARD95IV25
57   !Ward et al., (FAT 1995, 077617)
```

```
1    !Figure 2
2    !Data via digitizit
3    CLEARIT
4    CDMICE
5    SET TSTOP=24.0
6    SET IVDOSE=2500., tchng=0.025
7    END
8
9    PROCED PMWARD95IV25
10   PLOT /D=MWARD95IV25, CVB
11   END
12
13   DATA MWARD95IV25(T,CVB)
14   0.53     3299.60
15   1.06     3244.54
16   1.54     3190.71
17   3.07     2803.13
18   4.07     2544.36
19   5.02     2237.77
20   6.02     2063.59
21   7.02     1873.10
22   8.02     1521.92
23   9.03     1670.30
24   10.03    1423.12
25   END
26
27   ! Procs for pegnant IV below: MWARDGD9IV25, MWARDGD18IV25, MWARDGD18IV5, MWARDGD18IV1
28   ! Oral
29   PROCED MWARDPO25
30   !Ward et al., (FAT 1995, 077617)
31   !Figure 2, data from Ward model cmd
32   !Data was checked via digitizit - within +/-5% of cmd file
33   CLEARIT
34   CDMICE
35   SET TSTOP=24, DOSE=2500
36   END
37
38   PROCED PMWARDPO25
39   PLOT /D=MWARDPO25, CVB
40   END
41
42   DATA MWARDPO25(T,CVB)
43   0.504    2370
44   0.96     2645
45   1.44     2705
46   1.992    2719
47   2.208    2781
48   3        2704
49   4.008    2370
50   4.992    2617
51   6        2516
52   7.008    2635
53   7.992    2213
54   9        2370
55   10.008   2028
56   10.992   1916
57   12       1347
```

```
1    13.008   1467
2    13.992   1354
3    15       1175
4    16.008   864.3
5    16.992   745.2
6    18       422.4
7    19.01    428
8    21       243
9    24       136
10   END
11
12   !Procs for pregnant Oral below: MDORGD8PO15, MWARDGD18PO25
13   !Inhalation
14   ! QPC set to measured as in Perkins et al., (FAT, 1995, 085259) for each concentration
15
16   PROCED MPERKIN25
17   !Perkins et al., (FAT, 1995, 085259)
18   !Fig. 2 data in Ward cmd file
19   CLEARIT
20   CDMICE
21   SET TSTOP=24, CONCppm=2500, vchc=5000
22   SET QPC = 29., QCC=29.
23   SET TCHNG=8
24   END
25
26   PROCED PMPERKIN25
27   PLOT /D=MPERKIN25, CVB
28   END
29
30   !This data from DigitizIt
31   DATA MPERKIN25(T,CVB)
32   2.0      414.0
33   4.0      453.0
34   6.0      586.0
35   8.25     694.0
36   12       282.0
37   16       0.6
38   END
39
40   !This data from cmd file
41   !DATA MPERKIN25(T,CVB)
42   !1.99           386.49
43   !4.01           617.57
44   !6.00           816.22
45   !8.26           970.27
46   !12.00          393.24
47   !16.0           13.51
48   END
49
50   PROCED MPERKIN50
51   !Perkins et al., (FAT, 1995, 085259)
52   !Fig. 2, data in Ward cmd file
53   !Data in command file higher than appears in figure
54   CLEARIT
55   CDMICE
56   SET TSTOP=24, CONCppm=5000, vchc=5000
57   SET TCHNG=8, qpc=24.,qcc=24.
```

```
1    END
2
3    PROCED PMPERKIN50
4    PLOT /D=MPERKIN50, CVB
5    END
6
7    !this from Digitizit, Fig 2 Perkins et al (1995, 085259)
8    DATA MPERKIN50(T,CVB)
9    1       644.00
10   2       877.00
11   3       1340.00
12   4       1450.00
13   6       2040.00
14   8.25    2290.0
15   12      1410.0
16   16      583.0
17   20      271.0
18   24      9.7
19   END
20
21   !This data from cmd file
22   !DATA MPERKIN50(T,CVB)
23   !1.0     906.76
24   !2.0     1202.7
25   !3.0     1828.38
26   !4.0     1986.49
27   !6.0     2800
28   !8.3     3125.68
29   !12.0    1914.86
30   !16.0    806.76
31   !20.0    367.57
32   !24.0    10.81
33   !END
34
35   PROCED MPERKIN100
36   !Perkins et al., (FAT, 1995, 085259)
37   !Fig. 2 data in Ward cmd file
38   !Note, Table 6 in Ward paper - max value of 3260 +/- 151
39   CLEARIT
40   CDMICE
41   SET TCHNG=8, CONCppm=1,0000, tstop=36,vchc=5000
42   SET QPC=21,qcc=21
43   END
44
45   PROCED PMPERKIN100
46   PLOT /D=MPERKIN100, CVB
47   END
48
49   !this from Digitizit, Fig 2 Perkins et al
50   DATA MPERKIN100(T,CVB)
51   2.0     2080.0
52   4.0     2530.0
53   6.0     3350.0
54   8.25    3350.0
55   12      2370.0
56   16      1830.0
57   20      1080.0
```

1	24	591.0
2	28	44.6
3	END	
4		
5	!DATA MPERKIN100(T,CVB)	
6	!This from original cmd file	
7	!2.0	2809.46
8	!4.0	3405.4
9	!6.0	4528.38
10	!8.3	4524.32
11	!12.0	3212.16
12	!16.0	2456.76
13	!20.0	1439.19
14	!24.0	798.65
15	!28.0	55.4
16	!END	

17
18   ! Procs for Preg mouse Inhalaiton date below: MDOR8IN10,MDOR8IN15
19   !and:MROGGD7IN10, MROGGD6IN1, MROGGD6IN2, MROGGD6IN5, MROGGD6IN10
20
21   !pregnant mice
22   ! IV
23   PROCED MWARDGD9IV25
24   !Ward et al., (DMD, 1996, 025978)
25   !Not used in the manuscript, only in cmd file
26   CLEARIT
27   CDMICE
28   SET TSTOP=24
29   SET IVDOSE=2500., TINF=0.025
30   END
31
32   PROCED PMWARDGD9IV25
33   PLOT /D=MWARDGD9IV25, CVB
34   END
35

36	DATA MWARDGD9IV25(T,CVB)	
37	0.0833	4606.2
38	0.25	4079.5
39	0.5	3489.3
40	1	2939.6
41	2	3447.6
42	4	2605.0
43	6	2690.5
44	8	2574.9
45	12	1506.1
46	18	498.6
47	24.	NaN
48	END	

49
50   PROCED PROCED MWARDGD18IV25
51   !Ward et al., (DMD, 1996, 025978)
52   !Note, Table 6 in Ward paper - max value of 3521+/- 492
53   CLEARIT
54   CDMICE
55   SET TSTOP=24
56   SET IVDOSE=2500., TINF=0.025
57   END

```
 1
 2    PROCED PMWARDGD18IV25
 3    PLOT /D=MWARDGD18IV25, CVB
 4    END
 5
 6    DATA MWARDGD18IV25(T,CVB)
 7    0.0833   4250.0
 8    0.25     3445.1
 9    0.5      2936.8
10    1.0      2470.5
11    2.0      2528.1
12    4.0      2292.3
13    6.0      2269.4
14    8.0      2057.0
15    12       1805.9
16    18       1482.2
17    24.0     496.1
18    END
19
20    PROCED MWARDGD18IV5
21    !Ward et al., (DMD, 1996, 025978)
22    !Note, Table 6 in Ward paper - max value of 868.8 +/- 53.9
23    CLEARIT
24    CDMICE
25    SET TSTOP=6
26    SET IVDOSE=500., TINF=0.025
27    END
28
29    PROCED PMWARDGD18IV5
30    PLOT /D=MWARDGD18IV5, CVB
31    END
32
33    DATA MWARDGD18IV5(T,CVB)
34    0.25     854.7
35    0.5      720.2
36    1.0      624.1
37    2.0      453.2
38    3.0      307.6
39    4.0      217.7
40    4.5      202.6
41    END
42
43    PROCED MWARDGD18IV1
44    !Ward et al., (DMD, 1996, 025978)
45    !Ward Proc GD8, but must be 18 as per PBPK manuscript
46    !Note, Table 6 in Ward paper - max value of 252 +/- 12.9
47    !table matches file
48    CLEARIT
49    CDMICE
50    SET TSTOP=4
51    SET IVDOSE=100.
52
53    PROCED PMWARDGD18IV1
54    PLOT /D=MWARDGD18IV1, CVB
55    END
56
57    DATA MWARDGD18IV1(T,CVB)
```

```
1    0.25    252
2    0.52    242.2
3    1.0     222.7
4    2       176.4
5    3       134.2
6    3.5     94.41
7    END

9    ! Oral

11   PROCED MDORGD8PO15
12   !Ward et al.(1997, 083652) , cmd file
13   !Note, Table 6 in Ward paper - max value of 1610 +/- 704
14   !Table and file match w/in round off
15   !Data must be from Dorman
16   !Dorman Teratology, 1995, Fig. 1
17   !within error for Digitiz data the same
18   CLEARIT
19   CDMICE
20   SET TSTOP=24, DOSE=1500
21   END

23   PROCED PMDORGD8PO15
24   PLOT /D=MDORGD8PO15, CVB
25   END

27   DATA MDORGD8PO15(T,CVB)
28   1       1609.6
29   2       1331.2
30   4       1241.6
31   8       707.2
32   16      160.0
33   24      38.4
34   END

36   PROCED MWARDGD18PO25
37   !Ward et al., (DMD, 1996, 025978)
38   !Note, Table 6 in Ward paper - max value of 3205 +/- 291
39   CLEARIT
40   CDMICE
41   SET TSTOP=24, DOSE=2500
42   END

44   PROCED PMWARDGD18PO25
45   PLOT /D=MWARDGD18PO25, CVB
46   END

48   !from cmd file, replaced with digitized
49   !DATA MWARDGD18PO25(T,CVB)
50   !0.25    2770.
51   !0.5     3299.
52   !1       3336.
53   !2       3502.
54   !4       3217.
55   !6       2999.
56   !10      2036.
57   !12      1832.
```

```
1    !15      949.1
2    !18      403.5
3    !21      40.47
4    !24.     16.03
5    !END
6
7    !Digitizit data
8    DATA MWARDGD18PO25(T,CVB)
9    0.5      2024
10   1        2554
11   2        3193
12   4        3002
13   6        2933
14   10       1976
15   12       1922
16   15       1339
17   18       1033
18   21       832
19   24       580
20   END
21
22   !Inhalation
23
24   PROCED MDOR8IN10
25   ! Ward et al., (TAP, 1997, 083652)
26   !Note, Table 6 in Ward paper - max value of 2080 +/- 800
27   !Fig 7? Table 6 attributes to Dorman
28   !Digitizit of Dorman Fig 2 matches cmd file
29   !actual exposure ppm 9900
30   CLEARIT
31   CDMICE
32   SET TCHNG=6, CONCppm=9900, tstop=36
33   END
34
35   PROCED PMDOR8IN10
36   PLOT /D=MDOR8IN10, CVB
37   END
38
39   DATA MDOR8IN10(T,CVB)
40   1        771.2
41   2        1017.6
42   4        1788.8
43   6        2076.8
44   8        2281.6
45   16       1152.0
46   24       268.8
47   END
48
49   PROCED MDOR8IN15
50   ! Ward et al., (TAP, 1997, 083652)
51   !Note, Table 6 in Ward paper - max value of 7136 +/- 736
52   !Fig 7? Table 6 attributes to Dorman
53   !Digitizit of Dorman Fig 2 matches cmd file
54   CLEARIT
55   CDMICE
56   SET TCHNG=6, CONCppm=15000, tstop=36
57   SET vchc=5000000000
```

```
1    END
2
3    PROCED PMDOR8IN15
4    PLOT /D=MDOR8IN15, CVB
5    END
6
7    DATA MDOR8IN15(T,CVB)
8    1      1475.2
9    2      2486.4
10   4      4588.8
11   6      7123.2
12   8      5888.0
13   16     3456.0
14   24     1446.4
15   END
16
17   !Files above provided in cmd file from Ward, (TAP, 1997, 083652) PBPK model
18   !Files below added for this evaluation,
19   !sources described in proc files and in notebook
20
21   PROCED MROGGD7IN10
22   ! Rogers et al., (1997, 009755), Teratology
23   ! Actual Values kindly Provided by Rogers
24   CLEARIT
25   CDMICE
26   SET TCHNG=7, CONCppm=1,0000, tstop=36
27   SET vchc=500000000,bw=0.032
28   END
29
30   PROCED PMROGGD7IN10
31   PLOT /D=MROGGD7IN10, CVB
32   END
33
34   DATA MROGGD7IN10(T,CVB)
35   1      930
36   4      2800
37   6      3360
38   7      3990
39   7.5    3980
40   8      4120
41   9      3270
42   12     2630
43   16     1690
44   26     60
45   END
46
47   PROCED MROGGD6IN1
48   CLEARIT
49   !Rogers et al., (1993, 032696)
50   !Rogers data from GD 6 and 10
51   !In Table 2
52   CDMICE
53   SET TCHNG=7, CONCppm=1,000, tstop=36,vchc=500000000,bw=0.032
54   END
55
56   PROCED PMROGGD6IN1
57   PLOT /D=MROGGD6IN1, CVB
```

```
1    END
2
3    DATA MROGGD6IN1(T,CVB)
4    7        63
5    7        131
6    END
7
8
9    PROCED MROGGD6IN2
10   ! Rogers et al., (1993, 032696)
11   !Rogers data from GD 6 and 10
12   !In Table 2
13   CLEARIT
14   CDMICE
15   SET TCHNG=7, CONCppm=2000, tstop=36, vchc=500000000,bw=0.032
16   END
17
18   PROCED PMROGGD6IN2
19   PLOT /D=MROGGD6IN2, CVB
20   END
21
22   DATA MROGGD6IN2(T,CVB)
23   7        487
24   7   641
25   END
26
27   PROCED MROGGD6IN5
28   ! Rogers et al., (1993, 032696)
29   !Rogers data from GD 6 and 10
30   !In Table 2
31   CLEARIT
32   CDMICE
33   SET TCHNG=7, CONCppm=5000, tstop=36,vchc=500000000,bw=0.032
34   END
35
36   PROCED PMROGGD6IN5
37   PLOT /D=MROGGD6IN5, CVB
38   END
39
40   DATA MROGGD6IN5(T,CVB)
41   7        2126
42   7   1593
43   END
44
45   PROCED MROGGD6IN10
46   ! Rogers et al., (1993, 032696)
47   !Rogers data from GD 6, 10, 15
48   !In Table 2
49   CLEARIT
50   CDMICE
51   SET TCHNG=7, CONCppm=1,0000, tstop=36,vchc=500000000,bw=0.032
52   END
53
54   PROCED PMROGGD6IN10
55   PLOT /D=MROGGD6IN10, CVB
56   END
57
```

```
1    DATA MROGGD6IN10(T,CVB)
2    7       4653
3    7   4304
4    7   3655
5    END
6
7    !Human inhalation dta
8
9    PROCED HJOHIN1
10   !Ernstgard et al. (2005, 088075) SOT poster 200 ppm human
11   !Digitized from Fig 2
12   !Also personal communication - Ernstgard
13   !QPC from Johanson et al. (1986, 006760) Scand J. Work Env. 86 =52.6
14   !If Assume value = alveolar. similar to Astrand '83 value of 56 L/hr/kr^0.75
15   !Fracin - 50% of total (from poster) ~76%
16   !QCC from Corley et al (TAP 129, 1994, 041977)
17   CLEARIT
18   HUMAN
19   SET TCHNG=2, CONCppm=100, tstop=16
20   SET QPC=52.6,qcc=26,vchc=500000000
21   END
22
23   PROCED PHJOHIN1
24   PLOT /D=HJOHIN1, CVB
25   END
26
27   DATA HJOHIN1(T,CVB)
28   0.20    0.87
29   0.46    1.50
30   0.97    2.31
31   1.46    3.24
32   1.91    3.65
33   2.17    3.52
34   2.50    2.55
35   2.91    2.23
36   3.51    1.59
37   4.01    1.72
38   5.02    0.41
39   6.00    0.50
40   9.24    0.12
41   END
42
43   PROCED HJOHIN2
44   !Ernstgard et al. (2005, 088075) SOT poster 200 ppm human
45   !Digitized from Fig 2
46   !Also personal communication - Ernstgard
47   !QPC from Johanson et al. (1986, 006760) Scand J. Work Env. 86 =52.6
48   !If Assume value = alveolar. similar to Astrand '83 value of 56 L/hr/kr^0.75
49   !Fracin - 50% of total (from poster) ~75%
50   !QCC from Corley et al (TAP 129, 1994, 041977)
51   CLEARIT
52   HUMAN
53   SET TCHNG=2, CONCppm=200, tstop=16
54   SET QPC=52.6,qcc=26,vchc=500000000
55   END
56
57   PROCED PHJOHIN2
```

```
1    PLOT /D=HJOHIN2, CVB
2    END
3
4    DATA HJOHIN2(T,CVB)
5    0.22    1.63
6    0.49    2.92
7    0.92    4.76
8    1.47    6.30
9    1.90    7.65
10   2.16    6.20
11   2.47    5.49
12   2.91    4.96
13   3.50    3.64
14   4.00    3.43
15   4.99    1.94
16   5.97    1.03
17   8.90    0.21
18   END
19
20   PROCED HOSTERIN2
21   ! Osterloh et al., (JOEM 1996, 056314)
22   ! Digitized data provided by EPA
23   ! Subtracted background from exposure blood levels
24   CLEARIT
25   HUMAN
26   SET TCHNG=4, CONCppm=200, tstop=16
27   SET vchc=500000000, BW=78.2
28   END
29
30   PROCED PHOSTERIN2
31   PLOT /D=HOSTERIN2, CVB
32   END
33
34   DATA HOSTERIN2(T,CVB)
35   0.05    0.54
36   0.25    1.39
37   0.50    1.82
38   0.75    2.28
39   1.00    2.42
40   1.50    2.94
41   2.00    3.37
42   2.50    3.90
43   3.00    4.21
44   3.50    4.61
45   4.00    4.82
46   5.00    2.99
47   6.00    2.30
48   7.00    1.40
49   7.95    1.07
50   END
51
52   PROCED HBATIN82
53   !Batterman et al., (1998, 086797) Int Arch Occ Health
54   !Digitized Data
55   CLEARIT
56   HUMAN
57   SET TCHNG=2, CONCppm=800, tstop=16
```

```
1    SET vchc=500000000
2    END
3
4    PROCED PHBATIN82
5    PLOT /D=HBATIN82, CVB
6    END
7
8    DATA HBATIN82(T,CVB)
9    2.223   13.658
10   2.495   13.282
11   2.742   11.928
12   3.230   9.456
13   4.231   6.197
14   5.247   3.953
15   6.262   2.325
16   7.251   1.551
17   8.216   1.176
18   END
19
20   PROCED HBATIN81
21   !Batterman et al., (1998, 086797) Int Arch Occ Health
22   !Digitized Data
23   CLEARIT
24   HUMAN
25   SET TCHNG=1, CONCppm=800, tstop=16
26   SET vchc=500000000
27   END
28
29   PROCED PHBATIN81
30   PLOT /D=HBATIN81, CVB
31   END
32
33   DATA HBATIN81(T,CVB)
34   1.096   6.477
35   1.398   6.136
36   1.644   5.345
37   2.143   4.270
38   3.178   2.661
39   4.188   1.307
40   5.199   0.732
41   6.266   0.552
42   7.292   0.356
43   8.209   0.093
44   END
45
46   PROCED HBATIN830
47   !Batterman et al., (1998, 086797) Int Arch Occ Health
48   !Digitized Data
49   !body weight not provided
50   CLEARIT
51   HUMAN
52   SET TCHNG=0.5, CONCppm=800, tstop=16
53   SET vchc=500000000
54   END
55
56   PROCED PHBATIN830
57   PLOT /D=HBATIN830, CVB
```

```
1    END
2
3    DATA HBATIN830(T,CVB)
4    0.579   4.608
5    0.857   4.685
6    1.137   4.870
7    1.650   3.452
8    2.650   2.082
9    3.662   0.910
10   4.693   0.316
11   5.713   0.320
12   6.643   0.292
13   7.696   0.547
14   END
15
16   PROCED HSEDIN231
17   !Sedivec et al., (1981, 031154) Int Arch Occ Health
18   !Digitized Data
19   !Note, urine volumes not given, these are estimates
20   !urine production of 0.75 mg/hr, this for info purposes only!!!
21   CLEARIT
22   HUMAN
23   SET TCHNG=8, CONCppm=231, tstop=24
24   SET vchc=500000000
25   END
26
27   PROCED PHSEDIN231
28   PLOT /D=HSEDIN231, Metb
29   END
30
31   DATA HSEDIN231(T,Metb)
32   0.043   0.0042
33   2.174   0.33
34   4.478   0.87
35   6.478   1.46
36   8.522   2.15
37   10.348  2.63
38   12.130  2.91
39   14.044  3.07
40   18.870  3.32
41   23.696  3.52
42   END
43
44   PROCED HSEDIN157
45   !Sedivec et al., (1981, 031154) Int Arch Occ Health
46   !Digitized Data
47   !Note, urine volumes not given, these are estimates
48   !urine production of 0.75 mg/hr, this for info purposes only!!!CLEARIT
49   HUMAN
50   SET TCHNG=8, CONCppm=157, tstop=24
51   SET vchc=500000000
52   END
53
54   PROCED PHSEDIN157
55   PLOT /D=HSEDIN157, Metb
56   END
57
```

```
1    DATA HSEDIN157(T,Metb)
2    0.126    0.0038
3    2.204    0.228
4    4.242    0.576
5    6.196    0.975
6    8.326    1.47
7    10.163   1.81
8    12.094   2.00
9    14.016   2.12
10   18.8966  2.34
11   23.776   2.53
12   END
13
14   PROCED HSEDIN78
15   !Sedivec et al., (1981, 031154) Int Arch Occ Health
16   !Digitized Data
17   !Note, urine volumes not given, these are estimates
18   !urine production of 0.75 mg/hr, this for info purposes only!!!
19   CLEARIT
20   HUMAN
21   SET TCHNG=8, CONCppm=78, tstop=24
22   SET vchc=500000000
23   END
24
25   PROCED PHSEDIN78
26   PLOT /D=HSEDIN78, Metb
27   END
28
29   DATA HSEDIN78(T,Metb)
30   0.03     0.013
31   2.06     0.189
32   3.96     0.397
33   6.09     0.652
34   8.09     0.820
35   10.11    0.933
36   11.93    1.02
37   13.92    1.09
38   18.89    1.27
39   END
40
41   !AUC, Cmax estimation procedures
42   Proced mousin
43   !To determine AUC for 7 hr exposure in mice
44   CLEARIT
45   CDMICE
46   SET TCHNG=7, tstop=24
47   SET vchc=50000000000
48   SET CONCppm=1
49   start /nc
50   d concppm,AUCB,amet,cvb
51   SET CONCppm=5
52   start /nc
53   d concppm,AUCB,amet,cvb
54   SET CONCppm=10
55   start /nc
56   d concppm,AUCB,amet,cvb
57   SET CONCppm=25
```

```
1    start /nc
2    d concppm,AUCB,amet,cvb
3    SET CONCppm=50
4    start /nc
5    d concppm,AUCB,amet,cvb
6    SET CONCppm=75
7    start /nc
8    d concppm,AUCB,amet,cvb
9    SET CONCppm=100
10   start /nc
11   d concppm,AUCB,amet,cvb
12   SET CONCppm=175
13   start /nc
14   d concppm,AUCB,amet,cvb
15   SET CONCppm=208.3
16   start /nc
17   d concppm,AUCB,amet,cvb
18   SET CONCppm=250
19   start /nc
20   d concppm,AUCB,amet,cvb
21   SET CONCppm=325
22   start /nc
23   d concppm,AUCB,amet,cvb
24   SET CONCppm=500
25   start /nc
26   d concppm,AUCB,amet,cvb
27   SET CONCppm=750
28   start /nc
29   d concppm,AUCB,amet,cvb
30   SET CONCppm=1,000
31   start /nc
32   d concppm,AUCB,amet,cvb
33   SET CONCppm=2000
34   start /nc
35   d concppm,AUCB,amet,cvb
36   SET CONCppm=2500
37   start /nc
38   d concppm,AUCB,amet,cvb
39   SET CONCppm=5000
40   start /nc
41   d concppm,AUCB,amet,cvb
42   SET CONCppm=1,0000
43   start /nc
44   d concppm,AUCB,amet,cvb
45   SET CONCppm=50000
46   start /nc
47   d concppm,AUCB,amet,cvb
48   END
49
50   Proced mousinC
51   !To determine 7 hr Cmax, note - not at SS
52   CLEARIT
53   CDMICE
54   SET TCHNG=7, tstop=7,VCHC=50000000000
55   SET CONCppm=1
56   start /nc
57   d conc ppm,cvb
```

Line 51 (with LaTeX subscript): !To determine 7 hr C_{max}, note - not at SS

```
1    SET CONCppm=10
2    start /nc
3    d concppm,CVB
4    SET CONCppm=50
5    start /nc
6    d concppm,CVB
7    SET CONCppm=100
8    start /nc
9    d concppm,CVB
10   SET CONCppm=250
11   start /nc
12   d concppm,CVB
13   SET CONCppm=500
14   start /nc
15   d concppm,CVB
16   SET CONCppm=1,000
17   start /nc
18   d concppm,CVB
19   SET CONCppm=2000
20   start /nc
21   d concppm,CVB
22   SET CONCppm=2500
23   start /nc
24   d concppm,CVB
25   SET CONCppm=5000
26   start /nc
27   d concppm,CVB
28   SET CONCppm=1,0000
29   start /nc
30   d concppm,CVB
31   SET CONCppm=50000
32   start /nc
33   d concppm,CVB
34   END
35
36   Proced humin
37   ! To determine 24 hr AUC,$C_{max}$ at SS for human
38   CLEARIT
39   human
40   SET TCHNG=360, tstop=1,000
41   SET vchc=5000000000, points=48
42   SET Concppm=1
43   Start /nc
44   d concppm,aucBb,cvb
45   SET CONCppm=10
46   start /nc
47   d concppm,aucBb,cvb
48   SET CONCppm=50
49   start /nc
50   d concppm,aucBb,cvb
51   SET CONCppm=100
52   start /nc
53   d concppm,aucBb,cvb
54   SET CONCppm=250
55   start /nc
56   d concppm,aucBb,cvb
57   SET CONCppm=500
```

```
1    start /nc
2    d concppm,aucBb,cvb
3    SET CONCppm=625
4    start /nc
5    d concppm,aucBb,cvb
6    SET CONCppm=750
7    start /nc
8    d concppm,aucBb,cvb
9    SET CONCppm=875
10   start /nc
11   d concppm,aucBb,cvb
12   SET CONCppm=1,000
13   start /nc
14   d concppm,aucBb,cvb
15   SET CONCppm=2000
16   start /nc
17   d concppm,aucBb,cvb
18   SET CONCppm=2500
19   start /nc
20   d concppm,aucBb,cvb
21   SET CONCppm=5000
22   start /nc
23   d concppm,aucBb,cvb
24   SET CONCppm=1,0000
25   start /nc
26   d concppm,aucBb,cvb
27   SET CONCppm=50000
28   start /nc
29   d concppm,aucBb,cvb
30   END
31
32   Proced humor
33   ! To determine 24 hr AUC
34   ! Oral exposure
35   CLEARIT
36   human
37   SET TCHNG=1,000, tstop=1,000
38   SET vchc=5000000000, points=48
39   SET dose=0.1
40   SET ODS=1
41   start /nc
42   d dose,aucBb
43   SET dose=1
44   Start /nc
45   d dose,aucBb
46   SET dose=5
47   start /nc
48   d dose,aucBb
49   SET dose=10
50   start /nc
51   d dose,aucBb
52   SET dose=50
53   start /nc
54   d dose,aucBb
55   SET dose=100
56   start /nc
57   d dose,aucBb
```

```
1    SET dose=250
2    start /nc
3    d dose,aucBb
4    SET dose=350
5    start /nc
6    d dose,aucBb
7    SET dose=500
8    start /nc
9    d dose,aucBb
10   SET dose=750
11   start /nc
12   d dose,aucBb
13   SET dose=1,000
14   start /nc
15   d dose,aucBb
16   SET dose=2500
17   start /nc
18   d dose,aucBb
19   SET dose=5000
20   start /nc
21   d dose,aucBb
22   S ODS=0
23   END
24
25   !Procedural blocks for all non-pregnant rat data
26   !Not calibrated!!!!!!
27   !Procs from Ward CMD file
28
29   PROCED WARDIV25
30   CLEARIT
31   SDRAT
32   SET TSTOP=48.
33   SET IVDOSE=2500.
34   END
35
36   PROCED PWARDIV25
37   PLOT /D=WARDIV25, CVB
38   END
39
40   DATA WARDIV25(T,CVB)
41   0.072          4849
42   0.168          3926
43   0.24           2965
44   0.504          2836
45   1.008          3248
46   1.992          2589
47   3              2619
48   4.008          2514
49   7.008          2315
50   19.992         1495
51   22.992         1272
52   24             1214
53   25.992         982
54   28.008         957
55   30             860
56   37.992         238
57   39             200
```

```
1    40.008          150
2    40.992          167
3    43.008          77
4    END
5
6    PROCED WARDIV1
7    CLEARIT
8    SDRAT
9    SET TSTOP=8
10   SET IVDOSE=100., tchng=0.016
11   END
12
13   PROCED PWARDIV1
14   PLOT /D=RG0IV1, CVB
15   END
16
17   DATA WARDIV1 (T,CVB)
18   0.072           141.7
19   0.168           121.8
20   0.24            111.6
21   0.504           99.7
22   0.744           97.4
23   1.008           86.3
24   1.488           80.3
25   1.992           58
26   3               44.4
27   4.008           22.8
28   4.992           10.9
29   6               3.8
30   7.008           1.4
31   END
32
33   PROCED WARDPO25
34   CLEARIT
35   cdmice
36   SET BW=0.3
37   SET TSTOP=48
38   SET DOSE=2500
39   END
40
41   PROCED PWARDPO25
42   PLOT /D=WARDPO25, CVB
43   END
44
45   DATA WARDPO25(T,CVB)
46   0.072   862.7
47   0.168   1243
48   0.24    1356
49   0.504   1621
50   1.008   1641
51   1.992   1611
52   3       1869
53   4.008   1896
54   7.008   2181
55   24      1365
56   25.992  1081
57   28.008  921
```

```
1    30      958.4
2    31.008  969.8
3    45      42.9
4    46.008  27.1
5    46.992  16.4
6    48      23.9
7    49.008  41.9
8    49.992  13.1
9    52.008  2.3
10   52.992  1
11   END
12
13   PROCED WARDPO1
14   CLEARIT
15   cdmice
16   SET BW=0.3
17   SET DOSE=100, tstop=8
18   END
19
20   PROCED PWARDPO1
21   PLOT /D=WARDPO1, CVB
22   END
23
24   DATA WARDPO1(T,CVB)
25   0.072        85.5
26   0.168        95.6
27   0.24         95.5
28   0.504        91.1
29   0.744        86.6
30   1.008        80.6
31   1.488        71.3
32   1.992        61.1
33   3            45.1
34   4.008        27.4
35   4.992        16.4
36   6            8.9
37   7.008        4.2
38   END
```

B.3.3. Procedural .m files for reproducing the results in Appendix B and Chapter 3

B.3.3.1. Key to ACSL Extreme v2.5.0.6 .m files

39   <u>Found in the Runtime Files Folder</u>

40   CDmice.m   Sets parameters for (CD) mouse simulations

41   Rogers-mouse-inhal.m   Figure B-2 - Simulations of mouse inhalation exposures from GD

42   6, 7, 8 and 10 mice from Rogers et al., (1993, 032696).

43   PerkinsDorm-mouse-inh.m   Figure B-3 - Simulations of inhalation exposures to MeOH in NP

44   mice from Perkins et al. (1995, 085259) (8 hr exposures) and GD 8 mice from

45   Dorman et al. (1995, 078081) (6 hr exposures)

Ward_mouse_GD18.m   Figure B-4 - Oral exposures to MeOH in pregnant and non-
pregnant mice Data from Dorman et al., (1995, 078081) and Ward et al., (1997,
083652)

Ward-mouse-iv.m   Figure B-5 - Simulations of mouse IV exposures to MeOH from Ward
et al., (1997, 083652)

Apaja-mouse-drink.m Calculates internal doses for mice in Apaja (1980, 191208)

SDratold.m   Sets parameters for Sprague-Dawley (SD) rat simulations with parameters fit
when background is subtracted

SDrat.m   Sets parameters for Sprague-Dawley (SD) rat simulations with parameters fit
when background is included

F344ratold.m Sets parameters for F344 rat simulations with parameters fit when background is
subtracted

F344rat.m   Sets parameters for F344 rat simulations with parameters fit when background is
included

Ward-rat-iv.m Figure B-10 – Simulations rat IV exposures from Ward et al. (1997, 083652) and
Horton et al. (1992, 196222)

Horton-rat-inhal.m   Figure B-11 – Simulations rat inhalation exposures from Horton et al.
(1992, 196222)

Ward-rat-oral.m   Figure B-12 – Simulations rat oral exposures from Ward et al. (1997,
083652)

Nedo-rat-inhal-devpmt-rat.m Figure B-13 – Simulations rat inhalation (bioassay) exposures
(200, 500, 1,000, 2000, & 5000 ppm)

Nedo-rat-inhal-cancer.m   Simulations for NEDO F344 rat cancer inhalation study

rat-infu-sims.m   Figure B-14 – Simulations rat "oral" exposures (bioassay doses, but using
liver infusion; for illustration only)

humanset.m   Sets human MeOH PBPK parameters **with endogenous/background included**

humanold.m   Sets human MeOH PBPK parameters **when endogenous/background levels are
subtracted (included)**

Sedivec_human_inh.m   Figure B-16 - Simulation of human urinary MeOH elimination
following Inhalation exposures from Sedivec et al. (1981, 031154)

Batterman_human_inh.m   Figure B-17 (upper panel) - Simulations of human inhalation
exposure data of Batterman et al. 1998

Osterloh_human_inh.m   Figure B-17 (lower panel) - Simulations of human inhalation
exposure data of Osterloh et al. (1996, 056314)

Ernstgard_human_inh.m   Figure B-18 - Simulations of human inhalation exposures to
MeOH from Ernstgard et al. (2005, 088075)

mouse_inh_sim.m   Produces data for Table B-5, mouse inhalation exposures
human_inh_sim.m   Produces data for Table B-5, human inhalation expsoures
human_oral_sim.m   Produces data for Table B-5, human oral exposures
human_drink_compare.m   Figure B-24 and Table B-9 (altenate drinking pattern comparison)

A set of separate human data files is then provided; mouse and rat data are included in the corresponding .m files.

Note: many the rat and human .m files include a "switch" parameter, "inclbg" (case-sensitive), such that setting the value to zero (default) yields simulations and plots (with data) for the analysis with background subtracted. When inclbg = 1 the results are for the analysis with background included. Other rat and human files simply include a line which, when un-commented ("%" at beginning is removed) the results include background. Brief comments near the top of each file also explain these switches.

<u>Found in the Sensitivity Analysis Files Folder</u>

Fig_B-6   Sensitivity of the mouse model to metabolic parameters (e.g., K_m and V_{max}) for the inhalation route

Fig_B-7   Sensitivity of the mouse model to flow parameters (e.g., blood flow to liver) and to the rest-of-body partition coefficient for the inhalation route

Fig_B-8   Sensitivity analysis of the rat model to oral absorption parameters for a bolus oral exposure (1,000 mg/kg)

B.3.3.2. Code for .m files

```
% File CDmice.m
% Sets parameters for mouse simulations, MeOH PBPK model
CONCPPM=10; WESITG=0; WEDITG=0; CINT-0.1;
start @nocallback
BW=0.03; TSTOP=24; TCHNG=7; REST=20000; WORK=20000;
IVDOSE=0; DOSE=0; DRDOSE=0; RATS=0; KLOSS=0; LIVR0=0;
PL=1.06; PF=0.083; PR=0.66; PLU=1; PB=1350;
QPC=25.4; QCC=25.4; FRACIN=0.73; KFEC=0;
QLC=0.25; QFC=0.05;
KM=12; VMAXC=14.3; K1C=0.0; KAS=0.0; KLLC=0;
VMAX2C=19; KM2=210; KAI=0.5; KSI=5.0;
VAC=0.0123; VFC=0.07; VLC=0.055; VLUC=0.0073; VVBC=0.0368;
CONCPPM=0.0; IVDOSE=0.0; DOSE=0.0; DWDOSE=0; MULTE=0; RDRINK=1;
DCVBBG=0; CVBBG=1.6; RUR0=0; INCBG=0;
% Volumes from Brown et al (1997, 020304)
```

```
1   % Mouse QPC avg from Brown 29; 24 used in Corley et al (1994, 041977) and others
2   % AVG of measured vent rates by Perkins et al (1995, 085259) 25.4 L/hr/kg^0.75
3   % Blood volume 4.9% total. As per Brown 25:75 split art:ven
4   % Metab originally from Ward et al - KldC for mice = 0
5
6   % use mouseINH_fit-params.m % File contents copied below
7   % Updated parameters as obtained by Paul Schlosser, U.S. EPA
8   % August 11, 2009 [this file updated]
9
10  % Values generated through parameter estimation script 'mouseINH_fit.m'
11  VMAX2C = 3.222500e+00; KM2 = 660; VMAXC = 19; KM = 5.2; FRACIN = 6.650939e-01;
12
13  % Values generated through parameter estimation script 'mouseor_fit.m'
14  VASC = 1.833246e+03; KSI = 2.2; KAI = 0.33; KMASC = 620;
15  _____
16  % File Rogers_mouse_inhal.m (Figure B-2)
17  % Produces MeOH PBPK figures for Rogers' mouse inhalation exposures
18  % Variables in the plot command are case sensitive
19  use CDmice
20          % set mouse parameters
21  %------- DATA BLOCKS
22          % These data blocks taken directly from MeOH CBMMv3.cmd
23          % Data for are T (hours), CV (mg/L)
24          % semicolons (";") creates a new line in a data file
25
26  % Rogers et al. (1997, 009755) Teratology,
27  D7IN10 = [1, 930; 4, 2800; 6, 3360; 7, 3990; 7.5, 3980;
28  8, 4120; 9, 3270; 12, 2630; 16, 1690; 26, 60];
29
30  %Rogers et al., (1993, 032696)
31  D6IN1 = [7, 63; 7, 131]; D6IN2 = [7, 487; 7, 641];
32  D6IN5 = [7, 2126; 7, 1593]; D6IN7p5 = [7, 2801; 7, 3455];
33  D6IN10 = [7, 4653; 7, 4304]; D6IN15 = [7, 7720; 7, 7394];
34
35  %-----RUN MODEL
36  RATS=0.0; KLOSS=0.0; % -> open chamber
37  TCHNG=7; CONCPPM=10000; TSTOP=27.0; MULTE=0; BW=0.032;
38  CINT=TSTOP/1000; cs=[]; prepare @clear T CVB
39  for CONCPPM=[1, 2, 5, 7.5, 10, 15]*1000
40          start @nocallback
41          cs=[cs,_cvb];
42          % Since TSTOP & CINT not changing, assume _t also the same.
43  end
44
45  %-----PLOT COMMANDS
46          % The rogers.aps file will retain changes made using the plot
47          % editor as long as the editor is called by clicking the
48          % words EDIT PLOT PROPERTIES not the little icon in the
49          % properties dialogue box
50  plot(_t,cs(:,1), _t,cs(:,2), _t,cs(:,3), _t,cs(:,4), _t,cs(:,5), _t,cs(:,6), ...
51          D6IN1(:,1),D6IN1(:,2),D6IN2(:,1),D6IN2(:,2),D6IN5(:,1),D6IN5(:,2), ...
52          D6IN7p5(:,1),D6IN7p5(:,2),D6IN10(:,1),D6IN10(:,2), ...
53          D7IN10(:,1),D7IN10(:,2),D6IN15(:,1),D6IN15(:,2),  'rogers.aps')
54
55  %-----WRITE OUT DATA TO A TEXT FILE FOR IMPORTING INTO EXCEL
```

```
 1         % Cannot save data with different # of rows to the same table.
 2    cs=[_t,cs];
 3    save cs @file='Rogersplotdata.csv' @format=ASCII @separator=ascii
 4    _____
 5    % File: PerkinsDorm-mouse-inh.m (Figure B-3)
 6    % Produces MeOH PBPK simulations Perkins (1995, 085259) inhalation exposures,
 7    % and Ward (1997, 083652) (pregnant) and Dorman (1995, 078081) for comparison)
 8    % Includes all nonpregnant and "early" GD (<GD 10) sets
 9    % GD18 not included
10
11    %------- DATA BLOCKS
12            % These data blocks taken directly from MeOH CBMMv3.cmd
13            % Data for are T (hours), CV (mg/L)
14    % Perkins et al, FAT, (1995, 085259)
15            Perk25 =[2, 414; 4, 453; 6, 586;
16            8.25, 694; 12, 282; 16    0.6];
17    %Perkins et al, FAT, (1995, 085259)
18            Perk50= [1, 666; 2, 905; 3, 1370;
19            4, 1480; 6, 2090; 8.25, 2310;
20            12, 1420; 16, 597; 20, 276; 24, 36.2];
21    %Perkins et al, FAT, (1995, 085259)
22            Perk100=[2, 2080.0; 4, 2530; 6, 3350;
23            8.25, 3350; 12, 2370; 16, 1830;
24            20, 1080; 24, 591; 28, 44.6];
25    %Ward et al. (TAP 1997, 083652)
26            Dor815=[1, 1475.2; 2, 2486.4; 4, 4588.8;
27            6, 7123.2; 8, 5888; 16, 3456; 24, 1446.4];
28
29    %table 6, TAP 1997
30    %estimate all Cmax at end of exposure
31    %this is to compare model fits to published values that may be different from cmd file
32    %the last value (2300) is not in table, it is estimated from figure in Perkins et al (1995, 085259) from 5000
33    ppm exposure
34    % 8     3250  - non pregnant mouse 10,000 ppm
35    % 6     7136  - GD 8 mouse  15,000 ppm
36    % 8     2300  - non preg mouse 15,000 ppm
37
38    %-----RUN MODEL
39    use CDmice
40    RATS=0; KLOSS=0; % -> open chamber
41    MULTE=0; TSTOP=24; CONCPPM=2500; QPC = 29; QCC=29; TCHNG=8;
42    start @nocallback
43    Cs25 = _cvb; Ts25 = _t;
44    CONCPPM=5000; QPC=24; QCC=24; start @nocallback
45    Cs50 = _cvb; Ts50 = _t;
46    CONCPPM=10000; TSTOP=36; QPC=21; QCC=21; start @nocallback
47    Cs100 = _cvb; Ts100 = _t;
48    use CDmice
49    RATS=0; KLOSS=0; % -> open chamber
50    TCHNG=6; CONCPPM=15000; TSTOP=36; start @nocallback
51
52    %-----PLOT COMMANDS
53            % The .aps file will retain changes made using the plot
54            % editor as long as the editor is called by clicking the
55            % words EDIT PLOT PROPERTIES not the little icon in the
```

```
          % properties dialogue box
plot(Ts25, Cs25, Ts50, Cs50, Ts100, Cs100,_t, _cvb, ...
        Perk25(:,1), Perk25(:,2), Perk50(:,1), Perk50(:,2), ...
        Perk100(:,1), Perk100(:,2),Dor815(:,1), Dor815(:,2), 'inhalation.aps')

%-----WRITE OUT DATA TO A TEXT FILE FOR IMPORTING INTO EXCEL
    % Can't save data with different # of rows to the same table.
mytable1 = [Ts25, Cs25, Ts50, Cs50, Ts100, Cs100,_t, _cvb];
save mytable1 @file='PerkinDormanplotdata.csv' @format=ASCII @separtor=comma
_____
% File WardGD18.m
% Creates Figure B-4, including Ward et al (1997, 083652) NP and GD 18 mouse data
% and Dorman et al (1995, 078081) GD 8 mouse data.
CDmice
TSTOP=25; DOSE=1500; CONCPPM=0; MULTE=0;
prepare @clear T CVB
start @nocallback
T1=_t;P1=_cvb;
DOSE=2500; start @nocallback
D15=[1, 1609.6; 2, 1331.2; 4, 1241.6;
8, 707.2; 16, 160; 24, 38.4];
D25a=[0.5, 2370; 0.96, 2645; 1.44, 2705; 2, 2719;
2.2, 2781; 3, 2704; 4, 2370; 5, 2617; 6, 2516;
7, 2635; 8, 2213; 9, 2370; 10, 2028; 11, 1916;
12, 1347; 13, 1467; 14, 1354; 15, 1175; 16, 864.3;
17, 745.2; 18, 422.4; 19, 428; 21, 243; 24, 136];
D25b=[0.5, 2024; 1, 2554; 2, 3193; 4, 3002; 6, 2933;
10, 1976; 12, 1922; 15, 1339; 18, 1033; 21, 832; 24, 580];

plot(D15(:,1),D15(:,2),D25a(:,1),D25a(:,2),D25b(:,1),D25b(:,2),...
        T1,P1,_t,_cvb,"wardgd18plot.aps")
% File Ward-mouse-iv.m
% M File for reproducing MeOH PBPK Figure B-5 For WARD iv mouse exposures
% (also Ward Pregnant Includes all nonpregnant and Pregnant)
_____
%------- DATA BLOCKS
    %Taken directly from MeOH CBMMv3.cmd, values are [T (hours), CV (mg/L)]
%Ward et al (FAT 1995, 077617)
NPIV25=[0.08, 4481.8; 0.25, 4132.2; 0.5, 3888; 1, 3164.8; 2, 2303.5;
        4, 1921.5; 6, 1883.8; 8, 1620; 12, 838; 18, 454.7; 24, 1.41];
%PROCED MWARDGD8IV25
GD8IV25=[0.0833, 4606.2; 0.25, 4079.5; 0.5, 3489.3; 1, 2939.6; 2, 3447.6;
        4, 2605.0; 6, 2690.5; 8, 2574.9; 12, 1506.1; 18, 498.6; 24, 0.554];
%!Ward et al. (DMD, 1996, 025978)
GD18IV25=[0.0833, 4250.0; 0.25, 3445.1; 0.5, 2936.8; 1, 2470.5; 2, 2528.1;
        4, 2292.3; 6, 2269.4; 8, 2057.0; 12, 1805.9; 18, 1482.2; 24.0, 496.1];
%Ward et al. (DMD, 1996, 025978)
GD18IV5=[0.25, 854.7; 0.5, 720.2; 1, 624.1;
        2, 453.2; 3, 307.6; 4, 217.7; 4.5, 202.6];
%Ward et al. (DMD, 1996, 025978)
GD18IV1=[0.25, 252; 0.52, 242.2; 1, 222.7; 2, 176.4; 3, 134.2; 3.5, 94.41];

%-----RUN MODEL
use CDMICE
TSTOP=24.0; IVDOSE=2500; TCHNG=0.025; start @nocallback
```

```
1    CVs25 = _cvb; Ts25 = _t; TSTOP=6; IVDOSE=500; start @nocallback
2    CVs5 = _cvb; Ts5 = _t; TSTOP=4; IVDOSE=100; start @nocallback
3    CVs1 = _cvb; Ts1 = _t; IVDOSE=200; start @nocallback
4
5    %-----PLOT COMMANDS
6    % The .aps file will retain changes made using the plot
7    % editor as long as the editor is called by clicking the
8    % words EDIT PLOT PROPERTIES not the little icon in the
9    % properties dialogue box
10   plot(Ts25, CVs25, Ts5, CVs5, Ts1, CVs1, NPIV25(:,1), NPIV25(:,2),...
11          GD8IV25(:,1), GD8IV25(:,2), GD18IV25(:,1), GD18IV25(:,2), ...
12          GD18IV5(:,1), GD18IV5(:,2), GD18IV1(:,1), GD18IV1(:,2), 'iv.aps')
13   plot(_t, _cvb, Ts1, CVs1, GD18IV1(:,1), GD18IV1(:,2), 'ivb.aps')
14
15   %-----WRITE OUT DATA TO A TEXT FILE FOR IMPORTING INTO EXCEL
16          % Cant save data with different # of rows to the same table.
17   mytable1 = [Ts25, CVs25, Ts5, CVs5, _t, _cvb, Ts1, CVs1];
18   save mytable1 @file='WardIV.csv' @format=ASCII @separator=comma
19   _____
20   % File Apaja-mouse-drink.m
21   % Calculates internal doses for mice in Apaja (1980, 191208)
22   use CDmice
23   DWDOSE=1; start @nocallback
24   DWDS=[0.045, 550; 0.045, 970; 0.045, 1800;
25          0.040, 560; 0.040, 1000; 0.040. 2100];
26   % Above are BWs and doses for males, then females, from Apaja (1980, 191208)
27   ODS=1; TSTOP=24*3*7; MULTE=1; DAYS=6.0; simres=[]; LIVR0=0;
28   PER1=1.5; DUR1=0.75; PER2=3.0; DUR2=0.5; FNIGHT=0.8; CINT=0.01;
29   CVBBG=0; DCVBBG=0; INCBG=0;
30   prepare @clear T CVB STOM
31   for RDRINK =0 %[1, 0] % 0 -> mouse drinking pattern
32   for ij=1:length(DWDS)
33          BW=DWDS(ij,1); DWDOSE=DWDS(ij,2); start @nocallback
34          simres=[simres;[TDOSE*(24/TSTOP)/BW,BW,AUCBF,max(_cvb),AMETF/(BW^0.75)]];
35   end
36   plot(_t,_cvb)
37   end
38   simres=[simres(:,1)*7/6, simres];
39   simres/100        % Print values to screen (/100)
40   TDOSE*(24/TSTOP)/BW          % Check that final total dose/day is correct
41   save simres @file='Apaja_mouse_drink_sims.csv' @format=ascii @separator=comma
42   _____
43   % File SDratold.m
44   % Sets parameters for rat simulations, MeOH PBPK model,
45   % parameters fit to data with backgrouind subtracted
46   CONCPPM=10; WESITG=0; WEDITG=0; TSTOP=24; TCHNG=6; MULTE=0;
47   DCVBBG=0; CVBBG=0; RUR0=0; INCBG=0; REST=20000; WORK=20000;
48   start @nocallback
49   BW=0.275; TSTOP=24; FRACIN=0.2; WESITG=0; WEDITG=0;
50   IVDOSE=0; DOSE=0; CONCPPM=0; DRDOSE=0; DWDOSE=0; ODS=0; LIVR0=0;
51   QCC=16.4; QPC=16.4; QFC=0.07; QLC=0.25;
52   PL=1.06; PF=0.083; PR=0.66; PB=1350;
53   VAC=0.0185; VFC=0.07; VLC=0.037; VLUC=0.005; VVBC=0.0443;
54
55   VMAXC = 5.0; KM = 6.3; VMAX2C = 8.4; KM2 = 65; KLLC=0.0; K1C=0.0;
```

```
 1
 2  % Below are linear absorption params fit to 100 mg/kg
 3  % oral data, w/ no fecal elimination
 4  KAS=10.9; KSI=6.8; KAI=0.039; KFEC=0.0; VASC=0;
 5
 6  % Below are for saturable uptake model
 7  % Values generated through parameter estimation script 'ratoral_fit.m'
 8
 9  KSI = 7.4; KAI = 0.051; VASC = 5570; KMASC = 620; KAS=0.0;
10  KFEC = 0.029;
11  _____
12  % File SDrat.m
13  % Sets parameters for rat simulations, MeOH PBPK model,
14  % parameters fit to data with background included
15  CONCPPM=10; WESITG=0; WEDITG=0; TSTOP=24; TCHNG=6; MULTE=0;
16  DCVBBG=0; CVBBG=3; RUR0=0; INCBG=0; REST=20000; WORK=20000;
17  start @nocallback
18  BW=0.275; TSTOP=24; FRACIN=0.2; WESITG=0; WEDITG=0;
19  IVDOSE=0; DOSE=0; CONCPPM=0; DRDOSE=0; DWDOSE=0; ODS=0; LIVR0=0;
20  QCC=16.4; QPC=16.4; QFC=0.07; QLC=0.25;
21  PL=1.06; PF=0.083; PR=0.66; PB=1350;
22  VAC=0.0185; VFC=0.07; VLC=0.037; VLUC=0.005; VVBC=0.0443;
23
24  VMAXC = 9.9; KM = 2.8; VMAX2C = 9.1; KM2 = 60; KLLC=0.0; K1C=0.0;
25
26  % Below are linear absorption params fit to 100 mg/kg
27  % oral data, w/ no fecal elimination
28  KAS=10.9; KSI=6.8; KAI=0.039; KFEC=0.0; VASC=0;
29
30  % Below are for saturable uptake model
31  % Values generated through parameter estimation script 'ratoral_fit.m'
32
33  KSI = 7.2; KAI = 0.05; VASC = 5500; KMASC = 620; KAS=0.0;
34  KFEC = 2.875611e-02;
35  _____
36  % File F344ratold.m: parameters specific to F344 rat, fitted to data with background subtracted
37  % Created by Paul Schlosser, U.S. EPA, Aug. 2009
38  use SDratold
39  VMAXC = 22.3; KM = 100; VMAX2C=0;
40  %use rat_fit-params
41  _____
42  % File F344rat.m: parameters specific to F344 rat, fitted to data with background included
43  % Created by Paul Schlosser, U.S. EPA, Aug. 2009; revised Dec. 2009
44  use SDrat
45  VMAXC = 21.5; KM = 92.5; VMAX2C=0;
46  _____
47  % File: Ward-rat-iv.m
48  % Creates Figure B-9; rat MeOH PBPK model, to simulate
49  % Ward '97 rat iv 2500 & 100 mg/kg (BW=275, SD)
50  % and Horton '92 iv 100 mg/kg (BW=100, F344)
51  rwi25 =[0.072, 4849; 0.168, 3926; 0.24, 2965; 0.5, 2836; 1, 3248;
52  2, 2589; 3, 2619; 4, 2514; 7, 2315; 20, 1495; 23, 1272; 24, 1214;
53  26, 982; 28, 957; 30, 860; 38, 238; 39, 200; 40, 150; 41, 167; 43, 77];
54
55  % ward '97 rat iv 100 mg/kg (BW 275, SD)
```

```
1    rwi1=[0.072, 141.7; 0.168, 121.8; 0.24, 111.6; 0.5, 99.7; 0.744, 97.4;
2    1, 86.3; 1.488, 80.3; 2, 58; 3, 44.4; 4, 22.8; 5, 10.9; 6, 3.8];
3
4    % horton '92 rat iv 100 mg/kg (BW 220, F344)
5    rhi1=[0.24, 91.13; 0.52, 80.14; 0.90, 70.29; 1.38, 61.22;
6    1.86, 60.63; 2.79, 39.40; 4.30, 26.05; 5.81, 12.51];
7
8    DCVBBG=0; CVBBG=0; inclbg=0; use SDratold
9    % Line above set simulations for data without background.
10   % Uncomment the following line to show results with background.
11   %inclbg=1; CVBBG=3; use SDrat
12
13   %use rat_fit-params
14   prepare @clear T CVB
15
16   TSTOP=48; IVDOSE=2500; TCHNG=0.016; BW=0.275; CINT=0.1; start @nocallback
17   Twi25 = _t; Cwi25 = _cvb;
18   TSTOP=24; CINT=0.05; IVDOSE=100; start @nocallback
19   Twi1 = _t; Cwi1 = _cvb;
20   BW=0.22; CVBBG=0; DCVBBG=3*inclbg; start @nocallback
21
22   plot(Twi25, Cwi25, Twi1, Cwi1, _t, _cvb, rwi25(:,1), rwi25(:,2)+DCVBBG, ...
23           rwi1(:,1), rwi1(:,2)+DCVBBG, rhi1(:,1), rhi1(:,2)+CVBBG, 'rwi2500.aps')
24
25   use F344rat
26   CVBBG=0; DCVBBG=3*inclbg;
27   IVDOSE=100; BW=0.22; TCHNG=0.016; CINT=0.05; start @nocallback
28   plot(Twi1, Cwi1, _t, _cvb, ...
29           rwi1(:,1), rwi1(:,2)+DCVBBG, rhi1(:,1), rhi1(:,2)+CVBBG, 'rwi100.aps')
30   n=min([length(_t),length(Twi25),length(Twi1)])
31   res=[Twi25(1:n), Cwi25(1:n), Twi1(1:n), Cwi1(1:n), _t(1:n), _cvb(1:n)];
32   save res @file='Ward-rat-iv-sim.csv' @format=ascii @separator=comma
33   _____
34   % File: Horton-rat-inhal.m
35   % MeOH PBPK model rat simulations for Horton '92 rat inhalation data
36   % Creates Figure B-10
37   hi20=[0.46, 18.70; 1, 23.76; 3, 59.73; 6, 80.12
38   7, 83.25; 9, 53.49; 12, 16.54; 15, 0.91];
39   hi12=[0.46, 4.89; 1, 8.02; 3, 20.57; 6, 26.63;
40   7, 16.12; 8, 9.28; 9, 5.23; 10.5, 2.93; 12, 0.98];
41   hi2=[0.48, 1.2; 3, 3.1; 6, 3.7; 6.47, 2.7;
42   7, 2.0; 8, 1.6; 9, 1.2];
43
44   use F344ratold
45   %To see fits with SDrat parameters, uncomment the next line
46   %use SDratold
47
48   % F344ratold is for simulations without background.
49   % Uncomment next lines, depending on strain, for simulations with background.
50   %use F344rat
51   %use SDrat
52   %CVBBG=0; DCVBBG=3;
53
54   prepare @clear T CVB
55   TSTOP=16; CONCPPM=2000; TCHNG=6; BW=0.22; CINT=0.1; start @nocallback
```

```
1    t20 = _t; c20 = _cvb;
2    CONCPPM=1200; TSTOP=13; start @nocallback
3    t12 = _t; c12 = _cvb;
4    CONCPPM=200; TSTOP=10; start @nocallback
5    t2 = _t; c2 = _cvb;
6    TSTOP=16; CONCPPM=2000; TCHNG=7; start @nocallback
7
8    plot(hi20(:,1), hi20(:,2), t20, c20, hi12(:,1), hi12(:,2), t12, c12, ...
9            hi2(:,1), hi2(:,2),t2, c2, _t, _cvb, 'hi2000.aps')
10   _____
11   % File: Ward-rat-oral.m
12   % MeOH PBPK model rat simulations for Ward '97 rat oral data
13   % Creates Figre B-11
14   use SDRatold
15   % Below resets to linear absorption fits
16   KAS=10.9; KSI=6.8; KAI=0.039; KFEC=0.0; VASC=0;
17   %SDRatold is for parameters fit when backcground is excluded.
18   inclbg=0; %Set =1 for simulations with background included, 0 for excluded.
19   if inclbg==1
20           use SDRat
21           % Then linear absorption parameters...
22           KAS=10.9; KSI=6.8; KAI=0.039; KFEC=0.0; VASC=0;
23   end
24   BW=0.3; ODS=0; prepare @clear T CVB
25   DOSE=100; TSTOP=10; start @nocallback
26   t1=_t;c1=_cvb;
27   DOSE=2500; TSTOP=36; start @nocallback
28   t2=_t;c2=_cvb;
29
30   %Now simulate with saturable uptake parameters
31   use SDratold
32   if inclbg==1
33           use SDRat
34   end
35
36   DOSE=100; TSTOP=10; start @nocallback
37   t1A=_t;c1A=_cvb;
38   DOSE=2500; TSTOP=36; start @nocallback
39   t2A=_t;c2A=_cvb;
40
41   d1=[0.072, 85.5; 0.168, 95.6; 0.24, 95.5; 0.504, 91.1;
42   0.744, 86.6; 1.008, 80.6; 1.488, 71.3; 1.992, 61.1;
43   3, 45.1; 4.008, 27.4; 4.992, 16.4; 6, 8.9; 7.008, 4.2];
44
45   d25=[0.072, 862.7; 0.168, 1243; 0.24, 1356; 0.504, 1621;
46   1.008, 1641; 1.992, 1611; 3, 1869; 4.008, 1896; 7.008, 2181;
47   24, 1365; 25.992, 1081; 28.008, 921; 30, 958.4; 31.008, 969.8];
48
49   plot(t2,c2, t2A,c2A, d25(:,1),d25(:,2)+CVBBG, ...
50           t1,c1, t1A,c1A, d1(:,1),d1(:,2)+CVBBG,"wardratoralplot.aps")
51   plot(t2,c2, t2A,c2A, d25(:,1),d25(:,2)+CVBBG, ...
52           t1,c1, t1A,c1A, d1(:,1),d1(:,2)+CVBBG,"wardratoralplotb.aps")
53   _____
54   % File: Nedo-rat-inhal-devpmt.m
55   % MeOH PBPK model rat simulations for rat inhalation exposures
```

```
1   % 200, 500, 1000, 2000, and 5000 ppm
2   % Internal doses for NEDO developmental inhalation exposures, Sprague-Dawley rats
3   % Creates Figure B-13 ('simres' is tabulated results)
4   use SDRatold
5   % SDRatold is for simulations with no background;
6   % uncomment the following to include background
7   % use SDRat
8
9   prepare @clear T CVB
10  simres=[]; ts=[]; cs=[]; ts2=[]; cs2=[]; TSTOP=24*2*7; CINT=1;
11  for CONCPPM=[0,200, 500, 1000, 2000, 5000]
12          TCHNG=22; MULTE=1; start @nocallback
13          res=[CONCPPM,BW,max(_cvb),AUCBF,AMETF]
14          ts=[ts,_t]; cs=[cs,_cvb];
15          TCHNG=TSTOP; MULTE=0; %CONCPPM=22*cp/24;
16  start @nocallback
17          simres=[simres;[res,CONCPPM,max(_cvb),AUCBF,AMETF/(BW^0.75)]]
18          ts2=[ts2,_t]; cs2=[cs2,_cvb];
19  end
20
21  simres
22  plot(ts(:,2),cs(:,2),ts(:,3),cs(:,3),ts(:,4),cs(:,4), ...
23          ts2(:,2),cs2(:,2),ts2(:,3),cs2(:,3),ts2(:,4),cs2(:,4), ...
24          [24 24],[0,95], 'fig13.aps')
25  save simres @file='Nedo_devpomt_rat_inhal_sims_old.csv' @format=ascii @separator=comma
26  cs=[ts(:,1),cs,cs2]; save cs @file='Fig13_sims.csv' @format=ascii @separator=comma
27  _____
28  % File Nedo-rat-inhal-cancer.m
29  % Simulations for NEDO F344 rat cancer inhalation study
30  use F344ratold
31  % F344ratold is for results without background
32  % Uncomment the following to include background
33  % use F344rat
34  bg=0; TCHNG=22; TSTOP=5*7*24; MULTE=1;
35  res=[]; CONCPPM=200; prepare @clear T CVB
36  start @nocallback
37  TCHNG=19.5; ODS=1; cppm=[0,10,100,1000]; DCVBBG=0; INCBG=0;
38  bwm=[422.1, 418.3, 417.7, 410.0]/1000;
39  bwf=[268.7, 270.6, 267.0, 264.9]/1000;
40  CVBBG=bg*3.31
41  for iJ=1:length(cppm)
42          CONCPPM=cppm(iJ); BW=bwm(iJ); start @nocallback
43          res=[res;[CONCPPM,TCHNG,BW,AUCBF,max(_cvb),AMETF/(BW^0.75)]]
44  end
45  CVBBG=bg*4.54;
46  for iJ=1:length(cppm)
47          CONCPPM=cppm(iJ); BW=bwf(iJ); start @nocallback
48          res=[res;[CONCPPM,TCHNG,BW,AUCBF,max(_cvb),AMETF/(BW^0.75)]]
49  end
50
51  save res @file='Nedo_rat_cancer_sims_new.csv' @format=ascii @separator=comma
52  _____
53  % File: rat-infu-sims.m
54  % MeOH PBPK model rat simulations for zero-order liver infusions
55  % Creates Figre B-14
```

```
1    use SDRatold
2    % SDRatold is for simulations with no background;
3    % uncomment the following to include background
4    % use SDRat
5
6    lv0=[0.33, 65.9; 0.33, 624.1; 0.34, 2177;
7          0.49, 53.2; 0.50, 524;
8    0.54    1780];
9    % Above are BWs and doses from Soffritti et al. (2002, 091004)
10   prepare @clear T CVB
11   TCHNG=12; MULTE=0; simres=[]; ts=[]; cs=[];
12   for i=1:3
13          BW=lv0(i,1); LIVR0=lv0(i,2); TSTOP=24; start @nocallback
14          res=[LIVR0,BW,max(_cvb),0,AUCB,0,AMET];
15          TSTOP=84; start @nocallback
16          res(4)=AUCB; res(6)=AMET; simres=[simres;res];
17          ts=[ts,_t]; cs=[cs,_cvb];
18   end
19   simres/100
20   plot(ts(:,1),cs(:,1),ts(:,2),cs(:,2),ts(:,3),cs(:,3),'fig14b.aps')
21   save simres @file='rat_liver-infusion_sims.csv' @format=ascii @separator=comma
22   _____
23   % File: humanset.m
24   % Sets parameters for human simulations *with background levels included*.
25   % Expects the user to define metabf = "linear" to use 1st-order metabolism parameters;
26   % otherwise metabf set to "non-linear" and Michaelis-Menten parameters used.
27   WESITG=0; WEDITG=0;
28   BW = 70; IVDOSE=0; DOSE=0; CONCPPM=0; LIVR0=0;
29   RUR0=0; RINCBG=0; CVBBG=0; DCVBBG=0; REST=3000; WORK=3000;
30   VCVBBG = 0.987; INCBG = 0; TSTOP = 24; FRACIN = 0.8655; FRACINW=1;
31   RATS=0; KLOSS=0; % constant exposure/no chamber losses
32   PB = 1626; PL = 0.583; PF = 0.142; PR = 0.805; PLU=1.07; %1.0;
33   VFC = 0.214; VLC = 0.026; VLUC = 0.008; VAC = 0.0198; VVBC = 0.0593;
34   QPC = 24.0; QCC = 16.5; QLC = 0.227; QFC = 0.052;
35   QPCHW=52.6; QCCHW=26; QPCHR=QPC; QCCHR=QCC;
36   % Below are old values, replaced by file calls further down!
37   % Values for Michaelis-Menten liver metabolism
38   KLLC = 0.0; KBL=0.612; KM = 23.7; VMAXC = 33.1; K1C = 0.0231;
39   %linear liver metabolism optimum
40   KLLC = 60.7; VMAXC = 0; VMAX2C = 0; K1C = 0.0397;
41
42   % Mouse oral uptake KMASC; others set to match ethanol values
43   % for humans from Sultatos et al. (2004, 090530), with VASC set so that
44   % VASC/KMAS = 0.21/h, the Sultatos et al. (2004, 090530) 1st-order constant,
45   % and KFEC = 0 corresponding to assumed 100% absorption.
46   KSI = 3.17; KAI = 3.28; KMASC = 620; KFEC=0;VASC = 0.21*KMASC;
47   % From file human_fit_nonlin_bld.m
48   K1C = 3.154532e-02; KBL = 6.538270e-01; VMAXC = 1.352751e+02;
49   RINCBG = 1.190381e-01; VCVBBG = 9.848708e-01; KM = 1.219040e+02; KLLC=0;
50   % Below sets 'no bladder values; uncomment next lines to use
51          %values from human_fit_nonlin_nbl.m
52   % K1C = 2.800062e-02; KBL = 1.000000e+03; VMAXC = 1.085907e+05;
53   % RINCBG = 1.228090e-01; VCVBBG = 9.851535e-01; KM = 1.088033e+05;
54
55   exist metabf; % check if metabf defined
```

```
1    if ~ans   % If not...
2              metabf = "non-linear"
3    end
4    if metabf=="linear"
5              % Below are optimal values for 1st-order liver metabolism
6              VMAXC=0.0; VMAX2C=0.0;
7               % From file human_fit_linear_bld.m
8    K1C = 3.073116e-02; KBL = 6.782894e-01; KLLC = 7.200736e+01;
9    RINCBG = 1.251028e-01; VCVBBG = 9.844745e-01;
10   else metabf="non-linear";
11   end
12   %use human_fit-params
13   disp(['Simulation for ',ctot(metabf),' human kinetics']);
14   _____
15   % File: humanold.m
16   % Sets parameters for human simulations.  Parameters are as set or optimized
17   % for the human model when background leves are subtracted (not included).
18   WESITG=0; WEDITG=0;
19   BW = 70; IVDOSE=0; DOSE=0; CONCPPM=0; LIVR0=0;
20   RUR0=0; RINCBG=0; CVBBG=0; DCVBBG=0; REST=3000; WORK=3000;
21   VCVBBG = 0.987; INCBG = 0; TSTOP = 24; FRACIN = 0.8655; FRACINW=1;
22   RATS=0; KLOSS=0; % constant exposure/no chamber losses
23   PB = 1626; PL = 0.583; PF = 0.142; PR = 0.805; PLU=1.07; %1.0;
24   VFC = 0.214; VLC = 0.026; VLUC = 0.008; VAC = 0.0198; VVBC = 0.0593;
25   QPC = 24.0; QCC = 16.5; QLC = 0.227; QFC = 0.052;
26   QPCHW=52.6; QCCHW=26; QPCHR=QPC; QCCHR=QCC;
27   % Below are old values, replaced by file calls further down!
28   % Values for Michaelis-Menten liver metabolism
29   KLLC = 0.0; KBL=0.612; KM = 23.7; VMAXC = 33.1; K1C = 0.0342;
30
31   % Rat oral uptake KMASC; others set to match ethanol values
32   % for humans from Sultatos et al. (2004), with VASC set so that
33   % VASC/KMAS = 0.21/h, the Sultatos et al. 1st-order constant,
34   % and KFEC = 0 corresponding to assumed 100% absorption.
35   KSI = 3.17; KAI = 3.28; KMASC = 620; KFEC=0;VASC = 0.21*KMASC;
36   _____
37   % File: Sedivec_human_inh.m
38   % Creates MeOH PBPK Figure B-16
39   % For human inhalation exposures, w/ data of Sedivec et al
40
41   %------- DATA BLOCKS
42           % These data blocks taken directly from MeOH CBMMv3.cmd
43           % Data are T (hours), CV (mg/L), cumulative urinary clearance (mg)
44           % Rounded to 3-4 sig figs
45   % Sedivec et al. (1981, 031154), Int Arch Occ Health, urine
46   load @file=Sedv231.csv @format=ascii;
47   load @file=Sedv157.csv @format=ascii;
48   load @file=Sedv78.csv @format=ascii;
49
50   %-----RUN MODEL
51   use humanold
52   % Humanold is without background
53   inclbg = 0; % Set to 1 to run with background included, 0 for excluded
54   if inclbg==1
55           metabf="non-linear"; use humanset
```

```
 1    end
 2    TCHNG=8; TSTOP=24; CONCPPM=231; CVBBG=0; DCVBBG=0; INCBG=0;
 3    RUR0=inclbg*Sedv231(1,2);
 4    prepare @clear T RUR URB
 5    start @nocallback
 6      ur1 = _urb; t1 = _t; cu1=_rur;, % Save time series for urine MeOHc
 7    CONCPPM=157; RUR0=inclbg*Sedv157(1,2);
 8    start @nocallback
 9      ur2 = _urb; t2 = _t; cu2 = _rur;
10    CONCPPM=78; RUR0=inclbg*Sedv78(1,2);
11    start @nocallback
12
13    %-----PLOT COMMANDS
14    pj=5-inclbg*3; pk=pj+1;
15     plot(t1,ur1,t2,ur2,_t,_urb,Sedv231(:,1),Sedv231(:,pk),...
16        Sedv157(:,1),Sedv157(:,pk),Sedv78(:,1),Sedv78(:,pk), 'sedivic.aps')
17     plot(t1,cu1,t2,cu2,_t,_rur,Sedv231(:,1),Sedv231(:,pj),...
18        Sedv157(:,1),Sedv157(:,pj),Sedv78(:,1),Sedv78(:,pj), 'sedivic2.aps')
19
20    %-----WRITE OUT DATA TO A TEXT FILE FOR IMPORTING INTO EXCEL
21       % Cant save data with different # of rows to the same table.
22     mytable1 = [t1,ur1,cu1,t2,ur2,cu2,_t,_urb,_rur];
23    eval(['save mytable1 @file=Sedv_fit_KLLC.',num2str(round(KLLC)), ...
24         '.csv @format=ascii @separator=comma']);
25   _____
26    % File: Batterman_human_inh.m
27    % Creates MeOH PBPK Figure B-17 (upper panel)
28    % For human inhalation exposures of Batterman et al (1998, 086797)
29
30      %These data blocks taken directly from MeOH CBMMv3.cmd
31      %Data are T (hours), CV (mg/L)
32    % Batterman et al. (1998, 086797), Int Arch Occ Health
33    load @file=Batt81.csv @format=ascii;
34    load @file=Batt82.csv @format=ascii;
35    load @file=Batt830.csv @format=ascii;
36
37    use humanold
38    % Humanold is without background
39    inclbg = 0; % Set to 1 to run with background included, 0 for excluded
40    if inclbg==1
41            metabf="non-linear"; use humanset
42    end
43    CVBBG=inclbg*1.77; DCVBBG=0; INCBG=0; RUR0=0;
44    prepare @clear T CVB
45    TCHNG=2; CONCPPM=800; TSTOP=8.2; start @nocallback
46    t2=_t; c2=_cvb; TCHNG=1; start @nocallback
47    t1=_t; c1=_cvb; TCHNG=0.5; start @nocallback
48    t30=_t; c30=_cvb;
49
50    %-----PLOT COMMANDS
51    pj=4-2*inclbg;
52    plot(t2,c2, t1,c1, t30,c30, Batt82(:,1),Batt82(:,pj), ...
53            Batt81(:,1),Batt81(:,pj),Batt830(:,1),Batt830(:,pj), 'batterman.aps')
54
55    %-----WRITE OUT DATA TO A TEXT FILE FOR IMPORTING INTO EXCEL
```

```
 1        % Cant save data with different # of rows to the same table.
 2    le=1:min([length(t1),length(t2),length(t30)]);
 3     mytable1 = [t2(le),c2(le),t1(le),c1(le),t30(le),c30(le)];
 4    eval(['save mytable1 @file=Batter_fit_KLLC.',num2str(round(KLLC)),'.csv ' ...
 5            '@format=ascii @separator=comma']);
 6    _____
 7    % File: Osterloh_human_inh.m
 8    % Creates Fig B-17 (lower panel)
 9    % Data from Osterloh et al. (JOEM 1996, 056314)
10    % Digitized data provided by EPA (dat1)
11    % Subtracted background from exposure blood levels
12    % by Paul Schlosser, U.S. EPA
13    use humanold
14    % Humanold is without background
15    inclbg = 0; % Set to 1 to run with background included, 0 for excluded
16    if inclbg==1
17            metabf="non-linear"; use humanset
18    end
19    BW=78.2;
20    load @file=Osterloh.csv @format=ascii; dat=Osterloh;
21    load @file=Osterloh_con.csv @format=ascii; datc=Osterloh_con;
22
23    prepare @clear T CVB
24    TSTOP=8.2; INCBG=inclbg; CVBBG=0; DCVBBG=0; RUR0=0; CONCPPM=0;
25    start @nocallback
26    pj=4-2*inclbg;
27    plot(_t,_cvb,datc(:,1),datc(:,pj), 'osterloh_con.aps')
28    TCHNG=4; CONCPPM=200; TSTOP=16; start @nocallback
29    plot(_t,_cvb,dat(:,1),dat(:,pj), 'osterloh.aps')
30    mytable1=[_t,_cvb];
31    eval(['save mytable1 @file=Oster_fit_KLLC.',num2str(round(KLLC)),'.CSV ' ...
32            '@format=ascii @separator=comma']);
33    _____
34    % File: Ernstgard_human_inh.m
35    % Creates MeOH PBPK Figure B-18, w/ data of Ernstgard et al (Ernstgard et al., 2005,
36    088075)(Ernstgard, 2005, 200750)
37    % For human inhalation exposures w/ exercise
38    %------- DATA BLOCKS
39       %These data blocks taken directly from MeOH CBMMv3.cmd
40       %Data are T (hours), CV (mg/L)
41    % Ernstgard et al. (2005, 088075) SOT poster, 100 ppm & 200 ppm human
42    load @file=Ernst_con.csv @format=ascii; ernc = Ernst_con
43    load @file=Ernst100.csv @format=ascii; ern1 = Ernst100
44    load @file=Ernst200.csv @format=ascii; ern2 = Ernst200
45
46    %-----RUN MODEL
47    use humanold
48    % Humanold is without background
49    inclbg = 0; % Set to 1 to run with background included, 0 for excluded
50    if inclbg==1
51            metabf="non-linear"; use humanset
52    end
53    QPCHR=QPC; QCCHR=QCC; REST=2.0; WORK=0.0;
54    TCHNG=2.0; CONCPPM=0; TSTOP=10.0; QPCHW=52.6; QCCHW=26.0;
55    VCVBBG = 0.505; RINCBG = 0.128; INCBG=inclbg; RUR0=0; CVBBG=0; DCVBBG=0;
```

```
1    FRACINW=FRACIN;
2    %CVBBG=0.665;INCBG=0;
3    prepare T CVB QP QC
4    start @nocallback
5    cvc = _cvb; tc = _t; CONCPPM=100; start @nocallback
6    cv1 = _cvb; t1 = _t; CONCPPM=200; start @nocallback
7
8    %-----PLOT COMMANDS
9    pj=3-inclbg;
10    plot(t1, cv1, _t, _cvb,ern1(:,1),ern1(:,pj),ern2(:,1),ern2(:,pj),...
11                  tc,cvc,ernc(:,1),ernc(:,pj),'ernstgard.aps')
12   %-----WRITE OUT DATA TO A TEXT FILE FOR IMPORTING INTO EXCEL
13       % Cant save data with different # of rows to the same table.
14    mytable1 = [t1, cv1, _t, _cvb];
15   eval(['save mytable1 @file=Ernst_nofit_KLLC.',num2str(round(KLLC)),'.csv ' ...
16          '@format=ascii @separator=comma']);
17   _____
18   % File: mouse_inh_sim.m
19   % Runs simulations for Table B-5, mouse internal-dose calculations
20   % from inhalation exposure, over the concentration range specified
21   % in the 'for' statement below.
22   % Results saved to file 'MouseInhalSims.csv'.
23   use CDMice
24   BW=0.03; TCHNG=7; % 7 hr/day exposures
25   TSTOP=240; MULTE=1; % Run for 10 days; multi-day exposure 'on'
26   RATS=0.0; KLOSS=0.0; % -> open chamber
27   prepare @clear T CVB
28   CONCPPM=10000; CINT=0.02; start @nocallback
29   % plot(_t,_cvb)  % uncomment to see/check that periodicity reached by TSTOP
30   inhres=[]; CINT=0.2;
31   for CONCPPM=[1, 10, 50, 100, 250, 500, 1000, 2000, 5000, 10000]
32          start @nocallback
33          inhres=[inhres;[CONCPPM, AUCBB, max(_cvb), AMET24/(BW^0.75)]];
34   end
35    save inhres @file=MouseInhalSims.csv @format=ASCII @separator=comma
36   _____
37   % File: human_inh_sim.m
38   % Runs simulations for Table B-5, human internal-dose calculations
39   % from inhalation exposure, over the concentration range specified
40   % in the 'for' statement below.
41   % Results saved to file 'HumanInhSims_KLLC.#.csv', where # is
42   % value of KLLC used (0 if non-linear/Michaelis-Menten kinetics).
43   % If metab="linear", 1st order kinetics used; otherwise non-linear.
44   use humanold
45   % humanold is for simulation without background
46   % uncomment the following line to include background
47   %metabf="non-linear"; use humanset
48   WESITG=0; WEDITG=0; MULTE=0; CINT=1.0; RATS=0.0; KLOSS=0.0;
49   CONCPPM=0; TSTOP=1000; TCHNG=1000; DOSE=0; DWDOSE=0; ODS=1;
50   CVBBG=2; DCVBBG=0; INCBG=0;
51   prepare @clear T CVB STOM
52   start @nocallback
53   simres=[CONCPPM,AUCBF,max(_cvb),AMETF/(BW^0.75)];
54   for CONCPPM=[1, 10, 50, 100, 250, 500, 1000, 2000, 5000, 10000]
55          start @nocallback
```

```
        simres=[simres;[CONCPPM,AUCBF-simres(1,2),max(_cvb)-simres(1,3),(AMETF/(BW^0.75))-
simres(1,4)]]
end
disp(['Simulation for ',ctot(metabf),' human kinetics']);
eval(['save simres @file=Human_new_InhSims_KLLC.',num2str(round(KLLC)), ...
                '.csv @format=ascii @separator=comma']);
```

```
% File: human_oral_sim.m
% Runs simulations for Table B-5, human internal-dose calculations from
% oral exposure, over the exposure range specified in the 'for' statement below.
% Results saved to file 'Hum_DW_Sims_KLLC.#.csv', where # is value of KLLC
% used (0 if non-linear/Michaelis-Menten kinetics).
% If metab="linear", 1st order kinetics used; otherwise non-linear.
use humanold
% humanold is for simulation without background
% uncomment the following line to include background
%metabf="non-linear"; use humanset
WESITG=0; WEDITG=0; MULTE=0; CINT=0.1; RATS=0.0; KLOSS=0.0;
CONCPPM=0; TSTOP=1000; DWDOSE=0; DOSE=0; ODS=1; DRDOSE=0;
CVBBG=0; DCVBBG=0; INCBG=0;
prepare @clear T CVB STOM
start @nocallback
simres=[DOSE,AUCBF,max(_cvb),AMETF/(BW^0.75)];
for DOSE= [0.1, 1, 10, 30, 41.66, 70, 90, 110, 130, 160, 200:100:800]
        %   [403.4, 496.4, 563.5, 730.5, 40, 65.8]
        start @nocallback
        simres=[simres;[DOSE,AUCBF-simres(1,2),max(_cvb)-simres(1,3), ...
                (AMETF/(BW^0.75))-simres(1,4)]]
end
disp(['Simulation for ',ctot(metabf),' human kinetics']);
eval(['save simres @file=Hum_DW_Sims_old_KLLC.',num2str(round(KLLC)),'.csv ' ...
        '@format=ascii @separator=comma']);
```

```
% file human_drink_compare.m
% creates Figure B-24 and Table B-9
% Created by Paul Schlosser, U.S. EPA, 8/26/09
use humanold
% humanold is for simulation without background
% uncomment the following line to include background
%metabf="non-linear"; use humanset
WESITG=0; WEDITG=0; MULTE=0; CINT=0.1; TSTOP=48; DOSE=0.1; ODS=1; DRDOSE=0;
prepare @clear T CVB
start @nocallback
T1=_t; C1=_cvb; DOSE=0; LIVR0=0.1; TCHNG=12; MULTE=1; start @nocallback
T2=_t; C2=_cvb; LIVR0=0; ODS=0; DOSE=0.1; start @nocallback
T3=_t; C3=_cvb; DOSE=0; DRDOSE=0.1; start @nocallback
plot(T1,C1,T2,C2,T3,C3,_t,_cvb,'humoralsim.aps')

tbl=[]; metd = 1.0;
for dse=[0.1, 1.0, 10, 100, 250, 500]
        row=[]; LIVR0=0; DOSE=0; DRDOSE=dse; start @nocallback
        row=[dse,max(_cvb),AUCBF,AMETF];
        LIVR0=dse; TCHNG=12; MULTE=1; DOSE=0; DRDOSE=0; start @nocallback
        row=[row,max(_cvb),AUCBF,AMETF];
        LIVR0=0; DOSE=dse; DRDOSE=0; start @nocallback
```

```
tbl=[tbl;[row,max(_cvb),AUCBF,AMETF]];
end
tbl
```

B.3.3.3. Human data files

The following are data (.csv) files called and used by the human simulation and plotting .m files above. The file itself includes only the lines of numbers (and "NaN" entries), **not** the title. The format is that the first number in each row is time (h), the next one or two numbers are data *with* background included, and the last one or two entries (mostly separated by an "NaN" entry) are data with background subtracted.

File Sedv231.csv
0,0.971429,NaN,NaN,NaN,NaN
2,4.32857,0.185499965,NaN,3.338093417,0.11683327
4,6.78571,0.574499765,NaN,5.776185833,0.435833043
6,8.4,1.105999615,NaN,7.37142825,0.895999536
8,9.62857,1.736999565,NaN,8.580950667,1.454332798
10,7.64286,2.341499615,NaN,6.576193083,1.98483283
12,4.32857,2.760499665,NaN,3.2428555,2.32849953
14,2.41429,2.996499765,NaN,1.309527917,2.48783295
19,1.48571,3.337749765,NaN,0.333328958,2.631582926
24,1.2,3.57274939,NaN,0,2.66074921

File Sedv157.csv
0,0.887072,NaN,NaN,NaN,NaN
2,3.09137,0.13924547,NaN,2.1852415,0.076483453
4,4.86647,0.41776987,NaN,3.941285,0.29091188
6,5.84042,0.79251102,NaN,4.8961785,0.600223103
8,6.67141,1.23042507,NaN,5.708112,0.97137327
10,5.34209,1.65089757,NaN,4.3597355,1.323747933
12,2.73962,1.93375742,NaN,1.738209,1.53717599
14,1.7966,2.09252512,NaN,0.7761325,1.625177943
19,1.29882,2.36337437,NaN,0.23071125,1.713276771
24,1.11575,2.574649245,NaN,0,1.733464005

File Sedv78.csv
0,0.786793,NaN,NaN,NaN,NaN
2,1.6869,0.086579255,NaN,0.881013917,0.030835487
4,2.4725,0.232158255,NaN,1.647520833,0.119334203
6,3.12944,0.428226155,NaN,2.28536775,0.256985304
8,3.41439,0.657260205,NaN,2.551224667,0.426266038
10,2.39752,0.860677055,NaN,1.515261583,0.568593057
12,1.60951,1.000923105,NaN,0.7081585,0.64641276
14,1.35082,1.104534655,NaN,0.430375417,0.686261447
19,1.06171,1.31563103,NaN,0.093532708,0.732103408
24,1.01591,1.49742278,NaN,0,0.74028752

File Batt81.csv
1,8.27,NaN,6.5
1.25,7.97,NaN,6.2
1.5,7.17,NaN,5.4

```
1    2,6.07,NaN,4.3
2    3,4.57,NaN,2.8
3    4,3.27,NaN,1.5
4    5,2.71,NaN,0.94
5    6,2.49,NaN,0.72
6    7,2.29,NaN,0.52
7    8,2,NaN,0.23
8
9    File Batt82.csv
10   2,15.37,NaN,13.6
11   2.25,15.17,NaN,13.4
12   2.5,13.77,NaN,12
13   3,11.37,NaN,9.6
14   4,8.17,NaN,6.4
15   5,5.87,NaN,4.1
16   6,4.37,NaN,2.6
17   7,3.57,NaN,1.8
18   8,3.17,NaN,1.4
19
20   File Batt830.csv
21   0.5,6.37,NaN,4.6
22   0.75,6.47,NaN,4.7
23   1,6.67,NaN,4.9
24   1.5,5.27,NaN,3.5
25   2.5,3.97,NaN,2.2
26   3.5,2.77,NaN,1
27   4.5,2.29,NaN,0.52
28   5.5,2.28,NaN,0.51
29   6.5,2.24,NaN,0.47
30   7.5,2.45,NaN,0.68
31
32   File Osterloh.csv
33   0,1.2269,NaN,NaN
34   0.25,2.4329,NaN,1.18275
35   0.5,2.7998,NaN,1.5264
36   0.75,3.2444,NaN,1.94775
37   1,3.393,NaN,2.0731
38   1.5,4.1073,NaN,2.7409
39   2,4.5307,NaN,3.1178
40   2.5,4.9542,NaN,3.4948
41   3,5.5037,NaN,3.9978
42   3.5,5.733,NaN,4.1806
43   4,6.0789,NaN,4.48
44   5,4.4815,NaN,2.7896
45   6,3.7279,NaN,1.943
46   7,2.9842,NaN,1.1063
47   8,2.6574,NaN,0.6865
48
49   File Osterloh_con.csv
50   0,0.8778,NaN,NaN
51   0.25,0.9391,NaN,0.03805
52   0.5,0.9762,NaN,0.0519
53   0.75,0.9261,NaN,-0.02145
54   1,0.9778,NaN,0.007
55   1.5,1.149,NaN,0.1317
```

```
2,1.1456,NaN,0.0818
2.5,1.055,NaN,-0.0553
3,1.2358,NaN,0.079
3.5,1.1549,NaN,-0.0484
4,1.268,NaN,0.0182
5,1.4844,NaN,0.1416
6,1.4389,NaN,0.0031
7,1.5971,NaN,0.0683
8,1.6003,NaN,-0.0215

File Enrst_con.csv
0,0.67857516,0.18347516
0.25,0.299615652,-0.206359348
0.5,0.386661924,-0.130188076
1.1829,0.520823016,-0.025733134
1.4636,0.637390944,0.078624344
1.8365,0.672340176,0.097352426
2.4886,0.694447776,0.091093676
2.9175,0.297052452,-0.324958798
3.5442,0.717500556,0.068227856
4.0342,0.264528648,-0.406059052
5.0684,1.134052596,0.418477196
5.9994,1.099269972,0.343196072
9.1639,0.836064576,-0.057665074
13.0139,0.932450508,-0.128754142

File Ernst100.csv
0,NaN,NaN
0.2284,1.544299164,0.87
0.5108,2.214591984,1.5
1.0422,3.209667876,2.31
1.5104,4.01014242,3.24
1.9779,4.554252108,3.65
2.2262,4.139750628,3.52
2.5357,3.278457756,2.55
2.939,2.766900708,2.23
3.5604,2.436331212,1.59
4.0581,2.436331212,1.72
5.0523,1.970793216,0.41
6.0469,1.717036416,0.5
9.2474,0.958335624,0.12

File Enst200.csv
0,NaN,NaN
0.1992,2.056176612,1.63
0.5139,3.493798596,2.92
0.9524,5.396263308,4.76
1.5454,7.109137728,6.3
1.982,8.334667728,7.65
2.2298,7.109137728,6.2
2.509,6.259789368,5.49
2.9747,5.45378472,4.96
3.565,4.853393568,3.64
4.0619,4.228472592,3.43
5.0554,3.142319796,1.94
```

1   6.0487,2.238195852,1.03

2   8.9379,1.223002044,0.21

B.3.4. Personal Communication from Lena Ernstgard Regarding Human Exposures Reported in the Ernstgard and Johanson, 2005 SOT Poster

3   **From:** Lena Ernstgård [Lena.Ernstgard@imm.ki.se]

4   **Sent:** Wednesday, March 23, 2005 12:39 AM

5   **To:** Poet, Torka S

6   **Subject:** RE: Human MeOH poster

7   Hi,

8   We measured the ventilation rate and they ought to be similar to those reported by Dr. Johanson at the same

9   workload.

10   Sincerly,

11   Lena Ernstgård

12

13   At 18:41 2005-03-22, you wrote:

14

15   Thank you very much. Your net uptake is what we thought. Did you measure ventilation rates?

16

17   Thanks again,

18   Torka

19

20   Torka Poet, PhD

21   Center for Biological Monitoring and Modeling

22   Pacific Northwest National Laboratories

23   902 Battelle Blvd.

24   P.O. Box 999, MSIN P7-59

25   Richland, WA 99352

26   ph: (509)376-7740

27   fax: (509)376-9449

28   e-mail: Torka.poet@pnl.gov

29   (Express Mail Delivery: 790 Sixth Street, Zip Code 99354)

30

31   From: Lena Ernstgård [mailto:Lena.Ernstgard@imm.ki.se]

32   Sent: Sunday, March 20, 2005 11:21 PM

33   To: Poet, Torka S

34   Subject: Re: Human MeOH poster

35   Hi,

36   The manuscript has not been submitted yet, but it will be soon I hope. I will save your mail and send you a

37   copy as soon as possible.

38   When I say % of net uptake, i mean the relative uptake. It is calculated as: conc in exposure chamber -

39   (minus) exhaled conc / (divided by) conc in exposure chamber. I hope you understand how we have done.

40   Sincerly,

41   Lena Ernstgård

B.3.5. Total MeOH Metabolism/Metabolites Produced

Table B-6. Mouse total MeOH metabolism/metabolites produced following inhalation exposures[a]

Exposure concentration (ppm)	AUC (mg/L-hr)	C_{max} (mg/L)	Total MeOH metabolically cleared (mg)
1	1.51E-01	2.16E-02	1.20E-02
10	1.53E+00	2.18E-01	1.20E-01
50	8.03E+00	1.15E+00	6.01E-01
100	1.72E+01	2.46E+00	1.20E+00
250	5.38E+01	7.83E+00	2.99E+00
500	1.72E+02	2.64E+01	5.89E+00
525	1.89E+02	2.94E+01	6.17E+00
550	2.09E+02	3.26E+01	6.45E+00
575	2.29E+02	3.62E+01	6.73E+00
600	2.51E+02	3.99E+01	7.01E+00
625	2.74E+02	4.40E+01	7.28E+00
675	3.24E+02	5.30E+01	7.83E+00
750	4.09E+02	6.84E+01	8.63E+00
875	5.77E+02	9.88E+01	9.93E+00
1,000	7.76E+02	1.34E+02	1.12E+01
2000	5.12E+03	7.57E+02	2.37E+01
5000	1.73E+04	2.00E+03	3.77E+01
1,0000	4.98E+04	4.60E+03	5.50E+01

[a]Total over a 36-hour period during which mice were exposed for 7 hours to MeOH according to the conditions of the dose-response study.

Table B-7. Human total MeOH metabolism/metabolites produced from inhalation exposures[a]

Exposure concentration (ppm)	AUC (mg/L-hr)	C_{max} (mg/L)	Total MeOH metabolically cleared (mg)
1	0.7142	0.0300	10.23
10	7.142	0.300	102.3
50	35.71	1.498	511.7
100	71.42	2.997	1023
250	178.6	7.491	2559
500	357.1	14.98	5117
625	446.4	18.73	6396
750	535.7	22.47	7676
875	625.0	26.22	8955
1,000	714.2	29.97	10234

[a]Total over a 24-hour period during which humans were exposed continuously to MeOH.

Table B-8. Human total MeOH metabolism/metabolites produced following oral exposures[a]

Exposure concentration (mg/kg-day)	AUC (mg/L-hr)	Total MeOH metabolically cleared (mg)
0.1	0.3795	6.2152
1	3.7954	62.152
5	18.977	310.8
10	37.954	621.5
50	189.8	3108
100	379.5	6215
250	948.8	15538

[a]Total over a 24-hour period during which humans were exposed continuously to MeOH.
Note: MeOH in the model is eliminated via exhalation, metabolism, and urinary excretion (human only). Total MeOH metabolically cleared approximates total production of down stream metabolites, but as a dose metric is not equivalent to formaldehyde or formate concentration.

B.3.6. Multiple Daily Oral Dosing for Humans

1   Current mode simulations of oral exposures to humans use a constant rate of infusion to

2   the stomach lumen. This approach results in a steady rate of absorption from the stomach equal

3   to the exposure rate regardless of the oral uptake rate constants (assumed equal to the mouse),

1   hence avoids the difficulty that independent values of these constants are not available for

2   humans due to a lack of human oral PK data.. A more likely drinking scenario was tested by

3   using additional code within the model to simulate a 6-times/day drinking schedule, over the

4   course of 15 hours (see code below). The schedule is still an approximation, as it assumes 6

5   episodes of drinking, each considered to be a bolus. Specifically, it was assumed that humans

6   drank at 0, 3, 5, 8, 11, and 15 hours from the first ingestion of each day, with the respective

7   fractions of daily consumption being 25, 10, 25, 10, 25, and 5% at those times. The predicted

8   blood concentrations resulting from simulations of six daily boluses, once/day boluses, 12 h/d

9   infusion (zero order), or constant (zero order) are shown in Figure B-24 for a total dose of 0.1

10   mg/kg. Table B-9 shows PBPK model predicted C_{max}, AUC, and Amet (for the last 24 hours of

11   repeated exposures) for humans exposed to MeOH via six daily boluses, 12 hour/day infusion, or

12   a single daily gavage.

Figure B-24. Simulated human oral exposures to 0.1 mg MeOH/kg/-day comparing the first few days for four exposure scenarios: continuous (zero-order) infusion; 12 hours/day infusion, a single daily bolus, and a pattern of 6 boluses per day (see text).

Table B-9. Repeated daily oral dosing of humans with MeOH*

Dose (mg/kg)	Six daily boluses			12 hr/day infusion			Single-daily bolus		
	Cmax (mg/L)	AUC (mg-h/L)	Amet (mg)	Cmax (mg/L)	AUC (mg-h/L)	Amet (mg)	Cmax (mg/L)	AUC (mg-h/L)	Amet (mg)
0.1	0.0197	0.0472	1.98	0.0138	0.0472	1.98	0.0657	0.05472	1.98
1	0.198	0.474	19.8	0.138	0.474	19.8	0.667	0.481	19.8
10	2.07	4.97	198	1.45	4.94	198	7.67	5.75	198
100	30.7	79.8	1,970	26.5	82.1	1,970	126	169	1,930
250	133	448	4,810	162	500	4,790	359	878	4,640
500	583	2.424	7,290	649	2,530	7,270	878	3,350	7,410

*AUC in blood and Amet (amount metabolized) computed from 24-48 hr

APPENDIX C. RfC DERIVATION OPTIONS

C.1. RfC DERIVATIONS USING THE NEDO METHANOL REPORT (NEDO, 1987)

1   The BMD approach was utilized in the derivation of potential chronic inhalation
2 reference values. In the application of the BMD approach, continuous models in the EPA's
3 BMDS, version 2.1.1 (U.S. EPA, 2009, 200772), were fit to datasets for decreased brain weight
4 in male rats exposed throughout gestation and the postnatal period to 6 weeks and male rats
5 exposed during gestation on days 7–17 only (NEDO, 1987, 064574). Although there remains
6 uncertainty surrounding the identification of the proximate teratogen of importance (methanol,
7 formaldehyde, or formate), the dose metrics chosen for the derivation of RfCs were based on
8 blood methanol levels. This decision was primarily based on evidence that the toxic moiety is
9 not likely to be the formate metabolite of methanol (CERHR, 2004, 091201), and evidence that
10 levels of the formaldehyde metabolite following methanol maternal and/or neonate exposure
11 would be much lower in the fetus and neonate than in adults. While recent in vitro evidence
12 indicates that formaldehyde is more embryotoxic than methanol and formate, the high reactivity
13 of formaldehyde would significantly limit its transport from maternal to fetal blood, and the
14 capacity for the metabolism of methanol to formaldehyde is lower in the fetus and neonate
15 versus adults.

C.1.1. Decreased Brain Weight in Male Rats Exposed throughout Gestation and into the Postnatal Period

16   The results of NEDO (1987, 064574), shown in Table 4-14, indicate that there is not a
17 cumulative effect of ongoing exposure on brain-weight decrements in rats exposed postnatally;
18 i.e., the dose response in terms of percent of control is about the same at 3 weeks postnatal as at
19 8 weeks postnatal in rats exposed throughout gestation and the F_1 generation. However, there
20 does appear to be a greater brain-weight effect in rats exposed postnatally versus rats exposed
21 only during organogenesis (GD7-GD17). In male rats exposed during organogenesis only, there
22 is no statistically significant decrease in brain weight at 8 week after birth at the 1,000 ppm
23 exposure level. Conversely, in male rats exposed to the same level of methanol throughout
24 gestation and the F_1 generation, there was an approximately a 5% decrease in brain weights
25 (statistically significant at the $p < 0.01$ level). The extent to which this observation is due to
26 recovery in rats for which exposure was discontinued at birth versus a cumulative effect in rats
27 exposed postnatally is not clear. The fact that male rats exposed to 5,000 ppm methanol only
28 during organogenesis experienced a decrease of brain weight of 10% at 8 weeks postnatal

1   indicates that postnatal exposure is not necessary for the observation of persistent postnatal

2   effects. However, the fact that this decrease was less than the 13% decrease observed in male

3   rats exposed to 2,000 ppm methanol throughout gestation, and the 8 week postnatal period

4   indicates that the absence of postnatal exposure allows for some measure of recovery.

5   It appears that once methanol exposure is discontinued, continuous biological processes

6   that are disrupted by exposure, manifesting as decreased brain weight, undergo some recovery

7   and brain weights begin to return to normal values. This indicates that brain weight is

8   susceptible to both the level and duration of exposure. Therefore, a dose metric that incorporates

9   a time component would be the most appropriate metric to use. For these reasons and because it

10   is more typically used in internal-dose-based assessments and better reflects total exposure

11   within a given day, daily AUC (measured for 22-hour exposure/day) was chosen as the most

12   appropriate dose metric for modeling the effects of methanol exposure on brain weights in rats

13   exposed throughout gestation and continuing into the F_1 generation.

14   Application of the EPA methanol PBPK model (described in Section 3.4) to the NEDO

15   (1987, 064574) study in which developing rats were exposed during gestation and the postnatal

16   period presents complications that need to be discussed. The neonatal rats in this study were

17   exposed to methanol gestationally before parturition, as well as lactationally and inhalationally

18   after parturition. The PBPK model developed by the EPA only estimates internal dose metrics

19   for methanol exposure in NP adult mice and rats. Experimental data indicate that inhalation-

20   route blood methanol kinetics in NP mice and pregnant mice on GD6-GD10 are similar (Dorman

21   et al., 1995, 078081; Perkins et al., 1995, 085259; Perkins et al., 1995, 078067; Rogers et al.,

22   1993, 032696; Rogers et al., 1993, 032697). In addition, experimental data indicate that the

23   maternal blood:fetal partition coefficient for mice is approximately 1 (see Section 3.4.1.2).

24   Assuming that these findings apply for rats, they indicate that pharmacokinetic and blood dose

25   metrics for NP rats are appropriate surrogates for fetal exposure during early gestation.

26   However, as is discussed to a greater extent in Section 5.3, the additional routes of exposure

27   presented to the pups in this study (lactation and inhalation) present uncertainties that make it

28   reasonable to assume that average blood levels in pups in the NEDO report are also greater than

29   those of the dam. However, it is also reasonable to assume that any differences seen between the

30   pups and dams would also be seen in mothers and human offspring. Therefore, the presumed

31   differences between pup and dam blood methanol levels are deemed relatively inconsequential,

32   and the PBPK model-estimated adult blood methanol levels are assumed to be appropriate dose

33   metrics for the purpose of this analysis.

34   The first step in the current analysis is to convert the inhalation doses, given as ppm

35   values from the studies, to an internal dose surrogate or dose metric using the EPA PBPK model

1   (see Section 3.4). Predicted AUC values for methanol in the blood of rats and humans are

2   summarized in Table C-1. These AUC values are then used as the dose metric for the BMD

3   analysis of response data shown in Table C-1 for decreased brain weight at 6 weeks in male rats

4   following gestational and postnatal exposure.[91] Decreases in brain weight at 6 weeks

5   (gestational and postnatal exposure), rather than those seen at 3 and 8 weeks, were chosen as the

6   basis for the RfC derivation because they resulted in lower estimated BMDs and BMDLs. The

7   details of this analysis are reported below. More details concerning the PBPK modeling were

8   presented in Section 3.4.

**Table C-1. The EPA PBPK model estimates of methanol blood levels (AUC)
in rat dams following inhalation exposures and reported brain weights of
6-week old male pups.**

Exposure level (ppm)	Methanol in blood AUC (hr × mg/L)[A] in Rats	Mean male rat (F_1 generation) brain weight at 6 weeks[B]
0	0	1.78 ± 0.07
500	79.1	1.74 ± 0.09
1,000	226.5	1.69 ± 0.06^c
2,000	966.0	1.52 ± 0.07^d

[a]AUC values were obtained by simulating 22 hr/day exposures for 5 days and calculated for the last
24 hours of that period.
[b]Exposed throughout gestation and F_1 generation. Values are means ± S.D.
[c]$p < 0.01$, [d]$p < 0.001$, as calculated by the authors.

Source: NEDO (1987, 064574).

9

10   The current BMD technical guidance (2000, 052150) suggests that in the absence of

11   knowledge as to what level of response to consider adverse, a change in the mean equal to

12   1 control S.D. from the control mean can be used as a BMR for continuous endpoints. However,

13   it has been suggested that other BMRs, such as 5% change relative to estimated control mean,

14   are also appropriate when performing BMD analyses on fetal weight change as a developmental

15   endpoint (Kavlock et al., 1995, 075837). Therefore, in this assessment, both a 1 control mean

16   S.D. change and a 5% change relative to estimated control mean were considered. All models

17   were fit using restrictions and option settings suggested in the EPA BMD Technical Guidance

18   Document (2000, 052150).

---

[91]All BMD assessments in this review were performed using BMDS version 2.1.1 (U.S. EPA, 2009, 200772).

C.1.1.1. BMD Approach with a BMR of 1 Control Mean S.D. – Gestation and into the Postnatal Period

A summary of the results most relevant to the development of a POD using the BMD approach (BMD, BMDL, and model fit statistics) for decreased brain weight at 6 weeks in male rats exposed to methanol throughout gestation and continuing into the F_1 generation, with a BMR of 1 control mean S.D (NEDO, 1987, 064574), is provided in Table C-2. The 6 week male brain weight responses were chosen because they resulted in lower BMD and BMDL estimates than male responses at 3 and 8 weeks and female responses at any time point (data not shown). Model fit and was determined by statistics (AIC and χ^2 residuals of individual dose groups) and visual inspection, as recommended by EPA (U.S. EPA, 2000, 052150). There is a 2.5-fold range of BMDL estimates from adequately fitting models, indicating considerable model dependence. In addition, the fit of the Hill and more complex Exponential models is better than the other models in the dose region of interest as indicated by a lower scaled residual at the dose group closest to the BMD (0.09 versus -0.67 or -0.77) and visual inspection. In accordance with EPA BMD Technical Guidance (2000, 052150), the BMDL from the Hill model (bolded), is selected as the most appropriate basis for an RfC derivation because it results in the lowest BMDL from among a broad range of BMDLs and provides a superior fit in the low dose region nearest the BMD. The detailed results of the Hill model run, including text and plot (Figure C-1) are shown after Table C-2. The $BMDL_{1SD}$ was determined to be 90.9 hr × mg/L using the 95% lower confidence limit of the dose-response curve expressed in terms of the AUC for methanol in blood.

Table C-2. Comparison of BMD$_{1SD}$ results for decreased brain weight in male rats at 6 weeks of age using modeled AUC of methanol as a dose metric

Model	BMD$_{1SD}$ (AUC, hr × mg/L) [A]	BMDL$_{1SD}$ (AUC, hr × mg/L) [A]	*p*-value	AIC [C]	Scaled residual [D]
Linear	277.75	224.85	0.5387	-203.84	-0.77
2nd degree polynomial	277.75	224.85	0.5387	-203.84	-0.77
3rd degree polynomial	277.75	224.85	0.5387	-203.84	-0.77
Power	277.75	224.85	0.5387	-203.84	-0.77
Hill [b]	170.43	**90.86**	0.836	-203.04	0.09
Exponential 2	260.42	208.68	0.613	-204.10	-0.67
Exponential 3	260.42	208.68	0.613	-204.10	-0.67
Exponential 4	171.95	96.85	0.82	-203.03	0.09
Exponential 5	171.95	96.85	0.82	-203.03	0.09

[a]The BMDL is the 95% lower confidence limit on the AUC estimated to decrease brain weight by 1 control mean S.D. using BMDS 2.1.1 (U.S. EPA, 2009, 200772) and model options and restrictions suggested by EPA BMD technical guidance (U.S. EPA, 2000, 052150).
[b]There is a 2.5-fold range of BMDL estimates from adequately fitting models, indicating considerable model dependence. In addition, the fit of the Hill and more complex Exponential models is better in the dose region of interest as indicated by a lower scaled residual at the dose group closest to the BMD (0.09 versus -0.67 or -0.77) and visual inspection. Thus, in accordance with EPA BMD technical guidance (U.S. EPA, 2000, 052150), the BMDL from the Hill model (bolded) is considered the most appropriate POD for us in an RfC derivation.
[c]AIC = Akaike Information Criterion = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters, and P is the number of modeled degrees of freedom (usually the number of parameters estimated).
[d]χ^2d residual (measure of how model-predicted responses deviate from the actual data) for the dose group closest to the BMD scaled by an estimate of its S.D. Provides a comparative measure of model fit near the BMD. Residuals that exceed 2.0 in absolute value should cause one to question model fit in this region.

Source: NEDO (1987, 064574).

```
1    ====================================================================
2            Hill Model. (Version: 2.14;  Date: 06/26/2008)
3            Input Data File: C:\Usepa\BMDS21\Data\Methanol\NEDO\Gest-F1\hil_m-6wk-brw_Hil-
4    Restrict.(d)
5            Gnuplot Plotting File:  C:\Usepa\BMDS21\Data\Methanol\NEDO\Gest-F1\hil_m-6wk-
6    brw_Hil-Restrict.plt
7                                          Sat Dec 26 23:15:13 2009
8     ====================================================================
9
10    BMDS Model Run
11   ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
12
13       The form of the response function is:
14
15       Y[dose] = intercept + v*dose^n/(k^n + dose^n)
16
17
18       Dependent variable = Mean
19       Independent variable = Dose
20       rho is set to 0
21       Power parameter restricted to be greater than 1
22       A constant variance model is fit
23
```

```
 1      Total number of dose groups = 4
 2      Total number of records with missing values = 0
 3      Maximum number of iterations = 250
 4      Relative Function Convergence has been set to: 1e-008
 5      Parameter Convergence has been set to: 1e-008
 6
 7
 8
 9                      Default Initial Parameter Values
10                          alpha =   0.00539333
11                            rho =           0    Specified
12                      intercept =         1.78
13                              v =        -0.26
14                              n =      1.08342
15                              k =        400.5
16
17
18           Asymptotic Correlation Matrix of Parameter Estimates
19
20           ( *** The model parameter(s)  -rho     -n
21                 have been estimated at a boundary point, or have been specified by
22      the user,
23                 and do not appear in the correlation matrix )
24
25                      alpha     intercept            v             k
26
27         alpha            1     6.7e-009    -3.6e-008     1.5e-008
28
29     intercept     6.7e-009            1         0.54        -0.64
30
31             v    -3.6e-008         0.54            1        -0.99
32
33             k     1.5e-008        -0.64        -0.99            1
34
35
36
37                              Parameter Estimates
38
39                                                      95.0% Wald Confidence
40      Interval
41          Variable         Estimate        Std. Err.     Lower Conf. Limit    Upper Conf.
42      Limit
43             alpha       0.0049574      0.00100155            0.0029944
44      0.00692039
45         intercept         1.77822       0.0184934              1.74197
46      1.81447
47                 v       -0.601684        0.341665             -1.27134
48      0.0679677
49                 n               1              NA
50                 k         1286.01         1321.63             -1304.34
51      3876.35
52
53      NA - Indicates that this parameter has hit a bound
54          implied by some inequality constraint and thus
55          has no standard error.
56
57
58         Table of Data and Estimated Values of Interest
59
60      Dose        N     Obs Mean     Est Mean    Obs Std Dev   Est Std Dev    Scaled Res.
61      ------      ---    --------     --------    -----------   -----------    ----------
62
63          0       12        1.78         1.78           0.07        0.0704         0.0876
64       79.1       12        1.74         1.74           0.09        0.0704        -0.165
65      226.5       11        1.69         1.69           0.06        0.0704         0.0887
66        966       14        1.52         1.52           0.07        0.0704        -0.00679
67
```

```
Model Descriptions for likelihoods calculated


Model A1:        Yij = Mu(i) + e(ij)
          Var{e(ij)} = Sigma^2

Model A2:        Yij = Mu(i) + e(ij)
          Var{e(ij)} = Sigma(i)^2

Model A3:        Yij = Mu(i) + e(ij)
          Var{e(ij)} = Sigma^2
    Model A3 uses any fixed variance parameters that
    were specified by the user

Model  R:        Yi = Mu + e(i)
          Var{e(i)} = Sigma^2


                    Likelihoods of Interest

           Model      Log(likelihood)   # Param's      AIC
            A1          105.539862           5      -201.079724
            A2          106.570724           8      -197.141449
            A3          105.539862           5      -201.079724
         fitted         105.518430           4      -203.036861
            R            77.428662           2      -150.857324


                    Explanation of Tests

 Test 1:  Do responses and/or variances differ among Dose levels?
          (A2 vs. R)
 Test 2:  Are Variances Homogeneous? (A1 vs A2)
 Test 3:  Are variances adequately modeled? (A2 vs. A3)
 Test 4:  Does the Model for the Mean Fit? (A3 vs. fitted)
 (Note:  When rho=0 the results of Test 3 and Test 2 will be the same.)

                    Tests of Interest

   Test    -2*log(Likelihood Ratio)  Test df       p-value

   Test 1            58.2841            6           <.0001
   Test 2             2.06173           3           0.5597
   Test 3             2.06173           3           0.5597
   Test 4             0.042863          1            0.836

The p-value for Test 1 is less than .05.  There appears to be a
difference between response and/or variances among the dose levels
It seems appropriate to model the data

The p-value for Test 2 is greater than .1.  A homogeneous variance
model appears to be appropriate here


The p-value for Test 3 is greater than .1.  The modeled variance appears
 to be appropriate here

The p-value for Test 4 is greater than .1.  The model chosen seems
to adequately describe the data


        Benchmark Dose Computation

Specified effect =              1
```

```
1   Risk Type        =       Estimated standard deviations from the control mean
2
3   Confidence level =          0.95
4
5           BMD =          170.432
6
            BMDL =          90.8618
```

Hill Model with 0.95 Confidence Level

Figure C-1. Hill model, BMR of 1 Control Mean S.D. - Decreased Brain weight in male rats at 6 weeks age versus AUC, F1 Generation inhalational study

Source: NEDO (1987, 064574).

7   Once the $BMDL_{1SD}$ was obtained in units of hr × mg/L, it was used to derive a chronic

8   inhalation reference value. The first step is to calculate the HEC using the PBPK model

9   described in Appendix B. An algebraic equation is provided (Equation 1 of Appendix B) that

10   describes the relationship between predicted methanol AUC and the human equivalent inhalation

11   exposure concentration (HEC) in ppm.

$$BMDL_{HEC} \text{ (ppm)}= 0.02525*BMDL_{1SD}+(1290*BMDL_{1SD})/(765.5 + BMDL_{1SD})$$
$$BMDL_{HEC} \text{ (ppm)}= 0.02525*90.9+(1290*90.9)/(765.5+ 90.9) = 139 \text{ ppm}$$

Next, because RfCs are typically expressed in units of mg/m^3, the HEC value in ppm was converted using the conversion factor specific to methanol of 1 ppm = 1.31 mg/m^3:

$$\text{HEC (mg/m}^3) = 1.31 \times 139 \text{ ppm} = 182 \text{ mg/m}^3$$

Finally, this HEC value was divided by a composite 100-fold UF (3 for uncertainty associated with animal to human differences, 10 for consideration of human variability, and 3 for database deficiencies) to obtain the chronic inhalation reference value:

$$\text{RfC (mg/m}^3) = 182 \text{ mg/m}^3 \div 100 = 1.8 \text{ mg/m}^3$$

C.1.1.2. BMD Approach with a BMR of 0.05 Change Relative to Estimated Control Mean – Gestation and into the Postnatal Period (NEDO, 1987, 064574)

A summary of the results most relevant to the development of a POD using the BMD approach (BMD, BMDL, and model fit statistics) for decreased brain weight at 6 weeks in male rats exposed to methanol throughout gestation and continuing into the F_1 generation, with a BMR of 0.05 change relative to estimated control mean, is provided in Table C-3. The 6 week male brain weight responses were chosen because they resulted in lower BMD and BMDL estimates than male responses at 3 and 8 weeks and female responses at any time point (data not shown). Model fit was determined by statistics (AIC and χ^2 residuals of individual dose groups) and visual inspection, as recommended by the EPA BMD Technical Guidance (U.S. EPA, 2000, 052150). There is a 2.4-fold range of BMDL estimates from adequately fitting models, indicating considerable model dependence. In addition, the fit of the Hill and more complex Exponential models is better than the other models in the dose region of interest as indicated by a lower scaled residual at the dose group closest to the BMD (0.09 versus -0.67 or -0.77) and visual inspection. In accordance with EPA BMD Technical Guidance (U.S. EPA, 2000, 052150), the BMDL from the Hill model (bolded), is selected as the most appropriate basis for an RfC derivation because it results in the lowest BMDL from among a broad range of BMDLs and provides a superior fit in the low dose region nearest the BMD. Output from the hill model, including text and plot (Figure C-2), is shown after Table C-3. The BMDL$_{05}$ was determined to be 123.9 hr × mg/L, using the 95% lower confidence limit of the dose-response curve expressed in terms of the AUC for methanol in blood.

Table C-3. Comparison of BMD_{05} results for decreased brain weight in male rats at 6 weeks of age using modeled AUC of methanol as a dose metric

Model	BMD_{05} (AUC, hr × mg/L)[A]	$BMDL_{05}$ (AUC, hr × mg/L)[A]	*p*-value	AIC[C]	Scaled Residual[D]
Linear[b]	343.82	297.35	0.5387	-203.84	-0.77
2nd degree polynomial	343.82	297.35	0.5387	-203.84	-0.77
3rd degree polynomial	343.82	297.35	0.5387	-203.84	-0.77
Power	343.82	297.35	0.5387	-203.84	-0.77
Hill	222.98	123.77	0.836	-203.04	-0.09
Exponential 2	325.20	277.72	0.613	-204.10	-0.67
Exponential 3	325.20	277.72	0.613	-204.10	-0.67
Exponential 4	223.74	129.86	0.82	-203.03	0.09
Exponential 5	223.74	129.86	0.82	-203.03	0.09

[a]The BMDL is the 95% lower confidence limit on the AUC estimated to decrease brain weight by 5% using BMDS 2.1.1 (U.S. EPA, 2009, 200772) and model options and restrictions suggested by EPA BMD Technical Guidance (U.S. EPA, 2000, 052150).
[b]There is a 2.4-fold range of BMDL estimates from adequately fitting models, indicating considerable model dependence. In addition, the fit of the Hill and more complex Exponential models is better in the dose region of interest as indicated by a lower scaled residual at the dose group closest to the BMD (0.09 versus -0.67 or -0.77) and visual inspection. Thus, in accordance with EPA BMD Technical Guidance (U.S. EPA, 2000, 052150), the BMDL from the Hill model (bolded) is considered the most appropriate POD for us in an RfC derivation.
[c]AIC = Akaike Information Criterion = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters, and P is the number of modeled degrees of freedom (usually the number of parameters estimated).
[d]χ^2d residual (measure of how model-predicted responses deviate from the actual data) for the dose group closest to the BMD scaled by an estimate of its S.D. Provides a comparative measure of model fit near the BMD. Residuals that exceed 2.0 in absolute value should cause one to question model fit in this region.

Source: NEDO (1987, 064574)

```
1
2
3   ======================================================================
4         Hill Model. (Version: 2.14;  Date: 06/26/2008)
5         Input Data File: C:\Usepa\BMDS21\Data\Methanol\NEDO\Gest-F1\hil_m-6wk-brw_Hil-
6   ConstantVariance-BMR05-Restrict.(d)
7         Gnuplot Plotting File:  C:\Usepa\BMDS21\Data\Methanol\NEDO\Gest-F1\hil_m-6wk-
8   brw_Hil-ConstantVariance-BMR05-Restrict.plt
9                                          Sat Dec 26 23:05:11 2009
10  ======================================================================
11
12   BMDS Model Run
13  ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
14
15     The form of the response function is:
16
17     Y[dose] = intercept + v*dose^n/(k^n + dose^n)
18
19
20     Dependent variable = Mean
21     Independent variable = Dose
22     rho is set to 0
23     Power parameter restricted to be greater than 1
24     A constant variance model is fit
```

```
     Total number of dose groups = 4
     Total number of records with missing values = 0
     Maximum number of iterations = 250
     Relative Function Convergence has been set to: 1e-008
     Parameter Convergence has been set to: 1e-008



                   Default Initial Parameter Values
                        alpha =    0.00539333
                          rho =           0    Specified
                    intercept =        1.78
                            v =       -0.26
                            n =     1.08342
                            k =       400.5


          Asymptotic Correlation Matrix of Parameter Estimates

          ( *** The model parameter(s)  -rho     -n
                have been estimated at a boundary point, or have been specified by
the user,
                and do not appear in the correlation matrix )

                    alpha     intercept            v            k

       alpha           1      6.7e-009     -3.6e-008    1.5e-008

   intercept    6.7e-009             1          0.54        -0.64

           v   -3.6e-008          0.54             1        -0.99

           k    1.5e-008         -0.64         -0.99             1




                            Parameter Estimates


                                                      95.0% Wald Confidence
Interval
       Variable        Estimate         Std. Err.    Lower Conf. Limit    Upper Conf.
Limit
          alpha       0.0049574        0.00100155           0.0029944
0.00692039
      intercept         1.77822         0.0184934             1.74197
1.81447
              v       -0.601684         0.341665            -1.27134
0.0679677
              n               1               NA
              k         1286.01          1321.63            -1304.34
3876.35

NA - Indicates that this parameter has hit a bound
     implied by some inequality constraint and thus
     has no standard error.



     Table of Data and Estimated Values of Interest

   Dose       N    Obs Mean    Est Mean   Obs Std Dev  Est Std Dev   Scaled Res.
   ------     ---  --------    --------   -----------  -----------   ----------

      0       12      1.78        1.78          0.07       0.0704        0.0876
   79.1       12      1.74        1.74          0.09       0.0704       -0.165
  226.5       11      1.69        1.69          0.06       0.0704        0.0887
```

```
   966      14        1.52          1.52           0.07        0.0704         -0.00679



   Model Descriptions for likelihoods calculated


   Model A1:        Yij = Mu(i) + e(ij)
           Var{e(ij)} = Sigma^2

   Model A2:        Yij = Mu(i) + e(ij)
           Var{e(ij)} = Sigma(i)^2

   Model A3:        Yij = Mu(i) + e(ij)
           Var{e(ij)} = Sigma^2
     Model A3 uses any fixed variance parameters that
     were specified by the user

   Model  R:        Yi = Mu + e(i)
           Var{e(i)} = Sigma^2


                    Likelihoods of Interest

           Model      Log(likelihood)   # Param's      AIC
            A1          105.539862           5      -201.079724
            A2          106.570724           8      -197.141449
            A3          105.539862           5      -201.079724
         fitted         105.518430           4      -203.036861
            R            77.428662           2      -150.857324



                    Explanation of Tests

   Test 1:  Do responses and/or variances differ among Dose levels?
            (A2 vs. R)
   Test 2:  Are Variances Homogeneous? (A1 vs A2)
   Test 3:  Are variances adequately modeled? (A2 vs. A3)
   Test 4:  Does the Model for the Mean Fit? (A3 vs. fitted)
   (Note:  When rho=0 the results of Test 3 and Test 2 will be the same.)

                    Tests of Interest

     Test    -2*log(Likelihood Ratio)  Test df      p-value

     Test 1            58.2841            6          <.0001
     Test 2             2.06173           3          0.5597
     Test 3             2.06173           3          0.5597
     Test 4             0.042863          1           0.836

The p-value for Test 1 is less than .05.  There appears to be a
difference between response and/or variances among the dose levels
It seems appropriate to model the data

The p-value for Test 2 is greater than .1.  A homogeneous variance
model appears to be appropriate here


The p-value for Test 3 is greater than .1.  The modeled variance appears
 to be appropriate here

The p-value for Test 4 is greater than .1.  The model chosen seems
to adequately describe the data



         Benchmark Dose Computation
```

```
 1     Specified effect =              0.05
 2
 3     Risk Type        =        Relative risk
 4
 5     Confidence level =              0.95
 6
 7             BMD =            222.984
 8
 9            BMDL =            123.773
```

Hill Model with 0.95 Confidence Level

09:40 08/24 2009

Figure C-2. Hill model, BMR of 0.05 relative risk - decreased brain weight in male rats at 6 weeks age versus AUC, F_1 Generation inhalational study.

10   Once the $BMDL_{05}$ was obtained in units of hr × mg/L, it was used to derive a chronic

11   inhalation reference value. The first step is to calculate the HEC using the PBPK model

12   described in Appendix B. An algebraic equation is provided (Equation 1 of Appendix B) that

13   describes the relationship between predicted methanol AUC and the human equivalent inhalation

14   exposure concentration (HEC) in ppm.

1 $$\text{BMDL}_{HEC} \text{ (ppm)} = 0.02525 * \text{BMDL}_{05} + (1290 * \text{BMDL}_{05})/(765.5 + \text{BMDL}_{05})$$

2 $$\text{BMDL}_{HEC} \text{ (ppm)} = 0.02525 * 123.77 + (1290 * 123.77)/(765.5 + 123.77) = 183 \text{ ppm}$$

3 Next, because RfCs are typically expressed in units of mg/m^3, the HEC value in ppm was

4 converted using the conversion factor specific to methanol of 1 ppm = 1.31 mg/m^3:

5 $$\text{HEC (mg/m}^3) = 1.31 \times 183 \text{ ppm} = 240 \text{ mg/m}^3$$

6 Finally, this HEC value was divided by a composite 100-fold UF (3 for uncertainty

7 associated with animal to human differences, 10 for consideration of human variability, and 3 for

8 database deficiencies) to obtain the chronic inhalation reference value:

9 $$\text{RfC (mg/m}^3) = 240 \text{ mg/m}^3 \div 100 = 2.4 \text{ mg/m}^3$$

C.1.2. Decreased Brain Weight in Male Rats Exposed During Gestation Only (GD7-GD17)

10 C_{max}, as calculated by the EPA's PBPK model, was selected as the dose metric for this

11 exposure scenario, in concordance with the choice of this dose metric for the increased incidence

12 of cervical rib in mice in the Rogers et al. (Rogers et al., 1993, 032696). Exposures occurred

13 only during the major period of organogenesis in both studies. As there is evidence that C_{max} is a

14 better predictor of response than AUC for incidence of cervical rib (see Appendix D), it was

15 assumed appropriate to consider C_{max} the better predictor for decreased brain weight as well.

16 The first step in the current analysis is to convert the inhalation doses, given as ppm

17 values from the studies, to an internal dose surrogate or dose metric using the EPA PBPK model

18 (see Section 3.4). Predicted C_{max} values for methanol in the blood of rats are summarized in

19 Table C-4.

Table C-4. EPA's PBPK model estimates of methanol blood levels (C_{max}) in rats following inhalation exposures

Exposure level (ppm)	Methanol in lood C_{max} (mg /L)[a] in rats
200	1.2
1,000	10.6
5000	630.5

[a]C_{max} values were obtained by simulating 22 hr/day exposures

The current BMD technical guidance (U.S. EPA, 2000, 052150) suggests that in the absence of knowledge as to what level of response to consider adverse, a change in the mean equal to 1 control S.D. from the control mean can be used as a BMR for continuous endpoints. However, it has been suggested that other BMRs, such as 5% change relative to estimated control mean, are also appropriate when performing BMD analyses on fetal weight change as a developmental endpoint (Kavlock et al., 1995, 075837). Therefore, in this assessment, both a 1 control mean S.D. change and a 5% change relative to estimated control mean were considered. All models were fit using restrictions and option settings suggested in the EPA's BMD Technical Guidance Document (U.S. EPA, 2000, 052150).

C.1.2.1. BMD *Approach with a BMR of 1 Control Mean S.D. (GD7-GD17)*

A summary of the results most relevant to the development of a POD using the BMD approach (BMD, BMDL, and model fit statistics) (NEDO, 1987, 064574) for decreased brain weight at 8 weeks in male rats exposed to methanol during gestation from days 7–17, with a BMR of 1 control mean S.D, is provided in Table C-5. Male brain weight responses were chosen because they resulted in lower BMD and BMDL estimates than female responses (data not shown). Model fit was determined by statistics (AIC and χ^2 residuals of individual dose groups) and visual inspection, as recommended by EPA (2000b). The polynomial and power models reduced to linear form and returned identical modeling results. In contrast, the more complex Hill and Exponential4 models, which estimate a response "plateau" or asymptote, returned similar, markedly nonlinear results. This is because these models approximated the response "plateau" to be near the maximum drop in brain weight observed in the study (approximately 10% at the high dose), resulting in a distinctly "L" shaped dose-response curve (see figure C-3).[92] In this case, the only PBPK model estimated C_{max} dose that is associated with a significant response over controls, the high-dose, is 60-fold higher than the mid-dose C_{max} estimate. Thus, there are many plausible curve shapes and, consequently, a wide range of BMDL estimates. Per EPA (2000, 052150) guidance and to err on the side of public health protection, the lowest BMDL$_{1SD}$ of 10.26 mg methanol/L in blood estimated from adequate and plausible models was chosen for use in the RfC derivation (details of the Hill model results follow Table C-5). However, it should be noted that there is a great deal of uncertainty and model dependence associated with these dose-response data.

---

[92] The extent of the "L" shape is dependent on the asymptote term, or "plateau" level, estimated for the data. If the asymptote term (v) in the Hill model is set to -.4 (representing a 20% drop from the control brain weight of 2 grams), the model result is more linear and the BMD and BMDL estimates are approximately fourfold higher.

Table C-5. Comparison of BMD_{1SD} results for decreased brain weight in male rats at 8 weeks of age using modeled C_{max} of methanol as a dose metric

Model	BMD_{1SD} (C_{max}, mg/L)[A]	$BMDL_{1SD}$ (C_{max}, mg/L)[A]	*p*-value	AIC[C]	Scaled residual[D]
Linear	207.18	135.22	0.7881	-173.12	-0.43
2nd degree polynomial	207.18	135.22	0.7881	-173.12	-0.43
3rd degree polynomial	207.18	135.22	0.7881	-173.12	-0.43
Power	207.18	135.22	0.7881	-173.12	-0.43
Hill[b]	43.08	10.26	0.9602	-171.59	-0.10
Exponential 2	199.98	127.55	0.9494	-173.13	-0.42
Exponential 3	199.98	127.55	0.9494	-173.13	-0.42
Exponential 4[b]	39.53	10.26	Not reported	-171.59	0.10

[a]The BMDL is the 95% lower confidence limit on the C_{max} estimated to decrease brain weight by 1 control mean S.D. using BMDS 2.1.1 (U.S. EPA, 2009, 200772) and model options and restrictions suggested by EPA BMD technical guidance (U.S. EPA, 2000, 052150).
[b]Per EPA (2000, 052150) guidance and to err on the side of public health protection, the lowest $BMDL_{1SD}$ of 10.26 mg methanol/L in blood estimated from adequate and plausible models was chosen for use in the RfC derivation
[c]AIC = Akaike Information Criterion = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters, and P is the number of modeled degrees of freedom (usually the number of parameters estimated).
[d]χ^2d residual (measure of how model-predicted responses deviate from the actual data) for the dose group closest to the BMD scaled by an estimate of its S.D. Provides a comparative measure of model fit near the BMD. Residuals that exceed 2.0 in absolute value should cause one to question model fit in this region.

Source: NEDO (1987, 064574)

```
1   ====================================================================
2           Hill Model. (Version: 2.14;  Date: 06/26/2008)
3           Input Data File: C:\Usepa\BMDS21\Data\Methanol\NEDO\Gest-only\hilm-8wk-brwHil-
4   Restrict.(d)
5           Gnuplot Plotting File:  C:\Usepa\BMDS21\Data\Methanol\NEDO\Gest-only\hilm-8wk-
6   brwHil-Restrict.plt
7                                           Tue Aug 25 12:40:30 2009
8    ====================================================================
9
10   BMDS Model Run
11  ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
12
13     The form of the response function is:
14
15     Y[dose] = intercept + v*dose^n/(k^n + dose^n)
16
17
18     Dependent variable = Mean
19     Independent variable = Dose
20     Power parameter restricted to be greater than 1
21     The variance is to be modeled as Var(i) = exp(lalpha  + rho * ln(mean(i)))
22
23     Total number of dose groups = 4
24     Total number of records with missing values = 0
```

```
       Maximum number of iterations = 250
       Relative Function Convergence has been set to: 1e-008
       Parameter Convergence has been set to: 1e-008




                       Default Initial Parameter Values
                              lalpha =      -4.68678
                                 rho =             0
                           intercept =             2
                                   v =         -0.19
                                   n =      0.861776
                                   k =       303.331



            Asymptotic Correlation Matrix of Parameter Estimates

       ( *** The model parameter(s)  -n
             have been estimated at a boundary point, or have been specified by the user,
             and do not appear in the correlation matrix )

                        lalpha          rho     intercept            v            k

          lalpha             1           -1       -0.083          0.6        -0.18

             rho            -1            1        0.096         -0.6         0.18

       intercept        -0.083        0.096            1         0.19        -0.55

               v           0.6         -0.6         0.19            1        -0.73

               k         -0.18         0.18        -0.55        -0.73            1




                               Parameter Estimates

                                                         95.0% Wald Confidence Interval
       Variable          Estimate        Std. Err.    Lower Conf. Limit    Upper Conf. Limit
       lalpha            7.03732          4.98399           -2.73112             16.8058
       rho              -18.1432          7.32604           -32.502             -3.78448
       intercept         2.0068         0.0134454            1.98045             2.03316
              v        -0.232906        0.0881494           -0.405676           -0.0601362
              n              1               NA
              k         121.949          194.687            -259.631             503.529

       NA - Indicates that this parameter has hit a bound
            implied by some inequality constraint and thus
            has no standard error.



          Table of Data and Estimated Values of Interest

        Dose        N     Obs Mean    Est Mean    Obs Std Dev   Est Std Dev   Scaled Res.
        ------     ---    --------    --------    -----------   -----------   ----------

           0       11          2        2.01        0.047        0.0608        -0.371
         1.2       11       2.01           2        0.075        0.0614         0.295
        10.6       12       1.99        1.99        0.072        0.0662         0.0954
       630.5       10       1.81        1.81        0.161         0.154        -0.0338




       Model Descriptions for likelihoods calculated

```

```
Model A1:         Yij = Mu(i) + e(ij)
          Var{e(ij)} = Sigma^2

Model A2:         Yij = Mu(i) + e(ij)
          Var{e(ij)} = Sigma(i)^2

Model A3:         Yij = Mu(i) + e(ij)
          Var{e(ij)} = exp(lalpha + rho*ln(Mu(i)))
    Model A3 uses any fixed variance parameters that
    were specified by the user

Model  R:          Yi = Mu + e(i)
          Var{e(i)} = Sigma^2


                    Likelihoods of Interest

          Model      Log(likelihood)   # Param's      AIC
           A1          83.205960            5      -156.411920
           A2          92.060485            8      -168.120970
           A3          90.797178            6      -169.594356
         fitted        90.795933            5      -171.591867
            R          70.761857            2      -137.523714


                     Explanation of Tests

  Test 1:  Do responses and/or variances differ among Dose levels?
           (A2 vs. R)
  Test 2:  Are Variances Homogeneous? (A1 vs A2)
  Test 3:  Are variances adequately modeled? (A2 vs. A3)
  Test 4:  Does the Model for the Mean Fit? (A3 vs. fitted)
  (Note:  When rho=0 the results of Test 3 and Test 2 will be the same.)

                      Tests of Interest

   Test    -2*log(Likelihood Ratio)  Test df        p-value

   Test 1            42.5973             6           <.0001
   Test 2            17.7091             3          0.000505
   Test 3            2.52661             2          0.2827
   Test 4           0.00248896           1          0.9602

The p-value for Test 1 is less than .05.  There appears to be a
difference between response and/or variances among the dose levels
It seems appropriate to model the data

The p-value for Test 2 is less than .1.  A non-homogeneous variance
model appears to be appropriate

The p-value for Test 3 is greater than .1.  The modeled variance appears
 to be appropriate here

The p-value for Test 4 is greater than .1.  The model chosen seems
to adequately describe the data


          Benchmark Dose Computation

Specified effect =             1

Risk Type      =     Estimated standard deviations from the control mean

Confidence level =         0.95

          BMD =       43.0842
```

1   `BMDL =        10.2551`

Hill Model with 0.95 Confidence Level

12:40 08/25 2009

Figure C-3. Hill model, BMR of 1 Control Mean S.D. - decreased brain weight in male rats at 8 weeks age versus C_{max}, Gestation only inhalational study.

Source: NEDO (1987, <u>064574</u>).

2   Once the $BMDL_{1SD}$ was obtained in units of mg/L, it was used to derive a chronic

3   inhalation reference value. The first step is to calculate the HEC using the PBPK model

4   described in Appendix B. An algebraic equation is provided (Equation 1 of Appendix B) that

5   describes the relationship between predicted methanol AUC and the human equivalent inhalation

6   exposure concentration (HEC) in ppm. This equation can also be used to estimate model

7   predictions for HECs from C_{max} values because C_{max} values and AUC values, were estimated at

8   steady-state for constant 24-hour exposures (i.e., AUC = 24 x C_{max}).

9

10         $BMDL_{HEC}$ (ppm)= 0.02525*$BMDL_{1SD}$*24+(1290*$BMDL_{1SD}$*24)/(765.5 + $BMDL_{1SD}$*24)

1   BMDL_{HEC} (ppm)= 0.02525*10.3*24+(1290*10.3*24)/(765.5+ 10.3*24) = 321 ppm

2   Next, because RfCs are typically expressed in units of mg/m^3, the HEC value in ppm was

3 converted using the conversion factor specific to methanol of 1 ppm = 1.31 mg/m^3:

4   HEC (mg/m^3) = 1.31 × 321 ppm = 421 mg/m^3

5   Finally, this HEC value was divided by a composite 100-fold UF (3 for uncertainty

6 associated with animal to human differences, 10 for consideration of human variability, and 3 for

7 database deficiencies) to obtain the chronic inhalation reference value:

8   RfC (mg/m^3) = 421 mg/m^3 ÷ 100 = 4.2 mg/m^3

C.1.2.2. BMD *Approach with a BMR of 0.05 Change Relative to Control Mean (GD7-GD17)*

9   A summary of the results most relevant to the development of a POD using the BMD

10 approach (BMD, BMDL, and model fit statistics) for decreased brain weight at 8 weeks in male

11 rats exposed to methanol during gestation from days 7 to 17, with a BMR of 0.05 change relative

12 to estimated control mean, is provided in Table C-6. Model fit was determined by statistics (AIC

13 and χ^2 residuals of individual dose groups) and visual inspection, as recommended by EPA

14 (2000, 052150). Modeling considerations and uncertainties for this dataset were discussed in

15 C.1.2.1 and, as was done for the BMR of 1 S.D., the lowest BMDL_{05} of 21.07 mg methanol/L in

16 blood estimated from the BMDS exponential 4 model was chosen for use in the RfC derivation

17 (NEDO, 1987, 064574). Results from the exponential 4 model, including text and plot (see

18 Figure C-4), are shown after Table C-6.

Table C-6. Comparison of BMD$_{05}$ modeling results for decreased brain weight in male rats at 8 weeks of age using modeled C$_{max}$ of methanol as a common dose metric

Model	BMD$_{05}$ (C$_{max}$, mg/L)^A	BMDL$_{05}$ (C$_{max}$, mg/L)^A	*p*-value	AIC^C	Scaled residual^D
Linear[b]	328.84	226.08	0.7881	-173.12	0.02
2nd degree polynomial	328.84	226.08	0.7881	-173.12	0.02
3rd degree polynomial	328.84	226.08	0.7881	-173.12	0.02
Power	328.84	226.08	0.9446	-173.12	0.02
Hill[b]	92.30	Not reported	0.9602	-171.59	0.10
Exponential 2	320.62	215.13	0.9494	-173.13	0.02
Exponential 3	320.62	215.13	0.9494	-173.13	0.02
Exponential 4[b]	76.36	21.07	Not reported	-171.59	0.10

[a]The BMDL is the 95% lower confidence limit on the C$_{max}$ estimated to decrease brain weight by 5% using BMDS 2.1.1 (U.S. EPA, 2009, 200772) and model options and restrictions suggested by EPA BMD Technical Guidance (2000, 052150).
[b]Per EPA (2000, 052150) guidance and to err on the side of public health protection, the lowest BMDL$_{05}$ of 21.07 mg methanol/L in blood estimated from adequate and plausible models was chosen for use in the RfC derivation.
[c]AIC = Akaike Information Criterion = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters, and P is the number of modeled degrees of freedom (usually the number of parameters estimated).
[d]χ^2d residual (measure of how model-predicted responses deviate from the actual data) for the dose group closest to the BMD scaled by an estimate of its S.D. Provides a comparative measure of model fit near the BMD. Residuals that exceed 2.0 in absolute value should cause one to question model fit in this region.

Source: NEDO (1987, 064574).

```
1     ====================================================================
2            Exponential Model. (Version: 1.61;  Date: 7/24/2009)
3            Input Data File: C:\Usepa\BMDS21\Data\Methanol\NEDO\Gest-only\expm-8wk-
4     brwSetting.(d)
5            Gnuplot Plotting File:
6                                          Tue Aug 25 14:15:15 2009
7      ===================================================================
8
9      BMDS Model Run
10    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
11
12       The form of the response function by Model:
13          Model 2:     Y[dose] = a * exp{sign * b * dose}
14          Model 3:     Y[dose] = a * exp{sign * (b * dose)^d}
15          Model 4:     Y[dose] = a * [c-(c-1) * exp{-b * dose}]
16          Model 5:     Y[dose] = a * [c-(c-1) * exp{-(b * dose)^d}]
17
18        Note: Y[dose] is the median response for exposure = dose;
19              sign = +1 for increasing trend in data;
20              sign = -1 for decreasing trend.
21
22          Model 2 is nested within Models 3 and 4.
23          Model 3 is nested within Model 5.
```

```
     Model 4 is nested within Model 5.


Dependent variable = Mean
Independent variable = Dose
Data are assumed to be distributed: normally
Variance Model: exp(lnalpha +rho *ln(Y[dose]))
The variance is to be modeled as Var(i) = exp(lalpha + log(mean(i)) * rho)

Total number of dose groups = 4
Total number of records with missing values = 0
Maximum number of iterations = 250
Relative Function Convergence has been set to: 1e-008
Parameter Convergence has been set to: 1e-008

MLE solution provided: Exact


                          Initial Parameter Values

   Variable          Model 2          Model 3          Model 4          Model 5
   --------          -------          -------          -------          -------
   lnalpha                NC               NC          7.32457               NC
       rho                NC               NC         -18.5236               NC
         a                NC               NC           2.1105               NC
         b                NC               NC       0.00239093               NC
         c                NC               NC         0.816778               NC
         d                NC               NC               --               NC




                         Parameter Estimates by Model

   Variable          Model 2          Model 3          Model 4          Model 5
   --------          -------          -------          -------          -------
   lnalpha                NC               NC          7.03418               NC
       rho                NC               NC         -18.1386               NC
         a                NC               NC          2.00677               NC
         b                NC               NC       0.00941775               NC
         c                NC               NC         0.902498               NC
         d                NC               NC               --               NC

   NC = No Convergence


            Table of Stats From Input Data

   Dose       N        Obs Mean      Obs Std Dev
   -----     ---      ----------     ------------
       0      11               2     0.047
     1.2      11            2.01     0.075
    10.6      12            1.99     0.072
   630.5      10            1.81     0.161


                    Estimated Values of Interest

   Model      Dose       Est Mean       Est Std      Scaled Residual
   -------    ------     ----------     ---------     ----------------
      4          0          2.007       0.06082          -0.3692
                1.2          2.005       0.06142           0.2932
               10.6          1.988       0.06617           0.09527
              630.5          1.812       0.1538           -0.03335




   Other models for which likelihoods are calculated:
```

```
    Model A1:        Yij = Mu(i) + e(ij)
              Var{e(ij)} = Sigma^2

    Model A2:        Yij = Mu(i) + e(ij)
              Var{e(ij)} = Sigma(i)^2

    Model A3:        Yij = Mu(i) + e(ij)
              Var{e(ij)} = exp(lalpha + log(mean(i)) * rho)

    Model  R:        Yij = Mu + e(i)
              Var{e(ij)} = Sigma^2


                        Likelihoods of Interest

                  Model      Log(likelihood)      DF        AIC
                  -------    ----------------     ----    ------------
                   A1          83.20596            5      -156.4119
                   A2          92.06049            8      -168.121
                   A3          90.61606            6      -169.2321
                    R          70.76186            2      -137.5237
                    4          90.79579            5      -171.5916


  Additive constant for all log-likelihoods =     -40.43.  This constant added to the
  above values gives the log-likelihood including the term that does not
  depend on the model parameters.



                          Explanation of Tests

  Test 1:  Does response and/or variances differ among Dose levels? (A2 vs. R)
  Test 2:  Are Variances Homogeneous? (A2 vs. A1)
  Test 3:  Are variances adequately modeled? (A2 vs. A3)

  Test 6a: Does Model 4 fit the data? (A3 vs 4)



                          Tests of Interest

    Test          -2*log(Likelihood Ratio)        D. F.          p-value
   --------       ------------------------       ------        --------------
    Test 1                        42.6              6            < 0.0001
    Test 2                       17.71              3            0.000505
    Test 3                       2.889              2            0.2359
   Test 6a                     -0.3595              1                 N/A


    The p-value for Test 1 is less than .05.  There appears to be a
    difference between response and/or variances among the dose
    levels, it seems appropriate to model the data.

    The p-value for Test 2 is less than .1.  A non-homogeneous
    variance model appears to be appropriate.

    The p-value for Test 3 is greater than .1.  The modeled
    variance appears to be appropriate here.

    The p-value for Test 6a is less than .1.  Model 4 may not adequately
    describe the data; you may want to consider another model.


  Benchmark Dose Computations:

    Specified Effect = 0.050000
```

```
Risk Type = Relative deviation

Confidence Level = 0.950000


                BMD and BMDL by Model

     Model            BMD               BMDL
     -------      ------------      ----------
       2               0                 0        Not computed
       3               0                 0        Not computed
       4            76.3561          21.0664
       5               0                 0        Not computed
```


Exponential Model 4 with 0.95 Confidence Level

14:15 08/25 2009

Figure C-4. Exponential4 model, BMR of 0.05 relative risk - Decreased Brain weight in male rats at 8 weeks age versus C_{max}, Gestation only inhalational study.

Source: NEDO (1987, <u>064574</u>).

Once the $BMDL_{05}$ was obtained in units of mg/L, it was used to derive a chronic inhalation reference value. The first step is to calculate the HEC using the PBPK model described in Appendix B. An algebraic equation is provided (Equation 1 of Appendix B) that

describes the relationship between predicted methanol AUC and the human equivalent inhalation exposure concentration (HEC) in ppm. This equation can also be used to estimate model predictions for HECs from C_{max} values because C_{max} values, and AUC values were estimated at steady-state for constant 24-hour exposures (i.e., AUC = 24 x C_{max}).

$$BMDL_{HEC} \text{ (ppm)} = 0.02525*BMDL_{05}*24+(1290*BMDL_{05}*24)/(765.5 + BMDL_{05}*24)$$
$$BMDL_{HEC} \text{ (ppm)} = 0.02525*21.1*24+(1290*21.1*24)/(765.5+ 21.1*24) = 526 \text{ ppm}$$

Next, because RfCs are typically expressed in units of mg/m^3, the HEC value in ppm was converted using the conversion factor specific to methanol of 1 ppm = 1.31 mg/m^3:

$$HEC \text{ (mg/m}^3) = 1.31 \times 526 \text{ ppm} = 690 \text{ mg/m}^3$$

Finally, this HEC value was divided by a composite 100-fold UF (3 for uncertainty associated with animal to human differences, 10 for consideration of human variability, and 3 for database deficiencies) to obtain the chronic inhalation reference value:

$$RfC \text{ (mg/m}^3) = 690 \text{ mg/m}^3 \div 100 = 6.9 \text{ mg/m}^3$$

C.2. RFC DERIVATIONS USING ROGERS ET AL.

For the purposes of deriving an RfC for methanol from developmental endpoints using the BMD method and mouse data, cervical rib incidence data were evaluated from Rogers et al. (1993, 032696). In this paper, Rogers et al. (1993, 032696) also utilized a BMD methodology, examining the dosimetric threshold for cervical ribs and other developmental impacts by applying a log-logistic maximum likelihood model to the dose-response data. Using air exposure concentrations (ppm) as their dose metric, a value for the lower 95% confidence limit on the benchmark dose for 5% additional risk in mice was 305 ppm (400 mg/m^3), using the log-logistic model. Although the teratology portion of the NEDO study (1987, 064574) also reported increases in cervical rib incidence in Sprague-Dawley rats, the Rogers et al. (1993, 032696) study was chosen for dose-response modeling because effects were seen at lower doses, it was peer-reviewed and published in the open literature, and data on individual animals were available for a more statistically robust analysis utilizing nested models available in BMDS 2.1.1 (U.S. EPA, 2009, 200772).

The first step in the current BMD analysis is to convert the inhalation doses, given as ppm values from the studies, to an internal dose surrogate or dose metric using the EPA's PBPK

1   model (see Section 3.4). For cervical rib malformations, C_{max} of methanol in blood (mg/L) is

2   chosen as the appropriate internal dose metric (see Appendix D for further explanation).

3   Predicted C_{max} values for methanol in the blood of mice are summarized in Table C-7.

Table C-7. EPA's PBPK model estimates of methanol blood levels (C_{max}) in mice following inhalation exposures

Exposure concentration (ppm)	Methanol in blood C_{max} (mg/L)[A] in mice
1	0.0216
10	0.218
50	1.14
100	2.46
250	7.83
500	26.4
1,000	134

[a]Rounded to three significant figures.

4   These C_{max} values are then used as the dose metric for the BMD analysis of cervical rib

5   incidence. A 10% BMR level is the value typically calculated for comparisons across chemicals

6   and endpoints for dichotomous responses because this level is near the low end of the observable

7   range for many types of toxicity studies. However, reproductive and developmental studies

8   having a nested design often have a greater sensitivity, and a 5% BMR is typically appropriate

9   for determination of a POD (Allen et al., 1994, 197125; U.S. EPA, 2000, 052150). Rogers et al.

10   (1993, 032696) utilized a 5% added risk for the BMR in the original study. This assessment

11   utilizes both a 10% and 5% extra risk level as a BMR for the determination of a POD.[93] The

12   nested suite of models available in BMDS 2.1.1 (U.S. EPA, 2009, 200772) was used to model

13   the cervical rib data. In general, data from developmental toxicity studies are best modeled

14   using nested models, as these models account for any intralitter correlation (i.e., the tendency of

15   littermates to respond similarly to one another relative to other litters in a dose group). All

16   models were fit using restrictions and option settings suggested in the EPA's BMD Technical

17   Guidance Document (2000, 052150).

---

[93] Starr and Festa (2003, 052598) have argued that the Rogers et al. (1993, 032696) study's experimental design lacked the statistical power to detect a 5% risk and that a 5% level lay below the observable response data. However, EPA's BMD guidance (U.S. EPA, 2000, 052150) does not preclude the use of a BMR that is below observable response data and EPA has deemed that the Rogers et al. (1993, 032696) is adequate for the consideration of a 5% BMR.

C.2.1. BMD Approach with a BMR of 0.10 Extra Risk

1   A summary of the results most relevant to the development of a POD using the BMD
2   approach (BMD, BMDL, and model fit statistics) for increased incidence of cervical rib in mice
3   exposed to methanol during gestation from days 6 to 15, with a BMR of 0.10 extra risk, is
4   provided in Table C-8. Model fit was determined by statistics (AIC and χ^2 residuals of
5   individual dose groups) and visual inspection, as recommended by U.S. EPA (U.S. EPA, 2000,
6   052150). The best model fit to these data (from visual inspection and comparison of AIC values)
7   was obtained using the Nested Logistic (NLogistic) model. The textual and graphic (see Figure
8   C-5) output from this model follows Table C-8. The $BMDL_{10}$ was determined to be 94.3 mg/L
9   using the 95% lower confidence limit of the dose-response curve expressed in terms of the C_{max}
10 for methanol in blood (Rogers et al., 1993, 032696).

Table C-8. Comparison of BMD modeling results for cervical rib incidence in mice using modeled C_{max} of methanol as a common dose metric

Model	BMD_{10} (C_{max}, mg/L)[A]	$BMDL_{10}$ (C_{max}, mg/L)[A]	*p*-value	AIC[C]	Scaled residual[D]
NLogistic[b]	141.492	94.264	0.293	1046.84	0.649
NCTR	207.945	103.972	0.241	1048.92	0.662
Rai and Van Ryzin	221.509	110.754	0.163	1051.65	0.661

[a]Daily C_{max} was estimated using a mouse PBPK model as described in section 3.4 of the methanol toxicological review; the BMDL is the 95% lower confidence limit on the C_{max} for a 10% extra risk (dichotomous endpoints) estimated by the model using the likelihood profile method (U.S. EPA, 2000, 052150).
[b]Model choice based on adequate *p* value (> 0.1), visual inspection, low AIC, and low (absolute) scaled residual.
[c]AIC = Akaike Information Criterion = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters, and P is the number of modeled degrees of freedom (usually the number of parameters estimated).
[d]χ^2d residual (measure of how model-predicted responses deviate from the actual data) for the dose group closest to the BMD scaled by an estimate of its S.D. Provides a comparative measure of model fit near the BMD. Residuals exceeding 2.0 in absolute value should cause one to question model fit in this region.

Source: Rogers et al. (1993, 032696).

```
11   ======================================================================
12   NLogistic Model.
13   (Version: 2.13; Date: 02/20/2007)
14   Input Data File: U:\Methanol\BMDS\CervicalRib\Cmax\NLog_Cmax_10_default.(d)
15   Wed Nov 07 15:45:40 2007
16   ======================================================================
17
18   BMD Method for RfC: Incidence of Cervical Rib in Mice versus Cmax Methanol, GD 6-15
19   inhalational study (Rogers,et al., 1993)
20   ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
21     The probability function is:
22
23    Prob. = alpha + theta1*Rij + [1 - alpha - theta1*Rij]/
24
```

```
                        [1+exp(-beta-theta2*Rij-rho*log(Dose))],

             where Rij is the litter specific covariate.

   Restrict Power rho >= 1.


   Total number of observations = 166
   Total number of records with missing values = 0
   Total number of parameters in model = 9
   Total number of specified parameters = 0

   Maximum number of iterations = 250
   Relative Function Convergence has been set to: 1e-008
   Parameter Convergence has been set to: 1e-008

                    Default Initial Parameter Values
                           alpha =     0.297863
                            beta =     -7.94313
                          theta1 =            0
                          theta2 =            0
                             rho =      1.09876
                            phi1 =     0.213134
                            phi2 =     0.309556
                            phi3 =     0.220142
                            phi4 =     0.370587


                            Parameter Estimates

          Variable           Estimate           Std. Err.
           alpha             0.102434               *
            beta             -4.80338               *
          theta1            0.0325457               *
          theta2            -0.436115               *
             rho                   1                *
            phi1             0.200733               *
            phi2             0.307656               *
            phi3             0.212754               *
            phi4             0.368426               *

   * - Indicates that this value is not calculated.

    Log-likelihood: -515.422    AIC: 1046.84

                            Litter Data
```

Dose	Lit.-Spec. Cov.	Est._Prob.	Litter Size	Expected	Observed	Scaled Residual
0.0000	1.0000	0.135	1	0.135	0	-0.3950
0.0000	1.0000	0.135	1	0.135	0	-0.3950
0.0000	2.0000	0.168	2	0.335	0	-0.5790
0.0000	2.0000	0.168	2	0.335	1	1.1490
0.0000	2.0000	0.168	2	0.335	0	-0.5790
0.0000	2.0000	0.168	2	0.335	2	2.8770
0.0000	2.0000	0.168	2	0.335	0	-0.5790
0.0000	3.0000	0.200	3	0.600	0	-0.7317
0.0000	3.0000	0.200	3	0.600	0	-0.7317
0.0000	3.0000	0.200	3	0.600	1	0.4874
0.0000	3.0000	0.200	3	0.600	1	0.4874
0.0000	4.0000	0.233	4	0.930	0	-0.8699
0.0000	4.0000	0.233	4	0.930	1	0.0650
0.0000	4.0000	0.233	4	0.930	0	-0.8699
0.0000	4.0000	0.233	4	0.930	1	0.0650
0.0000	5.0000	0.265	5	1.326	0	-1.0004
0.0000	5.0000	0.265	5	1.326	1	-0.2458
0.0000	5.0000	0.265	5	1.326	3	1.2632
0.0000	5.0000	0.265	5	1.326	1	-0.2458

1	0.0000	5.0000	0.265	5	1.326	0	-1.0004
2	0.0000	5.0000	0.265	5	1.326	1	-0.2458
3	0.0000	5.0000	0.265	5	1.326	1	-0.2458
4	0.0000	5.0000	0.265	5	1.326	0	-1.0004
5	0.0000	5.0000	0.265	5	1.326	0	-1.0004
6	0.0000	5.0000	0.265	5	1.326	1	-0.2458
7	0.0000	6.0000	0.298	6	1.786	3	0.7656
8	0.0000	6.0000	0.298	6	1.786	6	2.6578
9	0.0000	6.0000	0.298	6	1.786	1	-0.4959
10	0.0000	6.0000	0.298	6	1.786	0	-1.1267
11	0.0000	6.0000	0.298	6	1.786	0	-1.1267
12	0.0000	6.0000	0.298	6	1.786	1	-0.4959
13	0.0000	6.0000	0.298	6	1.786	2	0.1348
14	0.0000	6.0000	0.298	6	1.786	0	-1.1267
15	0.0000	6.0000	0.298	6	1.786	2	0.1348
16	0.0000	6.0000	0.298	6	1.786	3	0.7656
17	0.0000	6.0000	0.298	6	1.786	5	2.0271
18	0.0000	6.0000	0.298	6	1.786	0	-1.1267
19	0.0000	6.0000	0.298	6	1.786	3	0.7656
20	0.0000	6.0000	0.298	6	1.786	3	0.7656
21	0.0000	6.0000	0.298	6	1.786	3	0.7656
22	0.0000	6.0000	0.298	6	1.786	5	2.0271
23	0.0000	7.0000	0.330	7	2.312	0	-1.2513
24	0.0000	7.0000	0.330	7	2.312	1	-0.7100
25	0.0000	7.0000	0.330	7	2.312	2	-0.1688
26	0.0000	7.0000	0.330	7	2.312	3	0.3725
27	0.0000	7.0000	0.330	7	2.312	2	-0.1688
28	0.0000	7.0000	0.330	7	2.312	3	0.3725
29	0.0000	7.0000	0.330	7	2.312	5	1.4551
30	0.0000	7.0000	0.330	7	2.312	0	-1.2513
31	0.0000	7.0000	0.330	7	2.312	2	-0.1688
32	0.0000	7.0000	0.330	7	2.312	5	1.4551
33	0.0000	7.0000	0.330	7	2.312	1	-0.7100
34	0.0000	7.0000	0.330	7	2.312	2	-0.1688
35	0.0000	7.0000	0.330	7	2.312	1	-0.7100
36	0.0000	8.0000	0.363	8	2.902	1	-0.9020
37	0.0000	8.0000	0.363	8	2.902	4	0.5204
38	0.0000	8.0000	0.363	8	2.902	3	0.0463
39	0.0000	8.0000	0.363	8	2.902	8	2.4170
40	0.0000	8.0000	0.363	8	2.902	2	-0.4279
41							
42	134.0000	1.0000	0.494	1	0.494	0	-0.9887
43	134.0000	1.0000	0.494	1	0.494	0	-0.9887
44	134.0000	2.0000	0.430	2	0.859	0	-1.0732
45	134.0000	2.0000	0.430	2	0.859	2	1.4251
46	134.0000	3.0000	0.383	3	1.150	3	1.7287
47	134.0000	3.0000	0.383	3	1.150	1	-0.1400
48	134.0000	3.0000	0.383	3	1.150	2	0.7944
49	134.0000	3.0000	0.383	3	1.150	1	-0.1400
50	134.0000	4.0000	0.356	4	1.425	3	1.1858
51	134.0000	4.0000	0.356	4	1.425	0	-1.0729
52	134.0000	5.0000	0.346	5	1.732	0	-1.0898
53	134.0000	5.0000	0.346	5	1.732	4	1.4275
54	134.0000	5.0000	0.346	5	1.732	0	-1.0898
55	134.0000	5.0000	0.346	5	1.732	1	-0.4604
56	134.0000	5.0000	0.346	5	1.732	0	-1.0898
57	134.0000	6.0000	0.350	6	2.099	3	0.4839
58	134.0000	6.0000	0.350	6	2.099	2	-0.0534
59	134.0000	7.0000	0.363	7	2.543	3	0.2128
60	134.0000	7.0000	0.363	7	2.543	2	-0.2530
61	134.0000	7.0000	0.363	7	2.543	2	-0.2530
62	134.0000	7.0000	0.363	7	2.543	2	-0.2530
63	134.0000	7.0000	0.363	7	2.543	2	-0.2530
64	134.0000	7.0000	0.363	7	2.543	0	-1.1847
65	134.0000	8.0000	0.383	8	3.068	2	-0.4373
66	134.0000	8.0000	0.383	8	3.068	0	-1.2562
67	134.0000	8.0000	0.383	8	3.068	8	2.0195

```
1
2       526.0000    2.0000    0.703    2    1.406    2     0.8346
3       526.0000    3.0000    0.631    3    1.892    3     1.1101
4       526.0000    4.0000    0.562    4    2.250    2    -0.1967
5       526.0000    4.0000    0.562    4    2.250    1    -0.9842
6       526.0000    5.0000    0.506    5    2.530    3     0.3091
7       526.0000    5.0000    0.506    5    2.530    5     1.6241
8       526.0000    5.0000    0.506    5    2.530    3     0.3091
9       526.0000    5.0000    0.506    5    2.530    1    -1.0058
10      526.0000    6.0000    0.466    6    2.796    3     0.1162
11      526.0000    6.0000    0.466    6    2.796    3     0.1162
12      526.0000    6.0000    0.466    6    2.796    3     0.1162
13      526.0000    6.0000    0.466    6    2.796    5     1.2556
14      526.0000    6.0000    0.466    6    2.796    6     1.8253
15      526.0000    6.0000    0.466    6    2.796    5     1.2556
16      526.0000    6.0000    0.466    6    2.796    2    -0.4534
17      526.0000    6.0000    0.466    6    2.796    0    -1.5928
18      526.0000    6.0000    0.466    6    2.796    2    -0.4534
19      526.0000    6.0000    0.466    6    2.796    0    -1.5928
20      526.0000    6.0000    0.466    6    2.796    5     1.2556
21      526.0000    6.0000    0.466    6    2.796    4     0.6859
22      526.0000    6.0000    0.466    6    2.796    3     0.1162
23      526.0000    6.0000    0.466    6    2.796    2    -0.4534
24      526.0000    6.0000    0.466    6    2.796    4     0.6859
25      526.0000    6.0000    0.466    6    2.796    2    -0.4534
26      526.0000    7.0000    0.444    7    3.105    0    -1.5658
27      526.0000    7.0000    0.444    7    3.105    4     0.4511
28      526.0000    7.0000    0.444    7    3.105    5     0.9554
29      526.0000    7.0000    0.444    7    3.105    1    -1.0615
30      526.0000    7.0000    0.444    7    3.105    4     0.4511
31      526.0000    7.0000    0.444    7    3.105    1    -1.0615
32      526.0000    7.0000    0.444    7    3.105    5     0.9554
33      526.0000    7.0000    0.444    7    3.105    3    -0.0531
34      526.0000    7.0000    0.444    7    3.105    4     0.4511
35      526.0000    7.0000    0.444    7    3.105    1    -1.0615
36      526.0000    7.0000    0.444    7    3.105    3    -0.0531
37      526.0000    7.0000    0.444    7    3.105    3    -0.0531
38      526.0000    8.0000    0.437    8    3.496    0    -1.5793
39      526.0000    8.0000    0.437    8    3.496    7     1.5832
40      526.0000    8.0000    0.437    8    3.496    5     0.6796
41      526.0000    9.0000    0.443    9    3.985    0    -1.6270
42      526.0000    9.0000    0.443    9    3.985    6     0.8225
43
44      2005.0000   1.0000    0.926    1    0.926    1     0.2834
45      2005.0000   1.0000    0.926    1    0.926    1     0.2834
46      2005.0000   1.0000    0.926    1    0.926    1     0.2834
47      2005.0000   2.0000    0.894    2    1.789    1    -1.5502
48      2005.0000   2.0000    0.894    2    1.789    2     0.4157
49      2005.0000   3.0000    0.853    3    2.559    3     0.5454
50      2005.0000   3.0000    0.853    3    2.559    1    -1.9294
51      2005.0000   3.0000    0.853    3    2.559    1    -1.9294
52      2005.0000   3.0000    0.853    3    2.559    3     0.5454
53      2005.0000   4.0000    0.802    4    3.208    4     0.6851
54      2005.0000   4.0000    0.802    4    3.208    4     0.6851
55      2005.0000   4.0000    0.802    4    3.208    4     0.6851
56      2005.0000   4.0000    0.802    4    3.208    2    -1.0440
57      2005.0000   4.0000    0.802    4    3.208    3    -0.1795
58      2005.0000   4.0000    0.802    4    3.208    4     0.6851
59      2005.0000   4.0000    0.802    4    3.208    4     0.6851
60      2005.0000   5.0000    0.743    5    3.714    1    -1.7660
61      2005.0000   5.0000    0.743    5    3.714    3    -0.4648
62      2005.0000   5.0000    0.743    5    3.714    5     0.8364
63      2005.0000   5.0000    0.743    5    3.714    5     0.8364
64      2005.0000   5.0000    0.743    5    3.714    4     0.1858
65      2005.0000   5.0000    0.743    5    3.714    4     0.1858
66      2005.0000   6.0000    0.681    6    4.086    6     0.9945
67      2005.0000   6.0000    0.681    6    4.086    2    -1.0836
```

```
1    2005.0000    6.0000    0.681    6    4.086    4    -0.0445
2    2005.0000    6.0000    0.681    6    4.086    5     0.4750
3    2005.0000    6.0000    0.681    6    4.086    6     0.9945
4    2005.0000    6.0000    0.681    6    4.086    5     0.4750
5    2005.0000    6.0000    0.681    6    4.086    4    -0.0445
6    2005.0000    6.0000    0.681    6    4.086    5     0.4750
7    2005.0000    6.0000    0.681    6    4.086    3    -0.5641
8    2005.0000    6.0000    0.681    6    4.086    6     0.9945
9    2005.0000    6.0000    0.681    6    4.086    0    -2.1227
10   2005.0000    6.0000    0.681    6    4.086    0    -2.1227
11   2005.0000    7.0000    0.623    7    4.361    7     1.1486
12   2005.0000    7.0000    0.623    7    4.361    5     0.2781
13   2005.0000    7.0000    0.623    7    4.361    5     0.2781
14   2005.0000    7.0000    0.623    7    4.361    7     1.1486
15   2005.0000    7.0000    0.623    7    4.361    6     0.7133
16   2005.0000    8.0000    0.576    8    4.606    0    -1.7419
```

Combine litters with adjacent levels of the litter-specific covariate
within dose groups until the expected count exceeds 3.0, to help improve
the fit of the X^2 statistic to chi-square.

Grouped Data

```
                   Mean                                    Scaled
      Dose    Lit.-Spec. Cov.    Expected    Observed     Residual
    -------------------------------------------------------------
     0.0000       1.0000           0.270         0        -0.5586
     0.0000       2.0000           1.675         3         1.0237
     0.0000       3.0000           2.401         2        -0.2443
     0.0000       4.0000           3.722         2        -0.8049
     0.0000       5.0000           3.977         4         0.0098
     0.0000       5.0000           3.977         2        -0.8614
     0.0000       5.0000           3.977         1        -1.2970
     0.0000       5.0000           1.326         1        -0.2458
     0.0000       6.0000           3.573         9         2.4207
     0.0000       6.0000           3.573         1        -1.1474
     0.0000       6.0000           3.573         1        -1.1474
     0.0000       6.0000           3.573         2        -0.7013
     0.0000       6.0000           3.573         5         0.6367
     0.0000       6.0000           3.573         5         0.6367
     0.0000       6.0000           3.573         6         1.0827
     0.0000       6.0000           3.573         8         1.9747
     0.0000       7.0000           4.624         1        -1.3869
     0.0000       7.0000           4.624         5         0.1441
     0.0000       7.0000           4.624         5         0.1441
     0.0000       7.0000           4.624         5         0.1441
     0.0000       7.0000           4.624         7         0.9096
     0.0000       7.0000           4.624         3        -0.6214
     0.0000       7.0000           2.312         1        -0.7100
     0.0000       8.0000           5.805         5        -0.2698
     0.0000       8.0000           5.805        11         1.7418
     0.0000       8.0000           2.902         2        -0.4279

   134.0000       1.0000           0.989         0        -1.3982
   134.0000       2.0000           1.718         2         0.2488
   134.0000       3.0000           3.449         6         1.3759
   134.0000       3.0000           1.150         1        -0.1400
   134.0000       4.0000           2.850         3         0.0799
   134.0000       5.0000           3.463         4         0.2388
   134.0000       5.0000           3.463         1        -1.0962
   134.0000       5.0000           1.732         0        -1.0898
   134.0000       6.0000           4.199         5         0.3044
   134.0000       7.0000           5.086         5        -0.0284
   134.0000       7.0000           5.086         4        -0.3578
   134.0000       7.0000           5.086         2        -1.0166
   134.0000       8.0000           3.068         2        -0.4373
   134.0000       8.0000           3.068         0        -1.2562
   134.0000       8.0000           3.068         8         2.0195
```

```
 1
 2    526.0000    2.0000    1.406    2    0.8346
 3    526.0000    3.0000    1.892    3    1.1101
 4    526.0000    4.0000    4.500    3   -0.8351
 5    526.0000    5.0000    5.060    8    1.3670
 6    526.0000    5.0000    5.060    4   -0.4926
 7    526.0000    6.0000    5.592    6    0.1644
 8    526.0000    6.0000    5.592    8    0.9700
 9    526.0000    6.0000    5.592   11    2.1785
10    526.0000    6.0000    5.592    2   -1.4469
11    526.0000    6.0000    5.592    2   -1.4469
12    526.0000    6.0000    5.592    9    1.3729
13    526.0000    6.0000    5.592    5   -0.2384
14    526.0000    6.0000    5.592    6    0.1644
15    526.0000    7.0000    3.105    0   -1.5658
16    526.0000    7.0000    3.105    4    0.4511
17    526.0000    7.0000    3.105    5    0.9554
18    526.0000    7.0000    3.105    1   -1.0615
19    526.0000    7.0000    3.105    4    0.4511
20    526.0000    7.0000    3.105    1   -1.0615
21    526.0000    7.0000    3.105    5    0.9554
22    526.0000    7.0000    3.105    3   -0.0531
23    526.0000    7.0000    3.105    4    0.4511
24    526.0000    7.0000    3.105    1   -1.0615
25    526.0000    7.0000    3.105    3   -0.0531
26    526.0000    7.0000    3.105    3   -0.0531
27    526.0000    8.0000    3.496    0   -1.5793
28    526.0000    8.0000    3.496    7    1.5832
29    526.0000    8.0000    3.496    5    0.6796
30    526.0000    9.0000    3.985    0   -1.6270
31    526.0000    9.0000    3.985    6    0.8225
32
33   2005.0000    1.0000    2.777    3    0.4909
34   2005.0000    2.0000    3.577    3   -0.8022
35   2005.0000    3.0000    5.118    4   -0.9786
36   2005.0000    3.0000    5.118    4   -0.9786
37   2005.0000    4.0000    3.208    4    0.6851
38   2005.0000    4.0000    3.208    4    0.6851
39   2005.0000    4.0000    3.208    4    0.6851
40   2005.0000    4.0000    3.208    2   -1.0440
41   2005.0000    4.0000    3.208    3   -0.1795
42   2005.0000    4.0000    3.208    4    0.6851
43   2005.0000    4.0000    3.208    4    0.6851
44   2005.0000    5.0000    3.714    1   -1.7660
45   2005.0000    5.0000    3.714    3   -0.4648
46   2005.0000    5.0000    3.714    5    0.8364
47   2005.0000    5.0000    3.714    5    0.8364
48   2005.0000    5.0000    3.714    4    0.1858
49   2005.0000    5.0000    3.714    4    0.1858
50   2005.0000    6.0000    4.086    6    0.9945
51   2005.0000    6.0000    4.086    2   -1.0836
52   2005.0000    6.0000    4.086    4   -0.0445
53   2005.0000    6.0000    4.086    5    0.4750
54   2005.0000    6.0000    4.086    6    0.9945
55   2005.0000    6.0000    4.086    5    0.4750
56   2005.0000    6.0000    4.086    4   -0.0445
57   2005.0000    6.0000    4.086    5    0.4750
58   2005.0000    6.0000    4.086    3   -0.5641
59   2005.0000    6.0000    4.086    6    0.9945
60   2005.0000    6.0000    4.086    0   -2.1227
61   2005.0000    6.0000    4.086    0   -2.1227
62   2005.0000    7.0000    4.361    7    1.1486
63   2005.0000    7.0000    4.361    5    0.2781
64   2005.0000    7.0000    4.361    5    0.2781
65   2005.0000    7.0000    4.361    7    1.1486
66   2005.0000    7.0000    4.361    6    0.7133
67   2005.0000    8.0000    4.606    0   -1.7419
```

```
 Chi-square =      105.13   DF = 98    P-value = 0.2930

To calculate the BMD and BMDL, the litter specific covariate is fixed
 at the mean litter specific covariate of all the data: 5.379518
=====================================================================
Specified effect =           0.1
Risk Type        =      Extra risk
Confidence level =          0.95
              BMD =      141.492
             BMDL =       94.264
```


Nested Logistic Model with 0.95 Confidence Level

13:20 11/13 2007

Figure C-5. Nested Logistic Model, 0.1 Extra Risk - Incidence of Cervical Rib in Mice versus C_{max} Methanol, GD 6-15 inhalational study.

Source: Rogers et al. (1993, 032696).

Once the $BMDL_{10}$ was obtained in units of mg/L, it was used to derive a chronic inhalation reference value. The first step is to calculate the HEC using the PBPK model described in Appendix B. An algebraic equation is provided (Equation 1 of Appendix B) that describes the relationship between predicted methanol AUC and the human equivalent inhalation exposure concentration (HEC) in ppm. This equation can also be used to estimate model predictions for HECs from C_{max} values because C_{max} values and AUC values were estimated at steady-state for constant 24-hour exposures (i.e., AUC = 24 x C_{max}).

$BMDL_{HEC}$ (ppm) = 0.0224*$BMDL_{10}$*24+(1334*$BMDL_{10}$*24)/(794+ $BMDL_{10}$*24)

$BMDL_{HEC}$ (ppm) = 0.0224*94.3*24 + ((1334*94.3*24)/(794+ 94.3*24)) = 1038 ppm

Next, because RfCs are typically expressed in units of mg/m^3, the HEC value in ppm was converted using the conversion factor specific to methanol of 1 ppm = 1.31 mg/m^3:

$$HEC \text{ (mg/m}^3) = 1.31 \times 1038 \text{ ppm} = 1360 \text{ mg/m}^3$$

Finally, this HEC value was divided by a composite 100-fold UF (3 for uncertainty associated with animal to human differences, 10 for consideration of human variability, and 3 for database deficiencies) to obtain the chronic inhalation reference value:

$$RfC \text{ (mg/m}^3) = 1360 \text{ mg/m}^3 \div 100 = 13.6 \text{ mg/m}^3$$

C.2.2. BMD Approach with a BMR of 0.05 Extra Risk

A summary of the results most relevant to the development of a POD using the BMD approach (BMD, BMDL, and model fit statistics) for increased incidence of cervical rib in mice exposed to methanol during gestation from days 6 to 15, with a BMR of 0.05 extra risk, is provided in Table C-9. Model fit was determined by statistics (AIC and χ^2 residuals of individual dose groups) and visual inspection, as recommended by U.S. EPA (U.S. EPA, 2000, 052150). The best model fit to these data (from visual inspection and comparison of AIC values) was obtained using the NLogistic model. The text and graphic (see Figure C-6) output from this model follow Table C-6. The $BMDL_{05}$ was determined to be 44.7 mg/L using the 95% lower confidence limit of the dose-response curve expressed in terms of the C_{max} for methanol in blood (Rogers et al., 1993, 032696).

Table C-9. Comparison of BMD modeling results for cervical rib incidence in mice using modeled C_{max} of methanol as a common dose metric

Model	BMD_{05} (C_{max}, mg/L)[A]	$BMDL_{05}$ (C_{max}, mg/L)[A]	*p*-value	AIC[C]	Scaled residual[D]
NLogistic[b]	67.022	44.651	0.293	1046.84	0.649
NCTR	101.235	50.618	0.241	1048.92	0.662
Rai and Van Ryzin	107.838	53.919	0.163	1051.65	0.661

[a]Daily C_{max} was estimated using a mouse PBPK model as described in section 3.4 of the methanol toxicological review; the BMDL is the 95% lower confidence limit on the C_{max} for a 5% extra risk (dichotomous endpoints) estimated by the model using the likelihood profile method (U.S. EPA, 2000, 052150).
[b]Model choice based on adequate *p* value (> 0.1), visual inspection, low AIC, and low (absolute) scaled residual.
[c]AIC = Akaike Information Criterion = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters, and P is the number of modeled degrees of freedom (usually the number of parameters estimated).
[d]χ^2d residual (measure of how model-predicted responses deviate from the actual data) for the dose group closest to the BMD scaled by an estimate of its S.D. Provides a comparative measure of model fit near the BMD. Residuals exceeding 2.0 in absolute value should cause one to question model fit in this region.

Source: Rogers et al. (1993, 032696).

```
1   ======================================================================
2   NLogistic Model.
3   (Version: 2.13; Date: 02/20/2007)
4   Input Data File: U:\Methanol\BMDS\CervicalRib\Cmax\NLog_Cmax_10_default.(d)
5   Wed Nov 07 15:45:40 2007
6   ======================================================================
7   BMD Method for RfC: Incidence of Cervical Rib in Mice versus Cmax Methanol, GD6-GD15
8   inhalational study (Rogers et al., 1993, 032696)
9   ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
10    The probability function is:
11
12   Prob. = alpha + theta1*Rij + [1 - alpha - theta1*Rij]/
13
14                     [1+exp(-beta-theta2*Rij-rho*log(Dose))],
15
16          where Rij is the litter specific covariate.
17
18   Restrict Power rho >= 1.
19
20   Total number of observations = 166
21   Total number of records with missing values = 0
22   Total number of parameters in model = 9
23   Total number of specified parameters = 0
24
25   Maximum number of iterations = 250
26   Relative Function Convergence has been set to: 1e-008
27   Parameter Convergence has been set to: 1e-008
28
29                   Default Initial Parameter Values
30                       alpha =    0.297863
```

```
 1                                       beta =      -7.94313
 2                                     theta1 =             0
 3                                     theta2 =             0
 4                                        rho =       1.09876
 5                                       phi1 =      0.213134
 6                                       phi2 =      0.309556
 7                                       phi3 =      0.220142
 8                                       phi4 =      0.370587
 9
10                              Parameter Estimates
11
12          Variable           Estimate              Std. Err.
13            alpha            0.102434                  *
14             beta           -4.80338                   *
15           theta1           0.0325457                  *
16           theta2          -0.436115                   *
17              rho                  1                    *
18             phi1           0.200733                   *
19             phi2           0.307656                   *
20             phi3           0.212754                   *
21             phi4           0.368426                   *
22
23   * - Indicates that this value is not calculated.
24
25    Log-likelihood: -515.422   AIC: 1046.84
26                          Litter Data
27
28            Lit.-Spec.            Litter                        Scaled
29     Dose      Cov.    Est._Prob.   Size    Expected   Observed  Residual
30   -------------------------------------------------------------------
31    0.0000    1.0000     0.135       1       0.135        0      -0.3950
32    0.0000    1.0000     0.135       1       0.135        0      -0.3950
33    0.0000    2.0000     0.168       2       0.335        0      -0.5790
34    0.0000    2.0000     0.168       2       0.335        1       1.1490
35    0.0000    2.0000     0.168       2       0.335        0      -0.5790
36    0.0000    2.0000     0.168       2       0.335        2       2.8770
37    0.0000    2.0000     0.168       2       0.335        0      -0.5790
38    0.0000    3.0000     0.200       3       0.600        0      -0.7317
39    0.0000    3.0000     0.200       3       0.600        0      -0.7317
40    0.0000    3.0000     0.200       3       0.600        1       0.4874
41    0.0000    3.0000     0.200       3       0.600        1       0.4874
42    0.0000    4.0000     0.233       4       0.930        0      -0.8699
43    0.0000    4.0000     0.233       4       0.930        1       0.0650
44    0.0000    4.0000     0.233       4       0.930        0      -0.8699
45    0.0000    4.0000     0.233       4       0.930        1       0.0650
46    0.0000    5.0000     0.265       5       1.326        0      -1.0004
47    0.0000    5.0000     0.265       5       1.326        1      -0.2458
48    0.0000    5.0000     0.265       5       1.326        3       1.2632
49    0.0000    5.0000     0.265       5       1.326        1      -0.2458
50    0.0000    5.0000     0.265       5       1.326        0      -1.0004
51    0.0000    5.0000     0.265       5       1.326        1      -0.2458
52    0.0000    5.0000     0.265       5       1.326        1      -0.2458
53    0.0000    5.0000     0.265       5       1.326        0      -1.0004
54    0.0000    5.0000     0.265       5       1.326        0      -1.0004
55    0.0000    5.0000     0.265       5       1.326        1      -0.2458
56    0.0000    6.0000     0.298       6       1.786        3       0.7656
57    0.0000    6.0000     0.298       6       1.786        6       2.6578
58    0.0000    6.0000     0.298       6       1.786        1      -0.4959
59    0.0000    6.0000     0.298       6       1.786        0      -1.1267
60    0.0000    6.0000     0.298       6       1.786        0      -1.1267
61    0.0000    6.0000     0.298       6       1.786        1      -0.4959
62    0.0000    6.0000     0.298       6       1.786        2       0.1348
63    0.0000    6.0000     0.298       6       1.786        0      -1.1267
64    0.0000    6.0000     0.298       6       1.786        2       0.1348
65    0.0000    6.0000     0.298       6       1.786        3       0.7656
66    0.0000    6.0000     0.298       6       1.786        5       2.0271
67    0.0000    6.0000     0.298       6       1.786        0      -1.1267
```

1	0.0000	6.0000	0.298	6	1.786	3	0.7656
2	0.0000	6.0000	0.298	6	1.786	3	0.7656
3	0.0000	6.0000	0.298	6	1.786	3	0.7656
4	0.0000	6.0000	0.298	6	1.786	5	2.0271
5	0.0000	7.0000	0.330	7	2.312	0	−1.2513
6	0.0000	7.0000	0.330	7	2.312	1	−0.7100
7	0.0000	7.0000	0.330	7	2.312	2	−0.1688
8	0.0000	7.0000	0.330	7	2.312	3	0.3725
9	0.0000	7.0000	0.330	7	2.312	2	−0.1688
10	0.0000	7.0000	0.330	7	2.312	3	0.3725
11	0.0000	7.0000	0.330	7	2.312	5	1.4551
12	0.0000	7.0000	0.330	7	2.312	0	−1.2513
13	0.0000	7.0000	0.330	7	2.312	2	−0.1688
14	0.0000	7.0000	0.330	7	2.312	5	1.4551
15	0.0000	7.0000	0.330	7	2.312	1	−0.7100
16	0.0000	7.0000	0.330	7	2.312	2	−0.1688
17	0.0000	7.0000	0.330	7	2.312	1	−0.7100
18	0.0000	8.0000	0.363	8	2.902	1	−0.9020
19	0.0000	8.0000	0.363	8	2.902	4	0.5204
20	0.0000	8.0000	0.363	8	2.902	3	0.0463
21	0.0000	8.0000	0.363	8	2.902	8	2.4170
22	0.0000	8.0000	0.363	8	2.902	2	−0.4279
23							
24	134.0000	1.0000	0.494	1	0.494	0	−0.9887
25	134.0000	1.0000	0.494	1	0.494	0	−0.9887
26	134.0000	2.0000	0.430	2	0.859	0	−1.0732
27	134.0000	2.0000	0.430	2	0.859	2	1.4251
28	134.0000	3.0000	0.383	3	1.150	3	1.7287
29	134.0000	3.0000	0.383	3	1.150	1	−0.1400
30	134.0000	3.0000	0.383	3	1.150	2	0.7944
31	134.0000	3.0000	0.383	3	1.150	1	−0.1400
32	134.0000	4.0000	0.356	4	1.425	3	1.1858
33	134.0000	4.0000	0.356	4	1.425	0	−1.0729
34	134.0000	5.0000	0.346	5	1.732	0	−1.0898
35	134.0000	5.0000	0.346	5	1.732	4	1.4275
36	134.0000	5.0000	0.346	5	1.732	0	−1.0898
37	134.0000	5.0000	0.346	5	1.732	1	−0.4604
38	134.0000	5.0000	0.346	5	1.732	0	−1.0898
39	134.0000	6.0000	0.350	6	2.099	3	0.4839
40	134.0000	6.0000	0.350	6	2.099	2	−0.0534
41	134.0000	7.0000	0.363	7	2.543	3	0.2128
42	134.0000	7.0000	0.363	7	2.543	2	−0.2530
43	134.0000	7.0000	0.363	7	2.543	2	−0.2530
44	134.0000	7.0000	0.363	7	2.543	2	−0.2530
45	134.0000	7.0000	0.363	7	2.543	2	−0.2530
46	134.0000	7.0000	0.363	7	2.543	0	−1.1847
47	134.0000	8.0000	0.383	8	3.068	2	−0.4373
48	134.0000	8.0000	0.383	8	3.068	0	−1.2562
49	134.0000	8.0000	0.383	8	3.068	8	2.0195
50							
51	526.0000	2.0000	0.703	2	1.406	2	0.8346
52	526.0000	3.0000	0.631	3	1.892	3	1.1101
53	526.0000	4.0000	0.562	4	2.250	2	−0.1967
54	526.0000	4.0000	0.562	4	2.250	1	−0.9842
55	526.0000	5.0000	0.506	5	2.530	3	0.3091
56	526.0000	5.0000	0.506	5	2.530	5	1.6241
57	526.0000	5.0000	0.506	5	2.530	3	0.3091
58	526.0000	5.0000	0.506	5	2.530	1	−1.0058
59	526.0000	6.0000	0.466	6	2.796	3	0.1162
60	526.0000	6.0000	0.466	6	2.796	3	0.1162
61	526.0000	6.0000	0.466	6	2.796	3	0.1162
62	526.0000	6.0000	0.466	6	2.796	5	1.2556
63	526.0000	6.0000	0.466	6	2.796	6	1.8253
64	526.0000	6.0000	0.466	6	2.796	5	1.2556
65	526.0000	6.0000	0.466	6	2.796	2	−0.4534
66	526.0000	6.0000	0.466	6	2.796	0	−1.5928
67	526.0000	6.0000	0.466	6	2.796	2	−0.4534

```
1    526.0000    6.0000    0.466    6    2.796    0    -1.5928
2    526.0000    6.0000    0.466    6    2.796    5     1.2556
3    526.0000    6.0000    0.466    6    2.796    4     0.6859
4    526.0000    6.0000    0.466    6    2.796    3     0.1162
5    526.0000    6.0000    0.466    6    2.796    2    -0.4534
6    526.0000    6.0000    0.466    6    2.796    4     0.6859
7    526.0000    6.0000    0.466    6    2.796    2    -0.4534
8    526.0000    7.0000    0.444    7    3.105    0    -1.5658
9    526.0000    7.0000    0.444    7    3.105    4     0.4511
10   526.0000    7.0000    0.444    7    3.105    5     0.9554
11   526.0000    7.0000    0.444    7    3.105    1    -1.0615
12   526.0000    7.0000    0.444    7    3.105    4     0.4511
13   526.0000    7.0000    0.444    7    3.105    1    -1.0615
14   526.0000    7.0000    0.444    7    3.105    5     0.9554
15   526.0000    7.0000    0.444    7    3.105    3    -0.0531
16   526.0000    7.0000    0.444    7    3.105    4     0.4511
17   526.0000    7.0000    0.444    7    3.105    1    -1.0615
18   526.0000    7.0000    0.444    7    3.105    3    -0.0531
19   526.0000    7.0000    0.444    7    3.105    3    -0.0531
20   526.0000    8.0000    0.437    8    3.496    0    -1.5793
21   526.0000    8.0000    0.437    8    3.496    7     1.5832
22   526.0000    8.0000    0.437    8    3.496    5     0.6796
23   526.0000    9.0000    0.443    9    3.985    0    -1.6270
24   526.0000    9.0000    0.443    9    3.985    6     0.8225
25
26   2005.0000   1.0000    0.926    1    0.926    1     0.2834
27   2005.0000   1.0000    0.926    1    0.926    1     0.2834
28   2005.0000   1.0000    0.926    1    0.926    1     0.2834
29   2005.0000   2.0000    0.894    2    1.789    1    -1.5502
30   2005.0000   2.0000    0.894    2    1.789    2     0.4157
31   2005.0000   3.0000    0.853    3    2.559    3     0.5454
32   2005.0000   3.0000    0.853    3    2.559    1    -1.9294
33   2005.0000   3.0000    0.853    3    2.559    1    -1.9294
34   2005.0000   3.0000    0.853    3    2.559    3     0.5454
35   2005.0000   4.0000    0.802    4    3.208    4     0.6851
36   2005.0000   4.0000    0.802    4    3.208    4     0.6851
37   2005.0000   4.0000    0.802    4    3.208    4     0.6851
38   2005.0000   4.0000    0.802    4    3.208    2    -1.0440
39   2005.0000   4.0000    0.802    4    3.208    3    -0.1795
40   2005.0000   4.0000    0.802    4    3.208    4     0.6851
41   2005.0000   4.0000    0.802    4    3.208    4     0.6851
42   2005.0000   5.0000    0.743    5    3.714    1    -1.7660
43   2005.0000   5.0000    0.743    5    3.714    3    -0.4648
44   2005.0000   5.0000    0.743    5    3.714    5     0.8364
45   2005.0000   5.0000    0.743    5    3.714    5     0.8364
46   2005.0000   5.0000    0.743    5    3.714    4     0.1858
47   2005.0000   5.0000    0.743    5    3.714    4     0.1858
48   2005.0000   6.0000    0.681    6    4.086    6     0.9945
49   2005.0000   6.0000    0.681    6    4.086    2    -1.0836
50   2005.0000   6.0000    0.681    6    4.086    4    -0.0445
51   2005.0000   6.0000    0.681    6    4.086    5     0.4750
52   2005.0000   6.0000    0.681    6    4.086    6     0.9945
53   2005.0000   6.0000    0.681    6    4.086    5     0.4750
54   2005.0000   6.0000    0.681    6    4.086    4    -0.0445
55   2005.0000   6.0000    0.681    6    4.086    5     0.4750
56   2005.0000   6.0000    0.681    6    4.086    3    -0.5641
57   2005.0000   6.0000    0.681    6    4.086    6     0.9945
58   2005.0000   6.0000    0.681    6    4.086    0    -2.1227
59   2005.0000   6.0000    0.681    6    4.086    0    -2.1227
60   2005.0000   7.0000    0.623    7    4.361    7     1.1486
61   2005.0000   7.0000    0.623    7    4.361    5     0.2781
62   2005.0000   7.0000    0.623    7    4.361    5     0.2781
63   2005.0000   7.0000    0.623    7    4.361    7     1.1486
64   2005.0000   7.0000    0.623    7    4.361    6     0.7133
65   2005.0000   8.0000    0.576    8    4.606    0    -1.7419
66
67   Combine litters with adjacent levels of the litter-specific covariate
```

within dose groups until the expected count exceeds 3.0, to help improve
the fit of the X^2 statistic to chi-square.

Grouped Data

Dose	Mean Lit.-Spec. Cov.	Expected	Observed	Scaled Residual
0.0000	1.0000	0.270	0	-0.5586
0.0000	2.0000	1.675	3	1.0237
0.0000	3.0000	2.401	2	-0.2443
0.0000	4.0000	3.722	2	-0.8049
0.0000	5.0000	3.977	4	0.0098
0.0000	5.0000	3.977	2	-0.8614
0.0000	5.0000	3.977	1	-1.2970
0.0000	5.0000	1.326	1	-0.2458
0.0000	6.0000	3.573	9	2.4207
0.0000	6.0000	3.573	1	-1.1474
0.0000	6.0000	3.573	1	-1.1474
0.0000	6.0000	3.573	2	-0.7013
0.0000	6.0000	3.573	5	0.6367
0.0000	6.0000	3.573	5	0.6367
0.0000	6.0000	3.573	6	1.0827
0.0000	6.0000	3.573	8	1.9747
0.0000	7.0000	4.624	1	-1.3869
0.0000	7.0000	4.624	5	0.1441
0.0000	7.0000	4.624	5	0.1441
0.0000	7.0000	4.624	5	0.1441
0.0000	7.0000	4.624	7	0.9096
0.0000	7.0000	4.624	3	-0.6214
0.0000	7.0000	2.312	1	-0.7100
0.0000	8.0000	5.805	5	-0.2698
0.0000	8.0000	5.805	11	1.7418
0.0000	8.0000	2.902	2	-0.4279
134.0000	1.0000	0.989	0	-1.3982
134.0000	2.0000	1.718	2	0.2488
134.0000	3.0000	3.449	6	1.3759
134.0000	3.0000	1.150	1	-0.1400
134.0000	4.0000	2.850	3	0.0799
134.0000	5.0000	3.463	4	0.2388
134.0000	5.0000	3.463	1	-1.0962
134.0000	5.0000	1.732	0	-1.0898
134.0000	6.0000	4.199	5	0.3044
134.0000	7.0000	5.086	5	-0.0284
134.0000	7.0000	5.086	4	-0.3578
134.0000	7.0000	5.086	2	-1.0166
134.0000	8.0000	3.068	2	-0.4373
134.0000	8.0000	3.068	0	-1.2562
134.0000	8.0000	3.068	8	2.0195
526.0000	2.0000	1.406	2	0.8346
526.0000	3.0000	1.892	3	1.1101
526.0000	4.0000	4.500	3	-0.8351
526.0000	5.0000	5.060	8	1.3670
526.0000	5.0000	5.060	4	-0.4926
526.0000	6.0000	5.592	6	0.1644
526.0000	6.0000	5.592	8	0.9700
526.0000	6.0000	5.592	11	2.1785
526.0000	6.0000	5.592	2	-1.4469
526.0000	6.0000	5.592	2	-1.4469
526.0000	6.0000	5.592	9	1.3729
526.0000	6.0000	5.592	5	-0.2384
526.0000	6.0000	5.592	6	0.1644
526.0000	7.0000	3.105	0	-1.5658
526.0000	7.0000	3.105	4	0.4511
526.0000	7.0000	3.105	5	0.9554
526.0000	7.0000	3.105	1	-1.0615

```
1     526.0000          7.0000               3.105      4       0.4511
2     526.0000          7.0000               3.105      1      -1.0615
3     526.0000          7.0000               3.105      5       0.9554
4     526.0000          7.0000               3.105      3      -0.0531
5     526.0000          7.0000               3.105      4       0.4511
6     526.0000          7.0000               3.105      1      -1.0615
7     526.0000          7.0000               3.105      3      -0.0531
8     526.0000          7.0000               3.105      3      -0.0531
9     526.0000          8.0000               3.496      0      -1.5793
10    526.0000          8.0000               3.496      7       1.5832
11    526.0000          8.0000               3.496      5       0.6796
12    526.0000          9.0000               3.985      0      -1.6270
13    526.0000          9.0000               3.985      6       0.8225
14
15    2005.0000         1.0000               2.777      3       0.4909
16    2005.0000         2.0000               3.577      3      -0.8022
17    2005.0000         3.0000               5.118      4      -0.9786
18    2005.0000         3.0000               5.118      4      -0.9786
19    2005.0000         4.0000               3.208      4       0.6851
20    2005.0000         4.0000               3.208      4       0.6851
21    2005.0000         4.0000               3.208      4       0.6851
22    2005.0000         4.0000               3.208      2      -1.0440
23    2005.0000         4.0000               3.208      3      -0.1795
24    2005.0000         4.0000               3.208      4       0.6851
25    2005.0000         4.0000               3.208      4       0.6851
26    2005.0000         5.0000               3.714      1      -1.7660
27    2005.0000         5.0000               3.714      3      -0.4648
28    2005.0000         5.0000               3.714      5       0.8364
29    2005.0000         5.0000               3.714      5       0.8364
30    2005.0000         5.0000               3.714      4       0.1858
31    2005.0000         5.0000               3.714      4       0.1858
32    2005.0000         6.0000               4.086      6       0.9945
33    2005.0000         6.0000               4.086      2      -1.0836
34    2005.0000         6.0000               4.086      4      -0.0445
35    2005.0000         6.0000               4.086      5       0.4750
36    2005.0000         6.0000               4.086      6       0.9945
37    2005.0000         6.0000               4.086      5       0.4750
38    2005.0000         6.0000               4.086      4      -0.0445
39    2005.0000         6.0000               4.086      5       0.4750
40    2005.0000         6.0000               4.086      3      -0.5641
41    2005.0000         6.0000               4.086      6       0.9945
42    2005.0000         6.0000               4.086      0      -2.1227
43    2005.0000         6.0000               4.086      0      -2.1227
44    2005.0000         7.0000               4.361      7       1.1486
45    2005.0000         7.0000               4.361      5       0.2781
46    2005.0000         7.0000               4.361      5       0.2781
47    2005.0000         7.0000               4.361      7       1.1486
48    2005.0000         7.0000               4.361      6       0.7133
49    2005.0000         8.0000               4.606      0      -1.7419
50
51     Chi-square =      105.13    DF = 98     P-value = 0.2930
52
53    To calculate the BMD and BMDL, the litter specific covariate is fixed
54     at the mean litter specific covariate of all the data: 5.379518
55     =======================================================================
```

```
Specified effect =            0.05
Risk Type        =      Extra risk
Confidence level =            0.95
            BMD  =         67.0227
            BMDL =         44.6514
```


Figure C-6. Nested Logistic Model, 0.05 Extra Risk - Incidence of Cervical
Rib in Mice versus C_{max} Methanol, GD 6-15 inhalational study.

Source: Rogers et al. (1993, 032696).

1   Once the $BMDL_{05}$ was obtained in units of mg/L, it was used to derive a chronic

2   inhalation reference value. The first step is to calculate the HEC using the PBPK model

3   described in Appendix B. An algebraic equation is provided (Equation 1 of Appendix B) that

4   describes the relationship between predicted methanol AUC and the human equivalent inhalation

5   exposure concentration (HEC) in ppm. This equation can also be used to estimate model

6   predictions for HECs from C_{max} values because C_{max} values and AUC values were estimated at

7   steady-state for constant 24-hour exposures (i.e., AUC = 24 x C_{max}).

8    $BMDL_{HEC}$ (ppm) = 0.0224*$BMDL_{05}$*24+(1334*$BMDL_{05}$*24)/(794+ $BMDL_{05}$*24)

9    $BMDL_{HEC}$ (ppm) = 0.0224*44.7*24 + ((1334*44.7*24)/(794+ 44.7*24)) = 791 ppm

10   Next, because RfCs are typically expressed in units of mg/m^3, the HEC value in ppm was

11   converted using the conversion factor specific to methanol of 1 ppm = 1.31 mg/m^3:

$$\text{HEC (mg/m}^3) = 1.31 \times 791 \text{ ppm} = 1036 \text{ mg/m}^3$$

Finally, this HEC value was divided by a composite 100-fold UF (3 for uncertainty associated with animal to human differences, 10 for consideration of human variability, and 3 for database deficiencies) to obtain the chronic inhalation reference value:

$$\text{RfC (mg/m}^3) = 1036 \text{ mg/m}^3 \div 100 = 10.4 \text{ mg/m}^3$$

C.3. RfC-DERIVATIONS USING BURBACHER ET AL.

The BMD approach was utilized in the derivation of potential chronic inhalation reference values from effects seen in monkeys due to prenatal methanol exposure. Deficits in VDR were evaluated from Burbacher et al. (1999, 009752; 1999, 009753). In the application of the BMD approach, continuous models in the EPA's BMDS 2.1.1 (U.S. EPA, 2009, 200772) were fit to the dataset for increased latency in VDR in neonatal monkeys. As the EPA's PBPK model was not parameterized for monkeys, external concentration (ppm) was used as the dose metric.

The VDR test, which assesses time (from birth) it takes for an infant to grasp for a brightly colored object containing an applesauce-covered nipple, is a measure of sensorimotor development. Beginning at 2 weeks after birth, infants were tested 5 times/day, 4 days/week. Performance on that test, measured as age from birth at achievement of test criterion (successful object retrieval on 8/10 consecutive trials over 2 testing sessions), was reduced in all treated male infants. The times (days after birth) to achieve the criteria for the VDR test were 23.7 ± 4.8 (n = 3), 32.4 ± 4.1 (n = 5), 42.7 ± 8.0 (n = 3), and 40.5 ± 12.5 (n = 2) days for males and 34.2 ± 1.8 (n = 5), 33.0 ± 2.9 (n = 4), 27.6 ± 2.7 (n = 5), and 40.0 ± 4.0 (n = 7) days for females in the control to 1800 ppm groups, respectively. As discussed in Section 4.3.2, this type of response data is sometimes adjusted to account for premature births by subtracting time (days) premature from the time (days from birth) needed to meet the test criteria (Wilson and Cradock, 2004, 196726). When this type of adjustment is applied, the times (days after birth or, if shorter, days after control mean gestation length) to achieve the criteria for VDR test were 22.0 ± 9.54 (n = 3), 26.2 ± 8.61 (n = 5), 33.3 ± 10.0 (n = 3), and 39.5 ± 16.3 (n = 2) days for males and 32.0 ± 4.3 (n = 5), 21.8 ± 5.6 (n = 4), 24.0 ± 5.7 (n = 5), and 32.0 ± 14.8 (n = 7) days for females in the control to 1800 ppm groups, respectively. When these data were modeled within BMDS 2.1.1 (U.S. EPA, 2009, 200772), there was no significant difference between unadjusted responses and/or variances among the dose levels for males and females combined ($p = 0.244$), for males only ($p = 0.321$) and for males only with the high-dose group excluded ($p = 0.182$), or

1   for adjusted responses of males and females combined ($p = 0.12$), males only ($p = 0.448$) and

2   males only with the high-dose group excluded ($p = 0.586$).[94] The only data that offered a

3   significant dose-response trend was that for unadjusted ($p = 0.0265$) and adjusted ($p = 0.009$)

4   female responses, but the model fits for the adjusted female response data were unacceptable.

5   Only the unadjusted female VDR response data offered both a dose-response trend and

6   acceptable model fits. The modeling results for this data set are presented in Table C-10.

7   The current BMD technical guidance (U.S. EPA, 2000, 052150) suggests that in the

8   absence of knowledge as to what level of response to consider adverse, a change in the mean

9   equal to 1 control S.D. from the control mean can be used as a BMR for continuous endpoints. A

10   summary of the results most relevant to the development of a POD using the BMD approach

11   (BMD, BMDL, and model fit statistics) for increased latency of VDR in female neonatal

12   monkeys exposed to methanol with a BMR of 1 control mean S.D. is provided in Table C-10.

13   Model fit was determined by statistics (AIC and χ^2 residuals of individual dose groups) and

14   visual inspection, as recommended by EPA (U.S. EPA, 2000, 052150). The 3rd degree

15   polynomial model returned a lower AIC than the other models.[95] The text and graphic (see

16   Figure C-7) output from this model follows Table C-10. The $BMDL_{1SD}$ was determined to be

17   81.7 hr×mg/L, using the 95% lower confidence limit of the dose-response curve expressed in

18   terms of the ppm of external methanol concentration.

---

[94] BMDS (U.S. EPA, 2009, 200772) continuous models contain a test for dose-response trend, test 1, which compares a model that fits a distinct mean and variance for each dose group to a model that contains a single mean and variance. The dose response is considered to be significant if this comparison returns a p value < 0.05.

[95] A detailed analysis of this dose response revealed that modeling results, particularly the BMDL estimation, are very sensitive to the high-dose response. There is no data to inform the shape of the curve between the mid- and high-exposure levels, making the derivation of a BMDL very uncertain. The data were analyzed without the high dose to determine if the downward trend in the low- and mid-exposure groups is significant. It was not, so nonnegative restriction on the β coefficients of the poly models was retained.

Table C-10. Comparison of BMD modeling results for VDR in female monkeys using AUC blood methanol as the dose metric

Model	BMD$_{1SD}$ (AUC, hr × mg/L)[A]	BMDL$_{1SD}$ (AUC, hr × mg/L)[A]	p-value	AIC[C]	Scaled residual[D]
Linear	119.058	51.9876	0.1440	110.4492	0.5380
2nd degree polynomial	114.094	59.6412	0.2388	109.43782	0.0994
3rd degree polynomial	120.176	81.6513	0.2718	109.17894	0.0199
Power[b]	133.517	63.0615	0.1112	111.11010	0.0000
Hill	132.283	--	NA	113.11010	0.0000

[a]AUC was estimated using a rat PBPK model as described in section 3.4 of the methanol toxicological review; the BMDL is the 95% lower confidence limit on the AUC of a decrease of 1 control mean S.D. estimated by the model using the likelihood profile method (U.S. EPA, 2000, 052150).
[b]Model choice based on adequate *p* value (> 0.1), visual inspection, low AIC, and low (absolute) scaled residual.
[c]AIC = Akaike Information Criterion = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters, and P is the number of modeled degrees of freedom (usually the number of parameters estimated).
[d]χ^2d residual (measure of how model-predicted responses deviate from the actual data) for the dose group closest to the BMD scaled by an estimate of its S.D. Provides a comparative measure of model fit near the BMD. Residuals that exceed 2.0 in absolute value should cause one to question model fit in this region.

Source: Burbacher et al. (1999, 009752).

```
 1    ======================================================================
 2    Polynomial Model.
 3    (Version: 2.13;  Date: 04/08/2008)
 4    Input Data File: C:\USEPA\BMDS2\Data\Burbacher\PolfemSet.(d)
 5    Gnuplot Plotting File:  C:\USEPA\BMDS2\Data\Burbacher\PolfemSet.plt
 6                                          Fri Dec 12 15:30:29 2008
 7    ======================================================================
 8    VDR in female monkeys using AUC blood methanol as the dose metric
 9    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
10       The form of the response function is:
11
12      Y[dose] = beta_0 + beta_1*dose + beta_2*dose^2 + ...
13
14      Dependent variable = F_VDR
15      Independent variable = F_Dose
16      The polynomial coefficients are restricted to be positive
17      The variance is to be modeled as Var(i) = exp(lalpha + log(mean(i)) * rho)
18
19      Total number of dose groups = 4
20      Total number of records with missing values = 0
21      Maximum number of iterations = 250
22      Relative Function Convergence has been set to: 1e-008
23      Parameter Convergence has been set to: 1e-008
24
25                    Default Initial Parameter Values
26                         lalpha =     4.07254
27                            rho =           0
28                         beta_0 =        34.2
29                         beta_1 =           0
30                         beta_2 =           0
31                         beta_3 =           0
32
33          Asymptotic Correlation Matrix of Parameter Estimates
34
```

```
         ( *** The model parameter(s)  -beta_1    -beta_2
                have been estimated at a boundary point, or have been specified by
the user,
                and do not appear in the correlation matrix )

                    lalpha          rho        beta_0        beta_3

    lalpha              1           -1       -0.0076         0.018
       rho             -1            1        0.0076        -0.018
    beta_0        -0.0076       0.0076            1         -0.37
    beta_3         0.018       -0.018         -0.37             1

                            Parameter Estimates

                                                  95.0% Wald CI
        Variable         Estimate        Std. Err.    Lower Conf. Limit    Upper Conf.
Limit
         lalpha        -13.5062          9.81148         -32.7363
5.72395
            rho         4.90831          2.77841        -0.537284
10.3539
         beta_0         31.5013          1.49057          28.5798
34.4228
         beta_1       8.36431e-025            NA
         beta_2              0             NA
         beta_3       3.19775e-006     1.53534e-006       1.88544e-007         6.20695e-
006

NA - Indicates that this parameter has hit a bound
      implied by some inequality constraint and thus
      has no standard error.

      Table of Data and Estimated Values of Interest

  Dose        N    Obs Mean      Est Mean    Obs Std Dev    Est Std Dev    Scaled Res.
 ------      ---   --------      --------    ----------     -----------    ----------

     0        5       34.2          31.5         4.09           5.55          1.09
  6.73        4         33          31.5         5.83           5.55          0.54
 28.28        5       27.6          31.6         5.94           5.58         -1.59
 138.1        7         40          39.9        10.7            9.93          0.0199

  Model Descriptions for likelihoods calculated

  Model A1:        Yij = Mu(i) + e(ij)
            Var{e(ij)} = Sigma^2
  Model A2:        Yij = Mu(i) + e(ij)
            Var{e(ij)} = Sigma(i)^2
  Model A3:        Yij = Mu(i) + e(ij)
            Var{e(ij)} = exp(lalpha + rho*ln(Mu(i)))
      Model A3 uses any fixed variance parameters that
      were specified by the user

  Model  R:        Yi = Mu + e(i)
            Var{e(i)} = Sigma^2

                    Likelihoods of Interest

         Model      Log(likelihood)   # Param's       AIC
          A1         -51.042924            5       112.085848
          A2         -47.867444            8       111.734888
          A3         -49.286738            6       110.573475
       fitted        -50.589469            4       109.178938
          R          -55.013527            2       114.027055

                Explanation of Tests

  Test 1:  Do responses and/or variances differ among Dose levels?
```

```
            (A2 versus R)
 Test 2:  Are Variances Homogeneous? (A1 vs A2)
 Test 3:  Are variances adequately modeled? (A2 versus A3)
 Test 4:  Does the Model for the Mean Fit? (A3 versus fitted)
 (Note:  When rho=0 the results of Test 3 and Test 2 will be the same.)

                   Tests of Interest

   Test    -2*log(Likelihood Ratio)  Test df        p-value

   Test 1              14.2922          6            0.02654
   Test 2               6.35096         3            0.09573
   Test 3               2.83859         2            0.2419
   Test 4               2.60546         2            0.2718

The p-value for Test 1 is less than .05.  There appears to be a
difference between response and/or variances among the dose levels
It seems appropriate to model the data

The p-value for Test 2 is less than .1.  A non-homogeneous variance
model appears to be appropriate

The p-value for Test 3 is greater than .1.  The modeled variance appears
 to be appropriate here

The p-value for Test 4 is greater than .1.  The model chosen seems
to adequately describe the data
Specified effect =            1
Risk Type        =    Estimated S.D.s from the control mean
Confidence level =         0.95
             BMD =      120.176
            BMDL =      81.6513
```

Polynomial Model with 0.95 Confidence Level

**Figure C-7. 3rd Degree Polynomial Model, BMR of 1 Control Mean S.D. –
VDR in female monkeys using AUC blood methanol as the dose metric.**

Source: Burbacher et al. (1999, 009752; 1999, 009753)

1   Once the $BMDL_{1SD}$ was obtained in units of ppm, it was used to derive a chronic
2   inhalation reference value. The first step is to calculate the HEC using the PBPK model
3   described in Appendix B. An algebraic equation is provided (Equation 1 of Appendix B) that
4   describes the relationship between predicted methanol AUC and the human equivalent inhalation
5   exposure concentration (HEC) in ppm.

6    $BMDL_{HEC}$ (ppm) = $0.0224*BMDL_{1SD}+(1334*BMDL_{1SD})/(794+ BMDL_{1SD})$
7    $BMDL_{HEC}$ (ppm) = $0.0224*81.7+(1334*81.7)/(794+ 81.7) = 126.3$ ppm

8   Next, because RfCs are typically expressed in units of mg/m^3, the HEC value in ppm was
9   converted using the conversion factor specific to methanol of 1 ppm = 1.31 mg/m^3:

10   HEC (mg/m^3) = 1.31×126.3 ppm = 165 mg/m^3

1   Finally, this HEC value was divided by a composite 100-fold UF (3 for uncertainty

2   associated with animal to human differences, 10 for consideration of human variability, and 3 for

3   database deficiencies) to obtain the chronic inhalation reference value:

4 $$\text{RfC (mg/m}^3) = 165 \text{ mg/m}^3 \div 100 = 1.7 \text{ mg/m}^3$$

APPENDIX D. RfC DERIVATION – COMPARISON OF DOSE METRICS

D.1. METHODS

D.1.1. Dose Metric Comparisons

1   Three potential dose metrics were evaluated for possible use in risk extrapolation of
2 methanol-induced developmental effects: AUC of methanol in the blood; C_{max} of methanol in the
3 blood; and total metabolism of methanol. The latter metric was considered because
4 developmental effects may be caused by metabolites of methanol, particularly formaldehyde, and
5 formate. These three metrics were evaluated by determining how well they were able to explain
6 the variation in response for incidence of cervical ribs (CR) and supernumerary ribs (SNR) in a
7 concentration-time bioassay by Rogers et al. (1995, raw data obtained from personal
8 communication). In particular, pregnant CD-1 mice were exposed to 2,000, 5,000, 10,000, or
9 15,000 ppm methanol for 1, 2, 3, 5, or 7 hours on GD7 and developmental effects evaluated at
10 GD17. This endpoint was selected because it was the most sensitive of those examined and gave
11 a reasonable dose-response relationship overall.
12   Initially, the fraction of pups within each litter carrying either or both CR and SNR was
13 calculated, and then the average across all litters in each concentration-time combination was
14 computed. However, as shown in Figure D-1, the resulting data appear to be nonmonotonic,
15 with the responses from 5-hour exposures exceeding those from 7-hour exposures, and the
16 responses from 2-hour exposures exceeding those from 3-hour exposures. It was noted that the
17 study was done with a block-design, where the dams/litters for some concentration-time
18 combination were divided between multiple blocks and the average CR + SNR incidence in
19 controls varied from 30–52% among the 8 blocks. Therefore block-control response (percent)
20 was subtracted from each exposed litter's response (percent) *before* calculating an average
21 response among litters in a given concentration-time combination. The resulting data are
22 presented in Figure D-1.

Figure D-1. Exposure-response data for methanol-induced CR plus SNR malformations in mice at various concentration-time combinations. The percent response in each litter was first calculated, with direct averages shown in the first panel relative to the grand-mean for the controls. In the second panel, the percent response in controls for each block of exposures in the study was first subtracted from each litter's response in that block before taking averages across litters.

Source: Rogers et al. (1995, 196165).

1   While the correction for background differences does not completely correct the apparent

2   nonmonotonic dose, the 2-hour response is now less than or below the 3-hour response at 5,000

3   and 10,000 ppm, and the strong disparity that appeared between the 5- and 7-hour data at 2,000

4   ppm is eliminated. Overall, the data show a more consistent dependence on duration of

5   exposure, except for the response to 3 hours of 15,000 ppm methanol. Therefore these

1 background-corrected response measures will be used to evaluate the 3 dose metrics, with the

2 exception that the 3-hour 15,000 ppm data point will be dropped as an outlier. In particular, the

3 dose-response relationship based on these data will be plotted against each of the dose metrics to

4 determine which provides the most consistent overall dose-response relationship.

D.2. RESULTS

D.2.1. Dose Metric Comparisons

5 The average incidence of CR plus SNR from the concentration-time developmental

6 bioassay of Rogers et al. (1995, 196165), with block-specific control values subtracted from each

7 litter average before calculating overall average responses, is plotted in Figure D-2 against three

8 dose metrics: AUC, C_{max}, and total amount metabolized of methanol (The volume units for C_{max}

9 and AUC were adjusted to put all three data sets on approximately the same scale for

10 comparison).

Figure D-2. Internal dose-response relationships for methanol-induced CR plus SNR malformations in mice at various concentration-time combinations for three dose metrics. The percent response in controls for each block of exposures in the study was first subtracted from each litter's response in that block before taking averages across litters. The set of response values plotted for each metric is the same, only the metric associated with those responses changes.

Source: Rogers et al. (1995, 196165).

1   While none of the metrics results are in complete alignment of the dose-response data,

2   the scatter for the C_{max} dose-response (i.e., the range of response values associated with a given

3   small range of the dose metric – scatter in the y-direction) is quite a bit less than either of the

4   other two metrics. Thus, C_{max} appears to be a better predictor of response than AUC or amount

5   metabolized. Looking at the exposure-response data in Figure D-1, one can see that 2- and

6   3-hour exposures at 5,000 ppm elicit no increase over control, while 5- and 7-hour exposures at

7   this level do.

8   If AUC or amount metabolized were true measures of risk, then one would expect a

9   graded response, where the 2- and 3-hour exposures were intermediate between controls and 5–

10   7-hour exposures. But the lack of response at those shorter times indicates that the concentration

11   (C_{max}) has not risen high enough in such a short exposure to cause a response, while it has at the

12   longer durations. From Figure D-2, it appears that a C_{max} of 11 mg/cL (1,100 mg/L) is a

13   NOAEL, with a linear increase in CR + SNR from that level to 38 mg/cL, after which the

14   response begins to plateau. Note that while the plot is of response above background, the plateau

15   is effectively at 100% total incidence: the highest points in Figure D-1 are from the 7-hour

16   exposures at 15,000 ppm, where actual incidence was 98% (30% in controls); and the next

17   highest points are from the 5-hour 15,000 and 10,000 ppm exposures, where the incidences were

18   94% and 93%, respectively (32% in controls; both from the same block).

APPENDIX E. EVALUATION OF THE CANCER POTENCY OF METHANOL

E.1. INTRODUCTION

Two studies were selected for the evaluation of the cancer potency of methanol (NEDO, 1987, 064574; NEDO, 2008, 196316; Soffritti et al., 2002, 091004; Soffritti et al., 2002, 196736). The Soffritti et al. (2002, 091004) study is the only oral study available with effects that show a statistically significant increase in incidence of any cancer endpoints in the treated groups versus the concurrent control group (pair-wise comparison) and is used to derive the POD for deriving an oral cancer slope factor. The NEDO (1987, 064574)(2008, 196316) 24-month rat study is the only inhalation study available with effects that show a statistically significant increase in incidence of any cancer endpoints and was used to derive the POD for the inhalation cancer unit risk. A third study, Apaja (1980, 191208), reported statistically significant increases in malignant lymphomas in Eppley Swiss Webster mice over historical controls (pair-wise comparison) following drinking water exposure to methanol. Because this study did not involve a concurrent control group it is not used for the derivation of a cancer oral slope factor, but its dose-response is evaluated here for comparative purposes.

E.2. ORAL CANCER SLOPE FACTOR POD

The Soffritti et al. (2002, 196736) study, conducted by the Ramazzini Foundation, presents a number of challenges if these data are to be used in dose-response modeling to assess the carcinogenic potency of methanol. One challenge, determining the appropriate HED, is best addressed using a PBPK model to derive an HED dose that considers the kinetic differences in humans and the animal model, i.e., species extrapolation. Such a model was developed by the EPA and is not addressed in this appendix; however, the dose metrics derived from that PBPK model are used in the modeling of the data.

The other major challenge, which is addressed in this appendix, is how to model the nonstandard protocol by which methanol was tested, as reported in Soffritti et al. (2002, 196736). In most oncogenicity studies, typified by those conducted by the NTP, animals are dosed for 104 weeks, with a scheduled sacrifice of all surviving animals at the end of treatment. In the study for methanol reported by Soffritti et al. (2002, 196736), while the animals were treated with methanol for 104 weeks, animals were not euthanized and examined on a specified schedule but were followed until their natural death. It is well known that the incidence of background tumors in a number of organs is different between that seen at a scheduled sacrifice

at 104 or 105 weeks and in the same sex/strain that is followed for a lifetime. A higher

background incidence can increase the difficulty of detecting chemically related responses

(Melnick et al., 2007, 196236). Further, performing pathological examinations on tissues

collected after natural death can create difficulties associated with cell autolysis.[96] At the same

time, the shorter duration of the 2-year bioassays used at the NTP misses about two thirds of the

life span of the rodent, potentially missing late stage or late appearing chemically related tumor

responses (Melnick et al., 2007, 196236). ERF believes that "cutting short an experiment after

two years may mask a possible carcinogenic response," but ERF further suggests that all chronic

cancer studies "should continue until spontaneous animal death" (Soffritti et al., 2002, 196736).

Soffritti et al. (2002, 196736) cite ERF studies of benzene, xylenes, mancozeb, and vinyl acetate

monomer as examples for which carcinogenic responses were observed after the 2-year

treatment period.

The Soffritti et al. (2002, 196736) methanol data were evaluated using three different

approaches and two different dose-response models (EPA's multistage cancer and a multistage

Weibull time-to-tumor model). These approaches involved using EPA's multistage cancer model

on response information and estimations of administered mg/kg-day doses that rely upon the

published data (Option 1), application of a time-to-tumor model using administered mg/kg-day

doses and unpublished individual animal response information that would be provided by the

Ramazzini Foundation (Option 2), and a third option (Option 3) that applies the time-to-tumor

and EPA multistage cancer model using internal doses estimated by a PBPK model developed for

methanol by the EPA.

E.2.1. Selection of the Data to Model for Oral CSF Derivation

The individual animal data from the Ramazzini Foundation study was provided to EPA in

the standard NTP format in which the number of days on study, the tissues examined and the

tumor types found were given for each animal. The tumors with incidences that were

statistically significantly increased or were considered to be rare tumors and considered for dose-

response modeling were the incidence of hepatocellular carcinoma in male rats and the incidence

of hemolymphoreticular neoplasms in both male and female rats. The incidence of lympho-

immunoblastic lymphomas was modeled separately, and the combined incidence of all the

lymphomas was considered for dose-response modeling. Table E-2 provides the incidence of

these neoplasms reported in each dose group. The incidence of histiocytic sarcomas and myeloid

---

[96] Autolysis may develop in carcasses of animals if they are not processed immediately after death or if the animals become severely moribund prior to death. These types of changes can compromise pathological diagnosis and subclassification of neoplasms.

1 leukemias were not significantly increased in either sex. The incidence of these tumors was not

2 combined with the lymphoblastic lymphomas because they are of a different cell line and the

3 combination is not typically evaluated either for statistical significance or dose-response

4 modeling (McConnell et al., 1986, 073655).

E.2.2. Estimation of HED – Default Method (Without Use of a PBPK model)

5 The drinking water concentrations provided in the Soffritti et al. (2002, 196736) study

6 were converted to doses in mg/kg-day. Initially, an attempt was made to estimate the dose of

7 methanol to individual animals for development of an average dose; however, water

8 consumption information was available only on a cage-by-cage basis. Based on the available

9 information, the average water consumption for each treatment group was calculated using the

10 available data reported for weeks 1–104. Although individual body weights were available, the

11 corresponding intake was not available. The average body weight over the period of dosing for

12 the experiment (using measurements taken on day 1-day 736) was calculated for each dosed

13 group. A weighted average was calculated for the body weights using the number of animals for

14 which body weights were recorded at each time point.   The average body weight and the

15 average water consumption in (mL/day) were used to calculate the mg/kg-day doses. The

16 equation used for this calculation is:

$$\text{Dose(mg/kg–day)} = \frac{\text{Dose(ppm)} \times \text{WaterConsumption(mL/day)}}{1000 \times \text{BodyWeight(kg)}}.$$

17 Table E-1 provides the values used in the above equation to obtain the mg/kg-day doses,

18 as well as the resulting mg/kg-day doses. In addition, the average and median times of death

19 were calculated for each group (both dosed and control), for the only the dosed groups combined

20 (excluding the controls), and for all the groups in the study combined (including control). These

21 values were obtained using the reported weeks on study for each animal. One male rat (ID #

22 129) in the 20,000 ppm group was not examined microscopically and was excluded from the

23 time of death calculations and all modeling. If this animal was included in the calculations for

24 the average and median times of death, the median time of death for all male rat dosed groups

25 would increase from 97 to 98 weeks; all of the other average and median times of death that

26 include the 20,000 ppm group do not change.

27 When a PBPK model is not used, extrapolation from animal to human is based on the

28 default assumption of body weight$^{3/4}$. This extrapolation was applied to the animal POD

29 estimates to obtain the HEDs reported in Tables E-3 and E-4. This extrapolation was calculated

using the average body weight of the dosed animals excluding controls (0.33 kg for the female

rats and 0.51 kg for the male rats) over the dosing period of the study (through day 736) and 70

kg for the human body weight. The equation used for the body weight$^{3/4}$ extrapolation is

$$\left(\frac{Animal\ Body\ Weight\ (kg)}{Human\ Body\ Weight\ (kg)}\right)^{1/4}$$

and results in a value of 0.26 for the female rats and 0.29 for the male rats.

E.2.3. Dose-Response Modeling Options for Oral CSF Derivation

E.2.3.1. Option 1 – Multistage-Cancer Dose-Response Modeling Using Administered mg/kg-day Doses

Under this option, the standard default modeling approach outlined in the Cancer

Guidelines (U.S. EPA, 2005, 088823) was applied. The PODs were calculated using the

multistage-cancer model available in the BMDS program (U.S. EPA, 2009, 200772).

BMDS (U.S. EPA, 2009, 200772) was used to estimate BMDs and 95% lower bounds on

the BMDs or BMDLs associated with a 10% extra risk (BMDL$_{10}$). For this assessment, the

multistage model was determinded to be an appropriate model for characterization of the dose-

response curve in the observable range. At this time, the MOA for the tumors observed

following exposure to methanol is not known; therefore, linear extrapolation was conducted to

estimate a POD for use in the CSF derivation.

E.2.3.4. Option 2 – Time-to-Tumor Dose-Response Modeling Using Administered mg/kg-day Doses

This option is similar to Option 1; however, rather than the use of the Agency's

multistage-cancer model, a time-to-tumor model was applied to the selected datasets. Data for

this analysis was provided by the Ramazzini Foundation and can be obtained from their web site

(http://www.ramazzini.it/fondazione/study.asp). The same assumptions regarding the HED and

low-dose extrapolation were applied. Because BMDS (U.S. EPA, 2009, 200772) did not include

time-to-tumor modeling at the time of this analysis, the QRISK portion of Statox was employed.

 Statox is an internal EPA program that is used for gathering and analyzing animal bioassay data

and contains the QRISK component for dose-response modeling. The QRISK component of

Statox Version 5.5 fits a multistage Weibull model to the data. The multistage Weibull model is

multistage in dose and Weibull in time and essentially assesses the probability that a tumor

would have been identified at time t. The multistage Weibull model has the form:

$$p(d,t) = 1 - e^{-(q_0 + q_1 \times d + q_2 \times d^2 \cdots + q_k \times d^k) \times (t - t_0)^c}$$

1   with dose (*d*) and time (*t*) as the variables. The parameters estimated by fitting the model to the

2   data are the dose parameters q_0 through q_k, the induction time *(t₀)* and the power term for

3   time *(c)*.

4   If t_0 is interpreted as the time (assumed to be the same for all animals) from when a tumor

5   is observable (i.e., capable of being detected if the animal were to be sacrificed and a necropsy

6   performed) to the time the tumor causes the death of the animal, then these models can be

7   applied to data on incidental and fatal tumors simultaneously. Note that *t* and t_0 only appear in

8   the model in the form of *t-t₀*. To make this explicit, we write *P(d,t) = F(d,t-t₀)*. The probability

9   of an incidental tumor by time *t* is taken to be *F(d,t) (t₀ = 0)* and the probability of a fatal tumor

10   by time *t* is taken to be *F(d,t-t₀)*. There are three possible types of incidence contexts for each

11   animal which contribute separately to the likelihood function for this model. These are:

12   ▪   Censored response – animal died without having the tumor(s) being modeled

13   ▪   Incidental response – the animal died with the tumor(s) but the death was not

14   caused by the tumor(s) (i.e., the time to death from those tumors would have been

15   later than the actual death time); and

16   ▪   Fatal incidence – the tumor(s) being modeled was the cause of death.

17   The contribution of each animal to the likelihood is then defined for its time of death *(t)*.

18   The complete likelihood is defined as:

19
$$\prod_{j=1}^{g}\left\{\left[\prod_{\text{Incidence}(i,j)=\text{Censored}}(1-F(d_j,t))\right]\times\left[\prod_{\text{Incidence}(i,j)=\text{Incidental}}(F(d_j,t)-F(d_j,t-t_0))\right]\times\left[\prod_{\text{Incidence}(i,j)=\text{Fatal}}(\frac{\partial F(d_j,t-t_0)}{\partial t})\right]\right\}$$

20   where *g* is the number of dose groups in the study, including the control group, and *i* varies from

21   1 to the total number of animals in the study examined for the tumor type(s) being modeled.

22   As with the multistage-cancer modeling, the lower bound on a dose at an extra risk of

23   10% was estimated. Goodness-of-fit was determined by visually inspecting graphical output of

24   the modeling. AIC values were also calculated for the time-to-tumor model fit.

25   A time-to-tumor modeling is typically applied to account for differences in survival

26   among treated and control groups. However, in this case there were no differences detected in

27   the survival times. Figures E-1 and E-2 are graphs of the proportion surviving versus the weeks

28   on study for the female rats and male rats, respectively. In addition, the Life Table program

29   (Thomas et al., 1977, 196727) was run on the data. None of the statistical tests in this program

30   indicated a difference in survival between the control and the dosed groups. However, the

31   protocol used by the Ramazzini Foundation was different from that typically employed in

32   chronic rat bioassays. In typical rodent bioassays, a compound is administered to the animals for

33   approximately 104 weeks, and the animals sacrificed within a short period (days) following the

34   end of treatment. In the Ramazzini Foundation bioassays (i.e., for methanol, formaldehyde,

1 MTBE, and aspartame), the animals were administered compounds for 104 weeks but were

2 allowed to live until a natural death, which, in some animals, occurred months after the

3 completion of chemical administration. This can have an impact on the tumor incidence and

4 therefore, the potential risk of tumor development associated with administration of a given

5 compound. Thus, at the time-to-tumor model was used in this case to attempt to adjust for the

6 extended life span of the some of the animals in this study.

7 For time-to-tumor modeling, the POD must consider a specific time as well as a specific

8 risk level. Since this study was not a standard study with a fixed study length, several

9 assumptions can be made with regard to the time to be used. For this modeling exercise, Two

10 different possible approaches were considered.

11 For the first approach, the model was fit to animal data using all the times reported up to

12 the last death time or 153 weeks for the female rats and 148 weeks for the male rats. Every

13 tumor observed was assumed to be a fatal tumor or the cause of death in the animal. While the

14 animals lived longer than 104 or 105 weeks, the POD was calculated at 105 weeks, since it was

15 assumed that an animal life span of 148–153 weeks would not correspond to the average 70-year

16 human life span.

17 For the second approach, an attempt was made to simulate what might have occurred if

18 the study had been a standard 2-year protocol that was terminated at 105 weeks, with all

19 surviving animals sacrificed at 105 weeks. It was assumed that the tumors discovered in the

20 animals that survived longer than 105 weeks would have been present and found at necropsy.

21 Therefore, all tumors in animals that died in weeks 105 and earlier were assumed to be fatal or

22 the cause of death in the animals, and all tumors that would have been discovered at the necropsy

23 of animals were assumed to be incidental or not the cause of death. The life span assumed for

24 this analysis was 105 weeks in the rat and the POD was calculated for a 10% risk to a human at

25 105 weeks. This approach was conducted mainly for comparative purposes to evaluate the

26 potential impact on the POD if the study duration was shortened and for a more direct

27 comparison to the multistage-cancer PODs and serves only as bounding exercise for the risk.

E.2.3.5. Option 3 – Dose-Response Modeling Using Internal Dose Metrics Estimated by EPA's PBPK Model

28 For this option, PK dose metrics obtained from the PBPK model (Section 3.4) were used

29 as the doses. Both time-to-tumor modeling and multistage-cancer modeling was done.[97] The

30 Statox program was used to estimate MLEs and lower bounds on dose associated with a 10%

---

[97] Time-to-tumor modeling was done on doses estimated from an earlier version of the PBPK model which estimated total metabolized methanol as mg/day. Quantal modeling was done on doses estimated from the more recent version of the PBPK model which estimates allometrically scaled metabolized methanol as $mg/kg^{0.75}$-day.

1   extra risk (LED10s), and BMDS (U.S. EPA, 2009, 200772) multistage model was used to

2   estimate BMDs and 95% lower bounds on the BMDs or BMDLs associated with a 10% extra

3   risk (BMDL10). Each of the dose metrics, provided in Table E-5, was used in this option of the

4   dose-response modeling.

E.2.4. Dose-Response Modeling Results for Oral CSF

E.2.4.1. Option 1 – Results for Multistage-Cancer Dose-Response Modeling Using Administered mg/kg-day Doses

5   For this option, multistage-cancer dose-response modeling was conducted using

6   estimated mg/kg-day doses and the incidence of lympho-immunoblastic neoplasms and the

7   combined lymphomas for the female rat and the hepatocellular carcinomas, the lympho-

8   immunoblastic neoplasms, and the combined lymphomas for the male rat. The results of the

9   multistage-cancer modeling for this option are given in Table E-3. The multistage-cancer model

10   gave an adequate fit (p value > 0.05) and was able to derive $BMDL_{10}$ values for all of the

11   lymphoma data. However, for the male rat hepatocellular carcinomas, the multistage-cancer

12   model failed to estimate a $BMDL_{10}$. Human equivalent $BMDL_{10}$ values[98] are also provided in

13   Table E-3.

14   The HED POD values estimated range from 131 mg/kg-day for lympho-immunoblastic

15   tumors in male rats to 277.5 mg/kg-day for lympho-immunoblastic tumors in female rats.

E.2.4.2. Option 2 – Results for Time-to-Tumor Dose-Response Modeling Using Administered mg/kg-day Doses

16   Results of the time-to-tumor modeling using estimated mg/kg-day doses are given in

17   Table E-4. Approach 2 gives smaller POD estimates than Approach 1. With Approach 2, an

18   artificial end of the study is assumed of 105 weeks and the designation of approximately half of

19   the total tumors changed from fatal to incidental. This approach evaluates the potential impact

20   on the POD of terminating the study at 105 weeks, rather than allowing the animals to live until

21   their natural death, assuming that the same animals bearing tumors would be "observed" at 105

22   weeks, rather than at later time points. For Approach 1, the model was fit to the actual observed

23   weeks-on-study, and a time of 105 weeks was used in calculating the POD. For the female rat,

24   the PODs based on the lympho-immunoblastic neoplasms were 349 mg/kg-day for approach 1

25   and 179 mg/kg-day for Approach 2. The PODs for the combined lymphomas ranged were 321

26   and 198 mg/kg-day for the two approaches. For the PODs calculated from the male rat data, the

---

[98] Computed from the animal values by multiplying by the body weight$^{3/4}$ animal-to-human extrapolation value (0.26 for females and 0.29 for males)

1 values were 783 and 612 mg/kg-day for the hepatocellular carcinomas, 174 and 91 mg/kg-day

2 for the lympho-immunoblastic neoplasms, and 192 and 92 mg/kg-day for the combined

3 lymphomas. Figures E-3 through E-7 show the modeling results for the time-to-tumor modeling

4 using Approach 1 where the time is fixed at 105 weeks and the doses are allowed to vary.

5 Figures E-8 and E-9 show Kaplan-Meier curves versus the model fit to the combined lymphoma

6 data for the females and males, respectively. In these graphs each line corresponds to a specific

7 dose, and time is allowed to vary up to the study end of 153 or 148 weeks. For the male rat

8 combined lymphomas (Figure E-9), the multistage Weibull predicted values more closely match

9 the Kaplan-Meier at 105 weeks than at the average life span (94 weeks) or the end of study (148

10 weeks). For the female rat combined lymphomas, the closest match of the Kaplan-Meier curves

11 to the model predicted values appears to be around the average life span of 96 weeks.

E.2.4.3. Option 3 – Results for Dose-Response Modeling Using Internal Dose Metrics Estimated by the EPA's PBPK Model

12 Both time-to-tumor and multistage-cancer dose-response modeling were conducted using

13 the incidence of lympho-immunoblastic neoplasms and the combined lymphomas for the female

14 rat and the hepatocellular carcinomas, the lympho-immunoblastic neoplasms, and the combined

15 lymphomas for the male rat and the three PBPK dose metrics (blood methanol AUC, peak blood

16 concentration, and metabolized methanol per day[99])obtained from the EPA's PBPK model

17 (Table E-5).

18 Only Approach 1 described for option 2 was used for the time-to-tumor dose-response

19 modeling using PBPK dose metrics, and results are given in Table E-6a; HEDs corresponding to

20 this approach are provided in Table E-6b.

21 The results of the multistage-cancer modeling are given in Table E-7. Most model runs

22 gave an adequate fit to the data by the χ^2 Goodness of Fit p-value (e.g., p-values > 0.05),

23 although for male rat hepatocellular carcinomas, the calculations using the AUC or amount

24 metabolized dose metric were unable to converge for the model fit or the derivation of a BMDL.

25 A plot of the model fit for male rat combined lymphomas using total methanol metabolized per

26 day as the dose metric (the endpoint and dose metric used in the derivation of the oral CSF) is

27 shown in Figure E-10; HEDs corresponding to this approach are provided in Table E-8.

---

[99] Time-to-tumor modeling was done on doses estimated from an earlier version of the PBPK model which estimated total metabolized methanol as mg/day. Quantal modeling was done on doses estimated from the most recent version of the PBPK model which estimates allometrically scaled metabolized methanol as $mg/kg^{0.75}$-day.

E.3. INHALATION UNIT RISK (IUR) POD

The NEDO (1987, 064574)(2008, 196316) study was conducted using a standard protocol with exposure for 104 weeks, followed by sacrifice of all animals surviving to 104 weeks. As with the Soffritti (2002, 196736) study, pharmacokinetic dose metrics for use in the dose-response assessment were determined for the inhalation exposures using the EPA's PBPK model.

E.3.1. Selection of the Data to Model for IUR Derivation

The individual animal data from the NEDO (2008, 196316) study were provided in a 2008 translation of the study from Japanese to English. Although the translation provided the number of days on study and the neoplastic responses seen in each animal, the translation did not provide results if a tissue was examined histopathologically with no neoplastic responses. This makes it difficult to determine which of the individual animals were not examined, although the tables did indicate that, for some of the animals, selected organs (specifically a few lungs in males and a few adrenal glands in females) were not examined. Therefore, time-to-tumor analysis could not be conducted with results from the inhalation data as was done with the oral data. However, survival analysis of all the data from the NEDO (2008, 196316) study did not indicate that there were any survival problems (Figures E-11 and E-12). This suggests that a time-to-tumor analysis is not necessary.

The tumors with significantly increased incidence that were considered for dose-response modeling were the female rat adrenal gland pheochromocytomas and the male rat lung tumors (papillary adenomas and adenocarcinomas combined or papillary adenomas, adenocarcinomas and adenomatosis combined); Table E-9 gives the incidence of these tumors.

E.3.2. Dose-Response Modeling Approach for IUR Derivation

For the selected endpoints from the NEDO (2008, 196316) study, only multistage-cancer dose-response modeling using pharmacokinetic internal dose metrics estimated by the PBPK model (described in Section 3.4 and Appendix B) was conducted. Each of the dose metrics provided in Table E-10 was used in the BMDS software (U.S. EPA, 2009, 200772) with the incidence data in Table E-9 to estimate the BMDs and 95% lower confidence limits (BMDLs) associated with a 10% extra risk ($BMDL_{10}$).

E.3.3. Dose-Response Modeling Results for the IUR

Multistage-cancer dose-response modeling was conducted using the incidence of adrenal gland phoechromocytomas in female rats and the combined incidence of lung adenomas and

adenocarcinomas or lung adenomas, adenocarcinomas and adenomatosis in male rats using the pharmacokinetics dose metrics derived from the EPA's PBPK model. The results of this modeling are given in Table E-11. The multistage model gave an adequate fit to the data in all instances as determined by the χ^2 goodness-of-fit *p*-value (e.g., *p*-values > 0.05). A plot of the model fit for female rat pheochromocytomas using total methanol metabolized per day as the dose metric (the endpoint and dose metric used in the derivation of the IUR) is shown in Figure E-13. HECs are provided in Table E-12.

E.4. ANALYSIS OF APAJA (1980) DRINKING WATER STUDY

The Apaja (1980, 191208) study was similar to the Soffritti et al. (2002, 196736) study in that it was a life span drinking water study. The primary differences are that Apaja (1980, 191208) used Eppley Swiss Webster mice, did not stop exposure at 104 weeks and did not employ an untreated concurrent control group. Methanol exposure groups of this study served as controls for malonaldehyde exposed mice. As with the Soffritti (2002, 196736) study, pharmacokinetic dose metrics for use in the dose-response assessment were determined for the oral exposures using the EPA's PBPK mouse model.

E.4.1. Selection of the Data to Model

Individual animal data from the Apaja (1980, 191208) study were not available. Therefore, time-to-tumor analysis could not be conducted. The tumors with significantly increased incidence that were considered for dose-response modeling were malignant lymphomas in male and female mice; Table E-13 gives the incidence of these tumors.

E.4.2. Dose-Response Modeling Approach

E.4.2.1. Multistage-Cancer Dose-Response Modeling Using Internal Dose Metrics Estimated by the EPA's PBPK Model

A 1st degree multistage model was used to evaluate the malignant lymphoma response from the Apaja (1980, 191208) study versus pharmacokinetic dose metrics without background[100] was conducted. Each of the dose metrics provided in Table E-14 was used in the BMDS software (U.S. EPA, 2009, 200772) with the incidence data in Table E-13 to estimate the BMDs and 95% lower confidence limits (BMDLs) associated with a 10% extra risk (BMDL$_{10}$).

---

[100] The exclusion of background doses is consistent with what was done for the derivation of the oral CSF and EPA practice.

E.4.3. Dose-Response Modeling Results

1   Multistage-cancer dose-response modeling was conducted using the incidence of
2 malignant lymphoma in male and female Eppley Swiss Webster mice using the pharmacokinetics
3 dose metrics derived from the EPA's PBPK model. The results of this modeling are given in
4 Table E-15. The 1st degree multistage model gave an adequate fit to the data in all instances as
5 determined by the χ^2 goodness-of-fit p-value (e.g., p-values > 0.05). A plot of the model fits for
6 male and female mice using scaled methanol metabolism (daily average) as the dose metric is
7 shown in Figure E-14. $BMDL_{10}$ HECs associated with each dose metric are listed in Table E-16.

E.5. BACKGROUND DOSE ANALYSES

8   The primary purpose of this assessment is for the determination of noncancer and cancer
9 risk associated with exposures that increase the body burden of methanol or its metabolites (e.g.,
10 formate, formaldehyde) above prevailing, endogenous levels. Thus, the focus of model
11 development was on obtaining predictions of increased body burdens over background following
12 external exposures. To accomplish this, the PBPK models used in this assessment do not
13 account for background levels of methanol, formaldehyde or formate. In addition, background
14 levels were subtracted from the reported data before use in model fitting or validation (in many
15 cases the published data already have background subtracted by study authors). This approach
16 for dealing with endogenous background levels of methanol and its metabolites assumes that (1)
17 endogenous levels do not contribute significantly to the adverse effects of methanol or its
18 metabolites; and (2) the exclusion of endogenous levels does not significantly alter PBPK model
19 predictions. Section 3.4.3.2.1 describes an analysis EPA performed regarding the latter
20 assumption, via PBPK models that include background estimation, which indicates that the
21 exclusion of background does not have a marked impact on PBPK model predictions. Available
22 human data do not allow for direct validation of the former assumption, that endogenous
23 background levels do not contribute to the adverse effects of methanol exposure. However, EPA
24 has developed "background dose" models that allow for the analysis of dose-response data
25 assuming that background responses are due solely to background doses (U.S. EPA, 2009,
26 200772). The following analysis was performed to compare background doses estimated by the
27 "background dose" PBPK models described in Section 3.4.3.2.1 to background doses estimated
28 by the EPA Multistage "background dose" dose-response model (Multistage-bgdose) for dose-
29 response data evaluated in this Appendix (Tables E-2, E-5, E-9, and E-10).
30   As described in Section 3.4.3.2, alternate (test) versions of the rat, mouse and human
31 PBPK models were created which incorporate a zero-order liver infusion term for methanol
32 designed to approximate reported rat and human background levels. These models were used to

1 estimate background levels of blood methanol AUC (mg-h/L), peak blood methanol

2 concentration (mg/L), and allometrically scaled metabolized methanol per day (mg/kg$^{0.75}$-day)

3 associated with the Soffritti et al. (2002, 196736) and NEDO (2008, 196316) studies evaluated in

4 this Appendix (Table E-17).

5   Dose-response data in Tables E-2, E-5, E-9, and E-10 were evaluated with the EPA's

6 Multistate-background-dose model. As can be seen from Table E-18, the AUC methanol, Cmax

7 methanol and metabolized methanol background doses estimated by Multistage-bgdose to

8 explain the responses observed in the Soffritti et al. (2002, 196736) and NEDO (2008, 196316)

9 studies are generally higher than the background levels predicted by EPA's background dose

10 PBPK model (Table E-17). In the case of lymphoma responses in Sprague-Dawley rats, the

11 background doses for the AUC and Cmax metrics predicted by Multistage-bgdose are 1,000- to

12 2,500-fold higher than the background doses predicted for the SD rats by the background dose

13 PBPK model. However, the Multistage-bgdose model predictions of metabolized methanol

14 background doses for the Soffritti et. al. (2002, 196736) data and all forms of background doses

15 for the NEDO (2008, 196316) data were just two- to sevenfold higher than the background doses

16 for these metrics estimated by the background dose PBPK model. While this analysis is not

17 conclusive, it does not rule out the possibility of a relationship between background doses and

18 background cancer, particularly for doses characterized as allometrically scaled metabolized

19 methanol (mg/kg$^{0.75}$-day).

Table E-1. Calculation of mg/kg-day doses

Dose (ppm)	Female Sprague-Dawley Rats					Male Sprague-Dawley Rats				
	Body weight (kg)	Water consump. (g/day or mL/day)	Dose (mg/kg -day)	Average time of death (wk)	Median time of death (wk)	Body weight (kg)	Water consump. (g/day or mL/day)	Dose (mg/kg -day)	Average time of death (wk)	Median time of death (wk)
0	0.33	42.55	0	98	102	0.50	52.57	0	91	91
500	0.33	43.05	66.0	96	99	0.49	52.06	53.2	97	98
5,000	0.33	41.11	624.1	94	97	0.50	52.58	524	93	93
20,000	0.34	37.26	2,177	98	101	0.54	48.32	1,780	93	100
Averaged over all dosed groups (excluding control)	0.33			96	99	0.51			94	97
Averaged over all groups (including control)	0.33			97	100	0.51			93	96

Dose (ppm)	Female Sprague-Dawley Rats					Male Sprague-Dawley Rats				
	Body weight (kg)	Water consump. (g/day or mL/day)	Dose (mg/kg-day)	Average time of death (wk)	Median time of death (wk)	Body weight (kg)	Water consump. (g/day or mL/day)	Dose (mg/kg -day)	Average time of death (wk)	Median time of death (wk)

Source: Soffritti et al. (2002, 196736).

Table E-2. Incidence for neoplasms considered for dose-response modeling

Dose (ppm)	Dose (mg/kg-day)	Number of animals examined	Hepatocellular carcinomas	Histiocytic sarcoma	Leukemia monocytic	Leukemia myloid	Lymphoma lymphoblastic	Lymphoma lymphocytic	Lymphoma lympho-immunoblastic	All lymphomas combined
Female Sprague-Dawley rats										
0	0	100		1		3	0	0	9	9
500	66.0	100		2		3	1	1	17	19[a]
5,000	624.1	100		2		3	1	0	19[a]	20[a]
20,000	2,177	100		3		3	1	0	21[a]	22[b]
Cochran Armitage Trend Test				0.19		0.5	0.3	0.8	0.04	0.04
Male Sprague-Dawley rats										
0	0	100	0	2	1	8	1		16	17
500	53.2	100	2	4	0	4	3		24	27
5,000	524	100	2	1	0	6	1		28[a]	29[a]
20,000	1,780	99	3	1	0	1	1		37[b]	38[b]
Cochran Armitage Trend Test			0.10	0.9	0.8	0.98	0.7		0.0007	0.001

[a]Fisher's Exact p-value < 0.05; [b]Fisher's Exact p-value < 0.01

Source: Soffritti et al. (2002, 196736).

Table E-3. Results from multistage-cancer (1º) modeling rat data using mg/kg-day exposures and default HED derivation method

		AIC	*p*-value	Scaled residual at observed dose closest to BMD	Animal values		
					BMD_{10}	$BMDL_{10}$	Human equivalent $BMDL_{10}$[a]
Female Sprague-Dawley rat	All organs lympho-immunoblastic	359.16	0.19	-0.07	2,179.51	1,058.99	277.5
	All organs - all lymphomas	371.95	0.11	-0.07	2,141.88	1,033.69	270.9
Male Sprague-Dawley rat	Hepatocellular carcinoma	72.84	0.38	Failed[a]			
	All organs lympho-immunoblastic	455.67	0.34	0.14	714.26	448.43	131.0
	All organs – all lymphomas	468.79	0.24	0.11	744.35	456.11	133.3

[a]Model failed to optimize.

Source: Soffritti et al. (2002, 196736).

Table E-4. Results from time-to-tumor modeling data using mg/kg-day exposures and default HED derivation method

		AIC	Prediction time (weeks)	MLE (mg/kg-day)	LED$_{10}$ (mg/kg-day)
				Human values[b]	
Approach 1 - Model fit to actual death times, dose estimates computed at 105 weeks[a]					
Female Sprague-Dawley rat	All organs lympho-immunoblastic	831.42	105	729.0	348.6
	All organs all lymphomas	900.46	105	679.1	320.9
Male Sprague-Dawley rat	Hepatocellular carcinoma	105.45	105	4,250.7	783.3
	All organs lympho-immunoblastic	1,254.58	105	302.0	173.8
	All organs all lymphomas	1,309.86	105	356.7	191.8
Approach 2 - Truncating study at 105 weeks[a]					
Female Sprague-Dawley rat	All organs lympho-immunoblastic	631.81	105	370.7	178.5
	All organs all lymphomas	664.43	105	431.9	198.0
Male Sprague-Dawley rat	Hepatocellular carcinoma	1.16E+05[c]	105	1,013.7	612.2
	All organs lympho-immunoblastic	914.42	105	150.8	91.2
	All organs – all lymphomas	935.29	105	157.1	92.2

[a]Individual animal pathology data needed for the modeling reported in this table can be obtained from the Ramazzini Foundation web site (http://www.ramazzini.it/fondazione/study.asp).
[b]Human values are computed by converting the animal doses to HED before modeling by multiplying by the body weight^{¾} animal-to-human extrapolation value (0.26 for females and 0.29 for males).
[c]Model failed to optimize.

Source: Soffritti et al. (2002, 196736).

Table E-5. PBPK model estimated dose-metrics for doses to S.D. rats

Sex	Dose (mg/kg-day)	Body weight (kg)	AUC (mg-h/L)	Peak (mg/L)	Total metabolized (mg/day)[a]	Allometricallyh Scaled Metabolized Methanol (mg/kg$^{0.75}$-day)[a]
Female Sprague-Dawley	66	0.33	66.83	5.95	18.39	42.24
	6,24.1	0.33	9,547.77	500.68	126.68	290.96
	2,177	0.34	91,322.96	4,160.22	141.60	318.01
Male Sprague-Dawley	53.2	0.49	55.75	4.81	21.82	37.25
	524	0.50	7,502.85	395.60	168.85	283.98
	1,780	0.54	80,473.32	3,631.08	200.03	317.54

[a]Time-to-tumor modeling was done on doses estimated from an earlier version of the PBPK model which estimated total metabolized methanol as mg/day. Multistage-cancer modeling was done on doses estimated from the most recent version of the PBPK model which estimates allometrically scaled metabolized methanol as mg/$^{kg0.75}$-day.

Source: Soffritti et al. (2002, 196736).

Table E-6a. Results from time-to-tumor modeling of data using PBPK dose metrics

Approach 1 - Model fit to actual death times, dose estimates computed at 105 weeks	Prediction Time (wk)	AUC (mg-h/L)			Peak (mg/L)			Amount Metabolized (mg/d)		
		AIC	MLE	LED$_{10}$	AIC	MLE	LED$_{10}$	AIC	MLE	LED$_{10}$
Female Sprague-Dawley rat — All organs lympho-immunoblastic	105	832.43	152281	64486	832.35	6763.4	2895.3	829.24	160.45	90.7
All organs all lymphomas	105	901.43	143138	59574	901.36	6356.1	2675.3	898.24	145.53	82.2
Male Sprague-Dawley rat — Hepatocellular carcinoma	105	110.47	undefined	119186	110.45	undefined	5385.9	109.60	undefined	300.4
All organs lympho-immunoblastic	105	1242.72	55409	30059	1244.61	2460.2	1341.3	1242.66	141.63	77.3
All organs – all lymphomas	105	1297.74	66211	33315	1297.66	2939.5	1487.2	1295.95	143.14	82.7

Source: Soffritti et al. (2002, 196736)

Table E-6b. HEDs from time-to-tumor modeling of data using PBPK dose metrics

Approach 1 - Model fit to actual death times, dose estimates computed at 105 weeks	AUC (mg-h/L)	Peak (mg/L)	Total Metabolized (mg/day)[a]
	HED$_{10}$ (mg/kg-day)	HED$_{10}$ (mg/kg-day)	HED$_{10}$ (mg/kg-day)
Female Sprague-Dawley rat — All organs lympho-immunoblastic	669.1	699.6	87.7
All organs all lymphomas	639.1	667.4	79.4
Male Sprague-Dawley rat — Hepatocellular carcinoma	1001.9	1063.1	260.0
All organs lympho-immunoblastic	457.5	470.8	62.4
All organs – all lymphomas	477.8	470.8	66.7

[a] Human simulations used BW = 70 kg.

Source: Soffritti et al. (2002, 196736)

Table E-7. Results of multistage-cancer (1º) modeling of data using PBPK dose metrics

AUC (mg-h/L)					Peak (mg/L)					Allometrically Scaled Metabolized Methanol (mg/kg$^{0.75}$-day)				
AIC	*p*-value	Scaled residual at dose nearest to BMD	BMD$_{10}$	BMDL$_{10}$	AIC	*p*-value	Scaled residual at dose nearest to BMD	BMD$_{10}$	BMDL$_{10}$	AIC	*p*-value	Scaled residual at dose nearest to BMD	BMD$_{10}$	BMDL$_{10}$
Female Sprague-Dawley rats														
All organs lympho-immunoblastic														
359.5	0.135	-0.13	109125	48795.3	359.4	0.139	-0.15	4872.1	2196.42	357.4	0.336	-0.91	312.17	173.183
All organs – all lymphomas														
372.3	0.076	-0.13	107826	47804	372.2	0.078	-1.79	4814.4	2152.01	370.1	0.184	-1.14	299.73	166.302
Male Sprague-Dawley rats														
Hepatocellular carcinoma														
73.21	0.371	Failed[a]			73.19	0.372	Failed[a]			72.56	0.352	Failed[a]		
All organs lympho-immunoblastic														
455.1	0.183	1.051	36526	21916.1	455.0	0.195	-1.39	1626.7	979.618	454.2	0.273	-0.65	160.10	103.214
All organs – all lymphomas														
468.1	0.147	0.878	37848	22209.5	468.0	0.154	-1.53	1687.5	993.655	467.5	0.179	-0.86	166.50	104.38

[a]BMD computation failed. BMD is larger than three times maximum input doses.

Source: Soffritti et al. (2002, 196736).

Table E-8. Application of human PBPK model to derive HEDs from results of multistage-cancer (1°) modeling of data using PBPK dose metrics

		AUC (mg-h/L)	Peak (mg/L)	Allometrically Scaled Metabolized Methanol (mg/kg$^{0.75}$-day)[a]
		HED BMDL$_{10}$ (mg/kg-day)	HED BMDL$_{10}$ (mg/kg-day)	HED BMDL$_{10}$ (mg/kg-day)
Female Sprague-Dawley rat	All organs lympho-immunoblastic	573.1	597.1	60.80
	All organs – all lymphomas	567.1	590.6	58.37
Male Sprague-Dawley rat	Hepatocellular carcinoma	N/A	N/A	N/A
	All organs lympho-immunoblastic	406.2	416.4	36.17
	All organs – all lymphomas	408.1	418.5	36.58[b]

[a] The human internal BMDL$_{10}$ is assumed to be identical to the female rat mg/kg$^{0.75}$-day BMDL$_{10}$. The human PBPK model (Appendix B) was then used to convert this human mg/kg$^{0.75}$-day value for scaled methanol metabolized back to a human equivalent methanol inhalation concentration, HED(BMDL$_{10}$).
[b] This value was used in the derivation of the methanol oral cancer slope factor.

Source: Soffritti et al. (2002, 196736).

Table E-9. Incidence for neoplasms considered for dose-response modeling

Dose (ppm)	Examined	Adrenal gland phoechromocytoma	Lung adenoma and adenocarcinoma	Lung adenoma, adenocarcinoma, adenomatosis
Female F344 rats				
0	50	2		
10	51	3		
100	49	2		
1,000	51	7		
Male F344 rats				
0	52		1	5
10	50		5	6
100	52		2	7
1,000	52		7[a]	11
Cochran Armitage Trend Test p_values		0.015	0.0259	0.0415

[a] Fisher's Exact p-values < 0.05

Source: NEDO (2008, 196316).

Table E-10. PBPK dose metrics for doses to F344 rats

Dose (ppm)	AUC (mg-h/L)	Peak (mg/L)	Allometrically Scaled Metabolized Methanol (mg/kg$^{0.75}$-day)
Female F344 rats			
0	0.00	0.00	0.00
10	3.70	0.19	0.79
100	37.51	1.93	7.91
1,000	433.94	22.67	78.38
Male F344 rats			
0	0	0	0
10	3.70	0.19	0.79
100	37.51	1.93	7.91
1,000	433.28	22.66	78.38

Source: NEDO (2008, 196316).

Table E-11. Benchmark results from multistage-cancer dose-response modeling data using PBPK dose-metrics

Model	AUC (mg-h/L)					Peak (mg/L)					Allometrically Scaled Metabolized Methanol (mg/kg$^{0.75}$-day)				
	AIC	p-value	Scaled residual at dose nearest to BMD	BMD$_{10}$	BMDL$_{10}$	AIC	p-value	Scaled residual at dose nearest to BMD	BMD$_{10}$	BMDL$_{10}$	AIC	p-value	Scaled residual at dose nearest to BMD	BMD$_{10}$	BMDL$_{10}$
Female F344 rats															
Adrenal glands – pheochromocytoma															
Multistage (3°)	101.37	0.88	0.000	441.78	216.816	101.37	0.88	0.000	23.0796	11.3203	101.37	0.8788	0	79.7954	39.4421
Male F344 rats															
Lung – adenomas and adenocarcinomas															
Multistage (3°)	107.99	0.16	0.000	454.6	230.5	107.99	0.16	0.000	23.8	12.1	107.99	0.16	0.001	82.2394	42.0223
Lung – adenomas, adenocarcinomas and adenomatosis															
Multistage (1°)	168.77	0.78	0.013	393.9	173.1	168.77	0.78	0.012	20.6	9.05	168.77	0.78	0.017	71.1444	31.2902

Source: NEDO (2008, 196316).

Table E-12. Application of human PBPK model to derive HECs from BMDL$_{10}$ estimates in Table E-11 using multistage-cancer modeling

		AUC (mg-h/L)	Peak (mg/L)	Allometrically Scaled Metabolized Methanol (mg/kg$^{0.75}$-day)[a]
		HEC BMCL$_{10}$ (mg/m^3)	HEC BMCL$_{10}$ (mg/m^3)	HEC BMCL$_{10}$ (mg/m^3)
Female F344 rat	Adrenal glands – pheochromocytoma	380	452	80.5[b]
Male F344 rat	Lung - adenomas and adenocarcinomas	399	474	85.8
	Lung - adenomas, adenocarcinomas and adenomatosis	317	381	63.9

[a] The human internal BMDL$_{10}$ is assumed to be identical to the female rat mg/kg$^{0.75}$-day BMDL$_{10}$. The human PBPK model (Appendix B) was then used to convert this human mg/kg$^{0.75}$-day value for scaled methanol metabolized back to a human equivalent methanol inhalation concentration, HEC(BMCL$_{10}$).
[b] This value was used in the derivation of the methanol inhalation unit risk.

Source: NEDO (2008, 196316)

Table E-13. Incidence for malignant lymphoma in Eppley Swiss Webster mice

Dose (ppm)	Examined	Malignant Lymphoma
Female Swiss Webster mice		
Historical untreated controls [a,b]	200	38
10	25	4
100	25	9[c]
1,000	25	10[d]
Male Swiss Webster mice		
Historical untreated controls [a]	100	8
10	25	1
100	25	6[d]
1,000	25	4

[a] Toth et al. (1977, 196730); [b] Hinderer et al. (1979, 200845); [c] p-value = 0.06; [d] p-values < 0.05

Source: Apaja (1980, 191208)

Table E-14. PBPK dose metrics for doses in Apaja (1980, 191208)

Daily Dose (mg/kg-d)	Weekly Avg. Dose (mg/kg-d)	Body Weight (kg)	AUC (mg-h/L)	Peak (mg/L)	Amount metabolized (mg/kg$^{0.75}$/d)
Female Swiss Webster mice
0	0	0.040	0	0	0
560	480	0.040	485	88.4	205.5
1000	857	0.040	3468	383.2	318.1
2100	1800	0.040	19,517	1,462.8	438.1
Male Swiss Webster mice
0	0	0.045	0	0	0
550	471	0.045	501	89.8	207.7
970	831	0.045	3406	373.8	318.9
1800	1543	0.045	15008	1163.2	428.4

Source: Apaja (1980, 191208).

Table E-15. Multistage-cancer dose-response modeling of malignant lymphoma in Eppley Swiss Webster mice using PBPK dose-metrics

Gender	AUC (mg-h/L)					Peak (mg/L)					Amount metabolized (mg/kg$^{0.75}$-d)				
	AIC	p-value	Scaled residual at dose nearest to BMD	BMD$_{10}$	BMDL$_{10}$	AIC	p-value	Scaled residual at dose nearest to BMD	BMD$_{10}$	BMDL$_{10}$	AIC	p-value	Scaled residual at dose nearest to BMD	BMD$_{10}$	BMDL$_{10}$
Female mice[a]	288.91	0.32	1.354	5812.4	2959.6	288.42	0.43	1.090	428.7	225.2	288.07	0.55	-0.937	253.96	112.47
Male mice[a]	122.09	0.083	-0.580	11173.2	4345.99	121.58	0.12	-0.641	798.7	339.0	120.97	0.21	1.309	365.9	187.3

[a]Multistage-cancer (1º) used for AUC and Peak metrics; Multistage-cancer (2º) used for Amount metabolized metric

Source: Apaja (1980, 191208).

Table E-16. Application of human PBPK model to derive HEDs from BMDL$_{10}$ estimates of Table E-15, Multistage (1°) modeling of malignant lymphoma in Eppley Swiss Webster mice using PBPK dose metrics

	AUC (mg-h/L)	Peak (mg/L)	Amount metabolized (mg/kg$^{0.75}$-d)[a]
	HED BMDL$_{10}$ (mg/kg-day)	HED BMDL$_{10}$ (mg/kg-day)	HED BMDL$_{10}$ (mg/kg-day)
Female mice	253	286	39.4
Male mice	274	311	65.8

[a]**Human simulations performed with BW = 70 kg.**

Source: Apaja (1980, 191208).

Table E-17. Background doses estimated for Soffritti et al. (2002, 196736) and NEDO (2008, 196316) studies

AUC (mg-h/L)	Peak (mg/L)	Allometrically Scaled Metabolized Methanol (mg/$^{kg0.75}$-day)
Female SD rats[A]		
72.00	3.00	133.44
Male SD rats[A]		
72.00	3.00	133.44
Female F344 rats[B]		
108.95	4.54	24.19
Male F344 rats[B]		
79.44	3.31	17.86

[a] Source: Soffritti et al. (2002, 196736); [b] Source: NEDO (2008, 196316)

Table E-18. Benchmark results for all tumor types using multistage (1º) "background dose" model (U.S. EPA, 2009, 200772) and PBPK dose-metrics

AUC (mg-h/L)					Peak (mg/L)					Amount metabolized (mg/kg$^{0.75}$-d)				
AIC	*p*-value	Back-ground Dose	BMD$_{10}$	BMDL$_{10}$	AIC	*p*-value	Back-ground Dose	BMD$_{10}$	BMDL$_{10}$	AIC	*p*-value	Back-ground Dose	BMD$_{10}$	BMDL$_{10}$
Female Sprague-Dawley rats (Soffritti et al., 2002, 196736)														
All organs lympho-immunoblastic														
359.5	0.135	162885	109125	48795	359.4	0.134	7233	4872	2196	357.4	0.336	376.6	312.2	173.2
All organs – all lymphomas														
372.3	0.076	173033	107826	47804	372.2	0.076	7686	4814	2152	370.1	0.184	389.8	299.7	166.3
Male Sprague-Dawley rats (Soffritti et al., 2002, 196736)														
Hepatocellular carcinoma														
Failed[a]					Failed[a]					Failed[a]				
All organs lympho-immunoblastic														
455.1	0.183	85557	36526	21916	455.0	0.195	3783.6	1626.7	979.6	454.2	0.273	311.3	160.1	103.2
All organs – all lymphomas														
468.1	0.147	96751	37848	22210	468.0	0.154	4288	1687.5	993.7	467.5	0.179	362.2	166.5	104.4
Female F344 rats (NEDO, 2008, 196316)														
Adrenal glands – pheochromocytoma														
101.5	0.827	198.2	459.0	213.7	101.5	0.828	10.4	24.0	11.2	101.5	0.816	35.7	83.2	38.8
Male F344 rats (NEDO, 2008, 196316)														
Lung – adenomas and adenocarcinomas														
108.2	0.143	248.0	507.5	225.8	108.2	0.143	13.0	26.5	11.8	108.2	0.140	44.8	92.2	41.0
Lung – adenomas, adenocarcinomas and adenomatosis														
168.8	0.778	451.9	393.9	173.1	168.8	0.778	23.7	20.6	9.05	168.8	0.775	81.3	71.1	31.3

[a] BMD computation failed because "BMD is larger than three times maximum input doses."


Figure E-1. Female rat survival.

Figure E-2. Male rats survival.

**Figure E-3. Female – Lymphomas lympho-immunoblastic – Multistage Weibull Model – Approach 1.**

Figure E-4. Female – All lymphomas – Multistage Weibull Model – Approach 1.

Source: Soffritti et al. (2002, 196736).

Figure E-5. Male – Hepatocellular carcinoma – Multistage Weibull Model – Approach 1.

Source: Soffritti et al. (2002, 196736).

Figure E-6. Male – Lymphomas lympho-immunoblastic – Multistage Weibull Model – Approach 1.

Source: Soffritti et al. (2002, 196736).

Figure E-7. Male – All lymphomas – Multistage Weibull Model – Approach 1.

Source: Soffritti et al. (2002, 196736).

Female Rats All Lymphomas Combined
Kaplan Meier Plots and Multistage Weibull Model

Figure E-8. Female rats – All lymphomas time-to-tumor model fit and Kaplan Meier curves.

Source: Soffritti et al. (2002, 196736).

Male Rats All Lymphomas Combined
Kaplan Meier Plots and Multistage Weibull Model

Figure E-9. Male rats – All lymphomas time-to-tumor model fit and Kaplan Meier curves.

Source: Soffritti et al. (2002, 196736).

Figure E-10. Male rats- All lymphomas; dose = allometrically scaled metabolized methanol (mg/kg$^{0.75}$-day); 1º multistage model.

Source: Soffritti et al. (2002, 196736).

Figure E-11. Female rat survival.

Source: NEDO (1987, 064574),(2008, 196316).

Figure E-12. Male rat survival.

Source: NEDO (1987, 064574), (2008, 196316).

23:33 12/28 2009

Figure E-13. Female rats- pheochromocytomas; dose = allometrically scaled metabolized methanol (mg/kg$^{0.75}$-day); 3° multistage model.

Source: NEDO (1987, 064574)(2008, 196316)

Figure E-14. Plots for female (top; p= 0.29) and male (bottom; p= 0.21) mice – malignant lymphoma; dose=amount metabolized (mg/kg$^{0.75}$-day); 2º multistage model.

Source: Apaja (1980, 191208)